

1 DAVID CHIU, State Bar # 189542  
2 City Attorney  
3 YVONNE R. MERE, State Bar # 175394  
4 Chief Deputy City Attorney  
5 SARA J. EISENBERG, State Bar # 296303  
6 Chief of Complex & Affirmative Litigation  
7 OWEN J. CLEMENTS, State Bar # 141805  
8 JAIME M. HULING DELAYE, State Bar #  
9 270784  
10 JOHN H. GEORGE, State Bar # 292332  
11 Deputy City Attorneys  
12 Fox Plaza  
13 1390 Market Street, Sixth Floor  
14 San Francisco, CA 94102  
15 Telephone: 415.554.3597  
16 jaime.hulingdelaye@sfcityatty.org

17 *Attorneys for Plaintiff The People of the State of*  
18 *California, acting by and through San Francisco*  
19 *City Attorney David Chiu*

20 [Additional counsel on signature page.]

21 UNITED STATES DISTRICT COURT  
22 NORTHERN DISTRICT OF CALIFORNIA  
23 SAN FRANCISCO DIVISION

24 THE CITY AND COUNTY OF SAN  
25 FRANCISCO, CALIFORNIA and THE  
26 PEOPLE OF THE STATE OF CALIFORNIA,  
27 Acting by and through San Francisco City  
28 Attorney DAVID CHIU,

Plaintiff,

v.

PURDUE PHARMA L.P., et al.

Defendants.

PLAINTIFF'S EXHIBIT LIST

Judge: Honorable Charles R. Breyer  
Case No. 3:18-cv-07591-CRB

**PLAINTIFF'S EXHIBIT LIST**

Plaintiff, the People of the State of California, are producing the attached Plaintiff's Exhibit List subject to the same understanding and reservations described in the Joint Trial Exhibit and Witness Stipulation and Order (Rec. Doc. 1048).

By serving this exhibit list, Plaintiff does not waive, and expressly reserves, all rights afforded under the Joint Trial Exhibit Stipulation, Local Rules, and orders and procedures established by the Court in this action to amend, modify, withdraw, and supplement Plaintiff's exhibit list before and during trial. Specifically, Plaintiff reserves the right to modify, withdraw, or supplement its exhibit list before and during trial under the following non-exclusive set of circumstances: (1) to include documents produced in this litigation by an opposing party on or after February 14, 2022; (2) upon receipt of other parties' exhibit lists and/or deposition designations or counter-designations and amendments to deposition designations or counter-designations; (3) in the event that additional relevant documents or materials are produced in this action, identified in supplemental expert reports, or discovered subsequent to the date of service of the exhibit list; (4) for purposes of adding any medical or scientific literature, other data, regulatory filings or communications issued or published after the date of submission of the exhibit list; (5) as required to cure an evidentiary objection; (6) in response to Plaintiff or Defendants proffering any documents they have not listed on their exhibit lists; (7) in response to rulings of the Court on any pretrial motions, including any expert motions, motions for summary judgement, motions *in limine*, or any other Court decisions that affect the scope of this trial; or (9) as necessary based on the future severance, settlement, and/or dismissal involving any party.

1 The inclusion of any exhibit on this exhibit list is not intended to waive or affect any  
2 prior confidentiality designation in this litigation. Plaintiff also reserves the right to object  
3 to the introduction and/or admissibility of any document listed on any party's exhibit list.  
4 The inclusion of a particular document on Plaintiff's exhibit list does not waive any right to  
5 object to the introduction and/or admissibility of that document for any purpose. Certain of  
6 Plaintiff's listed exhibits may also pertain to topics that are ultimately excluded from  
7 evidence at trial by motion *in limine* or any other motion. By listing such exhibits, Plaintiff  
8 does not intend to waive any right to object to the introduction and/or admissibility of those  
9 documents for any purpose. Plaintiff also reserves the right to use any deposition transcripts  
10 and any exhibits to deposition transcripts for any witnesses being called to testify at trial  
11 and/or use any deposition exhibits or other documents associated with any testimony that  
12 has been or will be designated or counter-designated by any party. Plaintiff reserves the  
13 right to use any and all documents or materials listed by any other party, including any  
14 defendant even if such defendant may later settle, be severed, or be otherwise dismissed.

15  
16  
17  
18  
19 Certain exhibits that were previously produced during discovery are further  
20 identified by bates number or native file name. Plaintiff expressly reserves the right to use  
21 alternative copies of such exhibits where appropriate, including physical, color, redacted,  
22 more legible, and/or native documents, or copies with or without deposition exhibit stickers.  
23 Plaintiff also reserves the right to use at trial summaries created in accordance with the  
24 federal rules and demonstrative exhibits, including without limitation: charts, graphs,  
25 photographs, animations, timelines, objects, models, PowerPoint slides, drawings, graphics,  
26 and other demonstrative aids. Plaintiff reserves the right to offer enlargements of any  
27  
28

exhibits on the list or on any party's exhibit list.

Date: April 19, 2022

Additional counsel:

LIEFF CABRASER HEIMANN & BERNSTEIN,  
LLP

/s/ Paulina do Amaral

Paulina do Amaral  
Elizabeth J. Cabraser  
Richard M. Heimann  
Kevin R. Budner  
Michael Levin-Gesundheit  
275 Battery Street, 29th Floor  
San Francisco, California 94111-3339  
Telephone: 415.956.1000  
Facsimile: 415.956.1008  
pdoamaral@lchb.com

David Chiu  
City Attorney  
Yvonne R. Mere  
Sara J. Eisenberg  
Owen J. Clements  
Jaime M. Huling Delaye  
John H. George  
Deputy City Attorneys  
Fox Plaza  
1390 Market Street, Sixth Floor  
San Francisco, CA 94102  
Telephone: 415.554.3957  
jaime.hulingdelaye@sfcityatty.org

ROBBINS GELLER RUDMAN  
& DOWD LLP  
AELISH M. BAIG  
TAEVA C. SHEFLER  
HADIYA K. DESHMUKH  
Post Montgomery Center  
One Montgomery Street, Suite 1800  
San Francisco, CA 94104  
Telephone: 415/288-4545  
415/288-4534 (fax)  
[aelishb@rgrdlaw.com](mailto:aelishb@rgrdlaw.com)  
[tshefler@rgrdlaw.com](mailto:tshefler@rgrdlaw.com)  
[hdeshmukh@rgrdlaw.com](mailto:hdeshmukh@rgrdlaw.com)

ROBBINS GELLER RUDMAN  
& DOWD LLP  
PAUL J. GELLER  
MARK J. DEARMAN  
DOROTHY P. ANTULLIS  
NICOLLE B. BRITO  
120 East Palmetto Park Road, Suite 500  
Boca Raton, FL 33432  
Telephone: 561/750-3000  
561/750-3364 (fax)  
[pgeller@rgrdlaw.com](mailto:pgeller@rgrdlaw.com)  
[mdearman@rgrdlaw.com](mailto:mdearman@rgrdlaw.com)  
[dantullis@rgrdlaw.com](mailto:dantullis@rgrdlaw.com)  
[nbrito@rgrdlaw.com](mailto:nbrito@rgrdlaw.com)

ROBBINS GELLER RUDMAN  
& DOWD LLP  
X. JAY ALVAREZ  
THOMAS E. EGLER  
655 West Broadway, Suite 1900  
San Diego, CA 92101  
Telephone: 619/231-1058  
619/231-7423 (fax)  
[jaya@rgrdlaw.com](mailto:jaya@rgrdlaw.com)  
[tome@rgrdlaw.com](mailto:tome@rgrdlaw.com)

Louise Renne  
RENNE PUBLIC LAW GROUP  
350 Sansome Street, Suite 300  
San Francisco, CA 94104  
Telephone: 415/848-7240  
415/848-7230 (fax)  
[lrenne@publiclawgroup.com](mailto:lrenne@publiclawgroup.com)

Jennie Lee Anderson  
Paul Laprairie  
ANDRUS ANDERSON LLP  
155 Montgomery Street, Suite 900  
San Francisco, CA 94104  
Telephone: 415/986-1400  
415/986-1474 (fax)  
[jennie@andrusanderson.com](mailto:jennie@andrusanderson.com)

Kevin Sharp  
SANFORD HEISLER SHARP, LLP  
611 Commerce Street, Suite 3100  
Nashville, TN 37203  
Telephone: 615/434-7000  
615/434-7020 (fax)  
[ksharp@sanfordheisler.com](mailto:ksharp@sanfordheisler.com)

1 Edward Chapin  
2 SANFORD HEISLER SHARP, LLP  
3 655 West Broadway, Suite 1700  
4 San Diego, CA 92101  
5 Telephone: 619/577-4253  
6 619/577-4250 (fax)  
7 echapin2@sanfordheisler.com

8 David S. Casey, Jr.  
9 Gayle M. Blatt  
10 Alyssa Williams  
11 CASEY GERRY SCHENK FRANCAVILLA  
12 BLATT & PENFIELD LLP  
13 110 Laurel Street  
14 San Diego, CA 92101-1486  
15 Telephone: 619/238-1811  
16 619/544-9232 (fax)  
17 dcasey@cglaw.com  
18 gmb@cglaw.com  
19 [awilliams@cglaw.com](mailto:awilliams@cglaw.com)

20 Ellen Relkin  
21 WEITZ & LUXENBERG P.C.  
22 700 Broadway  
23 New York, NY 10003  
24 Telephone: 212/558-5500  
25 212/344-5461 (fax)  
26 [erelkin@weitzlux.com](mailto:erelkin@weitzlux.com)

27 Paul F. Novak  
28 Tiffany Ellis  
WEITZ & LUXENBERG P.C  
3011 West Grand Boulevard  
24<sup>th</sup> Floor  
Detroit, MI 48202  
Telephone: 313/800-4166  
[pnovak@weitzluc.com](mailto:pnovak@weitzluc.com)  
[tellis@weitzlux.com](mailto:tellis@weitzlux.com)

*Attorneys for Plaintiff The People of the State of  
California, acting by and through San Francisco  
City Attorney David Chiu*

Jayne Conroy (pro hac vice)  
Justin Presnal (pro hac vice)  
SIMMONS HANLY CONROY  
112 Madison Avenue, 7th Floor  
New York, NY 10016  
(212) 784-6400  
(212) 213-5949 (fax)  
jconroy@simmonsfirm.com  
jpresnal@simmonsfirm.com

Peter J. Mougey (pro hac vice)  
LEVIN PAPANTONIO RAFFERTY LAW FIRM  
316 S. Baylen St., Ste. 600  
Pensacola, FL 32502  
(850) 435-7068  
pmougey@levinlaw.com

*MDL Co-Lead, Plaintiff Executive Committee  
Counsel*

Exhibit Number	Date	TREX List Description	TREX List Begin	TREX List End	Family Exhibits Over 10 Documents	Subject to Stipulation
P-00004	1/11/2011	Re: High Quantity Stores 682971	WAGFLDEA00000852	WAGFLDEA00000862		
P-00015	6/11/2013	WAG 2013 Settlement Agreement	WAGMDL00490963	WAGMDL00490974		
P-00015 Redact	6/11/2013	WAG 2013 Settlement Agreement	WAGMDL00490963	WAGMDL00490974		
P-00021	9/12/2013	NEJM Abusive Prescribing of Controlled Substances - A Pharmacy View (TAB 050C)	N/A	N/A		
P-00027	12/16/2012	FW: Proposed org chart; Controlled Substance Reporting; Pharmaceutical Integrity Organization PPT by Tasha Polster; RxIntegrity Proposed Org Chart 12.2012 POLSTER	WAGMDL00659270	WAGMDL00659274		
P-00028	3/21/2013	Re: New MPD Corporate Orientation; Pharmaceutical Integrity Overview One Pager; Pharmaceutical Integrity Overview One Pager	WAGMDL00303029	WAGMDL00303031		
P-00029	8/2/2013	Email FYI - this is work in progress but a good read. Data is still being validated so is preliminary 2013 08 01 Purdue core team working session vF PPT	PPLPC004000365800	PPLPC004000365802		
P-00035	9/27/2006	WAG #1 & #2 Rannazzisi Letters	WAGMDL00757790	WAGMDL00757797		
P-00036	12/27/2007	2007 WAG Rannazzisi Letter #2	WAGMDL00757798	WAGMDL00757801		
P-00037	10/27/2017	Re: DEA will hold Drug Take Back Day to snag unused opioids	WAGMDL00386743	WAGMDL00386745		
P-00042	6/25/2015	Industry Compliance Guidelines, Healthcare Distribution Management Association (HDMA) Industry Compliance Guidelines: Reporting Suspicious Orders and Preventing Diversion of Controlled Substances	ABDCMDL00000377	ABDCMDL00000392		
P-00055	5/17/2006	DEA letter to Mr. Polarolo regarding completed regulatory investigation of Walgreen Company	WAGMDL00709510	WAGMDL00709512		
P-00056	5/27/2006	Memorandum, Meeting Between Office of Diversion Control (OD) and McKesson Corp.	WAGMDL00709508	WAGMDL00709509		
P-00057	12/22/2008	Walgreens Internal Audit Report, DEA Compliance - Perrysburg Distribution Center	WAGMDLPER00000001	WAGMDLPER00000019		
P-00058	8/3/2010	Re: Suspicious Controlled Drug Orders with screenshots	WAGMDL00660331	WAGMDL00660337		
P-00059	1/4/2013	Re: Ceiling Update	WAGMDL00414048	WAGMDL00414049		
P-00060	3/1/2013	Walgreens Memo to Rex Swords from Tasha Polster, DEA Strategy Meeting Agenda	WAGMDL00302949	WAGMDL00302950		
P-00062	5/23/2016	Email State of Integrity, Attachment State of Rx Integrity 10 PPT	WAGMDL00010887	WAGMDL00010928		
P-00100	10/27/1970	21 USC Sections 801, 812, 821 and 823; Pertinent Sections of CSA	PLTF_2804_000067826	PLTF_2804_000067829		
P-00101	4/24/1970	21 CFR Section 1301.74 (Whole Reg)	N/A	N/A		
P-00102	1/9/2008	1984/1993 NWDA Suspicious Order Monitoring System	CAH_MDL_PRIORPROD_DEA07_00869965	CAH_MDL_PRIORPROD_DEA07_00870002		
P-00103	4/7/1987	U.S. Department of Justice, Seminar Report, Controlled Substances Manufacturers and Wholesalers Seminar	US-DEA-00025656	US-DEA-00025659		
P-00104	4/16/1996	U.S. Department of Justice, DEA, Diversion Investigators Manual, letter to Robert Giacalone	CAH_MDL2804_02203353	CAH_MDL2804_02203363		
P-00124	1/20/2011	Email Ft Pierce	WAGFLDEA00000872	WAGFLDEA00000884		
P-00125	7/31/2011	DEA statistics for WAG July 2011 show alarming number of orders being cut or reduced as opposed to being reported	WAGMDL00492171	WAGMDL00492171		
P-00126	2/28/2012	Fw: Spreadsheet Rolling 12 for top ten stores	WAGFLDEA00001733	WAGFLDEA00001734		
P-00127	4/7/2012	Fw: Update Rx Supply Chain Contingency Plan for Jupiter, Suspicious Ordering Reporting	WAGMDL00709395	WAGMDL00709397		
P-00128	4/23/2012	Fw: DEA Suspicious Order - Phase III; Functional Requirements & (Macro) Design, DEA Suspicious Ordering - Phase III, (Controlled Substance Threshold), Project Number W0018238	WAGMDL00325170	WAGMDL00325191		
P-00129	7/17/2012	Walgreen Co. Controlled Substance Anti-Diversion and Compliance Program PPT	WAGMDL00659801	WAGMDL00659856		
P-00130	10/11/2012	RE: CSR Version Summary 100812 with attachment Controlled Substance Ordering, Evolution of Controlled Substance Ordering Process	WAGMDL00667936	WAGMDL00667943		
P-00131	11/12/2012	FW: November 8th DEA meeting at NABP	WAGMDL00426251	WAGMDL00426254		
P-00132	11/28/2012	Email Walgreens State Controls Summaries; Attachment Walgreens_Analysis-States; Walgreens Map Control Percent Flagged	WAGMDL00774715	WAGMDL00774720		
P-00133	1/18/2013	Re: 13659 hydros 7.5/500	WAGMDL00246275	WAGMDL00246279		

Some of the documents listed herein are copies, including non-identical copies, of documents which have different document production numbers or may have been produced by different parties than the versions listed herein or bear deposition exhibit stickers. Plaintiffs reserve the right to use at trial any version of the documents listed herein, including versions that bear one or more deposition exhibit stickers.



P-00134	2/4/2013	U.S Department of Justice/Drug Enforcement Administration Subpoena to Walgreen Corporation	WAGMDL00493694	WAGMDL00493696		
P-00135	2/5/2013	Walgreens Corporation Administrative Inspection Warrant Perrysburg, OH	WAGMDL00493697	WAGMDL00493700		
P-00136	1/10/2013	Email DEA Update Presentation For Market Leadership; DEA Market Leadership Scrubbed Version Jan 2013	WAGMDL00049752	WAGMDL00049772		
P-00137	2/20/2013	Letter from Latham & Watkins Re: Walgreens Perrysburg, Ohio Distribution Center	WAGMDL00674280	WAGMDL00674281		
P-00138	4/16/2013	FW: Shrink Set	WAGMDL00429246	WAGMDL00429248		
P-00139	8/19/2013	Re: Controlled Substances Order Quantity Override Form	WAGMDL00021425	WAGMDL00021427		
P-00140	5/7/1969	US Government Memorandum to The Honorable John W. Dean, III from Michael R. Sonnenreich, Subject: Department of Health, Education, and Welfare's staff papers regarding the "Controlled Dangerous Substances Act of 1969"	PLTF_2804_000296556	PLTF_2804_000296564		
P-00143	6/18/2007	2006 Allergan Rannazzisi Letter	ALLERGAN_MDL_02467796	ALLERGAN_MDL_02467799		
P-00160	9/25/2012	Cegedim Relationship Management, Compliance Solutions Powered by Buzeo PDMA	TEVA_MDL_A_01060005	TEVA_MDL_A_01060012		
P-00162	11/22/2011	Email Slides for Tomorrow; Attachment Generic KADIAN Slides	Acquired_Actavis_00369838	Acquired_Actavis_00369839		
P-00204	2/21/2020	At Walgreens, Complaints of Medication Errors Go Missing - by Ellen Gabler The New York Times	N/A	N/A		
P-00207	1980	Jane Porter and Hershel Jick, "Addiction rare in patients treated with narcotics," New England Journal of Medicine 302(2), January 10, 1980	N/A	N/A		
P-00277	9/22/2011	Follow up report; Watson SOM	Teva IQVIA_0020874	Teva IQVIA_0020882		
P-00431	2019	Area Monday/Friday	N/A	N/A		
P-00576	12/4/2013	Email Walgreens and ABC OMP Meeting and attachment	ABDCMDL00278991	ABDCMDL00278992		
P-00967	2/19/2008	Email Programs	Acquired_Actavis_00002258	Acquired_Actavis_00002259		
P-00968	9/11/2012	Advertisement & Promotion Review/Approval for Kadian	MULTI0003292	MULTI0003315		
P-00991	9/6/2012	KAD-084 Kadian Intro Stocking Offer PDF FINAL 08-29-12	Acquired_Actavis_00369186	Acquired_Actavis_00369191		
P-01010	2/10/2015	Letter to Phil Walsky from Michael Clarke Re: Online Pharmacy Issue	Acquired_Actavis_00897875	Acquired_Actavis_00897878		
P-01019	12/7/2012	Email see attached presentations	Acquired_Actavis_00968401	Acquired_Actavis_00968404		
P-01023	2/15/2013	BuNa marketing plan...	Acquired_Actavis_01178982	Acquired_Actavis_01178991		
P-01034	2/10/2012	RE: SOM follow up from Cegedim -	Acquired_Actavis_01370513	Acquired_Actavis_01370519		
P-01041	9/21/2012	FW: SOM Training Completed 9/21/12	Acquired_Actavis_01509414	Acquired_Actavis_01509416		
P-01048	4/3/2008	Diclofenac Buy-Ins	ALLERGAN_MDL_03411273	ALLERGAN_MDL_03411276		
P-01050	9/30/2019	Inspector General Report - Review of DEA Opioid Enforcement	N/A	N/A		
P-01051	5/5/2015	Testimony of Rannazzisi	N/A	N/A		
P-01052	N/A	21 U.S. Code section 826 - Production quotas for CSs	N/A	N/A		
P-01058	5/28/2001	Quota letters to doctors and patients	PPLPC045000005398	PPLPC045000005404		
P-01059	7/12/2018	DEA Publishes Final Rule on CS Quotas	PPLPC032000404799	PPLPC032000404808		
P-01064	1/22/2013	Orders on OI hold Status (RDC)	Acquired_Actavis_00353871	Acquired_Actavis_00353875		
P-01065	5/8/2012	SFC submission	JAN00000001	JAN00000010		
P-01068	11/22/2010	PER4MA Form 2010 self appraisal	Acquired_Actavis_00185283	Acquired_Actavis_00185289		
P-01070	8/23/2012	Email re J. McCormick Resume	Acquired_Actavis_00588522	Acquired_Actavis_00588525		
P-01071	1/12/2010	Email re PER4MA self appraisal JPM	Acquired_Actavis_00604252	Acquired_Actavis_00604256		
P-01072	3/10/2009	RE: 2009 Individual Objectives	Acquired_Actavis_01539676	Acquired_Actavis_01539681		
P-01073	4/1/2009	RE: 2009 Individual Objectives	Acquired_Actavis_01539726	Acquired_Actavis_01539732		
P-01074	3/3/2009	DBPer4ma2009 Goals	Acquired_Actavis_01541043	Acquired_Actavis_01541047		
P-01075	11/15/2012	JM Final 2012 Level 2 3 PER4MA Self Assessment	Acquired_Actavis_01661039	Acquired_Actavis_01661046		
P-01076	3/3/2014	Email re A Message from Paul Bisaro and Bob Stewart - Launching Our Industry-Leading Commitment to Drug Diversion Education and Prevention	Acquired_Actavis_02236096	Acquired_Actavis_02236099		
P-01077	7/10/2012	Pain Market Overview 101911	ACTAVIS0264936	ACTAVIS0264949		
P-01078	8/2/2012	Slides for today's conference call	ALLERGAN_MDL_00026060	ALLERGAN_MDL_00026092		
P-01079	3/3/2009	Per4ma 2009 signed	ALLERGAN_MDL_00128725	ALLERGAN_MDL_00128730		
P-01081	2/2/2011	Incentive Comp and Retention Bonuses	ALLERGAN_MDL_00223522	ALLERGAN_MDL_00223535		
P-01082	6/29/2012	Email re supply situation Amphet Combo	ALLERGAN_MDL_00226916	ALLERGAN_MDL_00226918		
P-01083	8/7/2011	Email re Monday call	ALLERGAN_MDL_00235615	ALLERGAN_MDL_00235616		
P-01084	3/3/2009	Per4ma 2009 Goals	ALLERGAN_MDL_01023081	ALLERGAN_MDL_01023102		

P-01085	1/27/2009	Need Approval - Kadian-Coupon-2009-Program	ALLERGAN_MDL_01100742	ALLERGAN_MDL_01100752		
P-01086	4/8/2010	Email re Dr. Doraswamy, New Albany, Indiana	ALLERGAN_MDL_01194225	ALLERGAN_MDL_01194226		
P-01087	7/22/2011	FW: Oxymorphone training to KADIAN sales team	ACTAVIS0357036	ACTAVIS0357057		
P-01088	11/18/2010	Email re Ride Along-G. Stephens Rampton - Salt Lake City	ALLERGAN_MDL_01197942	ALLERGAN_MDL_01197944		
P-01089	1/24/2012	Email re Oxymorphone Prescription trends	ALLERGAN_MDL_02460224	ALLERGAN_MDL_02460226		
P-01090	9/12/2012	Effective Controls Against Diversion of Controlled Substances	ALLERGAN_MDL_03302011	ALLERGAN_MDL_03302319		
P-01091	10/3/2012	Email re SOM	ALLERGAN_MDL_03380592	ALLERGAN_MDL_03380593		
P-01092	11/11/2009	Email re Oxycodone ER launch	ALLERGAN_MDL_03998242	ALLERGAN_MDL_03998263		
P-01095	11/29/2011	Per4Ma 2011 Level 2 and 3 - JM final	ACTAVIS0481204	ACTAVIS0481210		
P-01097	7/15/2011	FW: Sales rep training material draft	ACTAVIS0506794	ACTAVIS0506798		
P-01103	9/2/2011	FW: Revised marketing plan	ACTAVIS0622787	ACTAVIS0622789		
P-01104	8/19/2011	RE: McKesson Marketing opportunities - Actavis Oxymorphone ER	ACTAVIS0623776	ACTAVIS0623781		
P-01126	8/26/2011	Re: Weekly Update	ACTAVIS0815204	ACTAVIS0815207		
P-01128	7/19/2011	RE: Recap of Sales/Marketing/Contracts Meeting - MONDAY, JULY 18TH	ACTAVIS0819308	ACTAVIS0819312		
P-01142	6/11/2013	WAG 2013 Settlement Agreement	WAGMDL00490963	WAGMDL00490978		
P-01171	11/21/2011	Re: Generic Kadian Update	ALLERGAN_MDL_00396954	ALLERGAN_MDL_00396960		
P-01172	10/10/2011	Fw: Kadian Prescriber Research Summary	ALLERGAN_MDL_00399112	ALLERGAN_MDL_00399137		
P-01176	6/4/2012	Meeting Notes NL	ALLERGAN_MDL_00432311	ALLERGAN_MDL_00432312		
P-01186	7/19/2011	RE: Recap of Sales/Marketing/Contracts Meeting - MONDAY, JULY 18TH	ALLERGAN_MDL_00505041	ALLERGAN_MDL_00505044		
P-01188	8/26/2011	Oxymorphone Promotion and chargeback results to date; Actavis Logo; Charge Back Details since launch 7/15/2011; various dates 2011 - Oxymorphone Promotional Plan	ALLERGAN_MDL_00508576	ALLERGAN_MDL_00508580		
P-01207	6/24/2008	Department of Justice: Remarks by Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, before the House Judiciary Committee Subcommittee on Crime, Terrorism, & Homeland Security Regarding "Online Pharmacies and the Problem of Internet Drug Abuse"	N/A	N/A		
P-01208	4/7/2014	Department of Justice, Statement of Joseph T. Rannazzisi before the Subcommittee on Health Committee on Energy and Commerce U.S. House of Representative for a hearing entitled "Improving Predictability and Transparency in DEA and FDA Regulation" presented on April 7, 2014	N/A	N/A		
P-01215	1/16/2014	Watson Product List	ALLERGAN_MDL_01149654	ALLERGAN_MDL_01149655		
P-01227	2/2/2010	Presentation	ALLERGAN_MDL_01236063	ALLERGAN_MDL_01236094		
P-01228	4/29/2010	Fw: Placebo--Hydro	ALLERGAN_MDL_01236095	ALLERGAN_MDL_01236096		
P-01242	8/4/2015	RE: Branded Legacy Actavis/Watson Products List	ALLERGAN_MDL_01334578	ALLERGAN_MDL_01334579		
P-01243	8/18/2015	RE: Annual Report Request Memo - Kadian (morphine sulfate) NDA	ALLERGAN_MDL_01334588	ALLERGAN_MDL_01334589		
P-01244	6/29/2015	RE: Tara's Email	ALLERGAN_MDL_01335569	ALLERGAN_MDL_01335570		
P-01248	3/8/2010	Letter to Thomas Abrams from Terri Nataline re: NDA 20-616	ALLERGAN_MDL_01396750	ALLERGAN_MDL_01396770		
P-01253	10/27/2010	Department of Justice -DEA East Main Street Pharmacy: Affirmance of Suspension Order	N/A	N/A		
P-01259	12/11/2015	Daily Backorder Report for 12/11	ALLERGAN_MDL_01489486	ALLERGAN_MDL_01489489		
P-01266	10/26/2012	SOM SOP and Business Procedure DIRECT final	ALLERGAN_MDL_01684748	ALLERGAN_MDL_01684752		
P-01275	10/27/2009	Kadian Speaker Program; Kadian_Slides_for_Speaker_Training_with_MLRCmts_2_22	ALLERGAN_MDL_01741585	ALLERGAN_MDL_01741639		
P-01276	1/28/2011	RE: Kadian	ALLERGAN_MDL_01745342	ALLERGAN_MDL_01745430		
P-01277	9/16/2011	RE: Advantage Logistics orders 387109-01-1, 387111-01-1 Pended for Zolpidem Tartrate ER (Supervalu)	ALLERGAN_MDL_01766993	ALLERGAN_MDL_01766997		
P-01282	11/14/2012	FW: Suspicious Order Letters - Update	ALLERGAN_MDL_01796473	ALLERGAN_MDL_01796475		
P-01286	8/2/2017	Request for DEA - SOMS info. Thank you	ALLERGAN_MDL_01836286	ALLERGAN_MDL_01836287		
P-01289	5/6/2011	FW: Actavis / BuzzeoPDMA - Customer Services Agreement - SOM Services	ALLERGAN_MDL_01860386	ALLERGAN_MDL_01860397		
P-01294	10/26/2012	SOM SOP and Business Procedure INDIRECT final	ALLERGAN_MDL_01979834	ALLERGAN_MDL_01979838		
P-01299	7/26/2010	Fentanyl VA Mailer and 7/26/10 Weekly Status	ALLERGAN_MDL_02053309	ALLERGAN_MDL_02053317		
P-01301	8/18/2009	FW: Suspicious Orders	ALLERGAN_MDL_02081243	ALLERGAN_MDL_02081245		
P-01318	2/9/2004	Re: Suspicious Order Reports	ALLERGAN_MDL_02166476	ALLERGAN_MDL_02166477		

P-01319	11/8/2013	Internal Assessment: Corona Controlled Substance Operations	ALLERGAN_MDL_02176551	ALLERGAN_MDL_02176553		
P-01321	6/26/2013	FW: Order(s) on Hold - MIAMI-LUKEN INC SD# 636885	ALLERGAN_MDL_02179760	ALLERGAN_MDL_02179772		
P-01322	8/3/2016	Letter to Tracy Thomas from Global Medical Scientific Information regarding request for Norco prescribing information	ALLERGAN_MDL_02185805	ALLERGAN_MDL_02185815		
P-01323	10/2/2012	FW: SOM Acknowledgement Form; Compliance Acknowledgement Form 060612	ALLERGAN_MDL_02186651	ALLERGAN_MDL_02186653		
P-01338	4/4/2012	SOMS Project Evolution	ALLERGAN_MDL_02468982	ALLERGAN_MDL_02468994		
P-01340	2/3/2005	Re: SOMS/OMS Project	ALLERGAN_MDL_02578082	ALLERGAN_MDL_02578083		
P-01495	10/29/2010	RE: Suspicious Rpt 7.17.5	ALLERGAN_MDL_03383828	ALLERGAN_MDL_03383828		
P-01498	6/11/2008	RE: DEA Suspicious Report 7.17.5	ALLERGAN_MDL_03412129	ALLERGAN_MDL_03412130		
P-01506	10/30/2008	Suspicious Order Monitoring Overview 1021	ALLERGAN_MDL_03535007	ALLERGAN_MDL_03535008		
P-01508	11/13/2008	Controlled Substance Seminar Summary	ALLERGAN_MDL_03535130	ALLERGAN_MDL_03535133		
P-01511	4/7/2009	CSOP_011-004, Suspicious Orders of Controlled Drugs	ALLERGAN_MDL_03641386	ALLERGAN_MDL_03641389		
P-01513	6/20/2011	Oxymorphone Launch Preparation	ALLERGAN_MDL_03684488	ALLERGAN_MDL_03684492		
P-01515	N/A	Watson Pharma, Inc. Memo To Mary Woods From Lynn DaCunha Re: Monthly Report	ALLERGAN_MDL_04512442	ALLERGAN_MDL_04512446		
P-01518	5/16/2019	Re Updated Guidance Issued For Reporting Suspicious Orders and Customer Due Diligence - Update 5/14/2019	ALLERGAN_MDL_04517769	ALLERGAN_MDL_04517771		
P-01520	10/21/2008	Suspicious Order Monitoring Overview 1021	ALLERGAN_MDL_03535009	ALLERGAN_MDL_03535010		
P-01521	6/27/2014	USOM-LIC-4000 License Maintenance	ALLERGAN_MDL_03750135	ALLERGAN_MDL_03750146		
P-01523	9/26/2012	Actavis Transition CRO_Admin.one	ALLERGAN_MDL_03776365	ALLERGAN_MDL_03776678		
P-01529	7/17/2007	Re: DEA Contact History	ALLERGAN_MDL_03952959	ALLERGAN_MDL_03952960		
P-01534	9/27/2012	RE: Order(s) on Hold - Cardinal SD# 574340	ALLERGAN_MDL_04173111	ALLERGAN_MDL_04173113		
P-01536	1/20/2015	Allergan Global Supplier Spend (Shareable) 12.29.2014	ALLERGAN_MDL_04240829	ALLERGAN_MDL_04240833		
P-01539	8/17/2009	Re: HELP please...Fw: Suspicious Orders	ALLERGAN_MDL_04333192	ALLERGAN_MDL_04333193		
P-01540	8/24/2009	RE: HELP please...Fw: Suspicious Orders	ALLERGAN_MDL_04333369	ALLERGAN_MDL_04333370		
P-01541	8/20/2009	FW: HELP please...Fw: Suspicious Orders	ALLERGAN_MDL_04333371	ALLERGAN_MDL_04333374		
P-01544	2/9/2017	Consulting - Risk and Program Management to Allergan from inVentiv Health for Opioid PMR Support	ALLERGAN_MDL_04382927	ALLERGAN_MDL_04382976		
P-01546	10/1/2007	Oxycodone Unit Dose 15mg Carton	ALLERGAN_MDL_04416289	ALLERGAN_MDL_04416292		
P-01547	5/10/2019	2019 Org Chart	ALLERGAN_MDL_04450023	ALLERGAN_MDL_04450029		
P-01548	5/30/2019	PLC - Mgmt Agreement - Fully Executed	ALLERGAN_MDL_04451501	ALLERGAN_MDL_04451514		
P-01549	6/7/2019	agn internal controls over financial reporting framework policy	ALLERGAN_MDL_04451515	ALLERGAN_MDL_04451518		
P-01550	6/8/2019	allergan gaap accounting policies	ALLERGAN_MDL_04451519	ALLERGAN_MDL_04451794		
P-01551	6/7/2019	ic 101 agn global inter-company loan and interest policy	ALLERGAN_MDL_04451804	ALLERGAN_MDL_04451815		
P-01552	6/13/2019	2016 - 2018 PL Activity For Allergan PLC	ALLERGAN_MDL_04451817	ALLERGAN_MDL_04451817		
P-01553	N/A	Nancy Baran CV from LinkedIn	Allergan-Baran-002	Allergan-Baran-002		
P-01561	4/13/2009	Email Ryan Haight Online Pharmacy Consumer Protection Act of 2008; Final Rule	ALLERGAN_MDL_01030377	ALLERGAN_MDL_01030378		
P-01562	2/16/2017	RE: Care	Anda_Opioids_MDL_0000624673	Anda_Opioids_MDL_0000624680		
P-01563	10/5/2015	Re: Report: 110 - Walmart Actavis Oxy Er & 80 MG - Vicki Mangus	Anda_Opioids_MDL_0000648631	Anda_Opioids_MDL_0000648632		
P-01564	11/11/2017	Email discussing CII CSOS ordering with ANDA	Anda_Opioids_MDL_0000384544	Anda_Opioids_MDL_0000384552		
P-01565	11/13/2015	Email Revised Report	Anda_Opioids_MDL_0000539140	Anda_Opioids_MDL_0000539150		
P-01566	11/12/2015	FW: Report from SOM Review	Anda_Opioids_MDL_0000546429	Anda_Opioids_MDL_0000539217		
P-01567	11/28/2012	Email Walgreens State Controls Summaries; Attachment #WALGREENS_ANALYSIS-STATES; Walgreens Map Control Percent Flagged PPT	Anda_Opioids_MDL_0000570888	Anda_Opioids_MDL_0000570893		
P-01568	11/17/2015	FW: rebate on the oxy Attachment	Anda_Opioids_MDL_0000648625	Anda_Opioids_MDL_0000648627		
P-01569	8/8/2015	RE: Walmart oxy ER Promo Report	Anda_Opioids_MDL_0000648633	Anda_Opioids_MDL_0000648634		
P-01570	1/23/2015	Re: publix oxy	Anda_Opioids_MDL_0000749742	Anda_Opioids_MDL_0000749743		
P-01572	12/7/2012	Fw: Potential DEA-HDMA Meeting -- Input Requested by December 12; Attachment HDMA Questions for DEA as Follow-up on Meeting about Suspicious Orders Monitoring Attachment 060111	Anda_Opioids_MDL_0000085677	Anda_Opioids_MDL_0000085690		
P-01573	7/13/2013	Controlled Substances Follow Up Customer Questionnaire	Anda_Opioids_MDL_0000089114	Anda_Opioids_MDL_0000089117		
P-01574	3/28/2013	FW: Walgreens Store # 07831 - Acct#95588 - Increase Oxycodone limit?	Anda_Opioids_MDL_0000089773	Anda_Opioids_MDL_0000089779		
P-01575	2/9/2018	RE: QTY discrepancy - Bimart	Anda_Opioids_MDL_0000151313	Anda_Opioids_MDL_0000151318		
P-01576	10/12/2007	Fw: Oxy	Anda_Opioids_MDL_0000274535	Anda_Opioids_MDL_0000274537		

P-01577	11/18/2015	FW: OXYCONTIN Opp.	Anda_Opioids_MDL_0000294581	Anda_Opioids_MDL_0000294584		
P-01578	5/10/2013	FW: Anda Walgreens Control Report as of 05/08/2013	Anda_Opioids_MDL_0000566549	Anda_Opioids_MDL_0000566551		
P-01579	1/20/2015	FW: HDMA Weekly Digest, January 20: Distribution Management Conference and Expo to Explore Critical Supply Chain Topics	Anda_Opioids_MDL_0000598068	Anda_Opioids_MDL_0000598071		
P-01580	5/7/2018	Email Anda Project Status Updates; Attachment Portfolio Dashboard Current, Business Case - Narcotic Trend File PPT; Narcotic Trend Analysis Business Case 5- 7-2018	Anda_Opioids_MDL_0000645181	Anda_Opioids_MDL_0000645214		
P-01581	12/12/2012	Walgreens Pharmacy Baseline Information Request, Store 575, Madeira Beach, FL	Anda_Opioids_MDL_0000646721	Anda_Opioids_MDL_0000646725		
P-01582	5/14/2013	Email Operation CII "Catch Up"	Anda_Opioids_MDL_0000647368	Anda_Opioids_MDL_0000647369		
P-01583	5/6/2013	FW: Controlled Substance Query Questions	Anda_Opioids_MDL_0000647586	Anda_Opioids_MDL_0000647586		
P-01584	3/14/2017	RE: Care Control Limit Reporting	Anda_Opioids_MDL_0000649247	Anda_Opioids_MDL_0000649249		
P-01585	2/25/2013	Re: Hospira Backorder	Anda_Opioids_MDL_0000721688	Anda_Opioids_MDL_0000721694		
P-01586	4/14/2014	Re: Contract Pricing Load for SUBSYS Items Being Sold to Deplete Old Walgreens Stock	Anda_Opioids_MDL_0000751640	Anda_Opioids_MDL_0000751642		
P-01587	12/16/2014	FW: Oxycodone HCl ER Tablets CII Offer for Publix	Anda_Opioids_MDL_0000752466	Anda_Opioids_MDL_0000752467		
P-01588	5/11/2016	FW: Anda csos order-#0744	Anda_Opioids_MDL_0000774654	Anda_Opioids_MDL_0000774658		
P-01589	5/11/2016	FW: Anda csos order-#0745	Anda_Opioids_MDL_0000774662	Anda_Opioids_MDL_0000774665		
P-01590	5/22/2018	RE: ANDA - SOM Alert: Sales Order 0002473245 - ACTION REQUIRED	Anda_Opioids_MDL_0000790217	Anda_Opioids_MDL_0000790223		
P-01592	8/3/2010	Re: DEA - Generic Depot #2 & 3	Anda_Opioids_MDL_0000104323	Anda_Opioids_MDL_0000104324		
P-01593	11/18/2011	Letter from DEA to Albert Paonessa RE: DEA Registration Number RA0180733	Anda_Opioids_MDL_0000001208	Anda_Opioids_MDL_0000001209		
P-01594	12/6/2011	Letter from Albert Paonessa to Gayle Lane DEA	Anda_Opioids_MDL_0000001210	Anda_Opioids_MDL_0000001212		
P-01595	5/3/2018	FW: Narcotic Trends - Business Case; Attachment 042619 Narcotic Trend Analysis Business Case PPT	Anda_Opioids_MDL_0000009064	Anda_Opioids_MDL_0000009066		
P-01596	4/12/2018	FW: Anda Request; Attachment letter RE: Vendor Due Diligence Summary	Anda_Opioids_MDL_0000009176	Anda_Opioids_MDL_0000009177		
P-01598	11/28/2017	Email Jay Spellman to Emily Schultz with Anda letter to DEA	Anda_Opioids_MDL_0000013173	Anda_Opioids_MDL_0000013174		
P-01599	7/2/2007	Email Excessive Order Report June 2007 Attachment	Anda_Opioids_MDL_0000013481	Anda_Opioids_MDL_0000013482		
P-01600	6/23/2017	Last Anda list of customers cut-off and alleged reported to the DEA	Anda_Opioids_MDL_0000016604	Anda_Opioids_MDL_0000016604		
P-01601	9/22/2017	Email Article	Anda_Opioids_MDL_0000018341	Anda_Opioids_MDL_0000018341		
P-01602	8/4/2017	FW: ACCT 380297 WILLAKENZIE...INVENTORY CK FOR PACKET	Anda_Opioids_MDL_0000018427	Anda_Opioids_MDL_0000018428		
P-01603	6/23/2017	Email Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_MDL_0000018800	Anda_Opioids_MDL_0000018801		
P-01604	1/19/2017	RE: C2 McKesson	Anda_Opioids_MDL_0000019361	Anda_Opioids_MDL_0000019364		
P-01605	10/27/2016	FW: EPIC Control Eligibility Status 10/19/16 (Please disregard previous attachment); Attachment EPIC- Control Eligibility 10.19.16	Anda_Opioids_MDL_0000019661	Anda_Opioids_MDL_0000019663		
P-01606	8/20/2004	Standard Operating Procedure OPS-028-00	Anda_Opioids_MDL_0000271322 Anda_Opioids_MDL_0000271410	Anda_Opioids_MDL_0000271411 Anda_Opioids_MDL_0000271431	Anda_Opioids_MDL_0000271410 - Anda_Opioids_MDL_0000271411	
P-01607	6/27/2016	Email Information requested by DEA Subpoena Received June 27, 2016; Attachment CO; SOP 028-information Needed to Set-up a New Account; Central Reporting Location Letter 07012015	Anda_Opioids_MDL_0000036508	Anda_Opioids_MDL_0000036522		
P-01608	1/5/2015	Standard Operating Procedure 28, Information Needed to Set-up a New Account	Anda_Opioids_MDL_0000036519	Anda_Opioids_MDL_0000036521		
P-01609	11/7/2007	FW: Distributor Notification	Anda_Opioids_MDL_0000038787	Anda_Opioids_MDL_0000038794		
P-01610	2/20/2012	RE: Oxycodone ordering; Rite Aid Store 10440 11192011 to 02172012	Anda_Opioids_MDL_0000111930	Anda_Opioids_MDL_0000111933		
P-01611	4/17/2007	Email Spring Promo 2007	Anda_Opioids_MDL_0000061184	Anda_Opioids_MDL_0000061185		
P-01612	10/19/2010	RE: 798 total product usage 3 mo	Anda_Opioids_MDL_0000070701	Anda_Opioids_MDL_0000070702		
P-01613	12/8/2010	RE: Account#476453 Attachment Richard Clyde Strockbine 1115	Anda_Opioids_MDL_0000076476	Anda_Opioids_MDL_0000076480		
P-01614	6/21/2010	RE: Rep Impact - accounts cut off from controls	Anda_Opioids_MDL_0000077648	Anda_Opioids_MDL_0000077650		
P-01615	7/24/2009	Re: Bi Mart - CSOS roll out - Max Limit Request	Anda_Opioids_MDL_0000077935	Anda_Opioids_MDL_0000077939		
P-01616	7/24/2009	Re: Approval	Anda_Opioids_MDL_0000077958	Anda_Opioids_MDL_0000077960		
P-01617	11/12/2015	Letter to Robert Brown to Ronald Buzzeo Re: ANDA SOM Review Nov 2015 v 2	Anda_Opioids_MDL_0000093629	Anda_Opioids_MDL_0000093639		
P-01618	3/16/2009	Fw: Assured Pharmacy new Chief Compliance Officer	Anda_Opioids_MDL_0000078156	Anda_Opioids_MDL_0000078158		

P-01619	12/3/2007	Email Re: Fw: KeySource Info	Anda_Opioids_MDL_0000078211	Anda_Opioids_MDL_0000078212		
P-01620	2/9/2010	Email Suspicious Orders; Attachment OPS 40- Anda SOP SOM	Anda_Opioids_MDL_0000078286	Anda_Opioids_MDL_0000078288		
P-01621	7/24/2012	RE: 2 Record Request	Anda_Opioids_MDL_0000078355	Anda_Opioids_MDL_0000078363		
P-01622	2/7/2012	Email Re: Drug City Pharmacy (MD) info to DEA	Anda_Opioids_MDL_0000078400	Anda_Opioids_MDL_0000078401		
P-01623	2/7/2012	Email Re: Drug City Pharmacy (MD) info to DEA	Anda_Opioids_MDL_0000078404	Anda_Opioids_MDL_0000078405		
P-01624	7/14/2010	Fw: Discussion Strategy document Attachment DEA Discussion Strategy Bullets	Anda_Opioids_MDL_0000108116	Anda_Opioids_MDL_0000108117		
P-01625	6/18/2010	Email Remedy CSOS Profile Related Question Pertaining to Anita's Account List: Sales for accounts cut off from controls; Attachment Control Sales - Customers Cut Off 061710	Anda_Opioids_MDL_0000078673	Anda_Opioids_MDL_0000078675		
P-01626	10/28/2011	RE: Suspicious Hold	Anda_Opioids_MDL_0000079269	Anda_Opioids_MDL_0000079274		
P-01627	6/28/2011	RE: FL HB 7905 Attachment DUE DILIGENCE PROGRAM OVERVIEW 2010; Policy 0.17 Due Diligence Program; LEVEL 3 - .0077 2011 Compliance Agreement; LEVEL 3 - .0075 QCP DEA DUE DILIGENCE QUESTIONNAIRE 20101022	Anda_Opioids_MDL_0000079594	Anda_Opioids_MDL_0000079604		
P-01628	4/14/2010	FW: QCP Business Increase and Allocation	Anda_Opioids_MDL_0000079605	Anda_Opioids_MDL_0000079606		
P-01629	4/16/2013	Email Conference - Cardinal SOM Program	Anda_Opioids_MDL_0000080620	Anda_Opioids_MDL_0000080620		
P-01630	3/7/2012	Email RA- Top 100 Products for Top 100 Stores Review (Combined with Misc Random Research) Attachment sharp.copier@watson.com 20120307 002711	Anda_Opioids_MDL_0000081549	Anda_Opioids_MDL_0000081587		
P-01631	11/5/2010	Anda Standard Operating Procedure 040	Anda_Opioids_MDL_0000082105	Anda_Opioids_MDL_0000082107		
P-01632	6/20/2012	RE: Actavis Match to Anda Attachment Actavis Master Match File Anda_RetailTargets_6_18_12_Controlled Substances 2	Anda_Opioids_MDL_0000082451	Anda_Opioids_MDL_0000082457		
P-01633	12/19/2011	RE: Customer 40008 - PILE DRUG STORE	Anda_Opioids_MDL_0000082857	Anda_Opioids_MDL_0000082858		
P-01634	12/13/2011	Email Acct # 206406	Anda_Opioids_MDL_0000082864	Anda_Opioids_MDL_0000082864		
P-01635	11/30/2011	Email with Anda draft response letter to the DEA	Anda_Opioids_MDL_0000082872	Anda_Opioids_MDL_0000082874		
P-01636	12/5/2014	RE: WH/Freight Hold ORR890	Anda_Opioids_MDL_0000084233	Anda_Opioids_MDL_0000084237		
P-01637	8/26/2014	Standard Operating Procedure 28, Information Needed to Set-up a New Account	Anda_Opioids_MDL_0000084434	Anda_Opioids_MDL_0000084437		
P-01638	8/26/2014	Standard Operating Procedure 40, Orders of Interest Monitoring System/Suspicious Order Monitoring	Anda_Opioids_MDL_0000084445	Anda_Opioids_MDL_0000084445		
P-01639	9/10/2014	Email Follow Up Items Attachment SOP 028-Information Needed to Set-up a New Account; SOP 040-Suspicious Order Monitoring System; Percentage Breakdown Overall and By Facility	Anda_Opioids_MDL_0000084481	Anda_Opioids_MDL_0000084488		
P-01640	4/10/2013	Fw: Rite Aid Presentation; Compliance Assistance Program PPT	Anda_Opioids_MDL_0000085419	Anda_Opioids_MDL_0000085420		
P-01642	9/11/2012	Email Example Attachment Calculation Example	Anda_Opioids_MDL_0000085935	Anda_Opioids_MDL_0000085936		
P-01643	7/19/2012	Fw: 2Record Request Attachment 491878DD; 491878 CQ	Anda_Opioids_MDL_0000086181	Anda_Opioids_MDL_0000086233		
P-01644	7/13/2012	Fw: Rite Aid	Anda_Opioids_MDL_0000086344	Anda_Opioids_MDL_0000086345		
P-01645	6/24/2014	RE: Actavis Brand CII Launch Review - MoxDuo	Anda_Opioids_MDL_0000086469	Anda_Opioids_MDL_0000086470		
P-01646	6/14/2012	RE: attached controlled info 2nd attempt	Anda_Opioids_MDL_0000086482	Anda_Opioids_MDL_0000086487		
P-01647	7/30/2013	Email Customer Questionnaire & Dispensed Data Required 7/31 - With Net Sales Attachment CQ DD Project with deadline 073013	Anda_Opioids_MDL_0000089123	Anda_Opioids_MDL_0000089124		
P-01648	3/4/2013	Re: Loading Walgreens Limits	Anda_Opioids_MDL_0000089949	Anda_Opioids_MDL_0000089949		
P-01649	2/25/2013	FW: Rite Aid	Anda_Opioids_MDL_0000090003	Anda_Opioids_MDL_0000090003		
P-01650	2/25/2013	Anda Rite Aid sales by state analysis	Anda_Opioids_MDL_0000090004	Anda_Opioids_MDL_0000090004		
P-01651	2/19/2013	Re: Customer's Not Actively Purchasing Controls (July 12 thru Jan 13)	Anda_Opioids_MDL_0000090024	Anda_Opioids_MDL_0000090025		
P-01652	11/28/2012	FW: Walgreens State Controls Summaries Attachment #WALGREENS_ANALYSIS-STATES; Walgreens Map Control Percent Flagged	Anda_Opioids_MDL_0000090454	Anda_Opioids_MDL_0000090456		
P-01653	7/19/2012	FW: MD letter for Anda Compliance Dept- United pharmacy #111507	Anda_Opioids_MDL_0000090805	Anda_Opioids_MDL_0000090807		
P-01654	7/10/2012	FW: MD letter for Anda Compliance Dept- United pharmacy #111508	Anda_Opioids_MDL_0000090857	Anda_Opioids_MDL_0000090858		
P-01655	6/19/2012	Email: Actavis Brand CII Launch Review - MoxDuo	Anda_Opioids_MDL_0000090905	Anda_Opioids_MDL_0000090907		
P-01656	7/1/2012	Authorized Distributor Agreement between Purdue and Anda	Anda_Opioids_MDL_0001097748	Anda_Opioids_MDL_0001097781		

P-01657	7/6/2012	Letter from University Neurology Associates to United Pharmacy	Anda_Opioids_MDL_0000090908	Anda_Opioids_MDL_0000090908		
P-01658	6/10/2012	Email Fwd: Oxy & Harvard	Anda_Opioids_MDL_0000091168	Anda_Opioids_MDL_0000091176		
P-01659	6/1/2012	Email and Attachments SOP 028-information Needed to Set-up a New Account; SOP 040-Suspicious Order Monitoring Order Monitoring System; SOP 045-Remedy Review Process	Anda_Opioids_MDL_0000091399	Anda_Opioids_MDL_0000091410		
P-01660	6/11/2014	Re: Best Care Pharm JOE 59213	Anda_Opioids_MDL_0000102893	Anda_Opioids_MDL_0000102896		
P-01661	7/13/2010	Email Continuing Education Documents --- Controlled Substances, Attachment Internal Communication - Control Update; 2 - Therapeutic Categories; Fax and Email Policy v2010; Do's And Don'ts v2010; AndaNet.AndaMeds.VipPharm Access Doc v2010; Acknowledgement of Receipt v2010	Anda_Opioids_MDL_0000104946	Anda_Opioids_MDL_0000104960		
P-01662	3/6/2012	Email: Additional Data Requested Attachment Store 10440 Data 3-5-12; Controlled Substance Purchasing Limits	Anda_Opioids_MDL_0000104996	Anda_Opioids_MDL_0000105009		
P-01663	7/18/2012	Email 2 Record Request	Anda_Opioids_MDL_0000105695	Anda_Opioids_MDL_0000105695		
P-01664	3/9/2011	Email Epic - Accounts Ineligible for Controls Attachment Epic Customers Gut-Off	Anda_Opioids_MDL_0000107744	Anda_Opioids_MDL_0000107746		
P-01665	2/11/2010	Anda/VIP CII Product Listing	Anda_Opioids_MDL_0000108234	Anda_Opioids_MDL_0000108243		
P-01666	2/23/2011	Are you ready for CSOC?	Anda_Opioids_MDL_0000109069	Anda_Opioids_MDL_0000109074		
P-01667	10/4/2010	FW: 210582 Neighborcare Cii order snafu	Anda_Opioids_MDL_0000109243	Anda_Opioids_MDL_0000109245		
P-01668	9/24/2010	RE: LIMIT INCREASE ACCT 51180	Anda_Opioids_MDL_0000109326	Anda_Opioids_MDL_0000109331		
P-01669	5/25/2010	Anda promotional flyer for a sale on 10 and 20 mg OxyContin	Anda_Opioids_MDL_0000110042	Anda_Opioids_MDL_0000110042		
P-01670	5/18/2010	Email thing Attachment Business justification JAY ALBERTO MIKE	Anda_Opioids_MDL_0000110043	Anda_Opioids_MDL_0000110044		
P-01671	6/30/2009	Anda/VIP Back in Stock Promotion for Oxycodone	Anda_Opioids_MDL_0000111235	Anda_Opioids_MDL_0000111235		
P-01672	12/13/2011	RE: ANDA's DEA inspection - Requested Information - URGENT CUSTOMER QUESTIONNAIRE 111611; SOP 028-information Needed to Set-up a New Account	Anda_Opioids_MDL_0000112251	Anda_Opioids_MDL_0000112259		
P-01673	6/22/2016	Email FINAL compliance docs for meeting tomorrow - BARB PLEASE SEND Attachments Anda Compliance overview for Teva meeting 6-22-2016; Anda Compliance overview for Teva meeting 6-22-2016; [15.3] DEA Letter; [15.3] DEA Response to Gayle Lane	Anda_Opioids_MDL_0000132043	Anda_Opioids_MDL_0000132066		
P-01674	12/4/2011	RE: DEA Meeting	Anda_Opioids_MDL_0000133096	Anda_Opioids_MDL_0000133097		
P-01675	12/2/2011	Fw: Draft response to DEA LOA	Anda_Opioids_MDL_0000133111	Anda_Opioids_MDL_0000133113		
P-01676	9/7/2011	FW: Remedy - Control Requests	Anda_Opioids_MDL_0000133286	Anda_Opioids_MDL_0000133287		
P-01677	3/29/2011	Email FW:	Anda_Opioids_MDL_0000133445	Anda_Opioids_MDL_0000133446		
P-01678	4/15/2011	RE: Suspicious Customer's Cut Off	Anda_Opioids_MDL_0000134998	Anda_Opioids_MDL_0000134998		
P-01679	2/26/2015	RE: Anda, Inc (Corporate) - 1st P&P Review Report Attachment VAWD.PP1 .Andax; AS400 Security; C-145 Employee Performance Conduct; E-135 Job Evaluation; SOP 036-New Vendor Set-up; SOP 005-Temperature Monitoring; SOP 046-CS Lost In Transit; SOP 028-information Needed to Set-up a New Account; SOP 026-Receiving Procedure; SOP 040-Suspicious Order Monitoring System; SOP 006-Vendor Returns	Anda_Opioids_MDL_0000140430	Anda_Opioids_MDL_0000140497		
P-01680	4/25/2013	Distribution and Supply Agreement By and Between Purdue Pharma L.P., and Watson Pharma, Inc.	Anda_Opioids_MDL_0000122223	Anda_Opioids_MDL_0000122272		
P-01681	8/22/2016	Email SOMS-Held Orders	Anda_Opioids_MDL_0000141492	Anda_Opioids_MDL_0000141492		
P-01682	9/22/2016	Fwd: Current Suspicious Order SOPs and attachments	Anda_Opioids_MDL_0000143508	Anda_Opioids_MDL_0000143569		
P-01683	2/2/2018	Anda Standard Operating Procedure 065, Description of Anda's SOM Statistical Model	Anda_Opioids_MDL_0000144364	Anda_Opioids_MDL_0000144397		
P-01684	3/4/2017	Anda Standard Operating Procedure 040, Suspicious Order Monitoring	Anda_Opioids_MDL_0000144378	Anda_Opioids_MDL_0000144380		
P-01685	10/31/2017	Anda Standard Operating Procedure 064, Suspicious Accounting Reporting	Anda_Opioids_MDL_0000144381	Anda_Opioids_MDL_0000144383		
P-01686	2/26/2018	Anda Standard Operating Procedure 028, Customer Due Diligence	Anda_Opioids_MDL_0000144398	Anda_Opioids_MDL_0000144401		
P-01687	12/15/2016	RE: Bucket	Anda_Opioids_MDL_0000147166	Anda_Opioids_MDL_0000147167		
P-01688	11/3/2017	FW: Questions regarding compliance decisions	Anda_Opioids_MDL_0000150162	Anda_Opioids_MDL_0000150163		



P-01689	12/10/2018	Performance and Development Process (P.D.P), Jay Spellman	Anda_Opioids_MDL_0000152155	Anda_Opioids_MDL_0000152155		
P-01690	7/24/2008	Re: Customer Limitations by Controlled Substance Chemical Family Attachment Anda Interoffice Memorandum Control Substance Reviews	Anda_Opioids_MDL_0000152299	Anda_Opioids_MDL_0000152302		
P-01691	11/5/2008	Re: Doug Towle	Anda_Opioids_MDL_0000153642	Anda_Opioids_MDL_0000153642		
P-01692	2/21/2006	Re: DEA CSOS Report Request	Anda_Opioids_MDL_0000155184	Anda_Opioids_MDL_0000155184		
P-01693	9/13/2007	Email HOMA Update and RAC Conference Call Cancellation Notice	Anda_Opioids_MDL_0000194634	Anda_Opioids_MDL_0000194636		
P-01694	11/9/2007	Re: Approval	Anda_Opioids_MDL_0000258572	Anda_Opioids_MDL_0000258572		
P-01695	11/9/2007	Re: Harvard	Anda_Opioids_MDL_0000258573	Anda_Opioids_MDL_0000258573		
P-01697	8/6/2007	Email Suspicious Orders Week Ending 8-5-07; Attachments Suspicious Week Ending 8-5-07 Wholesalers; Suspicious Week Ending 8-5-07 Pharmacy	Anda_Opioids_MDL_0000271616	Anda_Opioids_MDL_0000271618		
P-01698	2/12/2007	Email Suspicious Orders Week Ending 2-11-07 Attachments Suspicious Week Ending 2-11-07 Wholesalers; Suspicious Week Ending 2-11-07 Pharmacy	Anda_Opioids_MDL_0000271689	Anda_Opioids_MDL_0000271691		
P-01699	2/8/2006	Email Excessive Orders Week Ending January 2006 Attachment Excessive Order Report January 2006	Anda_Opioids_MDL_0000271861	Anda_Opioids_MDL_0000271862		
P-01700	12/7/2005	Email Excessive Orders Week Ending November 2005 Attachment Excessive Order Report November 2005	Anda_Opioids_MDL_0000271895	Anda_Opioids_MDL_0000271896		
P-01701	10/10/2005	Email Suspicious Orders Week Ending 10-9-05 Attachment Suspicious Week Ending 10-9-05 Wholesalers; Suspicious Week Ending 10-9-05 Pharmacy	Anda_Opioids_MDL_0000271912	Anda_Opioids_MDL_0000271914		
P-01703	12/11/2007	Email Changing Anda Customer Types	Anda_Opioids_MDL_0000272207	Anda_Opioids_MDL_0000272208		
P-01704	10/31/2007	Suspicious Orders PPT	Anda_Opioids_MDL_0000280987	Anda_Opioids_MDL_0000280992		
P-01705	12/11/2007	Email Re: Fw: Distributor Notification and attachment	Anda_Opioids_MDL_0000272213	Anda_Opioids_MDL_0000272216		
P-01706	2/26/2008	Email Re: Fw: united #111507 & medical mall # 440269	Anda_Opioids_MDL_0000272517	Anda_Opioids_MDL_0000272519		
P-01707	2/21/2008	Email Re: Fw: united #111507 & medical mall # 440269	Anda_Opioids_MDL_0000272520	Anda_Opioids_MDL_0000272520		
P-01708	9/9/2008	Email Re: Approval - Oxy Order for Super Value/Advantage Logistics	Anda_Opioids_MDL_0000273292	Anda_Opioids_MDL_0000273293		
P-01709	6/25/2008	Email Re: Need Approval - haven't seen approval come thru yet -	Anda_Opioids_MDL_0000273518	Anda_Opioids_MDL_0000273518		
P-01710	6/17/2008	Re: Approval	Anda_Opioids_MDL_0000273585	Anda_Opioids_MDL_0000273586		
P-01711	6/13/2008	Email Re: Need Approval	Anda_Opioids_MDL_0000273617	Anda_Opioids_MDL_0000273617		
P-01712	5/28/2008	Email Re: Need approval - Per Michael resend for approval	Anda_Opioids_MDL_0000273762	Anda_Opioids_MDL_0000273762		
P-01713	11/14/2007	Re: Fw FMC ACCT 400212	Anda_Opioids_MDL_0000274287	Anda_Opioids_MDL_0000274288		
P-01714	11/1/2007	Email OXYCODONE FAMILY LIMITS REVIEW Attachment Narcotic Product Family Listing 110107	Anda_Opioids_MDL_0000274353	Anda_Opioids_MDL_0000274355		
P-01715	10/16/2007	Fw Distributor Notification	Anda_Opioids_MDL_0000274531	Anda_Opioids_MDL_0000274532		
P-01716	9/18/2007	Email Re: Approval for Account 127978	Anda_Opioids_MDL_0000274800	Anda_Opioids_MDL_0000274800		
P-01717	8/24/2007	Email Re: Approval	Anda_Opioids_MDL_0000275048	Anda_Opioids_MDL_0000275048		
P-01718	8/10/2007	Re: Fw: Final Questionnaire and Cover Letter	Anda_Opioids_MDL_0000275445	Anda_Opioids_MDL_0000275455		
P-01719	7/17/2007	Re: Internal and External Communication	Anda_Opioids_MDL_0000275725	Anda_Opioids_MDL_0000275729		
P-01720	5/6/2008	Email Kyle Wright - SOMS	Anda_Opioids_MDL_0000276096	Anda_Opioids_MDL_0000276097		
P-01721	4/30/2008	Re: Fw Suspicious/Daily Reports	Anda_Opioids_MDL_0000276111	Anda_Opioids_MDL_0000276113		
P-01722	4/10/2008	Re: Fw- Daily Submissions	Anda_Opioids_MDL_0000276122	Anda_Opioids_MDL_0000276129		
P-01723	12/27/2007	DEA Letter to Anda from DEA	Anda_Opioids_MDL_0000276156	Anda_Opioids_MDL_0000276157		
P-01724	10/16/2007	Re: Fw Distributor Notification	Anda_Opioids_MDL_0000276197	Anda_Opioids_MDL_0000276199		
P-01725	9/26/2007	Email DEA/Industry Conference Report Attachment DEA & Industry Seminar Sept 2007	Anda_Opioids_MDL_0000276207	Anda_Opioids_MDL_0000276212		
P-01726	6/4/2008	FW - Ltr of Admonition response for DEA Attachment LAKEER-1; 0604125609 001	Anda_Opioids_MDL_0000276293	Anda_Opioids_MDL_0000276299		
P-01727	7/24/2008	Re: Customer Limitations by Controlled Substance Chemical Family	Anda_Opioids_MDL_0000276731	Anda_Opioids_MDL_0000276733		
P-01728	7/24/2008	Anda Controlled Substance Review Interoffice Memo Re: Controlled Substance Reviews	Anda_Opioids_MDL_0000276734	Anda_Opioids_MDL_0000276734		
P-01729	6/17/2008	Re: SOMs to DEA HQ	Anda_Opioids_MDL_0000276927	Anda_Opioids_MDL_0000276927		
P-01730	7/27/2007	Email Rough Draft Attachment Standard Operation Procedure 40	Anda_Opioids_MDL_0000276962	Anda_Opioids_MDL_0000276964		
P-01732	5/21/2010	Standard Operating Procedure & Revision History; OPS-035-01	Anda_Opioids_MDL_0000277385	Anda_Opioids_MDL_0000277386		

P-01733	5/21/2010	Anda Standard Operating Procedure OPS-028-03, Information Needed to Set up a New Account	Anda_Opioids_MDL_0000277387	Anda_Opioids_MDL_0000277390		
P-01734	10/22/2010	Email Re: Customer Control Limit Increases	Anda_Opioids_MDL_0000278594	Anda_Opioids_MDL_0000278615		
P-01735	9/10/2007	Summary of the DEA-HDMA Meeting on Suspicious Orders	Anda_Opioids_MDL_0000280939	Anda_Opioids_MDL_0000280940		
P-01736	6/15/2010	Fw: Scanned image from MX-SSOON Attachment The Detroit News, Feds suspect license of Harvard Drug group over painkiller sales	Anda_Opioids_MDL_0000281678	Anda_Opioids_MDL_0000281680		
P-01737	6/29/2010	FW: DEA Meeting OPS 40- Anda- SOP SOM	Anda_Opioids_MDL_0000281694	Anda_Opioids_MDL_0000281696		
P-01738	6/17/2010	RE: MASS UPDATE customer master#	Anda_Opioids_MDL_0000281703	Anda_Opioids_MDL_0000281703		
P-01739	6/22/2010	FW: DEA Meeting OPS 40- Anda- SOP SOM	Anda_Opioids_MDL_0000281704	Anda_Opioids_MDL_0000281706		
P-01740	2/3/2010	Re: SOP's	Anda_Opioids_MDL_0000282932	Anda_Opioids_MDL_0000282932		
P-01741	10/25/2007	Re: Approval	Anda_Opioids_MDL_0000282942	Anda_Opioids_MDL_0000282942		
P-01742	5/21/2010	Email seeking controls threshold increase	Anda_Opioids_MDL_0000283018	Anda_Opioids_MDL_0000283019		
P-01743	4/21/2010	Re: Approval	Anda_Opioids_MDL_0000283178	Anda_Opioids_MDL_0000283178		
P-01744	2/12/2009	Re: Partners	Anda_Opioids_MDL_0000284363	Anda_Opioids_MDL_0000284364		
P-01745	5/10/2011	Email Customer Cut Off Attachment Customers Cut Off	Anda_Opioids_MDL_0000286549	Anda_Opioids_MDL_0000286550		
P-01746	6/12/2009	Email Re: Approval	Anda_Opioids_MDL_0000287964	Anda_Opioids_MDL_0000287964		
P-01748	2/21/2018	Email ANDA Updated List of Reportable Customers as of February 21, 2018 Attachment Anda Customers to be Reported February 21 2018	Anda_Opioids_MDL_0000307230	Anda_Opioids_MDL_0000307231		
P-01749	7/12/2017	FW: Senate letter to DEA on production quotas for schedule II opioids	Anda_Opioids_MDL_0000316783	Anda_Opioids_MDL_0000316783		
P-01750	4/19/2012	15th Annual Controlled Substance, PDMA and State Conference, It's What You Know and Who You Know by Linden Barber PPT	Anda_Opioids_MDL_0000476052	Anda_Opioids_MDL_0000476080		
P-01751	9/12/2016	Email Held Orders: Week of Aug. 29 & Sept 6th	Anda_Opioids_MDL_0000332270	Anda_Opioids_MDL_0000332270		
P-01752	6/22/2015	RE: Request Attachment HELD ORDERS FOR DEA	Anda_Opioids_MDL_0000335585	Anda_Opioids_MDL_0000335587		
P-01753	12/9/2013	RE: Bucket	Anda_Opioids_MDL_0000339315	Anda_Opioids_MDL_0000339316		
P-01754	12/9/2013	RE: Bucket	Anda_Opioids_MDL_0000339317	Anda_Opioids_MDL_0000339317		
P-01755	5/20/2013	Email SOMS outline Attachment SOMS review 052013	Anda_Opioids_MDL_0000341339	Anda_Opioids_MDL_0000341341		
P-01756	5/9/2013	Email Accts-Control Flag -Y Attachment Accts with access to controls and No CQ 050913	Anda_Opioids_MDL_0000341486	Anda_Opioids_MDL_0000341487		
P-01757	10/18/2012	Email Chain Pharmacy Letter revised; CUSTOMER COMPLIANCE REVIEW CRITERIAx; CUSTOMER QUESTIONNAIRE 111611x; CUSTOMER QUESTIONNAIRE on remedy 10042012x; CUSTOMER QUESTIONNAIRE ON-SITE REVIEWx; Letter For Additional Information CS ACTIVEx; SOP 028-information Needed to Set-up a New Account; Letter for Additional Information CS TERM; SOP 040-Suspicious Order Monitoring Order Monitoring System; SOP 045-Remedy Review Process	Anda_Opioids_MDL_0000349594	Anda_Opioids_MDL_0000349622		
P-01758	10/31/2012	Email Control Product & Family List Attachment CONTROL_LIST 2012_08_07	Anda_Opioids_MDL_0000349665	Anda_Opioids_MDL_0000349666		
P-01759	10/19/2016	Email Notes Attachment Customer Questionnaire Project	Anda_Opioids_MDL_0000350910	Anda_Opioids_MDL_0000350911		
P-01760	10/15/2013	Email Just FYI Attachment Customer Questionnaire Project	Anda_Opioids_MDL_0000351076	Anda_Opioids_MDL_0000351077		
P-01761	8/22/2013	FW: Timeline Attachment CQ Project 2013	Anda_Opioids_MDL_0000351121	Anda_Opioids_MDL_0000351123		
P-01762	2/6/2016	Anda Standard Operating Procedure 028, Customer Due Diligence	Anda_Opioids_MDL_0000398204	Anda_Opioids_MDL_0000398207		
P-01763	7/31/2014	FW: 450176: 2 S Drug Mart	Anda_Opioids_MDL_0000415442	Anda_Opioids_MDL_0000415442		
P-01764	3/18/2014	Email Notes	Anda_Opioids_MDL_0000416492	Anda_Opioids_MDL_0000416493		
P-01765	3/5/2014	Email Customer Cut Off - Dispensing Data Not Provided	Anda_Opioids_MDL_0000416637	Anda_Opioids_MDL_0000416637		
P-01766	8/7/2013	RE: Urgent: Anda MidYear Controlled Substance Customer Questionnaire 7-15-2013 2 0	Anda_Opioids_MDL_0000418546	Anda_Opioids_MDL_0000418547		
P-01767	8/7/2013	Controlled Substances Follow Up Customer Questionnaire	Anda_Opioids_MDL_0000418548	Anda_Opioids_MDL_0000418550		



P-01768	7/18/2013	Email Customers Not Actively Purchasing Controls; Attachment (Dominic) Not Actively Purchasing Controls Jan thru June 13 (Sales)	Anda_Opioids_MDL_0000418832	Anda_Opioids_MDL_0000418834		
P-01769	7/18/2013	FW: Customer Questionnaire Meeting: Follow-Up Info; Attachments CQ & DD Project (Dec thru May 13 Sales breakdown PAD; CO & DD Project with deadline 061913 (Rep & Mgr)	Anda_Opioids_MDL_0000418852	Anda_Opioids_MDL_0000418854		
P-01770	7/8/2013	FW: Customer Questionnaire Meeting: Follow-Up Info; Attachments CQ & DD Project (Dec thru May 13 Sales breakdown PAD; CO & DD Project with deadline 061913 (Rep & Mgr)	Anda_Opioids_MDL_0000419072	Anda_Opioids_MDL_0000419075		
P-01771	4/26/2013	FW: SOMS order- 803415 PRESCRIPTION CENTER PHARMACIES	Anda_Opioids_MDL_0000419725	Anda_Opioids_MDL_0000419726		
P-01772	12/19/2012	RE: FYI Safeway (154132) -	Anda_Opioids_MDL_0000421668	Anda_Opioids_MDL_0000421670		
P-01773	10/23/2012	RE: Request for Clonazepam increase new QOL Meds location	Anda_Opioids_MDL_0000422114	Anda_Opioids_MDL_0000422117		
P-01774	7/3/2012	Email Acct #389613	Anda_Opioids_MDL_0000423540	Anda_Opioids_MDL_0000423540		
P-01775	4/13/2015	RE: Report: HEB DAILY CONTROL LIMIT REPORT (delivered daily) ms	Anda_Opioids_MDL_0000425692	Anda_Opioids_MDL_0000425693		
P-01776	1/11/2013	Email Added: DD report to O:drive (TPS: 66351)**No controls ever**	Anda_Opioids_MDL_0000453833	Anda_Opioids_MDL_0000453833		
P-01777	10/23/2012	RE: 825257	Anda_Opioids_MDL_0000460932	Anda_Opioids_MDL_0000460932		
P-01778	5/8/2013	SOMS/Data Analysis notes	Anda_Opioids_MDL_0000474368	Anda_Opioids_MDL_0000474369		
P-01779	6/15/2017	Email News	Anda_Opioids_MDL_0000485846	Anda_Opioids_MDL_0000485846		
P-01780	2/28/2017	Email FW: SOM Cloud User Manual; QuintilesIMS, US Compliance (Formerly BUZZEROPDMA) Cloud-Based Suspicious Order Monitoring System Users Manual	Anda_Opioids_MDL_0000489218	Anda_Opioids_MDL_0000489263		
P-01781	5/13/2013	Email Trends: Pills to Heroin; Attachment Article, As Pill Mills Fade Away, Heroin Fills the Void	Anda_Opioids_MDL_0000493332	Anda_Opioids_MDL_0000493336		
P-01782	11/11/2013	RE: Order #21212859/Acct #319849 - WAKE FOREST DRUG, INC	Anda_Opioids_MDL_0000493357	Anda_Opioids_MDL_0000493359		
P-01783	11/5/2013	RE: 087298: Star Pharmacy	Anda_Opioids_MDL_0000493634	Anda_Opioids_MDL_0000493635		
P-01784	12/13/2016	Email IMeetingNotes_2016-12-13_CS1: Controls Program; Attachment CSIPilot_AllAccounts_120916	Anda_Opioids_MDL_0000525995	Anda_Opioids_MDL_0000525997		
P-01785	9/9/2016	FW: Current Suspicious Order SOPs	Anda_Opioids_MDL_0000527935	Anda_Opioids_MDL_0000527938		
P-01787	8/30/2016	Email Held Orders: Week of August 22, 2016	Anda_Opioids_MDL_0000528119	Anda_Opioids_MDL_0000528119		
P-01788	11/13/2015	Email Revised Report	Anda_Opioids_MDL_0000539140	Anda_Opioids_MDL_0000539150		
P-01789	9/30/2016	RE: current Suspicious Order SOPs Attachment Actions on Pended Orders and Accounts V 1 o september 2016; Anda's Culture of Compliance v1 o September 2016; Due Diligence on New and Existing Customers V1 o September 2016	Anda_Opioids_MDL_0000540546	Anda_Opioids_MDL_0000540560		
P-01790	9/27/2006	Letter from DEA to Anda to reiterate the responsibilities of controlled substance distributors in view of the prescription drug abuse problem our nation currently faces	Anda_Opioids_MDL_0000540738	Anda_Opioids_MDL_0000540741		
P-01791	5/20/2016	RE: Updated List of Customers Not Eligible to Purchase Controls from Anda; Attachment Copy of Customers Cut Off	Anda_Opioids_MDL_0000543135	Anda_Opioids_MDL_0000543136		
P-01792	11/9/2015	FW: National Accounts Pipeline Attachment National Accounts Opportunity Master Pipeline 11-09-15	Anda_Opioids_MDL_0000546477	Anda_Opioids_MDL_0000546478		
P-01793	6/22/2012	Re: Status Update: Collect Dispensing Data - Shared Accounts (Buying Groups)	Anda_Opioids_MDL_0000554323	Anda_Opioids_MDL_0000554325		
P-01794	12/9/2013	RE: Glenn Burnie Pharmacist Settlement-Abuse Updates	Anda_Opioids_MDL_0000560658	Anda_Opioids_MDL_0000560660		
P-01795	5/10/2013	FW: Anda Walgreens Control Report as of 05/08/2013; Attachments 05092013_AndaWalgreensControlReport; FLORI DA_C I_LIM ITS_-IT FINAL_0405131 (1); Limits_Boston_IT File(Revised Limits); WALGREENS REQUEST FOR LIMIT INCREASE	Anda_Opioids_MDL_0000566449	Anda_Opioids_MDL_0000566453		
P-01797	11/27/2012	Anda Incorporated, Anda Overview, Celebrating 20 Years	Anda_Opioids_MDL_0000570925	Anda_Opioids_MDL_0000570944		
P-01798	2/7/2007	Letter from DEA to Anda to reiterate the responsibilities of controlled substance distributors in view of the prescription drug abuse problem our nation currently faces	Anda_Opioids_MDL_0000571720	Anda_Opioids_MDL_0000571723		
P-01799	8/18/2014	FW: AUDIT - Top Customers; Attachment Sales Customer Jan thru Jun 2014	Anda_Opioids_MDL_0000601903	Anda_Opioids_MDL_0000601905		
P-01800	9/10/2008	Email Supervalu	Anda_Opioids_MDL_0000610041	Anda_Opioids_MDL_0000610042		

P-01801	10/26/2007	Re: 60 days dating for first time c2 customers & Dava Oxy	Anda_Opioids_MDL_0000610161	Anda_Opioids_MDL_0000610161		
P-01802	3/1/2007	Re: extended dating TPS#4744/JDE#8600	Anda_Opioids_MDL_0000610178	Anda_Opioids_MDL_0000610184		
P-01803	12/12/2008	Email C2 Promo with Teva Fentanyl Patches...	Anda_Opioids_MDL_0000610875	Anda_Opioids_MDL_0000610875		
P-01804	2/26/2008	Fw Cardinal-Stafford, Texas	Anda_Opioids_MDL_0000611101	Anda_Opioids_MDL_0000611104		
P-01805	11/1/2007	Email OXYCODONE FAMILY LIMITS REVIEW Attachment Narcotic Product Family Listing 110107	Anda_Opioids_MDL_0000611188	Anda_Opioids_MDL_0000611189		
P-01806	4/12/2007	Re: Spring Promo 2007 - Please review and approve	Anda_Opioids_MDL_0000611326	Anda_Opioids_MDL_0000611327		
P-01807	2/23/2007	Email CSOS Update 2/23/07	Anda_Opioids_MDL_0000611409	Anda_Opioids_MDL_0000611410		
P-01808	2/21/2007	Anda Oxycodone 5% Off Promotion	Anda_Opioids_MDL_0000611413	Anda_Opioids_MDL_0000611413		
P-01809	2/1/2007	Anda Sales Promotion	Anda_Opioids_MDL_0000611426	Anda_Opioids_MDL_0000611426		
P-01810	2/17/2009	Re: Fw jim w - reminder for anda to achieve \$22m/qtr manuf - exec agreement of emphasis on hydrocodone and oc's	Anda_Opioids_MDL_0000611531	Anda_Opioids_MDL_0000611533		
P-01811	2/22/2007	Re: Fw: Watson Oxycodone HCL ER Update 2/22/07	Anda_Opioids_MDL_0000612614	Anda_Opioids_MDL_0000612614		
P-01812	2/22/2017	Email Watson Oxycodone HCL ER Update 2/22/07	Anda_Opioids_MDL_0000612615	Anda_Opioids_MDL_0000612616		
P-01813	4/23/2007	Email Audit Committee presentation	Anda_Opioids_MDL_0000612947	Anda_Opioids_MDL_0000612947		
P-01814	4/27/2007	Audit Committee Q1 2077 Financial Review PPT	Anda_Opioids_MDL_0000612948	Anda_Opioids_MDL_0000612971		
P-01815	7/13/2007	Email Anda questionnaire 2Q07	Anda_Opioids_MDL_0000613280	Anda_Opioids_MDL_0000613280		
P-01816	6/26/2007	Watson Memo to Tom Russillo, from Patty Elsenhour Re: Business Update 2Q 2007	Anda_Opioids_MDL_0000613281	Anda_Opioids_MDL_0000613285		
P-01817	4/18/2008	Re: Q1 Association dub	Anda_Opioids_MDL_0000613774	Anda_Opioids_MDL_0000613775		
P-01818	11/8/2007	Fw: WPI Unexciting Quarter While in Transition	Anda_Opioids_MDL_0000613997	Anda_Opioids_MDL_0000613998		
P-01819	3/17/2009	Leadership Meeting Minutes	Anda_Opioids_MDL_0000614431	Anda_Opioids_MDL_0000614435		
P-01820	5/15/2008	Re: Fw Consolidated Daily Sales for Anda & VIP through 5/13	Anda_Opioids_MDL_0000614720	Anda_Opioids_MDL_0000614725		
P-01821	5/8/2008	Fw Drug Channels - Stark News from Cardinal and McKesson	Anda_Opioids_MDL_0000615345	Anda_Opioids_MDL_0000615347		
P-01822	5/2/2008	Re: Fw Oxy forms - Purdue	Anda_Opioids_MDL_0000616305	Anda_Opioids_MDL_0000616305		
P-01823	3/17/2008	Drug Distribution Service Agreement between Purdue Pharma L.P. and Anda	Anda_Opioids_MDL_0000616309	Anda_Opioids_MDL_0000616334		
P-01824	3/13/2008	RE: Oxy forms - Purdue	Anda_Opioids_MDL_0000616366	Anda_Opioids_MDL_0000616366		
P-01825	3/13/2008	RE: Oxy forms - Purdue	Anda_Opioids_MDL_0000616367	Anda_Opioids_MDL_0000616374		
P-01826	5/15/2008	Re: C2 Promo May 15 - June 30th	Anda_Opioids_MDL_0000616505	Anda_Opioids_MDL_0000616507		
P-01827	9/17/2008	RE: Management Presentation	Anda_Opioids_MDL_0000616531	Anda_Opioids_MDL_0000616531		
P-01828	6/30/2008	Anda Management Presentation PPT	Anda_Opioids_MDL_0000616532	Anda_Opioids_MDL_0000616581		
P-01829	8/14/2008	Re: UBS questions	Anda_Opioids_MDL_0000616633	Anda_Opioids_MDL_0000616634		
P-01830	8/9/2008	Re: Cardinal CII questions	Anda_Opioids_MDL_0000616647	Anda_Opioids_MDL_0000616648		
P-01831	5/16/2008	Email Due diligence list	Anda_Opioids_MDL_0000616985	Anda_Opioids_MDL_0000616985		
P-01832	5/13/2008	Anda Project Alligator Diligence Request Log	Anda_Opioids_MDL_0000616986	Anda_Opioids_MDL_0000616986		
P-01833	1/22/2019	Anda Companies Financials	Anda_Opioids_MDL_0000616994	Anda_Opioids_MDL_0000616994		
P-01834	5/14/2008	Re: Vault Justification	Anda_Opioids_MDL_0000616999	Anda_Opioids_MDL_0000616999		
P-01835	8/1/2008	Re: FW: Sales to Distributors; Attachment vet and wholesale breakout Summary	Anda_Opioids_MDL_0000617047	Anda_Opioids_MDL_0000617049		
P-01836	9/26/2008	Re: Sales	Anda_Opioids_MDL_0000618116	Anda_Opioids_MDL_0000618116		
P-01837	9/9/2008	Re: Fw Oxy Order	Anda_Opioids_MDL_0000618121	Anda_Opioids_MDL_0000618123		
P-01838	12/9/2008	Re: Fw KMART ORDER Anda Buy - 11-19-08 Ship File-Comm	Anda_Opioids_MDL_0000618415	Anda_Opioids_MDL_0000618420		
P-01839	3/22/2018	RE: Attached Image	Anda_Opioids_MDL_0000645318	Anda_Opioids_MDL_0000645325		
P-01840	6/18/2010	RE: Remedy CSOS Profile Related Question Pertaining to Anita's Account List: Sales for accounts cut off from controls	Anda_Opioids_MDL_0000710734	Anda_Opioids_MDL_0000710735		
P-01841	3/22/2010	FW: CSOS Review (3-15-10); Attachment CSOS Review (3-16-10)- Revised	Anda_Opioids_MDL_0000711006	Anda_Opioids_MDL_0000711010		
P-01842	7/29/2013	Email EPIC & IPA NJ- Required Information Attachments Epic Group- Required Info-072913; IPA NJ Required information 072913	Anda_Opioids_MDL_0000711634	Anda_Opioids_MDL_0000711636		
P-01843	8/16/2010	RE: Control dosage units	Anda_Opioids_MDL_0000711662	Anda_Opioids_MDL_0000711663		
P-01844	8/28/2014	FW: New deck ready?	Anda_Opioids_MDL_0000721151	Anda_Opioids_MDL_0000721152		
P-01845	8/28/2014	Anda Incorporated, Anda Overview PPT	Anda_Opioids_MDL_0000721153	Anda_Opioids_MDL_0000721174		
P-01846	11/30/2012	FW: Controlled Substance Query Questions	Anda_Opioids_MDL_0000725880	Anda_Opioids_MDL_0000725883		
P-01847	11/30/2012	Spreadsheet analyzing Walgreens stores red flags by state	Anda_Opioids_MDL_0000725885	Anda_Opioids_MDL_0000725885		
P-01848	12/20/2011	FW: Customer 40008 - PILE DRUG STORE	Anda_Opioids_MDL_0000726938	Anda_Opioids_MDL_0000726939		
P-01849	1/13/2012	FW: Controlled Substance Sales	Anda_Opioids_MDL_0000728018	Anda_Opioids_MDL_0000728020		
P-01850	4/15/2014	FW: SUBSYS 222 For Linden Care Now In Route (Clearing Unused Walgreens Stock)	Anda_Opioids_MDL_0000751628	Anda_Opioids_MDL_0000751630		

P-01851	5/7/2018	FW: ASOM order inquiry	Anda_Opioids_MDL_0000789857	Anda_Opioids_MDL_0000789861		
P-01852	6/27/2008	Email SOP	Anda_Opioids_MDL_0000849741	Anda_Opioids_MDL_0000849741		
P-01853	8/1/2007	Anda Standard Operating Procedure OPS-000-40, Controlled Substance Monthly Override %	Anda_Opioids_MDL_0000849742	Anda_Opioids_MDL_0000849744		
P-01854	11/1/2012	Master list of Anda controlled CS customers and Due Diligence files	Anda_Opioids_MDL_0000850138	Anda_Opioids_MDL_0000850139		
P-01855	11/2/2017	Anda List of Nationwide Customers	Anda_Opioids_MDL_0000993524	Anda_Opioids_MDL_0000993524		
P-01856	10/18/2012	FW: BuzzeeoPDMA SOM Seminar - Electronic Presentations Attachments 1 - Opening R Buzzeeo P Hamby; 2 - Basics of SOM R Buzzeeo; 3 - Legal Considerations for SOM L Barber; 4 - Systems Considerations P Hamby; 5 -SOM Investigative Programs Caverly Williamson; 6 - Legal Case Studies J Gilbert	Anda_Opioids_MDL_0001099835	Anda_Opioids_MDL_0001099945		
P-01857	6/26/2008	Email Alligator - info sharing with CAH Attachment Oreo Pre-Mgmt Discussion DD Templates (Consolidated) v3	Anda_Opioids_MDL_0001101486	Anda_Opioids_MDL_0001101488		
P-01858	7/24/2008	Anda Inc. Interoffice Memorandum To Files, From Brian Witte, RE: Control Substance Reviews	Anda_Opioids_MDL_0001155073	Anda_Opioids_MDL_0001155073		
P-01859	5/4/2012	Mallinckrodt CDA - Anda v2	Anda_Opioids_MDL_0001222751	Anda_Opioids_MDL_0001222758		
P-01860	1/21/2003	Anda Corporation Memorandum to Patrick Cochrane, from Richard Lane Re: Stock Option Grant	Anda_Pcochrane_Personnel_039	Anda_Pcochrane_Personnel_055		
P-01861	1/27/2004	Anda Corporation Memorandum to Patrick Cochrane, from Angelo Malahias Re: Stock Option Grant	Anda_Pcochrane_Personnel_056	Anda_Pcochrane_Personnel_060		
P-01862	N/A	Patrick Cochrane Career Summary	Anda_Pcochrane_Personnel_080	Anda_Pcochrane_Personnel_081		
P-01863	3/15/2006	Anda Corporation Performance and Development Process (P.D.P) Patrick Cochrane	Anda_Pcochrane_Personnel_093	Anda_Pcochrane_Personnel_098		
P-01864	1/5/2005	Patrick Cochrane Letter from Andrx	Anda_Pcochrane_Personnel_117	Anda_Pcochrane_Personnel_118		
P-01865	12/15/2004	Anda Corporation Performance and Development Process (P.D.P) Patrick Cochrane	Anda_Pcochrane_Personnel_119	Anda_Pcochrane_Personnel_123		
P-01866	N/A	Sabrina Solis Resume	ANDA_SOLIS_PERSONNEL_019	ANDA_SOLIS_PERSONNEL_020		
P-01867	N/A	Sabrina Solis Resume	ANDA_SOLIS_PERSONNEL_032	ANDA_SOLIS_PERSONNEL_034		
P-01868	N/A	Jay Spellman Career Summary	Anda_Spellman_Personnel_082	Anda_Spellman_Personnel_083		
P-01869	3/31/2007	2007 Standard Operating Procedures (SOP) for Anda Pharmacy, AndaMeds, and VIP Commissioned Employees Compensation	Anda_Temporary_Compensation_001	Anda_Temporary_Compensation_072		
P-01870	2/7/2019	Albert R. Paonessa, III Resume	N/A	N/A		
P-01871	2/6/2019	Michael's Story Article	N/A	N/A		
P-01873	11/3/2016	Article United State Reaches \$900,000 Settlement with Drug City Pharmacy (MD)	N/A	N/A		
P-01874	11/13/2017	California Search and Seizure Warrant	N/A	N/A		
P-01881	N/A	Brian D. Witte, CPA Resume	N/A	N/A		
P-01882	11/9/2009	Brian Witte Personnel File	Temporary Anda Witte Personnel_001	Temporary Anda Witte Personnel_138		
P-02030	1998	1998 Report to U.S. Attorney General from Suspicious Orders Task Force	CAH_MDL_PRIORPROD_HOUSE_0002207	CAH_MDL_PRIORPROD_HOUSE_0002298		
P-02094	6/21/1993	NWDA Suspicious Order Monitoring System	CAH_MDL2804_01465723	CAH_MDL2804_01465761		
P-02106	N/A	Florida, West Virginia 30(b)(6) Quick Reference Sheet	N/A	N/A		
P-02111	11/2/2018	MDL 30(b)(6) Deposition - Amended Deposition Aid	N/A	N/A		
P-02117	6/13/2019	California PMK Amended Deposition Aid	N/A	N/A		
P-02121	11/2/2018	MDL 30(b)(6) Deposition - Amended Deposition Aid Topic 12	N/A	N/A		
P-02124	N/A	Timeline of Key Dates	N/A	N/A		
P-02130	N/A	Julie Snyder Continued PMK Deposition Responses to Questions Provided by Plaintiff's Counsel	N/A	N/A		
P-02133	10/29/2021	Defendant Allergan Finance LLC's First Amended Responses and Objections to Plaintiff's Rule 1.310(b)(6) Deposition Notice	N/A	N/A		
P-02135	11/19/2021	Allergan Defendant's Objections and Responses to Plaintiff's Notice of Deposition Pursuant to Rule 30(b)(7)	N/A	N/A		
P-02149	9/17/2021	Report of Carl C. Peck, M.D.	N/A	N/A		
P-02158	9/17/2021	Expert Report of Margaret K. Kyle, PH.D.	N/A	N/A		
P-02177	10/21/2021	Defendant Allergan Finance LLC's First Amended Responses and Objections to Plaintiff's Rule 1.310(b)(6) Deposition Notice	N/A	N/A		
P-02183	N/A	Florida-West Virginia 30(b)(6) Quick Reference Sheet	N/A	N/A		
P-02189	11/2/2018	MDL 30(b)(6) Deposition - Amended Deposition Aid	N/A	N/A		
P-02208	6/13/2019	California PMK Amended Deposition Aid	N/A	N/A		

P-02209	11/2/2018	MDL 30(b)(6) Deposition - Amended Deposition Aid Topic 12	N/A	N/A		
P-02236	N/A	Timeline of Key Dates	N/A	N/A		
P-02244	11/30/2006	GAO Report (2006) Improvements Needed in FDA's Oversight of Direct-to-Consumer Advertising	N/A	N/A		
P-02249	10/15/2017	Washington Post Article: The Drug Industry's Triumph Over the DEA - Higham and Bernstein	N/A	N/A		
P-02250	1/1/2016	Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report; Increases in Drug and Opioid Overdose Deaths - United States, 2000-2014	N/A	N/A		
P-02251	12/16/2016	Centers for Disease Control and Prevention; Increases in Drug and Opioid-Involved Overdose Deaths -United States, 2010-2015	N/A	N/A		
P-02252	2/13/2018	Altarium article: Economic Toll of Opioid Crisis in U.S. Exceeded \$1 Trillion since 2001	N/A	N/A		
P-02253	1/1/2015	National Institute on Drug Abuse "National Overdose Deaths"	N/A	N/A		
P-02254	8/30/2017	Centers for Disease Control and Prevention: Understanding the Epidemic	N/A	N/A		
P-02255	5/23/2018	Letter from the Surgeon General to Colleagues.	N/A	N/A		
P-02257	2/9/2017	Centers for Disease Control and Prevention -Opioid Data Analysis	N/A	N/A		
P-02259	7/24/2013	CNBC New Article Health Care Deadly Epidemic: Prescription drug overdoses	N/A	N/A		
P-02262	1/1/2010	Regulatory Section DEA Headquarters ODG Presentation	N/A	N/A		
P-02263	3/6/2018	U.S. Health and Human Services -What is the U.S. Opioid Epidemic	N/A	N/A		
P-02264	7/22/2016	21 USC § 823	N/A	N/A		
P-02270	3/20/2018	Congressional hearing Transcript: The Drug Enforcement Administration's Role in Combating the Opioid Epidemic	N/A	N/A		
P-02275	5/6/2008	FDA Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee & Drug Safety & Risk Management Advisory Committee	N/A	N/A		
P-02283	4/29/2014	CDC Washington: Examining the Growing Problems of Prescription Drug and Heroin Abuse, Ctrs. For Disease Control and Prevention	N/A	N/A		
P-02284	8/31/2016	Letter from Vivek H. Murthy, Surgeon General, Tide RX (Aug. 2016)	N/A	N/A		
P-02285	N/A	21 U.S.C. §802(10-11)	N/A	N/A		
P-02286	N/A	21 U.S.C. §822(a)(1-2)	N/A	N/A		
P-02287	10/17/2017	Nick Miroff, From Teddy Roosevelt to Trump: How Drug Companies Triggered an Opioid Crisis a Century Ago, The Washington Post	N/A	N/A		
P-02289	10/22/2013	Thomas W. Prevoznik, Office of Diversion Control, Distributor Initiative presentation	N/A	N/A		
P-02290	6/1/2020	U.S. Dept. of Justice, Drug Diversion Administration, Diversion Control Division website	N/A	N/A		
P-02291	10/14/2009	U.S. Dept. of Justice DEA, Diversion Control Division website, Pharmaceutical Industry Conference (Oct 14 & 15, 2009), Suggested Questions a Distributor should ask prior to shipping controlled substances, Drug Enforcement Administration	N/A	N/A		
P-02292	10/3/2010	Richard Widup, Jr., Kathleen H. Dooley, Esq., Pharmaceutical Production Diversion: Beyond the PDMA, Purdue Pharma and McGuireWoods LLC	N/A	N/A		
P-02294	8/31/2010	Walgreens fiscal year 2010 SEC Form 10-K	N/A	N/A		
P-02298	4/18/2014	RX Integrity Market 25 Presentation - Controlled Substance Trends	WAGMDL00673006	WAGMDL00673030		
P-02299	11/3/2014	Rx Integrity Market 3 Presentation - Controlled Substance Trends	WAGMDL00018177	WAGMDL00018207		
P-02301	11/7/2017	Are Business Tactics at Some Pharmacies Risking Your Health?	N/A	N/A		
P-02302	1/31/2020	How Chaos at Chain Pharmacies Is Putting Patients at Risk, The New York Times, Gabler, Ellen	N/A	N/A		

P-02303	12/15/2016	Pharmacies Miss Half of Dangerous Drug Combinations, The Chicago Tribune	N/A	N/A		
P-02304	6/5/2013	NABP, Performance Metrics and Quotas in the Practice of Pharmacy (Resolution 109-7-13)	N/A	N/A		
P-02305	8/8/2019	Distributors, pharmacies and manufacturers respond to previously unreleased DEA data about opioid sales, The Washington Post	N/A	N/A		
P-02306	8/31/2019	Walgreens Board Report on Oversight of Risk Related to Opioids	N/A	N/A		
P-02307	1/7/2009	Walmart Settles Drug Records Accusation, The Daily Herald	N/A	N/A		
P-02308	8/1/2019	Pharmacies Across Ohio Received Large Amounts of Painkillers as Opioid Epidemic Ramped Up	N/A	N/A		
P-02310	6/19/2017	DOJ, DEA, Docket No. 15-26, [FR Doc. No. 2017-13158], Decision and Order	N/A	N/A		
P-02311	9/26/2018	Oklahoma State Board of Pharmacy Minutes	N/A	N/A		
P-02312	6/7/2011	16 Charged in 'pill mill' pipeline, The Columbus Dispatch	N/A	N/A		
P-02313	7/16/2015	Leader of Ohio pill-mill trafficking scheme sentenced, Star Beacon	N/A	N/A		
P-02323	7/9/2012	States Take on 'Tourists' Trafficking Painkillers	N/A	N/A		
P-02324	N/A	Julie Snyder Continued PNK Deposition Responses to Questions Provided by Plaintiff's Counsel	N/A	N/A		
P-02325	10/29/2021	Defendant Allergan Finance LLC's First Amended Responses and Objections to Plaintiff's Rule 1.310(b)(6) Deposition Notice	N/A	N/A		
P-02326	11/19/2021	Allergan Defendant's Objections and Responses to Plaintiff's Notice of Deposition Pursuant to Rule 30(b)(7)	N/A	N/A		
P-02327	9/17/2021	Report of Carl C. Peck, M.D.	N/A	N/A		
P-02328	9/18/2021	Expert Report of Margaret K. Kyle, PH.D.	N/A	N/A		
P-02329	10/21/2010	Deal Lets Doctor Avoid Trial	N/A	N/A		
P-02331	7/26/2015	Master Purchase Agreement	ALLERGAN_MDL_01481207	ALLERGAN_MDL_01481341		
P-02332	12.29.2014	Allergan Global Supplier Spend (Shareable) 12.29.2014.xlsx	ALLERGAN_MDL_04240833	ALLERGAN_MDL_04240833		
P-02333	4/27/2012	Watson Announces Restructuring of Senior Leadership to Support Expanded Global Business	N/A	N/A		
P-02334	10/12/2011	Superseding Indictment	N/A	N/A		
P-02336	2004	Actiq 2004 Marketing Plan	TEVA_MDL_A_03244006	TEVA_MDL_A_03244063		
P-02337	2005	Actiq 2005 Marketing Plan	TEVA_MDL_A_03243914	TEVA_MDL_A_03243996		
P-02339	12/4/2006	Fentora Marketing Plan 2007	TEVA_MDL_A_06666094	TEVA_MDL_A_06666282		
P-02340	9/18/2008	Fentora Sales and Marketing 2008 Budget	TEVA_MDL_A_07253669	TEVA_MDL_A_07253669		
P-02342	8/12/2010	2010 Fentora Budget	TEVA_MDL_A_00708821	TEVA_MDL_A_00708821		
P-02343	1/5/2010	Fentora 2011 Brand Plan	TEVA_MDL_A_00550572	TEVA_MDL_A_0550593		
P-02344	9/20/2011	Fentora 2012 Budget Plan	TEVA_MDL_A_01184564	TEVA_MDL_A_01184564		
P-02345	4/24/2013	Fentora 2013 Marketing Budget	TEVA_MDL_A_00881002	TEVA_MDL_A_00881002		
P-02347	2/23/2012	RE: Proposal for Message / Concept Testing	ACTAVIS0319280	ACTAVIS0319282		
P-02348	6/5/2012	FW: Ad board - last 45 min; Actavis last 45 minutes of meeting file 0999	ACTAVIS0431150	ACTAVIS0431182		
P-02349	3/8/2013	RE: Agenda for Cancelled Nov-12 Meeting; JA NSM Presentation - KADI1224_Four strengths_Presentation Draft_09 11 2012; KAD-084 Kadian Intro Stocking Offer PrintFlyer 09-13-12 (2); KAD-089 Kadian Now Available Flyer 09-21-12; Kadian Launch Scenarios; Kadian New Strengths recommendations; New Strength Physician Flyer; New Strengths Pharmacy Flyer; New Strengths(2)x; NSM Objection Handling Tool_LAM edits 09 10 12x; NSM Presentation - Marketing Presentation	ACTAVIS0192957	ACTAVIS0193028		
P-02350	6/29/2011	Actavis US Kadian Advisory Board 2011	ACTAVIS0821336	ACTAVIS0821339		
P-02351	8/17/2011	Field Contact Form: Kristie Robinson	ACTAVIS0965746	ACTAVIS0965747		
P-02352	11/17/2011	New Script and Letter; KADI1189x; TMS Generic Kadian Telescript cleanx; TMS Generic Kadian Telescriptx	ACTAVIS0335906	ACTAVIS0335914		
P-02353	6/11/2012	RE: Speaker requests for the West Area	ACTAVIS0282841	ACTAVIS0282843		
P-02354	9/16/2011	FW: Advantage Logistics orders 387109-01-1, 387111-01-1 Pended for Zolpidem Tartrate ER (Supervalu)	ALLERGAN_MDL_03427457	ALLERGAN_MDL_03427460		
P-02355	2/11/2009	RE: Omnicare Finasteride	ALLERGAN_MDL_02128037	ALLERGAN_MDL_02128038		

P-02356	10/19/2012	ABC Meeting Presentation; Partnership Mtg ABC Oct 22 FINALNB	ACTAVIS1136380	ACTAVIS1136396		
P-02357	1/6/2016	RE: SOMS	ALLERGAN_MDL_02466960	ALLERGAN_MDL_02466964		
P-02358	10/30/2012	Re: New business	Acquired_Actavis_00667914	Acquired_Actavis_00667914		
P-02359	N/A	Jeannette Barrett Curriculum Vitae	N/A	N/A		
P-02360	1/24/2013	FW: PER4MA 2012 for Ivan Shaw and Jeannette Barrett; 2012 Level 2 3 PER4MA Evaluation.IvanTShaw02NOV2012x; 2012 Level 2 3 PER4MA Eval.JAB02NOV2012x	ALLERGAN_MDL_01877721	ALLERGAN_MDL_01877725		
P-02361	5/20/2012	Fw: Undeliverable: Fw: Thank you!; Fw: Thank you!	Acquired_Actavis_00000039	Acquired_Actavis_00000040		
P-02362	5/11/2012	APS: Dr. Katz in HI	ACTAVIS0292816	ACTAVIS0292821		
P-02363	6/2/2012	MoxDuo Advisory Board Preliminary Agenda; Attendee List - June 2; Attendee List - Actavis; Time - Event - Staff	Acquired_Actavis_00000730	Acquired_Actavis_00000735		
P-02364	7/12/2012	Emailing: QRxFDATimeline&correspondence; Medical AffairsPOA.03 JUL 2012.FINAL; QRxFDATimeline&correspondence.zip	ALLERGAN_MDL_00779388	ALLERGAN_MDL_00779708		
P-02365	6/26/2012	MOXDUE (morphine sulfate and oxycodone hydrochloride) capsules, CII. Complete Response Letter	Acquired_Actavis_00214654	Acquired_Actavis_00214654		
P-02366	N/A	KOL Profile	BARRETT_MDL_00000114	BARRETT_MDL_00000115		
P-02367	8/27/2012	Kadian Labeling for Alcohol Interaction Study; Effect of Coadministration of alcohol.21 AUG 2012 x	ACTAVIS0700416	ACTAVIS0700418		
P-02368	9/11/2012	Advertisement & Promotion Review/Approval: Kadian Objection Handler - Corporate Position	ALLERGAN_MDL_01128302	ALLERGAN_MDL_01128305		
P-02369	9/11/2012	Kadian Promotional Review Committee RECAP	ALLERGAN_MDL_01127805	ALLERGAN_MDL_01127805		
P-02370	9/11/2012	[KADIAN] Medical Affairs decks KADI1219, KADI1220 and KADI1232 - finals with corrected footers	ACTAVIS0003147	ACTAVIS0003194		
P-02371	10/22/2012	Training Materials and Updated Transition Plan; Actavis Open MI Calls Daily Rec 10-22x;AE and QC Daily Reconciliation 10-22x;Day 1 Department Contact List 10-19x;Department Responsibilities 10-19x;Flow Chart 10-18;Watson Actavis Proposed Med Info Transition Plan Version 10 - 10-19-12x	ALLERGAN_MDL_00848537	ALLERGAN_MDL_00848548		
P-02372	10/24/2012	Medical Review for Conversion Guide; Conversion Guide; References	ACTAVIS0685187	ACTAVIS0685227		
P-02373	7/24/2012	Kadian Value Proposition	BARRETT_MDL_00000850	BARRETT_MDL_00000875		
P-02374	1/27/2010	RE: 2010 Goals	ALLERGAN_MDL_03305226	ALLERGAN_MDL_03305230		
P-02375	11/18/2011	RE: Suboxone Walgreens offer	ACTAVIS0958177	ACTAVIS0958182		
P-02376	10/18/2006	Fw: Budget Presentation	ALLERGAN_MDL_01397096	ALLERGAN_MDL_01397159		
P-02377	3/10/2009	Re: Script Data	ALLERGAN_MDL_01058383	ALLERGAN_MDL_01058385		
P-02378	3/11/2009	RE: Triple i co-pay program	ALLERGAN_MDL_01725566	ALLERGAN_MDL_01725569		
P-02379	8/26/2011	Re: Weekly Update	ACTAVIS0965151	ACTAVIS0965154		
P-02380	2/25/2012	FW: final presentation; Leadership Summit Presentation final MP 2-2012	ALLERGAN_MDL_00676546	ALLERGAN_MDL_00676582		
P-02381	10/21/2009	Trying to give "consultants" a bad name; Actavis - Kadain physicians with Decile cut points.xls; Kadian Monthly TRxs	ACTAVIS1132528	ACTAVIS1132530		
P-02382	6/12/2011	Response to Kadian Return Goods Policy; Fwd: Pharm out of stock; RE: KADIAN Return Goods Policy; Re: KADIAN Return Goods Policy; Re: Safeway	ACTAVIS0822310	ACTAVIS0822321		
P-02383	11/14/2011	Kadian Weekly Update; Exec Dash 11.04.11.xls; ValueTrak Weekly Report Ending 10.30.11.xlsx	ACTAVIS0960324	ACTAVIS0960327		
P-02384	1/27/2012	FW: Value Centric; 35556_Value Centric Hosted Services Agreement	ALLERGAN_MDL_01898012	ALLERGAN_MDL_01898034		
P-02385	12/21/2011	Fwd: (No subject); Actavis FDC Launch Preparation Kickoff Dec21_2011v6	ACTAVIS0804497	ACTAVIS0804563		
P-02386	7/23/2010	Fw: DDMAC Warning Letter Correspondence KADIAN; 10-04-09 Response to FDA; 10-04-19 FDA Response; 10-05-03 Response to FDA; 10-05-20 FDA Response; 10-06-10 Response to FDA; 10-07-06 FDA Response; 10-07-16 Response to FDA; 10-02-18 FDA Warning Letter; 10-03-04 Response to Warning Letter; 10-03-05 Amendment to Response; 10-03-26 FDA Response	ALLERGAN_MDL_01871495 ALLERGAN_MDL_01871495	ALLERGAN_MDL_01871646 ALLERGAN_MDL_01871609	ALLERGAN_MDL_01871495 - ALLERGAN_MDL_01871609	
P-02387	12/5/2011	Michael Clarke Personnel File	ALLERGAN_MDL_SUPP00000339	ALLERGAN_MDL_SUPP00000394		
P-02388	N/A	Michael Clarke LinkedIn profile	N/A	N/A		



P-02389	8/14/2013	Brief Historical Overview - legacy Actavis SOM Program	ALLERGAN_MDL_03302398	ALLERGAN_MDL_03302398		
P-02390	9/12/2013	Napoli conversation notes	ALLERGAN_MDL_03302580	ALLERGAN_MDL_03302580		
P-02391	4/25/2012	FW: SOM Project Team Status/Upcoming Steering Committee Meeting	ALLERGAN_MDL_01729077	ALLERGAN_MDL_01729081		
P-02392	5/2/2012	RE: Suspicious Order Monitoring	ALLERGAN_MDL_02872193	ALLERGAN_MDL_02872194		
P-02393	6/8/2012	FW: Business Week article; 5.7 Barron's; 6.6 BBW-Oxycodone	ALLERGAN_MDL_00131633	ALLERGAN_MDL_00131645		
P-02394	7/9/2012	Rx Drug Abuse; Rx-Abuse Memo 7.9.12	ACTAVIS0717304	ACTAVIS0717308		
P-02396	9/20/2012	RE: DEA follow up to 09/12/12 Suspicious Order Monitoring Presentation	ALLERGAN_MDL_03382548	ALLERGAN_MDL_03382549		
P-02397	9/20/2012	SOM	ALLERGAN_MDL_01729059	ALLERGAN_MDL_01729059		
P-02398	9/26/2012	RE: Jupiter, FL Distribution Center	Acquired_Actavis_00761668	Acquired_Actavis_00761671		
P-02399	10/8/2012	FW: Document	ALLERGAN_MDL_03382700	ALLERGAN_MDL_03382702		
P-02400	10/22/2012	Suspicious Order Monitoring Partnership Meeting - AmerisourceBergen	ALLERGAN_MDL_03302607	ALLERGAN_MDL_03302621		
P-02401	10/22/2012	Suspicious Order Monitoring Partnership Meeting - AmerisourceBergen	ALLERGAN_MDL_03302890	ALLERGAN_MDL_03302904		
P-02402	1/14/2014	RE: Anti-Diversion Industry Working Group February Meeting	ALLERGAN_MDL_02187686	ALLERGAN_MDL_02187692		
P-02403	10/12/2012	Re: Pharmacy buying through multiple wholesalers	Acquired_Actavis_01621005	Acquired_Actavis_01621006		
P-02404	8/1/2007	New Employee New Data	ALLERGAN_MDL_SUPP_00001122	ALLERGAN_MDL_SUPP00001237		
P-02405	4/19/2012	Email, NACDS Actavis Deck	ACTAVIS0302153	ACTAVIS0302161		
P-02406	4/27/2011	FW: Q3/2010 Rebate Claim for Oxycodone and Alprazolam ODT	Acquired_Actavis_00485597	Acquired_Actavis_00485602		
P-02407	10/17/2011	RE: PBA - Chargebacks on CII's	Acquired_Actavis_00486766	Acquired_Actavis_00486770		
P-02408	3/11/2011	FW: Draft SOP - Suspicious orders Oxy IR tabs	ALLERGAN_MDL_01698571	ALLERGAN_MDL_01698574		
P-02409	2/18/2011	RE: Draft SOP - Suspicious order Oxy IR tabs	Acquired_Actavis_01257892	Acquired_Actavis_01257893		
P-02411	3/18/2011	RE: Oxycodone 15mg Orders	Acquired_Actavis_00237627	Acquired_Actavis_00237628		
P-02412	11/11/2011	RE: Appointment request Thursday December 8th	ALLERGAN_MDL_02879204	ALLERGAN_MDL_02879205		
P-02413	9/26/2011	RE: SOM Update	Acquired_Actavis_00096109	Acquired_Actavis_00096110		
P-02414	10/29/2014	RE: Hydro omits	Acquired_Actavis_00248484	Acquired_Actavis_00248489		
P-02415	7/23/2015	RE: HYDROCODONE-IBUPROFEN - new award	Acquired_Actavis_00254144	Acquired_Actavis_00254146		
P-02417	10/2/2017	WBAD Review	TEVA_MDL_A_01439745	TEVA_MDL_A_01439745		
P-02418	10/5/2018	RGD Discovery Letter Brief	N/A	N/A		
P-02419	10/26/2018	Defendants' Responses to Notice of Deposition - Allergan 30(b)(6)	N/A	N/A		
P-02420	1/31/2018	Teva-Allergan Settlement Agreement and Mutual Releases	N/A	N/A		
P-02421	12/31/2001	Watson Form 10-K, Annual Report for 2001	N/A	N/A		
P-02422	12/31/2005	Watson Form 10-K, Annual Report for 2005	N/A	N/A		
P-02423	10/26/2018	Timeline flow chart of opioid business acquisitions	N/A	N/A		
P-02424	2/6/2004	FDA approval of Amide Pharma Oxycodone Hydrochloride ANDA	N/A	N/A		
P-02425	8/2/2016	Allergan Organization Charts	ALLERGAN_MDL_03674503	ALLERGAN_MDL_03674506		
P-02426	12/31/2013	Actavis plc Form 10-K, Annual Report for 2013	N/A	N/A		
P-02427	12/31/2014	Actavis-Warner Chilcott Form 10-K, Annual Report for 2014	N/A	N/A		
P-02428	12/31/2017	Allergan-Warner Chilcott Form 10-K, Annual Report for 2017	N/A	N/A		
P-02429	5/21/2013	Article - Actavis: The latest Fortune 500 company to "leave" the US for tax reasons	N/A	N/A		
P-02430	10/22/2018	Allergan-Executive Leadership Team	N/A	N/A		
P-02431	9/30/2016	RE: Norco-WSJ	ALLERGAN_MDL_02024980	ALLERGAN_MDL_02024982		
P-02432	6/21/2011	RE: NSM Planning Meeting - Agenda	ALLERGAN_MDL_00403612	ALLERGAN_MDL_00403615		
P-02433	3/17/2010	RE: Kadian Alpha news	ALLERGAN_MDL_01418920	ALLERGAN_MDL_01418922		
P-02434	3/20/2010	Article - Inside the Painkiller: Business Golf, Laptops and Theater Trips for Rx Doctors	N/A	N/A		
P-02435	7/29/2010	RE: Fentanyl Advertisingm - DSN PI info Needed	Acquired_Actavis_00954338	Acquired_Actavis_00954341		
P-02436	12/6/2018	David Myers LinkedIn web printout.	N/A	N/A		
P-02437	6/5/2008	NJ Pharma Industry Group Charter Statement	HDS_MDL_00095906	HDS_MDL_00095907		
P-02438	6/23/2010	Emails, Customer Communication for SOMS	ALLERGAN_MDL_03738524	ALLERGAN_MDL_03738528		
P-02439	7/31/2014	FW: US Generic S&OP Deck	Acquired_Actavis_02476517	Acquired_Actavis_02476518		
P-02440	11/13/2014	FW: NJ PIG Meeting Agenda (Final)	PPLPC020000735777	PPLPC020000735782		
P-02441	1/14/2016	RE: McKesson DEA Suspensions	ALLERGAN_MDL_01551062	ALLERGAN_MDL_01551064		
P-02442	1/14/2016	RE: McKesson DEA Suspensions, Excel pdf	ALLERGAN_MDL_01551064	ALLERGAN_MDL_01551064		
P-02443	2/11/2009	Email, Kadian Labels	ACTAVIS1132973	ACTAVIS1132975		
P-02444	3/4/2009	Email, Monthly AE Tracking Log Report	ALLERGAN_MDL_01239746	ALLERGAN_MDL_01239748		

P-02445	3/3/2009	Email, Monthly Kadian Metric Report	ALLERGAN_MDL_01433239	ALLERGAN_MDL_01433247		
P-02446	5/1/2009	RE: Draft objectives for Regulatory and Medical Affairs	ACTAVIS1132882	ACTAVIS1132890		
P-02447	8/22/2009	Email, Alpharma Kadian 2009 Safety Report, July 2007 to June 2008.	ALLERGAN_MDL_01435115	ALLERGAN_MDL_01435141		
P-02448	5/20/2009	RE: URGENT VOTE NEEDED BY 12 noon Wednesday	ALLERGAN_MDL_01240070	ALLERGAN_MDL_01240072		
P-02449	7/23/2010	FW: DDMAC Warning Letter Correspondence KADIAN	ALLERGAN_MDL_01871495	ALLERGAN_MDL_01871646	ALLERGAN_MDL_01871495 - ALLERGAN_MDL_01871646	
P-02450	7/12/2010	Audit - Response to June 10, 2010 Internal Department Audit of the US Regulatory Affairs Department	ALLERGAN_MDL_01773318	ALLERGAN_MDL_01773336		
P-02451	7/28/2010	Email, Fentanyl filing cover letter	Acquired_Actavis_01387373	Acquired_Actavis_01387401		
P-02452	8/10/2010	Email, Kadian - Citizen Petition	ALLERGAN_MDL_01238285	ALLERGAN_MDL_01238314		
P-02453	11/11/2010	RE: Response Requested - PROSAR Update Request for Actavis South Atlantic LLC.	Acquired_Actavis_00196761	Acquired_Actavis_00196775		
P-02454	3/4/2011	Email, Weekly Regulatory surveillance report Feb 28- March 04, 2011	ACTAVIS1130843	ACTAVIS1130847		
P-02455	3/16/2011	RE: Susp Order Monitoring - White Board Requirements Planning (phase 1)	Acquired_Actavis_01169376	Acquired_Actavis_01169377		
P-02456	4/8/2011	FW: Suspicious order	ALLERGAN_MDL_02128396	ALLERGAN_MDL_02128396		
P-02457	4/19/2011	Fw: FDA Letters Re: REMS - Multiple Products	ACTAVIS0829313	ACTAVIS0829374		
P-02458	4/27/2011	Email, oxymorphone	ACTAVIS0827899	ACTAVIS0827965		
P-02459	6/8/2011	RE: Updated: Actavis Product Safety Board Meeting	ACTAVIS1130504	ACTAVIS1130519		
P-02460	10/25/2011	Email, MA Budget	ALLERGAN_MDL_01725633	ALLERGAN_MDL_01725634		
P-02461	3/6/2012	Re moxduo and Safe and Secure' Monitoring	ALLERGAN_MDL_02150237	ALLERGAN_MDL_02150238		
P-02462	3/8/2012	Project Compass - US RA organization - item F.2	ACTAVIS0792854	ACTAVIS0792861		
P-02463	3/29/2012	FW: REMS & GDUFA presentations	ALLERGAN_MDL_02154147	ALLERGAN_MDL_02154175		
P-02464	6/12/2012	Email, DSGP Report as of 06.11.2012.	ALLERGAN_MDL_00131646	ALLERGAN_MDL_00131660		
P-02465	6/6/2012	RE: KADIAN NAVIPPRO Questions	ALLERGAN_MDL_00656241	ALLERGAN_MDL_00656251		
P-02466	8/25/2012	Email, Kadian AAPC supplemental data	ALLERGAN_MDL_00630526	ALLERGAN_MDL_00630558		
P-02467	4/19/2012	MP 2011 PER4MA; Scanned from a Xerox multifunction device001	ALLERGAN_MDL_00682776	ALLERGAN_MDL_00682785		
P-02468	3/17/2011	Cardinal's Oxy 15mg suspicious ordering; image001.jpg; image003.jpg; image004.gif; Oxy IR Tabs Suspicious Order SOP revised 3-17-2011	Acquired_Actavis_00265989	Acquired_Actavis_00265995		
P-02469	4/26/2011	SOM; Suspicious Order Monitoring (2)	ALLERGAN_MDL_02872128	ALLERGAN_MDL_02872129		
P-02470	5/6/2011	RE: Meeting Today Regarding QK Healthcare Oxy Ordering Pattern	Acquired_Actavis_01317298	Acquired_Actavis_01317299		
P-02471	10/21/2011	SOM & Budget Considerations	ALLERGAN_MDL_01767006	ALLERGAN_MDL_01767006		
P-02472	2/14/2012	Re: safe and secure	ALLERGAN_MDL_02459892	ALLERGAN_MDL_02459895		
P-02473	3/31/2012	FW: Recap of SOM Meeting on Wednesday, March 21; Questionnaire 033012x; Indirect sales SOM SOP033012	ALLERGAN_MDL_02150276	ALLERGAN_MDL_02150293		
P-02474	4/8/2011	FW: Suspicious order	ALLERGAN_MDL_02128397	ALLERGAN_MDL_02128397		
P-02475	11/16/2010	Re: Oxycodone IR tabs - Outstanding orders by customer	ACTAVIS0632024	ACTAVIS0632027		
P-02476	2/2/2011	FW: Walgreens 2009 vs 2010 Oxycodone	Acquired_Actavis_00218780	Acquired_Actavis_00218786		
P-02477	3/22/2011	RE: Opti-source Oxy IR orders	ACTAVIS0524986	ACTAVIS0525000		
P-02478	1/12/2012	FW: 1-11-12 OptiSource Oxy Ir shipments.XLS; 1-11-12 Optisoure Oxy Ir shipments.XLS	ALLERGAN_MDL_00677641	ALLERGAN_MDL_00677643		
P-02479	5/24/2012	RE: Smith Drug - Oxycodone 30mg needs	ACTAVIS0288356	ACTAVIS0288361		
P-02480	9/13/2012	RE: DEA meeting	ACTAVIS0238164	ACTAVIS0238164		
P-02481	2/9/2010	sales presentation; Sales Meeting Feb 10.ppt	Acquired_Actavis_02233973	Acquired_Actavis_02233974		
P-02482	4/9/2009	RE: Oxy	Acquired_Actavis_01169947	Acquired_Actavis_01169947		
P-02483	2/25/2012	Email, my presentation...from the sales meeting...may be useful to you in your presentation; BRING YOU'RE A GAME MP - FINAL.ppsx	ALLERGAN_MDL_01021248	ALLERGAN_MDL_01021261		
P-02484	N/A	Timeline of Key Dates	N/A	N/A		
P-02485	N/A	30(b)(6) Topics and Subjects	N/A	N/A		
P-02486	11/2/2018	30(b)(6) Objections and Responses	N/A	N/A		
P-02487	11/2/2018	MDL 30(b)(6) Deposition - Topic 12	N/A	N/A		
P-02488	5/1/2009	Contract Sales Force Agreement by and between Ventiv Commercial Services, LLC and Actavis Kadian LLC	ALLERGAN_MDL_00988613	ALLERGAN_MDL_00988680		
P-02489	10/29/2018	Letter Re: Deficiencies in Allergan 30(b)(6) Topic 43 Testimony	N/A	N/A		



P-02490	1/10/2019	Sarita Thapar LinkedIn web printout	N/A	N/A		
P-02491	3/27/2001	Sarita Thapar employee file 2001-2014 (e.g. resume, compensation, confidentiality)	ALLERGAN_MDL_04349606	ALLERGAN_MDL_04349689		
P-02492	6/1/2001	Sarita Thapar employee file 2001-2014 (e.g. compensation, evaluations, exit interview)	ALLERGAN_MDL_04349690	ALLERGAN_MDL_04349782		
P-02493	5/2/2012	RE: Pharmacovigilance questionnaire	ALLERGAN_MDL_01554949	ALLERGAN_MDL_01554974		
P-02494	8/25/2009	FW: Kadian PSR cover letter and RiskMAP question	ALLERGAN_MDL_01435156	ALLERGAN_MDL_01435196		
P-02495	5/9/2007	Kadian Risk Management Plan (Alpharma)	ALLERGAN_MDL_01821586	ALLERGAN_MDL_01821607		
P-02496	7/9/2012	Email, LAO REMs approved today	ALLERGAN_MDL_01407270	ALLERGAN_MDL_01407282		
P-02497	7/9/2012	Kadian - FDA Supplemental New Drug Application Approval	ALLERGAN_MDL_02065422	ALLERGAN_MDL_02065510		
P-02498	2/20/2013	Email, Internal Actavis FAQs for Buprenorphine REMS questions	ACTAVIS0197024	ACTAVIS0197025		
P-02499	10/21/2011	Email, RiskMAP Gap Analysis	ALLERGAN_MDL_00293973	ALLERGAN_MDL_00293995		
P-02526	3/18/2009	Email, US-MA-001 and US-MA002	ALLERGAN_MDL_01774276	ALLERGAN_MDL_01774315		
P-02527	10/9/2009	Email, kadian	ALLERGAN_MDL_01435283	ALLERGAN_MDL_01435284		
P-02528	8/24/2012	Email, SOP Training Notification for US-MA-002-06 - Effective September 5, 2012	ALLERGAN_MDL_00858836	ALLERGAN_MDL_00858878		
P-02538	6/21/2010	RE: Request for refunds	ALLERGAN_MDL_01295958	ALLERGAN_MDL_01296001		
P-02543	5/11/2009	Email, KAI SOPs: ACT-001 and 002 SIGNED CONTRACT	ALLERGAN_MDL_03240373	ALLERGAN_MDL_03240416		
P-02553	10/26/2009	Email, Kadian Medical Information Modules	ALLERGAN_MDL_01288012	ALLERGAN_MDL_01288099		
P-02564	12/27/2007	Email, Oxycodone ER tablet AERS summarization	ALLERGAN_MDL_01136325	ALLERGAN_MDL_01136355		
P-02565	8/5/2011	Email, Reactions Weekly: Volume (1360) 16 JULY 2011	ALLERGAN_MDL_01297124	ALLERGAN_MDL_01297125		
P-02594	8/2/2010	FW: KADIAN 2010 PSR	ALLERGAN_MDL_01237796	ALLERGAN_MDL_01238207		
P-02595	3/4/2009	Email, Monthly AE Tracking Log Report	ALLERGAN_MDL_01239746	ALLERGAN_MDL_01239748		
P-02633	1/5/2012	Email, Monthly AE Tracking Log	ACTAVIS0803897	ACTAVIS0803923		
P-02634	3/26/2009	FW: Reports from Inflexxion	ALLERGAN_MDL_01433573	ALLERGAN_MDL_01433890		
P-02688	7/14/2009	Fw: June 2009 signal detection	Acquired Actavis_01692714	Acquired Actavis_01692747		
P-02712	3/5/2012	FW: By site, 483s & responses part 2 of 3	ALLERGAN_MDL_01770313	ALLERGAN_MDL_01770333		
P-02727	1/20/2012	Email, EIR for Medical Affair Audit in April 2011	ACTAVIS0800809	ACTAVIS0800847		
P-02740	4/14/2011	FW: fda request #23	ACTAVIS0830069	ACTAVIS0830103		
P-02805	3/20/2008	Email re: DEA Strategy Document and FDA Update	Anda_Opioids_MDL_0000157358	Anda_Opioids_MDL_0000157473		
P-02843	2/28/2011	Herald-Tribune Article, A Healthy Dose of Shaming	N/A	N/A		
P-02847	N/A	Title 21 United States Code Controlled Substances Act Subchapter 1 Control and Enforcement Part A - Introductory Provisions (2) the illegal importation, manufacture, distribution, and possession and improper use of controlled substances have a substantial and detrimental effect on the health and general welfare of the american people	N/A	N/A		
P-02849	3/6/2008	Healthcare Professionals Guide - version for submission	ALLERGAN_MDL_01134045	ALLERGAN_MDL_01134172		
P-02850	9/9/2014	DEA Affairs.one	ALLERGAN_MDL_03835569	ALLERGAN_MDL_03835637		
P-02851	12/1/2003	United States General Accounting Office- PRESCRIPTION DRUGS OxyContin Abuse and Diversion and Efforts to Address the Problem GAO-04-110	N/A	N/A		
P-02864	8/1/2017	Prescription Opioid Overdose Data, Key Data, Prescription Opioid Map, Prescription Opioid Graph	N/A	N/A		
P-02865	1/10/2018	Drug Overdose Mortality by State	N/A	N/A		
P-02867	2/11/2020	Stipulated Protective Order - Modified	N/A	N/A		
P-02877	1/1/2016	Public Law 114-145- April 19, 2016, Ensuring Patient Access and Effective Drug Enforcement Act of 2016	N/A	N/A		
P-02912	5/23/2020	Article, Drug Distributor Employees Emailed a Parody song about 'pillbillies' documents show, The Washington Post	N/A	N/A		
P-02968	3/20/2018	Pre-Hearing Written Statement Acting Administrator DEA, R. Patterson	N/A	N/A		
P-02969	9/00/2019	Review of the DEA's Regulatory and Enforcement Efforts to Control the Diversion of Opioids	N/A	N/A		
P-02974	4/24/2009	Sales team hires; TIM SULLIVAN Final; McClanahanUpdated Resume 04-21-09 FINAL; Christopher Hepp Resume-1; Mike Ryan Resumex; Cyndy Rastovski resume; Sam Hopkins Resume 4-9 FINALx	ALLERGAN_MDL_00449759	ALLERGAN_MDL_00449768		
P-02975	N/A	Christopher Hepp LinkedIn profile	N/A	N/A		

P-02976	11/3/2010	FW: KADIAN Konnection: October Edition; Kadian Newsletter October 2010	ACTAVIS1142879	ACTAVIS1142886		
P-02977	5/1/2009	Contract Sales Force Agreement by and between Ventiv Commercial Services, LLC and Actavis Kadian LLC	ALLERGAN_MDL_01469908	ALLERGAN_MDL_01470031		
P-02978	6/21/2010	FW: Perf review template; Perf Review Template '09 062110.doc	Acquired_Actavis_00365408	Acquired_Actavis_00365419		
P-02979	10/24/2011	2011 bonus plans; KADIAN ABM 2011 Bonus planx; KADIAN RBD 2011 Bonus Planx	ALLERGAN_MDL_00397811	ALLERGAN_MDL_00397822		
P-02980	11/28/2012	FW: Open Invoice; 201209 Actavis (0581) Fee & Expense.xls; Actavis(0581) 2012 Addl Q2 and Kadian Bonus 10-05-12 payout Inv.xls	ACTAVIS1000793	ACTAVIS1000795		
P-02981	2/2/2011	RE: OW Award - Kadian; Orange Way Award - Kadian Sales Team	ALLERGAN_MDL_00223518	ALLERGAN_MDL_00223521		
P-02982	4/12/2012	Kadian Learning System; LEARNING SYSTEM 07 01 2010	ALLERGAN_MDL_01450683	ALLERGAN_MDL_01450875		
P-02983	7/10/2012	fourth e-mail; Objection Handling Messaging 071311.pptx; October 2011 Kadian Promotional Training Slides.pptx	ALLERGAN_MDL_00026826	ALLERGAN_MDL_00026894		
P-02984	10/30/2011	Training Schedule-Agenda Adriana Knoblauch-ABS-Los Angeles; Kadian Training Agenda Nov. 1-2, 2011	ALLERGAN_MDL_01202831	ALLERGAN_MDL_01202833		
P-02985	12/7/2011	Field Contact Report-Knoblauch 12-7-2011; Field Contact Form-Updated-Knoblauch 12-07-2011	ALLERGAN_MDL_00396747	ALLERGAN_MDL_00396750		
P-02986	11/1/2010	Field Contact Form; Field Contact Form-Debbie Webb 10-26-2010.doc	ALLERGAN_MDL_01116174	ALLERGAN_MDL_01116176		
P-02987	1/26/2011	Field Contact Report; Field Contact Form-Richard Askew 01-20-2011	ALLERGAN_MDL_01199791	ALLERGAN_MDL_01199793		
P-02988	3/7/2011	Field Contact Report 03/01-02/2011; Field Contact Form-Hagy 03-01 to 03-02-2011.doc	ALLERGAN_MDL_00451338	ALLERGAN_MDL_00451340		
P-02989	9/2/2011	Field Contact Report; Field Contact Form-Askew 08-31-2011	Acquired_Actavis_00358141	Acquired_Actavis_00358143		
P-02990	2/25/2011	Steve Rampton-Warning Letter; Warning Letter-Steve Rampton 02-25-2011x	Acquired_Actavis_00182206	Acquired_Actavis_00182208		
P-02991	8/10/2011	Re: A347 Oxymorphone Training Materials	ACTAVIS0816997	ACTAVIS0817005		
P-02992	8/2/2011	Oxymorphone ER 7.5mg and 15mg Follow Up; Oxymorphone Sales Training v2 A347.pdf	Acquired_Actavis_02283431	Acquired_Actavis_02283450		
P-02994	5/2/2001	our meeting with DEA; Pain Forum Summary	PPLPC013000068568	PPLPC013000068572		
P-02995	6/1/2001	Issues Monitoring Report	E513_00138682	E513_00138682		
P-02996	8/9/2001	Fw: RE: fyi; Consensus Statement	PPLPC031000068582	PPLPC031000068586		
P-02997	9/10/2001	FW: News Conference Scheduled for Thursday, September 13, at 1pm; Hutchinson Invitation Letter; Consensus Statement; webMD article August 13, 2001	PPLPC018000022219	PPLPC018000022227		
P-02998	9/10/2001	FW: Update on News Conference w/DEA	PPLPC024000051478	PPLPC024000051480		
P-02999	N/A	DEA Joint Statement	N/A	N/A		
P-03360	11/7/2011	RE: oxymorphone Rx	ALLERGAN_MDL_00186509	ALLERGAN_MDL_00186514		
P-03361	2/12/2020	Stipulated Protective Order - Modified	N/A	N/A		
P-03362	1/5/2012	RE: Resumes; Mark_Killion_resume_010512	Acquired_Actavis_00365989	Acquired_Actavis_00365993		
P-03376	6/11/2013	SDF Press Release re WAG settlement of \$80 million with MOT & Addendum attached	N/A	N/A		
P-03411	N/A	Mark Killion LinkedIn profile	N/A	N/A		
P-03414	1/11/2011	KADIAN National Sales Meeting Awards Banquet	ACTAVIS0234399	ACTAVIS0234421		
P-03418	3/17/2011	Embeda Feedback	ALLERGAN_MDL_01193205	ALLERGAN_MDL_01193205		
P-03419	11/15/2010	Training this week; Actavis Agenda November 18-19 2010	Acquired_Actavis_00181912	Acquired_Actavis_00181914		
P-03420	5/27/2010	Fwd: Warning Letter	Acquired_Actavis_01354962	Acquired_Actavis_01354962		
P-03422	7/20/2011	Re: A347 Oxymorphone Training Materials	ACTAVIS0969302	ACTAVIS0969304		
P-03423	11/21/2011	Slides for Tomorrow; Generic KADIAN Slides 11.22.11.pptm	ACTAVIS0335093	ACTAVIS0335117		
P-03424	7/1/2011	Pfizer comments on draft REMS/REMS SD for Metrics Sub-team; IWG_Opioid_REMS_SD_01Jul11_Pfizer commentsx; IWG Proposed Opioid REMS 01Jul11 Pfizer commentsx	ACTAVIS0361094	ACTAVIS0361183		
P-03425	2/16/2018	Allergan plc and Warner Chilcott Limited, Form 10-K	N/A	N/A		
P-03426	2/28/2013	Actavis, Inc., Form 10-K	N/A	N/A		
P-03427	7/19/2018	Verified Answer of Watson, Actavis LLC, and Actavis Pharma, Inc. to Plaintiffs' Master Long Form Complaint	N/A	N/A		

P-03428	10/26/2018	Steve Kaufhold: Information collected in response to Plaintiff's' 30(b)(6) Notice	N/A	N/A		
P-03429	7/18/2018	Defendant Allergan Finance, LLC's Answer and Affirmative Defenses to Plaintiff's' Master Long Form Complaint and Jury Demand	N/A	N/A		
P-03430	2/18/2015	Actavis plc and Warner Chilcott Limited, Form 10-K	N/A	N/A		
P-03431	7/26/2015	Master Purchase Agreement by and between Allergan PLC and Teva Pharmaceutical Industries Ltd.	ALLERGAN_MDL_SUPP_00000174	ALLERGAN_MDL_SUPP_00000325		
P-03432	2/5/2020	Excerpts from Teva Full Product Catalog	N/A	N/A		
P-03433	1/31/2018	Teva Allergan Agreement	ALLERGAN_MDL_SUPP_00000132	ALLERGAN_MDL_SUPP_00000172		
P-03434	7/31/2019	Response of Specially Appearing Defendant Teva Pharmaceutical Industries Ltd. to Defendants Allergan Plc, Allergan Finance, LLC, Allergan Sales, LLC, and Allergan USA, Inc.'s Individual Motion for Summary Judgment	N/A	N/A		
P-03435	N/A	Schedule 1.1(f) - Transferred Entities	N/A	N/A		
P-03436	1/17/2020	Washington Post - Drilling into the DEA's pain pill database	N/A	N/A		
P-03437	3/1/2010	Watson Pharmaceuticals, Inc., Form 10-K	N/A	N/A		
P-03439	12/30/2008	FW: Kadian Closing; FINAL Actavis King Pharma APA Dec 12 2008; Kadian Strategic Analysis - 12-10-08.xls; Landscape Deck.ZIP; Kadian market 12-29-2008.xls; TRx Trends.xls	ALLERGAN_MDL_02092119	ALLERGAN_MDL_02092236		
P-03440	1/9/2013	Kadian Training Presentations; Co-Pay Cards - Sales Training pptx; Form Trak Training Presentation - Sales; Form Trak Presentation - Sales Training.pptx; HCC Compliance Training _KADI1236_LAM_091312.ppt; KADIAN Objection Handling 091212.ppt; KADIAN PI Workshop 091212.ppt; Managed Markets Technikes 091212.pptx; Pain Market Overview 091212.ppt; Marketing Presentation Formatted	ALLERGAN_MDL_00990330	ALLERGAN_MDL_00990594	ALLERGAN_MDL_00990330 - ALLERGAN_MDL_00990594	
P-03441	10/8/2012	Sept 2012 Reports; Kadian \$50 CoPay Card 2010 20121004.zip; Kadian Individual Groups 20121004.zip (10 excels attached)	ALLERGAN_MDL_00017884	ALLERGAN_MDL_00017894		
P-03443	12/1/2019	Excerpts from the Expert Report of James E. Rafalski: Failures by Distributors and Manufacturers of Controlled Substances Doing Business in New York to Maintain Effective Controls to Prevent Diversion of and to Identify, Report, and Block Suspicious Orders for Schedule II Opioid Drugs	N/A	N/A		
P-03444	8/19/2011	DEA Partnership Compliance Call with Watson	ALLERGAN_MDL_03799164	ALLERGAN_MDL_03799232		
P-03445	1/31/2020	Alliance for Patient Access, Associate Members Financial Supporters (January 2020)	N/A	N/A		
P-03446	3/27/2009	REMS Task Force - April 7 Working Group Meeting	Acquired_Actavis_01692390	Acquired_Actavis_01692404		
P-03447	3/5/2018	Conference DMC and Expo	N/A	N/A		
P-03448	2/8/2020	Teva Generics Product Search	N/A	N/A		
P-03449	5/31/2019	Allergan Finance, LLC's First Amended Objections and Responses to Plaintiff's' Fourth Set of Interrogatories (MDL)	N/A	N/A		
P-03450	7/30/2019	Allergan's Fifth Amended Objections and Responses to Plaintiff's' Corrected Second Set of Interrogatories (MDL)	N/A	N/A		
P-03451	7/30/2019	Allergan's Sixth Amended Objections and Responses to Plaintiff's' First Set of Interrogatories (MDL)	N/A	N/A		
P-03452	7/30/2019	Allergan's Third Amended Objections and Responses to Plaintiff's' Third Set of Interrogatories (MDL)	N/A	N/A		
P-03453	7/30/2019	Julie Snyder Verification - Allergan's Fifth Amended Objections and Responses to Plaintiff's' Corrected Second Set of Interrogatories (MDL)	N/A	N/A		
P-03454	7/30/2019	Julie Snyder Verification - Allergan Finance, LLC's First Amended Objections and Responses to Plaintiff's' Fourth Set of Interrogatories (MDL)	N/A	N/A		
P-03455	7/30/2019	Julie Snyder Verification - Allergan's Sixth Amended Objections and Responses to Plaintiff's' First Set of Interrogatories (MDL)	N/A	N/A		
P-03456	7/30/2019	Julie Snyder Verification - Allergan's Third Amended Objections and Responses to Plaintiff's' Third Set of Interrogatories (MDL)	N/A	N/A		

P-03457	7/15/2019	Allergan's Corrected and Amended Verified Responses to Plaintiff's Additional 30(b)(6) Questions - Stephen Kaufhold (MDL)	N/A	N/A		
P-03458	5/31/2019	Allergan Finance, LLC's First Amended Objections and Responses to Plaintiff's Fourth Set of Interrogatories; Julie Snyder Verification - Allergan Finance, LLC's First Amended Objections and Responses to Plaintiff's Fourth Set of Interrogatories (MDL)	N/A	N/A		
P-03459	9/17/2021	Allergan's Second Amended and Supplemental Responses to Plaintiff's First Set of Interrogatories to Allergan (No.6)	N/A	N/A		
P-03460	9/17/2021	Allergan's Second Amended and Supplemental Responses to Plaintiff's First Set of Interrogatories to Allergan (No.6), Exhibit 1	N/A	N/A		
P-03461	12/23/2020	Allergan's Responses to Plaintiff's First Set of Interrogatories	N/A	N/A		
P-03462	6/28/2021	Allergan's First Amended and Supplemental Responses to Plaintiff's First Set of Interrogatories to All Non-Stayed Defendants	N/A	N/A		
P-03463	3/8/2021	Allergan's Responses to Plaintiff's First Set of Interrogatories to All Non-Severed Defendants	N/A	N/A		
P-03464	9/13/2021	Allergan's Second Amended and Supplemental Responses to Plaintiff's First Set of Interrogatories to Allergan (Nos. 1-5, 7-15)	N/A	N/A		
P-03465	10/11/2021	Allergan's Third Amended and Supplemental Responses to Plaintiff's First Set of Interrogatories to Allergan (No. 11)	N/A	N/A		
P-03466	11/12/2021	Allergan's Responses to Plaintiff's Fourth Set of Interrogatories to the Allergan/Actavis Family of Defendants	N/A	N/A		
P-03467	7/9/2019	Plaintiff's Memorandum of Law in Opposition to Defendant Allergan PLC's Motion to Dismiss Pursuant to Rule 12(b)(2) for Lack of Personal Jurisdiction	N/A	N/A		
P-03468	7/9/2019	Declaration of Thomas E. Egler in Support of Plaintiff's Memorandum of Law in Opposition to Defendant Allergan PLC's Motion to Dismiss Pursuant to Rule 12(b)(2) for Lack of Personal Jurisdiction	N/A	N/A		
P-03469	12/31/2018	Excerpts from Allergan plc and Warner Chilcott Ltd YE 2018 10-K	N/A	N/A		
P-03470	4/1/2019	The Economic and Community Impact of Allergan to Ohio	N/A	N/A		
P-03471	4/15/2019	New Study Showcases Economic and Community Impact of Allergan's Operations in Ohio	N/A	N/A		
P-03472	3/21/2019	Excerpts from Third Amended Complaint and Jury Demand	N/A	N/A		
P-03473	6/20/2019	Letter to Timothy W. Knapp	N/A	N/A		
P-03474	6/15/2015	Actavis plc is now Allergan plc	N/A	N/A		
P-03475	10/1/2013	Actavis Completes Warner Chilcott Acquisition	N/A	N/A		
P-03476	12/31/2012	Excerpts from Actavis, Inc. YE 2012 10-K	N/A	N/A		
P-03477	12/31/2013	Excerpts from Actavis plc YE 2013 10-K	N/A	N/A		
P-03478	5/5/2016	Constitution of Allergan PLC - Memorandum of Association	N/A	N/A		
P-03479	8/2/2016	Allergan plc Completes Divestiture of Global Generics Business to Teva Pharmaceuticals	N/A	N/A		
P-03480	2/20/2017	RE: CRITICAL - Status of NORCI 5/325 NDC CHANGE TO RELEASE BACKORDERS; Supply Agreement - Executed - Copy	ALLERGAN_MDL_01385781	ALLERGAN_MDL_01385842		
P-03482	1/31/2018	Settlement Agreement and Mutual Releases - Teva and Allergan	N/A	N/A		
P-03483	12/31/2015	Excerpts from Allergan plc and Warner Chilcott Limited YE 2015 10-K	N/A	N/A		
P-03484	12/31/2016	Excerpts from Allergan plc 2016 Irish Annual Report	N/A	N/A		
P-03485	3/9/2018	Second Amended and Restated Operating Agreement of Allergan Finance, LLC	ALLERGAN_MDL_SUPP_00000326	ALLERGAN_MDL_SUPP_00000338		
P-03486	1/15/2016	Re: Fw: PwC Request - Year-End Sales Term Confirmations; Brand Sales Term Confirmations Part 1.zip	ALLERGAN_MDL_04241927	ALLERGAN_MDL_04242141		
P-03487	N/A	Original Workings	ALLERGAN_MDL_04452226	ALLERGAN_MDL_04452226		
P-03488	5/21/2015	RE: Chargeback Analysis Discussion; Chargeback Analysis.xlsx	ALLERGAN_SF_00171656	ALLERGAN_SF_00171658		

P-03600	7/16/2012	ZS Associates Endo Promotional Mix Optimization Brand Level Model Results and ROI	ENDO-CHI_LIT-00214471	ENDO-CHI_LIT-00214471		
P-03601	2004	2004 Actiq Marketing Plan	TEVA MDL A 01159263	TEVA MDL A 01159322		
P-03602	N/A	CD&E: The Critical Connection for Success in 2000 and Beyond	ENDO-OPIOID MDL-02344002	ENDO-OPIOID MDL-02344002		
P-03603	3/25/2022	Email Risk Management Presentation; Attachment EN3202 Risk Management PPT	ENDO-OPIOID MDL-04095507	ENDO-OPIOID MDL-04095508		
P-03604	2001	Pain Management Today, Vol 1, Number 1	ENDO-OPIOID MDL-01605952	ENDO-OPIOID MDL-01605958		
P-03605	1/1/2017	Responsible Opioid Prescribing, A Physician's Guide by Scott M. Fishman, M.D.	END00051370	END00051443		
P-03606	N/A	Actiq Label, November 1998	N/A	N/A		
P-03607	11/16/2000	Actiq "Master Plan"	TEVA CHI 00042757	TEVA CHI 00042817		
P-03608	2003	2003 Actiq Marketing Plan	TEVA CHI 00042882	TEVA CHI 00042950		
P-03609	2002	Actiq Marketing 2002, Sales Training, March 2002	TEVA MDL A 05734046	TEVA MDL A 05734097		
P-03610	2007	Fentora Marketing Plan 2007	TEVA MDL A 00364486	TEVA MDL A 00364486		
P-03611	12/1/2005	Cephalon FEBT (Fentanyl Effervescent Buccal Tablet) 2005-2006 Marketing Plan	TEVA MDL A 00368405	TEVA MDL A 00368625		
P-03613	1/15/2013	Re: Kadian Training Manual References - Detective work required! Attachment Kadian Training Manual; 28 Alpha Clean Final	ALLERGAN MDL_01610520	ALLERGAN MDL_01611060		
P-03614	N/A	Video	N/A	N/A		
P-03615	N/A	Reading This Could Help Ease Your Pain, Pain Action Guide, American Pain Foundation	CHI_000432493	CHI_000432507		
P-03616	N/A	Guideline for the Management of Pain in Osteoarthritis, Rheumatoid Arthritis, and Juvenile Chronic Arthritis, 2nd Edition	PKY181215547	PKY181215749		
P-03619	N/A	Mallinckrodt-Terifay-012	TEVA MDL A 03272549	TEVA MDL A 03272551		
P-03620	N/A	Mallinckrodt-Terifay-014	TEVA CHI 00049296	TEVA CHI 00049325		
P-03621	N/A	Mallinckrodt-Terifay-016	TEVA MDL A 07846839	TEVA MDL A 07846839		
P-03622	N/A	Mallinckrodt-Terifay-018	TEVA CHI 00043010	TEVA CHI 00043093		
P-03623	N/A	Mallinckrodt-Terifay-020	TEVA MDL A 07864370	TEVA MDL A 07864502		
P-03624	N/A	Mallinckrodt-Terifay-021	TEVA MDL A 06384299	TEVA MDL A 06384302		
P-03625	1/24/2005	Re: JAMA (1/19): Research Letter Finds Increased Reports on Methadone Diversion and Abuse	TEVA MDL A 03272549	TEVA MDL A 03272551		
P-03626	2002	Actiq 2002 Marketing Plan	TEVA MDL A 00454816	TEVA MDL A 00454959		
P-03627	2003	2003 Actiq Marketing Plan	TEVA CHI 00042882	TEVA CHI 00042950		
P-03628	4/9/2004	Email Important News: New Tools Available	TEVA MDL A 09667462	TEVA MDL A 09667463		
P-03629	12/13/2006	Email Do you Still Have Pain; Attachment Final printed patient brochure	TEVA MDL A 01399742	TEVA MDL A 01399750		
P-03630	12/19/2006	Educational Grant Draft Request and Memo, American Pain Foundation	TEVA MDL A 01174115	TEVA MDL A 01174147		
P-03631	10/2/2006	Email ACPA brochure; Attachment Breakthrough Pain 9-20-06	TEVA MDL A 02935839	TEVA MDL A 02935841		
P-03632	N/A	Managing Breakthrough Pain Brochure	N/A	N/A		
P-03633	5/10/2006	Educational Grant Draft Request and Letter, American Pain Foundation	TEVA MDL A 01089587	TEVA MDL A 01089589		
P-03634	N/A	Teva-Beckhardt-030	TEVA MDL A 01090493	TEVA MDL A 0109549		
P-03635	N/A	Teva-Brennan-005	N/A	N/A		
P-03636	N/A	Teva-Brennan-017	TEVA MDL A 01159525	TEVA MDL A 01159527		
P-03637	N/A	Meeting Reminder by A. Jordheim	TEVA MDL A 00890304	TEVA MDL A 00890382		
P-03638	2015	Incremental Performance Detail Q4 2015	TEVA MDL A 08657218	TEVA MDL A 08657224		
P-03639	2014	Discovery Channel Documentary Pain Matters Flyer	TEVA MDL A 08657349	TEVA MDL A 08657349		
P-03640	N/A	Teva-Day-026	N/A	N/A		
P-03641	N/A	Teva-Day-030	TEVA MDL A 00886736	TEVA MDL A 00886736		
P-03642	10/17/2014	Teva Opioid Market Share Calculation: All Opioids	TEVA MDL A 00455086	TEVA MDL A 00455094		
P-03643	7/16/2012	FW: DEA Suspicious Order Monitoring Program	TEVA MDL A 06618645	TEVA MDL A 06618656		
P-03644	9/25/2012	Compliance Solutions Powered by Buzzeo PDMA; Buzzeo Report re: Teva's SOM system	TEVA MDL A 01060005	TEVA MDL A 01060012		
P-03645	11/3/2017	SOM and Current Cases presentation	TEVA MDL A 02480067	TEVA MDL A 02480068		
P-03646	8/19/2015	FW: Global Internal Audit: DEA - Final Report	TEVA MDL A 02475564	TEVA MDL A 02475585		
P-03647	1/1/2001	Actiq Marketing Plan 2001	TEVA MDL A 01159143	TEVA MDL A 01159193		
P-03648	2002	Teva-Pyfer-018	TEVA MDL A 00454816	TEVA MDL A 00454871		
P-03649	2003	2003 Actiq Marketing Plan	TEVA MDL A 01159194	TEVA MDL A 01159262		

P-03650	N/A	Teva-Pyfer-028	TEVA_MDL_A_01159323	TEVA_MDL_A_01159406		
P-03651	N/A	Teva-Pyfer-033	TEVA_MDL_A_13619686	TEVA_MDL_A_05313123		
P-03652	N/A	Teva-Pyfer-034	TEVA_MDL_A_13619686	TEVA_MDL_A_05965744		
P-03653	10/19/2006	Field_Version3 video	TEVA_MDL_A_03571751	TEVA_MDL_A_03571751		
P-03654	N/A	Teva-Pyfer-038	TEVA_MDL_A_01129118	TEVA_MDL_A_01129120		
P-03655	N/A	Teva-Spokane-016	N/A	N/A		
P-03656	2/7/2007	DEA Letter	TEVA_MDL_A_01039159	TEVA_MDL_A_01039162		
P-03657	N/A	Teva-Tomkiewicz-012	TEVA_MDL_A_01060005	TEVA_MDL_A_01060012		
P-03658	8/19/2015	FW: Global Internal Audit: DEA - Final Report	TEVA_MDL_A_02475564	TEVA_MDL_A_02475585		
P-03659	11/3/2017	SOM and Current Cases presentation	TEVA_MDL_A_02480067	TEVA_MDL_A_02480068		
P-03660	3/2/2018	PowerPoint; 2017 Joe Tomkiewicz PDMA Conference - v2	TEVA_MDL_A_02480387	TEVA_MDL_A_02480388		
P-03661	10/16/2015	RE: PO# 1031374 for the OXYCODONE product	TEVA_MDL_A_01466124	TEVA_MDL_A_01466127		
P-03662	10/16/2015	2015-10-16 Christine Baeder Phone Call	TEVA_MDL_A_02063728	TEVA_MDL_A_02063728		
P-03663	10/28/2015	RE: Publix Anda weekly call	TEVA_MDL_A_01462200	TEVA_MDL_A_01462203		
P-03668	4/16/1996	U.S. Department of Justice, DEA, Diversion Investigators Manual, letter to Robert Giacalone	CAH_MDL2804_02203353	CAH_MDL2804_02203357		
P-03669	6/18/2007	2006 Allergan Rannazzisi Letter	ALLERGAN_MDL_02467796	ALLERGAN_MDL_02467799		
P-03670	12/27/2007	Rannazzisi letter	MCKMDL00478910	MCKMDL00478911		
P-03674	N/A	3301884 Exhibit 8 JosephRannazzisi	N/A	N/A		
P-03675	N/A	Endo-Romaine-020	ENDO-OPIOID_MDL-04908831	ENDO-OPIOID_MDL-04908832		
P-03676	N/A	Endo-Romaine-022	ENDO-OPIOID_MDL-04911467	ENDO-OPIOID_MDL-04911467		
P-03677	N/A	Endo-Romaine-025	ENDO-CHI_LIT-00543478	ENDO-CHI_LIT-00543495		
P-03680	N/A	Endo-Romaine-040	ENDO-OPIOID_MDL-00685033	ENDO-OPIOID_MDL-00685033		
P-03681	N/A	Opana ATU Final Rpt Wave 6 FINAL PPT	ENDO-CHI_LIT-00547543	ENDO-CHI_LIT-00547543		
P-03682	1999	Clinical Development & Education 1999 Objectives for Linda A. Kitlinski	ENDO-OPIOID_MDL-03258200	ENDO-OPIOID_MDL-03258202		
P-03683	N/A	Endo-Kitlinski-003	ENDO-OPIOID_MDL-02344002	ENDO-OPIOID_MDL-02344002		
P-03684	12/6/2001	3202 Draft Plans for 2002	ENDO-OPIOID_MDL-02002513	ENDO-OPIOID_MDL-02002514		
P-03685	8/24/2001	FW: 2002 Strategy Review	ENDO-OPIOID_MDL-03388209	ENDO-OPIOID_MDL-03388210		
P-03686	N/A	Pain Job lists	MDL_KP360_00000002	MDL_KP360_00000002		
P-03687	4/17/2003	LK Presentation for Advanced Rep Training	ENDO-OPIOID_MDL-02002702	ENDO-OPIOID_MDL-02002703		
P-03688	12/5/2011	Re: APF Corporate Roundtable Call - 10 am Central (8 am Pacific; 11 am Eastern)	JAN-MS-00925641	JAN-MS-00925643		
P-03689	11/14/2011	FW: V8 - Minor Tweaks Awakening to REMS RD Lunch and Learn Nov 15 2011 Draft Slides	ENDO-CHI_LIT-00241435	ENDO-CHI_LIT-00241436		
P-03690	4/5/2002	Business Planning Kick-Off Meeting Documents	ENDO-OPIOID_MDL-04908487	ENDO-OPIOID_MDL-04908488		
P-03691	N/A	Endo-Shusterman-004	ENDO-CHI_LIT-00543478	ENDO-CHI_LIT-00543495		
P-03692	N/A	Endo-Shusterman-014	ENDO-CHI_LIT-00241435	ENDO-CHI_LIT-00241436		
P-03693	6/1/2007	Risk Minimization Action Plan for Opana ER	ENDO-CHI_LIT-00234542	ENDO-CHI_LIT-00234587		
P-03694	2/6/2009	Letter re Opana ER from FDA	END00373370	END00373372		
P-03695	7/1/2009	FW: Percocet; Copy of Pain Care Forum Lists (06-2009)	ENDO-OPIOID_MDL-06146694	ENDO - OPIOID_MDL-06146696		
P-03696	12/27/2007	Rannazzisi letter	ABDCMDL00269685	ABDCMDL00269686		
P-03698	3/22/2013	Information for Monday's meeting and follow up from Wednesday; DEA response letter HSV tablets - final; DOC071312; FW: Summary of Yesterday's Meeting with DEA; SOMS Presentation 3-13-2013 (3)	ENDO-OPIOID_MDL-06458018	ENDO-OPIOID_MDL-06458048		
P-03699	3/22/2013	RE: Epi data for CEO	EPI002466743	EPI002466772		
P-03700	4/9/2013	Opana ER CEO Briefing_Core Deck_04.08.13	EPI001147124	EPI001147125		
P-03701	12/1/2013	Healthcare Compliance Guide on Interactions with Customers	ENDO_OPIOID_DEPMAT-000019855	ENDO_OPIOID_DEPMAT-000019992		
P-03702	6/30/2015	Endo Executive Leadership Team Meeting Agenda	ENDO-OPIOID_MDL-01899484	ENDO-OPIOID_MDL-01899484		
P-03704	9/27/2006	Rannazzisi Letter about suspicious orders	N/A	N/A		
P-03706	N/A	Teva-Pyfer-017	TEVA_MDL_A_05313123	TEVA_MDL_A_05313182		
P-03708	N/A	Teva-Beckhardt-001; Actiq and Fentora images	N/A	N/A		
P-03710	8/1/2001	Actiq Risk Management Program	TEVA_MDL_A_03272088	TEVA_MDL_A_03272117		
P-03711	N/A	Teva-Beckhardt-015	N/A	N/A		
P-03712	N/A	Teva-Beckhardt-017	N/A	N/A		
P-03713	N/A	Teva-Beckhardt-018	N/A	N/A		
P-03714	N/A	Educational Grant Draft Request, American Chronic Pain Association	TEVA_MDL_A_01089593	TEVA_MDL_A_01089596		
P-03714	N/A	Educational Grant Draft Request	TEVA_MDL_A_01089593	TEVA_MDL_A_01089596		

P-03715	N/A	Mallinckrodt-Terifay-002	N/A	N/A		
P-03716	N/A	Mallinckrodt-Terifay-006	N/A	N/A		
P-03717	N/A	Mallinckrodt-Terifay-009	N/A	N/A		
P-03718	N/A	Mallinckrodt-Terifay-010	TEVA_MDL_A_04108856	TEVA_MDL_A_04108858		
P-03719	N/A	Mallinckrodt-Terifay-013	N/A	N/A		
P-03720	N/A	Mallinckrodt-Terifay-015	N/A	N/A		
P-03721	N/A	Mallinckrodt-Terifay-019	N/A	N/A		
P-03722	2014	Suspicious Order Monitoring presentation	TEVA_MDL_A_02923616	TEVA_MDL_A_02923616		
P-03723	1/7/2014	SOM Documents	TEVA_MDL_A_03478588	TEVA_MDL_A_03478588		
P-03724	6/18/2018	SOP-8277, Suspicious Order Monitoring - DEA Order Holds	TEVA_MDL_A_01158453	TEVA_MDL_A_01158462		
P-03725	10/16/2015	RE: PO# 1031374 for the OXYCODONE product	TEVA_MDL_A_02063729	TEVA_MDL_A_02063733		
P-03726	N/A	Teva-Tomkiewicz-019	TEVA_MDL_A_01056272	TEVA_MDL_A_01056278		
P-03727	N/A	Teva-Day-015	TEVA_MDL_A_01211895	TEVA_MDL_A_01211895		
P-03730	N/A	Teva-McGinn-007	N/A	N/A		
P-03731	5/24/2012	RE: Cardinal SOM issues; DEA Suspicious Monitoring Compliance Draft	TEVA_MDL_A_01453866	TEVA_MDL_A_01453897		
P-03732	N/A	Suspicious Order Monitoring (SOM)	TEVA_MDL_A_02336504	TEVA_MDL_A_02336504		
P-03733	12/3/2015	Text exchange between Tomkiewicz and McGinn	TEVA_MDL_A_01056183	TEVA_MDL_A_01056183		
P-03735	10/15/2017	3301884 Exhibit 15 JosephRannazzisi	N/A	N/A		
P-03736	N/A	Healthcare Distribution Management Association (HDMA) Industry Compliance Guidelines: Reporting Suspicious Orders and Preventing Diversion of Controlled Substances	N/A	N/A		
P-03737	N/A	RE: Contract Actavis.com, image	ALLERGAN_MDL_00478433	ALLERGAN_MDL_00478435		
P-03738	N/A	Allergan-Boothe-001	composite	composite		
P-03739	N/A	FW: Sales rep training material draft	ACTAVIS0506794	ACTAVIS0506814		
P-03740	N/A	Controlled Substance Seminar Summary	ALLERGAN_MDL_03535130	ALLERGAN_MDL_03535133		
P-03741	N/A	2011 Goals DEA	ALLERGAN_MDL_02467983	ALLERGAN_MDL_02467998		
P-03742	4/5/2012	SOMS Presentation 4.5.12; SOMS Project Evolution IT Governance Meeting	ALLERGAN_MDL_02468982	ALLERGAN_MDL_02468994		
P-03743	N/A	RE: Hydrocodone Supply Issues - Market Demand; Hydrocodone APAP Weekly TRx's 2012-04-19; AR-M550N_20120412_082528	Acquired_Actavis_01179002	Acquired_Actavis_01179005		
P-03744	N/A	BuzzeePDMA SOM Seminar Agenda 2012	ALLERGAN_MDL_02467214	ALLERGAN_MDL_02467216		
P-03745	N/A	FW: Order(s) on Hold - MIAMI-LUKEN INC SD# 636885	ALLERGAN_MDL_02179760	ALLERGAN_MDL_02179772		
P-03746	N/A	Customer Analysis and SOMS Overview Import/Export PPT	ALLERGAN_MDL_02147093	ALLERGAN_MDL_02147110		
P-03747	N/A	SOM Project Just 2.19.15	ALLERGAN_MDL_03535253	ALLERGAN_MDL_03535257		
P-03748	N/A	Email Slides for Tomorrow; Attachment Generic KADIAN Slides	Acquired_Actavis_00369838	Acquired_Actavis_00369839		
P-03749	N/A	Re: Weekly Update	ACTAVIS0815204	ACTAVIS0815206		
P-03750	N/A	Allergan-Altier-009	ACTAVIS0389758	ACTAVIS0389800		
P-03751	N/A	Allergan-Altier-010	ACTAVIS0501884	ACTAVIS0501893		
P-03752	N/A	Allergan-McCormick-004	ACTAVIS0481204	ACTAVIS0481210		
P-03753	N/A	Allergan-McCormick-009	ACTAVIS0816122	ACTAVIS0816128		
P-03754	N/A	Allergan-McCormick-011	ACTAVIS1129567	ACTAVIS1129568		
P-03755	N/A	RE: Dr. Schwartz - Pharmacies	ACTAVIS0328319	ACTAVIS0328336		
P-03756	1/27/2012	RE: Actavis - ValueTrak Renewal (Trading Partners)	ALLERGAN_MDL_01213261	ALLERGAN_MDL_01213265		
P-03757	N/A	Allergan-McCormick-016	Acquired_Actavis_00951998	Acquired_Actavis_00952005		
P-03758	N/A	Allergan-McCormick-017	Acquired_Actavis_00379710	Acquired_Actavis_00379799		
P-03759	N/A	Allergan-McCormick-019	ACTAVIS0350871	ACTAVIS0350907		
P-03760	N/A	Allergan-McCormick-023	Acquired_Actavis_02114868	Acquired_Actavis_02114882		
P-03762	N/A	Documents referenced by Endo Defendants in response to Interrogatory No. 33 of their January 7, 2019 Objections and Responses to Plaintiffs' Third Set of Interrogatories, served In Re: National Prescription Opiate Litigation, United States District Court Northern District of Ohio, Eastern Division, MDL No. 2804, Case No. 17-md-2804	Compilation Exhibit: Non-Sequential Bates - see Attachment to P-03762	Compilation Exhibit: Non-Sequential Bates - see Attachment to P-03762		



P-03763	N/A	Documents referenced by Par Defendants in response to Interrogatory No. 33 of their June 27, 2019 Second Supplemental Objections and Responses to Plaintiffs' Interrogatory Nos 5, 22, 23, 24, 27, and 33, served In Re: National Prescription Opiate Litigation, United States District Court Northern District of Ohio, Eastern Division, MDL No. 2804, Case No. 17-md-2804	Compilation Exhibit: Non-Sequential Bates - see Attachment to P-03763	Compilation Exhibit: Non-Sequential Bates - see Attachment to P-03763		
P-03764	N/A	Documents referenced by Allergan Defendants in response to Interrogatory No. 32 of their July 30, 2019 Third Amended Objections and Responses to Plaintiff's Third Set of Interrogatories, served In Re: National Prescription Opiate Litigation, United States District Court Northern District of Ohio, Eastern Division, MDL No. 2804, Case No. 17-md-2804	Compilation Exhibit - see Attachment to P-03764	Compilation Exhibit - see Attachment to P-03764		
P-03765	N/A	Allergen-Leitch-008	ALLERGAN MDL_00638086	ALLERGAN MDL_00638097		
P-03770	N/A	Vitale 07	TEVA MDL_A_12122432	TEVA MDL_A_12122432		
P-03771	N/A	Vitale 09	TEVA MDL_A_01459814	TEVA MDL_A_01459866		
P-03772	7/16/2013	SOMS Customer Letter & Sales Rep Talking Points	ENDO-OPIOID MDL-02448143	ENDO-OPIOID MDL-02448143		
P-03776	N/A	Anda-Brown-006	Anda Opioids MDL_0000056015	Anda Opioids MDL_0000056016		
P-03777	10/16/2018	30(b)(6) Deposition Notice for Allergan defendants for representatives Stephen Kaufhold, Julie Snyder, and Mary Woods	N/A	N/A		
P-03778	2008	Doug Boothe Personal Details	Acquired_Actavis_01541043	Acquired_Actavis_0128730		
P-03783	N/A	Anda-Cochrane-006	Anda Opioids MDL_0000271410	Anda Opioids MDL_0000271411		
P-03784	7/27/2007	Standard Operating Procedure; SOP; OPS-040-00; SOP Number: OPS-000-40	Anda Opioids MDL_0000276963	Anda Opioids MDL_0000276964		
P-03785	11/7/2007	Re: Fw: Distributor Notification	Anda Opioids MDL_0000038787	Anda Opioids MDL_0000038794		
P-03786	12/7/2005	Excessive Order Reports November 2005	Anda Opioids MDL_0000271895	Anda Opioids MDL_0000271896		
P-03787	12/11/2007	Re: Fw: Distributor Notification	Anda Opioids MDL_0000272213	Anda Opioids MDL_0000272215		
P-03788	12/8/2010	Re: Account#476453; Richard Clyde Strockbine III5	Anda Opioids MDL_0000076476	Anda Opioids MDL_0000076479		
P-03789	N/A	Anda-Cochrane-044	Anda Opioids MDL_0000079594	Anda Opioids MDL_0000079595		
P-03790	9/11/2012	Calculation Example	Anda Opioids MDL_0000085935	Anda Opioids MDL_0000085935		
P-03791	2021	Craig McCann Resume	N/A	N/A		
P-03792	N/A	Allergan-Altier-007	ACTAVIS0255710	ACTAVIS0255713		
P-03793	N/A	Allergan-Altier-008	ACTAVIS0252398	ACTAVIS0252421		
P-03794	N/A	Allergan-Altier-011	ACTAVIS0672638	ACTAVIS0672645		
P-03807a	N/A	McCann's ARCOS as relied on by Dr. McCann in Frye - Raw ARCOS	N/A	N/A		
P-03807b	N/A	McCann's ARCOS as relied on by Dr. McCann in Frye - Processed ARCOS	N/A	N/A		
P-03812	N/A	Vitale 03	N/A	N/A		
P-03815	7/25/2007	Re: BJK	Anda Opioids MDL_0000275705	Anda Opioids MDL_0000275705		
P-03817	8/7/2007	Brighton Eggert cust #2168	Anda Opioids MDL_0000275535	Anda Opioids MDL_0000275535		
P-03818	8/24/2007	Re: Approval	Anda Opioids MDL_0000275048	Anda Opioids MDL_0000275048		
P-03819	8/24/2007	Re: Partners	Anda Opioids MDL_0000275053	Anda Opioids MDL_0000275054		
P-03820	10/16/2017	Re: Fw: Distributor Notification	Anda Opioids MDL_0000078798	Anda Opioids MDL_0000078800		
P-03821	10/16/2017	Fw: Distributor Notification	Anda Opioids MDL_0000274531	Anda Opioids MDL_0000274532		
P-03822	10/18/2007	Re: Fw: H J Harkins	Anda Opioids MDL_0000078222	Anda Opioids MDL_0000078225		
P-03824	4/15/2008	Memorandum of Understanding - Suspicious Orders	Anda Opioids MDL_0000276119	Anda Opioids MDL_0000276119		
P-03825	7/23/2008	Customers Limitations by Controlled Substance Chemical Family	Anda Opioids MDL_0000709809	Anda Opioids MDL_0000709809		
P-03826	7/24/2008	control substance review	Anda Opioids CA_SF_0072964	Anda Opioids CA_SF_0072965		
P-03827	7/28/2008	Re: control limits for bjk ct 217	Anda Opioids MDL_0000273439	Anda Opioids MDL_0000273440		
P-03828	2/12/2009	Re: Partners	Anda Opioids MDL_0000284363	Anda Opioids MDL_0000284364		
P-03829	2/20/2009	Re: Publix Order Pending	Anda Opioids MDL_0000282721	Anda Opioids MDL_0000282723		
P-03831	12/28/2009	Re: Urgent Approval	Anda Opioids MDL_0000283727	Anda Opioids MDL_0000283727		
P-03832	3/30/2010	Re: Need Approval	Anda Opioids MDL_0000287271	Anda Opioids MDL_0000287272		
P-03833	11/18/2011	Letter to Paonessa from DEA re DEA Registration Number RA0180733	Anda Opioids MDL_0000132162	Anda Opioids MDL_0000132163		
P-03834	10/20/2015	Documents; It Starts With Me PM Show 120913; Timeline for DEA Inspection of Groveport (2)	Anda Opioids MDL_0001096221	Anda Opioids MDL_0001096286		



P-03836	11/28/2011	Fax to Compliance Department with Customer Questionnaire	Anda_Opioids_PA_0036693	Anda_Opioids_PA_0036698		
P-03837	7/11/2012	Anda update July 10 2012	Anda_Opioids_MDL_0000726922	Anda_Opioids_MDL_0000726924		
P-03839	11/13/2012	FW: anda contract	Anda_Opioids_MDL_0001099189	Anda_Opioids_MDL_0001099216		
P-03840	12/11/2012	RE: DEA	Anda_Opioids_MDL_0000085675	Anda_Opioids_MDL_0000085676		
P-03841	3/7/2013	Contingency and SOM	Anda_Opioids_MDL_0000623204	Anda_Opioids_MDL_0000623205		
P-03842	1/23/2015	FW: 158602; Supplemental Questions	Anda_Opioids_MDL_0000597799	Anda_Opioids_MDL_0000597801		
P-03844	4/25/2012	Watson to Acquire Actavis Group for EUR4.25 Billion	N/A	N/A		
P-03845	11/1/2012	Watson Pharmaceuticals, Inc. Completes Actavis Acquisition	N/A	N/A		
P-03846	8/3/2016	Allergan Announces Sale of Anda Distribution Business to Teva Pharmaceuticals	N/A	N/A		
P-03847	8/4/2016	Generics distributor, Anda, Inc. has a new owner: Teva Pharma	N/A	N/A		
P-03848	10/3/2016	Teva Completes Acquisition of Anda, Inc.	N/A	N/A		
P-03849	12/31/2013	Actavis plc 2013 Revised Sections of Our Annual Report on Form 10-k for the year ended December 31, 2013 - Ex 99.1	N/A	N/A		
P-03850	N/A	Subsidiaries of ANDRX - Ex 21.1	N/A	N/A		
P-03851	2011	2011 HDMA Annual Photo Album	N/A	N/A		
P-03853	8/8/2021	HDA Board of Directors	N/A	N/A		
P-03854	8/8/2021	HDA Board of Directors - Albert Paonessa	N/A	N/A		
P-03855	3/21/2006	Re: Fw: Request for Information	Anda_Opioids_MDL_0000155548	Anda_Opioids_MDL_0000155560		
P-03856	2/12/2008	Fw: Independent Trade Associations	Anda_Opioids_MDL_0000609889	Anda_Opioids_MDL_0000609891		
P-03857	4/18/2008	Re: QI Association dues	Anda_Opioids_MDL_0000613774	Anda_Opioids_MDL_0000613777		
P-03858	2010	HDMA Business & Leadership Conference Photo Album	N/A	N/A		
P-03859	1/21/2011	FW: 2011 HDMA Membership	Anda_Opioids_MDL_0000727939	Anda_Opioids_MDL_0000727942		
P-03860	7/13/2011	FW: August 1 -- Factbook for Regionals & Controlled Substance Monitoring Discussion Agenda	Anda_Opioids_MDL_0000113447	Anda_Opioids_MDL_0000113449		
P-03861	9/27/2012	HDMA PR Campaign	Anda_Opioids_CA_SF_0073806	Anda_Opioids_CA_SF_0073887		
P-03862	4/28/2014	Anda facilitates business relationship-building	N/A	N/A		
P-03863	6/14/2014	6/1 HDMA Board of Directors Meeting - IMS Presentation	Anda_Opioids_MDL_0000719748	Anda_Opioids_MDL_0000719770		
P-03864	12/31/2014	Re: Request for an Interview with GAO	Anda_Opioids_MDL_0000084224	Anda_Opioids_MDL_0000084225		
P-03865	2/26/2015	Actavis Announces Intention to Adopt 'Allergan' Corporate Name	N/A	N/A		
P-03866	3/17/2015	Actavis Completes Allergan Acquisition	N/A	N/A		
P-03867	1/24/2013	Watson Pharmaceuticals, Inc. is Now Actavis, Inc.	N/A	N/A		
P-03868	5/14/2014	Announcing Proposed Executive Leadership Team for Combined Company Following Close of the Acquisition of Forest	N/A	N/A		
P-03869	12/31/2012	Actavis, Inc. Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 - Form 10-k	N/A	N/A		
P-03871	10/15/2008	Public Law 110-425 - Oct 15, 2008; Ryan Haight Online Pharmacy Consumer Protection Act of 2008	N/A	N/A		
P-03872	3/13/2006	Watson to Acquire ANDRX for \$1.9 Billion, Creating the Third Largest Specialty Pharmaceutical Company in the U.S.	N/A	N/A		
P-03873	3/13/2006	ANDRX Corporation Schedule 14A	N/A	N/A		
P-03875	9/30/2013	HDMA Annual Membership Meeting and Board of Directors Meeting	HDA_MDL_000217667_R	HDA_MDL_000217675_R		
P-03876	2017	Keysource Licensing New	N/A	N/A		
P-03877	2019	Keysource Licensing Renew	N/A	N/A		
P-03878	2020	Keysource, Praxis, Praxis Med, Key Pharmaceuticals Licensing	N/A	N/A		
P-03879	N/A	Jason Chung LinkedIn profile	N/A	N/A		
P-03880	7/7/2014	Overview; Sales and Marketing Overview 7-2014	Anda_Opioids_CA_SF_0008234	Anda_Opioids_CA_SF_0008290		
P-03881	5/13/2011	FW: control substance review	Anda_Opioids_CA_SF_0071393	Anda_Opioids_CA_SF_0071394		
P-03882	5/13/2011	FW: control substance review	Anda_Opioids_MDL_0000104761	Anda_Opioids_MDL_0000104761		
P-03883	12/1/2011	FW: Draft response to DEA LOA; control substance review	Anda_Opioids_MDL_0000133114	Anda_Opioids_MDL_0000133116		
P-03884	11/5/2015	DEA Letter and Response: DEA Response to Gayle Lane; sharp.copier@watson.com_20111122_042134; Control Substance Review	Anda_Opioids_MDL_0000539378	Anda_Opioids_MDL_0000539384		
P-04300	11/10/2017	In the Matter of Endo Health Solutions Inc. and Endo Pharmaceuticals Inc. Assurance of Discontinuance Under Executive Law Section 63 Subdivision 15, Filed in Suffolk County 11-10-2017	N/A	N/A		

P-04700	10/1/2021	Abatement Plan for Addressing the Opioid Crisis in the City and County of San Francisco, Expert Witness Report of G. Caleb Alexander, MD, MS	N/A	N/A		
P-04701	10/1/2021	Expert Witness Report of G. Caleb Alexander, MD, MS, Appendix A - John Hopkins Report "From Evidence to Impact"	N/A	N/A		
P-04702	10/1/2021	Expert Witness Report of G. Caleb Alexander, MD, MS, Appendix B - Curriculum Vitae	N/A	N/A		
P-04703	10/1/2021	Expert Witness Report of G. Caleb Alexander, MD, MS, Appendix C - Materials Relied Upon	N/A	N/A		
P-04704	10/1/2021	Expert Witness Report of G. Caleb Alexander, MD, MS, Appendix D - Expert Witness Engagement	N/A	N/A		
P-04705	10/1/2021	Expert Witness Report of G. Caleb Alexander, MD, MS, Appendix E - San Francisco Redress Model	N/A	N/A		
P-04706	10/1/2021	Expert Witness Report of G. Caleb Alexander, MD, MS, Appendix F - Potential Indicators of High Risk Opioid Distribution	N/A	N/A		
P-04707	10/4/2021	City and County of San Francisco Expert Report of Carmen A. Catizone, MS, RPh, DPh	N/A	N/A		
P-04708	1/21/2022	City and County of San Francisco Rebuttal Expert Report of Carmen A. Catizone, MS, RPh, DPh	N/A	N/A		
P-04709	10/5/2021	Expert Report of Daniel Ciccarone, MD, MPH	N/A	N/A		
P-04710	9/25/2021	Daniel Ciccarone, MD, MPH Curriculum Vitae	N/A	N/A		
P-04711	12/23/2021	Rebuttal Report of Professor David M. Cutler, In Re: National Prescription Opiate Litigation, Case No. 1:17-MD-2804, Case Track 4, San Francisco	N/A	N/A		
P-04712	10/5/2021	Expert Report of David Herzberg, PhD, The history of pharmaceutical opioids in the U.S.: From crisis, to control, to new crisis	N/A	N/A		
P-04713	10/19/2021	Report of Plaintiff's Expert Przenyslaw Jeziorski	N/A	N/A		
P-04714	11/17/2021	Amended Report of Plaintiff's Expert Przenyslaw Jeziorski	N/A	N/A		
P-04715	10/19/2021	Report of Plaintiff's Expert Przenyslaw Jeziorski, Appendix A - Summary of Relevant Research	N/A	N/A		
P-04716	10/19/2021	Report of Plaintiff's Expert Przenyslaw Jeziorski, Appendix B - Document List	N/A	N/A		
P-04717	10/19/2021	Report of Plaintiff's Expert Przenyslaw Jeziorski, Amended Appendix B - Document List	N/A	N/A		
P-04718	10/19/2021	Report of Plaintiff's Expert Przenyslaw Jeziorski, Appendix C - Impression Enumeration Details	N/A	N/A		
P-04719	10/19/2021	Report of Plaintiff's Expert Przenyslaw Jeziorski, Appendix D - Print Media Tabulations	N/A	N/A		
P-04720	10/19/2021	Report of Plaintiff's Expert Przenyslaw Jeziorski, Appendix E - Log-Linear Model	N/A	N/A		
P-04721	10/19/2021	Report of Plaintiff's Expert Przenyslaw Jeziorski, Appendix F - Website Screening	N/A	N/A		
P-04722	10/19/2021	Report of Plaintiff's Expert Przenyslaw Jeziorski, Appendix G - Allergan Generic Marketing	N/A	N/A		
P-04723	8/30/2021	Przenyslaw Jeziorski Curriculum Vitae	N/A	N/A		
P-04724	10/5/2021	Expert Report of Lacey R. Keller, The City and County of San Francisco	N/A	N/A		
P-04725	10/5/2021	Expert Report of Lacey R. Keller, The City and County of San Francisco, Appendix A - Additional Analysis	N/A	N/A		
P-04726	10/5/2021	Expert Report of Lacey R. Keller, The City and County of San Francisco, Appendix B - Qualifications, Remuneration, and Methodology	N/A	N/A		
P-04727	3/26/2019	Expert Report David Kessler, M.D.	N/A	N/A		
P-04728	4/23/2019	Dr. David Kessler Supplemental Reliance List	N/A	N/A		
P-04729	N/A	David A. Kessler, M.D. Second Supplemental Materials Considered List	N/A	N/A		
P-04730	10/5/2021	Expert Report of Katherine Keyes, PhD	N/A	N/A		

P-04731	10/5/2021	Expert Report of Katherine Keyes, PhD, Schedule A - Case Track 4 - San Francisco County	N/A	N/A		
P-04732	10/5/2021	Expert Report of Katherine Keyes, PhD, Schedule A - Case Track 4 - San Francisco County, Exhibit A - CV	N/A	N/A		
P-04733	10/5/2021	Expert Report of Katherine Keyes, PhD, Schedule A - Case Track 4 - San Francisco County, Exhibit B - Materials Considered	N/A	N/A		
P-04734	10/5/2021	Expert Report of Katherine Keyes, PhD, Schedule A - Case Track 4 - San Francisco County, Exhibit C - Keyes Compensation	N/A	N/A		
P-04735	10/5/2021	Expert Report of Katherine Keyes, PhD, Schedule A - Case Track 4 - San Francisco County, Exhibit D - Keyes Testimony	N/A	N/A		
P-04736	1/5/2022	Expert Report of Katherine Keyes, PhD, Corrected Schedule A - Case Track 4 - San Francisco County	N/A	N/A		
P-04737	1/5/2022	Expert Report of Katherine Keyes, PhD, Schedule A - Case Track 4 - San Francisco County, Updated Exhibit A - CV	N/A	N/A		
P-04738	1/5/2022	Expert Report of Katherine Keyes, PhD, Schedule A - Case Track 4 - San Francisco County, Supplemental Exhibit B - Materials Considered	N/A	N/A		
P-04739	10/19/2021	Expert Report, Anna Lembke, M.D.	N/A	N/A		
P-04740	9/22/2021	Dr. Anna Lembke's Supplemental Materials Considered Since December 23, 2021	N/A	N/A		
P-04741	4/15/2021	An Expert Report for the National Prescription Opiate Litigation, MDL 2804, Daniel C. Malone, BS Pharmacy, MS, PhD, FACMP	N/A	N/A		
P-04742	10/5/2021	Expert Report of Craig J. McCann, PH.D, CFA	N/A	N/A		
P-04743	10/23/2021	Rebuttal Expert Report of Craig J. McCann, PH.D, CFA	N/A	N/A		
P-04744	10/23/2021	Rebuttal Expert Report of Craig J. McCann, PH.D, CFA, Rebuttal Appendix 1	N/A	N/A		
P-04745	10/23/2021	Rebuttal Expert Report of Craig J. McCann, PH.D, CFA, Rebuttal Appendix 2	N/A	N/A		
P-04746	10/23/2021	Rebuttal Expert Report of Craig J. McCann, PH.D, CFA, Rebuttal Appendix 3	N/A	N/A		
P-04747	10/23/2021	Rebuttal Expert Report of Craig J. McCann, PH.D, CFA, Rebuttal Appendix 4	N/A	N/A		
P-04748	10/4/2021	Abatement Cost to Address the Opioid Crisis in the City and County of San Francisco, Expert Report of William V. Padula, PhD, MS, MSc	N/A	N/A		
P-04749	10/4/2021	Abatement Cost to Address the Opioid Crisis in the City and County of San Francisco, Expert Report of William V. Padula, PhD, MS, MSc, Appendix A - Curriculum Vitae	N/A	N/A		
P-04750	10/4/2021	Abatement Cost to Address the Opioid Crisis in the City and County of San Francisco, Expert Report of William V. Padula, PhD, MS, MSc, Appendix B - Materials Relied Upon	N/A	N/A		
P-04751	10/4/2021	Abatement Cost to Address the Opioid Crisis in the City and County of San Francisco, Expert Report of William V. Padula, PhD, MS, MSc, Appendix C - San Francisco Abatement Cost Model	N/A	N/A		
P-04752	10/19/2021	Expert Report of Elizabeth Park, Pharm.D., APH, The City & County of San Francisco	N/A	N/A		
P-04753	1/21/2022	Expert Report of Elizabeth Park, Pharm.D., APH, in Rebuttal, The City & County of San Francisco	N/A	N/A		
P-04754	10/18/2021	Expert Report of Matthew Perri III, BS Pharm, PhD, RPh	N/A	N/A		
P-04755	12/22/2021	Supplemental and Rebuttal Report of Matthew Perri III, BS Pharm, PhD, RPh	N/A	N/A		
P-04756	10/5/2021	Expert Report James E. Rafalski, Analysis of Regulatory Compliance to Maintain Effective Controls for the Prevention of Diversion of Controlled Substance on behalf of San Francisco, California	N/A	N/A		
P-04757	10/5/2021	Expert Report James E. Rafalski, Analysis of Regulatory Compliance to Maintain Effective Controls for the Prevention of Diversion of Controlled Substance on behalf of San Francisco, California, Schedule I	N/A	N/A		

P-04758	12/23/2021	Expert Report, Seth A. Waldman, M.D.	N/A	N/A		
P-04759	3/1/2022	Second Supplemental Report of Matthew Perri III, BS Pharm, PhD, RPh	N/A	N/A		
P-04760	3/1/2022	Second Supplemental Expert Report of Dr. Anna Lembke	N/A	N/A		
P-06067	10/26/2010	Affirmance of Suspension Order for East Main Street Pharmacy	N/A	N/A		
P-06076	12/19/2018	Report "Red Flags and Warning Signs Ignored: Opioid Distribution and Enforcement Concerns in West Virginia," prepared by the House Energy and Commerce Committee	N/A	N/A		
P-06078	6/1/2018	Follow the Money Report on Pharmaceutical Manufacturer Payments and Opioids Prescribing	N/A	N/A		
P-06097	5/10/2007	Purdue Frederick Company Inc. Violation Tracker	N/A	N/A		
P-06098	9/29/2008	Biopharmaceutical Company, Cephalon, to Pay \$425 Million & Enter Plea to Resolve Allegations of Off-Label Marketing	N/A	N/A		
P-06116	N/A	CFR Section 1301.74	N/A	N/A		
P-06123	12/12/1995	FDA Approval Oxy NDA	N/A	N/A		
P-06729	10/26/2017	DHHS Determination that a Public Health Emergency Exists - Eric D. Hargan	N/A	N/A		
P-06906	N/A	Kristie Provost Gorman LinkedIn profile	N/A	N/A		
P-06908	10/8/2012	FW: IMS C2 Analytics Capabilities	WAGMDL01167526	WAGMDL01167527		
P-06911	11/19/2012	Email Prescriber Dashboard Top 100 NJ and PA only Attachment Prescriber Dashboard Top 100 NJ and PA only	WAGMDL01132742	WAGMDL01132755		
P-06919	10/17/2012	RE: Communication pieces	WAGMDL01132835	WAGMDL01132836		
P-06934	1/3/2017	FW: Pharmacy Operations Compliance Risk Assessment Attachment Pharmacy Operations Risk Assessment 12292016	WAGMDL01133205	WAGMDL01133209		
P-06938	10/23/2012	Tableau Benefits - gathered from pilot by Loss Prevention	WAGMDL01134494	WAGMDL01134496		
P-06949	4/3/2013	Email Ray Stukel Project Update Attachment Ray Stukel Project Update	WAGMDL01167459	WAGMDL01167460		
P-06950	3/20/2013	Email Status update Attachment Ray Stukel Project Update	WAGMDL01167462	WAGMDL01167463		
P-06954	3/6/2013	Email Ray Stukel Project Update Attachment Ray Stukel Project Update	WAGMDL01167464	WAGMDL01167465		
P-06960	2/20/2013	Email Ray Stukel Project Update Attachment Ray Stukel Project Update	WAGMDL01167474	WAGMDL01167475		
P-06961	2/5/2013	Email Ray Stukel Project Update Attachment Ray Stukel Project Update	WAGMDL01167476	WAGMDL01167477		
P-06980	1/9/2013	Email Ray Stukel Project Update Attachment Ray Stukel Project Update	WAGMDL01167478	WAGMDL01167479		
P-06983	12/11/2012	Email Ray Stukel Project Update Attachment Ray Stukel Project Update	WAGMDL01167485	WAGMDL01167486		
P-06985	11/14/2012	Email Ray Stukel Project Update Attachment Ray Stukel Project Update	WAGMDL01167498	WAGMDL01167499		
P-06988	12/31/2012	FW: Final Version of Audit Committee Materials Attachments Item 3 (a) LP Update; Item 3 (b) Asset Protection Update	WAGMDL01174154	WAGMDL01174161.0002		
P-06996	1/18/2013	Email Executive Report: Top 500 Potential Risk Stores - Oxycodone - 3 months ending Dec 2012 Attachment Oxycodone Store Potential Risk Overview	WAGMDL01176297	WAGMDL01176298		
P-06999	10/25/2012	Email Prescriber Index Attachment Prescriber Index Approach_v2	WAGMDL01176493	WAGMDL01176496		
P-07006	8/13/2012	Email Updated Report July 2012: Exec Summary Top 100 - Oxy Potential Risk Store Index Attachment Store Potential Risk Index - end July 2012 - Exec Top 100	WAGMDL01176503	WAGMDL01176504		
P-07083	N/A	PART 1301 — REGISTRATION OF MANUFACTURERS, DISTRIBUTORS, AND DISPENSERS OF CONTROLLED SUBSTANCES SECURITY REQUIREMENTS §1301.71 Security requirements generally	N/A	N/A		
P-07706	2/27/2014	Brochure - Understanding your pain, Taking Oral Opioid Analgesics	ENDO-CHI_LIT-00084164	ENDO-CHI_LIT-00084176		
P-07707	3/12/2014	Opana ER with INTAC Digital MVA Navigator	END00059865	END00059919		

P-07711	2/22/2011	Request for estimate - Efficacy and Safety of Opana ER for Relief of Moderate to Severe Chronic Low Back Pain in Opioid-Experienced Patients	END00178042	END00178053		
P-07744	11/6/1975	State Board of Pharmacy v Steve Simon - Complaint	N/A	N/A		
P-07751	N/A	Pyfer LinkedIn	N/A	N/A		
P-07752	2/18/2019	Fentora	N/A	N/A		
P-07753	7/31/2011	Actiq Package Insert	N/A	N/A		
P-07768	N/A	Primary non-heroin opiates/synthetics admission rates, by State	N/A	N/A		
P-07769	N/A	Actiq Fentanyl Oral Transmucosal Lozenges Photo	N/A	N/A		
P-07785	4/21/2011	Email with Kadia AE Reporting and Training	ACTAVIS0977980	ACTAVIS0977998		
P-08045	7/9/2020	Opioid overdoses are skyrocketing as Covid-19 sweeps across US and old epidemic returns	N/A	N/A		
P-08050	4/27/2012	Email re Stauffer stuff	ACTAVIS0300588	ACTAVIS0300589		
P-08051	10/25/2012	Email re Chou and update Attachments: Chou 2009 - Opioid Treatment Guidelines - J Pain	ACTAVIS0685080	ACTAVIS0685122		
P-08052	10/15/2012	Email re Pain EDU Sponsorship Report Attachments: image001.gif; PainEDU Q3 2012 - Final; CWEmbed1	ALLERGAN_MDL_00312341	ALLERGAN_MDL_00312356		
P-08053	7/23/2012	Email re FW: Q2 2012 PainEDU Sponsorship Report - Attachments: PainEDU_Q2_2012_FINAL	ALLERGAN_MDL_01236315	ALLERGAN_MDL_01236335		
P-08054	9/20/2006	ACPA Breakthrough Pain 9-20-06	N/A	N/A		
P-08056	5/3/2004	Email re Dinner program feedback	TEVA_AAMD_00613716	TEVA_AAMD_00613717		
P-08057	2007	Emerging Solutions in Pain (ESP) - Knowledge Series Volume Three	TEVA_MDL_A_00844212	TEVA_MDL_A_00844246		
P-08058	2003	MediCom Worldwide, Inc. - Emerging Solutions in Pain Assessing and Managing Low Back Pain: The Option for Opioids	TEVA_MDL_A_01165648	TEVA_MDL_A_01165662		
P-08059	5/3/2004	Email re Faculty List	TEVA_MDL_A_01401012	TEVA_MDL_A_01401013		
P-08060	12/7/2010	Email - Follow-up from our meeting today Attachments: AAPM #75- Assessment of ESP; AAPM #76- Commercial Bias; ESP_Outcomes_Report_Final; image001.gif; PAINWeek ESP Poster 0120; PAINWeek ESP Poster_0128; Summary Slides of ESP OutcomesStudy_Final	TEVA_MDL_A_02012047	TEVA_MDL_A_02012063		
P-08063	4/27/2004	Email re status report - Attachments: Cephalon_status_report_042704	TEVA_MDL_A_02588709	TEVA_MDL_A_02588713		
P-08064	5/15/2004	Email re Faculty List-Correspondence Complete	TEVA_MDL_A_02588793	TEVA_MDL_A_02588794		
P-08067	3/12/2003	ACTIQ Sales Training	Teva_MSAG_03548605	Teva_MSAG_03548652		
P-08073	5/8/2012	Summary of Payments Made 1997-2012 in Response to Senate Finance Committee Request	JAN-MS-00000001	JAN-MS-00000010		
P-08074	3/17/2011	ABC Oxy IR 30mg tabs - suspicious order; Actavis Logo; Oxy IR Tabs Suspicious Order SOP revised 3-17-2011	ALLERGAN_MDL_00490299	ALLERGAN_MDL_00490307		
P-08089	4/21/2001	Email- FW: 10 Arrested in Pr. William As Raids Find New Narcotic; OxyContin Linked	JAN-MS-00307337	JAN-MS-00307339		
P-08093	N/A	Title 21 CFR 1304.04 Maintenance of records and inventories	N/A	N/A		
P-08144	6/22/2004	Purdue Consulting Agreement with KOL James N. Campbell	PPLP003477687	PPLP003477692		
P-08163	N/A	Title 21 CFR 1306.04 Purpose of issue of prescription	N/A	N/A		
P-08164	N/A	Title 21 CFR 1306.06 Persons entitled to fill prescriptions	N/A	N/A		
P-08166	10/12/2012	Holiday CVS, L.L.C., d/b/a CVS/Pharmacy Nos. 219 and 5195; Decision and Order	N/A	N/A		
P-08182	1/10/2011	High Quantity Stores 682971	WAGFLDEA00000846	WAGFLDEA00000851		
P-08183	2/15/2005	Handling Suspicious Drug Orders	WAGFLDEA00001854	WAGFLDEA00001855		
P-08184	3/19/2012	TIRF REMS Distributor Enrollment; GMCKR_E01022_DistributorEnrollmentDetail 3192012; GUOPDLAR 01 License Maintenance 3 6-12	ALLERGAN_MDL_01175570	ALLERGAN_MDL_01175585		
P-08196	10/15/2013	Hernandez Invite re DEA	EPI002479914	EPI002479915		
P-08208	5/16/2012	Payments from Pharmaceutical Companies	CHI_001978630	CHI_001978630		
P-08211	1/2/2013	PAIN CARE FORUM_directory	PPLP003985564	PPLP003985575		
P-08229	9/11/2007	15. DEA Website Printout (Feb. 15, 2012)	CAH_MDL_PRIORPROD_DEA12_00011059	CAH_MDL_PRIORPROD_DEA12_00011063		

P-08249	9/11/2007	DEA's Office of Diversion Control - 13th Pharmaceutical Industry Conference	CAH_MDL_PRIORPROD_DEA07_01185382	CAH_MDL_PRIORPROD_DEA07_01185426		
P-08284	9/25/2012	2012 Email Re: SOM meeting	ALLERGAN_MDL_01641955	ALLERGAN_MDL_01641956		
P-08285	9/22/2004	cSOP Training; OPD Call Center Index Guide; OPDCSS 01 DEA Registration Verification; OPDCC 02 Sample Fulfillment; OPDCC 03 Suspicious Orders of Controlled Drugs; OPDCSS 04 Process Controls for Sale and Distribution of Pharmaceutical Products; Call Center OPD Signature Training Log; OPDCC 05 Complaints and Medical Inquiries	ALLERGAN_MDL_01838989	ALLERGAN_MDL_01839024		
P-08294	9/26/2002	Procedures; Maximum Quantity; DEA Excess Controlled Substance New Prod Launch	ALLERGAN_MDL_01844862	ALLERGAN_MDL_01844865		
P-08327	12/3/2015	SOM. SORDS. Problem Order. Colleen McGinn chat with Joseph Tomkiewicz	TEVA_MDL_A_01056183	TEVA_MDL_A_01056183		
P-08343	2/24/2012	Declaration of Joseph Rannazzisi	N/A	N/A		
P-08344	3/28/2015	Birmingham Pharmacy Diversion Awareness Conference: DEA Perspective: Pharmaceutical Use & Abuse	N/A	N/A		
P-08345	8/19/2019	In re Nat'l Prescription Opiate Litig., No. 1:17-MD-2804, 2019 WL 3917575	N/A	N/A		
P-08358	7/24/2018	SOM Policy - DEA Order Holds	TEVA_MDL_A_01158453	TEVA_MDL_A_01158462		
P-08359	7/24/2018	SOM Policy - Do Not Ship List	TEVA_MDL_A_01158463	TEVA_MDL_A_01158469		
P-08360	7/24/2018	SOM Policy - Customer Due Diligence	TEVA_MDL_A_01158470	TEVA_MDL_A_01158478		
P-08368	2/11/2009	Fw: Omnicare Finasteride	ALLERGAN_MDL_02128035	ALLERGAN_MDL_02128036		
P-08369	10/6/2011	Email from Noemi Rebeco re: question	ALLERGAN_MDL_02128065	ALLERGAN_MDL_02128072		
P-08370	11/3/2010	Suspicious Order - logic; Suspicious Order Report-082009	ALLERGAN_MDL_02128513	ALLERGAN_MDL_02128514		
P-08372	5/30/2014	RE: Reminder: CSOPs Past Due for Periodic Review - Sales & Marketing; CSOP_011-004,_Suspicious_Orders_of_Controlled_Drugs	ALLERGAN_MDL_02146510	ALLERGAN_MDL_02146525		
P-08375	11/17/2011	Email from Noemi Rebeco re: New Jersey Pharmaceutical Industry Group Meeting - November 8, 2011	ALLERGAN_MDL_02166054	ALLERGAN_MDL_02166059		
P-08386	6/8/2012	Summary of Payments by Name and Year (1997 - May 8, 2012)	SFC00000001	SFC00000001		
P-08394	4/13/2016	KYC Master List; Actavis SOM logic; Actavis SOM logic; A_EmailArchive_42x42; Demand Management - 1st of the Month_32_5915148; Demand Management - 1st of the Month_32_59151; Email Archive; Emailing_ SOM Metrics; SOM Metrics; FW_ Catamaran_BrioRx of IN-Mail SD 902526; FW: Controls Questionnaire po# 020516ActavisJ2; BrioRx IN_Actavis Controls Questionnaire 2016; Managing Tools for Fraud Waste and Abuse of Controlled Substances; Identifying Components of a Valid Order; BrioRx_Jeffersonville IN_State Lic_Exp 12.31.17; BrioRx_Jeffersonville IN_DEA Lic_Exp 07.31.16; BrioRx_Jeffersonville IN_CSR Lic_Exp 12.31.17; Actavis control metrics; FW_ SOMS metrics for 2015 and YTD 2016; 2015 Control Metrics; 2016 YTD 03_21_ 2015 Control Metrics Report; FW_ Thrifty White Backup Documents on Controlled; 01.2016 ACTAVIS SALES OUT REPORT PS; 02.2016 Thrifty White Store Listing; Order of Interest Initial Review Form; Know Your Customer - Partner Form; SUSPICIOUS ORDER REVIEW FORM 05122015 v3; Thrifty White Warehouse #899 Policy; McKesson DEA Suspensions; RE_ 2015 CS Orders; Controls Shipped 2015; RE_ Actavis Controlled Substance Compliance(1); Compliance Acknowledgement Form - Actavis; RE_ Actavis Controlled Substance Compliance(1); RE_ Catamaran_BrioRx of IN-Mail SD 902526; RE: Chargeback; RE_ Chargeback(1); RE_ Chargeback(2); 00228203110 Feb 2016; RE_ Chargeback; Oxycodone 2-2016; RE_ McKesson DEA Suspensions; McKesson HANA Controlled Substance Sales Hist; RE_ Report(1);	ALLERGAN_MDL_02181123	ALLERGAN_MDL_02181337		

P-08461	11/8/2011	2012 Budget Customer Relations Presentation MW 3; 2012 Budget Assumptions Worksheet; Sales Admin/Customer Support Headcount Summary; Customer Relations Assumptions Worksheet; Customer Relations Assumptions Worksheet; Customer Relations Key Performance Indicators; Organization charts customer relations	ALLERGAN_MDL_02187056	ALLERGAN_MDL_02187091	ALLERGAN_MDL_02187057- ALLERGAN_MDL_02187074; ALLERGAN_MDL_02187076; ALLERGAN_MDL_02187078; ALLERGAN_MDL_02187081 - ALLERGAN_MDL_02187091	
P-08473	2/19/2015	Supporting Docs; SOM Cloud Services; SOMProjectJust2.19.15	ALLERGAN_MDL_02467540	ALLERGAN_MDL_02467550		
P-08481	4/2/2013	Re: DEA Holds This Afternoon	TEVA_MDL_A_01464010	TEVA_MDL_A_01464015		
P-08482	9/10/2012	Separate questions on hydrocodone - Federal C2s	WAGMDL00075673	WAGMDL00075673		
P-08483	7/2/2012	Discussion of ceiling limits - updated with x for review (slides 4+); Controlled Substance Order Review Business Logic (6/22/2012)	WAGMDL00077015	WAGMDL00077023		
P-08504	4/10/2013	FW: April 9th; 4_16 Wave of Stores going to ABC; CII_Amerisource; CII_ANDA	WAGMDL00095929	WAGMDL00095937		
P-08508	10/11/2012	FW: Walgreens Stores - Oxycodone Usage	WAGMDL00101696	WAGMDL00101699		
P-08509	3/13/2013	FW: Walgreens Threshold Limits	WAGMDL00102642	WAGMDL00102644		
P-08510	11/23/2016	Mills.Steven.Resume	WAGMDL00104075	WAGMDL00104077		
P-08511	10/8/2012	RE: Daily SOM Report	WAGMDL00107485	WAGMDL00107488		
P-08512	9/25/2012	FW: Daily SOM Report	WAGMDL00119536	WAGMDL00119538		
P-08513	4/19/2013	Status Format; Status 02.14.13	WAGMDL00245768	WAGMDL00245769		
P-08515	2/5/2013	FW: Walgreen Co.	WAGMDL00246239	WAGMDL00246241		
P-08518	4/1/2020	Opioid Treatments for Chronic Pain - Agency for Healthcare Research and Quality ( AHRQ )	N/A	N/A		
P-08520	2/2/2021	Issue brief: Reports of increases in opioid- and other drug-related overdose and other concerns during COVID pandemic	N/A	N/A		
P-08521	2/16/2021	Prop Letter to AMA RE: AMA's Opposition to Dose & Duration Guidance for Opioid Prescribing	N/A	N/A		
P-08522	5/29/2020	AMA Covid-19 Update - video	N/A	N/A		
P-08528	N/A	Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain	APS-MDL00000016	APS-MDL00000016		
P-08577	3/29/2012	OMS Meeting Agenda and HDMA Presentation	PPLPC004000317960	PPLPC004000317962		
P-08586	7/9/2013	Purdue Presentation re: Update On Order Monitoring And Retailer Due Diligence CCPC Meeting	PPLPC004000363084	PPLPC004000363085		
P-08617	2/5/2013	FW: Suspicious Order; What makes an order suspicious?	WAGMDL00303305	WAGMDL00303307		
P-08619	6/19/2013	DCs Suspicious Order Monitoring Policy and Procedure	WAGMDL00316771	WAGMDL00316785		
P-08620	2/8/2012	Suspicious Order Monitoring Process	WAGMDL00325129	WAGMDL00325130		
P-08624	8/7/2012	FW: NACDS Pharmacy Operations Committee -- Action Requested: DEA Interim Solution; Developing Interim Solution (2) final draft 8 6 12	WAGMDL00331103	WAGMDL00331110		
P-08626	3/1/2013	Perrysburg CII-CV - meeting notes.	WAGMDL00358471	WAGMDL00358473		
P-08655	10/27/1999	RE: Walgreens CE Programs Oct 25th @ 26th	PPLPC024000008341	PPLPC024000008342		
P-08656	1/17/2000	Tampa District - Walgreens' request for money	PPLPC024000010714	PPLPC024000010716		
P-08657	6/20/2001	The Use of Opioids for Chronic and Acute Pain	PPLPC022000010323	PPLPC022000010323		
P-08660	5/10/2001	Walgreens Meeting April 25, 2001	PKY180267742	PKY180267745		
P-08663	6/30/2001	Letter to CVS Pharmacists	PDD1501726314	PDD1501726314		
P-08704	9/26/2007	DEA & Industry Seminar Sept 2007	Acquired Actavis_00441354	Acquired Actavis_00441358		
P-08801	6/27/2007	Email from Michael Mapes (DEA) to Dwayne Pinon (Walgreens in house counsel)	WAGMDL00387635	WAGMDL00387637		
P-08802	7/28/2006	Letter D. Pinon (Walgreens) to B. Dobric (DEA)	WAGMDL00387642	WAGMDL00387650		
P-08803	3/26/2008	Dwayne Pinon (WAG in house counsel) email to Dallas DEA	WAGMDL00387651	WAGMDL00387652		
P-08804	6/11/2013	Appendix B	WAGMDL00387653	WAGMDL00387707		
P-08805	6/11/2013	Appendix	WAGMDL00387975	WAGMDL00387982		
P-08807	4/3/2007	DEA Suspicious Controlled Drug Report	WAGMDL00400357	WAGMDL00400357		
P-08808	10/12/2018	20130328 - Knowing Your Customer - Suspicious Orders Reporting	WAGMDL00400361	WAGMDL00400364		
P-08809	11/18/2013	Tramadol products classification; DI035P_items with drug_class_all_ndc_match	WAGMDL00436800	WAGMDL00436802		
P-08811	2/15/2013	RE: Weekly PMO Status of Top 20 SC projects; Weekly PMO Status - Thursday Update 2-14-2013	WAGMDL00477975	WAGMDL00477989		
P-08815	3/19/2008	Re: DEA and Suspicious Orders	PPLPC018000200323	PPLPC018000200324		



P-08873	1/25/2016	Email re: DEA related documents and links; 05a DEA Memorandum of Agreement (MOA) 2008 CAH and 2012	CAH_MDL2804_02465968	CAH_MDL2804_02466053		
P-08915	11/8/2011	SOM Project Status Review Presentation 110811 to exec team	ALLERGAN_MDL_03368470	ALLERGAN_MDL_03368479		
P-08954	5/12/2015	x Settlement Agreement_Signed	CVS-MDLT1-000060796	CVS-MDLT1-000060804		
P-08954_Redacted	5/12/2015	x Settlement Agreement_Signed	CVS-MDLT1-000060796	CVS-MDLT1-000060804		
P-08955	2/12/2016	CVS-Maryland Settlement 2-12-16	CVS-MDLT1-000060805	CVS-MDLT1-000060811		
P-08955_Redacted	2/12/2016	CVS-Maryland Settlement 2-12-16	CVS-MDLT1-000060805	CVS-MDLT1-000060811		
P-08966	8/26/2009	DEA Suspicious Order Item Limits - Phase II	WAGMDL00492067	WAGMDL00492069		
P-08968	5/1/2012	Functional Requirements & (Macro) Design, DEA Suspicious Ordering - Phase IV, Project Number W0003956	WAGMDL00492562	WAGMDL00492579		
P-08993	2/15/2016	FW: 9461 Roxicodone	WAGNYNS00001674	WAGNYNS00001675		
P-08994	2/6/2017	FW: Policy Council - Updates & Clarifications; RxIMPACT msg 01 24 2017; DEA 2016-28966; DEA EPCS IFR March 2010 Fr copy	WAGNYNS00005513	WAGNYNS00005654		
P-09000	9/19/2013	Controlled Substance Order (CSO) Override Form & Ceiling Limits Tool	WAGNYNS00015484	WAGNYNS00015485		
P-09001	1/6/2020	Control Data_NY	WAGNYNS00016301	WAGNYNS00016301		
P-09004	3/9/2018	Email DEA Red Flag Document	WAGNYNS00017983	WAGNYNS00017983		
P-09005	6/1/2012	Focus on Compliance - June 2012 - Summary Data; Focus on Compliance - June 2012 - All Response Data with Stores	WAGNYNS00022707	WAGNYNS00022708		
P-09013	10/11/2013	Pharmacist GFD Review Coaching Opportunities, Pharmaceutical Integrity Team PPT	WAGNYNS00031874	WAGNYNS00031896		
P-09015	5/12/2014	Good Faith Dispensing PPT	WAGNYNS00031920	WAGNYNS00031943		
P-09016	2/7/2013	Umbley Red Flags_CS Dispensing	WAGNYNS00032002	WAGNYNS00032004		
P-09018	8/22/2013	Email GFD Flowchart Attachment Visio-GFD Decision Tree	WAGNYNS00032416	WAGNYNS00032418		
P-09020	N/A	Cocktails from RPh coaching examples	WAGNYNS00048875	WAGNYNS00048876		
P-09021	N/A	Opioid Index Data	WAGNYNS00048877	WAGNYNS00048877		
P-09043	4/26/2012	Sales_Mkt Meeting 12012x Excel spreadsheet produced by Allergan Excel spreadsheet produced by Allergan Key source Weekly Report Excel spreadsheet Keysource 867 produced by Allergan C2 Order Summary 2009-2011 Organizational Chart	ALLERGAN_MDL_03802654	ALLERGAN_MDL_03802706		
P-09057	4/23/2012	2011 September Cmts OARRS	WAGMDL00580455	WAGMDL00580488		
P-09058	4/10/2018	NACDS Slate of nominations BoD 3-26-18	WAGMDL00593951	WAGMDL00593981		
P-09059	5/13/2016	NACDS Policy Council	WAGMDL00605718	WAGMDL00605721		
P-09060	5/23/2012	RE: URGENT/Manchin Amendment/Potential Call to Greg Wasson	WAGMDL00614056	WAGMDL00614059		
P-09061	5/23/2012	Fw: URGENT/Manchin Amendment/Potential Call to Greg Wasson	WAGMDL00614060	WAGMDL00614063		
P-09065	6/23/2008	DEA Suspicious Order Reporting - Proposal for defining "suspicious orders" in the Walgreen distribution system	WAGMDL00624503	WAGMDL00624509		
P-09066	8/13/2015	Agenda Minutes Consent Calendar 8-23-15	WAGMDL00633964	WAGMDL00634070		
P-09067	5/1/2012	RE: Document for Policy Council Call - DEA Issues - Tuesday May 1 @ 1:15 p.m.; Drug Diversion - PDUFA	WAGMDL00638068	WAGMDL00638072		
P-09069	5/31/2012	Fw: Cardinal Health News Alert - Fla Situation and Other Pharma Article of Interest	WAGMDL00642582	WAGMDL00642587		
P-09104	4/11/2013	Transferring Controlled Substances	WAGMDL00700161	WAGMDL00700161		
P-09105	10/1/2012	Re: OXYCODONE no longer being ordered via PDQ	WAGMDL00705318	WAGMDL00705320		
P-09111	7/26/2017	Distributor Initiative Briefing with AmerisourceBergen Drug	US-DEA-00000144	US-DEA-00000146		
P-09112	8/16/2005	Internet Presentation with AmerisourceBergen	US-DEA-00000147	US-DEA-00000164		
P-09113	9/9/2005	Internet Presentation with Anda Inc.	US-DEA-00000168	US-DEA-00000213		
P-09114	8/23/2005	Meeting with Cardinal Health, Inc. Concerning Internet Pharmacies	US-DEA-00000352	US-DEA-00000366		
P-09115	12/6/2005	Conference Call with. Mr John. Gilbert, Legal Counsel, representing the McKesson Corporation	US-DEA-00000369	US-DEA-00000370		



P-09116	1/3/2006	Meeting between Office of Diversion Control (OD) and McKesson Corp.	US-DEA-00000371	US-DEA-00000373		
P-09128	5/27/2006	1. Other Stuff	WAGMDL00709507	WAGMDL00709558		
P-09128	5/27/2006	1. Other Stuff	WAGMDL00709507	WAGMDL00709558		
P-09129	8/22/2013	FW: Analyst Report	WAGMDL00746694	WAGMDL00746711		
P-09130	4/13/2001	RE: mtg at aps - Meetings with pain societies	PPLPC045000004928	PPLPC045000004933		
P-09153	10/7/2013	Authentication of Prescription Order Policy	WAGMDL00749381	WAGMDL00749407		
P-09159	5/11/2011	Re: VAWD Question; RX Questionable Order Qty	WAGMDL00751821	WAGMDL00751823		
P-09173	3/9/2006	DEA Audit Recap Perrysburg 3/2/2006	WAGMDL00757762	WAGMDL00757773		
P-09175	9/25/2014	Inventory Controls Doc 1A - Suspicious Ordering Monitoring Program	WAGMDL00757776	WAGMDL00757784		
P-09176	12/11/2006	vawd store questionable qty	WAGMDL00757788	WAGMDL00757788		
P-09307	2/16/1990	DEA Diversion Investigators Manual	CAH MDL PRIORPROD DEA07 01176247	CAH MDL PRIORPROD DEA07 01176558		
P-09308	4/16/1996	Diversion Investigation Manual	CAH MDL PRIORPROD DEA07 01176914	CAH MDL PRIORPROD DEA07 01177162		
P-09320	11/17/1997	Duplicate DEA Compliance Manual	CAH MDL PRIORPROD DEA07 01383895	CAH MDL PRIORPROD DEA07 01384238		
P-09360	N/A	HDMA SOM Industry Compliance Guidelines	CAH MDL PRIORPROD DEA12 00000826	CAH MDL PRIORPROD DEA12 00000840		
P-09483	10/1/2012	HDMA Final Minutes Board Meeting 10-1-12	HDA MDL 000088237	HDA MDL 000088244		
P-09624	9/20/2011	Diversion Investigators Manual	CAH MDL2804 00953317	CAH MDL2804 00953703		
P-09662	10/8/2012	Wags- Admin Motion	CAH MDL2804 01431069	CAH MDL2804 01431124		
P-09896	3/22/2013	email re information for Monday's meeting and follow up from Wednesday w/ DEA Response Letter HSV Tablets - Final, SOMS Presentation 3-13-2013, and other attachments	ENDO-OPIOID_MDL-06458018 ENDO-OPIOID_MDL-06458018	ENDO-OPIOID_MDL-06458029 ENDO-OPIOID_MDL-06458059	ENDO-OPIOID_MDL-06458018 - ENDO-OPIOID_MDL-06458029	
P-09909	2/28/2013	Endo Health Solutions Management Discusses Q4 2012 Results - Earnings Call Transcript	N/A	N/A		
P-09910	5/11/2013	email re OPANA ER News	EPI001741801	EPI001741802		
P-09911	5/11/2013	email re Opana	EPI001388469	EPI001388470		
P-09912	5/11/2013	email re Opana	EPI001388515	EPI001388516		
P-09913	6/17/2013	email re Opana ER Briefing Materials 25 May 2013	ENDO-OPIOID_MDL-06386233	ENDO-OPIOID_MDL-06386277		
P-09914	7/11/2013	email re Executive Summary: Opana ER FDA Type A Meeting	EPI001761150	EPI001761152		
P-09915	6/14/2014	email re Opana Epi Program	ENDO-OPIOID_MDL-02468735	ENDO-OPIOID_MDL-02468737		
P-09919	7/17/2014	email re Opana follow up	ENDO-OPIOID_MDL-06484690	ENDO-OPIOID_MDL-06484690		
P-09939	4/22/2015	email re Final slides for Operations Committee mtg	ENDO-OPIOID_MDL-06483884	ENDO-OPIOID_MDL-06483891		
P-09961	6/5/2015	email re Time Magazine - Opana Full Article	ENDO-OPIOID_MDL-06448061	ENDO-OPIOID_MDL-06448070		
P-09980	5/7/2015	email re (BN) Abuse of Pain Pills Fuels Virus's Spread, Confounding Regul	ENDO-OPIOID_MDL-06483880	ENDO-OPIOID_MDL-06483883		
P-09982	2/24/2013	Endo Health Solutions Inc. Executive Employment Agreement with Rajiv De Silva	N/A	N/A		
P-09983	6/3/2013	Pain Action Guide American Pain Foundation	CHI_000435580	CHI_000435597		
P-09984	2/28/2016	Endo Health Solutions Inc. Executive Employment Agreement with Rajiv De Silva	N/A	N/A		
P-09986	9/22/2016	Separation Agreement between Endo and Mr. De Silva	N/A	N/A		
P-09992	12/27/2005	Cephalon Annual Sales Meeting - The Myth of Addiction by Phillip Rocco Feb 22-28	TEVA_AAMD_00791881	TEVA_AAMD_00791902		
P-09995	6/26/2001	Email re Chronic Opioid Therapy Handout	ENDO-OPIOID_MDL-02002494	ENDO-OPIOID_MDL-02002504		
P-10209	3/28/2013	CVS Oklahoma Settlement Agreement - signed	CVS-MDLT1-000060822	CVS-MDLT1-000060829		
P-10212	8/7/2015	CVS Settlement Agreement	CVS-MDLT1-000060847	CVS-MDLT1-000060855		
P-10212_Redact	8/7/2015	CVS Settlement Agreement	CVS-MDLT1-000060847	CVS-MDLT1-000060855		
P-10213	6/30/2016	CVS Fully Executed Settlement Agreement w Attachments	CVS-MDLT1-000060872	CVS-MDLT1-000060906		
P-10213_Redact	6/30/2016	CVS Fully Executed Settlement Agreement w Attachments	CVS-MDLT1-000060872	CVS-MDLT1-000060906		
P-10214	9/2/2014	CVS Settlement agreement with the USAO for the Southern District of Texas for \$1,912,500.00	CVS-MDLT1-000060907	CVS-MDLT1-000060914		
P-10214_Redact	9/2/2014	CVS Settlement agreement with the USAO for the Southern District of Texas for \$1,912,500.00	CVS-MDLT1-000060907	CVS-MDLT1-000060914		
P-10577	12/2/2013	Bellco - Qualitest SOMS letter and Quaire	ABDCMDL00337067	ABDCMDL00337073		
P-10578	8/22/2007	Email DEA meeting logistics - 8/23/07	Anda_Opioids_MDL_0000152278	Anda_Opioids_MDL_0000152278		
P-10579	7/31/2007	Email DEA teleconference re CS Distribution/Anda	Anda_Opioids_MDL_0000275627	Anda_Opioids_MDL_0000275627		
P-10580	7/9/2011	Question Regarding APS	ARGOFF006513	ARGOFF006515		
P-10581	6/1/2007	2007 MidYear Review-Building the Opana ER Story	BINGOL-OPIOID_MDL_00000369	BINGOL-OPIOID_MDL_00000369		
P-10582	6/9/2006	Email re Follow up to Endo/APF mtg	CHI_000254752	CHI_000254754		
P-10597	10/1/2007	Vault MVA, Designed for Durable Pain Control	END00000105	END00000118		

P-10598	10/1/2007	The Vault MVA Navigator	END00000119	END00000138		
P-10599	12/12/2005	Opana Business Plan	END00000923	END00000989		
P-10602	4/1/2009	Pain Medicine Official Journal of the AAPM Oxymorphone Issue	END00006991	END00007047		
P-10603	5/10/2013	FDA denying petition to approve new NDA for Opana ER	END00011254	END00011270		
P-10604	4/1/2007	Memo : New Sales Tools: Patient Profiles	END00018819	END00018830		
P-10607	1/1/2007	Responsible Opioid Prescribing by Dr. Scott M. Fishman	END00051370	END00051443		
P-10608	1/1/2007	PainEDU.org Manual, 3rd Edition	END00051444	END00051560		
P-10615	3/16/2009	Medwatch reports for Opana ER	END00069943	END00069957		
P-10617	4/28/2009	PCF REMS task force recommendations	END00077888	END00077921		
P-10618	1/4/2011	Discipline Review Letter	END00083981	END00084015		
P-10619	1/9/2013	Email re OER Pharmacy Market Research Revised Report	END00095867	END00095870		
P-10622	1/4/2013	Email re generic Opana ER	END00121820	END00121822		
P-10625	3/3/2011	RE: Biden Letter - Endo's Efforts to Address Prescription Medicine Abuse and Misuse	END00152457	END00152473		
P-10627	6/12/2012	MSL Meeting Report	END00154834	END00154856		
P-10628	11/11/2017	Email re Opana ER-New Objection Handler	END00195234	END00195235		
P-10631	6/29/2011	RE: DEA representative comments on Opana	END00259233	END00259235		
P-10632	10/13/2011	RE EN3288 REMS Docs for Approval	END00259236	END00259238		
P-10634	5/26/2011	2011 Q1 RiskMAP Update Report (Jan-March)	END00308789	END00308831		
P-10637	5/29/2012	Opana ER - Orange Book Notification Date	END00319755	END00319756		
P-10639	3/23/2009	Question re: Opana reports in TN	END00361412	END00361414		
P-10642	5/30/2012	Fwd: Unofficial Opana ER Weekly TRx	END00391916	END00391917		
P-10647	11/16/2012	Opana ER Risk Management Team Minutes 11/16/12	END00450532	END00450538		
P-10652	12/14/2012	Pain Management Summit - Focus on Opioid Therapy	END00648910	END00649052		
P-10654	1/13/2010	Donna Calvani Response to LK inquiry re NIDA Quote	END00661357	END00661359		
P-10655	5/7/2010	NIPC Dinner Dialogue Registration	END00662271	END00662274		
P-10656	4/17/2009	PainOverviewforEndo MM 2009 - Commentsx	END00366719	END00366758		
P-10663	6/30/2004	FDA Teleconference Minutes IND #56,919 / Special Protocol Assessment EN3202-031	END00747393	END00747396		
P-10666	N/A	Opana Net Sales	ENDO_DATA-OPIOID_MDL-00000008	ENDO_DATA-OPIOID_MDL-00000008		
P-10667	10/25/2018	2010 Contribution Margin Report	ENDO_DATA-OPIOID_MDL-00000012	ENDO_DATA-OPIOID_MDL-00000012		
P-10668	10/25/2018	2011 Contribution Margin Report	ENDO_DATA-OPIOID_MDL-00000013	ENDO_DATA-OPIOID_MDL-00000013		
P-10669	10/25/2018	2007-2016 Prescriber Level Rx Data	ENDO_DATA-OPIOID_MDL-00000021	ENDO_DATA-OPIOID_MDL-00000021		
P-10671	11/15/2018	2014-2018 Endo SOM Release Report	ENDO_DATA-OPIOID_MDL-00000022	ENDO_DATA-OPIOID_MDL-00000022		
P-10672	6/30/2017	June Endo Total Pills/Units Shipped	ENDO_DATA-OPIOID_MDL-00000025	ENDO_DATA-OPIOID_MDL-00000041		
P-10682	10/28/2014	Further Email Chain re SOM - Preferred Pharma Informing Brantley of Real Time Manual SOM Process	ENDO_HSGAC_0010368	ENDO_HSGAC_0010371		
P-10687	1/6/2016	ACCME Audit Report re REMS Activities	ENDO_OPIOID_MDL_DEPONENT-000015904	ENDO_OPIOID_MDL_DEPONENT-000016398		
P-10691	3/1/2007	"Bill has chronic moderate to severe low back pain"	ENDO-CHI_LIT-00033952	ENDO-CHI_LIT-00033953		
P-10694	1/1/2004	Patient Brochure - Understanding Your Pain	ENDO-CHI_LIT-00237186	ENDO-CHI_LIT-00237200		
P-10695	4/30/2012	DPDP Letter on Launch Materials	ENDO-CHI_LIT-00270448	ENDO-CHI_LIT-00270454		
P-10701	5/31/2012	Request to move Opana ER NDA 21-610 to the Orange Book Discontinued List	ENDO-CHI_LIT-00008100	ENDO-CHI_LIT-00008101		
P-10703	5/22/2013	Opana ER Risk Management Team (RMT) Minutes	ENDO-CHI_LIT-00009457	ENDO-CHI_LIT-00009485		
P-10704	6/21/2013	Opana ER Risk Management Team (RMT) Minutes	ENDO-CHI_LIT-00009486	ENDO-CHI_LIT-00009493		
P-10707	1/1/2010	Opana® ER Customer Satisfaction, Sales Force Effectiveness, Awareness & Usage - Research Program Wave 2	ENDO-CHI_LIT-00012060	ENDO-CHI_LIT-00012061		
P-10716	9/18/2009	Opana Brand Overview	ENDO-CHI_LIT-00022642	ENDO-CHI_LIT-00022647		
P-10718	5/1/2008	Opana Brand Situation Analysis	ENDO-CHI_LIT-00023299	ENDO-CHI_LIT-00023301		
P-10720	6/11/2009	Opana ER Situational Analysis Marketing Science - 2009	ENDO-CHI_LIT-00023394	ENDO-CHI_LIT-00023398		
P-10721	12/16/2008	Bingol CustFINAL-2009 Opana BrandPlan 12.16.08	ENDO-CHI_LIT-00024398	ENDO-CHI_LIT-00024398		
P-10722	1/1/2008	Taking a Long-Acting Opioid - What Does it Mean to Me?	ENDO-CHI_LIT-00024520	ENDO-CHI_LIT-00024528		
P-10724	5/22/2008	2008 Q1 RiskMAP Update Report (Jan-March)	ENDO-CHI_LIT-00032208	ENDO-CHI_LIT-00032237		
P-10726	5/1/2008	Opana Brand MVA	ENDO-CHI_LIT-00032925	ENDO-CHI_LIT-00032943		
P-10731	9/1/2010	Opana ER Launch List of Community Organizations Contacted	ENDO-CHI_LIT-00051623	ENDO-CHI_LIT-00051624		
P-10734	12/8/2009	Grunenthal-Endo Meeting Minutes	ENDO-CHI_LIT-00064406	ENDO-CHI_LIT-00064468		
P-10735	3/5/2009	FDA REMS Meeting and EN3317 UPDATED Draft Development Plan	ENDO-CHI_LIT-00067298	ENDO-CHI_LIT-00067327		
P-10736	12/8/2009	Test Battery Results PPT (Grunenthal)	ENDO-CHI_LIT-00067892	ENDO-CHI_LIT-00067954		
P-10738	8/15/2007	2008 - 2012 Opana Brand Tactical Plan	ENDO-CHI_LIT-00076050	ENDO-CHI_LIT-00076052		

P-10739	6/1/2006	Wachovia Securities Nantucket Equity Conference	ENDO-CHI_LIT-00078227	ENDO-CHI_LIT-00078229		
P-10741	8/17/2009	Email re Best Practices Workshops	ENDO-CHI_LIT-00080893	ENDO-CHI_LIT-00080900		
P-10742	10/6/2011	Email w/ Attached APF to DEA Letter	ENDO-CHI_LIT-00096310	ENDO-CHI_LIT-00096313		
P-10743	10/1/2011	"This is Frank" Patient Profile	ENDO-CHI_LIT-00099936	ENDO-CHI_LIT-00099944		
P-10746	1/1/2013	Pharmacy Detail Aid	ENDO-CHI_LIT-00133113	ENDO-CHI_LIT-00133120		
P-10747	12/13/2012	Opana ER Crush-Resistant Formulation Research Wave 5	ENDO-CHI_LIT-00135663	ENDO-CHI_LIT-00135666		
P-10748	11/26/2007	Opana ER W2 IVR VOCAL RESPONSE LISTING FOR STUDY #M509202	ENDO-CHI_LIT-00150016 ENDO-CHI_LIT-00150080	ENDO-CHI_LIT-00150588 ENDO-CHI_LIT-00150588	ENDO-CHI_LIT-00150080 - ENDO-CHI_LIT-00150588	
P-10749	3/25/2011	Larry Romaine New Hire Training Presentation	ENDO-CHI_LIT-00151712	ENDO-CHI_LIT-00151714		
P-10751	8/7/2008	Email FW: Opana ER Response Memo	ENDO-CHI_LIT-00166187	ENDO-CHI_LIT-00166188		
P-10754	5/15/2012	Email re New Language OER Selling Piece	ENDO-CHI_LIT-00206530	ENDO-CHI_LIT-00206531		
P-10755	6/11/2012	Email re Voicemail message (2 minutes 35 seconds)	ENDO-CHI_LIT-00207902	ENDO-CHI_LIT-00207903		
P-10758	6/1/2007	Risk Minimization Action Plan for Opana ER Extended-Release Tablets	ENDO-CHI_LIT-00234541	ENDO-CHI_LIT-00234625		
P-10760	11/14/2011	email re: VA-Minor Tweaks to REMS RD Lunch and Learn Nov. 15, 2011 DRAFT Slides	ENDO-CHI_LIT-00241435	ENDO-CHI_LIT-00241436		
P-10761	5/1/2012	Opana ER: INTAC Technology Extended-Release Sell Sheet (OP-02294) Implementation Guide	ENDO-CHI_LIT-00271331	ENDO-CHI_LIT-00271336		
P-10766	1/22/2011	Email re Oxymorphone Story	ENDO-CHI_LIT-00397314	ENDO-CHI_LIT-00397316		
P-10769	4/9/2013	email re: Congratulations Team on Listing Change by 3 Compendia Comps	ENDO-CHI_LIT-00441651	ENDO-CHI_LIT-00441652		
P-10771	5/14/2004	Corporate Reputation Management Presentation	ENDO-CHI_LIT-00445064	ENDO-CHI_LIT-00445067		
P-10774	8/1/2012	Opana ER Strategic Platform	ENDO-CHI_LIT-00467546	ENDO-CHI_LIT-00467550		
P-10775	2/12/2013	Email re Field Communication re Pharmacy Efforts	ENDO-CHI_LIT-00469215	ENDO-CHI_LIT-00469216		
P-10776	9/8/2007	Training- Understanding the Specialty MD and Their use of Opioids	ENDO-CHI_LIT-00473817	ENDO-CHI_LIT-00473883		
P-10778	2/24/2012	Compendia Discussion Recap w/ Attachment Compendia Submission Review and Path Forward	ENDO-CHI_LIT-00526010	ENDO-CHI_LIT-00526024		
P-10780	4/25/2008	Fw: Opana ER pharmacy level report Attachment Retail_Pharmacy_OPANA_ER	ENDO-CHI_LIT-00144050	ENDO-CHI_LIT-00144053		
P-10782	10/1/2009	Understanding Low Back Pain; Medscape WebMD Version of Opana.com	ENDO-CHI_LIT-00537750	ENDO-CHI_LIT-00538040		
P-10785	1/1/2006	Opana ER Patient Information within Allscripts Physicians Interactive Program	ENDO-CHI_LIT-00538058	ENDO-CHI_LIT-00538398		
P-10786	1/1/2007	Avoiding Opioid Abuse While Managing Pain by Dr. Lynn R. Webster	ENDO-CHI_LIT-00538693	ENDO-CHI_LIT-00538910		
P-10787	12/1/2006	Opana ER Product Monograph	ENDO-CHI_LIT-00539077	ENDO-CHI_LIT-00539276		
P-10788	12/1/2009	Opana ER Instant Savings Card and Resource Kit	ENDO-CHI_LIT-00541205	ENDO-CHI_LIT-00541210		
P-10789	9/15/2006	Endo Pharmaceuticals Crisis Preparedness and Management; Percocet Review Spontaneous Data Post Market Report; Percocet History Time & Events in the News Media; Untitled Image Management Presentation; OxyM Issues Management - Overall Approach, Stakeholder Communications and Crisis Management Strategies; Public Stakeholder Strategy for Oxymorphone	ENDO-CHI_LIT-00543377	ENDO-CHI_LIT-00543595		
P-10793	7/17/2006	RE: Graphic for Diversion Control Attachments data chart.doc; DEA questions 3 clean; distribution chart; Endo Opana; NAVIPPRObulletpoints	ENDO-OPIOID_MDL-00852918	ENDO-OPIOID_MDL-00852925		
P-10794	3/28/2012	RE: Pharmacies for Dr. Mohamed	ENDO-OPIOID_MDL-01030692	ENDO-OPIOID_MDL-01030698		
P-10795	11/29/2012	RE: CIs in Florida	ENDO-OPIOID_MDL-01033927	ENDO-OPIOID_MDL-01033929		
P-10796	5/18/2006	Key Stakeholder Outreach Info	ENDO-CHI_LIT-00543636	ENDO-CHI_LIT-00543681		
P-10797	9/21/2006	2007 - 2011 Opana Business Plan	ENDO-CHI_LIT-00545916	ENDO-CHI_LIT-00545916		
P-10799	10/12/2006	2006 Marketing Programs Update	ENDO-CHI_LIT-00547005	ENDO-CHI_LIT-00547006		
P-10802	12/1/2008	Opana ATU Final Report Wave 6	ENDO-CHI_LIT-00547543	ENDO-CHI_LIT-00547644		
P-10805	11/24/2014	Email Attached Image Attachments 1631_001 -Service Schedule No. 1 - Warehouse Distribution Services	ENDO-OPIOID_MDL-02060861	ENDO-OPIOID_MDL-02060891		
P-10808	3/1/2016	Endo AOD 030116 - Fully Executed	ENDO-OPIOID_MDL-01212932	ENDO-OPIOID_MDL-01212966		
P-10811	6/28/2006	Email re 2007 Opana Strategic Business Planning	ENDO-CHI_LIT-00552601	ENDO-CHI_LIT-00552605		
P-10813	7/14/2005	Opana Business Plan 2006-2010	ENDO-CHI_LIT-00552968	ENDO-CHI_LIT-00552970		
P-10814	6/9/2016	Email HDMA	ENDO-OPIOID_MDL-02426078	ENDO-OPIOID_MDL-02426078		

P-10817	5/16/2008	Selling OPANA ER and OPANA with the New Master Visual Aid	ENDO-CHL LIT-00555275	ENDO-CHL LIT-00555287		
P-10818	6/22/2006	Opana ER Approval Letter	ENDO-OPIOID MDL-00298948	ENDO-OPIOID MDL-00299000		
P-10820	3/21/2019	Dr. Adolf Harper Call Log	ENDO-OPIOID MDL-00673566	ENDO-OPIOID MDL-00673566		
P-10824	6/20/2016	Email HDA Follow Up June 2016 Attachment HDA Follow Up June 2016	ENDO-OPIOID MDL-02426557	ENDO-OPIOID MDL-02426560		
P-10825	2/1/2008	Original Opana ER Label	ENDO-OPIOID MDL-00076365	ENDO-OPIOID MDL-00076402		
P-10826	10/4/2001	FDA Minutes of Type C Meeting	ENDO-OPIOID MDL-00159347	ENDO-OPIOID MDL-00159353		
P-10829	6/30/2006	Letter to FDA re Opana ER Supplement-Changes Being Effectuated	ENDO-OPIOID MDL-00299009	ENDO-OPIOID MDL-00299010		
P-10831	6/8/2007	Labeling Supplement - Opana ER RiskMAP	ENDO-OPIOID MDL-00299955	ENDO-OPIOID MDL-00299956		
P-10833	2/10/2011	Don't be Blue opana ER BCBS of TN Initiative Update	ENDO-OPIOID MDL-00361036	ENDO-OPIOID MDL-00361038		
P-10834	8/20/1997	APS-AAPM Consensus Statement - The Use of Opioids for the Treatment of Chronic Pain	ENDO-OPIOID MDL-00364350	ENDO-OPIOID MDL-00364353		
P-10835	9/30/2003	Endo Pharmaceuticals Meeting with Drug Enforcement Administration	ENDO-OPIOID MDL-00451333	ENDO-OPIOID MDL-00451380		
P-10836	2/9/2012	Email re Pharmacies refusals	ENDO-OPIOID MDL-00468003	ENDO-OPIOID MDL-00468005		
P-10838	11/1/2011	CDC Vital signs - Prescription Painkillers Overdoses in the US	ENDO-OPIOID MDL-00527673	ENDO-OPIOID MDL-00527676		
P-10839	6/24/2012	Email re Opana ER Speaker Program update- Midwest Region	ENDO-OPIOID MDL-00644449	ENDO-OPIOID MDL-00644449		
P-10842	10/13/2006	Email re Myers ECR Oct 06	ENDO-OPIOID MDL-00678170	ENDO-OPIOID MDL-00678173		
P-10845	8/11/2010	Email McKesson Update: Item Substitution Fee and Service Level Penalty Fee Attachments McKesson One Stop Supplier; Generics; McKesson Item Substitution Fee \$152,966.56; McKesson Service Level Penalty Fee - \$729,593.68; McKesson Order Summary Prepared by L. Walker; McKesson Endo email trail on Penalties	ENDO-OPIOID MDL-05948106	ENDO-OPIOID MDL-05948137		
P-10846	3/23/2007	Email re 2007 President's Club Plan	ENDO-OPIOID MDL-00682574	ENDO-OPIOID MDL-00682575		
P-10847	4/18/2007	Email FW Opana SURGE Conf Call Matls	ENDO-OPIOID MDL-00683203	ENDO-OPIOID MDL-00683215		
P-10850	6/1/2007	2007.06 Opana ATU Pulse 3 Summary	ENDO-OPIOID MDL-00685032	ENDO-OPIOID MDL-00685039		
P-10851	2/6/2007	Cedric Corbett ECR	ENDO-OPIOID MDL-00686142	ENDO-OPIOID MDL-00686212		
P-10853	11/6/2007	Email FW Primary Care MDs and Opioids	ENDO-OPIOID MDL-00773070	ENDO-OPIOID MDL-00773075		
P-10855	12/13/2007	Email re Example ECR	ENDO-OPIOID MDL-00774115	ENDO-OPIOID MDL-00774119		
P-10856	12/5/2010	Email re Library Program Utilization Update - November	ENDO-OPIOID MDL-00817302	ENDO-OPIOID MDL-00817305		
P-10857	9/28/2012	Update in NE TN - Involvement of Law Enforcement	ENDO-OPIOID MDL-00835497	ENDO-OPIOID MDL-00835499		
P-10858	4/3/2006	RE: New and interesting article	ENDO-OPIOID MDL-00849177	ENDO-OPIOID MDL-00849186		
P-10859	10/18/2006	RE: Sharp Stick Notes- IMPORTANT Read promptly	ENDO-OPIOID MDL-00856649	ENDO-OPIOID MDL-00856650		
P-10860	10/20/2006	FW: IMPORTANT- Walgreens stores that have stocked Opana	ENDO-OPIOID MDL-00856807	ENDO-OPIOID MDL-00856808		
P-10861	10/20/2006	email re - Project Pizza w - Attach	ENDO-OPIOID MDL-00856825	ENDO-OPIOID MDL-00856831		
P-10862	11/27/2006	Email re Opana Weekly-11/17	ENDO-OPIOID MDL-00858402	ENDO-OPIOID MDL-00858403		
P-10863	1/25/2007	email re - Stevenson 2006 Performance Appraisal w - Attach	ENDO-OPIOID MDL-00860303	ENDO-OPIOID MDL-00860311		
P-10864	1/29/2007	Email: Attaching Percocet History - Time & Events in the News Media	ENDO-OPIOID MDL-00860364	ENDO-OPIOID MDL-00860748		
P-10865	9/7/2007	Email FW: Opana Top 50 Writers	ENDO-OPIOID MDL-00869053	ENDO-OPIOID MDL-00869054		
P-10866	8/24/2006	Email re Opana and Opana ER Marketing Update	ENDO-OPIOID MDL-00880262	ENDO-OPIOID MDL-00880263		
P-10868	10/16/2006	Email re Follow-up items from Friday's meeting	ENDO-OPIOID MDL-00880735	ENDO-OPIOID MDL-00880735		
P-10869	12/7/2006	Email re Opana FIR 11-30-06	ENDO-OPIOID MDL-00881701	ENDO-OPIOID MDL-00881704		
P-10870	7/31/2012	email re: Tamper -Resistant Technologies In Addictive Painkillers	ENDO-OPIOID MDL-00903642	ENDO-OPIOID MDL-00903648		
P-10876	2/18/2010	Email FW Opana Speaker Program Allocations	ENDO-OPIOID MDL-00961320	ENDO-OPIOID MDL-00961321		
P-10877	2/24/2010	Email re Midwest Weekly Summary Feb 5th	ENDO-OPIOID MDL-00982037	ENDO-OPIOID MDL-00982041		
P-10880	8/5/2006	FW: Field Voice Message	ENDO-OPIOID MDL-01001527	ENDO-OPIOID MDL-01001530		
P-10881	9/23/2011	BCBS TN Opana ER performance	ENDO-OPIOID MDL-01005844	ENDO-OPIOID MDL-01005853		
P-10882	1/17/2011	2011 Objectives for Larry Romaine	ENDO-OPIOID MDL-01006527	ENDO-OPIOID MDL-01006529		
P-10883	6/25/2012	Lower Performing OER Footprints	ENDO-OPIOID MDL-01007694	ENDO-OPIOID MDL-01007695		
P-10884	11/30/2012	Opana ER conf call	ENDO-OPIOID MDL-01018226	ENDO-OPIOID MDL-01018227		
P-10889	3/18/2013	Email FW; McKesson Contracts	ENDO-OPIOID MDL-01056072	ENDO-OPIOID MDL-01056200		
P-10892	9/25/2008	TENNCARE Medicaid Win	ENDO-OPIOID MDL-01067350	ENDO-OPIOID MDL-01067351		
P-10894	3/8/2016	email re: Follow-Up- AOD w/Attach	ENDO-OPIOID MDL-01107574	ENDO-OPIOID MDL-01107608		
P-10896	7/10/2006	Email re Cluster Meeting Presentations	ENDO-OPIOID MDL-01127252	ENDO-OPIOID MDL-01127273		
P-10897	4/1/2009	Email with attachment Opioid REMS Strategy Meeting	ENDO-OPIOID MDL-01134277	ENDO-OPIOID MDL-01134291		
P-10898	1/7/2010	B. Barto comments on PCF REMS recommendations	ENDO-OPIOID MDL-01134340	ENDO-OPIOID MDL-01134348		
P-10899	1/7/2010	The Force Newsletter	ENDO-OPIOID MDL-01138715	ENDO-OPIOID MDL-01138727		

P-10900	10/7/2005	F/U to yesterday's meeting in Toronto; Endo Commercial Capabilities Overview	ENDO-OPIOID_MDL-01139609	ENDO-OPIOID_MDL-01139615		
P-10902	7/15/2006	Opana Brand Advisory Board Meeting Transcript	ENDO-OPIOID_MDL-01141511	ENDO-OPIOID_MDL-01141585		
P-10904	3/29/2017	Consulting Services Agreement	ENDO-OPIOID_MDL-01149359	ENDO-OPIOID_MDL-01149374		
P-10910	2/25/2016	Email GovAffairs Update Endo Victory on Amended PROMISE Act	ENDO-OPIOID_MDL-01211917	ENDO-OPIOID_MDL-01211919		
P-10911	4/6/2016	email re: EXTERNAL re: For OPC SC and HST Review by 5pm ET on 4/5 ldraft Outline for Meta-Analysis w/ Attach	ENDO-OPIOID_MDL-01221985	ENDO-OPIOID_MDL-01222021		
P-10912	8/19/2016	NAVIPPRO Reformulated Opana ER surveillance report	ENDO-OPIOID_MDL-01232760	ENDO-OPIOID_MDL-01233015		
P-10915	2/1/2017	FW: Opana ER Risk Management -- Suspicious Order Monitoring (SOM) program	ENDO-OPIOID_MDL-01239749	ENDO-OPIOID_MDL-01239753		
P-10916	11/2/2011	email re: Nov. 2: CDC Director Calls Painkiller Overdose An Epidemic w/Attach	ENDO-OPIOID_MDL-01294267	ENDO-OPIOID_MDL-01294278		
P-10919	10/26/2012	Takeaways/follow up from NASCSA Meeting	ENDO-OPIOID_MDL-01381735	ENDO-OPIOID_MDL-01381740		
P-10921	10/29/2013	Opana ER Risk Management with attm SOM White Paper	ENDO-OPIOID_MDL-01398417	ENDO-OPIOID_MDL-01398420		
P-10925	9/11/2013	Email re FDA Response to PROP Petition	ENDO-OPIOID_MDL-01448657	ENDO-OPIOID_MDL-01448675		
P-10926	10/18/2013	Cover email w/ attachment DEA Compliance Trip Report - Visit to DEA HQ	ENDO-OPIOID_MDL-01448682	ENDO-OPIOID_MDL-01448685		
P-10927	8/19/2014	nAVIPPRO Reformulated Opana ER surveillance report	ENDO-OPIOID_MDL-01459827	ENDO-OPIOID_MDL-01459925		
P-10929	1/1/2009	2009 APS-AAPM Guideline for the Use of Opioid Therapy in Chronic Noncancer Pain	ENDO-OPIOID_MDL-01463855	ENDO-OPIOID_MDL-01464070		
P-10931	2/17/2009	email: Pink Sheet Articles & Meeting Next Week with attached Pink Sheet 2-16-09 - Opioid Approval Delay Poses Legal Questions; Pink Sheet 2-16 -09 - Opioid REMS will be massive; Pink Sheet 2-16-09 - The Downside Of REMS	ENDO-OPIOID_MDL-01485646	ENDO-OPIOID_MDL-01485653		
P-10934	2/19/2009	Risk Management Program for Opioid Analgesics, Focus on Oxycodone	ENDO-OPIOID_MDL-01500830	ENDO-OPIOID_MDL-01500937		
P-10936	3/21/2017	Publications Policy	ENDO-OPIOID_MDL-01519876	ENDO-OPIOID_MDL-01519906		
P-10941	4/20/2011	email re: Rx Abuse Update	ENDO-OPIOID_MDL-01592642	ENDO-OPIOID_MDL-01592643		
P-10942	1/7/2010	Email re Treating Pain: Arming New Yorkers with Access	ENDO-OPIOID_MDL-01594917	ENDO-OPIOID_MDL-01594920		
P-10944	1/1/2001	Pain Management Today	ENDO-OPIOID_MDL-01605952	ENDO-OPIOID_MDL-01605958		
P-10947	8/8/2001	RE Agenda for FDA Meeting APF Alert	ENDO-OPIOID_MDL-01652584	ENDO-OPIOID_MDL-01652586		
P-10948	2/12/2012	Opioid Abuse Articles Mentioning Endo	ENDO-OPIOID_MDL-01656768	ENDO-OPIOID_MDL-01656777		
P-10950	5/8/2014	Cover Email w attached UPS SOPs	ENDO-OPIOID_MDL-01680920	ENDO-OPIOID_MDL-01680975		
P-10952	8/31/2017	Email re Opana Transition Last Day to Ship	ENDO-OPIOID_MDL-01681499	ENDO-OPIOID_MDL-01681501		
P-10953	7/14/2003	Action Plan to Prevent Diversion	ENDO-OPIOID_MDL-01692316	ENDO-OPIOID_MDL-01692321		
P-10954	10/2/2003	Revised DEA Meeting Minutes	ENDO-OPIOID_MDL-01706006	ENDO-OPIOID_MDL-01706011		
P-10956	3/4/2004	FW: EN3202 draft RMP	ENDO-OPIOID_MDL-01710787	ENDO-OPIOID_MDL-01710839		
P-10957	10/2/2007	Opana Fastape Study	ENDO-OPIOID_MDL-01723746	ENDO-OPIOID_MDL-01723948	ENDO-OPIOID_MDL-01723746 - ENDO-OPIOID_MDL-01723748	
P-10958	8/2/2016	email re: Quick Question/ Clarification	ENDO-OPIOID_MDL-01731966	ENDO-OPIOID_MDL-01731966		
P-10959	8/31/2018	Curriculum Vitae of Dr. Shusterman	ENDO-OPIOID_MDL-01734712	ENDO-OPIOID_MDL-01734728		
P-10962	12/16/2016	Tennessee Actions	ENDO-OPIOID_MDL-01808034	ENDO-OPIOID_MDL-01808038		
P-10963	7/5/2017	FDA Minutes of Type A Meeting	ENDO-OPIOID_MDL-01831502	ENDO-OPIOID_MDL-01831508		
P-10964	3/21/2017	NDA 201655 Opana ER	ENDO-OPIOID_MDL-01848038	ENDO-OPIOID_MDL-01848038		
P-10966	11/30/2007	Email chain re Opana Compliance Issue-Dr McNeil (TN)	ENDO-OPIOID_MDL-01861269	ENDO-OPIOID_MDL-01861273		
P-10967	1/3/2008	Email re Physician removed from OER call plan by Craven	ENDO-OPIOID_MDL-01861288	ENDO-OPIOID_MDL-01861292		
P-10969	3/16/2016	Email re Opana ER - doses >30mg?	ENDO-OPIOID_MDL-01902659	ENDO-OPIOID_MDL-01902662		
P-10970	10/3/2016	Pilot Doctors pharmacy data with attm TN_opana_pharmacy_data	ENDO-OPIOID_MDL-01905809	ENDO-OPIOID_MDL-01905810		
P-10973	7/31/2002	Draft of APS Faculty-Program For Your Review	ENDO-OPIOID_MDL-01928251	ENDO-OPIOID_MDL-01928254		
P-10974	11/16/2003	FW NIPC Opioid Program - Fantastic Feedback	ENDO-OPIOID_MDL-01928285	ENDO-OPIOID_MDL-01928286		
P-10975	5/30/2012	Draft Rx Drug Abuse Deck for 6/5/12	ENDO-OPIOID_MDL-01941783	ENDO-OPIOID_MDL-01941784		
P-10976	8/6/2012	Email and attachment re West Opana ER Feedback attaching Feedback Form	ENDO-OPIOID_MDL-01968614	ENDO-OPIOID_MDL-01968617		
P-10977	10/30/2012	Email communication to the field	ENDO-OPIOID_MDL-01968698	ENDO-OPIOID_MDL-01968700		
P-10979	12/6/2001	3202 Draft Plans for 2002	ENDO-OPIOID_MDL-02002513	ENDO-OPIOID_MDL-02002515		
P-10981	6/12/2017	Cardinal Refuses to Order Opana ER	ENDO-OPIOID_MDL-02062332	ENDO-OPIOID_MDL-02062333		
P-10983	8/1/2003	EN 3202 PK Study: Request	ENDO-OPIOID_MDL-02069378	ENDO-OPIOID_MDL-02069394		



P-10984	12/19/2007	Email re Opana ATU Wave 3 Final Report & Brand IQ Summary	ENDO-OPIOID_MDL-02086096 ENDO-OPIOID_MDL-02086096	ENDO-OPIOID_MDL-02086099 ENDO-OPIOID_MDL-02086155	ENDO-OPIOID_MDL-02086096 - ENDO-OPIOID_MDL-02086099
P-10986	7/6/2016	email re: EXTERNAL re: OPC Meta-Analysis Manuscript w/ Attach	ENDO-OPIOID_MDL-02117646	ENDO-OPIOID_MDL-02117686	
P-10987	2/13/2007	Email FW: ECRs	ENDO-OPIOID_MDL-02147122	ENDO-OPIOID_MDL-02147123	
P-10991	12/20/2007	Email fwd Opana ER Successful Rep Research Final Report & Brand IQ Summary	ENDO-OPIOID_MDL-02162731	ENDO-OPIOID_MDL-02162734	
P-10993	10/1/2008	RE: Time to catch up live wire	ENDO-OPIOID_MDL-02206602	ENDO-OPIOID_MDL-02206606	
P-10994	2/11/2008	Email re: Popan Activities in the past months	ENDO-OPIOID_MDL-02210853	ENDO-OPIOID_MDL-02210855	
P-10996	10/27/2006	Project Pizza update - w - Attach	ENDO-OPIOID_MDL-02230226	ENDO-OPIOID_MDL-02230228	
P-10998	3/16/2004	email re: Nicolson Drugs (2003) Article re: Addiction	ENDO-OPIOID_MDL-02255331	ENDO-OPIOID_MDL-02255347	
P-11001	6/10/2003	RE: NIPC Input Needed for Meeting	ENDO-OPIOID_MDL-02261843	ENDO-OPIOID_MDL-02261845	
P-11002	6/13/2013	Supply Chain & DEA Compliance	ENDO-OPIOID_MDL-02278908	ENDO-OPIOID_MDL-02278917	
P-11003	8/30/2017	Approved-OPANA ER Wholesaler Promotion Update	ENDO-OPIOID_MDL-02290107	ENDO-OPIOID_MDL-02290110	
P-11005	5/2/2010	FDA Docket Recommendations PCF REMS Task Force	ENDO-OPIOID_MDL-02293305	ENDO-OPIOID_MDL-02293319	
P-11006	10/31/2011	Email w QT Presentation on Endo PAC & Public Policy	ENDO-OPIOID_MDL-02297404	ENDO-OPIOID_MDL-02297405	
P-11008	2/16/2010	2009 Mid Yr & Yr End & Self Eval Under Lortie	ENDO-OPIOID_MDL-02312040	ENDO-OPIOID_MDL-02312054	
P-11009	6/18/2012	Email FW: Opana mentioned in Pitts. Post story on abuse-FYI	ENDO-OPIOID_MDL-02314929	ENDO-OPIOID_MDL-02314931	
P-11010	9/11/2006	Email from TN pharmacist on the TennCare board concerned about addiction to Opana and Endo's response	ENDO-OPIOID_MDL-02317224	ENDO-OPIOID_MDL-02317226	
P-11011	10/4/2006	FW: OPANA & OPANA ER Weekly Report	ENDO-OPIOID_MDL-02317399	ENDO-OPIOID_MDL-02317403	
P-11014	4/11/2013	Email re Documents	ENDO-OPIOID_MDL-02324335	ENDO-OPIOID_MDL-02324411	
P-11015	1/30/2004	National Initiative on Pain Control - 2003 Year in Review	ENDO-OPIOID_MDL-02343835	ENDO-OPIOID_MDL-02343836	
P-11016	1/20/2000	CD&E: The Critical Connection for Success in 2000 and Beyond	ENDO-OPIOID_MDL-02344002	ENDO-OPIOID_MDL-02344002	
P-11019	4/23/2003	Opioid Analgesics - Advanced Sales Training	ENDO-OPIOID_MDL-02356776	ENDO-OPIOID_MDL-02356777	
P-11021	7/26/2012	RE: Know Your Customer	ENDO-OPIOID_MDL-02448133	ENDO-OPIOID_MDL-02448142	
P-11023	10/29/2012	CDC Health Advisory - Opana ER/TTP	ENDO-OPIOID_MDL-02452937	ENDO-OPIOID_MDL-02452937	
P-11024	11/1/2006	FW: Opana Cluster Workshops (3 or 4); Presentation EndoSell Training Program-Engender Thinking & Needs	ENDO-OPIOID_MDL-02489834	ENDO-OPIOID_MDL-02489844	
P-11026	11/13/2014	TN Opana ER	ENDO-OPIOID_MDL-02667004	ENDO-OPIOID_MDL-02667005	
P-11027	11/13/2014	Potentially closing off Opana ER distribution to TN	ENDO-OPIOID_MDL-02667006	ENDO-OPIOID_MDL-02667007	
P-11028	11/13/2012	Top 10 States -- Opana Sales with atm	ENDO-OPIOID_MDL-02791740	ENDO-OPIOID_MDL-02791742	
P-11030	6/26/2014	HR 659 Opioid Addiction Advisory Committee Meeting	ENDO-OPIOID_MDL-02795421	ENDO-OPIOID_MDL-02795472	
P-11031	4/14/2016	Final draft Rx Drug Abuse Plan	ENDO-OPIOID_MDL-02801542	ENDO-OPIOID_MDL-02801564	
P-11032	10/24/2007	Email re APF Briefing w/ Attachments	ENDO-OPIOID_MDL-02807881	ENDO-OPIOID_MDL-02807914	
P-11033	10/28/2007	Military Briefing Invite/Fact Sheet - re: Military/Veterans & Pain Media Briefing	ENDO-OPIOID_MDL-02807915	ENDO-OPIOID_MDL-02807922	
P-11039	3/15/2007	NP in TN shut down, Endo knew he was sketchy but still calling on him	ENDO-OPIOID_MDL-02883341	ENDO-OPIOID_MDL-02883342	
P-11041	4/1/2007	Case Challenges in Pain Management: Opioid Therapy for Chronic Pain; Memo: New Sales Tools - Case Study Article	ENDO-OPIOID_MDL-02885127 ENDO-OPIOID_MDL-02885143	ENDO-OPIOID_MDL-02885163 ENDO-OPIOID_MDL-02885149	ENDO-OPIOID_MDL-02885143 - ENDO-OPIOID_MDL-02885149
P-11045	3/7/2013	Email attaching Charts from DEA Meeting	ENDO-OPIOID_MDL-02975958	ENDO-OPIOID_MDL-02976118	
P-11046	6/11/2008	Cover Email re UPS Order Entry Working Instruction for Review	ENDO-OPIOID_MDL-02988138	ENDO-OPIOID_MDL-02988145	
P-11050	2/24/2004	Email re FDA needs the plan to be operational	ENDO-OPIOID_MDL-03003919	ENDO-OPIOID_MDL-03003924	
P-11052	2/9/2004	BB received the 2003 GAO Report	ENDO-OPIOID_MDL-03006241	ENDO-OPIOID_MDL-03006304	
P-11055	3/8/2004	Regulatory Agency Contact Report	ENDO-OPIOID_MDL-03113787	ENDO-OPIOID_MDL-03113790	
P-11057	1/23/2004	GAO (2003) Report - Oxycontin Abuse and Diversion and Efforts to Address the Problem	ENDO-OPIOID_MDL-03256654	ENDO-OPIOID_MDL-03256717	
P-11059	1/8/1999	Clinical Development & Education -- 1999 Objectives, Linda Kitlinski	ENDO-OPIOID_MDL-03258199	ENDO-OPIOID_MDL-03258202	
P-11060	9/5/2001	Percocet Death Reports (1999-2000)	ENDO-OPIOID_MDL-03259246	ENDO-OPIOID_MDL-03259247	
P-11061	1/29/2010	Byrne Edits REMS Task Force Doc Based on Barto Comments	ENDO-OPIOID_MDL-03344946	ENDO-OPIOID_MDL-03344953	
P-11062	8/24/2001	FW: 2002 Strategy Review	ENDO-OPIOID_MDL-03388209	ENDO-OPIOID_MDL-03388210	
P-11064	2/20/2004	EN3218 Revised Risk Management Plan Submission	ENDO-OPIOID_MDL-03457780	ENDO-OPIOID_MDL-03457781	
P-11068	3/15/2016	MMWR CDC Guideline for Prescribing Opioids for Chronic Pain-United States 2016	ENDO-OPIOID_MDL-03705630	ENDO-OPIOID_MDL-03705687	
P-11069	3/22/2017	email re: EXTERNAL: Re: After the Ad Comm	ENDO-OPIOID_MDL-03727328	ENDO-OPIOID_MDL-03727329	
P-11071	8/19/2010	Email re Opana ER Letters	ENDO-OPIOID_MDL-03830727	ENDO-OPIOID_MDL-03830731	
P-11072	12/22/2003	Email re Follow-up from Dallas (2.5 percocet launch)	ENDO-OPIOID_MDL-03839706	ENDO-OPIOID_MDL-03839706	
P-11073	4/7/2014	Opana Project Review	ENDO-OPIOID_MDL-03845063	ENDO-OPIOID_MDL-03845065	

P-11074	3/2/2009	REMS Meeting	ENDO-OPIOID_MDL-03850595	ENDO-OPIOID_MDL-03850597		
P-11075	12/11/2008	Email between B. Barto and B. Munroe re responding to PCF	ENDO-OPIOID_MDL-03902804	ENDO-OPIOID_MDL-03902806		
P-11076	3/20/2014	Code of Conduct	ENDO-OPIOID_MDL-03922439	ENDO-OPIOID_MDL-03922482		
P-11078	8/21/2001	email re: OAD Organization	ENDO-OPIOID_MDL-04088140	ENDO-OPIOID_MDL-04088141		
P-11079	3/25/2002	Email attaching Opana Risk Management Presentation	ENDO-OPIOID_MDL-04095507	ENDO-OPIOID_MDL-04095508		
P-11080	1/11/2004	2003 Year End Performance Appraisal Bob Barto	ENDO-OPIOID_MDL-04110672	ENDO-OPIOID_MDL-04110684		
P-11081	2/16/2007	Email FW Patient Story	ENDO-OPIOID_MDL-04118668	ENDO-OPIOID_MDL-04118671		
P-11083	10/17/2002	Percocet Business Plan - Executive Committee Presentation	ENDO-OPIOID_MDL-04136658	ENDO-OPIOID_MDL-04136661		
P-11086	9/20/2012	Notes from FDA Meeting	ENDO-OPIOID_MDL-04213456	ENDO-OPIOID_MDL-04213457		
P-11087	11/26/2014	Interesting Development - Hysingla Post-Marketing Requirements	ENDO-OPIOID_MDL-04278983	ENDO-OPIOID_MDL-04279030		
P-11088	12/12/2001	RE: Oxycontin - HEAT TURNED UP!	ENDO-OPIOID_MDL-04869680	ENDO-OPIOID_MDL-04869688		
P-11089	12/27/2007	Cover Email w Attached 12.27.2007 DEA Letter (HDMA Objecting) Priv Challenge	ENDO-OPIOID_MDL-04881787	ENDO-OPIOID_MDL-04881791		
P-11093	2/8/2002	IC Plans for 2002 and T3 2001	ENDO-OPIOID_MDL-04908071	ENDO-OPIOID_MDL-04908119		
P-11096	4/5/2002	Business Planning Kick-Off Meeting Documents	ENDO-OPIOID_MDL-04908487	ENDO-OPIOID_MDL-04908496		
P-11097	4/26/2002	FW: Copies of QBR Slides	ENDO-OPIOID_MDL-04908522	ENDO-OPIOID_MDL-04908590		
P-11098	7/23/2002	BMT Meeting -- Brand Strat's for Review	ENDO-OPIOID_MDL-04908831	ENDO-OPIOID_MDL-04908839		
P-11112	9/23/2013	Email re PAIN CONTEST and COE Ranks conference call follow up! Attachments: 2013 Pain Contest; 2013_07_08 2P13 Pain IC Overview v2 0; Copy of 2013_09_06 Pain Solns (Retail) Jun'13 Circle of Excellence based on 2P13 alignment v2 0	ENDO-NY-00474778	ENDO-NY-00474782		
P-11129	6/8/2003	Email re slides from Turnberry (fwd June POA slides)	ENDO-OPIOID_MDL-04911467	ENDO-OPIOID_MDL-04911471		
P-11130	8/21/2006	Email FW: Infor for you meeting on Tuesday	ENDO-OPIOID_MDL-04920194	ENDO-OPIOID_MDL-04920194		
P-11131	4/1/2002	Percocet-Stay on top of the pain Ad	ENDO-OPIOID_MDL-04929187	ENDO-OPIOID_MDL-04929194		
P-11134	7/6/2016	Opana slides!	ENDO-OPIOID_MDL-04951036	ENDO-OPIOID_MDL-04951038		
P-11136	5/7/2003	2003 Objectives Update	ENDO-OPIOID_MDL-05589327	ENDO-OPIOID_MDL-05589328		
P-11137	1/1/2006	Oxymorphone Learning System Module 3 - Oxymorphone Risk Management Program	ENDO-OPIOID_MDL-05654763	ENDO-OPIOID_MDL-05654814		
P-11138	5/9/2014	SOM Summary with attm	ENDO-OPIOID_MDL-05948280	ENDO-OPIOID_MDL-05948285		
P-11143	3/9/2014	CII orders handled by Memphis w attm Transportation Project - DEA Response	ENDO-OPIOID_MDL-05962559	ENDO-OPIOID_MDL-05962563		
P-11146	2/21/2012	Excessive Order Quantities Changed for Shipping	ENDO-OPIOID_MDL-05962953	ENDO-OPIOID_MDL-05962956		
P-11149	7/23/1998	Clinical Development & Education --1998 Mid-Year Update on Goals & Objectives	ENDO-OPIOID_MDL-05967764	ENDO-OPIOID_MDL-05967774		
P-11150	8/21/2009	RE APS Resident's Course - Syllabus Part 5 of 5	ENDO-OPIOID_MDL-05968029	ENDO-OPIOID_MDL-05968075		
P-11151	7/25/2012	Email re UPS's KYC Program	ENDO-OPIOID_MDL-05968927	ENDO-OPIOID_MDL-05968929		
P-11153	4/11/2014	Walker Confused re UPS KYC Due Diligence Reqs	ENDO-OPIOID_MDL-05968962	ENDO-OPIOID_MDL-05968963		
P-11155	5/13/2018	Email re New Endo and UPS SOM Programs UPS SCS SOM	ENDO-OPIOID_MDL-05969976	ENDO-OPIOID_MDL-05969988		
P-11157	3/16/2010	Email FW Opana ER Success Story	ENDO-OPIOID_MDL-06009589	ENDO-OPIOID_MDL-06009607		
P-11158	4/30/2009	OSAM-O-GRAM Opana (Jan 2009)	ENDO-OPIOID_MDL-06127944	ENDO-OPIOID_MDL-06127945		
P-11159	7/1/2009	Email re Organizing Response to PCF	ENDO-OPIOID_MDL-06146694	ENDO-OPIOID_MDL-06146696		
P-11162	3/14/2013	NAVIPPRO Reformulated Opana ER surveillance report	ENDO-OPIOID_MDL-06183930	ENDO-OPIOID_MDL-06184083		
P-11163	7/11/2012	American Pain: The Largest US Pill Mill's Rise and Fall	ENDO-OPIOID_MDL-06211237	ENDO-OPIOID_MDL-06211245		
P-11164	12/8/2011	Draft 2012 GA Strategic Plan	ENDO-OPIOID_MDL-06213500	ENDO-OPIOID_MDL-06213540		
P-11165	7/15/2014	Email re Talking Points for Opana ER Complete Response Discussion Attachments: Opana RnD Discussion_22-April-2014_v1	ENDO-OPIOID_MDL-01118096	ENDO-OPIOID_MDL-01118098		
P-11166	7/3/2003	L. Kitlinski Performance Appraisal	ENDO-OPIOID_MDL-06233891	ENDO-OPIOID_MDL-06233909		
P-11167	8/1/2001	Update from American Pain Foundation APF Overview and Report for Endo 7.31.01	ENDO-OPIOID_MDL-06234029	ENDO-OPIOID_MDL-06234037		
P-11168	11/19/1998	Notes from CCD&E regarding PER 1018 - American Pain Society	ENDO-OPIOID_MDL-06234663	ENDO-OPIOID_MDL-06234663		
P-11169	5/15/2012	Email re Opana Meeting Today	ENDO-OR-CID-00345837	ENDO-OR-CID-00345872		
P-11171	4/12/2011	email re: Drug Abusers in Kentucky Find a New, Deadly High In Opana The Courier-Journal Courier -Journal	ENDO-OR-CID-00582220	ENDO-OR-CID-00582224		
P-11173	6/3/2010	2010 Q1 RiskMAP Update Report (Jan-March)	ENDO-OR-CID-00607244	ENDO-OR-CID-00701534		
P-11174	5/1/2011	Drug Enforcement Administration - Drug Intelligence Brief	ENDO-OR-CID-00637454 ENDO-OR-CID-00694084	ENDO-OR-CID-00752213 ENDO-OR-CID-00694087	ENDO-OR-CID-00694084 - ENDO-OR-CID-00694087	
P-11175	1/23/2013	FDA denying petition to approve new NDA for Opana ER	ENDO-OR-CID-00627545	ENDO-OR-CID-00700066		



P-11177	8/22/2012	Appendix B to 4th Response to Senate Finance Committee	ENDO-OR-CID-00607216	ENDO-OR-CID-00749178		
P-11178	7/6/2012	Endo Response Package to Senate Inquiry	ENDO-OR-CID-00754369	ENDO-OR-CID-00831921		
P-11179	10/24/2012	Opana ER Risk Management Team Minutes 10/24/12	ENDO-OR-CID-00785398	ENDO-OR-CID-00785404		
P-11198	12/2/2011	2011 Q3 RiskMAP Update Report (July-Sept.)	EPI000015267	EPI000015298		
P-11199	11/30/2012	Email FW First Data Bank	EPI000086960	EPI000086960		
P-11201	10/4/2013	Opana ER Strategy 10 2013	EPI000091198	EPI000091200		
P-11202	10/10/2011	email re: FW: Differentiation Opportunities for Opana CRF	EPI000099628	EPI000099629		
P-11203	5/29/2009	2009 Q1 RiskMAP Update Report (Jan-March)	EPI000119178	EPI000119206		
P-11206	5/21/2012	2012 Q1 RiskMAP Update Report (Jan-March)	EPI000588532	EPI000588560		
P-11208	11/30/2012	Chapman Declaration in Support of Endo Lawsuit	EPI000591330	EPI000591436		
P-11209	10/29/2013	Email re: Opana ER Risk Management SOM Program	EPI000620553	EPI000620555		
P-11210	9/7/2010	Ad comm advice	EPI000633638	EPI000633640		
P-11211	10/2/2012	Conversation with TN IV Drug Abuser 01Oct2012	EPI000650543	EPI000650545		
P-11215	6/1/2007	Risk Minimization Action Plan	EPI000750018	EPI000750064		
P-11225	4/26/2012	Email re: Opana Rebate	EPI001080837	EPI001080838		
P-11227	10/7/2011	Endo Mtg w/ DEA w/ Attachments	EPI001179443	EPI001179451		
P-11229	11/4/2011	Email 1:1 Lorraine/JGilbert	EPI001232307	EPI001232322		
P-11231	8/16/2012	Further Follow Up on Ad hoc ESRB meeting on 16Aug2012	EPI001253792	EPI001253794		
P-11241	12/9/2011	Reformulation Approval Letter	EPI001314350	EPI001314441		
P-11242	8/22/2012	Submission of 6 TTP MW Forms	EPI001314726	EPI001314767		
P-11244	5/29/2009	RiskMAP	EPI001414374	EPI001414374		
P-11250	10/24/2012	Inflection Deliverable	EPI001480925	EPI001480932		
P-11259	5/17/2012	NAVIPPRO Reformulated Opana ER surveillance report	EPI001760591	EPI001760680		
P-11263	12/2/2008	Draft PCF response to FDA re REMS	EPI001789493	EPI001789499		
P-11264	8/12/2013	Background Materials	EPI001878724	EPI001878794		
P-11265	2/24/2013	Pharmacy Report - Update	EPI002036707	EPI002036709		
P-11269	5/22/2013	Opana ER Risk Management Team Minutes 5/22/13	EPI002378644	EPI002378672		
P-11271	8/29/2012	Opana ER Risk Management Team Minutes 8/29/12	EPI002454134 EPI002454185	EPI002454190 EPI002454223	EPI002454185 - EPI002454190	
P-11272	12/1/2012	Compendia Status Update	EPI002485010	EPI002485011		
P-11279	11/8/2006	NIPC [Endo] Dinner Dialogues "Advances in Opioid Analgesia: Maximizing Benefit While Minimizing Risk" Fall 2006 Dinner Dialogues Series Invitation to Grace Forde/Charles Presentation in Roslyn, NY	KP360_OHIOMDL_000003328	KP360_OHIOMDL_000003329		
P-11280	12/7/2006	Payment to Charles Argoff for Roslyn, NY NIPC Dinner Dialogue	KP360_OHIOMDL_000003707	KP360_OHIOMDL_000003707		
P-11281	4/8/2005	Opioid Analgesia Practical Treatment of the Patient With Chronic Pain	KP360_OHIOMDL_000050938	KP360_OHIOMDL_000051097		
P-11282	11/8/2006	Advanced in Opioid Analgesia - Maximizing Benefits While Minimizing Risks	KP360_OHIOMDL_000095691	KP360_OHIOMDL_000095691		
P-11287	N/A	Endo call notes	ENDO-NY-000000001	ENDO-NY-000000001		
P-11287a	N/A	Excerpt of P-11287; Opana ER Detailing Visits in New York State, 2008 - 2016	ENDO-NY-000000001	ENDO-NY-000000001		
P-11287b	N/A	Excerpt of P-11287; Endo call notes - export for Belfiore, Cubangbang, Lopez, Troyan	ENDO-NY-000000001	ENDO-NY-000000001		
P-11290	1/29/2015	email: RE: SOM Program	ENDO-OPIOID_MDL-05948286	ENDO-OPIOID_MDL-05948292		
P-11291	3/20/2012	email: FW: Annual Training Curriculum Review and Approval for Required Training	ENDO-OPIOID_MDL-05950068	ENDO-OPIOID_MDL-05950072		
P-11292	9/30/2010	DEA Investigation 2010	PAR_OPIOID_MDL_0001615734	PAR_OPIOID_MDL_0001615745		
P-11300	7/11/2013	Oxy HCL Opana Approval Letter	Acquired_Actavis_00677893	Acquired_Actavis_00677937		
P-11301	3/27/2013	Email re Naloxone Promotional Outreach	Acquired_Actavis_02290885	Acquired_Actavis_02290886		
P-11303	3/16/2016	Org charts	ALLERGAN_MDL_01373715	ALLERGAN_MDL_01373722		
P-11304	2/24/2016	US Commercial L4 Organization Structure	ALLERGAN_MDL_02186856	ALLERGAN_MDL_02186870		
P-11305	N/A	Allergan call logs	ALLERGAN_MDL_01890663	ALLERGAN_MDL_01890663		
P-11314	2011	2011 Q2 Bonus Plan	TEVA_CHI_00003803	TEVA_CHI_00003807		
P-11324	2003	2003 Actiq Marketing Plan	TEVA_CHI_00042882	TEVA_CHI_00042950		
P-11326	2/9/1999	Actiq RiskMap (August 1, 2001)	TEVA_CHI_00049233	TEVA_CHI_00049413		
P-11328	4/1/2006	Actiq End of Lifecycle Plan	TEVA_MDL_A_00010835	TEVA_MDL_A_00010836		
P-11331	11/28/2006	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use	TEVA_MDL_A_00025406	TEVA_MDL_A_00025424		

P-11332	5/2/2007	WLF-FENT 001 WLF Article "Fentanyl Buccal Tablets for the relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study"/FENT 115 Patient Privacy Sign-in Clipboard/FENT 121 FENTORA Core Sales Aid	TEVA_MDL_A_00025990	TEVA_MDL_A_00026027		
P-11334	3/7/2008	FENT 226 FENTORA Voucher FENT 219 Medication Guide	TEVA_MDL_A_00026762	TEVA_MDL_A_00026772		
P-11338	6/19/2009	Transmission of Fentora assistance card	TEVA_MDL_A_00027887	TEVA_MDL_A_00027915		
P-11340	4/30/2010	FEN 2025 PDR Content Converter/FEN 2026 Oncology Leave Behind	TEVA_MDL_A_00028503	TEVA_MDL_A_00028527		
P-11341	5/5/2010	FEN-2038 Convention Booth Quiz	TEVA_MDL_A_00028528	TEVA_MDL_A_00028536		
P-11343	2/18/2011	FEN-2225 Weinstein Reprint 2009/FEN-2226 Darwish Reprint 2007/FEN-2227 Portenoy Reprint 2006/FEN-2228 Darwish Reprint 2006/FEN-2229 Darwish Reprint 2006	TEVA_MDL_A_00029432	TEVA_MDL_A_00029483		
P-11344	7/23/2007	FDA Letter to Cephalon Re Investigational New Drug Application for Fentora	TEVA_MDL_A_00038282	TEVA_MDL_A_00038295		
P-11346	9/22/2005	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use	TEVA_MDL_A_00266319	TEVA_MDL_A_00266346		
P-11347	12/4/2009	Fentora 2010 Brand Plan	TEVA_MDL_A_00363031	TEVA_MDL_A_00363099		
P-11348	12/5/2005	2005-2006 Fentora Marketing Plan	TEVA_MDL_A_00368405	TEVA_MDL_A_00368625		
P-11359	6/1/2006	Gap" Core Sales Aid"	TEVA_MDL_A_00551447	TEVA_MDL_A_00551466		
P-11369	2006	2006-2015 Fentora Speaker Database	TEVA_MDL_A_00696812	TEVA_MDL_A_00696812		
P-11371	N/A	Amrix Specialty Code and Targeting Spreadsheet	TEVA_MDL_A_00700492	TEVA_MDL_A_00700492		
P-11385	2/5/2013	Email re HCPConnect Videocast	TEVA_MDL_A_00884392	TEVA_MDL_A_00884399		
P-11387	9/26/2012	Digital Core Visual Aid	TEVA_MDL_A_00981245	TEVA_MDL_A_00981285		
P-11395	1/31/2014	FEN-40133 Fentora Managed Care Leave-Behind (v1.0)	TEVA_MDL_A_01132030	TEVA_MDL_A_01132031		
P-11397	4/30/2009	Yearly review - BTP Education brochure	TEVA_MDL_A_01149871	TEVA_MDL_A_01149880		
P-11399	5/31/2009	YEARLY REVIEW: FEN-2009P-PM-00231 CVA	TEVA_MDL_A_01150240	TEVA_MDL_A_01150246		
P-11402	12/19/2006	APF Grant Approval Beckhardt; Memo re Unrestricted Educational Grant to Disseminate Patient Education Materials Developed by the American Pain Foundation; Educational Grant Requests	TEVA_MDL_A_01174085 TEVA_MDL_A_01174115	TEVA_MDL_A_01174543 TEVA_MDL_A_01174543	TEVA_MDL_A_01174115 - TEVA_MDL_A_01174543	
P-11406	11/13/2012	Fentora Historical Impact; Fentora Marketing Mix Analysis Refresh: Impact Assessment Findings Review Presentation	TEVA_MDL_A_01205574	TEVA_MDL_A_01205582		
P-11408	11/14/2011	Fentora Brand Plan PPT	TEVA_MDL_A_01211465	TEVA_MDL_A_01211479		
P-11416	3/10/2015	Email re DEA Quota Letter	TEVA_MDL_A_01465597	TEVA_MDL_A_01465598		
P-11419	4/29/2008	Fentora ROI Bayer Consulting; Promotional Response of Fentora Findings Presentation; Fentora 7 Business Questions Presentation	TEVA_MDL_A_01543546	TEVA_MDL_A_01543548		
P-11428	6/27/2005	6.27.2005 FDA Letter to Cephalon Re Actiq sNDA and RiskMap Changes	TEVA_MDL_A_01583458	TEVA_MDL_A_01583460		
P-11432	2010	List of Existing Promotional Pieces	TEVA_MDL_A_02207758	TEVA_MDL_A_02207759		
P-11436	5/30/2018	Re IQVIA market share data; Generic Weekly Tracking Report WE 5-18-18	TEVA_MDL_A_02315382	TEVA_MDL_A_02315384		
P-11439	2001	2001 - 2006 Actiq National Call Notes Database	TEVA_MDL_A_02416207	TEVA_MDL_A_02416207		
P-11446	6/9/2004	Email and Attached Actiq Inventory Update	TEVA_MDL_A_02867804	TEVA_MDL_A_02867805		
P-11449	1/29/2010	Email re Voucher Update with Voucher Attached	TEVA_MDL_A_02967123	TEVA_MDL_A_02967137		
P-11451	2004	Cephalon Speaker Bureau Policy (2004)	TEVA_MDL_A_03206962	TEVA_MDL_A_03206973		
P-11452	8/1/2001	Actiq RMP	TEVA_MDL_A_03272086	TEVA_MDL_A_03272117		
P-11454	9/10/2007	Cephalon Dear Doctor Letter re Fentora Deaths	TEVA_MDL_A_03400541	TEVA_MDL_A_03400549		
P-11455	9/2/2015	Vantrela Government Affairs Presentation MCO focus	TEVA_MDL_A_03548146	TEVA_MDL_A_03548147		
P-11456	10/9/2006	Fentora Launch Highlight Video	TEVA_MDL_A_03571749	TEVA_MDL_A_03571751		
P-11457	1/29/2010	ABC's of Pain Sales Aid	TEVA_MDL_A_03623393	TEVA_MDL_A_03623398		
P-11458	5/31/2010	Fentora BTP Education Station Form	TEVA_MDL_A_03626573	TEVA_MDL_A_03626579		
P-11460	6/14/2004	Memo from Roy Craig to U.S. Sales re "Ensuring Appropriate Targeting And Promotion of ACTIQ,"	TEVA_MDL_A_05445644	TEVA_MDL_A_05445712		
P-11470	2/8/2010	Fentora Promotional Materials Package	TEVA_MDL_A_07576590	TEVA_MDL_A_07576654		
P-11472	1/27/2010	Fentora Pain Tracker Device	TEVA_MDL_A_08198710	TEVA_MDL_A_08198717		
P-11473	10/26/2012	Email re Hydrocodone Presentation with Attached Presentation	ALLERGAN_MDL_01029477	ALLERGAN_MDL_01029500		
P-11475	N/A	SOP re Marketing Support of the Actiq Risk Management Program, Version Number: 1; SOP-0426-J02	Brennan_000085	Brennan_000088		

P-11485	7/6/2001	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use	TEVA_MDL_A_11110449	TEVA_MDL_A_11110535		
P-11486	3/5/2002	2002 Actiq Sales Aid	TEVA_MDL_A_11115315	TEVA_MDL_A_11115343		
P-11487	3/11/2002	Pocket Dosing Guide, Transmittal of Advertisements and Promotional Labeling	TEVA_MDL_A_11115489	TEVA_MDL_A_11115492		
P-11488	10/29/2004	Email re Andrea BeDan Resignation with Exit Interview	TEVA_MDL_A_11187000	TEVA_MDL_A_11187006		
P-11489	8/18/2010	Fentora Promo Materials 2009 - 2010	TEVA_MDL_A_11440517	TEVA_MDL_A_11440665		
P-11492	2/12/2004	Draft separation agreement with Brennan re confidentiality clause	Brennan_002273	Brennan_002277		
P-11493	N/A	Colleen McGinn LinkedIn	N/A	N/A		
P-11495	11/4/1998	"Actiq Label, November 1998," 1998. <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/207471bl">https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/207471bl</a>	TEVA_MDL_A_13743487	TEVA_MDL_A_13743515		
P-11500	10/21/2014	Email re Due Diligence and Revised SOM - TH Concern w lack of program ....	PAR_OPIOID_MDL_0000001708	PAR_OPIOID_MDL_0000001712		
P-11511	10/20/2015	Email w/ attachment re DEA Regulatory Risk of Offering One-Time Buys of Controlled Substances	PAR_OPIOID_MDL_0000005961	PAR_OPIOID_MDL_0000005962		
P-11512	11/12/2015	Cover Email w/ attached 3/6/2013 DEA Meeting Notes	PAR_OPIOID_MDL_0000006053	PAR_OPIOID_MDL_0000006057		
P-11513	3/7/2013	Email from TH re info captured from DEA meeting	PAR_OPIOID_MDL_0000006058	PAR_OPIOID_MDL_0000006059		
P-11519	10/28/2014	Email re BuzzeoPDMA 9th Regional DEA Seminar-Agenda and Presentations with Attach	PAR_OPIOID_MDL_0000016424	PAR_OPIOID_MDL_0000016639		
P-11520	1/16/2015	Email re: Report SOM's Customers (decision based on chargeback data)	PAR_OPIOID_MDL_0000017143	PAR_OPIOID_MDL_0000017143		
P-11522	5/7/2012	Cover Email w Attachments Qualitest SOM Presentation (18923)	PAR_OPIOID_MDL_0000018920	PAR_OPIOID_MDL_0000018937		
P-11523	10/7/2013	Cover email re Brantley Vision on SOM Program	PAR_OPIOID_MDL_0000018938	PAR_OPIOID_MDL_0000018943		
P-11528	12/30/2013	Email re Big Tex Pharmacy Ltr Recommendation to Discontinue -	PAR_OPIOID_MDL_0000020216	PAR_OPIOID_MDL_0000020219		
P-11532	12/31/2013	Email re BZ Pharmacy Ltr Recommendation to Discontinue -	PAR_OPIOID_MDL_0000020254	PAR_OPIOID_MDL_0000020257		
P-11537	1/17/2014	Email re Advanced Pharmacy Ltr Recommendation to Discontinue -	PAR_OPIOID_MDL_0000020402	PAR_OPIOID_MDL_0000020407		
P-11546	3/19/2014	Cover Email w Preferred Pharm (CA) Site Visit Report	PAR_OPIOID_MDL_0000020898	PAR_OPIOID_MDL_0000020901		
P-11563	2/9/2013	Email re DEA Compliance Initiative Presentation	PAR_OPIOID_MDL_0000034190	PAR_OPIOID_MDL_0000034241		
P-11564	3/22/2013	Cover email w/ attached Defined Risk and Solutions excel	PAR_OPIOID_MDL_0000035162	PAR_OPIOID_MDL_0000035164		
P-11566	9/4/2008	Email re Qualitest Audit Report with Attach	PAR_OPIOID_MDL_0000076009	PAR_OPIOID_MDL_0000076011		
P-11574	11/1/2011	Policy Impact - Prescription Painkiller Overdoses	N/A	N/A		
P-11581	11/4/2011	In re Actiq Sales and Marketing Practices Litigation Pyfer Deposition Transcript	TEVA_MDL_A_01158791	TEVA_MDL_A_01158918		
P-11584	3/27/2013	DEA March 6 Meeting Memo	PAR_OPIOID_MDL_0000216198	PAR_OPIOID_MDL_0000216201		
P-11593	1/24/2013	cover email w/ attachments re DEA SOM Compliance	PAR_OPIOID_MDL_0000363469	PAR_OPIOID_MDL_0000363473		
P-11598	3/13/2013	Cover email w/ attachment SOMS Presentation - DEA SOMS Action Plan PPT	PAR_OPIOID_MDL_0000365381	PAR_OPIOID_MDL_0000365408		
P-11601	11/27/2012	Qualitest Summary of DEA Quota Meeting	PAR_OPIOID_MDL_0000369253 PAR_OPIOID_MDL_0000369261	PAR_OPIOID_MDL_0000369263 PAR_OPIOID_MDL_0000369290	PAR_OPIOID_MDL_0000369261 - PAR_OPIOID_MDL_0000369263	
P-11602	5/23/2013	Email re DEA UPS Memphis Investigation and KYC Issues	PAR_OPIOID_MDL_0000369517	PAR_OPIOID_MDL_0000369519		
P-11603	7/15/2013	SOMs Customer Ltr and Sales Rep Talking Points	PAR_OPIOID_MDL_0000372485	PAR_OPIOID_MDL_0000372492		
P-11604	8/6/2013	Manufacturing/Quality Business Review COO Presentation attached	PAR_OPIOID_MDL_0000373333	PAR_OPIOID_MDL_0000373407		
P-11608	11/17/2013	SOMS Program Update PPT	PAR_OPIOID_MDL_0000376972	PAR_OPIOID_MDL_0000376994		
P-11612	11/16/2011	Email DEA Inspection Wrap-Up in Charlotte	PAR_OPIOID_MDL_0000390035	PAR_OPIOID_MDL_0000390037		
P-11614	7/2/2009	Email re Reports form recent reviews with Review of OM Program, Sugg Chng to SOP,TabPlant09	PAR_OPIOID_MDL_0000398174	PAR_OPIOID_MDL_0000398191		
P-11615	9/29/2008	Email re DEA visit notes	PAR_OPIOID_MDL_0000399716	PAR_OPIOID_MDL_0000399717		
P-11616	11/6/2013	UPS Audit re SOM Activities	PAR_OPIOID_MDL_0000404095	PAR_OPIOID_MDL_0000404097		
P-11617	2/13/2013	Summary Teleconference w/ UPS	PAR_OPIOID_MDL_0000404285	PAR_OPIOID_MDL_0000404285		
P-11627	7/15/2015	Buzzeo PDMA - DEA Audit Report 4.28-4.30.15 & Related Attachments-	PAR_OPIOID_MDL_0001024034	PAR_OPIOID_MDL_0001024079		
P-11628	8/27/2013	Confidential: DEA inspection of Corium	PAR_OPIOID_MDL_0001037379	PAR_OPIOID_MDL_0001037382		
P-11636	5/13/2010	Email w attach Final PAR Review Report (Audit Report)	PAR_OPIOID_MDL_0001053153	PAR_OPIOID_MDL_0001053168		
P-11637	5/8/2010	Ltr to Barbarite from Buzzeo re DEA compliance issues	PAR_OPIOID_MDL_0001053278	PAR_OPIOID_MDL_0001053299		
P-11638	6/21/2012	Email re: Suspicious Order Monitoring (SOM)	PAR_OPIOID_MDL_0001058273	PAR_OPIOID_MDL_0001058279		

P-11639	9/30/2014	Email w Notice of Violations Letter to Generics Bidco	PAR_OPIOID_MDL_0001059825	PAR_OPIOID_MDL_0001059827		
P-11644	1/22/2017	Cover Email w/ SOM 101 SOM Customer Resource SOM training 3 PPTs	PAR_OPIOID_MDL_0001355348	PAR_OPIOID_MDL_0001355421		
P-11648	10/5/2012	PAR SOP S02222.1	PAR_OPIOID_MDL_0001410189	PAR_OPIOID_MDL_0001410521		
P-11649	2/19/2013	Email re DEA Compliance Update SOMS Overview 2.19.2013 PPT	PAR_OPIOID_MDL_0001424664	PAR_OPIOID_MDL_0001424692		
P-11651	5/27/2010	Qualitest overview for BusDev	PAR_OPIOID_MDL_0001593258	PAR_OPIOID_MDL_0001593276		
P-11652	N/A	Prescription Opioid Sales and Deaths, 1999-2013	N/A	N/A		
P-11653	3/22/2016	Email re Cegedim for all Par Orders SOM	PAR_OPIOID_MDL_0001596366	PAR_OPIOID_MDL_0001596370		
P-11660	12/5/2014	Letter from EB to Morris & Dickson re SO's; King & Spaulding Endo Response to McCaskill 2017 Letter	PAR_OPIOID_MDL_0001596399	PAR_OPIOID_MDL_0001596446		
P-11663	12/7/2018	2008 QT Mapics Excel Printout	PAR_OPIOID_MDL_0001596805	PAR_OPIOID_MDL_0001596805		
P-11664	N/A	Terifay LinkedIn	N/A	N/A		
P-11665	12/7/2018	2009 - 2015 QT Mapics Excel Printout	PAR_OPIOID_MDL_0001596813	PAR_OPIOID_MDL_0001596819		
P-11668	6/16/2014	Frank W Kerr (MI) Site Visit Report	PAR_OPIOID_MDL_0001599706	PAR_OPIOID_MDL_0001599706		
P-11679	2/25/2014	Email with Revised SOM Advisory Board Charter	PAR_OPIOID_MDL_0001642692	PAR_OPIOID_MDL_0001642696		
P-11680	4/12/2013	Email to TH re: March 2013 DEA Meeting Minutes	PAR_OPIOID_MDL_0001647888	PAR_OPIOID_MDL_0001647891		
P-11681	5/8/2013	Email re: Revocation of TopRx Pharmacy Registration	PAR_OPIOID_MDL_0001648312	PAR_OPIOID_MDL_0001648356		
P-11685	12/1/2008	Email thread re: SOM Intro Call	PAR_OPIOID_MDL_0001656118	PAR_OPIOID_MDL_0001656121		
P-11686	5/17/2018	email re: An Important Message from Paul Campanelli: Endo's Open Letter on the Opioid Abuse Crisis	PAR_OPIOID_MDL_0001895807	PAR_OPIOID_MDL_0001895808		
P-11691	3/6/2013	Full DEA Meeting Binder - Effective Controls Against Diversion of Controlled Substances	PAR_OPIOID_MDL_0002016179	PAR_OPIOID_MDL_0002016589		
P-11694	10/25/2016	email thread re: SOMs	PAR_OPIOID_MDL_0002161313	PAR_OPIOID_MDL_0002161334	PAR_OPIOID_MDL_0002161313 - PAR_OPIOID_MDL_0002161334	
P-11696	1/29/2008	Email re Washington State Opioid Dosing Guideline	PPLP004024280	PPLP004024281		
P-11697	7/19/2013	Email re Follow UP	PPLP004270602	PPLP004270603		
P-11698	1/30/2008	Email re: Washington State Draft Opioid Guidelines w WA State Pain Plan Doc	PPLP004301238	PPLP004301241		
P-11699	9/25/2009	Comments on the Docket Successfully influenced FDA	PPLP004319668	PPLP004319672		
P-11701	7/8/2013	Email FW Grunenthal Intelligence	PPLPC012000432942	PPLPC012000432942		
P-11702	5/15/2007	Email re: Urge your member of congress to join the Bipartisan Congressional Caucus on Drug Policy	PPLPC018000141199	PPLPC018000141201		
P-11703	7/20/2007	Email re Request for discret check on Senate Judiciary drug abuse hearing	PPLPC019000154246	PPLPC019000154249		
P-11705	4/12/2006	Email forwarding May 3rd APF Corporate Roundtable Agenda	PPLPC023000090853	PPLPC023000090854		
P-11707	6/29/2016	2013, 2015 and 2016 UPS Know Your Customer Surveys	UPSSCS0002032	UPSSCS0002051		
P-11708	4/1/1999	Endo LHSI Agreement	UPSSCS0002916	UPSSCS0002935		
P-11709	2/1/2000	Endo LHSI Agreement	UPSSCS0002991	UPSSCS0003029		
P-11715	10/30/2013	Separation of Employment Agreement and General Release Terry Terifay	MNK-T1_0007896365	MNK-T1_0007896384		
P-11718	7/26/2012	Email re July 26 Physicians, Officials Seek Label Change	MNK-T1_0001052204	MNK-T1_0001052210		
P-11724	2018	Senate Homeland Security and Gov. Affairs Comm., 116th Cong., Report on Fueling an Epidemic Report Two: Exposing the Financial Ties Between Opioid Manufacturers and Third Party Advocacy Groups (2018)	N/A	N/A		
P-11725	9/27/2010	Saper, Joel R. The Influence of Pharma and Device Manufacturers on APS and other PMAs: A War Within a War	N/A	N/A		
P-11729	2/29/2012	Email re IMPORTANT: Opportunity Knocking: Can we get more?!?	MNK-T1_0006275884	MNK-T1_0006275887		
P-11731	2017	Christie C, Baker C, Cooper R, Kennedy PJ, Madras B, Bondi B. The President's Commission on Combating Drug Addiction and the Opioid Crisis.	N/A	N/A		
P-11976	10/17/2016	Re: Five Reasons To Quit Your Job -- And Five Reasons Not To - Forbes	WAGCASF00319492	WAGCASF00319494		
P-11987	4/19/2012	Email re The Score April 19	MNK-T1_0000747464	MNK-T1_0000747468		
P-11994	2/12/2013	Re: Drug Reports Attachment Perrysburg DEA Fax Template	WAGMDL01014299	WAGMDL01014302		
P-12057	7/3/2012	Email re THUMP Plan	MNK_TNSTA01033366	MNK_TNSTA01033366		
P-12059	7/2/2012	Exalgo THUMP Plan	MNK_TNSTA01033367	MNK_TNSTA01033367		
P-12060	7/2/2012	Thumper Hyper Target Spreadsheet	MNK_TNSTA01033368	MNK_TNSTA01033368		

P-12062	6/15/2012	Email re Exalgo 3-star prescribers	MNK_TNSTA01041644	MNK_TNSTA01041645		
P-12065	5/4/2012	Three Star Doctors Spreadsheet	MNK_TNSTA01041651	MNK_TNSTA01041651		
P-12215	12/1/2016	Percodan (Oxycodone and Aspirin Tablets, USP) Medication Guide	N/A	N/A		
P-12231	2019	Teva Form 10-K	N/A	N/A		
P-12238	12/1/2010	FW: McKesson Business Review; Business Review JnJ Nucynta December 2010	JAN-MS-01130533	JAN-MS-01130566		
P-12332	8/2/2012	Email re Free Trial Redemptions	MNK-T1_0004593635	MNK-T1_0004593635		
P-12343	3/4/2013	Email re Bearden Healthcare	MNK-T1_0006461012	MNK-T1_0006461012		
P-12357	6/14/2021	Article re Physician's Wife Sentenced for Selling Pain Pills	N/A	N/A		
P-12360	N/A	Vantrela ER, Fentora, Actiq Studies	N/A	N/A		
P-12365	N/A	Teva 30(b)(6) Medical Affairs Module - Part 2 - Clinical Studies Reference - Topic 18(a)	N/A	N/A		
P-12367	N/A	Topic 11	N/A	N/A		
P-12386	2/1/2013	Risk Evaluation and Mitigation Strategy (REMS) Document, Buprenorphine-containing Transmucosal products for Opioid Dependence (BTOD) REMS Program	N/A	N/A		
P-12407	7/12/2012	DEA Drug Intelligence Brief on Opana (Oxymorphone) Abuse	ENDO-OR-CID-00637454 ENDO-OR-CID-00694084	ENDO-OR-CID-00757898 ENDO-OR-CID-00694087	ENDO-OR-CID-00694084 - ENDO-OR-CID-00694087	
P-12416	11/1/2007	Managing Chronic Pain with Opioids in Primary Care by Nathaniel Katz and Bill McCarberg	END00051041	END00051077		
P-12462	10/7/2016	FW: Jon Kamp WSJ Article: The Pill Makers Next Door: How America's Opioid Crisis Is Spreading .msg	EEOC00008698	EEOC00008718		
P-12466	1/29/2013	RE: FDA Restriction on Hydrocodone	ENDO_AAC_00143866	ENDO_AAC_00143867		
P-12471	3/13/2015	EXTERNAL: CI Daily Newswire - March 13, 2015	ENDO_AAC_00254870	ENDO_AAC_00254877		
P-12483	7/17/2001	New Percocet Direct Mail Cover Letter.	ENDO_ALAG-00494596	ENDO_ALAG-00494596		
P-12487	9/20/2010	Sep. 20: FDA To Take More Time Reviewing Bevacizumab For Breast Cancer.msg	ENDO_ANK_000019164	ENDO_ANK_000019169		
P-12495	6/4/2015	RE: TIME story re: pain products	ENDO_ANK_CHI_0628092	ENDO_ANK_CHI_0628097		
P-12496	6/4/2015	EXTERNAL: RE: FW: Time Magazine- Why America Can't Kick Its Painkiller Problem	ENDO_ANK_CHI_0628111	ENDO_ANK_CHI_0628119		
P-12498	2/9/2016	EXTERNAL: ADF Media Alert - February 9, 2016	ENDO_ANK_CHI_0640520	ENDO_ANK_CHI_0640526		
P-12499	9/20/2010	More Sick, Elderly Selling Prescription Drugs	ENDO_AR-00164166	ENDO_AR-00164166		
P-12601	12/12/2006	NIPC Executive Summary- NIPC Dinner Dialogue Series	MDL_KP360_000000021	MDL_KP360_000000021		
P-12609	6/19/2012	Excel spreadsheet indicating 486 Attendees to the "Responsible Opioid Prescribing in the Era of REMS" Spring 2012 Dinner Dialogues Series indicating program was presented in NY	KP360_OHIOMDL_000336756	KP360_OHIOMDL_000336758		
P-12610	1/17/2004	National Initiative on Pain Control (NIPC) Education Council Meeting January 17-18, 2004 New York, New York	KP360-OHIOMDL-000605	KP360-OHIOMDL-000622		
P-12611	6/29/2009	Opioid Analgesia -- for webcast 6-29-09 PPT	KP360_OHIOMDL_000121628	KP360_OHIOMDL_000121728		
P-12649	8/1/2013	SAMHSA Center for Behavioral Health Statistics and Quality (CBHSQ) Data Review - Associations of Nonmedical Pain Reliever Use and Initiation of Heroin Use in the United States	N/A	N/A		
P-12650	11/1/2017	The President's Commission on Combating Drug Addiction and the Opioid Crisis - Meeting Draft of Final Report	N/A	N/A		
P-12659	10/22/2008	Email re MHRA Req I-7 / #314 with Attachments: ACTIQ Approved FAQs Oct 22 2008; Approved FAQ False Positive Oct 22 2008; Approved FAQ Seizure Oct 22 2008	TEVA_MDL_A_01240143	TEVA_MDL_A_01240221		
P-12666	1/25/2012	McKesson Manufacturer Marketing Contract Product Promotional Agreement	MCKMDL00353368	MCKMDL00353369		
P-12667	1/19/2012	McKesson Manufacturer Marketing Prepared For: Cephalon, Inc. - ACTIQ and FENTORA Proposal Chris Doerr - Associate Director, Trade Operations	MCKMDL00353374	MCKMDL00353379		
P-12669	2/28/2019	Frequently Asked Questions about Actiq	TEVA_MDL_A_13645355	TEVA_MDL_A_13645364		
P-12675	1/25/2019	List of Teva's Schedule II drugs	TEVA_MDL_A_13740387	TEVA_MDL_A_13740390		
P-12706	1/17/2018	Teva Defendants 30(b)(6) Deposition Aid	TEVA_MSAG_13718223	TEVA_MSAG_13718246		
P-12933	3/13/2015	FW: EXTERNAL: CI Daily Newswire - March 13, 2015	ENDO_AR-00183535	ENDO_AR-00183543		
P-13076	1/18/2008	Here they come... BSB Perf Eval	ENDO_FLAG-00422748	ENDO_FLAG-00422760		
P-13138	1/18/2008	Email between Walker and sales re: Oxy product promotions	MCKMDL00543462	MCKMDL00543463		

P-13347	2/24/1998	FSMB Letter re Proposed Model Policy Guidelines	PDD1706042217	PDD1706042217		
P-13449	12/13/2002	Email thread re OMP and Pain	PPLPC009000079874	PPLPC009000079877		
P-13744	2015	2015 Sales Schedule 2 thru 5 LI LII	PAR_OPIOID_MDL_0001596806	PAR_OPIOID_MDL_0001596806		
P-13745	2018	2018 YTD Sept Sales Schedule 2 thru 5 LI LII	PAR_OPIOID_MDL_0001596807	PAR_OPIOID_MDL_0001596807		
P-13746	2017	2017 Sales Schedule 2 thru 5 LI LII	PAR_OPIOID_MDL_0001596808	PAR_OPIOID_MDL_0001596808		
P-13747	2014	2014 Sales Schedule 2 thru 5 LI LII	PAR_OPIOID_MDL_0001596809	PAR_OPIOID_MDL_0001596809		
P-13748	2016	2016 Sales Schedule 2 thru 5 LI LII	PAR_OPIOID_MDL_0001596810	PAR_OPIOID_MDL_0001596810		
P-13749	N/A	2006 to 2012 Sales Schedule 2 thru 5 LI LII	PAR_OPIOID_MDL_0001596811	PAR_OPIOID_MDL_0001596811		
P-13751	2013	2013 Sales Schedule 2 thru 5 LI LII	PAR_OPIOID_MDL_0001596812	PAR_OPIOID_MDL_0001596812		
P-13752	2009	Mapics2009	PAR_OPIOID_MDL_0001596813	PAR_OPIOID_MDL_0001596813		
P-13753	2010	Mapics2010	PAR_OPIOID_MDL_0001596814	PAR_OPIOID_MDL_0001596814		
P-13754	2011	Mapics2011	PAR_OPIOID_MDL_0001596815	PAR_OPIOID_MDL_0001596815		
P-13755	2012	Mapics2012	PAR_OPIOID_MDL_0001596816	PAR_OPIOID_MDL_0001596816		
P-13756	2013	Mapics2013	PAR_OPIOID_MDL_0001596817	PAR_OPIOID_MDL_0001596817		
P-13757	2014	Mapics2014	PAR_OPIOID_MDL_0001596818	PAR_OPIOID_MDL_0001596818		
P-13758	2015	Mapics2015	PAR_OPIOID_MDL_0001596819	PAR_OPIOID_MDL_0001596819		
P-13759	N/A	Opioid Qualitest_Billed Sales Sep 2014 - Jun 2016 - additional products	PAR_OPIOID_MDL_0001596820	PAR_OPIOID_MDL_0001596820		
P-13760	12/31/1999	Highly Confidential - Contribution Margin Reports (1999)	ENDO_DATA-OPIOID_MDL-00000001	ENDO_DATA-OPIOID_MDL-00000001		
P-13761	12/31/2000	Highly Confidential - Contribution Margin Reports (2000)	ENDO_DATA-OPIOID_MDL-00000002	ENDO_DATA-OPIOID_MDL-00000002		
P-13762	12/31/2001	Highly Confidential - Contribution Margin Reports (2001)	ENDO_DATA-OPIOID_MDL-00000003	ENDO_DATA-OPIOID_MDL-00000003		
P-13763	12/31/2002	Highly Confidential - Contribution Margin Reports (2002)	ENDO_DATA-OPIOID_MDL-00000004	ENDO_DATA-OPIOID_MDL-00000004		
P-13764	12/31/2003	Highly Confidential - Contribution Margin Reports (2003)	ENDO_DATA-OPIOID_MDL-00000005	ENDO_DATA-OPIOID_MDL-00000005		
P-13765	12/31/2004	Highly Confidential - Contribution Margin Reports (2004)	ENDO_DATA-OPIOID_MDL-00000006	ENDO_DATA-OPIOID_MDL-00000006		
P-13766	12/31/2005	Highly Confidential - Contribution Margin Reports (2005)	ENDO_DATA-OPIOID_MDL-00000007	ENDO_DATA-OPIOID_MDL-00000007		
P-13768	12/31/2007	Highly Confidential - Contribution Margin Reports (2007)	ENDO_DATA-OPIOID_MDL-00000009	ENDO_DATA-OPIOID_MDL-00000009		
P-13769	12/31/2008	Highly Confidential - Contribution Margin Reports (2008)	ENDO_DATA-OPIOID_MDL-00000010	ENDO_DATA-OPIOID_MDL-00000010		
P-13770	12/31/2009	Highly Confidential - Contribution Margin Reports (2009)	ENDO_DATA-OPIOID_MDL-00000011	ENDO_DATA-OPIOID_MDL-00000011		
P-13771	12/31/2012	Highly Confidential - Contribution Margin Reports (2012)	ENDO_DATA-OPIOID_MDL-00000014	ENDO_DATA-OPIOID_MDL-00000014		
P-13772	12/31/2013	Highly Confidential - Contribution Margin Reports (2013)	ENDO_DATA-OPIOID_MDL-00000015	ENDO_DATA-OPIOID_MDL-00000015		
P-13773	N/A	Endo Pharmaceuticals Inc.	ENDO_DATA-OPIOID_MDL-00000016	ENDO_DATA-OPIOID_MDL-00000016		
P-13774	12/31/2015	Highly Confidential - Contribution Margin Reports (2015)	ENDO_DATA-OPIOID_MDL-00000017	ENDO_DATA-OPIOID_MDL-00000017		
P-13775	12/31/2016	Highly Confidential - Contribution Margin Reports (2016)	ENDO_DATA-OPIOID_MDL-00000018	ENDO_DATA-OPIOID_MDL-00000018		
P-13777	12/31/2017	Highly Confidential - Contribution Margin Reports (2017)	ENDO_DATA-OPIOID_MDL-00000019	ENDO_DATA-OPIOID_MDL-00000019		
P-13778	12/29/1999	Highly Confidential - Shipments (1999)	ENDO_DATA-OPIOID_MDL-00000025	ENDO_DATA-OPIOID_MDL-00000025		
P-13779	12/31/2000	Highly Confidential - Shipments (2000)	ENDO_DATA-OPIOID_MDL-00000026	ENDO_DATA-OPIOID_MDL-00000026		
P-13780	12/28/2001	Highly Confidential - Shipments (2001)	ENDO_DATA-OPIOID_MDL-00000027	ENDO_DATA-OPIOID_MDL-00000027		
P-13781	12/27/2002	Highly Confidential - Shipments (2002)	ENDO_DATA-OPIOID_MDL-00000028	ENDO_DATA-OPIOID_MDL-00000028		
P-13782	12/23/2003	Highly Confidential - Shipments (2003)	ENDO_DATA-OPIOID_MDL-00000029	ENDO_DATA-OPIOID_MDL-00000029		
P-13783	12/31/2004	Highly Confidential - Shipments (2004)	ENDO_DATA-OPIOID_MDL-00000030	ENDO_DATA-OPIOID_MDL-00000030		
P-13784	12/31/2005	Highly Confidential - Shipments (2005)	ENDO_DATA-OPIOID_MDL-00000031	ENDO_DATA-OPIOID_MDL-00000031		
P-13785	12/31/2006	Highly Confidential - Shipments (2006)	ENDO_DATA-OPIOID_MDL-00000032	ENDO_DATA-OPIOID_MDL-00000032		
P-13786	12/31/2007	Highly Confidential - Shipments (2007)	ENDO_DATA-OPIOID_MDL-00000033	ENDO_DATA-OPIOID_MDL-00000033		
P-13787	12/31/2008	Highly Confidential - Shipments (2008)	ENDO_DATA-OPIOID_MDL-00000034	ENDO_DATA-OPIOID_MDL-00000034		
P-13788	12/31/2010	Highly Confidential - Shipments (2010)	ENDO_DATA-OPIOID_MDL-00000036	ENDO_DATA-OPIOID_MDL-00000036		
P-13789	12/31/2011	Highly Confidential - Shipments (2011)	ENDO_DATA-OPIOID_MDL-00000037	ENDO_DATA-OPIOID_MDL-00000037		
P-13790	12/31/2012	Highly Confidential - Shipments (2012)	ENDO_DATA-OPIOID_MDL-00000038	ENDO_DATA-OPIOID_MDL-00000038		
P-13791	12/31/2013	Highly Confidential - Shipments (2013)	ENDO_DATA-OPIOID_MDL-00000039	ENDO_DATA-OPIOID_MDL-00000039		
P-13792	4/30/2014	Highly Confidential - Shipments (Jan 2014 to April 2014)	ENDO_DATA-OPIOID_MDL-00000040	ENDO_DATA-OPIOID_MDL-00000040		
P-13793	6/30/2017	Highly Confidential - Shipments (May 2014 to June 2017)	ENDO_DATA-OPIOID_MDL-00000041	ENDO_DATA-OPIOID_MDL-00000041		
P-13794	12/31/2009	Highly Confidential - Shipments (2009)	ENDO_DATA-OPIOID_MDL-00000035	ENDO_DATA-OPIOID_MDL-00000035		
P-14253	6/28/2011	KGC Kadian Qualitative Research Interviews - Prepared for ACTAVIS	ACTAVIS0361608	ACTAVIS0361653		
P-14267	2009	The Role of OPANA ER in the Management of Moderate to Severe Chronic Pain	ENDO-CHI_LIT-00043048 ENDO-CHI_LIT-00043049	ENDO-CHI_LIT-00043062 ENDO-CHI_LIT-00043049	ENDO-CHI_LIT-00043049-ENDO-CHI_LIT-00043049	
P-14346	1/6/2012	RE: Veeva Reports of Pain CAM TEs	ENDO_FLAG-00563300	ENDO_FLAG-00563303		
P-14355	12/31/2019	WAG TCS Pharmacy Renewal Work Order Signature Version	TCS00027465	TCS00027586		
P-14356	10/4/2019	Walgreens - Quality Engineering for Pharmacy Transformation Program; WBA Rx Renewal - TCS Proposal vDraft vShare	TCS00000893	TCS00000926		
P-14357	12/20/2019	Re: UX research readout session -- FEEDBACK;	TCS00027120	TCS00027208		



P-14358	11/12/2019	Latosha notes#1	TCS00000493	TCS00000558		
P-14359	2/29/2020	walgreens contextual inquiry bannockburn	TCS00027825	TCS00027827		
P-14360	2/29/2020	highland park pharmacist interview	TCS00027828	TCS00027829		
P-14361	2/29/2020	pharmacy manager interview	TCS00027832	TCS00027833		
P-14362	11/13/2019	Justin notes#1	TCS00000453	TCS00000492		
P-14363	1/2/2020	Re: UX research readout session -- FEEDBACK	TCS00027058	TCS00027119		
P-14364	1/3/2020	Re: UX research readout session -- FEEDBACK	TCS00027209	TCS00027274		
P-14365	1/16/2020	RE: Discussion on Updated Personas and Research Findings	TCS00027587	TCS00027589		
P-14366	3/2/2020	Justin Chats	TCS00028141	TCS00028145		
P-14367	1/22/2020	Justin Chats	TCS00028290	TCS00028487		
P-14368	1/17/2020	Re: Research Report Concerns	TCS00028547	TCS00028548		
P-14369	1/23/2020	Re: Discussion on Updated Personas and Research Findings	TCS00028573	TCS00028577		
P-14370	1/27/2020	Discussion on Updated Personas and Research Findings (Session 2)	TCS00025912	TCS00025969		
P-14371	1/27/2020	RE: Discussion on Updated Personas and Research Findings	TCS00027625	TCS00027633		
P-14437	7/15/2004	FW: Advisory Board Mtg Minutes	ENDO_FLAG-00564245	ENDO_FLAG-00564316		
P-14438	3/13/2015	EXTERNAL: CI Daily Newswire - March 13, 2015	ENDO_NMAG-00216764	ENDO_NMAG-00216772		
P-14439	3/1/2016	Assurance of Discontinuance to New York Attorney General	ENDO_OPIOID_DEPMAT-000027159	ENDO_OPIOID_DEPMAT-000027192		
P-14441	10/8/2010	Dr Hill	ENDO_SF-00001021	ENDO_SF-00001065		
P-14443	4/24/2007	FW: Dr. Hurwitz trial	ENDO_SF-00009236	ENDO_SF-00009240		
P-14444	4/21/2011	FW: Manougian Diversion Report	ENDO_SF-00012792	ENDO_SF-00012798		
P-14445	7/12/2012	Fwd: USA Today Article	ENDO_SF-00014469	ENDO_SF-00014470		
P-14472	9/5/2008	FW: Legal risk for prescribing painkillers is small	ENDO_SF-00028456	ENDO_SF-00028458		
P-14493	7/12/2012	Fwd: USA Today Article	ENDO_SF-00038489	ENDO_SF-00038490		
P-14494	10/4/2009	RE: Department of Community Health- For educational purposes only	ENDO_SF-00108612	ENDO_SF-00108614		
P-14495	8/22/2012	Displaying Powerpoint Slide Decks on iPad Abuse and Misuse	ENDO_SF-00135695	ENDO_SF-00135736		
P-14496	2/4/2013	2012_Year_End_Review___Individual_Leader___Endo_Bobbie_Sue_Brown	ENDO_SF-00144130	ENDO_SF-00144148		
P-14497	8/13/2004	Mid Year Eval for your Signature	ENDO_SF-00150981	ENDO_SF-00150988		
P-14498	10/31/2005	RE: Follow up to recent pain meetings	ENDO_SF-00151624	ENDO_SF-00151627		
P-14547	6/2/2006	PER List	ENDO_SF-00152695	ENDO_SF-00152696		
P-14557	9/6/2005	FW: Month in Review TE contact info	ENDO_SF-00153760	ENDO_SF-00153762		
P-14558	5/9/2006	Quarterly CD&E Update for BSB	ENDO_SF-00154239	ENDO_SF-00154252		
P-14637	8/21/2006	RE: Third Party Outreach Mtg Update	ENDO_SF-00155092	ENDO_SF-00155093		
P-14654	8/25/2006	RE: AAPM&R 2007 Pain Course	ENDO_SF-00155142	ENDO_SF-00155144		
P-14667	7/9/1996	Walmart Pharmacy CE - New Trends in the Use of Opioids in Pain Management	PKY180257493	PKY180257493		
P-14672	9/15/2002	Copy of the Chain Pharmacist Practice memo from the National Association of Chain Drug Stores: Special Issue: Prescription Drug Misuse and Abuse	PKY181864224	PKY181864229		
P-14687	10/23/2006	Understanding Your Pain: Taking Oral Opioid Analgesics	ENDO_SF-00155398	ENDO_SF-00155398		
P-14690	6/2/2000	FW:Pharmacy Support	PDD8801136088	PDD8801136089		
P-14691	N/A	Living Our Vision	PDD8801366607	PDD8801366664		
P-14692	N/A	Use of Opioids in Chronic Non Cancer Pain	PKY180293682	PKY180293697		
P-14693	4/12/2001	RE: Walgreens CE programs for 6/19/01 and 6/20/01	PKY181985212	PKY181985213		
P-14695	4/18/2011	Pain Management for the Primary Care Provider: A daylong course in the diagnosis, treatment, and legal Issues surrounding the treatment of pain	PPLP003469655	PPLP003469655		
P-14696	10/24/2001	National Accounts 2001	PPLPC008000021189	PPLPC008000021190		
P-14697	10/21/1999	FW: Walgreens Program	PPLPC012000007168	PPLPC012000007168		
P-14698	4/6/2011	HAD Activities 2011_04_06_v2	PPLPC021000370693	PPLPC021000370702		
P-14699	6/21/2011	ionEDGE_OL Listing 2011 Jun-21	PPLPC021000386842	PPLPC021000386842		
P-14700	3/5/2000	Walgreens RPH Invitation2	PPLPC024000012812	PPLPC024000012813		
P-14701	4/3/2000	Walgreens CEU Program	PPLPC024000014422	PPLPC024000014423		
P-14703	12/12/2011	Online Certified Education for Pharmacists from RxSchool	PPLPC024000596538	PPLPC024000596540		
P-14704	11/1/1999	RE: Walgreens CE Programs Oct 25th @ 26th	PPLPC025000005258	PPLPC025000005259		
P-14705	11/4/1999	End of Month Report - October 1999	PPLPC0280000008080	PPLPC0280000008083		
P-14706	6/23/2000	FW: A COMPLETE Value-Added Program	PPLPC029000019201	PPLPC029000019203		
P-14708	2/6/2004	Re: Jennifer Bolen, JD	PPLPC046000007359	PPLPC046000007360		



P-14710	12/27/1988	Edmund Choroski RPh LTR 12-27-1988 - Searchable (2)_Redacted	US-DEA-00025683	US-DEA-00025683		
P-14714	1/28/2013	Dec 2012 Reports	ACTAVIS0666771	ACTAVIS0666783		
P-14738	8/20/2011	Email FL FOC - Recap of Meeting with DEA (Forbes)	WAGFLDEA00001168	WAGFLDEA00001173		
P-14739	4/9/2013	RE: Walgreens Woodland Data - Red Stores Attachment Walgreens Woodland DC Mar 2013	WAGMDL00407671	WAGMDL00407674		
P-14743	12/2/2013	FW: Letter to Outlier Physicians Attachment GFD Outlier Letter #1v1HL	WAGMDL00407179	WAGMDL00407184		
P-14744	1/16/2013	Re: Executive Committee Meeting -- January 17, 2013 -- Chairman's Script Attachment	WAGMDL00502664	WAGMDL00502668		
P-14745	1/8/2014	Fwd: Targeted drugs for GFD	WAGMDL00704540	WAGMDL00704540		
P-14746	5/1/2013	New Rx Integrity Update May 2013 PPT	WAGMDL00655767	WAGMDL00655785		
P-14746_Redacted	5/1/2013	New Rx Integrity Update May 2013 PPT	WAGMDL00655767	WAGMDL00655785		
P-14748	1/9/2014	Email Controlled substance information Attachments Rx Integrity and Controlled Substance Dispensing;	WAGMDL00704532	WAGMDL00704539		
P-14749	3/20/2014	Re: DEA questions Costco's record keeping for hydrocodone pills Attachment purpose disclaimer	WAGMDL00705156	WAGMDL00705160		
P-14750	6/11/2013	Settlement and Memorandum of Agreement, Department of Justice and Walgreens Co.	WAGMDL00286197	WAGMDL00286209		
P-14750_Redact	6/11/2013	Settlement and Memorandum of Agreement, Department of Justice and Walgreens Co.	WAGMDL00286197	WAGMDL00286209		
P-14751	3/22/2013	DEA strategy meeting 3 22 13	WAGMDL00667587	WAGMDL00667588		
P-14752	6/11/2013	RE: Article: Walgreen Florida Facility Barred From Shipping Oxycodone	PPLPC029000522318	PPLPC029000522320		
P-14753	12/7/2012	FW: Executive Summary Attachment AAPM executive summary final	WAGMDL00704665	WAGMDL00704674		
P-14754	11/9/1998	Walgreen and Purdue Agree to the Following	PKY181268638	PKY181268643		
P-14756	11/26/2012	Email Pharmacy Manufacturer and Wholesaler Communication Plan Attachments Agenda-Pharmacy Manufacturer and Wholesaler Communication Plan; Copy of Frank's and Jeff's Contact List-Talking Points 12-2012 (2); Copy of J Berkowitz Contact List-Talking Points 12-2012 (3); Branded Pharmaceutical Manufacturers FAQs RE: Direct Purchase Agreements with Branded Pharmaceutical Manufacturers; Wholesaler FAQs- direct 11-2013--JP; ABDC RFP Letter 12-2012; Mfr RFP letter 12-2012; CAH RFP Letter 12-2012	WAGMDL00485568	WAGMDL00485581		
P-14757	10/27/2006	RE: Understanding Your Pain: Taking Oral Opioid Analgesics	ENDO_SF-00155413	ENDO_SF-00155413		
P-14758	9/26/2012	Email Article in WSJ	WAGMDL00528261	WAGMDL00528263		
P-14761	1/30/2015	FW: Store Feedback on ABC	WAGMDL00486353	WAGMDL00486355		
P-14766	2/26/2013	Re: Perrysburg CIII-CV - follow up	WAGMDL00358466	WAGMDL00358467		
P-14767	9/19/2012	RE: Jupiter Email	WAGMDL00308159	WAGMDL00308160		
P-14768	10/8/2012	FW: Jupiter - PB MDG Shift By Date Attachment C2 GA 10-8-12	WAGMDL00308088	WAGMDL00308090		
P-14769	2/20/2013	FW: Perrysburg CIII-CV - follow up	WAGMDL00357495	WAGMDL00357497		
P-14771	5/17/2016	FW: Follow-up on market sizing data	Anda_Opioids_MD_L_0000001218	Anda_Opioids_MD_L_0000001599		
P-14774	3/4/2011	Re: Fw: INC000002834005 <Store #3836 WIC#682971, ordered qty 148>	WAGFLDEA00000908	WAGFLDEA00000911		
P-14776	5/5/2011	Re: Fw: Oxycotin question	WAGFLDEA00001039	WAGFLDEA00001046		
P-14777	5/16/2011	Re: Fw: CII Order	WAGFLDEA00001049	WAGFLDEA00001059		
P-14778	1/9/2012	Email Woodland CIII - CV Expansion Attachment Perrysburg_CII_costsavings	WAGMDL00541656	WAGMDL00541657		
P-14781	4/6/2012	Email Talking Points on Current Field Activity	WAGMDL00317111	WAGMDL00317112		
P-14782	9/18/2012	Email USA Drug / FL DEA Issue: 9/18 update	WAGMDL00667931	WAGMDL00667934		
P-14783	9/27/2012	FW: ANDA backup C2 call summary	WAGMDL00541577	WAGMDL00541579		
P-14784	11/2/2012	Florida DBPR Notice of Violation to Walgreens	WAGMDL00426289	WAGMDL00426293		
P-14785	2/7/2013	RE: Questions for Walgreens Store	WAGMDL00132065 WAGMDL00132065	WAGMDL00132068 WAGMDL00132101	WAGMDL00132065 - WAGMDL00132068	
P-14786	2/21/2013	Re: CSOS to stores for Walgreens - Follow-up Meeting	WAGMDL00524763	WAGMDL00524771		
P-14787	4/3/2013	FW: Walgreens Schedule Recap	WAGMDL00303003	WAGMDL00303005		

P-14791	6/11/2013	Email WALGREENS / DEA END-OF-DAY MEDIA COVERAGE UPDATE -- 06/11/2013	WAGMDL00407509	WAGMDL00407511		
P-14859	N/A	Rhodes Oxy Shipments	PDD9316316938	PDD9316316940		
P-14872	5/28/1997	OxyContin allocation in Canada	PDD9316706531	PDD9316706532		
P-14961	6/18/2015	OxyContin Mid Month Reporting Workbook Mid June 2015	PPLPC012000511299	PPLPC012000511300		
P-14966	3/1/2003	Pain in Osteoarthritis, Rheumatoid Arthritis, and Juvenile Chronic Arthritis	PKY181215547	PKY181215749		
P-15011	8/29/2011	Hardcopy Walgreen Prescription; WALGREENS_STORE_9077_00042	WAGMDL01191610	WAGMDL01191611		
P-15037	9/17/2015	Walgreens Good Faith Dispensing Email and Policies	WAGMDL00001237	WAGMDL00001251		
P-15038	5/24/2016	TD GFD Policy without PMP printing	WAGMDL00001150	WAGMDL00001156		
P-15039	3/29/2007	RE: UPDATE - Upcoming meeting with AAPM&R	ENDO_SF-00159136	ENDO_SF-00159140		
P-15048	7/27/2006	Copy of this year's mod-to-sev pain budget for our call this afternoon	ENDO_SF-00162537	ENDO_SF-00162538		
P-15049	6/6/2006	URGENT: AAPM&R Proposed Program	ENDO_SF-00163310	ENDO_SF-00163312		
P-15050	11/30/2004	Controlled Drug Policy	WAGFLDEA00000020	WAGFLDEA00000020		
P-15051	2012	DEA Reference Tools	WAGFLDEA000000157	WAGFLDEA000000157		
P-15052	5/1/2011	Dispensing Prescription Drugs Policy	WAGFLDEA000000161	WAGFLDEA000000161		
P-15053	10/27/2011	Walgreens Good Faith Dispensing PPT Your Responsibilities - Training Module	WAGFLDEA000000184	WAGFLDEA000000205		
P-15054	11/8/2011	Controlled Substance Prescriptions & Good Faith Dispensing	WAGFLDEA000000206	WAGFLDEA000000207		
P-15056	8/29/2007	Preventing Diversion of Controlled Substances	WAGFLDEA000000271	WAGFLDEA000000271		
P-15057	3/2/2011	Refilling Prescriptions	WAGFLDEA000000276	WAGFLDEA000000276		
P-15058	6/27/2007	Theft or Diversion of Prescription Drugs by Walgreens Family of Companies Employees	WAGFLDEA000000328	WAGFLDEA000000328		
P-15059	3/6/2007	2006 Bobbie Sue Prown Performance Eval	ENDO_SF-00165110	ENDO_SF-00165120		
P-15060	11/4/2011	Action Required: Control Substance Powerpoint from Wednesday	WAGFLDEA000000477	WAGFLDEA000000507		
P-15061	N/A	Guidelines for Appropriate Dispensing of Oxycodone	WAGFLDEA000000658	WAGFLDEA000000658		
P-15062	N/A	Target Drug Good Faith Dispensing Checklist	WAGMDL000000360	WAGMDL000000360		
P-15064	5/15/2017	Target Drug Good Faith Dispensing Policy	WAGMDL00003569	WAGMDL00003578		
P-15066	5/11/2016	Controlled Substance Prescriptions & Good Faith Dispensing Policy	WAGMDL00003934	WAGMDL00003941		
P-15068	5/1/2017	Controlled Substance Prescriptions & Good Faith Dispensing Policy; Target Drug Good Faith Dispensing Checklist, Steps for the Technician to Complete; Target Drug Good Faith Dispensing Policy	WAGMDL00005358	WAGMDL00005373		
P-15070	6/19/2007	BSB 2007 objectives	ENDO_SF-00173455	ENDO_SF-00173458		
P-15071	3/6/2018	Target Drug Good Faith Dispensing Checklist, Steps for the Technician to Complete	WAGMDL00005573	WAGMDL00005577		
P-15073	6/25/2016	Target Drug Good Faith Dispensing Policy	WAGMDL00007207	WAGMDL00007218		
P-15074	2/21/2014	Controlled Substance Prescriptions and Good Faith Dispensing Policy (2/21/2014); Controlled Substance Prescriptions and Good Faith Dispensing Policy (8/1/2013); Controlled Substance Prescriptions and Good Faith Dispensing Policy (6/11/2012); Controlled Substance Prescriptions and Good Faith Dispensing Policy (8/11/2011); Controlled Substance Prescriptions and Good Faith Dispensing Policy (6/20/2011); Good Faith Practices and Fraudulent Prescriptions (3/28/2007); Good Faith Practices and Fraudulent Prescriptions; Target Drug Good Faith Dispensing Policy (6/1/2016); Target Drug Good Faith Dispensing Policy (9/1/2013)	WAGMDL00008070	WAGMDL00008132		
P-15075	12/10/2013	Butrans for approval	HBC_MDL00160082	HBC_MDL00160091		
P-15081	5/25/2015	FW: Catalina and Adheris Documents	HBC_MDL00181574	HBC_MDL00181619		
P-15084	2/6/2018	Target Drug Good Faith Dispensing Checklist, Steps for the Technician to Complete	WAGMDL00009436	WAGMDL00009439		
P-15085	9/9/2015	RE: Monthly DM webinars; Good Faith Dispensing DM Webinar	WAGMDL00037613	WAGMDL00037624		
P-15087	1/8/2013	Target Drug Good Faith Dispensing Policy; Target Drug Good Faith Dispensing REDLINE	WAGMDL00043333	WAGMDL00043338		
P-15089	8/18/2013	Email 6888 ken	WAGMDL01112709	WAGMDL01112709		

P-15090	9/3/2018	Good Faith Dispensing redline draft; GFD "Call to Prescriber" Template; Target Drug Good Faith Dispensing Policy	WAGMDL00049466	WAGMDL00049476		
P-15091	7/17/2009	RE: Kadian letters; Kadian Kick-off document; Microsoft Word - Diovan T2007-109;T2007-110	Acquired_Actavis_01357009	Acquired_Actavis_01357029		
P-15092	2012	Good Faith Dispensing of Controlled Substances - Policy Acknowledgement	WAGMDL00049534	WAGMDL00049546		
P-15093	8/1/2013	Controlled Substance Prescriptions & Good Faith Dispensing	WAGMDL00054578	WAGMDL00054586		
P-15094	6/6/2014	Market 4 RX integrity Presentation PPT	WAGMDL00060045	WAGMDL00060082		
P-15095	5/9/2014	Market 13 RX integrity Presentation PPT	WAGMDL00060207	WAGMDL00060246		
P-15096	9/12/2016	DM Walk July - August Monthly Compliance Walkx	WAGMDL00065344	WAGMDL00065353		
P-15097	11/9/2012	Draft Target Drug Good Faith Dispensing Policy	WAGMDL00066712	WAGMDL00066721		
P-15098	7/7/2009	Role of CAM slides	ENDO_SF-00175989	ENDO_SF-00175990		
P-15099	2/20/2016	Thank you for NSM Greatness	ENDO_SF-00211100	ENDO_SF-00211115		
P-15101	N/A	Current Fill Process Chart	WAGMDL00121783	WAGMDL00121787		
P-15104	1/4/2005	Document re: Eric Vandal 2004 Annual Review	ENDO_SF-00441165	ENDO_SF-00441177		
P-15105	11/12/2015	Prescription Drug Monitoring Program PPT	WAGMDL00269423	WAGMDL00269437		
P-15106	6/1/2016	Target Drug Good Faith Dispensing Policy	WAGMDL00289031	WAGMDL00289035		
P-15107	11/1/2012	November 2012 Target Drug Good Faith Dispensing Policy	WAGMDL00289036	WAGMDL00289039		
P-15108	9/23/2013	Target Drug Good Faith Dispensing Policy	WAGMDL00289040	WAGMDL00289044		
P-15109	10/2/2017	Target Drug Good Faith Dispensing Policy	WAGMDL00289045	WAGMDL00289049		
P-15110	2013	2013 National Target Drug Good Faith Dispensing Policy Final; National Target Drug Good Faith Dispensing Policy; Target Drug Good Faith Dispensing Policy (2012)	WAGMDL00289331	WAGMDL00289453		
P-15111	6/28/2001	Rep Letter	ENDO_SF-00441587	ENDO_SF-00441588		
P-15112	8/1/2002	2Q02 Bus Review PPT	ENDO_SF-00441665	ENDO_SF-00441666		
P-15113	12/19/2016	Preventing Theft or Loss of Controlled Substances	WAGMDL00294318	WAGMDL00294319		
P-15114	N/A	Good Faith Dispensing (GFD), District Leader Roles and Responsibilities	WAGMDL00302782	WAGMDL00302784		
P-15115	N/A	Good Faith Dispensing - Compliance Checklist	WAGMDL00303117	WAGMDL00303118		
P-15116	N/A	Good Faith Dispensing (GFD) Compass Communication edit 3	WAGMDL00303281	WAGMDL00303297		
P-15117	1/14/2013	Good Faith Dispensing Policy review	WAGMDL00303383	WAGMDL00303407		
P-15118	N/A	Pharmacy Manager letter TD GFD	WAGMDL00304139	WAGMDL00304144		
P-15119	2/9/2005	Good Faith Practices (2/9/2005); Good Faith Practices (3/24/2003); Good Faith Practices (4/3/2003); Good Faith Practices (1/6/2003); Good Faith Practices (6/14/2004); Good Faith Practices/Fraudulent Prescriptions (2/26/2006); Good Faith Practices (8/1/1998); Good Faith Practices (11/15/2005)	WAGMDL00335010	WAGMDL00335025		
P-15125	N/A	Preventing Filling of Prescriptions for Prescribers with Inactive DEA Registrations	WAGMDL00387991	WAGMDL00387994		
P-15126	10/17/2013	Walgreens Pharmacy and Health Care Code of Conduct and General Training	WAGMDL00444056	WAGMDL00444058		
P-15129	N/A	Good Faith Dispensing (GFD) Training FAQs	WAGMDL00491159	WAGMDL00491159		
P-15131	N/A	RX Integrity Calculating total dosage for opioids	WAGMDL00491170	WAGMDL00491170		
P-15132	N/A	Calculating MME equivalents	WAGMDL00491178	WAGMDL00491178		
P-15133	N/A	Target Drug Good Faith Dispensing FAQ	WAGMDL00491179	WAGMDL00491179		
P-15161	11/11/2015	DUR Pharmacy Operations Filling Prescriptions	WAGMDL00492959	WAGMDL00492959		
P-15162	N/A	Drug Utilization review DUR policies and standard operating procedures	WAGMDL00492960	WAGMDL00492960		
P-15166	N/A	Filling Instructions	WAGMDL00492965	WAGMDL00492965		
P-15169	5/1/2011	Pharmacist Training Program Trainer's Guide	WAGMDL00520675	WAGMDL00520731		
P-15170	N/A	Target Drug Good Faith Dispensing Policy Store manager LD report	WAGMDL00656588	WAGMDL00656594		
P-15171	4/17/2012	Routine and periodic training on CS and GFD	WAGMDL00657563	WAGMDL00657566		
P-15172	N/A	Target Drug (TD) Good Faith Dispensing (GFD) FAQ	WAGMDL00657585	WAGMDL00657590		
P-15173	2013	2013 DEA Subpoenas	WAGMDL00657806	WAGMDL00657828		
P-15174	6/1/2003	Good Faith Practices	WAGMDL00670946	WAGMDL00670947		
P-15175	6/18/2004	Good Faith Practices	WAGMDL00670948	WAGMDL00670949		
P-15176	6/26/2006	Good Faith Practices	WAGMDL00670950	WAGMDL00670951		
P-15177	2/24/2003	Good Faith Practices	WAGMDL00670954	WAGMDL00670955		
P-15178	11/15/2005	Good Faith Practices	WAGMDL00670963	WAGMDL00670964		

P-15179	2/1/2014	Best Practices for Filling Controlled Substance Prescriptions and Providing Good Customer Service	WAGMDL00675061	WAGMDL00675074		
P-15181	2013	2013 Targeted Drug Good Faith Dispensing Policy & Procedures	WAGMDL00698364	WAGMDL00698366		
P-15183	N/A	Pharmacy Losses Dashboard: HRxD	WAGMDL00736117	WAGMDL00736118		
P-15184	6/1/2017	Accepting New Verbal Prescriptions; Dispensing Prescription Drug Policy (1/10/2017)	WAGMDL00737720	WAGMDL00737770		
P-15187	N/A	Schedule II Narcotic Dispensing Guidelines v3	WAGMDL00746791	WAGMDL00746805		
P-15188	2012	Controlled Substance Prescriptions and Good Faith Dispensing Policy REDLINE	WAGMDL00767022	WAGMDL00767027		
P-15189	2012	Controlled Substance Prescriptions and Good Faith Dispensing Policy	WAGMDL00767028	WAGMDL00767030		
P-15190	2012	Controlled Substance Prescriptions and Good Faith Dispensing Policy	WAGMDL00767031	WAGMDL00767033		
P-15191	N/A	Target Drug Good Faith Dispensing - Prescriber Office Visit Checklist	WAGMDL00774701	WAGMDL00774706		
P-15192	10/1/2016	Walgreens SOP Fraudulent Prescriptions	WAGMDL00778614	WAGMDL00778615		
P-15194	4/18/2001	Memo re: Primary Contacts	ENDO_SF-00442193	ENDO_SF-00442195		
P-15195	1/19/2001	Document re: Eric Vandal Annual Performance Evaluation	ENDO_SF-00443040	ENDO_SF-00443044		
P-15196	6/1/2019	Pharmacy Manager development program screenshots; Code of Conduct and Business Ethics; DEA Pharmacist Manual; FAQ changes in this years program; Chapter 5 Executes with Excellence, Maintains Pharmacy Expertise, Manages Time Effectively; Chapter 6 Communicates with Credibility; Chapter 4 Builds Talent; Clues to the Queues - Best Practices on Managing Exception Queues; Chapter 10 Builds and Sustains Relationships; Chapter 7. Acts with Professional Integrity, Solves Problems, Focuses on Quality; Chapter. 8 Leads Change; Chapter 9. Advocates customer focus, counsels patients effectively	WAGMDL00779574 WAGMDL00779574	WAGMDL00779594 WAGMDL00779831	WAGMDL00779574 - WAGMDL00779594	
P-15197	1/23/2001	Document re: Eric Vandal 2001 Objectives	ENDO_SF-00443216	ENDO_SF-00443217		
P-15198	8/16/2000	Document re: Endo Discussion on Percocet	ENDO_SF-00443427	ENDO_SF-00443428		
P-15205	6/20/2000	2000 PERCO FRANCHISE STRATEGY_6	ENDO_SF-00443584	ENDO_SF-00443597		
P-15206	6/23/2004	Presentation re: EN3253 Update	ENDO_SF-00443605	ENDO_SF-00443610		
P-15207	5/7/2002	Pad Stamps for Percocet 7.5/325 and 10/325 - Stamps Cover Letter	ENDO_SF-00444101	ENDO_SF-00444102		
P-15210	7/8/2002	Six Wave Direct Mail for new Percocet 7.5/325 and 10/325	ENDO_SF-00444103	ENDO_SF-00444103		
P-15211	2/8/2002	PDR Cover Letter - Physicians' Desk Reference (PDR) Addendum for Percocet 7.5/325 and 10/325	ENDO_SF-00444112	ENDO_SF-00444112		
P-15212	8/17/2001	Direct Mail Cover Letter3 - Wave 3	ENDO_SF-00444122	ENDO_SF-00444122		
P-15213	4/1/2002	Direct Mail #1	ENDO_SF-00444127	ENDO_SF-00444128		
P-15214	3/11/2002	APAP Wheel Cover Letter	ENDO_SF-00444129	ENDO_SF-00444129		
P-15215	6/18/2002	FCB journal ad test summary PPT	ENDO_SF-00444317	ENDO_SF-00444318		
P-15216	6/18/2002	Presentation re: Percocet 7.5/325 and 10/325 BMT Meeting	ENDO_SF-00444365	ENDO_SF-00444366		
P-15222	11/2/2001	Document re: Percocet Marketing Plan 2002 - 2006	ENDO_SF-00444705	ENDO_SF-00444729		
P-15223	6/25/2003	Presentation re: Percocet 7.5/325 and 10/325 Sales Training	ENDO_SF-00444910	ENDO_SF-00444910		
P-15225	5/6/2011	Walgreens Pharmacy and Health Care Code of Conduct and General Training	WAGMDL00801267	WAGMDL00801270		
P-15226	5/3/2012	DEA Reference Tools	WAGMDL00801297	WAGMDL00801297		
P-15227	11/8/2011	Controlled Substance Prescriptions & Good Faith Dispensing	WAGMDL00801346	WAGMDL00801347		
P-15230	8/29/2007	Preventing Diversion of Controlled Substances	WAGMDL00801411	WAGMDL00801411		
P-15231	3/2/2011	Refilling Prescriptions	WAGMDL00801416	WAGMDL00801416		
P-15234	5/1/2011	Walgreens Pharmacy and Health Care Code of Conduct Policy	WAGMDL00801487	WAGMDL00801487		
P-15241	8/1/1998	Accepting and Filling New Prescriptions	WAGMDL00801504	WAGMDL00801507		
P-15244	9/7/2004	Accepting and Filling the Prescription Procedure 5	WAGMDL00801513	WAGMDL00801515		
P-15249	12/4/2002	Deleting Prescriptions with Stale Dates	WAGMDL00801523	WAGMDL00801523		
P-15272	10/15/1997	Refilling Prescriptions Policy	WAGMDL00801582	WAGMDL00801583		
P-15287	6/10/2014	Email RAD 10610 Snapshot; Attachment Copy of Rite Aid 10610 Pharm Snapshot_ap comments 06 09 14	WAGNYNS00046862	WAGNYNS00046863		
P-15288	4/18/2011	Email Follow Up - Pain Week; Attachment Pain Presentation 4.11.11; Pain Presentation 4.11.11	PPLPC024000543773	PPLPC024000543774		

P-15289	4/28/2015	Email Updated Slides; Attachments Rx Integrity District Manager Training PPT; Pharmacy Inventory	WAGMDL00004704	WAGMDL00004757		
P-15290	6/10/2016	Email C2 Tote Audit; Attachment DMAIC Storyboard DEFINE C2 tote audit PPT	WAGMDL00094053	WAGMDL00094067		
P-15291	8/16/2012	RE: Controlled Substance Order Quantity Override Form	WAGMDL00107470	WAGMDL00107472		
P-15292	8/9/2012	FW: Controlled Substance Order Quantity Override Form	WAGMDL00107532	WAGMDL00107533		
P-15293	4/19/2013	RE: Top 500 Potential Risk Stores - Oxycodone - 3 months ending February 2013 *UPDATED TOP 100*	WAGMDL00245776	WAGMDL00245780		
P-15294	5/13/2016	Re: ABC Meeting; Attachment WAG - Partial Controls Discussion Document 5.9.16 PPT	WAGMDL00283633	WAGMDL00283641		
P-15295	3/8/2013	Email notes from last Friday's DEA strategy meeting; Attachment DEA Strategy meeting 3.1.13	WAGMDL00302948	WAGMDL00302950		
P-15296	5/5/2014	RE: GFD Document Requests; Attachments Dir Rx Integrity Goals; Goal Details Nick Leners	WAGMDL00305702	WAGMDL00305736		
P-15297	1/14/2013	RE: Process Flow Documents Attachments DEA Controlled Substance Reporting; Decision Process Flow Chart for Ceiling Violation; Good Faith Dispensing Policy Review; Suspicious Order Monitoring Program Policy and Procedures for the Rx Integrity Team; Controlled Substance Reporting KPI Screen Shots; RXS Investigate Straw Man	WAGMDL00311317	WAGMDL00311341		
P-15298	11/12/2012	Email RXS Investigation of Stores Attachment What Should the RXS Investigate	WAGMDL00311366	WAGMDL00311367		
P-15299	1/7/2013	Email Re-look at store walk and 5 minute meeting notes re: GFD	WAGMDL00314402	WAGMDL00314402		
P-15300	1/14/2013	Report Re: Suspicious Order Reporting Query - WALGREENS CORPORATION Distribution Center - DEA #RW0294493	DEA-T3CC-00014231	DEA-T3CC-00014231		
P-15301	10/24/2012	Email SOM Attachment Controlled Substance Order and SOM procedures	WAGMDL00317049	WAGMDL00317050		
P-15303	6/5/2012	Email Controlled Substance Order Quantity Override Process Attachment Process for Ordering Specific Manufacturers	WAGMDL00371319	WAGMDL00371322		
P-15304	4/15/2013	NACDS DEA documents	WAGMDL00897784	WAGMDL00897810		
P-15305	10/4/2012	FL DM Good Faith Dispensing Training PPT	WAGMDL00389171	WAGMDL00389186		
P-15306	1/18/2012	RE: Confirmed: RxOps Meeting Attachments 01 - How much do you know about RxHWT; RxOps - RxHWT Strategy Workshop; 03 - RxHWT Roadmap - 01-18-2011	WAGMDL00484976	WAGMDL00485028		
P-15307	2/28/2017	Email Green Belt Project Introduction Attachments Project Kickoff Meeting - TDGFD Process Time Reduction PPT; TDGFD Charter V4	WAGMDL00573578	WAGMDL00573605		
P-15308	7/26/2010	PBM 101 Presentation - July 2012 PPT; Pharmacy Workload	WAGMDL00591279 WAGMDL00591347 WAGMDL00591379	WAGMDL00591444 WAGMDL00591364 WAGMDL00591381	WAGMDL00591347 - WAGMDL00591364; WAGMDL00591379 - WAGMDL00591381	
P-15309	3/1/2013	DEA Market Meeting Update March 2013 PPT	WAGMDL00674641	WAGMDL00674667		
P-15310	5/16/2017	Email Training material per DEA subpoena - FW: TIME UPDATE: Please deliver invitation to Grad Intern: Graduate Intern Orientation Meeting Attachments PHIG Orientation 2015 w-ap update PPT;	WAGMDL00674947	WAGMDL00675047		
P-15313	7/8/2013	Retail Pharmacy Kick Off PPT	WAGMDL00741752	WAGMDL00742113		
P-15314	6/11/2012	Email Materials for Today's Controlled Substance Action Plan Videoconference Attachments Controlled Substance Action Plan; FOC Survey - June 2012; Focus on Compliance June 2012; FOC Pain Management - Job Aid; Controlled Substance Prescriptions & Good Faith Dispensing Policy; FOC Pain Management - Job Aid; Controlled Substance Prescriptions & Good Faith Dispensing Policy	WAGMDL00742641	WAGMDL00742671		
P-15315	12/12/2012	Email Schedule II narcotic dispensing policy Attachments Schedule II Narcotic Dispensing Guidelines v3; Official Prescriber Sanction Letter; Prescriber Sanction Pilot; Prescriber Scorecard	WAGMDL00745731	WAGMDL00745745		
P-15317	2011	MOA between Walgreen Co and DEA re Store 06094	WAGMDL00757802	WAGMDL00757808		

P-15318	1/1/2013	GFD Milwaukee Jan 13 PPT	WAGMDL00779140	WAGMDL00779174		
P-15319	1/8/2013	Prescriber Index 01-08-13 all drugs through December	WAGMDL00790888	WAGMDL00790888		
P-15320	N/A	Controlled substances sold from store 10518 from 6/10/2012 to 5/16/2014	WAGMDL00790914	WAGMDL00790914		
P-15321	10/3/2013	FW: Overdue Legal PPL (DEADLINE 10/10)	WAGMDL00793450	WAGMDL00793467		
P-15322	9/4/2013	Email Good Faith Dispensing #3314	WAGMDL00798142	WAGMDL00798142		
P-15323	2/23/2013	FW: Controlled Substance Compass Project due 02-27	WAGMDL00798209	WAGMDL00798210		
P-15324	4/17/2012	Fw: #3310: Tue, Apr 17	WAGMDL00798644	WAGMDL00798645		
P-15331	3/15/2017	FW: #4159: Wed, Mar 14	WAGMDL00809643	WAGMDL00809644		
P-15333	12/30/2007	Walgreens Pharmacy Code of Conduct	WAGMDL00815828	WAGMDL00815834		
P-15334	1/2/2013	FW: UPDATES	WAGMDL00819840	WAGMDL00819841		
P-15335	7/14/2009	Re: Fw: c2 order pattern	WAGMDL00819852	WAGMDL00819854		
P-15336	1/9/2012	Fw: DEA Reporting - Revised Attachment DEA Controlled Substance Project - Report Design V3	WAGMDL00820291	WAGMDL00820296		
P-15337	12/22/2011	Re: Fw: Review Controlled Substance Order Report 4N1 - 1411 Lake Cook Attachments DEA Controlled Substance Project - Report Design V2; 2011-12-21 - Meeting Minutes, DEA Controlled Substance - Dashboard Design Concepts	WAGMDL00820304	WAGMDL00820312		
P-15339	1/26/2016	Email Action: Upskilling initiative Attachments DM(V2) Summit Slide pptx 1 25 16 PPT ; Phase 1V2 Facilitator Guide; Phase 1V2P Participant Guide; TimelinePhase1and 2 Plan PPT	WAGMDL00834231	WAGMDL00834328		
P-15340	6/18/2012	Email Conference call Attachments Notes June 11; ICE Roll-out Agenda	WAGMDL00838936 WAGMDL00838936	WAGMDL00839128 WAGMDL00839054	WAGMDL00838936 - WAGMDL00839054	
P-15341	6/1/2012	Re: #5206: Thu, May 31	WAGMDL00839567	WAGMDL00839568		
P-15342	4/21/2011	Email drug diversion training	WAGMDL00839611	WAGMDL00839611		
P-15343	N/A	Prescriber Index 02-19-13 all drugs through January UNDER CONSTRUCTION	WAGNYNS00032015	WAGNYNS00032015		
P-15344	2/12/2013	RE: Drug Reports	WAGNYNS00033436	WAGNYNS00033440		
P-15346	2/25/2013	Prescriber Index 02-19-13 all drugs through January UNDER CONSTRUCTION	WAGNYNS00042909	WAGNYNS00042909		
P-15354	9/28/2012	Email FOC Attachment FOC Survey - June 2012 vF	WAGMDL00113816	WAGMDL00113820		
P-15355	2/5/2013	Controlled Substance Order Monitoring System PPT Version 2	WAGMDL00675532	WAGMDL00675568		
P-15356	3/31/2013	Fwd: National TD GFD Powerpoint Update Attachments National TD GFD Powerpoint EPD Final PPT; National TD GFD Powerpoint EPD Final	WAGMDL00744592	WAGMDL00744624		
P-15357	4/15/2013	RE: Oxycodone 30mg override	WAGMDL00698309	WAGMDL00698309		
P-15358	6/12/2013	RE: CII Orders	WAGMDL00698445	WAGMDL00698445		
P-15360	6/12/2013	Re: CII order	WAGMDL00687021	WAGMDL00687021		
P-15361	6/12/2013	RE: Oxy/Apap	WAGMDL00697774	WAGMDL00697776		
P-15362	7/1/2013	FW: Controlled Substance Order Quantity Override Form	WAGMDL00698296	WAGMDL00698297		
P-15363	8/12/2013	FW: Percocet	WAGMDL00698150	WAGMDL00698150		
P-15364	8/22/2013	Re: Percocet 5/325	WAGMDL00698196	WAGMDL00698196		
P-15563	12/6/2011	RE: 802433 - drug Store Columbus Ohio	Anda_Opioids_MDL_0000136372	Anda_Opioids_MDL_0000136373		
P-15748	5/20/2013	Revised Recommendations for SOMs	Anda_Opioids_MDL_0000089435	Anda_Opioids_MDL_0000089438		
P-15773	9/19/2013	Email and docs re bucket accounts	Anda_Opioids_MDL_0000293556	Anda_Opioids_MDL_0000293559		
P-15846	12/21/2016	RE: Bucket Suspicious Order Multiplier Breakdown	Anda_Opioids_MDL_0000331722	Anda_Opioids_MDL_0000331725		
P-15847	5/16/2016	Fwd: Control Issue FL Sales Rep w/ EPIC Account	Anda_Opioids_MDL_0000543182	Anda_Opioids_MDL_0000543189		
P-15849	N/A	Mangus Resume	N/A	N/A		
P-15887	6/22/2012	Customer Questionnaire	Anda_Opioids_MDL_0000572654	Anda_Opioids_MDL_0000572657		
P-15896	2/14/2008	USA Today, Retired pharmacist: There is a correlation between workload and errors	N/A	N/A		
P-15921	Sep-12	Rannazzisi Drug trend presentation "Drug Trends"	N/A	N/A		
P-15946	12/4/2013	WAGS CII Overstocks	Anda_Opioids_MDL_0000645613	Anda_Opioids_MDL_0000645615		
P-15955	2/7/2015	DEA Controlled Substance and Legend Drug Diversion; A Law Enforcement and Regulatory Perspective. South Point Casino and Resort, Las Vegas, NV, February 7/8, 2015	N/A	N/A		
P-15958	3/20/2013	FL Walgreens Preliminary Determinations	Anda_Opioids_MDL_0000645835	Anda_Opioids_MDL_0000645835		
P-15962	N/A	DEA Controlled Substance and Legend Drug Diversion; A Law Enforcement and Regulatory Perspective. Sheraton Hotel, Norfolk, VA, May 30/31, 2015	N/A	N/A		



P-15971	3/23/2016	Generic Norco	Anda_Opioids_MDL_0000533527	Anda_Opioids_MDL_0000533528		
P-15974	12/15/2014	Anda Strategy Ppt	Anda_Opioids_MDL_0000752495	Anda_Opioids_MDL_0000752513		
P-16001	1/1/2011	Actavis per4ma for Employee Rachelle Galant including The Winning Formula	Acquired_Actavis_00184125	Acquired_Actavis_00184132		
P-16002	2/11/2011	Email Oxy IR Tabs Suspicious Order SOP	Acquired_Actavis_00184191	Acquired_Actavis_00184193		
P-16003	4/22/2011	ANDA Oxymorphone Hydrochloride - Proposal for Risk Minimization Action Plan	Acquired_Actavis_00188875	Acquired_Actavis_00188937		
P-16005	7/23/2015	Email re HydroCodone - how did ABC orders go thru our Ordering SOMS system	Acquired_Actavis_00254149	Acquired_Actavis_00254149		
P-16006	3/22/2011	Email re Cardinals Oxy 15 mg suspicious ordering	Acquired_Actavis_00265976	Acquired_Actavis_00265981		
P-16007	1/3/2013	Email re ABC orders pended in SOM for Oxy Tabs	Acquired_Actavis_00352198	Acquired_Actavis_00352202		
P-16008	10/27/2009	Email Re: Kadian Speaker Program	Acquired_Actavis_00366833	Acquired_Actavis_00366836		
P-16009	9/2/2011	Email re Follow-up discussion re Actavis oxymorphone campaign	Acquired_Actavis_00379710	Acquired_Actavis_00379713		
P-16010	3/11/2008	Email re Revised Kroger Choice Program	Acquired_Actavis_00452409	Acquired_Actavis_00452411		
P-16011	5/23/2012	Email re Miami Pharmacy buying Oxy 30mg from ABC	Acquired_Actavis_00488498	Acquired_Actavis_00488500		
P-16013	3/24/2011	Email re Opti-source Oxy IR Orders	Acquired_Actavis_00665233	Acquired_Actavis_00665238		
P-16014	N/A	Managing Chronic Pain and the Importance of Customizing Opioid Treatment PPT	Acquired_Actavis_00943442	Acquired_Actavis_00943445		
P-16016	9/13/2012	Email Re: IC Payouts	Acquired_Actavis_01356228	Acquired_Actavis_01356229		
P-16017	7/14/2010	Email FW: June CY 2010 Sales Report	Acquired_Actavis_01373039	Acquired_Actavis_01373041		
P-16019	5/23/2012	Email re Miami Pharmacy buying Oxy 30mg from ABC	Acquired_Actavis_01825237	Acquired_Actavis_01825239		
P-16020	8/29/2016	Email from DaCunha re Maryland Registrations for Allergan	Acquired_Actavis_01843335	Acquired_Actavis_01843336		
P-16021	9/19/2012	Kadian Screenshot of website	ACTAVIS0001189	ACTAVIS0001195		
P-16022	3/31/2007	Kadian (Morphine Sulfate Extended-Release Capsules) Pamphlet - Precise Relief. Personalized Pain Relief.	ACTAVIS0006823	ACTAVIS0006830		
P-16023	2/12/2012	Email re sales meeting presentation, Michael Perfetto Actavis Sales Meeting January 11, 2011 "Move The Needle"	ACTAVIS0323261	ACTAVIS0323277		
P-16024	9/15/2011	Email Re: Actavis Marketing / Media Plan	ACTAVIS0346651	ACTAVIS0346655		
P-16025	5/1/2012	APS Corporate Council Application - Jennifer Altier	ACTAVIS0448330	ACTAVIS0448337		
P-16026	9/21/2012	Kadian TeleSales Listing	ACTAVIS0689033	ACTAVIS0689037		
P-16027	5/9/2012	Email re valuetrack oxy high demand with Valuetrak Report	ACTAVIS0770217	ACTAVIS0770284		
P-16028	4/20/2012	Email Re: Introduction of Actavis to APF from Jennifer Altier	ACTAVIS0777465	ACTAVIS0777470		
P-16030	10/4/2012	Kadian \$50 Printed Cards Physician Mailings Jan 2009 NDC Utilization Report (part of large family)	ALLERGAN_MDL_00017884 ALLERGAN_MDL_00017893	ALLERGAN_MDL_00017884 ALLERGAN_MDL_00017893		
P-16031	9/27/2012	APS Planning Session Agenda; APS Corporate Member Advisory Meeting Participant List	ALLERGAN_MDL_00040477	ALLERGAN_MDL_00040495		
P-16032	7/26/2016	SOMS Buzzeo Contract	Anda_Opioids_MDL_0001222707	Anda_Opioids_MDL_0001222713		
P-16033	7/9/2012	Rx Drug Abuse	ALLERGAN_MDL_00377914	ALLERGAN_MDL_00377918		
P-16034	9/15/2011	RE: UA Mailing List	ALLERGAN_MDL_00399983	ALLERGAN_MDL_00399986		
P-16035	8/9/2011	Actavis Kadian Active Records Call List Data	ALLERGAN_MDL_00400744	ALLERGAN_MDL_00400746		
P-16036	7/15/2011	Email RE: NSM meeting info from Hepp to Altier re Half Moon Bay	ALLERGAN_MDL_00402200	ALLERGAN_MDL_00402203		
P-16037	3/16/2011	TMS Health TeleSales Script	ALLERGAN_MDL_00406752	ALLERGAN_MDL_00406759		
P-16038	3/16/2011	Email FW: Kadian January 2011 Report	ALLERGAN_MDL_00406876	ALLERGAN_MDL_00406929		
P-16040	5/27/2009	Kadian Patient Persistency and In-Class Case Study - Adheris	ALLERGAN_MDL_00450169	ALLERGAN_MDL_00450195		
P-16041	7/9/2009	Email Fw: Q2 Pain EDU Sponsorship Report from Inflexxion	ALLERGAN_MDL_00450676	ALLERGAN_MDL_00450692		
P-16042	6/6/2012	Email Re: Upload to Medical Affairs Intranet Site; APS_PP-Topline with American Pain Society (APS) 2012 PPT	ALLERGAN_MDL_00459174	ALLERGAN_MDL_00459246		
P-16043	2/8/2012	Email from Baran to Galant re Contract Actavis	ALLERGAN_MDL_00478433	ALLERGAN_MDL_00478436		
P-16044	1/31/2011	Email re Oxy IR Tabs Suspicious Order SOP	ALLERGAN_MDL_00493795	ALLERGAN_MDL_00493798		
P-16045	5/9/2011	Email re Brand featured in New AGS Guidelines Pocketcard	ALLERGAN_MDL_00507581	ALLERGAN_MDL_00507582		
P-16046	2/18/2010	Kadian Warning Letter	ALLERGAN_MDL_00638084	ALLERGAN_MDL_00638097		
P-16047	1/11/2020	2011 "Putting It All Together" Kadian National Sale Meeting Presentation	ALLERGAN_MDL_00990330 ALLERGAN_MDL_00990554	ALLERGAN_MDL_00990330 ALLERGAN_MDL_00990594	ALLERGAN_MDL_00990554 - ALLERGAN_MDL_00990594	
P-16048	9/12/2012	Email Re: DEA Action includes Bloomberg article, Two CVS Stores Barred from Selling Controlled Substances (08/11/2012)	ALLERGAN_MDL_01026090	ALLERGAN_MDL_01026093		
P-16049	2009	Kadian 2009 Budget (excerpts)	ALLERGAN_MDL_01101681	ALLERGAN_MDL_01101684		
P-16051	6/8/2010	Email Initial Mailing 7535 Targets - Physician 7818 Pharmacist 604	ALLERGAN_MDL_01108512	ALLERGAN_MDL_01108515		



P-16052	9/10/2009	Email Background Info for tomorrow's Meeting	ALLERGAN_MDL_01112578	ALLERGAN_MDL_01112608		
P-16054	4/12/2010	Email from Soltis to Stewart and Scott re DEA Request	ALLERGAN_MDL_01236097	ALLERGAN_MDL_01236098		
P-16055	3/7/2016	Teva Allergan - Unresolved Pipeline Overlaps PPT	ALLERGAN_MDL_01369663	ALLERGAN_MDL_01369793		
P-16056	1/31/2018	Teva Settlement Agreement and Mutual Releases	ALLERGAN_MDL_01396687	ALLERGAN_MDL_01396700		
P-16057	6/28/2011	2010 Kadian Expenses	ALLERGAN_MDL_01451249	ALLERGAN_MDL_01451251		
P-16058	12/31/2013	Kadian RepOnCall Program - Work Order	ALLERGAN_MDL_01612330	ALLERGAN_MDL_01612336		
P-16059	10/11/2011	FW: DEA Suspicious Order; DEA Suspicious Order	ALLERGAN_MDL_01724178	ALLERGAN_MDL_01724180		
P-16060	10/15/2009	Email Re: inVentiv Follow Up	ALLERGAN_MDL_01741504	ALLERGAN_MDL_01741526		
P-16061	7/15/2009	Email re Q2 Pain EDU Sponsorship Report from Inflexxion	ALLERGAN_MDL_01775311	ALLERGAN_MDL_01775317		
P-16063	7/6/2010	FDA Memo to Terri Nataline, Actavis US re NDA 20-816	ALLERGAN_MDL_01869098	ALLERGAN_MDL_01869105		
P-16064	10/19/2010	Controlled Substance Training Materials	Anda_Opioids_MDL_0000077289	Anda_Opioids_MDL_0000077289		
P-16065	8/1/2009	Actavis Kadian LLC Service Agreement with Adheris, an inVentiv health company	ALLERGAN_MDL_01890805	ALLERGAN_MDL_01890830		
P-16066	5/18/2009	Email Re Dr. Valenza Consulting Agreement	ALLERGAN_MDL_01893760	ALLERGAN_MDL_01893771		
P-16067	2012	Kadian 2012 Budget Spreadsheet	ALLERGAN_MDL_01895881	ALLERGAN_MDL_01895885		
P-16068	10/10/2020	Kadian Konnection - Message from Morristown	ALLERGAN_MDL_01990754	ALLERGAN_MDL_01990760		
P-16069	8/16/2011	PPT - Controlled Substance Awareness: Understanding the Threat	ALLERGAN_MDL_02054998	ALLERGAN_MDL_02055022		
P-16071	11/1/2010	Letter to Abrams re NDA 20-616 Kadian Capsules, CII MACMIS #18148	ALLERGAN_MDL_02106570 ALLERGAN_MDL_02106780	ALLERGAN_MDL_02106834 ALLERGAN_MDL_02106834	ALLERGAN_MDL_02106780 - ALLERGAN_MDL_02106834	
P-16072	1/6/2016	Actavis Standard Operating Procedure - Controlled Substance Order Monitoring Policy	ALLERGAN_MDL_02146297	ALLERGAN_MDL_02146311		
P-16074	11/9/2015	Customer Analysis and SOMS Overview Import/Export PPT	ALLERGAN_MDL_02147093	ALLERGAN_MDL_02147110		
P-16075	7/12/2006	Woods email re Watson SOMS	ALLERGAN_MDL_02945113	ALLERGAN_MDL_02945116		
P-16076	8/23/2011	Exhibit Request and Approval Form for Tennessee Academy of Physician Assistants Fall Fest	ALLERGAN_MDL_02949518	ALLERGAN_MDL_02949529		
P-16077	7/14/2012	Letter from DEA Compliance re Suspicious Order Report Summary	ALLERGAN_MDL_03328387	ALLERGAN_MDL_03328429		
P-16079	10/4/2012	Email from Baran re Incident	ALLERGAN_MDL_03380778	ALLERGAN_MDL_03380781		
P-16080	10/26/2012	Email from Baran re Direct and Indirect SOP's Actavis; SOM SOP and Business Procedure	ALLERGAN_MDL_03382709	ALLERGAN_MDL_03382719		
P-16081	9/25/2012	Email re 12/27/2007 Ltr from DOJ reiterating the responsibilities of informing DEA of Suspicious Orders	ALLERGAN_MDL_03525593	ALLERGAN_MDL_03525596		
P-16082	4/4/2007	Watson Pharma Call Center Operations - Licenses Admin Operational Procedures	ALLERGAN_MDL_03952754	ALLERGAN_MDL_03952793		
P-16083	12/30/2015	Actavis Pharma - US Order Management Master Data/License Admin Operational Procedure	ALLERGAN_MDL_03973135	ALLERGAN_MDL_03973160		
P-16084	8/22/2009	Email re Flaws to current DSGP Suspicious Orders	ALLERGAN_MDL_04333187	ALLERGAN_MDL_04333191		
P-16085	12/4/2007	Email from Pehlke to Treeger re assisting Cardinal to keep lost sales to a minimum	ALLERGAN_MDL_04416921	ALLERGAN_MDL_04416921		
P-16086	11/13/2003	RMP Meeting with RK 11/13/03	Brennan_002128	Brennan_002129		
P-16088	7/16/2012	Endo - Promotional Mix Optimization Brand Level Model Results and ROI, Prepared for Endo Pharmaceuticals	ENDO-CHI_LIT-00214468 ENDO-CHI_LIT-00214468 ENDO-CHI_LIT-00214471	ENDO-CHI_LIT-00214548 ENDO-CHI_LIT-00214469 ENDO-CHI_LIT-00214471	ENDO-CHI_LIT-00214471 - ENDO-CHI_LIT-00214471; ENDO-CHI_LIT-00214468 - ENDO-CHI_LIT-00214469	
P-16092	7/20/2011	Ltr to Rannazzisi from New Jersey Pharmaceutical Industry Group	ENDO-OPIOID_MDL-02219844	ENDO-OPIOID_MDL-02219851		
P-16095	2002	Percocet - Quarterly Business Review (First Quarter 2002)	ENDO-OPIOID_MDL-04927196	ENDO-OPIOID_MDL-04927248		
P-16113	2/23/2001	RE: Abuse letter	JAN-MS-00287030	JAN-MS-00287033		
P-16174	10/19/2010	CS Know Your Customer PPT	Anda_Opioids_MDL_0000077290	Anda_Opioids_MDL_0000077290		
P-16183	3/27/2013	Walgreens OH Store data	Anda_Opioids_MDL_0000725057	Anda_Opioids_MDL_0000725057		
P-16187	10/14/2010	Controlled Substances: Kow Your Customer ppt	Anda_Opioids_MDL_0000711451	Anda_Opioids_MDL_0000711470		
P-16193	1/19/2010	CII Actavis Credits	Anda_Opioids_MDL_0000629163	Anda_Opioids_MDL_0000629165		
P-16223	2/16/2018	Allergan - US Securities and Exchange Commission	N/A	N/A		
P-16225	2/18/2015	US Securities and Exchange Commission Form 10-K (Actavis)	N/A	N/A		
P-16227	1/17/2020	The Opioid Files, Drilling into the DEA's pain pill database - The Washington Post	N/A	N/A		
P-16233	3/29/2015	DEA Presentation Pharmaceutical Use & Abuse	N/A	N/A		
P-16237	N/A	Pain EDU Monitoring Patients on Chronic Opioid Therapy - PowerPoint	N/A	N/A		

P-16238	2012	Pain Care Forum 2012 Meetings Schedule	N/A	N/A		
P-16239	12/15/2016	Pro Painkiller Echo Chamber Shaped Policy Amid Drug Epidemic	N/A	N/A		
P-16240	N/A	Bill Profile: S.483 - Clients Lobbying - Ensuring Patient Access and Effective Drug Enforcement Act of 2016	N/A	N/A		
P-16241	4/19/2016	Congress.gov - S.483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2016	N/A	N/A		
P-16266	1/12/2010	Success Story - Oxy CR Made my Day!!	Anda_Opioids_MDL_0000629292	Anda_Opioids_MDL_0000629292		
P-16267	12/8/2009	Relaunch of Generic Oxycontin CR	Anda_Opioids_MDL_0000635640	Anda_Opioids_MDL_0000635645		
P-16268	11/13/2009	Launch of Generic Ultram ER	Anda_Opioids_MDL_0000635385	Anda_Opioids_MDL_0000635387		
P-16269	9/24/2010	CII Order	Anda_Opioids_MDL_0000283889	Anda_Opioids_MDL_0000283890		
P-16271	8/11/2011	Email from Rosen re DEA Quota	PPLP004287450	PPLP004287454		
P-16274	2011	AGS International Guidelines Center - Pain Mgm for Older Patients	PPLPC028000357562	PPLPC028000357563		
P-16277	8/13/2010	Customer #404255	Anda_Opioids_MDL_0000107989	Anda_Opioids_MDL_0000107989		
P-16278	8/26/2010	FW:	Anda_Opioids_MDL_0000107933	Anda_Opioids_MDL_0000107934		
P-16280	10/21/2004	DHHS letter re Actiq promotional materials	TEVA_MDL_A_00267691	TEVA_MDL_A_00267694		
P-16284	2/17/2012	Anda Overview 2-16-12	Anda_Opioids_MDL_0000111938	Anda_Opioids_MDL_0000111940		
P-16285	7/29/2010	Fentora - Promotional Response Study - Impact Assessment Discussion	TEVA_MDL_A_00556014	TEVA_MDL_A_00556014		
P-16291	12/31/2007	Email Electronic 2006 Brand Plan; Marketing Plan 2007 Fentora	TEVA_MDL_A_01128401	TEVA_MDL_A_01128402		
P-16292	7/16/2012	Suspicious Order Monitoring (SOM) PPT	TEVA_MDL_A_01130622	TEVA_MDL_A_01130622		
P-16294	12/23/2013	Email Strat Plan; 2014 Vantrela ER Launch Plan DRAFT	TEVA_MDL_A_01204102	TEVA_MDL_A_01204132		
P-16297	11/29/2005	DHHS letter re Actiq proposed pain management guide	TEVA_MDL_A_01583546	TEVA_MDL_A_01583550		
P-16301	6/30/2014	FW: FENTORA Impact Assessment Review; Fentora Marketing Mix Analysis Impact Assessment Findings Review	TEVA_MDL_A_02767664	TEVA_MDL_A_02767683		
P-16312	4/28/2014	Drug Store News: Pfizer confirms merger discussions with AstraZeneca	N/A	N/A		
P-16318	3/13/2007	Email Response from FDA Regarding Actiq Patient Testimonials; DHHS letter re Actiq promotional materials	TEVA_MDL_A_07424104	TEVA_MDL_A_07424109		
P-16322	9/26/2006	Fentora label	TEVA_MDL_A_13751010	TEVA_MDL_A_13751050		
P-16331	6/9/2011	Email re Question for Charles from Kitlinski	ENDO_OPIOID_DEPMAT-000034305	ENDO_OPIOID_DEPMAT-000034307		
P-16332	11/1/2011	Endo Payments to NIPC, 2003-2012	ENDO_OPIOID_DEPMAT-000034524	ENDO_OPIOID_DEPMAT-000034524		
P-16336	1997	The Use of Opioids for the Treatment of Chronic Pain - The Clinical Journal of Pain	ENDO-OPIOID_MDL-00925807	ENDO-OPIOID_MDL-00925809		
P-16337	1/28/2013	Important CE Lesson	Anda_Opioids_MDL_0000082600	Anda_Opioids_MDL_0000082615		
P-16339	9/25/2013	Controlled Substances CE Supported by Anda	Anda_Opioids_MDL_0000085212	Anda_Opioids_MDL_0000085230		
P-16340	3/17/2016	CE lesson for Anda	Anda_Opioids_MDL_0000091978	Anda_Opioids_MDL_0000091994		
P-16347	1/22/2013	Economic Reports by Pembroke Consulting	Anda_Opioids_AL_DCH_0047548	Anda_Opioids_AL_DCH_0047858		
P-16348	2/1/2008	CMP Version 20	Anda_Opioids_MDL_0000611157	Anda_Opioids_MDL_0000611159		
P-16352	6/15/2012	Letter to Chairman Baucus and Senator Grassley with Data: Submitted to Senate Finance Committee by Endo	ENDO-OR-CID-00632998	ENDO-OR-CID-00718236		
P-16358	8/1/2014	Email Re: estimate on timeline "What you should know about treating your pain with opioids"	ENDO-CHI_LIT-00549930	ENDO-CHI_LIT-00550090		
P-16361	5/10/2013	Letter to Chapman from Rappaport regarding NDA for Opana ER Tablets	ENDO-OR-CID-01174358	ENDO-OR-CID-01174331		
P-16362	9/18/2006	Final Opana and Opana ER MVA and Navigator	ENDO-OPIOID_MDL-01655584	ENDO-OPIOID_MDL-01655647		
P-16363	3/13/2008	CMP Version 21	Anda_Opioids_MDL_0000611090	Anda_Opioids_MDL_0000611092		
P-16365	4/4/2008	Ethex Oxycodone HCL 30 mg Close Out 1/09	Anda_Opioids_MDL_0000611078	Anda_Opioids_MDL_0000611082		
P-16368	5/17/2008	Watson vs. Barr - Generic Actiq Analysis	Anda_Opioids_MDL_0000611056	Anda_Opioids_MDL_0000611058		
P-16381	1/11/2008	No Subject.EML with attms Endo_Pharmaceuticals_2008_Gov't_Affairs_finalslides01-11-08 and environmentalassessmentdraft10[1]	ENDO-OPIOID_MDL-02210739	ENDO-OPIOID_MDL-02210763		
P-16382	7/24/2006	FW: OPANA and OPANA ER Pis	ENDO-OPIOID_MDL-00879677	ENDO-OPIOID_MDL-00879738		
P-16384	4/6/2004	April 6 2004 Endo Overview	ENDO-OPIOID_MDL-04137944	ENDO-OPIOID_MDL-04137945		
P-16447	11/4/2008	Teva Fentanyl TD Matric Patch Update	Anda_Opioids_MDL_0000618246	Anda_Opioids_MDL_0000618249		
P-16448	7/15/2016	WALGREENS DAILY SALES SUMMARY	Anda_Opioids_MDL_0000118070	Anda_Opioids_MDL_0000118071		
P-16449	5/2/2008	Oxy forms - Purdue Contract	Anda_Opioids_MDL_0000616305	Anda_Opioids_MDL_0000616334		
P-16450	2/22/2007	Method of Payment for Quarterly Rebates	Anda_Opioids_CA_SF_0003964	Anda_Opioids_CA_SF_0003966		
P-16451	10/30/2009	MYLAN CII FENTANYL TD MATRIX PATCH NOW IN STOCK	Anda_Opioids_MDL_0000110870	Anda_Opioids_MDL_0000110871		
P-16452	3/20/2017	One of Two for Today	Anda_Opioids_CA_SF_0073985	Anda_Opioids_CA_SF_0074015		

P-16453	4/23/2009	Sales Services Agreement between TMS Health and Actavis Kadian	ALLERGAN_MDL_01782063	ALLERGAN_MDL_01782087		
P-16454	2/1/2007	Internal Marketing Programs	Anda_Opioids_MDL_0000611425	Anda_Opioids_MDL_0000611426		
P-16455	2/1/2007	Oxycodone 10, 20, 40, 80 for CSOS Customers Flyer 22107	Anda_Opioids_MDL_0000611411	Anda_Opioids_MDL_0000611413		
P-16456	9/18/2014	remedi VW account #153679	Anda_Opioids_MDL_0000601127	Anda_Opioids_MDL_0000601127		
P-16457	10/4/2007	New Choice Pharmacy	Anda_Opioids_MDL_0000274587	Anda_Opioids_MDL_0000274589		
P-16458	8/26/2008	Tursack Inc. Kadian Insert Proof Verification	ALLERGAN_MDL_02521469	ALLERGAN_MDL_02521478		
P-16459	1/10/2012	LEADERSHIP	Anda_Opioids_CA_SF_0074804	Anda_Opioids_CA_SF_0074806		
P-16460	4/5/2006	2006.04.05.SOP 10 Draft.	Anda_Opioids_MDL_0000152092	Anda_Opioids_MDL_0000152104		
P-16461	4/5/2013	Zuchelli and Johnson Master Service Agreement	ALLERGAN_MDL_00001650	ALLERGAN_MDL_00001658		
P-16462	3/25/2010	2010.03.25 Email re SOP 40 Review with SOP 40 Attached	Anda_Opioids_MDL_0000110184	Anda_Opioids_MDL_0000110186		
P-16463	4/16/2010	2010.04.16 Emails re Review of SOPs	Anda_Opioids_MDL_0000079961	Anda_Opioids_MDL_0000079984		
P-16464	7/12/2010	2010.07.12 SOP 10.02 Draft and Email Chain	Anda_Opioids_MDL_0000104965	Anda_Opioids_MDL_0000104979		
P-16465	9/24/2010	2010.09.24 Packet of Anda Compliance Docs	Anda_Opioids_MDL_0000126908	Anda_Opioids_MDL_0000126998		
P-16466	11/5/2010	2010.11.05 Email re Updated Policies and Procedures	Anda_Opioids_MDL_0000082087	Anda_Opioids_MDL_0000082220		
P-16467	9/11/2014	2011.12.14 Email Chain re Anda DEA Inspection with SOP 13 Attached	Anda_Opioids_MDL_0000112232	Anda_Opioids_MDL_0000112240		
P-16468	9/10/2014	2014.09.10 Email re DEA Follow Up with SOPs 28-40	Anda_Opioids_MDL_0000084439	Anda_Opioids_MDL_0000084450		
P-16469	9/11/2014	2014.09.11 Email Chain to DEA re Meeting Follow Up SOP28 Attached	Anda_Opioids_MDL_0000084429	Anda_Opioids_MDL_0000084438		
P-16470	5/15/2015	2015.05.15 Email to VWB re3rd P&P Review	Anda_Opioids_MDL_0000140206	Anda_Opioids_MDL_0000140235		
P-16471	5/3/2016	2016.05.03 Email Chain with Multiple SOPs Attached	Anda_Opioids_MDL_0000332941	Anda_Opioids_MDL_0000332957		
P-16472	5/9/2016	2016.05.09 Emails re Review of SOPs	Anda_Opioids_MDL_0000143074	Anda_Opioids_MDL_0000143098		
P-16473	7/22/2016	2016.07.22 Email re Compliance Transition Plan with SOP 28 Attached	Anda_Opioids_MDL_0000038088	Anda_Opioids_MDL_0000038100		
P-16474	8/15/2016	2016.08.15 Brown to P.Cochrane Email re Draft SOP 41	Anda_Opioids_MDL_0000541121	Anda_Opioids_MDL_0000541123		
P-16475	9/9/2016	2016.09.09 Email Chain with SOPs 28, 40, 45	Anda_Opioids_MDL_0000019713	Anda_Opioids_MDL_0000019723		
P-16476	6/6/2012	Technekes Master Service Agreement	ALLERGAN_MDL_01447720	ALLERGAN_MDL_01447729		
P-16477	10/21/2016	2016.10.21 Email to VWB re Reaccreditation	Anda_Opioids_MDL_0000138017	Anda_Opioids_MDL_0000138017		
P-16478	12/6/2016	2016.12.06 Robert Brown Email to Mangus re SOP for National Accounts and GPOs	Anda_Opioids_MDL_0000539962	Anda_Opioids_MDL_0000539965		
P-16479	12/6/2016	2016.12.06 Robert Brown Email to Spellman re SOP for National Accounts and GPOs	Anda_Opioids_MDL_0000539966	Anda_Opioids_MDL_0000539969		
P-16480	2/8/2017	2017.02.08 Email re Teva SOP Review	Anda_Opioids_MDL_0000146904	Anda_Opioids_MDL_0000146910		
P-16481	3/8/2017	2017.03.08 Email re Request for Further Details Regarding Anda Sample Program Services	Anda_Opioids_MDL_0000149869	Anda_Opioids_MDL_0000149902		
P-16482	4/28/2017	2017.04.28 Email re MedPro Regroup	Anda_Opioids_MDL_0000398202	Anda_Opioids_MDL_0000398208		
P-16483	9/19/2017	2017.09.19 Email Chain to CA BOP SOP28 Attached	Anda_Opioids_MDL_0000145813	Anda_Opioids_MDL_0000145827		
P-16484	1/12/2018	2018.01.12 Email chain to Ohio Board of Pharmacy SOP28 Attached	Anda_Opioids_MDL_0000144565	Anda_Opioids_MDL_0000144577		
P-16485	3/9/2018	2018.03.09 Email Chain to Florida DBPR with SOP28 Attached	Anda_Opioids_MDL_0000144375	Anda_Opioids_MDL_0000144404		
P-16486	12/1/2009	PRODUCT UPDATE: Re-launch of Generic Oxycontin CR	Anda_Opioids_MDL_0000610604	Anda_Opioids_MDL_0000610615		
P-16487	9/20/2007	QVL - Follow up	Anda_Opioids_MDL_0000274741	Anda_Opioids_MDL_0000274751		
P-16488	2/25/2009	Bi-Mart 607	Anda_Opioids_MDL_0000078162	Anda_Opioids_MDL_0000078165		
P-16489	1/18/2018	Anda #28 - Two other ANDA locations	Anda_Opioids_MDL_0001160074	Anda_Opioids_MDL_0001160081		
P-16490	1/5/2010	RE: back fill - National Meeting	ALLERGAN_MDL_03319421	ALLERGAN_MDL_03319423		
P-16491	4/30/2012	IMPORTANT Oxycodone Data Request Phase 2	Anda_Opioids_CA_SF_0060643	Anda_Opioids_CA_SF_0060646		
P-16492	11/19/2013	oxy pricing	Anda_Opioids_MDL_0001141501	Anda_Opioids_MDL_0001141502		
P-16493	4/3/2008	Ethex Oxycodone HCL 30 mg Close Out 1/09	Anda_Opioids_MDL_0000611083	Anda_Opioids_MDL_0000611084		
P-16494	6/1/2009	Nucynta - J&J CII Guidelines Flyer	Anda_Opioids_MDL_0000103991	Anda_Opioids_MDL_0000103995		
P-16495	N/A	I Got My Life Back video	PURDUE0180625	PURDUE0180625		
P-16496	2/2/2011	Moms New Account	Anda_Opioids_CA_SF_0075353	Anda_Opioids_CA_SF_0075354		
P-16497	N/A	Poropat LinkedIn	N/A	N/A		
P-16498	1/13/2014	Bryant Ranch 305285 Codeine	Anda_Opioids_MDL_0000339195	Anda_Opioids_MDL_0000339196		
P-16499	2/13/2014	Bryant Ranch Prepak	Anda_Opioids_MDL_0000346640	Anda_Opioids_MDL_0000346641		
P-16593	4/24/1971	21 C.F.R. § 1301.76(c)	N/A	N/A		
P-16603	10/18/2007	HJ Harkins	Anda_Opioids_MDL_0000078228	Anda_Opioids_MDL_0000078233		
P-16689	2/6/2017	FW: Hub Org Chart Attachment Team Gates 1 PPT	WAGMDL01055400	WAGMDL01055401		
P-16701	12/12/2017	Statement of Demetra Ashley before the Judiciary Committee for a Hearing	N/A	N/A		

P-16702	1/30/2018	Letter from D. Ashley to Hon. D. Polster re ARCOS data	N/A	N/A	
P-16733	9/16/2010	Due Diligence Item from Checklist	Anda_Opioids_MDL_0001155092	Anda_Opioids_MDL_0001155093	
P-16734	3/31/2017	Publix Teva Oxycodone	Anda_Opioids_MDL_0000775234	Anda_Opioids_MDL_0000775248	
P-16735	1/15/2013	Controlled Substances CE Supported by Anda	Anda_Opioids_MDL_0000080961	Anda_Opioids_MDL_0000080964	
P-16736	7/19/2012	Acct 111507 United	Anda_Opioids_MDL_0001142185	Anda_Opioids_MDL_0001142190	
P-16737	7/19/2012	MD letter for Anda Compliance Dept United	Anda_Opioids_MDL_0000572476	Anda_Opioids_MDL_0000572479	
P-16738	7/20/2015	DSR - 7/17/15	Anda_Opioids_MDL_0001103696	Anda_Opioids_MDL_0001103707	
P-16739	8/13/2007	CSOS Mailing with updated accounts	Anda_Opioids_MDL_0000275417	Anda_Opioids_MDL_0000275420	
P-16740	11/2/2005	Suspicious Orders Week Ending 10-30-05	Anda_Opioids_MDL_0000271906	Anda_Opioids_MDL_0000271908	
P-16741	5/14/2006	Suspicious Orders Week Ending 5-14-06	Anda_Opioids_MDL_0000271816	Anda_Opioids_MDL_0000271818	
P-16742	5/31/2006	Suspicious Orders Week Ending 5-28-06	Anda_Opioids_MDL_0000271810	Anda_Opioids_MDL_0000271812	
P-16743	8/14/2006	Suspicious Orders Week Ending 8-6-06	Anda_Opioids_MDL_0000271774	Anda_Opioids_MDL_0000271778	
P-16744	4/9/2007	Suspicious Orders Week Ending 4-8-07	Anda_Opioids_MDL_0000271674	Anda_Opioids_MDL_0000271676	
P-16745	1/23/2006	Suspicious Orders Week Ending 1-22-06	Anda_Opioids_MDL_0000271872	Anda_Opioids_MDL_0000271874	
P-16746	1/30/2006	Suspicious Orders Week Ending 1-29-06	Anda_Opioids_MDL_0000271869	Anda_Opioids_MDL_0000271871	
P-16747	2/7/2006	Suspicious Orders Week Ending 2-5-06	Anda_Opioids_MDL_0000271863	Anda_Opioids_MDL_0000271865	
P-16748	6/5/2006	Suspicious Orders Week Ending 6-04-06	Anda_Opioids_MDL_0000271807	Anda_Opioids_MDL_0000271809	
P-16749	7/3/2006	Suspicious Orders Week Ending 7-2-06	Anda_Opioids_MDL_0000271791	Anda_Opioids_MDL_0000271793	
P-16777	12/14/2015	Walgreens Strategic Account Plan; Walmart Strategic Account Plan	PPLPC051000273619	PPLPC051000273629	
P-16780	1/17/2000	Walgreens request for money	E15_00007557	E15_00007557	
P-16781	10/28/2001	Walgreens Programs National Accounts	E15_00012925	E15_00012925	
P-16782	4/17/2001	Re: lipman CE for Walgreens	E15_00034535	E15_00034535	
P-16783	3/26/1999	Purdue's Letter to Mary Whitley RPh, Walgreens.	PDD1701269026	PDD1701269026	
P-16784	7/31/2000	RE: Walgreen's Program	PDD1800007497	PDD1800007498	
P-16790	4/19/2001	Walgreens District Mgrs. meeting 04/17/2001	PDD8801126584	PDD8801126585	
P-16792	11/11/2001	Walgreens Pharmacy Meeting	PDD8806098809	PDD8806098811	
P-16793	6/1/2001	Letter to Walgreens re drug diversion	PKY180136027	PKY180136027	
P-16801	4/18/2011	Pain Management for the Primary Care Provider: A daylong course in the diagnosis, treatment, and legal Issues surrounding the treatment of pain	PPLP003469655	PPLP003469655	
P-16802	N/A	Walgreens Timeline	PPLP004384930 PPLP004384979	PPLP004384980 PPLP004385066	PPLP004384979 - PPLP004384980
P-16807	11/16/2000	Walgreens; RE: Walgreen Store List; FW: Continuing Education	PPLPC008000013189	PPLPC008000013192	
P-16813	10/24/2001	Walgreens Continuing Education Seminar; Pain Management for Pharmacists	PPLPC008000021199	PPLPC008000021204	
P-16815	6/26/2002	Walgreen notes from 6/25/02 meeting; Walgreens meeting notes 6-25-02	PPLPC008000025396	PPLPC008000025401	
P-16816	3/31/2003	FW: CE programs and grants at Walgreens	PPLPC008000029920	PPLPC008000029921	
P-16817	3/7/2001	RE: Walgreens District Meetings	PPLPC012000027280	PPLPC012000027282	
P-16823	7/27/2000	RE: Walgreen's Program	PPLPC021000004460	PPLPC021000004461	
P-16827	11/8/2017	RE: Walgreens meeting	PPLPC023000963186	PPLPC023000963186	
P-16829	9/8/1999	Two Walgreens Programs Back To Back; 01051005-October 25,1999-Walgreens; 01051005-October 26,1999-Walgreens	PPLPC024000006603	PPLPC024000006610	
P-16830	2/16/2000	01051005 - March 14, 2000 - Walgreens (Strickland) & 01051005 - March 15, 2000 (Strickland)	PPLPC024000012000	PPLPC024000012006	
P-16833	12/18/2014	Email walgreen summary Attachment Walgreens_follow_up_notes	PPLPC025000186037	PPLPC025000186041	
P-16834	12/18/2014	Email walgreen Attachment Customer Meeting Template walgreens 1217	PPLPC025000186075	PPLPC025000186076	
P-16848	1/27/2016	Strategic Account Plan Walgreens 2016 January 27 PPT	PPLPC034001133571	PPLPC034001133571	
P-16850	10/31/2001	RE: Pharmacist Speaker that is also a Lawyer	PPLPC036000008325	PPLPC036000008326	
P-16858	1/23/2006	Suspicious Order Reporting Week of 1-23-06	Anda_Opioids_MDL_0000125011	Anda_Opioids_MDL_0000125011	
P-16904	5/14/2006	Suspicious Week Ending 1-22-06 Pharmacy	Anda_Opioids_MDL_0000277738	Anda_Opioids_MDL_0000277738	
P-16905	10/17/2005	Suspicious Week Ending 10-16-05	Anda_Opioids_PA_0052728	Anda_Opioids_PA_0052728	
P-16906	10/17/2005	Suspicious Week Ending 10-16-05	Anda_Opioids_PA_0052669	Anda_Opioids_PA_0052669	
P-16907	2/19/2007	Suspicious Week Ending 2-18-07 pharmacy	Anda_Opioids_MDL_0000125020	Anda_Opioids_MDL_0000125020	
P-16908	2/19/2007	Suspicious Week Ending 2-18-07 wholesalers	Anda_Opioids_MDL_0000124900	Anda_Opioids_MDL_0000124900	
P-16909	2/26/2007	Suspicious Week Ending 2-25-07 pharmacy	Anda_Opioids_MDL_0000125002	Anda_Opioids_MDL_0000125002	
P-16910	2/26/2007	Suspicious Week Ending 2-25-07 wholesalers	Anda_Opioids_MDL_0000124940	Anda_Opioids_MDL_0000124940	

P-16911	7/30/2018	CT1 Anda's Initial Response to Plaintiff's First Set of Request For Production	N/A	N/A		
P-16912	6/17/2020	CT4 Anda's Initial Responses and Objections to Plaintiff's Amended First Set of Request For Production to Anda	N/A	N/A		
P-16913	1/19/2021	CT4 Anda's Initial Responses and Objections to Plaintiff's Second Set of Request For Production to Anda	N/A	N/A		
P-16914	3/22/2021	CT4 Anda's Responses and Objections to Plaintiff's Third Set of Request For Production to Anda	N/A	N/A		
P-16915	11/12/2021	CT4 Anda's Responses and Objections to Plaintiff's Fourth Set of Request For Production to Anda	N/A	N/A		
P-16916	4/21/2004	Presentation re: Percocet 2.5/325 Sales Training	ENDO_SF-00444948	ENDO_SF-00444948		
P-16917	7/17/2007	Internal and External Communications	Anda_Opioids_MDL_0000078276	Anda_Opioids_MDL_0000078279		
P-16918	2/14/2007	Suspicious Week Ending 2-11-07	Anda_Opioids_MDL_0000280967	Anda_Opioids_MDL_0000280967		
P-16919	8/14/2007	CSOS Mailing with updated accounts	Anda_Opioids_MDL_0000275401	Anda_Opioids_MDL_0000275405		
P-16920	10/5/2007	New Choice Pharmacy	Anda_Opioids_MDL_0000274563	Anda_Opioids_MDL_0000274569		
P-16921	12/11/2007	Narcotic Limits	Anda_Opioids_MDL_0000274184	Anda_Opioids_MDL_0000274185		
P-16922	7/7/2010	Reports	Anda_Opioids_MDL_0000710002	Anda_Opioids_MDL_0000710088		
P-16923	8/28/2014	Overview Presentation for DEA 8.28	Anda_Opioids_MDL_0000281030	Anda_Opioids_MDL_0000281030		
P-16924	5/12/2017	RSC ohio 155242	Anda_Opioids_MDL_0000018982	Anda_Opioids_MDL_0000018983		
P-16925	1/28/2014	Leadership Presentation	Anda_Opioids_MDL_0000103188	Anda_Opioids_MDL_0000103194		
P-16926	9/7/2012	RSC OH NE DEA Power of Attorney	Anda_Opioids_MDL_0000134640	Anda_Opioids_MDL_0000134649		
P-16927	9/18/2014	remedi VW account #153679	Anda_Opioids_MDL_0000361505	Anda_Opioids_MDL_0000361505		
P-16928	11/13/2012	FENTANYL FROM ANDA	Anda_Opioids_MDL_0000421920	Anda_Opioids_MDL_0000421931		
P-16929	5/17/2016	Anda Overview for Teva	Anda_Opioids_MDL_0000003285 Anda_Opioids_MDL_0000003286	Anda_Opioids_MDL_0000003286 Anda_Opioids_MDL_0000003300	Anda_Opioids_MDL_0000003286 - Anda_Opioids_MDL_0000003286	
P-16930	2/17/2012	Anda Overview 2-16-12	Anda_Opioids_MDL_0000111945	Anda_Opioids_MDL_0000111947		
P-16931	8/5/2013	Actavis Sales Update June 2013	Anda_Opioids_MDL_0000116854	Anda_Opioids_MDL_0000116862		
P-16932	4/1/2015	Anda Regulatory Compliance Overview revised	Anda_Opioids_MDL_0000414235	Anda_Opioids_MDL_0000414236		
P-16933	9/25/2007	New Choice Pharmacy Usage Report 2	Anda_Opioids_MDL_0000278828	Anda_Opioids_MDL_0000278828		
P-16934	9/25/2007	New Choice Pharmacy Usage Report	Anda_Opioids_MDL_0000280941	Anda_Opioids_MDL_0000280941		
P-16935	N/A	Anda, Inc.'s Second Supplemental Response to Plaintiff's First Combined Discovery Requests to Distributor Defendants	N/A	N/A		
P-16936	9/24/2014	Anda Pharmacy ED Kicker Plan Addendum 5 FINAL	Anda_Opioids_MDL_0001096414	Anda_Opioids_MDL_0001096414		
P-16937	9/24/2014	2014 Anda Pharmacy Sales Reps Annual Kicker Plan Addendum 1 FINAL	Anda_Opioids_MDL_0001096415	Anda_Opioids_MDL_0001096416		
P-16938	11/7/2018	2017 Annual Bonus Plan - Anda National Accounts 6-23-17	Anda_Opioids_MDL_0001096417	Anda_Opioids_MDL_0001096421		
P-16939	2/6/2014	Addendum C-PractRx-ED Final	Anda_Opioids_MDL_0001096422	Anda_Opioids_MDL_0001096422		
P-16940	9/24/2014	2014 AndaMEDs Manager Kicker Plan Addendum B FINAL	Anda_Opioids_MDL_0001096423	Anda_Opioids_MDL_0001096423		
P-16941	4/2/2018	2018 Anda Pharmacy-ISSII 04-02-2018 version FINAL	Anda_Opioids_MDL_0001096424	Anda_Opioids_MDL_0001096435		
P-16942	9/24/2014	2014 AndaMEDS ED Kicker Plan Addendum C FINAL	Anda_Opioids_MDL_0001096436	Anda_Opioids_MDL_0001096436		
P-16943	2/6/2014	Addendum B-PractRx-Mgr Final	Anda_Opioids_MDL_0001096437	Anda_Opioids_MDL_0001096476		
P-16944	11/19/2013	2013-2014 Sales Management Incentive Plan FINAL	Anda_Opioids_MDL_0001096477	Anda_Opioids_MDL_0001096485		
P-16945	2/6/2014	Addendum A-PractRx-Reps Final	Anda_Opioids_MDL_0001096486	Anda_Opioids_MDL_0001096489		
P-16946	9/24/2014	AndaMEDs Sales Rep Kicker Plan Addendum A FINAL	Anda_Opioids_MDL_0001096490	Anda_Opioids_MDL_0001096490		
P-16947	11/10/2016	2016-2017 Sales Management Incentive Plan FINAL V3	Anda_Opioids_MDL_0001096491	Anda_Opioids_MDL_0001096500		
P-16948	2/5/2014	2013-2014 AndaMEDS Sales Commission-Incentive Plan Final	Anda_Opioids_MDL_0001096501	Anda_Opioids_MDL_0001096507		
P-16949	1/26/2018	2018 Anda Pharmacy-ISSI 11-30-2017 version FINAL	Anda_Opioids_MDL_0001096508	Anda_Opioids_MDL_0001096515		
P-16950	11/19/2013	Addendum 5 - ED FINAL	Anda_Opioids_MDL_0001096516	Anda_Opioids_MDL_0001096516		
P-16951	1/19/2018	2018 Anda Pharmacy Sales Management Incentive Plan 01_10_2018 FINAL	Anda_Opioids_MDL_0001096517	Anda_Opioids_MDL_0001096527		
P-16952	9/24/2014	2014 Anda Pharmacy Managers Kicker Plan Addendum 4 FINAL	Anda_Opioids_MDL_0001096528	Anda_Opioids_MDL_0001096528		
P-16953	11/19/2013	2013-2014 Anda Pharmacy Sales Commission-Sales Incentive Plan FINAL	Anda_Opioids_MDL_0001096529	Anda_Opioids_MDL_0001096538		
P-16954	11/7/2018	2018 Annual Bonus Plan - Anda National Accounts	Anda_Opioids_MDL_0001096539	Anda_Opioids_MDL_0001096543		
P-16955	3/26/2013	RE Manufacturers Repackagers.msg	Anda_Opioids_MDL_0000113661	Anda_Opioids_MDL_0000113661		
P-16956	3/26/2013	RE Manufacturers Repackagers.msg	Anda_Opioids_MDL_0000113662	Anda_Opioids_MDL_0000113662		
P-16957	10/16/2007	Fw Re Need Approval.htm	Anda_Opioids_MDL_0000274525	Anda_Opioids_MDL_0000274526		
P-16958	6/12/2008	Re # 51899 - Limits.htm	Anda_Opioids_MDL_0000273655	Anda_Opioids_MDL_0000273656		
P-16959	6/12/2008	Re # 51899 - Limits.htm	Anda_Opioids_MDL_0000273628	Anda_Opioids_MDL_0000273630		
P-16960	6/13/2008	Re # 51899 - Limits.htm	Anda_Opioids_MDL_0000276899	Anda_Opioids_MDL_0000276902		



P-16961	6/13/2008	Re # 51899 - Limits.htm	Anda_Opioids_MDL_0000273621	Anda_Opioids_MDL_0000273623		
P-16962	3/26/2009	Fw Hydrocodone Limits - .msg	Anda_Opioids_MDL_0000287909	Anda_Opioids_MDL_0000287910		
P-16963	6/17/2010	MASS UPDATE customer master #.msg	Anda_Opioids_MDL_0000078693	Anda_Opioids_MDL_0000078694		
P-16964	10/17/2007	Re Fw H J Harkins.msg	Anda_Opioids_MDL_0000078234	Anda_Opioids_MDL_0000078238		
P-16965	10/18/2007	Re Fw H J Harkins.msg	Anda_Opioids_MDL_0000078215	Anda_Opioids_MDL_0000078221		
P-16966	3/1/2001	Partners Against Pain Website	N/A	N/A		
P-16967	1/7/2010	Re Fw January Marketing Driver	Anda_Opioids_AL_DCH_0058017	Anda_Opioids_AL_DCH_0058021		
P-16968	6/13/2008	Re Need Approval.htm	Anda_Opioids_MDL_0000273612	Anda_Opioids_MDL_0000273613		
P-16969	3/1/2011	Exporters.msg	Anda_Opioids_MDL_0000109038	Anda_Opioids_MDL_0000109039		
P-16970	4/10/2002	Direct mail series postcards for Percocet 325	ENDO_SF-00445247	ENDO_SF-00445248		
P-16971	12/8/2006	FW: Dec 5 participant feedback.msg	ENDO_SF-00484097	ENDO_SF-00484098		
P-16972	1/22/2016	FW: Pain Brand Strategies	ENDO_SF-00488037	ENDO_SF-00488042		
P-16973	12/12/2016	Ferrone.rep one pager	ENDO_SF-00488051	ENDO_SF-00488052		
P-16974	12/16/2016	Ferrone Representative Performance and Goal Form - 2016 MF	ENDO_SF-00488081	ENDO_SF-00488088		
P-16975	3/22/2016	Ferrone Representative Performance and Goal Form - 2016	ENDO_SF-00538335	ENDO_SF-00538344		
P-16976	12/15/2016	FW: 1 More Call Initiative and Butrans weekly calls	ENDO_SF-00538531	ENDO_SF-00538533		
P-16977	12/15/2016	FW: POA II 2016	ENDO_SF-00538534	ENDO_SF-00538535		
P-16978	4/22/2016	Changes from Today	ENDO_TXMDL_00329524	ENDO_TXMDL_00329526		
P-16979	6/1/2004	Partners Against Pain Website	N/A	N/A		
P-16980	N/A	B442-3 San Francisco CA Mail List MMS	KP360_OHIOMDL_000082069	KP360_OHIOMDL_000082069		
P-16981	N/A	OP-03289(1) OPANAER Copay Slim Jim V2_R1	ENDO-OPIOID_MDL-05937474	ENDO-OPIOID_MDL-05937475		
P-16982	N/A	OP-04578b_Final1.0	ENDO-OPIOID_MDL-05937763	ENDO-OPIOID_MDL-05937767		
P-16983	N/A	OP-05015_Final1.0	ENDO-OPIOID_MDL-05943236	ENDO-OPIOID_MDL-05943245		
P-16984	N/A	OP-05016_Draft0.4_Final1.0	ENDO-OPIOID_MDL-05943256	ENDO-OPIOID_MDL-05943261		
P-16985	9/18/2021	CDW_CDW_MaterialsDropped_2016_20210918	ENDO-OPIOID_MDL-08000578	ENDO-OPIOID_MDL-08000578		
P-16986	7/6/2016	Abuse and Diversion Detection Program Reminders	ENDO-OPIOID_MDL-08468173	ENDO-OPIOID_MDL-08468183		
P-16987	8/8/2016	EXTERNAL: Global Exclude Report 08.08.16	ENDO-STAUBUS_LIT-00080063	ENDO-STAUBUS_LIT-00080064		
P-16988	6/16/2016	POA Follow Up	ENDO-STAUBUS_LIT-00718565	ENDO-STAUBUS_LIT-00718567		
P-16989	12/10/2021	2016.11.29 E Chung to Ferrone et al re Week 11-11 low sales Opana	FERRONE_00000058	FERRONE_00000060		
P-16990	N/A	Managing Chronic Pain with Opioids in Primary Care	ENO000049329	ENO000049335		
P-16991	7/1/2003	Oxymorphone Risk Management Plan	ENO000098794	ENO000098879		
P-16992	1/1/1998	CIOMS (1998) Benefit-Risk Balance for Marketed Drugs - Evaluating Safety Signals	N/A	N/A		
P-16993	2017	National Center for Health Statistics Drug Poisoning Mortality United States, 1999-2016	N/A	N/A		
P-16994	9/18/2010	New York Times: Officers See More Sick and Elderly Selling Prescription Drugs	N/A	N/A		
P-16995	1/1/1972	Watkins and Chambers (1972) Oxymorphone abuse among narcotic addicts	N/A	N/A		
P-16996	3/14/2017	Summary Minutes of March 13-14, 2017 Meeting of DSaRM and AADPAC	N/A	N/A		
P-16997	3/13/2019	PAR Total Unit Count	N/A	N/A		
P-16998	3/13/2019	QT Total Unit Count	N/A	N/A		
P-16999	N/A	Endo Total Pill shipped 1999-2017	N/A	N/A		
P-17000	8/22/2012	Appendix B to 4th Response to Senate Finance Committee	ENDO-OR-CID-00749100	ENDO-OR-CID-00749178		
P-17006	11/17/2003	Percocet 7.5325 and 10325 Update-2	ENDO-NY-00086312	ENDO-NY-00086312		
P-17039	9/16/2012	Re: CCI	WAGFLAG00093216	WAGFLAG00093218		
P-17156	2018	Salesforce Case_01195618	WAGCASF00598330	WAGCASF00598355		
P-17158	5/3/2013	43-5933267; U.S. Department of Justice DEA Report of Investigation	DEA-T3CC-00014159	DEA-T3CC-00014159		
P-17159	10/12/2012	Conference Call re Opposing the Rescheduling of Hydrocodone Products	PPLP004308925	PPLP004308926		
P-17161	12/2/2019	Rx Fulfillment Research Report Presentation research report v6 presentation	TCS00000396	TCS00000452		
P-17162	4/16/2018	FW: incident at store 783	WAGCASF00046090	WAGCASF00046096		
P-17163	1/6/2013	December 2012 Controlled Substances Sample Report	WAGFLAG00000003	WAGFLAG000000016		
P-17164	1/9/2013	Pharmacist Index 01-09-13.xlsx	WAGFLAG00012325	WAGFLAG00012325		
P-17165	12/26/2012	Re: 'Pill Mill' Crackdown Sets Off Rush - The Wall Street Journal.	WAGFLAG00016495	WAGFLAG00016497		

P-17166	8/8/2013	Melbourne - Rx Snapshot	WAGFLAG00027531	WAGFLAG00027532		
P-17168	6/14/2017	RE: Questions from pharmacist on GFD opportunity report	WAGMDL00000912	WAGMDL00000915		
P-17169	11/1/2013	FW: Rx Integrity - Southern Division Conference Call/Webinar; Pharmacist GFD Coaching Opportunities	WAGMDL00021304	WAGMDL00021328		
P-17170	9/11/2015	Rx Integrity Process Summaries	WAGMDL00037093	WAGMDL00037094		
P-17171	9/2/2014	HC Rescheduling	WAGMDL00053719	WAGMDL00053723		
P-17172	2/16/2013	Re: DEA Vegas Pilot; Las Vegas Market Comments on Target Drug Good Faith Dispensing; TD GFD V2 checklist_FINAL; Target Drug Good Faith Dispensing Policy V2[1]	WAGMDL00066740	WAGMDL00066747		
P-17173	10/26/2016	FW: GFD policy clarification	WAGMDL00093658	WAGMDL00093659		
P-17174	9/11/2013	FW: DEA Working Group Conference Call - August 28 at 4:00 p.m.  NACDS Corresponding Responsibility (DRAFT)x	WAGMDL00237364	WAGMDL00237373		
P-17175	1/11/2017	RE: RHD Deck FINAL  TribuneRHD Presentation FINAL	WAGMDL00250893	WAGMDL00250900		
P-17176	5/8/2017	Naloxone and GFD/TDGF for HCS Toolkit; TDGF October 2017; GFD May 2017 version; national_tdgfd_policy_10.2; naloxone_dispensing_policy; naloxone patient handout 07122016; naloxone_order_procedures_update_v3; naloxone_faqs_update	WAGMDL00258020	WAGMDL00258045		
P-17177	4/9/2013	National TD GFD Compass Communication	WAGMDL00316360	WAGMDL00316361		
P-17178	5/24/2012	RE: Controlled Substance Order Override Form	WAGMDL00325262	WAGMDL00325262		
P-17179	9/8/2010	Resp't 297 - Email Re. Mt. Vernon DEA Audit	WAGMDL00387641	WAGMDL00387641		
P-17180	5/22/2015	Pharmaceutical Integrity June BCI questions v2x	WAGMDL00487576	WAGMDL00487576		
P-17181	8/31/2015	"Compliance with Compassion"	WAGMDL00492867	WAGMDL00492887		
P-17182	12/13/2011	Ohio Automated Rx Reporting System	WAGMDL00580502	WAGMDL00580504		
P-17183	9/1/2013	FW: Fiscal 2013 - Store Audit Results - Report Issued February 28, 2014; FY13 Store Audit Report 2_28_14_FINAL	WAGMDL00580669	WAGMDL00580691		
P-17184	4/1/2014	FW: Follow-up on DEA takeback day	WAGMDL00590913	WAGMDL00590956		
P-17185	1/17/2013	DEA update Jan2013	WAGMDL00707642	WAGMDL00707653		
P-17186	9/30/2013	Good Faith Dispensing Conf Call 9-30-13	WAGMDL00708555	WAGMDL00708556		
P-17187	9/13/2012	ORDER TO SHOW CAUSE AND IMMEDIATE SUSPENSION OF REGISTRATION	WAGMDL00709398	WAGMDL00709411		
P-17188	4/16/2013	Walgreens National TD-GFD Policy (Updated FAQs); NATIONAL TARGET DRUG (TD) GOOD FAITH DISPENSING (GFD) FAQs	WAGMDL00744586	WAGMDL00744591		
P-17189	12/7/2012	Gov't 031 - 2012 Oxy 30mg Purchases Exceeding 2012 Trigger	WAGMDL00760271	WAGMDL00760293		
P-17190	3/15/2011	Gov't 046 - Oviedo Police Letters	WAGMDL00760560	WAGMDL00760575		
P-17191	10/26/2011	Gov't 047 - Oviedo Walgreens Arrests Presented to Walgreens.	WAGMDL00760576	WAGMDL00760576		
P-17192	12/3/2012	Gov't 048 - Oviedo Surveillance Stats Presented to Walgreens	WAGMDL00760577	WAGMDL00760578		
P-17193	11/27/2012	Resp't 239-A - RxSchool.com - The Pharmacist's Role	WAGMDL00766952	WAGMDL00766954		
P-17194	1/28/2013	Updated Top 500 Store Potential Risk Index; Oxycodone Fill Denied Complaints By Operation	WAGMDL00774516	WAGMDL00774517		
P-17195	6/26/2013	DEA Timeline	WAGMDL00778492	WAGMDL00778493		
P-17196	1/26/2013	FW: Updated GFD Filing Procedures	WAGMDL00781245	WAGMDL00781248		
P-17197	11/11/2015	Pharmacy Standard Operating Procedures (SOPs) – Drug Utilization Review (DUR); Performing a Drug Utilization Review (DUR)	WAGMDL00792693	WAGMDL00792703		
P-17198	8/18/2020	Suspicious Order Report	WAGMDL00852039	WAGMDL00852039		
P-17199	11/27/2012	Re: Payroll Concerns	WAGMDL00862246	WAGMDL00862250		
P-17200	2/19/2020	Compliance Budget Summary	WAGMDL00864374	WAGMDL00864392		
P-17201	12/19/2012	GFD - Store Walk and Key Initiative for Jan	WAGMDL00871295	WAGMDL00871295		
P-17202	4/27/2011	Fw: Pharmacy Renewal updated deck; Pharmacy Renewal V14.2 04272011 DRAFT	WAGMDL00883946	WAGMDL00883995		
P-17203	5/11/2019	INFO: FW: Additional DF for 070119 RLT Call; This Policy Sets Forth Walgreens' Requirements Related to Prescription Product Dispensing Activities	WAGMDL00895339	WAGMDL00895370		



P-17204	5/11/2012	Final copies (and store checklist) from contingency planning (evening 5/10/12); Process Talking Points; DEA Contingency Plan; Final copies (and store checklist) from contingency planning (evening 5/10/12)	WAGMDL00897156	WAGMDL00897169		
P-17205	2/11/2013	RE: Training deployed dates	WAGMDL00912297	WAGMDL00912298		
P-17206	4/8/2013	Walgreens Policies and Procedures	WAGMDL00922999	WAGMDL00923132		
P-17207	8/8/2018	PDMP Integration Business Case_krw comments; Prescription Drug Monitoring Program Integration	WAGMDL00939067	WAGMDL00939074		
P-17208	3/19/2013	Top 500 Potential Risk Stores - Oxycodone - 3 months ending February 2013 Ohio Market	WAGMDL01068350	WAGMDL01068351		
P-17209	10/15/2013	RxIntegrity Videoconference - Update Pharmacist GFD Coaching Opportunities	WAGMDL01107122	WAGMDL01107145		
P-17210	6/18/2013	FW: GFD Site Announcement	WAGMDL01109033	WAGMDL01109034		
P-17211	12/29/2012	Fwd: SIMS Enhancement For Controlled Substance Orders	WAGMDL01109065	WAGMDL01109069		
P-17212	1/26/2020	RE: Discussion on Updated Personas and Research Findings	WAGMDL01109276	WAGMDL01109282		
P-17213	4/17/2013	Compass 4/17/13	WAGMDL01132111	WAGMDL01132118		
P-17214	1/28/2013	Good Faith Dispensing Policy - Drug Diversion Self-Education Module DLPm Role - GFD 1-2013x Director Kerlikowske Presentation	WAGMDL01132293	WAGMDL01132324		
P-17215	10/15/2012	Pharmacy Fill Denied Complaint trend report	WAGMDL01132853	WAGMDL01132855		
P-17216	1/5/2013	Re: GFD customer concerns	WAGMDL01166670	WAGMDL01166670		
P-17217	5/24/2013	FW: RXS Feedback Call Notes_5/24/13 - Please respond by June 27,2013; RXS Feedback Call Notes	WAGMDL01166881	WAGMDL01166884		
P-17218	5/12/2013	FW: OpsAdmin Weekly dashboard 5/8  Field Feedback - Pharmacy Managers n Current Challenges and Pain Points	WAGMDL01166990	WAGMDL01166995		
P-17219	12/13/2012	Executive Report: Nov 2012 Top 500 Potential Risk Stores - Oxycodone; Oxycodone Store Potential Risk Overview	WAGMDL01176292	WAGMDL01176293		
P-17220	1/14/2013	Heat Map Slides end of December 2012	WAGMDL01176413	WAGMDL01176425		
P-17221	12/13/2012	Top 500 Potential Store Index for Field Distribution: 3 mo end Nov 2012	WAGMDL01176484	WAGMDL01176485		
P-17222	11/27/2012	For Your Review: October Store Index Report; Top 500 Store Index	WAGMDL01176488	WAGMDL01176490		
P-17223	9/19/2012	Updated Reports for Aug 2012: Exec Summary Top 100 Potential Risk Stores; Store Potential Risk Index - end Aug 2012 - Exec Top 100	WAGMDL01176500	WAGMDL01176500		
P-17224	7/2/2012	Fw: Controlled Substance Program Exec Sum 7 2 12 Final; Controlled Substance Program Exec Sum 7 2 12 Final	WAGMDL01189805	WAGMDL01189807		
P-17225	6/17/2012	FW: Status Report -- Controlled Substances Program; Controlled Substance Program Exec Sum 6 18 12	WAGMDL01189978	WAGMDL01189980		
P-17226	11/21/2008	DEA Exhibit Review Perrysburg DC	WAGMDLPER00000313	WAGMDLPER00000313		
P-17227	12/15/2016	Hotel Notice - NACDS Policy Council; Are More Mistakes Happening at Pharmacies?; Pharmacies Miss Half of Dangerous Drug Combinations; Risks Inherent in Pharmacists' Workloads Earn Attention of Legislators; Reducing Regulatory Burdens Imposed by the Patent Protection and Affordable Care Act & Improving Healthcare Choices to Empower Patients; State Medicaid Activity and Status Chart; June Policy Council Meeting Agenda	WAGNMAG00009844	WAGNMAG00009910		
P-17228	2/27/2015	Good Faith Dispensing: Training Overdue	WAGNYNS00033695	WAGNYNS00033696		
P-17229	12/12/2012	Guidelines for Prescriber Comments	WAGNYNS00033698	WAGNYNS00033698		

P-17232	2000-2020	WAG Annual Report Composite Exhibit	WAGFLAG00082714 - WAGFLAG00082809; WAGMDL_T1_TX00000328 - WAGMDL_T1_TX00000344; WAGMDL_T1_TX00000392 - WAGMDL_T1_TX00000405; WAGMDL_T1_TX00002774 - WAGMDL_T1_TX00002806; WAGMDL_T1_TX00003549 - WAGMDL_T1_TX00003586; WAGMDL_T1_TX00010347 - WAGMDL_T1_TX00010497; WAGMDL_T1_TX00011607 - WAGMDL_T1_TX00011754; N/A	composite		
P-17236	5/5/2015	pharmacy_metadata (8)	WAGNMAG00053391	WAGNMAG00053392		
P-17237	3/8/2018	EDW Pharmacy Metadata 20171020	WAGMDL00790910	WAGMDL00790910		
P-17238	10/26/2012	FY2013 Goals are loaded in TMP	WAGFLAG00090568	WAGFLAG00090572		
P-17240	12/12/2011	OARRS letter to Ohio Pharmacists	WAGMDL00580508	WAGMDL00580508		
P-17242	12/10/2012	LP Market Tour/Roadshow	WAGMDL01132507	WAGMDL01132568		
P-17243	7/1/2021	Copy of ITProvided ZipCodes	WAGMDL01191401	WAGMDL01191401		
P-17244	1/7/2021	GFD2.0	WAGMDL01191402	WAGMDL01191457		
P-17245	7/9/2021	DUR Policies and Procedures	WAGMDL01191458	WAGMDL01191458		
P-17246	7/1/2020	Medispan Email	WAGMDL01191463	WAGMDL01191465		
P-17247	2/6/2017	WAG DUR Overview	WAGMDL01191469	WAGMDL01191489		
P-17249	7/28/2015	Orientation Combined Powerpoint PMP	WAGMDL00823234	WAGMDL00823272		
P-17250	2018	Internal Investigation Form: : IC1000823913	WAGCASF00314274	WAGCASF00314277		
P-17251	9/8/2014	District Report for week 9/1/14 to 9/7/14; Consumer Relations District Report	WAGFLAG00081129	WAGFLAG00081130		
P-17252	3/16/2015	RE: Insurance/Property Loss Claim – Approved	WAGNMAG00083194	WAGNMAG00083207		
P-17253	4/26/2016	One Box Presentation; R16 Driving Operational Efficiency in Pharmacy; R16 RX Skills - 10 Questions; Region 16 HCS Strategy Session	WAGMDL00797936	WAGMDL00797993		
P-17254	2/19/2018	RE: incident at store 7832	WAGCASF00086509	WAGCASF00086517		
P-17256	9/4/2018	RE: Review:Respond: YAGAR Concern Reporting Party	WAGCASF00598808	WAGCASF00598810		
P-17257	9/11/2018	Re: Employee Relations - R. Yagar Follow-Up	WAGCASF00598811	WAGCASF00598812		
P-17258	6/12/2018	Store #7832 Update	WAGCASF00599010	WAGCASF00599011		
P-17259	11/7/2019	RE: The Washington Post Article Has Posted	WAGMDL00998827	WAGMDL00998833		
P-17260	N/A	GFD refusal to fill	WAGMDL01090486	WAGMDL01090486		
P-17261	9/11/2012	Pharmacy Customer Needs Segmentation; 091112 Pharmacy Sementation	WAGFLAG00630300	WAGFLAG00630307		
P-17262	2/20/2014	FW: Review Retention and Acquisition Insights	WAGFLAG02022668	WAGFLAG02022689		
P-17263	2/16/2012	January FY12: Pharmacy CSAT Module	WAGFLAG00092711	WAGFLAG00092785		
P-17264	10/1/2013	Brian's ppt's for meeting Thursday	WAGMDL01109353	WAGMDL01109470		
P-17265	11/30/2011	Customer Sementation and Differentiation Pilot	WAGMDL00974409 WAGMDL00974765	WAGMDL00974765 WAGMDL00974794	WAGMDL00974765 - WAGMDL00974765	
P-17266	11/4/2013	Qualitative Assessment: Retail Pharmacists Impressions of Recent Opioid-dispensing Policies	PPLPC019000856325	PPLPC019000856325		
P-17267	3/21/2017	RE: NPS scoring	WAGMDL00112746	WAGMDL00112747		
P-17284	2/4/2014	FW: Opana.com - Prescriber Resources (ACTION REQUIRED)	ENDO-CHI_LIT-00016986	ENDO-CHI_LIT-00017002		
P-17301	11/23/2009	FW Opana ER RiskMAP Update Report - Comments Due December 2	ENDO-CHI_LIT-00069072	ENDO-CHI_LIT-00069386		
P-17302	2/27/2014	Understand Pain Opioid Analgesics	ENDO-CHI_LIT-00084048	ENDO-CHI_LIT-00084059		
P-17303	2/27/2014	FW: Account Plans	ENDO-CHI_LIT-00088726	ENDO-CHI_LIT-00088758		
P-17304	10/19/2007	Percocet 7.5325 and 10325 Update	ENDO-CHI_LIT-00780239	ENDO-CHI_LIT-00780240		
P-17306	4/12/2021	2021.04.12_Report_Veeva (MSL)	ENDO-CHI_LIT-DATA-00000009	ENDO-CHI_LIT-DATA-00000009		
P-17322	6/20/2001	Letter from R. Reder to CVS Pharmacists re: "How to Stop Drug Diversion & Protect Your Pharmacy."	PPLPC008000017909	PPLPC008000017909		
P-17322a	2001	How to Stop Drug Diversion and Protect Your Pharmacy	PKY180282111	PKY180282111		

P-17382	6/11/2001	Purdue Memo To Jim Lang From Steve Seid Re: NACDS Meeting Summary, June 7, 2001	PKY181081066	PKY181081067		
P-17384	9/1/2002	National Association of Chain Drug Stores, Chain Pharmacist Practice Memo, Volume 6, Number 9 This Month's Briefing on Key Practice and Operational Concerns	PKY181291507	PKY181291512		
P-17386	1/21/2013	McKinsey modified Pharmacy presentation by Seid and Must v2	PPLP004465011	PPLP004465011		
P-17387	6/3/2013	Russ - Walgreens 053013	PPLP004471589	PPLP004471590		
P-17388	2/5/2010	FDA Docket Recommendations PCF REMS Task Force	ENDO-OPIOID MDL-02293305	ENDO-OPIOID MDL-02293319		
P-17389	4/10/2015	HIV Outbreak in Southern Indiana	ENDO-OPIOID MDL-01188455	ENDO-OPIOID MDL-01188458		
P-17391	1/21/2014	Inflexxion 3Q2013 report	ENDO-OPIOID MDL-01320650	ENDO-OPIOID MDL-01320740		
P-17402	11/19/2015	FW: Lit references regarding Heroin abuse	ENDO-OPIOID MDL-01555414	ENDO-OPIOID MDL-01555455		
P-17409	1997	AAPM and APS - The Use of Opioids for the Treatment of Chronic Pain	PDD1501721211	PDD1501721214		
P-17427	11/17/2003	RE: NIPC OPIOID Cinci Program - Fantastic Feedback	ENDO-OPIOID MDL-01766783	ENDO-OPIOID MDL-01766784		
P-17428	8/11/2014	RE: Call with Teleflex (Tara, Steve, Nancy, Donna, Bob) (Key Doc is Cost-Effectiveness of Distributing Naloxone to Heroin Users for Lay Overdose Reversal)	ENDO-OPIOID MDL-01832015	ENDO-OPIOID MDL-01832113		
P-17429	6/29/2010	RE WA CA State Issues and Some Great News from Kaiser	ENDO-OPIOID MDL-02276421	ENDO-OPIOID MDL-02276423		
P-17430	4/3/2007	RE: Agenda & Lunch RSVP for Endo/AAPMR Meeting on Wednesday	ENDO-OPIOID MDL-02284253	ENDO-OPIOID MDL-02284256		
P-17431	3/1/2016	Email between Munroe and Jory re CDC call on opioid guidelines cancelled	ENDO-OPIOID MDL-02289179	ENDO-OPIOID MDL-02289179		
P-17447	3/6/2013	Opana ER INTAC Sell Sheet	ENDO-OPIOID MDL-02365119	ENDO-OPIOID MDL-02365120		
P-17448	5/1/2015	Re: Opana ER - Communications Update	ENDO-OPIOID MDL-02676735	ENDO-OPIOID MDL-02676737		
P-17449	4/18/2016	Re: FOR YOUR REVIEW Announcement- NEW PROMOTIONAL TOOL	ENDO-OPIOID MDL-02716741	ENDO-OPIOID MDL-02716743		
P-17451	6/14/2000	Endo Organizational Announcement of employment of Eric Vandel coming to Endo from Schering-Plough	ENDO-OPIOID MDL-02877121	ENDO-OPIOID MDL-02877121		
P-17452	5/12/2016	CORP-04628 ER LA OA REMS Final	ENDO-OPIOID MDL-02924107	ENDO-OPIOID MDL-02924111		
P-17453	6/3/2002	May 29 2002 Percocet Surfer complaint	ENDO-OPIOID MDL-03001718	ENDO-OPIOID MDL-03001720		
P-17456	2/2/2011	CLBP and treatment docs Part 1 of 2	ENDO-OPIOID MDL-03862729	ENDO-OPIOID MDL-03863481		
P-17459	1/24/2008	RE: Purdue new items	PPLPC004000146529	PPLPC004000146531		
P-17465	5/12/2004	C&W Presentation 5 14 1 PPT	ENDO-OPIOID MDL-04137791	ENDO-OPIOID MDL-04137791		
P-17475	6/4/2015	RE: TIME story re: pain products	ENDO-OPIOID MDL-07060316	ENDO-OPIOID MDL-07060321		
P-17476	3/30/2009	All TE Interactions	ENDO-OPIOID MDL-07397125	ENDO-OPIOID MDL-07397126		
P-17480	3/23/2012	Keyword News: [painkillers]	ENDO-OPIOID MDL-07461654	ENDO-OPIOID MDL-07461655		
P-17482	3/28/2007	RE: Finalized List of Mod-to-Sev CP TE's Needed by Robert/Peter	ENDO-OPIOID MDL-07470034	ENDO-OPIOID MDL-07470036		
P-17486	4/19/2013	Oxycontin Sale and Inventory Analysis Findings	PPLPC004000354499	PPLPC004000354500		
P-17487	7/30/2018	CT1 Anda Initial Response to Plaintiff's 1st Set Interrogatories	N/A	N/A		
P-17488	7/31/2018	CT1 Anda Initial Response to Plaintiff's 1st Combined Request for Production	N/A	N/A		
P-17490	9/11/2018	CT1 Anda 1st Supplemental Response to Plaintiff's 1st Set of Interrogatories Nos. 2 & 26	N/A	N/A		
P-17491	9/14/2018	CT1 Anda 2nd Supplemental Response to Plaintiff's 1st Set of Interrogatories	N/A	N/A		
P-17492	11/30/2018	CT1 Anda 1st Supplemental Response to Plaintiff's 1st Request for Production	N/A	N/A		
P-17493	11/30/2018	CT1 Anda Supplemental Response to Plaintiff's 1st Combined Discovery Requests to Distributor Defendants	N/A	N/A		
P-17494	1/17/2019	CT1 Anda 2nd Supplemental Response to Plaintiff's 1st Combined Discovery Requests to Distributor Defendants	N/A	N/A		
P-17495	4/12/2019	CT1 Anda 3rd Supplemental Response to Plaintiff's 1st Combined Discovery Requests to Distributor Defendants	N/A	N/A		
P-17496	4/12/2019	CT1 Exhibit A to Anda 3rd Supplemental Response to Plaintiff's 1st Combined Discovery Requests to Distributor Defendants	N/A	N/A		
P-17497	4/12/2019	CT1 Exhibit B to Anda 3rd Supplemental Response to Plaintiff's 1st Combined Discovery Requests to Distributor Defendants	N/A	N/A		
P-17498	4/12/2019	CT1 Exhibit C to Anda 3rd Supplemental Response to Plaintiff's 1st Combined Discovery Requests to Distributor Defendants	N/A	N/A		

P-17499	4/12/2019	CT1 Exhibit D to Anda 3rd Supplemental Response to Plaintiff's 1st Combined Discovery Requests to Distributor Defendants	N/A	N/A		
P-17500	8/29/2018	CT1 Annotated w SM Cohen's rulings. Anda Response to First and Second 30(b)(6) Notices	N/A	N/A		
P-17501	1/11/2019	CT1 Anda's First Sup Response to Plaintiff's' First and Second 30(b)(6) Notices	N/A	N/A		
P-17502	1/19/2021	CT4 Verified Responses to Plaintiff's' First Set of Interrogatories to Anda	N/A	N/A		
P-17503	1/19/2021	CT4 Appendix A to Verified Responses to Plaintiff's' First Set of Interrogatories to Anda	N/A	N/A		
P-17504	2/18/2021	CT4 Anda's Verified First Supplemental Responses to Plaintiff's' First Set of Interrogatories to Anda	N/A	N/A		
P-17505	2/18/2021	CT4 Exhibit A to Anda's Verified First Supplemental Responses to Plaintiff's' First Set of Interrogatories to Anda	N/A	N/A		
P-17506	2/18/2021	CT4 Exhibit B to Anda's Verified First Supplemental Responses to Plaintiff's' First Set of Interrogatories to Anda	N/A	N/A		
P-17507	3/4/2021	CT4 Anda Verified Responses to Plaintiff's' First Set of Interrogatories to All Non-Severed Defendants	N/A	N/A		
P-17509	5/14/2021	CT4 Anda Verified Responses to Plaintiff's' Second Set of Interrogatories to Anda	N/A	N/A		
P-17511	5/14/2021	CT4 Appendix B to Anda Verified Responses to Plaintiff's' Second Set of Interrogatories to Anda	N/A	N/A		
P-17512	5/24/2021	CT4 Anda Verified Second Supplemental Responses to Plaintiff's' First Set of Interrogatories to Anda	N/A	N/A		
P-17513	11/12/2021	CT4 Appendix A to Anda Verified Responses to Plaintiff's' Third Set of Interrogatories to Anda	N/A	N/A		
P-17514	11/12/2021	CT4 Anda Verified Responses to Plaintiff's' Second Set of Interrogatories to All Non-Severed Defendants	N/A	N/A		
P-17515	11/12/2021	CT4 Anda Verified Responses to Plaintiff's' Third Set of Interrogatories to Anda	N/A	N/A		
P-17516	6/23/2005	Slide I promised you on NIPC	ENDO-OPIOID_MDL-07497961	ENDO-OPIOID_MDL-07497962		
P-17517	6/26/2006	FW: Notes on Completing the Meeting Report	ENDO-OPIOID_MDL-07501304	ENDO-OPIOID_MDL-07501306		
P-17518	10/27/2006	FW: IMPORTANT- Walgreens stores that have stocked Opana	ENDO-OPIOID_MDL-07502819	ENDO-OPIOID_MDL-07502821		
P-17522	5/20/2013	Thomson resignation email	ENDO_WVAG-00006826	ENDO_WVAG-00006827		
P-17530	10/31/2005	Tormo Email to Thomson Re: Opioid Abuse Resistance Conf.	ENDO-OPIOID_MDL-00379668	ENDO-OPIOID_MDL-00379669		
P-17531	4/17/2008	Email with APS board member lists	JAN-MS-02533819	JAN-MS-02533844		
P-17532	5/1/2012	Birner to Thomson re: HOPE team metrics Attachment to 5, MSL outreach spreadsheet	ENDO-OPIOID_MDL-08428188	ENDO-OPIOID_MDL-08428190		
P-17533	8/21/2006	Email regarding methadone and Opana ER	ENDO_SF-00155079	ENDO_SF-00155081		
P-17534	4/10/2007	Thomson email re: Argoff and letter to editor re new dose increase data for CP	ENDO_FLAG-00559665	ENDO_FLAG-00559666		
P-17535	6/11/2009	Thomson email re: Opana slide bank project, Opana slide deck attachment to Thomson email	ENDO-CHI_LIT-00033753	ENDO-CHI_LIT-00033755		
P-17536	9/2/2009	Thomson email forwarding her edits to oxymorphone chapter	ENDO-OPIOID_MDL-08391500	ENDO-OPIOID_MDL-08391513		
P-17623	9/9/2014	20140909 Purdue BDC CMD v2.6	PPLPC016000255302	PPLPC016000255303		
P-17630	8/27/2009	Thomson email update on KOL abuse questions	EPI001050014	EPI001050014		
P-17631	8/26/2009	Kitlinski congratulates Thomson on oxymorphone chapter	ENDO-CHI_LIT-00249152	ENDO-CHI_LIT-00249152		
P-17638	8/26/2009	Thomson credits Barto for help with KOL abuse questions	ENDO-OPIOID_MDL-08390897	ENDO-OPIOID_MDL-08390897		
P-17639	2/2/2009	Thomson emails Wieman re oxymorphone history	ENDO-OPIOID_MDL-06246556	ENDO-OPIOID_MDL-06246557		
P-17640	10/15/2008	Thomson email re Mainecare presentation	ENDO-OPIOID_MDL-01765272	ENDO-OPIOID_MDL-01765273		
P-17641	2/22/2013	Thomson emails NASCSA meeting notes	END00648257	END00648263		
P-17642	5/10/2013	Thomson emails APS meeting notes	ENDO-OPIOID_MDL-02478040	ENDO-OPIOID_MDL-02478043		
P-17644	11/12/2008	Thomson email regarding Opana on Maine Care	ENDO_SF-00430854	ENDO_SF-00430856		
P-17701	10/10/2006	Thomson email re using PROMISE AND EDU Brochures in WV	ENDO_FLAG-01040488	ENDO_FLAG-01040489		
P-17702	5/15/2006	Thomson email re list of patient groups in key abuse states	ENDO_OPIOID_MDL-07500772	ENDO-OPIOID_MDL-07500773		
P-17705	12/7/2009	3rd Annual Anda Supply Chain Symposium, April 23, 2010	Anda Opioids MDL 0000631333	Anda Opioids MDL 0000631334		
P-17706	N/A	RSVP Statistics; Breakdown of attendees at Golf Event	N/A	N/A		
P-17707	N/A	Anda Customer Background Checklist	Anda Opioids AL DCH 0057819	Anda Opioids AL DCH 0057819		
P-17708	9/7/2016	RE: Genoa Oxycodone limit	Anda Opioids MDL 0000332389	Anda Opioids MDL 0000332391		

P-17709	11/19/2012	RE: Scanned image from Anda Sales PR1- cUST 154132 SAFEWAY PHARMACY	Anda_Opioids_CA_SF_0075015	Anda_Opioids_CA_SF_0075016		
P-17710	4/27/2015	RE: Buprenorphine for one of our locations in Indiana	Anda_Opioids_CA_SF_0038489	Anda_Opioids_CA_SF_0038491		
P-17711	1/8/2013	FW: Prime CII's	Anda_Opioids_MDL_0000421533	Anda_Opioids_MDL_0000421534		
P-17712	6/1/2004	Partners Against Pain Website	N/A	N/A		
P-17713	4/17/2007	Spring Promo 2007	Anda_Opioids_MDL_0000611284	Anda_Opioids_MDL_0000611285		
P-17714	11/7/2007	Re: Approval - Control Increase - Mom's/Specialty Pharmacies	Anda_Opioids_CA_SF_0075375	Anda_Opioids_CA_SF_0075375		
P-17715	7/12/2014	Pain Care Forum microsite on Drug Store News	N/A	N/A		
P-17716	N/A	Customer List and Information	N/A	N/A		
P-17717	9/17/2008	Fw:Moms Controls limits	Anda_Opioids_MDL_0000273278	Anda_Opioids_MDL_0000273278		
P-17718	11/11/2008	Fw: Moms Oxy	Anda_Opioids_MDL_0000155577	Anda_Opioids_MDL_0000155577		
P-17719	2/2/2011	RE: Moms New Account	Anda_Opioids_CA_SF_0017602	Anda_Opioids_CA_SF_0017605		
P-17720	1/13/2011	Controlled Meds increase- Please review	Anda_Opioids_MDL_0000133636	Anda_Opioids_MDL_0000133638		
P-17721	9/10/2012	RE: THRESHOLD INCREASE (QCP)	Anda_Opioids_MDL_0000132685	Anda_Opioids_MDL_0000132686		
P-17722	8/10/2007	Re: Controls Usage	Anda_Opioids_MDL_0000275456	Anda_Opioids_MDL_0000275458		
P-17723	8/15/2007	Re: Fw: Acct 127978	Anda_Opioids_MDL_0000275283	Anda_Opioids_MDL_0000275284		
P-17724	5/30/2018	Suspicious Order - Manufacturer Perspective	Anda_Opioids_MDL_0000650347	Anda_Opioids_MDL_0000650347		
P-17725	10/18/2017	RE: new acct # 507203	Anda_Opioids_MDL_0001181291	Anda_Opioids_MDL_0001181295		
P-17726	10/18/2017	Complete Care Compounding Pharmacy Current Drug Usage Report	Anda_Opioids_MDL_0001181296	Anda_Opioids_MDL_0001181298		
P-17727	8/3/2007	Fw: Control Limit Letter - Final Final Draft	Anda_Opioids_MDL_0001155100	Anda_Opioids_MDL_0001155108		
P-17728	8/10/2007	Re: Suggested Limit Increases on VIP Accounts	Anda_Opioids_MDL_0001155043	Anda_Opioids_MDL_0001155046		
P-17729	4/27/2012	Oxy Review - Data Request - Phase 2 (VIP & WC)	Anda_Opioids_MDL_0001155827	Anda_Opioids_MDL_0001155828		
P-17731	6/12/2012	Here are the printed material for your managers today	Anda_Opioids_MDL_0001155821	Anda_Opioids_MDL_0001155823		
P-17732	9/19/2012	PPT	Anda_Opioids_MDL_0001155809	Anda_Opioids_MDL_0001155814		
P-17733	8/15/2007	Re: Urgent Approval	Anda_Opioids_MDL_0000275269	Anda_Opioids_MDL_0000275270		
P-17734	12/22/2009	Re: Urgent Approval	Anda_Opioids_MDL_0000077705	Anda_Opioids_MDL_0000077706		
P-17735	1/6/2010	Re: Account #5310	Anda_Opioids_MDL_0000077697	Anda_Opioids_MDL_0000077699		
P-17736	1/18/2010	Re: Urgent Approval	Anda_Opioids_MDL_0001154404	Anda_Opioids_MDL_0001154405		
P-17737	8/28/2007	Fw: Heads-up on a DEA Media Briefing	Anda_Opioids_MDL_0001155040	Anda_Opioids_MDL_0001155041		
P-17738	5/9/2018	FW: 273810	Anda_Opioids_MDL_0001162261	Anda_Opioids_MDL_0001162264		
P-17739	5/9/2018	273810	Anda_Opioids_MDL_0001149945	Anda_Opioids_MDL_0001149945		
P-17740	8/13/2018	RE: Suspicious Orders	Anda_Opioids_PA_0046875	Anda_Opioids_PA_0046877		
P-17741	11/16/2018	Anda Updated List of Reportable Customers as of November 16, 2019	Anda_Opioids_CA_SF_0051926	Anda_Opioids_CA_SF_0051927		
P-17742	5/29/2014	Johnson "Chronic Pain Sufferers Advocate" on Drug Store News microsite	N/A	N/A		
P-17743	6/18/2010	FW: Sales for accounts cut off from controls	Anda_Opioids_MDL_0001155094	Anda_Opioids_MDL_0001155096		
P-17744	8/26/2014	SOP 040-Suspicious Order Monitoring System	Anda_Opioids_MDL_0000140495	Anda_Opioids_MDL_0000140497		
P-17745	8/21/2014	SOP 040-Suspicious Order Monitoring Monitoring System	Anda_Opioids_MDL_0000527936	Anda_Opioids_MDL_0000527938		
P-17747	2/26/2018	SOP 065-Description of Anda's SOM Statistical Model	Anda_Opioids_MDL_0000144384	Anda_Opioids_MDL_0000144397		
P-17749	10/11/2008	Email re prescription abuse in WV	ENDO_FLAG-00998849	ENDO_FLAG-00998850		
P-17751	5/25/2010	FW: A Message from Al Paonessa III - Anda Organizational Changes & Promotions	Anda_Opioids_MDL_0000079643	Anda_Opioids_MDL_0000079647		
P-17752	5/10/2016	Pharmaceuticals Purchasing Agreement for Virtual Warehouse Program	Anda_Opioids_MDL_0000648116	Anda_Opioids_MDL_0000648134		
P-17753	8/24/2015	RE: Oxycodone ER (AG) - Floors TBC Publix	Anda_Opioids_MDL_0001147748	Anda_Opioids_MDL_0001147751		
P-17754	2/23/2016	RE: WALMART DC (Oxy Promo)	Anda_Opioids_MDL_0001147886	Anda_Opioids_MDL_0001147888		
P-17755	8/4/2009	Fw: July Marketing Driver	Anda_Opioids_MDL_0000619359	Anda_Opioids_MDL_0000619362		
P-17756	12/1/2009	Re: Fw: PRODUCT UPDATE: Re-launch of Generic Oxycontin CR (Oxycodone CR 10, 20, 40, 80mg) from Actavis	Anda_Opioids_MDL_0001142458	Anda_Opioids_MDL_0001142468		
P-17757	10/29/2013	MOVE OUT SPECIALS - TODAY ONLY	Anda_Opioids_MDL_0001130730	Anda_Opioids_MDL_0001130731		
P-17758	12/11/2013	SATURDAY SPECIALS - Take Advantage of these GREAT SPECIALS	Anda_Opioids_MDL_0001130725	Anda_Opioids_MDL_0001130726		
P-17759	8/20/2013	Fw: Schedules August - SOX Testing Anda	Anda_Opioids_MDL_0001145955	Anda_Opioids_MDL_0001146079		
P-17760	6/18/2010	Sales for accounts cut off from controls	Anda_Opioids_MDL_0000078676	Anda_Opioids_MDL_0000078678		
P-17761	10/20/2014	September Internal PMs Review (10/20/14)	Anda_Opioids_MDL_0001143888	Anda_Opioids_MDL_0001143894		
P-17762	N/A	Anda Leadership Meeting 9/18/12 PowerPoint	Anda_Opioids_CA_SF_0074552	Anda_Opioids_CA_SF_0074553		
P-17763	11/15/2007	Re: Control Limit Increases	Anda_Opioids_MDL_0000274275	Anda_Opioids_MDL_0000274276		
P-17764	10/15/2008	Re: Please provide input	Anda_Opioids_MDL_0000273197	Anda_Opioids_MDL_0000273199		

P-17765	2/25/2010	RE: Okeechobee Drug	Anda_Opioids_MDL_0001142404	Anda_Opioids_MDL_0001142405		
P-17766	8/3/2010	FW: Kum Tulsinarine - QA Escalation	Anda_Opioids_MDL_0000104333	Anda_Opioids_MDL_0000104333		
P-17767	4/10/2015	RE: Reports; Sales Reporting Package-Mar 2015.xlsm	Anda_Opioids_MDL_0001142871	Anda_Opioids_MDL_0001142872		
P-17769	9/15/2010	Leadership & Ops Committee Minutes - September 14th, 2010	Anda_Opioids_MDL_0000079528	Anda_Opioids_MDL_0000079533		
P-17770	3/10/2017	Kimberly Poropat Severance Notification and Benefits Summary	N/A	N/A		
P-17771	3/10/2017	Kimberly Poropat signed Separation Agreement and General Release	N/A	N/A		
P-17772	N/A	Exhibits A-D; Kimberly Poropat	N/A	N/A		
P-17773	1/11/2019	Anda's First Supp. Obj. and Resp. to Pl.'s First and Second NOD re 30(b)(6)	N/A	N/A		
P-17774	7/26/2017	Distributor Initiative Briefing with Anda	US-DEA-00000165	US-DEA-00000167		
P-17775	11/18/2013	CSOS and Data Detail	Anda_Opioids_MDL_0000561271	Anda_Opioids_MDL_0000561294		
P-17776	1/21/2008	RE DEA Request - Response	ALLERGAN_MDL_03954195	ALLERGAN_MDL_03954197		
P-17777	11/30/2012	WAGS Report for Stores	Anda_Opioids_MDL_0000647306	Anda_Opioids_MDL_0000647307		
P-17778	10/19/2015	FW: Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_MDL_0000587083	Anda_Opioids_MDL_0000587084		
P-17779	10/22/2015	RE: Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_MDL_0000586782	Anda_Opioids_MDL_0000586786		
P-17780	10/26/2005	Suspicious Orders Week Ending 10-23-05	Anda_Opioids_MDL_0000271909	Anda_Opioids_MDL_0000271911		
P-17781	11/21/2005	Suspicious Orders Week Ending 11-20-05	Anda_Opioids_MDL_0000271903	Anda_Opioids_MDL_0000271905		
P-17782	11/28/2004	Suspicious Orders Week Ending 11-27-05	Anda_Opioids_MDL_0000271900	Anda_Opioids_MDL_0000271902		
P-17783	12/6/2005	Suspicious Orders Week Ending 12-04-05	Anda_Opioids_MDL_0000271897	Anda_Opioids_MDL_0000271899		
P-17784	12/12/2005	Suspicious Orders Week Ending 12-11-05	Anda_Opioids_MDL_0000271892	Anda_Opioids_MDL_0000271894		
P-17785	12/19/2005	Suspicious Orders Week Ending 12-18-05	Anda_Opioids_MDL_0000271889	Anda_Opioids_MDL_0000271891		
P-17786	12/26/2005	Suspicious Orders Week Ending 12-15-05	Anda_Opioids_MDL_0000271886	Anda_Opioids_MDL_0000271888		
P-17787	1/2/2006	Suspicious Orders Week Ending 1-1-06	Anda_Opioids_MDL_0000271883	Anda_Opioids_MDL_0000271885		
P-17788	1/9/2006	Suspicious Orders Week Ending 1-8-06	Anda_Opioids_MDL_0000271880	Anda_Opioids_MDL_0000271882		
P-17789	1/16/2006	Suspicious Orders Week Ending 1-15-06	Anda_Opioids_MDL_0000271875	Anda_Opioids_MDL_0000271877		
P-17790	12/26/2006	Suspicious Orders Week Ending 12-24-06	Anda_Opioids_MDL_0000271711	Anda_Opioids_MDL_0000271713		
P-17791	2/13/2006	Suspicious Orders Week Ending 2-12-06	Anda_Opioids_MDL_0000271858	Anda_Opioids_MDL_0000271860		
P-17792	2/20/2006	Suspicious Orders Week Ending 2-19-06	Anda_Opioids_MDL_0000271855	Anda_Opioids_MDL_0000271857		
P-17793	2/27/2006	Suspicious Orders Week Ending 2-26-06	Anda_Opioids_MDL_0000271852	Anda_Opioids_MDL_0000271854		
P-17794	3/7/2006	Suspicious Orders Week Ending 3-5-06	Anda_Opioids_MDL_0000271849	Anda_Opioids_MDL_0000271851		
P-17795	3/14/2006	Suspicious Orders Week Ending 3-12-06	Anda_Opioids_MDL_0000271844	Anda_Opioids_MDL_0000271846		
P-17796	3/20/2006	Suspicious Orders Week Ending 3-19-06	Anda_Opioids_MDL_0000271841	Anda_Opioids_MDL_0000271843		
P-17797	3/27/2006	Suspicious Orders Week Ending 3-26-06	Anda_Opioids_MDL_0000271838	Anda_Opioids_MDL_0000271840		
P-17798	4/3/2006	Suspicious Orders Week Ending 4-2-06	Anda_Opioids_MDL_0000271835	Anda_Opioids_MDL_0000271837		
P-17799	4/10/2006	Suspicious Orders Week Ending 4-9-06	Anda_Opioids_MDL_0000271830	Anda_Opioids_MDL_0000271832		
P-17800	4/17/2006	Suspicious Orders Week Ending 4-16-06	Anda_Opioids_MDL_0000153415	Anda_Opioids_MDL_0000153417		
P-17801	4/24/2006	Suspicious Orders Week Ending 4-23-06	Anda_Opioids_MDL_0000271827	Anda_Opioids_MDL_0000271829		
P-17802	5/1/2006	Suspicious Orders Week Ending 4-30-06	Anda_Opioids_MDL_0000271824	Anda_Opioids_MDL_0000271826		
P-17803	11/6/2006	Suspicious Orders Week Ending 11-5-06	Anda_Opioids_MDL_0000271734	Anda_Opioids_MDL_0000271736		
P-17805	5/8/2006	Suspicious Orders Week Ending 5-08-06	Anda_Opioids_MDL_0000271819	Anda_Opioids_MDL_0000271821		
P-17806	6/12/2006	Suspicious Orders Week Ending 6-11-06	Anda_Opioids_MDL_0000271804	Anda_Opioids_MDL_0000271806		
P-17808	6/19/2006	Suspicious Orders Week Ending 6-18-06	Anda_Opioids_MDL_0000271799	Anda_Opioids_MDL_0000271801		
P-17810	6/27/2006	Suspicious Orders Week Ending 6-25-06	Anda_Opioids_MDL_0000271796	Anda_Opioids_MDL_0000271798		
P-17813	7/10/2006	Suspicious Orders Week Ending 7-09-06	Anda_Opioids_MDL_0000271788	Anda_Opioids_MDL_0000271790		
P-17814	7/17/2006	Suspicious Orders Week Ending 7-16-06	Anda_Opioids_MDL_0000271785	Anda_Opioids_MDL_0000271787		
P-17815	7/24/2006	Suspicious Orders Week Ending 7-23-06	Anda_Opioids_MDL_0000271782	Anda_Opioids_MDL_0000271784		
P-17816	7/31/2006	Suspicious Orders Week Ending 7-30-06	Anda_Opioids_MDL_0000271779	Anda_Opioids_MDL_0000271781		
P-17817	9/1/2004	DEA/OD 11th Pharmaceutical Industry Conference, Risk Management of Pharmaceutical Controlled Substances, Tuesday, September 16, New Orleans, Louisiana	PPLPC030000179742	PPLPC030000179742		
P-17818	3/22/2012	Let's Talk Pain website	N/A	N/A		
P-17819	8/21/2006	Suspicious Orders Week Ending 8-20-06	Anda_Opioids_MDL_0000271771	Anda_Opioids_MDL_0000271773		
P-17820	8/28/2006	Suspicious Orders Week Ending 8-27-06	Anda_Opioids_MDL_0000271768	Anda_Opioids_MDL_0000271770		
P-17821	9/5/2006	Suspicious Orders Week Ending 9-3-06	Anda_Opioids_MDL_0000271765	Anda_Opioids_MDL_0000271767		
P-17822	9/14/2006	Suspicious Orders Week Ending 9-10-06	Anda_Opioids_MDL_0000271762	Anda_Opioids_MDL_0000271764		
P-17823	9/18/2006	Suspicious Orders Week Ending 9-17-06	Anda_Opioids_MDL_0000271759	Anda_Opioids_MDL_0000271761		
P-17824	9/29/2006	Suspicious Orders Week Ending 9-24-06	Anda_Opioids_MDL_0000271756	Anda_Opioids_MDL_0000271758		



P-17825	10/2/2006	Suspicious Orders Week Ending 10-1-06	Anda_Opioids_MDL_0000271753	Anda_Opioids_MDL_0000271755		
P-17826	10/9/2006	Suspicious Orders Week Ending 10-8-06	Anda_Opioids_MDL_0000271748	Anda_Opioids_MDL_0000271750		
P-17827	10/16/2006	Suspicious Orders Week Ending 10-15-06	Anda_Opioids_MDL_0000271745	Anda_Opioids_MDL_0000271747		
P-17828	10/23/2006	Suspicious Orders Week Ending 10-22-06	Anda_Opioids_MDL_0000271742	Anda_Opioids_MDL_0000271744		
P-17829	10/30/2006	Suspicious Orders Week Ending 10-29-06	Anda_Opioids_MDL_0000271739	Anda_Opioids_MDL_0000271741		
P-17830	11/13/2006	Suspicious Orders Week Ending 11-12-06	Anda_Opioids_MDL_0000271731	Anda_Opioids_MDL_0000271733		
P-17831	11/20/2006	Suspicious Orders Week Ending 11-19-06	Anda_Opioids_MDL_0000271728	Anda_Opioids_MDL_0000271730		
P-17832	11/27/2006	Suspicious Orders Week Ending 11-26-06	Anda_Opioids_MDL_0000271725	Anda_Opioids_MDL_0000271727		
P-17833	12/4/2006	Suspicious Orders Week Ending 12-3-06	Anda_Opioids_MDL_0000271722	Anda_Opioids_MDL_0000271724		
P-17834	12/11/2006	Suspicious Orders Week Ending 12-10-06	Anda_Opioids_MDL_0000271717	Anda_Opioids_MDL_0000271719		
P-17835	12/18/2006	Suspicious Orders Week Ending 12-17-06	Anda_Opioids_MDL_0000271714	Anda_Opioids_MDL_0000271716		
P-17836	1/8/2007	Suspicious Orders Week Ending 1-7-07	Anda_Opioids_MDL_0000271708	Anda_Opioids_MDL_0000271710		
P-17837	1/15/2007	Suspicious Orders Week Ending 1-14-07	Anda_Opioids_MDL_0000271703	Anda_Opioids_MDL_0000271705		
P-17838	1/22/2007	Suspicious Orders Week Ending 1-21-07	Anda_Opioids_MDL_0000271700	Anda_Opioids_MDL_0000271702		
P-17839	1/29/2007	Suspicious Orders Week Ending 1-28-07	Anda_Opioids_MDL_0000271697	Anda_Opioids_MDL_0000271699		
P-17840	2/5/2007	Suspicious Orders Week Ending 2-4-07	Anda_Opioids_MDL_0000271694	Anda_Opioids_MDL_0000271696		
P-17841	3/13/2007	Suspicious Orders Week Ending 3-11-07	Anda_Opioids_MDL_0000271686	Anda_Opioids_MDL_0000271688		
P-17842	3/19/2007	Suspicious Orders Week Ending 3-18-07	Anda_Opioids_MDL_0000271683	Anda_Opioids_MDL_0000271685		
P-17843	3/26/2007	Suspicious Orders Week Ending 3-25-07	Anda_Opioids_MDL_0000271680	Anda_Opioids_MDL_0000271682		
P-17844	4/3/2007	Suspicious Orders Week Ending 4-1-07	Anda_Opioids_MDL_0000271677	Anda_Opioids_MDL_0000271679		
P-17845	4/16/2007	Suspicious Orders Week Ending 4-15-07	Anda_Opioids_MDL_0000271669	Anda_Opioids_MDL_0000271671		
P-17846	4/23/2007	Suspicious Orders Week Ending 4-22-07	Anda_Opioids_MDL_0000271666	Anda_Opioids_MDL_0000271668		
P-17850	4/30/2007	Suspicious Orders Week Ending 4-29-07	Anda_Opioids_MDL_0000271663	Anda_Opioids_MDL_0000271665		
P-17851	5/7/2007	Suspicious Orders Week Ending 5-6-07	Anda_Opioids_MDL_0000271660	Anda_Opioids_MDL_0000271662		
P-17852	5/14/2007	Suspicious Orders Week Ending 5-13-07	Anda_Opioids_MDL_0000271655	Anda_Opioids_MDL_0000271657		
P-17853	5/21/2007	Suspicious Orders Week Ending 5-20-07	Anda_Opioids_MDL_0000271652	Anda_Opioids_MDL_0000271654		
P-17854	5/29/2007	Suspicious Orders Week Ending 5-27-07	Anda_Opioids_MDL_0000271649	Anda_Opioids_MDL_0000271651		
P-17855	6/4/2007	Suspicious Orders Week Ending 6-3-07	Anda_Opioids_MDL_0000271646	Anda_Opioids_MDL_0000271648		
P-17857	6/11/2007	Suspicious Orders Week Ending 6-10-07	Anda_Opioids_MDL_0000271643	Anda_Opioids_MDL_0000271645		
P-17858	6/20/2007	Suspicious Orders Week Ending 6-17-07	Anda_Opioids_MDL_0000271640	Anda_Opioids_MDL_0000271642		
P-17859	6/25/2007	Suspicious Orders Week Ending 6-24-07	Anda_Opioids_MDL_0000271637	Anda_Opioids_MDL_0000271639		
P-17860	7/2/2007	Suspicious Orders Week Ending 7-1-07	Anda_Opioids_MDL_0000271634	Anda_Opioids_MDL_0000271636		
P-17861	7/9/2007	Suspicious Orders Week Ending 7-8-07	Anda_Opioids_MDL_0000271629	Anda_Opioids_MDL_0000271631		
P-17862	7/16/2007	Suspicious Orders Week Ending 7-15-07	Anda_Opioids_MDL_0000271626	Anda_Opioids_MDL_0000271628		
P-17864	7/24/2007	Suspicious Orders Week Ending 7-22-07	Anda_Opioids_MDL_0000271622	Anda_Opioids_MDL_0000271624		
P-17865	7/30/2007	Suspicious Orders Week Ending 7-29-07	Anda_Opioids_MDL_0000271619	Anda_Opioids_MDL_0000271621		
P-17866	8/6/2007	Suspicious Orders Week Ending 8-5-07	Anda_Opioids_MDL_0000013466	Anda_Opioids_MDL_0000013468		
P-17867	1/10/2006	Excessive Order Report December 2005	Anda_Opioids_MDL_0000271878	Anda_Opioids_MDL_0000271879		
P-17868	2/6/2006	Fw: Acct #77982	Anda_Opioids_MDL_0000155222	Anda_Opioids_MDL_0000155222		
P-17870	3/10/2006	Excessive Order Report February 2006	Anda_Opioids_MDL_0000271847	Anda_Opioids_MDL_0000271848		
P-17871	4/6/2006	Excessive Order Report March 2006	Anda_Opioids_MDL_0000271833	Anda_Opioids_MDL_0000271834		
P-17872	5/2/2006	Excessive Order Report April 2006	Anda_Opioids_MDL_0000271822	Anda_Opioids_MDL_0000271823		
P-17874	6/14/2006	Excessive Order Report May 2006	Anda_Opioids_MDL_0000271802	Anda_Opioids_MDL_0000271803		
P-17876	7/3/2006	Excessive Order Report June 2006	Anda_Opioids_MDL_0000271794	Anda_Opioids_MDL_0000271795		
P-17877	10/2/2006	Excessive Order Report September 2006	Anda_Opioids_MDL_0000271751	Anda_Opioids_MDL_0000271752		
P-17878	11/3/2006	Excessive Order Report October 2006	Anda_Opioids_MDL_0000271737	Anda_Opioids_MDL_0000271738		
P-17879	1/8/2007	Excessive Order Report December 2006	Anda_Opioids_MDL_0000271706	Anda_Opioids_MDL_0000271707		
P-17880	2/8/2007	Excessive Order Report January 2007	Anda_Opioids_MDL_0000271692	Anda_Opioids_MDL_0000271693		
P-17881	4/11/2007	Excessive Order Report March 2007	Anda_Opioids_MDL_0000013525	Anda_Opioids_MDL_0000013526		
P-17883	5/8/2007	Excessive Order Report April 2007	Anda_Opioids_MDL_0000013511	Anda_Opioids_MDL_0000013512		
P-17884	6/4/2007	Excessive Order Report May 2007	Anda_Opioids_MDL_0000013495	Anda_Opioids_MDL_0000013496		
P-17885	9/14/2007	Excessive Order Report August 2007	Anda_Opioids_MDL_0000124942	Anda_Opioids_MDL_0000124942		
P-17886	7/22/2010	Draft 2 - DEA Summary	Anda_Opioids_MDL_0000108096	Anda_Opioids_MDL_0000108100		
P-17887	11/15/2012	FW: momsocdisp	Anda_Opioids_MDL_0000972860	Anda_Opioids_MDL_0000972862		
P-17888	11/9/2006	Specialty Pharmacies Inc.	Anda_Opioids_MDL_0000154659	Anda_Opioids_MDL_0000154662		
P-17890	9/11/2013	Customer Questionnaire - Central Drug Store	Anda_Opioids_CA_SF_0074985	Anda_Opioids_CA_SF_0074988		
P-17891	8/22/2014	Control Eligibility Status-Active Accounts	Anda_Opioids_CA_SF_0002132	Anda_Opioids_CA_SF_0002134		
P-17893	11/15/2010	Central Drug Email	Anda_Opioids_MDL_0000285584	Anda_Opioids_MDL_0000285584		
P-17894	7/15/2013	Customer Questionnaire Follow Up	Anda_Opioids_CA_SF_0026725	Anda_Opioids_CA_SF_0026727		
P-17895	1/14/2014	Customer Questionnaire - Visitation Valley Pharmacy	Anda_Opioids_CA_SF_0074951	Anda_Opioids_CA_SF_0074954		

P-17896	1/14/2014	Controlled Substances Supplemental Questions- Visitacion Valley Pharmacy	Anda_Opioids_CA_SF_0074989	Anda_Opioids_CA_SF_0074989		
P-17897	2/7/2014	Visitacion Valley Pharmacy Fax	Anda_Opioids_CA_SF_0074908	Anda_Opioids_CA_SF_0074919		
P-17899	2/10/2014	DEA Verification Report	Anda_Opioids_CA_SF_0074956	Anda_Opioids_CA_SF_0074979		
P-17900	2/10/2012	Visitacion Valley Pharmacy Dispense Data	Anda_Opioids_CA_SF_0074995			
				Anda_Opioids_CA_SF_0075014		
P-17901	8/13/2013	Customer Questionnaire - Charlie's Pharmacy	Anda_Opioids_MDL_0001052087	Anda_Opioids_MDL_0001052090		
P-17902	12/20/2013	RE: 144099: Lucky Pharmacy #776	Anda_Opioids_CA_SF_0039859	Anda_Opioids_CA_SF_0039861		
P-17903	3/28/2012	Bryant Ranch Customer list	Anda_Opioids_MDL_0001088721	Anda_Opioids_MDL_0001088723		
P-17904	12/20/2016	Bryant Ranch Wholesaler Letter	Anda_Opioids_MDL_0000539806	Anda_Opioids_MDL_0000539812		
P-17905	10/21/2008	Thomson email re WV Overdose report	ENDO-OPIOID_MDL-08387125	ENDO-OPIOID_MDL-08387126		
P-17906	4/20/2010	Thomson email re Value story for TRF	END00130471	END00130472		
P-17908	10/1/2012	Prescription Opioid Abuse Slide Deck	ENDO_OPIOID_DEPMAT-000141616	ENDO_OPIOID_DEPMAT-000141638		
P-17914	3/1/2007	Performance evaluations for H. Thomson	ENDO_FLAG-00307819	ENDO_FLAG-00307851		
P-17967	7/15/2010	Conference Call Recap and Action Items	ENDO_AAC_00093641	ENDO_AAC_00093641		
P-18005	N/A	AAPM Council of Past Presidents	N/A	N/A		
P-18018	1/2/2008	Letter to Dr. Roger Chou RE: Opioid Guidelines from MHNI	N/A	N/A		
P-18019	7/1/2008	Letter to Dr. Paice and Dr. Sitzman RE: Opioid Guidelines from MHNI	N/A	N/A		
P-18029	3/1/2013	Teva Advocacy Mapping: Identifying Advocacy Partners to Enhance Patient Care	TEVA_MDL_A_13738751	TEVA_MDL_A_13738857		
P-18059	9/29/2008	Press Release, United States Department of Justice, Pharmaceutical Company Cephalon to Pay \$425 Million for off-Label Drug Marketing	N/A	N/A		
P-18064	2/12/2004	Exhibit A, To David Brennan, From Carl Savini, Termination of Employment	Brennan_002235	Brennan_002237		
P-18067	5/1/2016	Alliance for Patient Access, Associate Members and Financial Supporters	N/A	N/A		
P-18068	10/14/2011	Teva Completes Acquisition of Cephalon, FiercePharma	N/A	N/A		
P-18071	N/A	Pain Matters materials from Teva's website	N/A	N/A		
P-18086	N/A	Teva call notes	TEVA_MDL_A_00763718	TEVA_MDL_A_00763718		
P-18088	N/A	TEVA Produced Document	TEV_FE00023073	TEV_FE00023127		
P-18093	3/1/2008	FW: Fentora LMNs and Cover Letters; FENTORA email cover note(patient specific) 022908 FINAL; LMN - BTP, Chronic, Noncancer; Letter of Medical Necessity for Low Back Pain; LMN-NC BTP, Chronic Neuropathic Pain	TEVA_CHI_00001939	TEVA_CHI_00001983		
P-18102	1/18/2007	January 18th FAST Meeting Deck	TEVA_CHI_00006141	TEVA_CHI_00006154		
P-18110	10/12/2006	PCS Q4 2006	TEVA_CHI_00041421	TEVA_CHI_00041423		
P-18119	7/19/2007	FW: FAST Team meeting; FAST Meeting draft ver8	TEVA_MDL_A_00010346	TEVA_MDL_A_00010354		
P-18121	1/29/2019	Janssen Prescribe Responsibly website	N/A	N/A		
P-18124	7/23/2007	Fentora Objections and Company Approved Responses	TEVA_MDL_A_00021115	TEVA_MDL_A_00021125		
P-18126	10/22/2007	RiskMap Quarterly Report	TEVA_MDL_A_00037913	TEVA_MDL_A_00037972		
P-18129	5/24/2006	FEBT Launch Playbook	TEVA_MDL_A_00338518	TEVA_MDL_A_00338660		
P-18133	10/7/2010	Sales Training and Development FENTORA Timeline of Events Leading up to the Rems Requirement for Opioid Analgesics	TEVA_MDL_A_00349300	TEVA_MDL_A_00349301		
P-18137	12/4/2006	Final Show	TEVA_MDL_A_00364495	TEVA_MDL_A_00364495		
P-18150	11/1/2006	FW: FENTORA launch update	TEVA_MDL_A_00403881	TEVA_MDL_A_00403881		
P-18151	N/A	- TEVA Produced Document	TEVA_MDL_A_00455086	TEVA_MDL_A_00455094		
P-18152	N/A	Documents referenced by Teva Defendants in response to Interrogatory No. 74 of their July 23, 2020 Supplemental Responses to People's Second Set of Interrogatories, served in The People v. State of California v. Purdue Pharma L.P. et al, Orange County California Superior Court Case No. 30-2014-00725287-CU-BT-CXC - List of Opioid Containing Products manufactured by the Teva Defendants	TEVA_MDL_A_00455201	TEVA_MDL_A_00455206		
P-18154	3/1/2013	March 2013 - TEVA Produced Document; Pain Advocacy Organizations Index	TEVA_MDL_A_00499645	TEVA_MDL_A_00499822		
P-18161	10/5/2003	TEVA Produced Document	TEVA_MDL_A_00505284	TEVA_MDL_A_00505491		
P-18165	6/6/2012	Teva Global Publication Policy	TEVA_MDL_A_00553097	TEVA_MDL_A_00553102		
P-18183	6/11/2010	100611 21947-GEN CORR FDA REMS MTG MINS	TEVA_MDL_A_00651161	TEVA_MDL_A_00651168		

P-18190	3/21/2012	FW: Please Do Not Reply - DNC Alert	TEVA_MDL_A_00694519	TEVA_MDL_A_00694520		
P-18191	7/23/2013	RE: Policy Revision - Promotional Peer-to-Peer Speaker Programs	TEVA_MDL_A_00694677	TEVA_MDL_A_00694679		
P-18193	9/16/2013	Prescription Drug Abuse & Alliance to Prevent the Abuse of Medicines	TEVA_MDL_A_00694962	TEVA_MDL_A_00694963		
P-18198	9/19/2006	Fentora video with news clips	TEVA_MDL_A_00715630	TEVA_MDL_A_00715630		
P-18200	2/2/2007	AZ Kara[1].CURRENT	TEVA_MDL_A_00717111	TEVA_MDL_A_00717111		
P-18201	2/2/2007	Doug_PatientProfile	TEVA_MDL_A_00717114	TEVA_MDL_A_00717114		
P-18202	2/9/2007	AZ Eric - 2[1].7.07 PM	TEVA_MDL_A_00717116	TEVA_MDL_A_00717116		
P-18203	2/9/2007	BondOpen_NOBlackberry	TEVA_MDL_A_00717117	TEVA_MDL_A_00717117		
P-18204	1/11/2006	ACTIQ_Wisdom_1_11	TEVA_MDL_A_00717855	TEVA_MDL_A_00717855		
P-18207	2016	Documents referenced by Teva Defendants in response to Interrogatory No. 39 of their July 23, 2020 Supplemental Responses to People's Second Set of Interrogatories, served in The People v. State of California v. Purdue Pharma L.P. et al, Orange County California Superior Court Case No. 30-2014-00725287-CU-BT-CXC - Fentora voucher and co-pay distribution data from 2012 to 2016	TEVA_MDL_A_00763714	TEVA_MDL_A_00763714		
P-18208	2/2/2018	PAIN-40493 Pain Matters Phase 8 Website [Responsive]	TEVA_MDL_A_00765944	TEVA_MDL_A_00766163		
P-18220	3/13/2006	Pain Bowl War Games - Thursday, March 16	TEVA_MDL_A_00865754	TEVA_MDL_A_00865760		
P-18223	1/2/2013	Re: Cutoff Analysis	Anda_Opioids_MDL_0000421657	Anda_Opioids_MDL_0000421658		
P-18228	10/15/2007	EMPLOYEE SELF APPRAISAL bearer 2007	TEVA_MDL_A_00873332	TEVA_MDL_A_00873335		
P-18232	5/30/2014	PAINWeek Marketing Activities 5-29-2014	TEVA_MDL_A_00886734	TEVA_MDL_A_00886736		
P-18235	10/25/2007	RE: Marketing Feedback Requested	TEVA_MDL_A_00891861	TEVA_MDL_A_00891862		
P-18237	8/2/2007	Fentora M2 no cancer	TEVA_MDL_A_00893086	TEVA_MDL_A_00893187		
P-18238	10/26/2007	RE: Marketing Feedback Requested	TEVA_MDL_A_00895570	TEVA_MDL_A_00895571		
P-18242	10/15/2008	Self Appraisal	TEVA_MDL_A_00916554	TEVA_MDL_A_00916556		
P-18246	4/12/2011	RE: Template Letters of Medical Necessity (LMNs) for FENTORA and NUVIGIL	TEVA_MDL_A_00944595	TEVA_MDL_A_00944596		
P-18252	2/19/2018	Report: COMPLIANCE - CUST ALLOWED CONTROLS	Anda_Opioids_MDL_0000005983	Anda_Opioids_MDL_0000005984		
P-18259	1/28/2006	FW: Actiq reimbursement hotline	TEVA_MDL_A_00982470	TEVA_MDL_A_00982474		
P-18260	10/3/2006	RE: this is an example of what I'm talking about	TEVA_MDL_A_00982526	TEVA_MDL_A_00982529		
P-18263	7/14/2010	Discussion Strategy document Attachment DEA Discussion Strategy Bullets	Anda_Opioids_MDL_0000108116	Anda_Opioids_MDL_0000108119		
P-18267	3/8/2017	RE: Actavis Controlled Substance Order Monitoring Policy; Controlled Substance Order Monitoring Policy	TEVA_MDL_A_01037227	TEVA_MDL_A_01037235		
P-18268	7/14/2016	Cochrane/Patrick Louis Travel Invoice for Travel Date 10Aug - FSMJMK	Anda_Opioids_MDL_0000117177	Anda_Opioids_MDL_0000117179		
P-18270	6/16/2008	FW: POA2 Follow-Up	ENDO_AAC_00094737	ENDO_AAC_00094740		
P-18271	2/7/2007	DEA Letter_Copy	TEVA_MDL_A_01039159	TEVA_MDL_A_01039162		
P-18273	2/23/2009	RE: Michael Jadali DO	ENDO_AAC_00110424	ENDO_AAC_00110425		
P-18280	1/22/2016	Teva Response Letter (00180592) Letterhead	TEVA_MDL_A_01046053	TEVA_MDL_A_01046053		
P-18286	4/16/2009	PAMF Lunch Program	ENDO_AAC_00112085	ENDO_AAC_00112085		
P-18293	4/20/2010	Specialist for the Day 4/16 w/ Dr. Cullen	ENDO_AAC_00118715	ENDO_AAC_00118715		
P-18294	1/2/2013	OP-02609 Memo to All Customer Facing Roles FINAL	ENDO_NMAG-00040893	ENDO_NMAG-00040899		
P-18296	10/30/2015	2015-10-29 Marianne Geiger Chat	TEVA_MDL_A_01056182	TEVA_MDL_A_01056182		
P-18299	10/16/2015	Publix Halted Order OXYCODONE	TEVA_MDL_A_01056272	TEVA_MDL_A_01056278		
P-18303	1/27/2009	Tracking 6 Month Calls for TBR	ENDO_PA_00232552	ENDO_PA_00232554		
P-18307	12/13/2017	2017-12-13 R&S Suspicious Order Report; 2018-01-16 R&S Suspicious Order Report	TEVA_MDL_A_01057272	TEVA_MDL_A_01057277		
P-18308	N/A	Teva Pain Matters Website pages 1/1/2015	N/A	N/A		

P-18309	1/16/2018	2018-01-16 RDC Rochester Suspicious Order Report; 2018-01-16 RDC Fairfield Suspicious Order Report; 2018-01-17 RDC Rochester Suspicious Order Report; 2018-01-17 RDC Fairfield Suspicious Order Report; 2018-01-18 RDC Rochester Suspicious Order Report; 2018-01-23 RDC Fairfield Suspicious Order Report; 2018-01-23 RDC Rochester Suspicious Order Report; 2018-02-06 RDC Fairfield Suspicious Order Report; 2018-02-06 RDC Rochester Suspicious Order Report; 2018-02-07 RDC Rochester Suspicious Order Report; 2018-02-13 RDC Rochester Suspicious Order Report; 2018-02-15 RDC Rochester Suspicious Order Report; 2018-02-21 RDC Fairfield Suspicious Order Report; 2018-03-30 RDC Fairfield Suspicious Order Report; 2018-03-30 RDC Rochester Suspicious Order Report	TEVA_MDL_A_01057581 TEVA_MDL_A_01057584	TEVA_MDL_A_01057613 TEVA_MDL_A_01057613	TEVA_MDL_A_01057584 - TEVA_MDL_A_01057613	
P-18314	12/16/2020	December 2020 Senate Finance Committee Report	N/A	N/A		
P-18318	12/4/2015	Evolving Roles Same Goals: Responsible Pain Management Clinical Presentations -YouTube video	N/A	N/A		
P-18319	7/28/2012	INTAC-Technology Sell-Sheet	ENDO_SF-00043425	ENDO_SF-00043426		
P-18320	4/18/2013	FW: Walgreens Update	ENDO_SF-00015793	ENDO_SF-00015796		
P-18321	1/14/2010	Opana ER Program in SF: Monday 1/25	ENDO_SF-00040324	ENDO_SF-00040326		
P-18322	10/4/2010	RE: Outstanding Regional POA; Standards and Expectations Bay Area 2010 PPT	ENDO_SF-00040543	ENDO_SF-00040550		
P-18331	11/12/2008	Re: Dr. Snook's Program 11/19	ENDO_SF-00041719	ENDO_SF-00041723		
P-18340	4/18/2018	2018-04-18 R&S Philadelphia Suspicious Order Report	TEVA_MDL_A_01061044	TEVA_MDL_A_01061045		
P-18342	7/19/2018	SOP 8278	TEVA_MDL_A_01061094	TEVA_MDL_A_01061098		
P-18348	3/24/2008	FW: Fentora LMNs and Cover Letters	TEVA_MDL_A_01065540	TEVA_MDL_A_01065541		
P-18350	6/13/2016	FW: CEO Leadership Forum Deck	TEVA_MDL_A_01071814	TEVA_MDL_A_01071826		
P-18351	8/18/2016	FW: Request for input: CNS Field Sales Weekly Communication - WE 8-19	TEVA_MDL_A_01077432	TEVA_MDL_A_01077449		
P-18353	8/30/2017	Teva response to Sen. McCaskill request	TEVA_MDL_A_01087806	TEVA_MDL_A_01087808		
P-18354	8/5/2009	Business Overview Presentation Annie and Brian	ENDO_SF-00041861	ENDO_SF-00041862		
P-18355	3/9/2012	FW: Walgreens	ENDO_SF-00013743	ENDO_SF-00013744		
P-18356	6/19/2007	FW: APF Distributed the Treatment Options Guidebook to Soldiers and Family Members; APF Treatment Options - A Guide for People Living in Pain	TEVA_MDL_A_01090493	TEVA_MDL_A_01090579		
P-18357	1/21/2010	Opana ER Dinner Program: Monday 1/25 @ La Folie	ENDO_SF-00042008	ENDO_SF-00042010		
P-18359	10/28/2008	37130 MidAtlanticArea	TEVA_MDL_A_01095970	TEVA_MDL_A_01095982		
P-18361	9/13/2013	FENTORA Fall Managers Meeting DRAFT 9-13	TEVA_MDL_A_01102506	TEVA_MDL_A_01102511		
P-18363	2/20/2007	J.R.AMRP - Nomination Form FINAL	TEVA_MDL_A_01105616	TEVA_MDL_A_01105648		
P-18364	9/24/2007	Very interesting...	TEVA_MDL_A_01108445	TEVA_MDL_A_01108459		
P-18367	8/16/2006	ACTIQ Funeral Attire	TEVA_MDL_A_01129118	TEVA_MDL_A_01129120		
P-18368	6/27/2018	Veeva Catalog of Materials 6-27-2018	TEVA_MDL_A_01130623	TEVA_MDL_A_01130623		
P-18369	6/27/2018	ZINC Catalog of Materials 6-27-2018	TEVA_MDL_A_01140791	TEVA_MDL_A_01140791		
P-18370	7/24/2018	SOM Policy - Customer Site Visits	TEVA_MDL_A_01158479	TEVA_MDL_A_01158490		
P-18372	11/16/2000	Actiq "Master Plan"	TEVA_MDL_A_01159082	TEVA_MDL_A_01159142		
P-18373	1/1/2001	Actiq Marketing 2001	TEVA_MDL_A_01159143	TEVA_MDL_A_01159193		
P-18374	2003	2003 Actiq Marketing Plan	TEVA_MDL_A_01159194	TEVA_MDL_A_01159262		
P-18376	2005	2005 Actiq Marketing Plan	TEVA_MDL_A_01159323	TEVA_MDL_A_01159406		
P-18377	8/1/2001	Actiq Risk Management Program	TEVA_MDL_A_01159407	TEVA_MDL_A_01159436		
P-18381	3/12/2010	Separation of Employment, Agreement and General Release for Paul Pyfer	TEVA_MDL_A_01159463	TEVA_MDL_A_01159470		
P-18383	2/23/2004	Letter to Kerry Woods from Dave Brennan to inform of compliance issues	TEVA_MDL_A_01159525	TEVA_MDL_A_01159527		
P-18384	11/13/2003	RMP Meeting with RK	TEVA_MDL_A_01159545	TEVA_MDL_A_01159546		
P-18385	12/15/2003	Memo Re: Actions to Respond to Audit Findings Regarding the Actiq Risk Management Program	TEVA_MDL_A_01159549	TEVA_MDL_A_01159553		
P-18386	5/9/2006	Quality Assurance Memorandum to QA File, from Dave Brennan Re: Internal Audit of Actiq Risk Management Program, 2nd Qtr 2003	TEVA_MDL_A_01159577	TEVA_MDL_A_01159584		

P-18387	12/2/2003	Quality Assurance Memorandum to QA File, from Dave Brennan Re: Internal Audit of Actiq Risk Management Program, 2nd Qtr 2003	TEVA_MDL_A_01159585	TEVA_MDL_A_01159592		
P-18403	1/11/2012	Clinical Oncology December 2011	TEVA_MDL_A_01208114	TEVA_MDL_A_01208130		
P-18404	10/8/2008	Cephalon PCS Training Report July ITC 2008	TEVA_MDL_A_01211892	TEVA_MDL_A_01211896		
P-18410	6/8/2007	Slide Decks	TEVA_MDL_A_01188837	TEVA_MDL_A_01188853		
P-18422	5/12/2005	Horan Spokane Segment Training Piece Attachment Actiq Physician Segmentation Guide	TEVA_MDL_A_01327078	TEVA_MDL_A_01327082		
P-18429	3/14/2012	Intro to PhV for Regulatory Affairs (Jim Ottinger's group) - 14 March 2012	TEVA_MDL_A_01352261	TEVA_MDL_A_01352262		
P-18430	2003	Quality Assurance Memorandum	N/A	N/A		
P-18431	6/28/2004	2004 Org Chart	TEVA_MDL_A_01373058	TEVA_MDL_A_01373150		
P-18433	12/13/2006	Do You Still Have Pain	TEVA_MDL_A_01399742	TEVA_MDL_A_01399750		
P-18435	12/28/2006	Fentora CSP Programs to Date	TEVA_MDL_A_01399870	TEVA_MDL_A_01399872		
P-18441	7/30/2012	Opana ER Dinner Program: Tues 7/31 6:30PM at Acquerello	ENDO_SF-00042203	ENDO_SF-00042203		
P-18445	5/3/2004	RE: Prescribing specialties -- 15%	TEVA_MDL_A_01405193	TEVA_MDL_A_01405194		
P-18447	8/4/2006	Talk Show	TEVA_MDL_A_01406061	TEVA_MDL_A_01406068		
P-18449	6/19/2015	Opioid addiction awareness	TEVA_MDL_A_01410208	TEVA_MDL_A_01410209		
P-18451	1/25/2016	ABC order management revised	TEVA_MDL_A_01428524	TEVA_MDL_A_01428525		
P-18452	5/31/2016	ABC order management revised	TEVA_MDL_A_01428583	TEVA_MDL_A_01428584		
P-18453	12/8/2016	Dakota order management revised	TEVA_MDL_A_01436274	TEVA_MDL_A_01436282		
P-18457	11/22/2010	3Q10 - Sep Scorecards	ENDO_SF-00042761	ENDO_SF-00042762		
P-18463	3/14/2013	RE: FYI	TEVA_MDL_A_01456869	TEVA_MDL_A_01456869		
P-18469	10/28/2015	RE: Publix Anda weekly call	TEVA_MDL_A_01462200	TEVA_MDL_A_01462203		
P-18474	8/14/2012	Re: pharmacy white glove request Opana ER 5mg	ENDO_SF-00042924	ENDO_SF-00042926		
P-18478	4/19/2012	Work Session Planner Apr 2012	ENDO_SF-00043095	ENDO_SF-00043096		
P-18479	3/18/2014	DEA Compliance Organization	TEVA_MDL_A_01464602	TEVA_MDL_A_01464603		
P-18485	10/16/2015	FW: PO# 1031374 for the OXYCODONE product	TEVA_MDL_A_01466124	TEVA_MDL_A_01466127		
P-18499	10/16/2017	RE: 60 Minutes	TEVA_MDL_A_01470384	TEVA_MDL_A_01470384		
P-18509	8/3/2006	A Few Good Salesmen_v1_072106	TEVA_MDL_A_01490945	TEVA_MDL_A_01490952		
P-18512	6/15/2016	Re: Ex-Pharma Sales Staff Arrested on Anti-Kickback Charges and more...	TEVA_MDL_A_01506132	TEVA_MDL_A_01506137		
P-18513	2/10/2017	Spokane Resume	TEVA_MDL_A_01506383	TEVA_MDL_A_01506386		
P-18515	5/14/2008	Pink Sheet Coverage of the Advisory Committee Meeting; Fentora The Pink Sheet 5	TEVA_MDL_A_01536499	TEVA_MDL_A_01536506		
P-18516	6/21/2011	RE: ONE LAST REVIEW -- 2011 Opana ER Speaker Nomination Process ACTION REQUIRED - 6/10/2011	ENDO_SF-00304763	ENDO_SF-00304766		
P-18520	7/12/2004	2004 Letter Teva to FDA 2004 Cephalon Actiq Information Package 684Pg. for FDA Office of Drug Evaluation Meeting	TEVA_MDL_A_01575289	TEVA_MDL_A_01575972		
P-18523	6/2/2014	041019 20747-FDA JULY 14 MTG MINS	TEVA_MDL_A_01582360	TEVA_MDL_A_01582377		
P-18524	4/18/2005	15-APR-2005 20747 DDMAC Meeting minutes	TEVA_MDL_A_01584973	TEVA_MDL_A_01584989		
P-18525	2003	2003 Clinical Research & Regulatory Affairs	TEVA_MDL_A_01861562	TEVA_MDL_A_01861572		
P-18530	10/23/2012	Fw: Hydrocodone C33237/1099 and C33237/1106 protocols for your endorsement	TEVA_MDL_A_01874331	TEVA_MDL_A_01874488		
P-18536	1/16/2007	Email from Castagno re PR updates	TEVA_MDL_A_02022444	TEVA_MDL_A_02022447		
P-18539	7/5/2012	Fwd: Opana - Hard to find	ENDO_TXMDL_00388431	ENDO_TXMDL_00388432		
P-18545	3/23/2007	my ppt so far; ShareYourPain.org page; If you're wondering if BTP is real flyer	TEVA_MDL_A_02030685	TEVA_MDL_A_02030697		
P-18552	3/11/2011	Fentora Ad Board; Webster Lynn - Ad Bd Agreement; Argoff Charles - Ad Bd Agreement; Fine Perry - Ad Bd Agreement; Passik Steven - Ad Bd Agreement; Portenoy Russell - Ad Bd Agreement; Rathmell James - Ad Bd Agreement; Wallace Mark - Ad Bd Agreement	TEVA_MDL_A_07249902	TEVA_MDL_A_07249953		
P-18553	8/8/2005	Lynn Webster - FD 3039	TEVA_AAMD_00629997	TEVA_AAMD_00629997		
P-18554	6/28/2016	CON Webster, Lynn 3.30.16	TEVA_MDL_A_06746958	TEVA_MDL_A_06746967		
P-18555	10/16/2015	RE: PO# 1031374 for the OXYCODONE product	TEVA_MDL_A_02063729	TEVA_MDL_A_02063733		
P-18556	9/16/2006	Cephalon Fentora Actiq Report	TEVA_MDL_A_13610632	TEVA_MDL_A_13610632		
P-18556a	9/16/2006	2002-2013 Actiq and Fentora speaker program database filtered for New York State only	TEVA_MDL_A_13610632	TEVA_MDL_A_13610632		
P-18558	12/2/2004	ACTIQ Directors Meeting 12_04 FINAL	TEVA_MDL_A_03252903	TEVA_MDL_A_03252903		

P-18561	9/15/2016	RE: 1 on 1	TEVA_MDL_A_01393092	TEVA_MDL_A_01393093		
P-18564	9/1/2020	U.S. Department of Health and Human Services Office of Inspector General - FDA's Risk Evaluation and Mitigation Strategies: Uncertain Effectiveness in Addressing the Opioid Crisis	N/A	N/A		
P-18565	12/16/2020	2020 Senate Finance Committee - Findings from the Investigation of Opioid Manufacturers' Financial Relationships with Patient Advocacy Groups and other Tax-Exempt Entities	N/A	N/A		
P-18566	9/25/2006	Letter from FDA to Carol Marchione regarding NDA for Fentora	TEVA_MDL_A_02074924	TEVA_MDL_A_02074969		
P-18569	3/20/2012	RE: Effentora - Product Working Group	TEVA_MDL_A_02077435	TEVA_MDL_A_02077436		
P-18571	7/13/2012	FW: Opana ER Update Call - Recap.msg	ENDO_TXMDL_00445055	ENDO_TXMDL_00445058		
P-18572	11/26/2008	OPANA Patient Profiles Bill Wanda Stella Mike	ENDO-CA-00124200	ENDO-CA-00124224		
P-18578	6/20/2006	FW: Celebration of 3 Major Milestones for the US Pain Franchise	TEVA_MDL_A_02217508	TEVA_MDL_A_02217508		
P-18580	2/10/2011	PDRC approved reprints for use by reps....; FEN-2226 Darwish Absolute & Relative Bioavailability	TEVA_MDL_A_02238176	TEVA_MDL_A_02238221		
P-18581	1/26/2011	2011 Opana ER Patient Starter Kit	ENDO-OPIOID_MDL-02104161	ENDO-OPIOID_MDL-02104171		
P-18583	2/6/2018	2018-02-06 RDC Fairfield Suspicious Order Report	TEVA_MDL_A_02248089	TEVA_MDL_A_02248089		
P-18585	2/6/2018	2018-02-06 RDC Rochester Suspicious Order Report	TEVA_MDL_A_02248091	TEVA_MDL_A_02248091		
P-18587	2/7/2018	2018-02-07 RDC Rochester Suspicious Order Report	TEVA_MDL_A_02248093	TEVA_MDL_A_02248093		
P-18588	1/16/2018	2018-01-16 RDC Fairfield Suspicious Order Report	TEVA_MDL_A_02248777	TEVA_MDL_A_02248778		
P-18589	1/16/2018	2018-01-16 RDC Rochester State Suspicious Order Report	TEVA_MDL_A_02248780	TEVA_MDL_A_02248781		
P-18591	1/17/2018	2018-01-17 RDC Fairfield Suspicious Order Report	TEVA_MDL_A_02248786	TEVA_MDL_A_02248787		
P-18592	1/17/2018	2018-01-17 RDC Rochester Suspicious Order Report	TEVA_MDL_A_02248788	TEVA_MDL_A_02248788		
P-18594	1/18/2018	2018-01-18 RDC Rochester Suspicious Order Report	TEVA_MDL_A_02248792	TEVA_MDL_A_02248793		
P-18595	1/23/2018	2018-01-23 RDC Fairfield Suspicious Order Report	TEVA_MDL_A_02248796	TEVA_MDL_A_02248797		
P-18597	1/23/2018	2018-01-23 RDC Rochester Suspicious Order Report	TEVA_MDL_A_02248800	TEVA_MDL_A_02248801		
P-18604	11/12/2014	FW: Updated Creative for Unbranded Initiative	TEVA_MDL_A_02296564	TEVA_MDL_A_02296569		
P-18607	5/4/2011	Re Patient Brochures OP-01354, 01355 & 01356	ENDO-OPIOID_MDL-02777150	ENDO-OPIOID_MDL-02777172		
P-18609	1/8/2008	Patient Brochure 1-7	ENDO-OPIOID_MDL-02899346	ENDO-OPIOID_MDL-02899355		
P-18610	1/3/2017	2017-01-02 Hope Pharmacy - California Board of Pharmacy Accusation	TEVA_MDL_A_02311163	TEVA_MDL_A_02311181		
P-18612	7/21/2010	FW: OPANA Conference Call - 7/19/10	ENDO-OR-CID-01289063	ENDO-OR-CID-01289063		
P-18613	1/2/2008	2008 Rebate Kit and Patient Brochure	EPI000303738	EPI000303759		
P-18615	N/A	Sir Speedy Order Confirmations	ENDO_OPIOID_DEPMAT-000127819	ENDO_OPIOID_DEPMAT-000127833		
P-18620	3/19/2013	RE: Customer Service Training PPT; Teva SOM Customer Service Training FINALx	TEVA_MDL_A_02331426	TEVA_MDL_A_02331428		
P-18621	4/1/2008	RE Anniversary Awards	ENDO_ANK_000238048	ENDO_ANK_000238050		
P-18623	1/29/2014	Suspicious Order Monitoring - Chargeback Review; Suspicious Order Monitoring - DEA Order Holds	TEVA_MDL_A_02332290	TEVA_MDL_A_02332320		
P-18624	5/13/2009	B737-2 San Fran 5-13-09.MP3	KP360_OHIOMDL_000119637	KP360_OHIOMDL_000119637		
P-18626	11/13/2006	B151-003 San Francisco, CA_11-13-06_MOSOWITZ_REISNER.MP3	KP360_OHIOMDL_000095693	KP360_OHIOMDL_000095693		
P-18627	7/6/2012	SOM Presentation	TEVA_MDL_A_02336503	TEVA_MDL_A_02336504		
P-18628	4/25/2008	Master grantor report Spring 2008	ENDO_FLAG-00463411	ENDO_FLAG-00463412		
P-18633	11/10/2006	National Initiative on Pain Control Dinner Dialogues Series - B151-3 San Francisco	ENDO_SF-00482200	ENDO_SF-00482202		
P-18636	3/28/2008	Honorarium-B442-3	KP360_OHIOMDL_000082181	KP360_OHIOMDL_000082182		
P-18637	4/10/2008	NIPC April 10 2008 Chronic Opioid Therapy Invite	KP360_OHIOMDL_000081713	KP360_OHIOMDL_000081714		
P-18638	12/1/2007	Patient Pain Diary (OP-0254D)	ENDO-CHI_LIT-00538404	ENDO-CHI_LIT-00538437		
P-18639	1/1/2008	Patient Information Brochure (OP-0254C)	ENDO-CHI_LIT-00538441	ENDO-CHI_LIT-00538449		
P-18640	5/1/2008	OPANA Instant Savings Card (OP-0313A)	ENDO-CHI_LIT-00540525	ENDO-CHI_LIT-00540528		
P-18646	11/1/2007	OPANA ER Slim Jim (OP-0152)	ENDO-CHI_LIT-00544926	ENDO-CHI_LIT-00544939		
P-18647	4/1/2014	Package Insert (114045)	ENDO-CHI_LIT-00556860	ENDO-CHI_LIT-00556863		
P-18648	1/1/2011	HCP Sell Sheet (OP-02606)	EPI000197199	EPI000197200		
P-18649	2/1/2013	HCP Sell Sheet (OP-02606)	EPI000197470	EPI000197471		
P-18654	6/13/2006	Org Chart - Pharm Ops w Oncology; Marketing Org Chart	TEVA_MDL_A_02383516	TEVA_MDL_A_02383526		
P-18655	1/1/2008	HCP Sell Sheet (OP-02606)	EPI000294158	EPI000294159		
P-18656	8/8/2006	Email attaching Fentora Sales Launch Meeting agenda	TEVA_MDL_A_02383994	TEVA_MDL_A_02384006		
P-18658	1/1/2008	ISC with Pain Mgmt. Resource Kit (OP-0254A)	EPI000303758	EPI000303759		



P-18668	N/A	Net sales data from 2012–2017 for generic opioid products	TEVA_MDL_A_02416208	TEVA_MDL_A_02416208		
P-18669	2012	2012-2015 TEVA Produced Document	TEVA_MDL_A_02419959	TEVA_MDL_A_02419959		
P-18678	8/19/2015	FW: Global Internal Audit: DEA - Final Report; DEA - Final Report	TEVA_MDL_A_02475564	TEVA_MDL_A_02475585		
P-18679	4/1/2011	cLBP Consultative Brochure (OP-01283)	EPI000387938	EPI000387942		
P-18682	9/18/2016	RE: ADIWG Meeting; ADIWG Draft#1.9.18.16	TEVA_MDL_A_02475899	TEVA_MDL_A_02475901		
P-18683	1/1/2011	Patient Experience Kit (OP-00888a)	COLOR_EPI000442791	COLOR_EPI000442792		
P-18685	9/1/2010	Opiana ER Prescribing Information (Packs of 25) (OP-00503)	EPI000445866	EPI000445873		
P-18691	2/1/2013	Dear Pharmacist from HCP Fax Template with Implementation Guide (OP-02670)	EPI000470496	EPI000470496		
P-18692	6/1/2008	Slim Jim Leave Behind (OP-0302)	EPI000489182	EPI000489197		
P-18693	1/1/2006	MVA - October 2006 (OP-0015R)	COLOR_EPI000561199	COLOR_EPI000561214		
P-18694	4/1/2009	Premium Materials Depicted	EPI000562410	EPI000562447		
P-18695	11/3/2017	2017-11 Q4 Dept Meeting - JJT	TEVA_MDL_A_02480067	TEVA_MDL_A_02480068		
P-18696	3/2/2018	Email PowerPoint; Tomkiewicz Presentation Re Selling High Risk Drugs	TEVA_MDL_A_02480387	TEVA_MDL_A_02480388		
P-18699	1/1/2011	Patient Experience Kit (OP-00888b)	EPI000713763	EPI000713764		
P-18710	7/29/2014	SOP - 8277, Suspicious Order Monitoring - DEA Order Holds; SOP - 8279 Suspicious Order Monitoring - Customer Due Diligence; SOM SO8279 - Customer Due Diligence; SOP - 8280, Suspicious Order Monitoring - Customer Site Visits	TEVA_MDL_A_02660891	TEVA_MDL_A_02660942		
P-18711	5/1/2008	Master Visual Aid (OP-0301)	COLOR_EPI000734772	COLOR_EPI000734787		
P-18712	1/12/2011	Book Avoiding Opioid Abuse While Managing Pain (OP-0249)	END00006930	END00006931		
P-18713	12/24/2010	OPANA ER 2010 Rebate Kits (REFRESHED) (OP-0254 Refreshed, R1)	END00006938	END00006939		
P-18732	5/1/2011	OPANA Direct Mail - OA with CYP450 Message (OP-0457)	END00007068	END00007069		
P-18734	5/1/2011	OPANA Direct Mail - OA with CYP450 Message (OP-0457)	END00007070	END00007071		
P-18737	5/1/2011	OPANA Direct Mail - OA Message (OP-0459)	END00007072	END00007073		
P-18743	7/1/2012	DDI Handbook (OP-02403)	END00019736	END00019768		
P-18745	N/A	Navigator - May 2008 (ST-2175)	END00050163	END00050184		
P-18747	10/1/2016	OPANA Educational Teleconference (OP-0081)	END00052053	END00052054		
P-18750	9/7/2018	Generic TIRF - Veeva Catalog of Materials run 9-5-2018 Ann Collection Request	TEVA_MDL_A_02914333	TEVA_MDL_A_02914333		
P-18752	3/3/2012	Opiana ER DMVA Navigator (OP-01947p, -)	END00052999	END00053030		
P-18754	10/5/2016	Hydrocodone.Apap Tabs ANDA APPROVAL	TEVA_MDL_A_02922014	TEVA_MDL_A_02922034		
P-18755	3/16/2017	SOM Intro 2014	TEVA_MDL_A_02923615	TEVA_MDL_A_02923623		
P-18757	N/A	Patient Brochure Holder (OP-02539)	END00058556	END00058556		
P-18759	11/1/2010	Master Visual Aid (OP-00526)	COLOR_END00063638	COLOR_END00063649		
P-18760	1/1/2011	Dosing and Conversion Guide (OP-00907)	END00064985	END00065002		
P-18763	11/14/2007	speech	TEVA_MDL_A_02936923	TEVA_MDL_A_02936952		
P-18768	1/1/2011	Navigator - January 2011 (OP-00931a)	COLOR_END00167572	COLOR_END00167591		
P-18769	12/21/2017	Re: Vantrela	TEVA_MDL_A_02974065	TEVA_MDL_A_02974073		
P-18773	10/9/2015	CCALC meeting minutes--final comment period for bylaws	TEVA_MDL_A_03130348	TEVA_MDL_A_03130386		
P-18777	3/8/2017	SOM SO8489 - DEA Order Holds - Other Locations	TEVA_MDL_A_03160147	TEVA_MDL_A_03160175		
P-18781	5/3/2005	FW: Updated Presentation; Final Presentation 041205	TEVA_MDL_A_06669297	TEVA_MDL_A_06669299		
P-18784	2/13/2012	2011 FY Hist Sales Data	TEVA_MDL_A_03193699	TEVA_MDL_A_03193700		
P-18789	12/17/2001	ACTIQ Marketing Plan 2002-FINAL	TEVA_MDL_A_03248905	TEVA_MDL_A_03248959		
P-18790	11/29/2004	Actiq scenarios	TEVA_MDL_A_03272381	TEVA_MDL_A_03272391		
P-18791	1/24/2005	RE: JAMA (1/19): Research Letter Finds Increased Reports of Methadone Diversion and Abuse	TEVA_MDL_A_03272549	TEVA_MDL_A_03272551		
P-18795	N/A	Dosing & Cnvrns Guide (OP-00907b(1))	END00167942	END00167959		
P-18798	1/1/2012	OPANA ER Tablet Visual Guide (OP-02695)	END00168819	END00168820		
P-18802	11/25/2003	RE: Actiq Investigation segment on Channel 6 News	TEVA_MDL_A_03316708	TEVA_MDL_A_03316710		
P-18805	1/1/2000	OPANA ER TimeRx Flashcard (OP-0121, R1)	END00178030	END00178031		
P-18806	7/1/2004	Letter from FDA re meeting request	TEVA_MDL_A_03317917	TEVA_MDL_A_03317921		
P-18814	1/7/2014	SOM Documents; Cegedim TEVA SOM Review	TEVA_MDL_A_03478588	TEVA_MDL_A_03478620		
P-18815	N/A	OPANA ER Pharmacy	END00190194	END00190194		
P-18816	6/1/2014	FDS -DEF OPS Enhancements	TEVA_MDL_A_03479110	TEVA_MDL_A_03479129		
P-18823	2/19/2014	FW: Corporate Safety Board meeting minutes; Microsoft PowerPoint Presentation2x	TEVA_MDL_A_03486360	TEVA_MDL_A_03486366		

P-18824	4/1/2011	Brochure OP 01284	END00190248	END00190252		
P-18827	11/1/2013	FW: Non-505(q) Citizen Petition Granted in Part, Denied in Part - FDA-2013-0703	TEVA_MDL_A_03487762	TEVA_MDL_A_03487773		
P-18833	4/18/2016	Re: Units Template for Branded Generic Priced IR Hydro and Oxy - File attached	TEVA_MDL_A_03551263	TEVA_MDL_A_03551266		
P-18835	1/1/2011	Navigator January 2011 (OP-00972a)	END00438120	END00438139		
P-18837	11/1/2012	Dear HCP 7.5 & 15mg	END00501079	END00501080		
P-18838	11/3/2006	RE: Cephalon Oncology Weekly Media Monitoring Report 11 3 1006	TEVA_MDL_A_03571871	TEVA_MDL_A_03571874		
P-18839	1/16/2007	FW: FENTORA letter	TEVA_MDL_A_03573630	TEVA_MDL_A_03573643		
P-18841	9/29/2008	Pharmalot	TEVA_MDL_A_03611242	TEVA_MDL_A_03611250		
P-18844	4/1/2009	FINAL Registry ad board_show	TEVA_MDL_A_03615095	TEVA_MDL_A_03615096		
P-18851	8/24/2015	CI NEWS - Opioid Use Disorder - The Continued Rise of Opioid Abuse and Misuse	TEVA_MDL_A_03967973	TEVA_MDL_A_03967979		
P-18856	4/28/2004	RE: Associated Press Article: Increase in abuse reported of narcotic lollipops for cancer patients	TEVA_MDL_A_04108856	TEVA_MDL_A_04108858		
P-18858	6/19/2006	RE: News Article - FYI - Abuse of Fentanyl patch for chronic pain increasing	TEVA_MDL_A_04154661	TEVA_MDL_A_04154662		
P-18860	5/1/2009	OPANA Rebate Kit Label (OP-0254N)	END00688408	END00688408		
P-18874	1/1/2008	ISC with Pain Mgmt. Resource Kit (OP-0254B)	EPI001035652	EPI001035652		
P-18876	11/19/2013	FDA Sub - PRN 11539 - 2253 FINAL	TEVA_MDL_A_04342622	TEVA_MDL_A_04342886		
P-18877	10/28/2015	FINAL slide deck for RA workshop	TEVA_MDL_A_04344415	TEVA_MDL_A_04344417		
P-18881	2/22/2005	FW: Hotline	TEVA_MDL_A_04420139	TEVA_MDL_A_04420141		
P-18882	10/19/2004	Actiq Presentation	TEVA_MDL_A_04426360	TEVA_MDL_A_04426362		
P-18883	7/22/2004	Re: Actiq White Paper Feedback	TEVA_MDL_A_04478352	TEVA_MDL_A_04478356		
P-18884	12/1/2004	Email Dr. Guarino for Actiq Managed Care Training	TEVA_MDL_A_04481825	TEVA_MDL_A_04481825		
P-18885	7/21/2004	FW: Actiq White Paper Feedback	TEVA_MDL_A_04484212	TEVA_MDL_A_04484214		
P-18888	5/31/2002	Letter Re: NDA 20-747	TEVA_MDL_A_04578854	TEVA_MDL_A_04578878		
P-18889	8/30/2002	Letter Re: NDA 20-747	TEVA_MDL_A_04578879	TEVA_MDL_A_04578911		
P-18890	12/9/2002	14th RMP Quarterly Report	TEVA_MDL_A_04578912	TEVA_MDL_A_04578936		
P-18891	3/24/2003	15th RMP Quarterly Report	TEVA_MDL_A_04578937	TEVA_MDL_A_04578963		
P-18892	9/25/2003	17th RMP Quarterly Report	TEVA_MDL_A_04578988	TEVA_MDL_A_04579017		
P-18893	2004	2004 Managed Care and Reimbursement Objectives	TEVA_MDL_A_04838485	TEVA_MDL_A_04838490		
P-18895	N/A	RE: Actiq reimbursement hotline	TEVA_MDL_A_04848188	TEVA_MDL_A_04848191		
P-18898	2/1/2001	Actiq Marketing 2001 PPT	TEVA_MDL_A_05313123	TEVA_MDL_A_05313195		
P-18899	12/4/2003	Dan Winkleman memo re: David Brennan's RMP Audit	TEVA_MDL_A_05331899	TEVA_MDL_A_05331900		
P-18910	10/12/2004	Accounts Payable Check Request, American Pain Society	TEVA_MDL_A_05510585	TEVA_MDL_A_05510594		
P-18913	3/1/2002	Actiq Marketing 2002, Sales Training March 2002	TEVA_MDL_A_05734046	TEVA_MDL_A_05734097		
P-18917	12/31/2002	Actiq PPT	TEVA_MDL_A_05965700	TEVA_MDL_A_05965772		
P-18921	11/28/2006	RE: Decision Tree	TEVA_MDL_A_06384299	TEVA_MDL_A_06384302		
P-18923	1/4/2017	RE: Prescription Supply, Inc.	TEVA_MDL_A_06418852	TEVA_MDL_A_06418855		
P-18926	4/12/2013	Medical Scientific Evaluation, Medical Safety Evaluation Hierarchy	TEVA_MDL_A_06437421	TEVA_MDL_A_06437428		
P-18928	12/1/2012	INTAC Tech Demo Cards (box of 40) (OP-01945b)	EPI001109683	EPI001109683		
P-18936	12/18/2014	FW: hcpConnect Speaker Availability - January	TEVA_MDL_A_06464830	TEVA_MDL_A_06464835		
P-18938	3/31/2009	P. Andrew Pyfer Resume April 2009	TEVA_MDL_A_06470335	TEVA_MDL_A_06470339		
P-18941	11/3/2006	FW: Important Wall Street Journal Coverage of ACTIQ Promotion	TEVA_MDL_A_06474656	TEVA_MDL_A_06474659		
P-18953	1/1/2011	OPANA ER Master Visual Aid (OP-00931)	COLOR_EPI001111837	COLOR_EPI001111858		
P-18956	10/24/2014	RE: Walks, dinners, medical education programs information; 2013 and 2014 Advocacy Grant History Report	TEVA_MDL_A_06557274	TEVA_MDL_A_06557278		
P-18960	6/18/2012	FW: DEA Suspicious Order Monitoring Program	TEVA_MDL_A_06618645	TEVA_MDL_A_06618656		
P-18961	9/19/2016	CSOP 001-165, Controlled Substance Compliance Policy	TEVA_MDL_A_06619166	TEVA_MDL_A_06619257		
P-18962	7/18/2007	2007 Q3 Compliance Memo to Board	TEVA_MDL_A_06654609	TEVA_MDL_A_06654614		
P-18967	4/1/2013	Opana ER Pharmacy Locator Post-Its (Updated) (OP-02093)	EPI001224452	EPI001224452		
P-18973	9/1/2007	ISC with Pain Mgmt. Resource Kit (OP-0254E)	EPI001301100	EPI001301101		
P-18989	7/1/2012	Class-wide REMS Opana ER PI (Packs of 10) (OP-02431c)	EPI001818648	EPI001818651		
P-18991	2/1/2012	OPANA ER Pharmacy Information Sheet (OP-02054)	EPI002453631	EPI002453634		
P-18992	6/1/2016	12 Hour Dosing Leave Behind (OP-04578a(1))	ENDO-OPIOID_MDL-00046086	ENDO-OPIOID_MDL-00046090		
P-19001	10/17/2007	POA Slides for discussion meeting	TEVA_MDL_A_07178404	TEVA_MDL_A_07178405		
P-19019	1/5/2007	FW: APS 2007	TEVA_MDL_A_07417516	TEVA_MDL_A_07417517		

P-19022	3/26/2008	FW: Nurses Advisory Board	TEVA_MDL_A_07489637	TEVA_MDL_A_07489638		
P-19026	1/1/2009	Long Acting OPIOID Brochure (OP-0254C, R)	COLOR_ENDO-OPIOID_MDL-00303902	COLOR_ENDO-OPIOID_MDL-00303911		
P-19027	1/1/2009	Patient Pain Diary (OP-0254D, R)	ENDO-OPIOID_MDL-00303912	ENDO-OPIOID_MDL-00303921		
P-19029	2/1/2009	Package Insert (2002861)	ENDO-OPIOID_MDL-00336725	ENDO-OPIOID_MDL-00336762		
P-19030	1/1/2009	Patient Experience Kit (OP-00888)	COLOR_ENDO-OPIOID_MDL-00360288	COLOR_ENDO-OPIOID_MDL-00360289		
P-19033	7/14/2006	Final FBT Marketing Plan PR_06_29_06 - presented to Lynne	TEVA_MDL_A_07846839	TEVA_MDL_A_07846839		
P-19035	4/27/2008	Memorandum From Bob Rappaport To Chair, Members and Invited Guests Re: Overview of the May 6, 2008 ALSDAC Meeting to Discuss Supplement 005 to NDA 21-947 for an Expanded Indication for Fentora for Use in Breakthrough Pain in Patients with Chronic Pain Not Caused by Malignancy	TEVA_MDL_A_07864370	TEVA_MDL_A_07864502		
P-19054	6/29/2011	2nd Semester Bonus Plan	TEVA_MDL_A_08213457	TEVA_MDL_A_08213458		
P-19058	10/25/2018	Clinical Study Listing Table	TEVA_MDL_A_08235305	TEVA_MDL_A_08235315		
P-19059	12/10/2004	Media Coverage of Arrest of Dr. Lisnichy	TEVA_MDL_A_08238220	TEVA_MDL_A_08238222		
P-19060	6/7/2004	FW: FDA Contact Report- FDA Raises Concerns about Actiq Off-Label Use and Diversion	TEVA_MDL_A_08242371	TEVA_MDL_A_08242373		
P-19061	6/23/2004	FW: Data for 15% Actiq TRx Meeting	TEVA_MDL_A_08242504	TEVA_MDL_A_08242506		
P-19062	7/8/2004	981104 20747 Approval	TEVA_MDL_A_08242682	TEVA_MDL_A_08242693		
P-19063	8/31/2004	Draft DDMAC Meeting Minutes	TEVA_MDL_A_08245587	TEVA_MDL_A_08245590		
P-19064	5/4/2005	ACTIQ 20-747 Correspondence Log	TEVA_MDL_A_08261144	TEVA_MDL_A_08261145		
P-19065	7/21/2006	FW: Hydrocodone ER	TEVA_MDL_A_08380029	TEVA_MDL_A_08380030		
P-19066	8/18/2006	990210 20747-003 RMP Rev	TEVA_MDL_A_08387848	TEVA_MDL_A_08388059		
P-19067	9/8/2006	FDALetter9-7-06; 8.29.2006 FDA Letter to Cephalon Re Discipline Review Letter	TEVA_MDL_A_08399238	TEVA_MDL_A_08399332		
P-19070	9/25/2009	FW: Good Reprint Practices Review Team	TEVA_MDL_A_08475177	TEVA_MDL_A_08475180		
P-19071	2/11/2005	Cephalon, Inc. SOPs re Marketing Support of RMP	TEVA_MDL_A_08531804	TEVA_MDL_A_08531810		
P-19079	9/1/2010	2011 Opana ER Copay Brochure (OP-01311)	ENDO-OPIOID_MDL-00457445	ENDO-OPIOID_MDL-00457446		
P-19081	1/1/2011	Patient Experience Kit (OP-00888c)	COLOR_ENDO-OPIOID_MDL-00457606	COLOR_ENDO-OPIOID_MDL-00457607		
P-19084	7/9/2014	Poster_v11	TEVA_MDL_A_08657346	TEVA_MDL_A_08657356		
P-19086	3/20/2017	NBO recommendation to TEC Commercial 031917	TEVA_MDL_A_08658857	TEVA_MDL_A_08658859		
P-19088	4/17/2012	Fentora Presentation for iPad Meeting 4-19 v2.1	TEVA_MDL_A_08697903	TEVA_MDL_A_08697905		
P-19090	5/24/2004	Speaker Evaluation - 2004	TEVA_MDL_A_08873054	TEVA_MDL_A_08873067		
P-19094	11/17/2017	A207338N000DPM Approved	TEVA_MDL_A_08981644	TEVA_MDL_A_08981651		
P-19104	10/31/2006	MDM Monthly Update 10-31-06 number 9	TEVA_MDL_A_09068993	TEVA_MDL_A_09068994		
P-19105	11/21/2006	FW: Wall Street Journal (11/21/06) - Cephalon Used Improper Tactics	TEVA_MDL_A_09069589	TEVA_MDL_A_09069591		
P-19126	4/11/2018	Product Ops Team - Portfolio Review & Site Closure Planned Deletions & Updates - 04-10-18	TEVA_MDL_A_09134804	TEVA_MDL_A_09134869		
P-19127	4/2/2014	Global Specialty Medicines 2014 Biographies_bearer	TEVA_MDL_A_09144726	TEVA_MDL_A_09144727		
P-19128	11/18/2015	Re: Managed care mag article for opioids	TEVA_MDL_A_09165564	TEVA_MDL_A_09165566		
P-19130	6/3/2016	FW: Thank You	TEVA_MDL_A_09191592	TEVA_MDL_A_09191604		
P-19133	8/3/2004	ACTIQ 2004 Marketing Plan	TEVA_MDL_A_09437449	TEVA_MDL_A_09437509		
P-19136	2/28/2007	Fentora MCO slides	TEVA_MDL_A_09457158	TEVA_MDL_A_09457161		
P-19142	2/24/2016	Email re Vantrela ER 2016 BP for 2017 updating with Attachment: US MP Vantrela ER 20April2015	TEVA_MDL_A_08773243	TEVA_MDL_A_08773267		
P-19145	3/1/2012	Opana ER Pharmacy Locator Flyer (OP-02093a)	ENDO-OPIOID_MDL-00470548	ENDO-OPIOID_MDL-00470548		
P-19152	8/19/2009	RE: Suspicious Order Monitoring; Order Management SOP	TEVA_MDL_A_09576608	TEVA_MDL_A_09576612		
P-19153	1/12/2017	Opana ER Pharmacy Locator Flyer (OP-02093a)	ENDO-OPIOID_MDL-00497484	ENDO-OPIOID_MDL-00497485		
P-19154	5/22/2018	FW: Letters	TEVA_MDL_A_09588503	TEVA_MDL_A_09588507		
P-19156	4/21/2003	FW: New Orleans Evaluations Summary; 3306_Evaluation Summary_4-11	TEVA_MDL_A_09591981	TEVA_MDL_A_09591987		
P-19157	1/1/2012	Opana ER Pharmacy Locator Flyer (OP-02093a)	ENDO-OPIOID_MDL-00505096	ENDO-OPIOID_MDL-00505097		
P-19158	5/9/2003	FW: West Coast National Evaluation Summary; 3308_Evaluation Summary_5-2	TEVA_MDL_A_09592057	TEVA_MDL_A_09592069		
P-19159	1/1/2012	EPSP Resource Sheet (OP-01979c)	ENDO-OPIOID_MDL-00578027	ENDO-OPIOID_MDL-00578027		
P-19161	6/23/2003	FW: Greenbrier Evaluation Summary, Final Attendance and Agenda; 3868_Greenbrier Final Attendance Report	TEVA_MDL_A_09592303	TEVA_MDL_A_09592309		
P-19162	1/1/2008	Package Insert (413542)	ENDO-OPIOID_MDL-00661403	ENDO-OPIOID_MDL-00661404		
P-19164	10/6/2003	FW: Nemaacolin Woodlands Evaluation Summary, Final Attendance and Agenda; 3863_Evaluation Summary_8-15-03	TEVA_MDL_A_09592721	TEVA_MDL_A_09592726		

P-19165	10/1/2010	OPANA ER Conversion Guide (OP-00528)	ENDO-OPIOID_MDL-00815873	ENDO-OPIOID_MDL-00815879		
P-19185	10/14/2014	OLT Generic Update v2	TEVA_MDL_A_09639482	TEVA_MDL_A_09639483		
P-19186	10/22/2014	RE: Hey John re: TEVA, ENDP, ACT -- you aware of this escalating Opioid sitch snowballing?	TEVA_MDL_A_09639501	TEVA_MDL_A_09639501		
P-19187	1/7/2016	Global Ops 060215	TEVA_MDL_A_09640868	TEVA_MDL_A_09640875		
P-19190	7/25/2017	Company presentation - February 2017 - from Corporate - global focus	TEVA_MDL_A_09643585	TEVA_MDL_A_09643590		
P-19195	1/9/2017	RE: Follow-Up Meeting: Status Check- ANDA Holder Fee Clean-Up; All Teva Companies and Product ANDA numbers	TEVA_MDL_A_09655240	TEVA_MDL_A_09655245		
P-19196	1/1/2010	Osteoarthritis Consultative Brochure (OP-0423)	ENDO-OPIOID_MDL-00924894	ENDO-OPIOID_MDL-00924901		
P-19197	4/9/2004	Important News: New Tools Available	TEVA_MDL_A_09667462	TEVA_MDL_A_09667463		
P-19211	9/19/2006	FW: Opportunity	TEVA_MDL_A_10030379	TEVA_MDL_A_10030379		
P-19213	8/25/2004	FW: Addition of Tennant Study to Actiq White Paper	TEVA_MDL_A_10070409	TEVA_MDL_A_10070410		
P-19214	1/20/2005	ACPA 2005 Medications and Chronic Pain Supplement	TEVA_MDL_A_10070432	TEVA_MDL_A_10070435		
P-19215	1/4/2006	FW: White Papers	TEVA_MDL_A_10105779	TEVA_MDL_A_10105782		
P-19217	4/20/2010	Fw: Cases to QA dept - Breakthrough pain on FENTANYL	TEVA_MDL_A_10159045	TEVA_MDL_A_10159046		
P-19219	10/20/2006	Interoffice Memo: Notification of Response to Medical Inquiry	TEVA_MDL_A_10177280	TEVA_MDL_A_10177281		
P-19231	1/14/2014	FW: New non-505(q) Citizen Petition posted - FDA-2013-1606	TEVA_MDL_A_10197053	TEVA_MDL_A_10197054		
P-19238	12/3/2018	2015 - Performance Management Evaluation	TEVA_MDL_A_10226863	TEVA_MDL_A_10226868		
P-19242	3/4/2010	Oxycodone Supplement History	TEVA_MDL_A_10602657	TEVA_MDL_A_10602670		
P-19243	3/4/2010	07-06-25 CBE	TEVA_MDL_A_10604467	TEVA_MDL_A_10604633		
P-19244	8/17/2011	1-2-1-cover-letters	TEVA_MDL_A_10662653	TEVA_MDL_A_10662665		
P-19246	4/25/2018	Periodic Adverse Drug Experience Report	TEVA_MDL_A_11065997	TEVA_MDL_A_11066038		
P-19252	11/13/2014	FW: Pharmacovigilance Training Nov 2014	TEVA_MDL_A_11283916	TEVA_MDL_A_11283918		
P-19257	5/12/2011	FW: Internal Audit Sales & Marketing Compliance Programs	TEVA_MDL_A_11429532	TEVA_MDL_A_11429543		
P-19258	9/29/2008	FW: Press Release	TEVA_MDL_A_11436747	TEVA_MDL_A_11436752		
P-19260	4/20/2004	Payment Policies	TEVA_MDL_A_11578212	TEVA_MDL_A_11578215		
P-19261	7/22/2004	3rd Quarter Bonus Plan	TEVA_MDL_A_11578216	TEVA_MDL_A_11578222		
P-19268	1/1/2010	Understanding Low Back Pain Poster (OP-0426)	ENDO-OPIOID_MDL-00926304	ENDO-OPIOID_MDL-00926304		
P-19277	1/1/2006	Opana Detail Aid (OP-0015)	COLOR_ENDO-OPIOID_MDL-01053361	COLOR_ENDO-OPIOID_MDL-01053376		
P-19278	3/6/2007	Fw: TEVA TO SELL OXYCODONE THROUGH THE END OF 2007; Oxy-Final-E-060307	TEVA_MDL_A_12122429	TEVA_MDL_A_12122432		
P-19279	10/1/2007	Opana ER MVA (OP-0150, R)	ENDO-OPIOID_MDL-01144692	ENDO-OPIOID_MDL-01144705		
P-19282	1/1/2011	OPANA ER Pharmacy Locator Highlight Sheets (Padded) (OP-00894)	ENDO-OPIOID_MDL-01612473	ENDO-OPIOID_MDL-01612473		
P-19285	N/A	Dosing & Cnvrns Guide (OP-00907b)	ENDO-OPIOID_MDL-01664971	ENDO-OPIOID_MDL-01664988		
P-19289	11/1/2012	Dosing & Cnvrns Guide (OP-00907b)	COLOR_ENDO-OPIOID_MDL-01679385	COLOR_ENDO-OPIOID_MDL-01679389		
P-19291	1/1/2007	Clinical Reprint - Katz (OP-0106)	ENDO-OPIOID_MDL-02016448	ENDO-OPIOID_MDL-02016459		
P-19296	1/1/2011	Patient Experience Kit (OP-00888d)	COLOR_ENDO-OPIOID_MDL-02104167	COLOR_ENDO-OPIOID_MDL-02104167		
P-19299	1/1/2008	Patient Profile - Stella (OP-0365)	COLOR_ENDO-OPIOID_MDL-02173611	COLOR_ENDO-OPIOID_MDL-02173616		
P-19307	2/4/2013	Sales & Marketing (POA) Meeting Presentations 1/7 - 1/10/2013	TEVA_MDL_A_12682275 TEVA_MDL_A_12682275 TEVA_MDL_A_12682278 TEVA_MDL_A_12682281	TEVA_MDL_A_12682284 TEVA_MDL_A_12682275 TEVA_MDL_A_12682278 TEVA_MDL_A_12682284	TEVA_MDL_A_12682275 - TEVA_MDL_A_12682275, TEVA_MDL_A_12682278, TEVA_MDL_A_12682281- TEVA_MDL_A_12682282	
P-19308	2/17/2013	FW: BuNa marketing plan...; BuNa Shared Marketing Plan	TEVA_MDL_A_12682371	TEVA_MDL_A_12682380		
P-19311	12/21/2015	US Commercial Integration Status Update	TEVA_MDL_A_12698266	TEVA_MDL_A_12698267		
P-19317	1/31/2017	US Gx Market for TEC_v4	TEVA_MDL_A_12710597	TEVA_MDL_A_12710602		
P-19318	3/28/2017	Teva US 2017 Launch Update TEC 3-25-17	TEVA_MDL_A_12711058	TEVA_MDL_A_12711059		
P-19329	10/28/2010	Email No Subject - 111 EML	TEVA_MDL_A_13240798	TEVA_MDL_A_13240802		
P-19336	11/1/2008	Patient Profile - Mike (OP-0363)	COLOR_ENDO-OPIOID_MDL-02173617	COLOR_ENDO-OPIOID_MDL-02173622		
P-19338	N/A	Teva - Consultant Contract Info-Consultants and Consulting Services Spreadsheet (2017)	TEVA_MDL_A_13253980	TEVA_MDL_A_13253988		
P-19342	10/6/2016	PartnersAgainstPain.com	N/A	N/A		
P-19347	4/7/2013	Buprenorphine Naloxone Address/Phone List; Buprenorphine Physician Treatment Centers and State Agencies	TEVA_MDL_A_13470477	TEVA_MDL_A_13470478		
P-19348	8/1/2012	PK Flashcard (OP-01983d)	ENDO-OPIOID_MDL-02454350	ENDO-OPIOID_MDL-02454351		
P-19349	9/8/2016	Teva - Allergan Agreements; Allergan Master Purchase Agreement; 1.4.2.5 TSA - Executed	TEVA_MDL_A_13477897	TEVA_MDL_A_13479451		
P-19350	1/1/2010	Chronic Low Back Pain Consultative Brochure (OP-0422)	ENDO-OPIOID_MDL-02476005	ENDO-OPIOID_MDL-02476012		

P-19351	9/27/2017	Government Affairs: Opioid Workgroup	TEVA MDL A 13481057	TEVA MDL A 13481058		
P-19352	11/1/2017	GGM In Depth Business Review Nov 2017 vFinal	TEVA MDL A 13481729	TEVA MDL A 13481736		
P-19358	5/31/2011	PhV Internal Audit report - Final	TEVA MDL A 13580697	TEVA MDL A 13580863		
P-19367	N/A	Pyfer, Paul Andrew; Pyfer's Vitae; Separation of Employment Agreement and General Release; Employee Termination Form; Memorandum to Pyfer from Baldino; Performance Summary; New Employee Review - Three Month Performance Evaluation; Salary Adjustment Report	TEVA MDL A 13619586	TEVA MDL A 13620002		
P-19372	1/23/2019	US Government Affairs PowerPoint	TEVA MDL A 13646476	TEVA MDL A 13646493		
P-19391	1/1/2008	Opiana ER Co-Pay Card Brochure (OP-03289)	ENDO-OPIOID MDL-02542649	ENDO-OPIOID MDL-02542650		
P-19392	7/1/2015	UnitedHealthcare Formulary Update LB Implementation Guide (OP-04043a)	ENDO-OPIOID MDL-02678587	ENDO-OPIOID MDL-02678587		
P-19393	8/1/2014	OPANA ER Visual Guide Sell Sheet (OP-02695(2))	ENDO-OPIOID MDL-02707832	ENDO-OPIOID MDL-02707835		
P-19394	6/1/2016	Efficacy & Tolerability Rep Leave-Behind (OP-04578c)	ENDO-OPIOID MDL-02719071	ENDO-OPIOID MDL-02719076		
P-19396	11/1/2006	Master Visual Aid (OP-0015R1)	COLOR ENDO-OPIOID MDL-02847709	COLOR ENDO-OPIOID MDL-02847724		
P-19397	9/12/2012	Memorandum Distributor Briefing with Actavis Elizabeth, LLC (RK016806), on September 12, 2012	US-DEA-00000001	US-DEA-00000141		
P-19400	1/1/2007	OPANA ER Journal Ad Leave Behind (OP-0127)	COLOR ENDO-OPIOID MDL-03654611	COLOR ENDO-OPIOID MDL-03654614		
P-19410	9/27/2006	Suspicious order letters	US-DEA-00001767	US-DEA-00001772		
P-19412	1/1/2007	OPANA ER Patient TearSheet (OP-0225)	ENDO-OPIOID MDL-03655100	ENDO-OPIOID MDL-03655105		
P-19413	1/1/2008	Opioid Therapy in the 21st Century (OP-0384)	ENDO-OPIOID MDL-03655208	ENDO-OPIOID MDL-03655310		
P-19419	9/19/2005	DEA Audit Report 2005	US-DEA-00026903	US-DEA-00026924		
P-19422	1/19/2010	DEA Audit Report 2010	US-DEA-00026925	US-DEA-00026937		
P-19424	8/1/2007	Aetna CYP450 Sell Sheet (OP-0202)	ENDO-OPIOID MDL-03655853	ENDO-OPIOID MDL-03655855		
P-19431	5/1/2007	OPANA ER HumanaTRICARE TIMERx N Fact Sheet (OP-0164)	ENDO-OPIOID MDL-03655911	ENDO-OPIOID MDL-03655912		
P-19433	4/1/2007	Argoff Case Study (OP-0144)	ENDO-OPIOID MDL-03655996	ENDO-OPIOID MDL-03655999		
P-19435	2/1/2011	Reprint – Pharmacist's Prescriber's Letter (OP-02741)	ENDO-OPIOID MDL-03678108	ENDO-OPIOID MDL-03678113		
P-19436	8/1/2011	Hale Study Brochure (OP-01647)	ENDO-OPIOID MDL-03900848	ENDO-OPIOID MDL-03900852		
P-19437	5/1/2016	Opioid Analgesics REMS HCP Leave Behind (CORP-04628)	ENDO-OPIOID MDL-04721704	ENDO-OPIOID MDL-04721704		
P-19438	5/1/2008	OPANA ER Retail Sell Sheet for CVS Only (OP-0306A)	ENDO-OPIOID MDL-04734972	ENDO-OPIOID MDL-04734972		
P-19439	1/1/2008	OPANA ER Retail Sell Sheet (OP-0306)	ENDO-OPIOID MDL-04734973	ENDO-OPIOID MDL-04734973		
P-19440	8/1/2006	Opiana Pharmacy Sell Sheet (OP-0010)	ENDO-OPIOID MDL-04920839	ENDO-OPIOID MDL-04920839		
P-19441	1/1/2006	ER Pharmacy Sell Sheet (OP-0009)	ENDO-OPIOID MDL-04920840	ENDO-OPIOID MDL-04920840		
P-19444	5/29/2008	ODL-08-057 / DEA Response to NCPA	US-DEA-00005911	US-DEA-00005917		
P-19447	7/1/2006	OPANA Rebate Kit –2009 (OP-0313, R [sic])	ENDO-OPIOID MDL-05392275	ENDO-OPIOID MDL-05392276		
P-19449	N/A	Endo Pain Evaluator Tool (OP-0356)	ENDO-OPIOID MDL-05609006	ENDO-OPIOID MDL-05609006		
P-19452	1/1/2013	Katz Reprint Imp Guide (OP-02602a)	ENDO-OPIOID MDL-05611212	ENDO-OPIOID MDL-05611215		
P-19453	6/22/2016	FW: Follow-up from HDA Board Meeting; Final Final Questions for DEA 06-01-11; Final HDMA Questions for DEA Discussion on 07-31-13	US-DEA-00008563	US-DEA-00008583		
P-19454	N/A	Opiana ER 2012 Co Pay HolderCards (OP-02159c)	ENDO-OPIOID MDL-05617890	ENDO-OPIOID MDL-05617890		
P-19455	11/1/2010	OPANA ER MVA Slim Jim (Refresh) (OP-00527)	COLOR ENDO-OPIOID MDL-05623352	COLOR ENDO-OPIOID MDL-05623363		
P-19456	8/1/2011	Opiana ER full Prescribing Information (LEGACY PI) (OP-00503a)	ENDO-OPIOID MDL-05625389	ENDO-OPIOID MDL-05625391		
P-19459	N/A	OPANA ER Pharmacy Locator Sticky Notes (OP-00746)	ENDO-OPIOID MDL-05628156	ENDO-OPIOID MDL-05628156		
P-19461	1/1/2007	Hale Reprint Imp Guide (OP-02601a)	ENDO-OPIOID MDL-05631491	ENDO-OPIOID MDL-05631496		
P-19463	5/1/2011	Opiana ER App Business Card (OP-01382b)	ENDO-OPIOID MDL-05631718	ENDO-OPIOID MDL-05631719		
P-19465	5/1/2013	OPANA ER Pharmacy Information Sell Sheet (R3) (OP-02054f(1))	ENDO-OPIOID MDL-05631881	ENDO-OPIOID MDL-05631882		
P-19469	1/1/2010	OP-02740a Pergolizli Implementation Guide (OP-02740a)	ENDO-OPIOID MDL-05632595	ENDO-OPIOID MDL-05632596		
P-19470	4/1/2013	Cytochrome P450 Reprint Implementation Guide (OP-02741a)	ENDO-OPIOID MDL-05637198	ENDO-OPIOID MDL-05637199		
P-19472	3/1/2016	Copay Card Brochure (OP-03289(1)a)	ENDO-OPIOID MDL-05937500	ENDO-OPIOID MDL-05937500		
P-19475	4/1/2016	Rep Summary Leave- Behind (OP-04578)	ENDO-OPIOID MDL-05938375	ENDO-OPIOID MDL-05938377		
P-19478	7/7/2012	FINAL Rannazzisi test Senate drug caucus written stmt July 6	US-DEA-00016467	US-DEA-00016479		
P-19479	7/1/2016	Patient Profile Tool (OP-04654(1))	ENDO-OPIOID MDL-05938473	ENDO-OPIOID MDL-05938478		
P-19481	8/1/2014	Opiana ER Patient Brochure (OP-02533(1))	COLOR ENDO-OPIOID MDL-05940191	COLOR ENDO-OPIOID MDL-05940198		
P-19482	9/1/2015	Navigator - September 2015 (OP-02590(1))	COLOR ENDO-OPIOID MDL-05941149	COLOR ENDO-OPIOID MDL-05941179		
P-19483	12/27/2007	December 2007 Rannazzisi Letter	US-DEA-00017912	US-DEA-00017913		
P-19486	5/1/2013	OPANA ER Tablet Visual Guide (R1) (OP-02695(1))	ENDO-OPIOID MDL-05941213	ENDO-OPIOID MDL-05941214		
P-19488	11/1/2012	Opiana ER Copay Slim JimCard (Packs of 25) (OP 02159h)	ENDO-OPIOID MDL-05942254	ENDO-OPIOID MDL-05942257		
P-19489	5/1/2013	OPANA Copay Brochure (Packs of 10) (OP-02159i(1))	ENDO-OPIOID MDL-05942258	ENDO-OPIOID MDL-05942259		
P-19491	1/1/2010	Package Insert (2005648)	ENDO-OPIOID MDL-06378822	ENDO-OPIOID MDL-06378823		



P-19493	1/1/2015	INTAC Sell Sheet (OP-02294b(1))	ENDO_BALT_00151108	ENDO_BALT_00151110		
P-19494	11/1/2008	Patient Profile -- Bill (OP-0362)	COLOR_ENDO-CA-00124201	COLOR_ENDO-CA-00124206		
P-19495	11/1/2008	Patient Profile -- Wanda (OP-0364)	COLOR_ENDO-CA-00124207	COLOR_ENDO-CA-00124212		
P-19496	N/A	Speaker Program Data	ENDO-CA-DATA-00000003	ENDO-CA-DATA-00000003		
P-19497	7/1/2015	UnitedHealthcare Formulary Update Leave Behind (OP-04043)	ENDO-STAUUBUS_LIT-00345252	ENDO-STAUUBUS_LIT-00345254		
P-19498	1/1/2005	Opna ER Adams Reprint Metabolic Pathways (OX 0045)	ENDO-STAUUBUS_LIT-00457988	ENDO-STAUUBUS_LIT-00457996		
P-19499	2/7/2007	February 2007 Rannazzisi Letter	US-DEA-00022457	US-DEA-00022466		
P-19500	1/1/2006	Patient Profiles (Mike, Anne, Bill) (OP-0119)	COLOR_ENDO-STAUUBUS_LIT-00713547	COLOR_ENDO-STAUUBUS_LIT-00713552		
P-19501	9/1/2012	Navigator - September 2012 (OP-02477j)	ENDO-STAUUBUS_LIT-00593048	ENDO-STAUUBUS_LIT-00593082		
P-19506	8/1/2013	Appropriate Use Patient Brochure (OP-02510(1))	COLOR_ENDO-STAUUBUS_LIT-00599703	COLOR_ENDO-STAUUBUS_LIT-00599718		
P-19508	9/1/2015	OPANA ER Dosing Guide (10 per pack) (OP-00907b(3))	ENDO-STAUUBUS_LIT-00599724	ENDO-STAUUBUS_LIT-00599749		
P-19513	11/19/1997	Notice of Establishment of Task Force on Suspicious Orders	US-DEA-00025302	US-DEA-00025302		
P-19515	8/1/2014	Pharmacy Sell Sheet (OP-02054f(2))	ENDO-STAUUBUS_LIT-00599750	ENDO-STAUUBUS_LIT-00599752		
P-19518	7/23/1988	Chris Zimmerman Ltr 07-23-1998 (2) Redacted	US-DEA-00025671	US-DEA-00025671		
P-19524	6/21/1993	NWDA Suspicious Order Monitoring System	US-DEA-00026139	US-DEA-00026150		
P-19525	12/8/1993	Excessive Purchase Reports (FFS: 630-04 D1)	US-DEA-00026154	US-DEA-00026155		
P-19528	5/1/2007	OPANA ER HumanaTRICARE CYP450 Fact Sheet (OP-0163)	ENDO-CHI_LIT-00858316	ENDO-CHI_LIT-00858317		
P-19529	1/1/2012	Staff Pharmacist Bonus Program	WAGFLDEA00000007	WAGFLDEA00000009		
P-19530	9/30/2011	Accepting and Filling New Prescriptions Policy	WAGFLDEA00000045	WAGFLDEA00000046		
P-19532	10/1/2007	Master Visual Aid (OP-0150)	COLOR_ENDO-CHI_LIT-00919860	COLOR_ENDO-CHI_LIT-00919873		
P-19533	7/6/2010	Re: Question about Fla board holding rph's liable for excessive c2 rx's	WAGFLDEA00000356	WAGFLDEA00000356		
P-19534	8/6/2010	Email Fw: RXM Meeting- Oxycodone; Pharmacist Manager Meeting - role in main management video class	WAGFLDEA00000363	WAGFLDEA00000364		
P-19535	9/7/2011	WALGREENS OXYCODONE Controlled Substance Best Practices Update Email	WAGFLDEA00000396	WAGFLDEA00000397		
P-19536	7/5/2011	Florida prescription drug monitoring program protocol	WAGFLDEA00000383	WAGFLDEA00000383		
P-19537	10/25/2011	DEA RED FLAGS	WAGFLDEA00000467	WAGFLDEA00000468		
P-19538	7/8/2010	re: oxycodone 30 mgEl	WAGFLDEA00000459	WAGFLDEA00000460		
P-19539	10/1/2007	OPANA ER MVANavigator (OP-0151)	ENDO-CHI_LIT-00919883	ENDO-CHI_LIT-00919893		
P-19540	7/27/2010	Email Re: Handling Pain Management RXs; Pain Management problem in Florida	WAGFLDEA00000659	WAGFLDEA00000660		
P-19541	4/1/2008	OPANA Brand Initiation & Titration Dosing Guide (OP-0329)	ENDO-CHI_LIT-00920000	ENDO-CHI_LIT-00920013		
P-19542	4/16/2012	WALGREENS Store 06997 Standards of Practice for the Dispensing of Controlled Substances for Treatment of Pain	WAGFLDEA00000766	WAGFLDEA00000772		
P-19543	8/2/2010	Email Oxycodone Sales; WAG concerned Florida pharmacists are turning away good scripts	WAGFLDEA00000812	WAGFLDEA00000823		
P-19544	3/25/2011	Best Practices conf call	WAGFLDEA00000988	WAGFLDEA00000988		
P-19545	3/25/2011	FL best practices conf call continued	WAGFLDEA00000989	WAGFLDEA00000990		
P-19546	3/28/2011	FW: STORE 3099 increase in oxy scripts	WAGFLDEA00001011	WAGFLDEA00001012		
P-19547	11/26/2011	Fw: U.S. Department of Justice	WAGFLDEA00001248	WAGFLDEA00001249		
P-19548	2/22/2012	EJS Reply: Florida Controlled Substances (Merten)	WAGFLDEA00001478	WAGFLDEA00001487		
P-19549	3/25/2011	Re: Pharmacist Best Practices	WAGFLDEA00001013	WAGFLDEA00001016		
P-19550	3/28/2011	STORE 3099-RxS Due Diligence	WAGFLDEA00001017	WAGFLDEA00001019		
P-19551	5/21/2011	change in sales drug counts	WAGFLDEA00001710	WAGFLDEA00001710		
P-19552	3/30/2011	Pharmacist Best Practices (Svihra)	WAGFLDEA00001022	WAGFLDEA00001031		
P-19553	5/18/2011	Fw: Florida Physicians	WAGFLDEA00001080	WAGFLDEA00001080		
P-19554	7/20/2011	Oxycodone dispensing- IMPORTANT	WAGFLDEA00001154	WAGFLDEA00001155		
P-19555	8/23/2011	District #227 Oxycodone Action Plan	WAGFLDEA00001174	WAGFLDEA00001175		
P-19556	10/19/2011	Fw: Controlled Substance Update: Florida Prescription Drug Monitoring Program	WAGFLDEA00001213	WAGFLDEA00001216		
P-19557	5/17/2011	Florida Focus on Profit (Svihra)	WAGFLDEA00001890	WAGFLDEA00001896		
P-19558	3/17/2012	Re: DEA Compliance Suggestions Ed Lanzetti	WAGFLDEA00001569	WAGFLDEA00001570		
P-19559	5/1/2016	WAG / ABDC - Fifth Amendment to the Pharmaceutical Purchase and Distribution Agreement	WAGMDL00000369	WAGMDL00000373		
P-19560	5/31/2017	Sixth Amendment to the Pharmaceutical Purchase And Distribution Agreement	WAGMDL00000374	WAGMDL00000380		
P-19561	6/1/2017	WAG/ADDC - Joinder Agreement & Seventh Amendment to the Pharmaceutical Purchase And Distribution Agreement	WAGMDL00000381	WAGMDL00000384		



P-19562	3/18/2013	WAG/ABDC - Pharmaceutical Purchase and Distribution Agreement	WAGMDL00000417	WAGMDL00000492		
P-19563	4/2/2012	DEA meeting aks about pharmacists using PDMP data	WAGFLDEA00001626	WAGFLDEA00001626		
P-19565	1/1/2008	Instant Savings Card Program (OP-0154)	ENDO-CHI_LIT-00938115	ENDO-CHI_LIT-00938115		
P-19566	6/28/2010	DEA issue at store 6094 (Cheryl Creek & Tasha Polster) guidelines for dispensing	WAGFLDEA00001861	WAGFLDEA00001868		
P-19568	6/28/2010	DEA issue at store 6094 (Cheryl Creek & Tasha Polster)	WAGFLDEA00001869	WAGFLDEA00001876		
P-19569	2/10/2012	State of Florida Individual District Plans Oxycodone related	WAGFLDEA0001297_unitized	WAGFLDEA00001309_unitized		
P-19571	1/9/2012	Opana ER Dear Patient Letter Pack (OP-PTLTR)	ENDO_NMAG-00040507	ENDO_NMAG-00040507		
P-19572	12/9/2014	Rx Integrity Tools & Reports	WAGMDL00015162	WAGMDL00015165		
P-19573	2/26/2015	CPO Server RxIntegrity and Third Party	WAGMDL00015204	WAGMDL00015229		
P-19574	7/19/2012	FW: Targeted drugs for GFD; DEA Financial Impact Project Control3	WAGMDL00015230	WAGMDL00015236		
P-19575	9/9/2010	Regulatory Investigation	US-DEA-00030873	US-DEA-00030897		
P-19576	8/30/2012	Regulatory Investigation	US-DEA-00030898	US-DEA-00030920		
P-19577	8/14/2013	Draft RXS communication	WAGMDL00021189	WAGMDL00021190		
P-19578	9/10/2015	RE: Important Good Faith Dispensing Webcast - You Are Invited	WAGMDL00037567	WAGMDL00037569		
P-19579	1/1/2010	Pergolizzi Reprint CYP450 Pharmacokinetic Drug- Drug Interactions OP-02740	ENDO_TXMDL_00436716	ENDO_TXMDL_00436725		
P-19582	6/1/2007	Flashcard Durable Efficacy	ENDO_FLAG-00058111	ENDO_FLAG-00058112		
P-19584	7/7/2015	BCI Breakdown	WAGMDL00039478	WAGMDL00039479		
P-19585	1/1/2001	Clinical Reprint - Davis (OP-0252)	ENDO_FLAG-00101375	ENDO_FLAG-00101385		
P-19587	7/7/2015	RE: Asset Protection Solutions BCI Update	WAGMDL00045776	WAGMDL00045778		
P-19588	7/6/2015	BCI 2015-06 Pharmaceutical Integrity	WAGMDL00045782	WAGMDL00045784		
P-19589	6/6/2013	FW: CII ordering	WAGMDL00060486	WAGMDL00060488		
P-19590	5/11/2015	FW: EOC meeting Friday; GFD Training Overview	WAGMDL00045935	WAGMDL00045936		
P-19591	9/17/2013	RE: Good Faith Dispensing	WAGMDL00049236	WAGMDL00049237		
P-19592	11/16/2012	Executive Summary for the American Academy of Pain Medicine on Walgreen's Opioid Dispensing Policy AAPM executive summary_V4	WAGMDL00049722	WAGMDL00049738		
P-19593	11/30/2012	Target Drug (TD) Good Faith Dispensing (GFD) Parameters Pilot	WAGMDL00049864	WAGMDL00049887		
P-19594	3/24/2014	RE: Issue with a prescriber	WAGMDL00053882	WAGMDL00053883		
P-19595	4/1/2013	Pharmacist GFD Review - Pharmaceutical Integrity Team Pharmacist Coaching Opportunities	WAGMDL00054501	WAGMDL00054523		
P-19596	1/1/2007	Detail Aid - CYP 450 (OP-0256)	ENDO_FLAG-00129363	ENDO_FLAG-00129366		
P-19597	1/1/2004	Adams reprint (OP-0063 OP-0019/OX-0031)	ENDO_ALAG-00012197	ENDO_ALAG-00012205		
P-19598	2/4/2014	Completed Market 12 Presentation; Market 12 Rx Integrity Presentation	WAGMDL00095316	WAGMDL00095336		
P-19599	1/1/2006	Opana Dosing Pocket Guide (OP-0071)	ENDO_PA_00345644	ENDO_PA_00345663		
P-19600	3/5/2013	RE: Lortab out of stock 6033	WAGMDL00060597	WAGMDL00060599		
P-19601	6/1/2007	State Formulary Card (OP-0185)	ENDO_NMAG-00233471	ENDO_NMAG-00233570		
P-19602	2/19/2013	Re: Interstore from 11171 of gen. 10/650	WAGMDL00101723	WAGMDL00101732		
P-19603	2/1/2008	Package Insert (2002862)	ENDO_SF-00119940	ENDO_SF-00119945		
P-19604	8/15/2014	Rx Integrity tools & reports	WAGMDL00094965	WAGMDL00094967		
P-19605	2/7/2014	Non-Dispensing Controlled Substance Pharmacist Report	WAGMDL00095304	WAGMDL00095307		
P-19606	8/7/2013	Board Briefing Jan2013	WAGMDL00095577	WAGMDL00095579		
P-19607	1/24/2014	RE: RPH Non-dispensing report; Pharmacist Controlled Substance Dispensing Opportunities V3 (4)	WAGMDL00099513	WAGMDL00099515		
P-19608	7/25/2013	Re: DEA	WAGMDL00099852	WAGMDL00099854		
P-19609	1/25/2013	Order Inquiry	WAGMDL00107084	WAGMDL00107084		
P-19610	11/4/2016	Aug-Oct '16 COVP Slides; Monthly Store Manager Compliance Walk Through PPT (Tasha Polster)	WAGMDL00112831	WAGMDL00112850		
P-19611	11/12/2012	System Job Title: Manager Pharmaceutical Integrity	WAGMDL00112893	WAGMDL00112899		
P-19612	8/15/2013	Good Faith Dispensing Opportunities Report Now Available!	WAGMDL00113763	WAGMDL00113763		
P-19613	6/26/2006	Good Faith Practices/Fraudulent Prescriptions; TDGFD June 2016 Version; GFD Video	WAGMDL00254688	WAGMDL00254838		
P-19614	6/16/2017	TDGFD Green Belt Project Meeting	WAGMDL00254666	WAGMDL00254683		
P-19615	6/1/2006	Promise Brochure (RM-0001)	COLOR ENDO_SF-00154854	COLOR ENDO_SF-00154855		

P-19616	7/15/2017	RE: National TD GFD policy Powerpoint; Pharmacist Coaching Opportunities V2; Day 1 Policies, Prescription Processing	WAGMDL00256671	WAGMDL00256729		
P-19617	11/5/2012	FW: GFD Audit for store 2865 in Modesto, CA	WAGMDL00113808	WAGMDL00113810		
P-19618	N/A	Opana ER Dosing Guide (Updated) (OP-00907a)	ENDO_FLAG-00315547	ENDO_FLAG-00315564		
P-19619	9/27/2012	Changes in Schedule II Controlled Substances PDQ Ordering Process	WAGMDL00113824	WAGMDL00113824		
P-19620	12/7/2012	Pharmacy Purchasing & Supply Chain Quarterly Meeting; Pharmacy Purchasing & Supply Chain PP & SC Qtrly Meeting 013113 Final	WAGMDL00114602	WAGMDL00114625		
P-19621	3/1/2011	Patient Profile Joan OP-01065	COLOR_ENDO_FLAG-00320454	COLOR_ENDO_FLAG-00320459		
P-19622	4/27/2012	DEA Suspicious Store Ordering; DEA Suspicious Store Ordering Application Proposed Enhancement	WAGMDL00119539	WAGMDL00119541		
P-19623	3/1/2011	Opana ER Patient Profile Ray Shrinkwrapped in 25s OP-01066	COLOR_ENDO_FLAG-00320460	COLOR_ENDO_FLAG-00320467		
P-19624	10/25/2013	3 District Analysis	WAGMDL00286665	WAGMDL00286684		
P-19625	4/16/2012	RE: C2 orders for #13056	WAGMDL00119552	WAGMDL00119555		
P-19626	8/26/2013	Status 2013-08-26 - RX integrity Status (Polster and Bratton)	WAGMDL00286693	WAGMDL00286694		
P-19627	2/22/2013	GFD Pilot – Drug Sales Trends	WAGMDL00289179	WAGMDL00289185		
P-19628	3/1/2018	RE: UPDATED: REQUEST: Opioid Questions for Scripts Over 90MMEQs	WAGMDL00295193	WAGMDL00295199		
P-19629	4/17/2014	WAG pharmacist not following GFD	WAGMDL00300924	WAGMDL00300925		
P-19630	2/14/2013	FW: TD GFD Info	WAGMDL00303246	WAGMDL00303247		
P-19631	10/2/2012	Business Requirements DEA Suspicious Ordering - Phase 5 Project Number INVSO-54	WAGMDL00133996	WAGMDL00134003		
P-19632	11/12/2012	Investigation of Stores	WAGMDL00311368	WAGMDL00311369		
P-19633	10/31/2013	ABC visit	WAGMDL00237263	WAGMDL00237265		
P-19634	3/26/2013	FW: National Target Drug Good Faith Dispensing (TD GFD) Documents	WAGMDL00312837	WAGMDL00312884		
P-19635	4/30/2014	Tasha Polster Audit Goals	WAGMDL00316927	WAGMDL00316961		
P-19637	10/16/2012	RE: Walgreens # 2865 DEA: BW4243426	WAGMDL00242055	WAGMDL00242057		
P-19638	5/1/2014	Rx Integrity Audit Questions 2 & 3	WAGMDL00316962	WAGMDL00316991		
P-19639	12/7/2012	RE: Saturdays' holiday meeting challenges - Action Required!	WAGMDL00317073	WAGMDL00317074		
P-19640	4/10/2018	Lean Six Sigma Center of Excellence Update	WAGMDL00320805	WAGMDL00320835		
P-19641	10/9/2012	FW: ORDER OF INTEREST - WALGREENS 5088 (DEA # BB6213487)	WAGMDL00246284	WAGMDL00246285		
P-19642	1/9/2018	Re: UPDATED: REQUEST: Opioid Questions for Scripts Over 90MMEQs	WAGMDL00400710	WAGMDL00400714		
P-19643	1/8/2018	RE: UPDATED: REQUEST: Opioid Questions for Scripts Over 90MMEQs	WAGMDL00400743	WAGMDL00400746		
P-19644	11/5/2013	RE: NE Pharmacies	WAGMDL00407147	WAGMDL00407149		
P-19645	3/7/2012	The VIGIL System For Community Pharmacy Practice	WAGMDL00424919	WAGMDL00424936		
P-19646	10/16/2013	Rx Integrity Stored Procedures	WAGMDL00487296	WAGMDL00487297		
P-19647	8/6/2013	Status 2013-08-06 - Bratton; WAG RX integrity status (Polster and Bratton)	WAGMDL00491116	WAGMDL00491116		
P-19648	7/20/2017	RE: CSOS Multi Wholesaler flex estimate	WAGMDL00499380	WAGMDL00499383		
P-19649	12/12/2012	TD GFD market feedback	WAGMDL00502517	WAGMDL00502520		
P-19650	4/13/2013	DEA strategy meeting 4 12 13	WAGMDL00574828	WAGMDL00574831		
P-19651	4/7/2011	San Diego MOA	WAGMDL00578349	WAGMDL00578356		
P-19652	6/13/2012	Mindmap of Controlled Substances Program	WAGMDL00578421	WAGMDL00578437		
P-19653	9/13/2018	nacds pay history	WAGMDL00286426	WAGMDL00286428		
P-19654	N/A	Lunch and Learn Program (OP-007DR)	ENDO_FLAG-00353272	ENDO_FLAG-00353273		
P-19655	3/3/2015	GFD Training Outline notes	WAGMDL00656248	WAGMDL00656249		
P-19656	12/21/2012	Rannazzisi Presentation - Drug Trends Indianapolis - December 2012	WAGMDL00289068	WAGMDL00289178		
P-19657	5/5/2015	GFD Training Overview	WAGMDL00656379	WAGMDL00656380		
P-19658	1/1/2004	Adams Reprint: PK and Dose-proportionality Immediate Release (OP-0067 [sic])	ENDO_FLAG-00353347	ENDO_FLAG-00353350		
P-19659	1/1/2004	Gimbel Reprint Carrier: Postsurgical Pain Immediate Release (OP-0066)	ENDO_FLAG-00353355	ENDO_FLAG-00353358		
P-19662	3/6/2013	FW: Cardinal Meeting Today	WAGMDL00302958	WAGMDL00302960		
P-19663	1/1/2005	Clinical Reprint - Adams (OP-0063)	ENDO_FLAG-00353359	ENDO_FLAG-00353362		

P-19664	5/16/2017	FW: Rx integrity presentation; Market 26 6-11-14	WAGMDL00674920	WAGMDL00674946		
P-19665	9/9/2013	AMA GFD document 9 9 13 v2	WAGMDL00675213	WAGMDL00675214		
P-19666	10/22/2015	rxintegritywebcast 101915	WAGMDL00692057	WAGMDL00692126		
P-19667	6/11/2011	Customer Satisfaction Action Plan -editing; WAGMDL00698804	WAGMDL00698803	WAGMDL00698833		
P-19668	7/19/2013	Market Leader Meeting DEA Settlement Overview	WAGMDL00700079	WAGMDL00700138		
P-19669	9/14/2013	FY14 Performance and Bonus Metrics_v0	WAGMDL00706260	WAGMDL00706301		
P-19670	1/24/2014	FY14 RXM Tier 1 Bonus Plan	WAGMDL00706302	WAGMDL00706309		
P-19671	8/26/2018	FY19 Business Planning, Pharmacy & Retail Operations	WAGMDL00706531	WAGMDL00706589		
P-19672	8/26/2018	Talking Points for District and Area Leaders - IMPROVE Changes for FY19	WAGMDL00706590	WAGMDL00706592		
P-19673	7/26/2013	Controlled Substance Legend Drug Diversion Law Enforcement and Regulatory Perspective	WAGMDL00707693	WAGMDL00707780		
P-19674	10/1/2012	DEA Rx Mail Communications from June 2012; Email Controlled Substance Action Plan: Exception Store Visits and Survey	WAGMDL00316373	WAGMDL00316393		
P-19675	8/17/2012	Good Faith Dispensing Policy Actions Timeline	WAGMDL00709439	WAGMDL00709447		
P-19676	5/3/2012	Walgreens CII Drugs Procedure to Create President's Plaza Order Schedule II Three Distribution Places. New or Relocating Stores must set up schedule in SIMS. AS/400 Steps	WAGFLDEA00000117	WAGFLDEA00000117		
P-19677	12/7/2015	RE: triple cocktail Attachment CVS Decision	WAGMDL00037521	WAGMDL00037554		
P-19679	1/9/2013	RE: CII Orders	WAGMDL00415348	WAGMDL00415350		
P-19680	10/1/2012	Exception Store Audit Process	WAGMDL00317131	WAGMDL00317133		
P-19681	1/24/2019	Tab 10 - DEA Communication	WAGMDL00757759	WAGMDL00757761		
P-19682	10/12/2012	BuzzeePDMA SOM Seminar - Electronic Presentations; SOM Seminar - Regulatory Issues and Handling Increased Enforcement; The Basics: SOM Regulatory and Police Requirements; Through the Looking Glass: Legal Considerations for Your SOM Program; System Considerations-Computer Models, Algorithms, Statistics and More; Building an Effective Investigation Program; 2012 Powerpoint: Case Study- Real World SOM Challenges	WAGMDL00319129	WAGMDL00319239		
P-19683	1/8/2014	Re: Targeted drugs for GFD; Project Control3	WAGMDL00745706	WAGMDL00745711		
P-19684	6/11/2012	Controlled Substance Program Exec Sum 6 11 12	WAGMDL00745752	WAGMDL00745754		
P-19685	1/1/2007	OPANA ER Pill Comparison Sell Sheet (OP-0211)	ENDO_FLAG-00355432	ENDO_FLAG-00355433		
P-19686	9/1/2009	Walgreen Co. Management Incentive Plan	WAGMDL00747972	WAGMDL00747975		
P-19687	2/9/2015	FW: Controlled Substance Order Monitoring Process Review - Attachment A Draft; GFD Review Attach A Closing Meeting 2_05_15	WAGMDL00750223	WAGMDL00750242		
P-19688	2/5/2013	Operation Oxymoron	WAGMDL00762092	WAGMDL00762093		
P-19689	5/24/2012	Re: Walgreens Florida	WAGMDL00766469	WAGMDL00766475		
P-19690	11/27/2012	Navigating the Management of Chronic Pain	WAGMDL00766955	WAGMDL00766971		
P-19691	8/12/2015	Fiscal 2016 Pay Ranges for Front End Team Members and Fiscal 2016 Pay Ranges for Pharmacy Technicians and Pharmacy Interns	WAGMDL00773916	WAGMDL00773917		
P-19692	8/13/2012	Fw: MetroHealth 340B; Stores-Volume 073012	WAGMDL00797482	WAGMDL00797486		
P-19693	12/11/2017	Opioid Crisis Webinar 12-11-2017 Final	WAGMDL00334471	WAGMDL00334495		
P-19694	9/26/2012	FW: Check out this page on Nj.com	WAGNYAG00000018	WAGNYAG00000020		
P-19696	12/17/2019	Suffolk County Stores	WAGNYNS00000793	WAGNYNS00000793		
P-19697	4/2/2017	Re: Rx Compliance Issue	WAGNYNS00005866	WAGNYNS00005873		
P-19698	1/1/2012	Opana ER Branded Extended Release Sell Sheet (OP-02294)	ENDO_FLAG-00475229	ENDO_FLAG-00475234		
P-19699	7/21/2016	Stakeholders Challenges and Warning Signs Executive Summary and Consensus	WAGNYNS00017965	WAGNYNS00017982		
P-19700	8/27/2018	Improve Scorecard Talking Points (District and Area Leaders) 08272018 vF	WAGNYNS00020927	WAGNYNS00020989		
P-19701	12/7/2012	Prescriber Index - Potential Risk Prescriber Indexing	WAGNYNS00032014	WAGNYNS00032014		
P-19702	1/20/2020	Nassau pharmacists	WAGNYNS00032149	WAGNYNS00032149		
P-19704	2/5/2014	Manhattan Bronx clinic illegal distribution	WAGNYNS00032742	WAGNYNS00032746		
P-19705	11/16/2012	crazy idea; WALGREENS Pharmacy Baseline Information Request	WAGNYNS00033235	WAGNYNS00033241		
P-19706	1/30/2013	NY Hydrocodone	WAGNYNS00033288	WAGNYNS00033289		

P-19707	5/25/2012	Follow-up to Conference Call: Call Center Outreach; Store FAQ for Closing Prescriptions vF 5-25-201	WAGNYNS00033723	WAGNYNS00033725		
P-19708	9/23/2011	Oxy ER IOH vs Sales 09222011	WAGNYNS00033904	WAGNYNS00033905		
P-19709	10/28/2011	Suspicious Orders 7-1-11 to 7-15-11	WAGNYNS00033983	WAGNYNS00033984		
P-19710	6/5/2012	Corporate Org Chart	WAGMDL00387629	WAGMDL00387629		
P-19711	1/1/2012	Pharmacy Services Org Chart	WAGMDL00387631	WAGMDL00387631		
P-19712	N/A	Pharmacy Purchasing & Supply Chain Org Chart	WAGMDL00387632	WAGMDL00387632		
P-19713	7/21/2011	Suspicious Order 7/01/11 to 7/15/11	WAGNYNS00033985	WAGNYNS00033986		
P-19714	6/23/2011	Suspicious Order 06/01/2011 to 06/15/2011	WAGNYNS00033987	WAGNYNS00033988		
P-19715	7/6/2011	Suspicious Order June 15-30	WAGNYNS00033989	WAGNYNS00033990		
P-19716	6/11/2013	Appendix	WAGMDL00387708	WAGMDL00387974		
P-19717	9/28/2016	Annual Performance Review FY16 - Support Office Non-Retail-STEVEN MILLS	WAGMDL00389389	WAGMDL00389397		
P-19718	8/31/2016	Annual Performance Review FY16 - Support Office Non-Retail-STEVEN MILLS (1)	WAGMDL00389398	WAGMDL00389408		
P-19719	6/8/2011	Suspicious Order; 05-17-11 to 05-31-11	WAGNYNS00033991	WAGNYNS00033992		
P-19720	1/3/2012	Suspicious Control Drug Orders for Month of 12/2011	WAGMDL00394499	WAGMDL00394500		
P-19721	6/3/2014	more info from Naddi listserv	WAGNYNS00036489	WAGNYNS00036491		
P-19722	3/13/2013	RE: Walgreens Not Approved Orders; Control Data for Anda Stores	WAGNYNS00042555	WAGNYNS00042563		
P-19723	6/1/2012	NY Hydrocodone Report May 2012	WAGNYNS00043501	WAGNYNS00043501		
P-19724	4/20/2007	Suspicious Control Drug Orders for Month of 12/2006	WAGMDL00396133	WAGMDL00396134		
P-19727	9/26/2018	ohio cso override history updated drug list	WAGMDL00400358	WAGMDL00400358		
P-19730	6/25/2012	Pharmaceutical Distribution and Dispensing Integrity	WAGMDL00589682	WAGMDL00589690		
P-19731	N/A	Adams Reprint Carrier PK Dose	ENDO_FLAG-00577979	ENDO_FLAG-00577980		
P-19732	N/A	Store Manager Pharmacist Bonus Program	WAGFLDEA00000010	WAGFLDEA00000013		
P-19733	7/13/2010	Standards of Practice for the Dispensing of Controlled Substances for Treatment of Pain	WAGFLDEA00000463	WAGFLDEA00000464		
P-19734	11/4/2011	Control Substances and Good Faith Dispensing Outline	WAGFLDEA00000471	WAGFLDEA00000475		
P-19735	12/7/2011	Oxy percent data	WAGFLDEA00001288	WAGFLDEA00001327		
P-19736	N/A	NY Transactional Data	WAGNYNS00032151	WAGNYNS00032151		
P-19737	10/1/2011	Patient Profiles (OP-01758)	ENDO_GAAG-00018369	ENDO_GAAG-00018370		
P-19738	9/5/2012	Bill Winsley's presentation; Pain Clinics or Pill Mills - William T Winsley Presentation	WAGMDL00441397	WAGMDL00441431		
P-19739	10/1/2011	Patient Profiles (OP-01758)	ENDO_GAAG-00021745	ENDO_GAAG-00021752		
P-19740	5/3/2012	CII Strategy Set Up Process	WAGFLDEA00000124	WAGFLDEA00000124		
P-19741	5/6/2011	Walgreens Pharmacy and Health Care Code of Conduct and General Training	WAGFLDEA00000127	WAGFLDEA00000130		
P-19743	3/12/2013	National Target Drug Good Faith Dispensing Policy Final	WAGMDL00049775	WAGMDL00049780		
P-19744	12/17/2017	Good Faith Dispensing Checklist	WAGMDL00064897	WAGMDL00064898		
P-19745	8/1/1998	Good Faith Practices	WAGMDL00093366	WAGMDL00093368		
P-19746	3/12/2013	Store Potential Risk Index 03-07-13 through February	WAGMDL00489274	WAGMDL00489274		
P-19747	4/3/2013	Store Potential Risk Index 04-03-13 through March	WAGMDL00489276	WAGMDL00489276		
P-19748	8/7/2015	SOP Blocked Prescriber Process	WAGMDL00094681	WAGMDL00094683		
P-19749	4/1/2013	National Target Drug Good Faith Dispensing Policy	WAGMDL00289026	WAGMDL00289030		
P-19750	3/27/2013	National Target Drug Good Faith Dispensing Policy	WAGMDL00289054	WAGMDL00289057		
P-19751	6/1/2006	Opana ER PI Booklet (OP-0049 R1)	ENDO_SF-00333938	ENDO_SF-00333969		
P-19752	N/A	OPANA PI Booklet (OP-0048 R1)	ENDO_SF-00333970	ENDO_SF-00333997		
P-19756	4/4/2003	Good Faith Practices	WAGMDL00670938	WAGMDL00670939		
P-19757	8/1/1998	Good Faith Practices	WAGMDL00670940	WAGMDL00670941		
P-19758	1/20/2010	Project 09002 - Intercept Suspicious Orders Micro-ORPB305	WAGMDL00492076	WAGMDL00492081		
P-19759	2/9/2005	Good Faith Practices	WAGMDL00670942	WAGMDL00670943		
P-19760	2/24/2009	Q'sCommentNotess Suspicious Orders	WAGMDL00492160	WAGMDL00492163		
P-19761	10/11/2018	Managing Controlled Substance Theft or Loss	WAGMDL00674143	WAGMDL00674143		
P-19762	11/23/2012	Target Drug (TD) Good Faith Dispensing (GFD)	WAGMDL00675592	WAGMDL00675618		
P-19764	1/1/2006	Opana PI Booklet (OP-0048 R2)	ENDO_SF-00334082	ENDO_SF-00334109		
P-19767	6/20/2011	Controlled Substance Prescriptions & Good Faith Dispensing Policy	WAGMDL00767020	WAGMDL00767021		
P-19768	2/5/2013	20130205 DEA Subpoena No 17-13-341894	WAGMDL00493701	WAGMDL00493703		
P-19769	2/5/2013	20130205 DEA Subpoena No 17-13-341994	WAGMDL00493704	WAGMDL00493706		

P-19770	2/5/2013	20130205 DEA Subpoena No 17-13-342226	WAGMDL00493707	WAGMDL00493709		
P-19771	2/5/2013	20130205 DEA Subpoena No 17-13-342388	WAGMDL00493710	WAGMDL00493712		
P-19772	2/5/2013	20130205 DEA Subpoena No 17-13-342624	WAGMDL00493713	WAGMDL00493715		
P-19773	2/5/2013	20130205 DEA Subpoena No 17-13-343964	WAGMDL00493716	WAGMDL00493718		
P-19776	1/1/2013	Good Faith Dispensing PPT	WAGMDL00779090	WAGMDL00779114		
P-19777	3/22/2013	Good Faith Dispensing (GFD), Pharmaceutical Integrity	WAGMDL00779115	WAGMDL00779139		
P-19778	5/26/2015	Emailing Pharmaceutical Integrity June BCI questions	WAGFLAG00092402	WAGFLAG00092404		
P-19779	6/1/2006	OPANA ER Patient Information Brochure (OP-0072)	COLOR ENDO_SF-00445381	COLOR ENDO_SF-00445388		
P-19781	9/16/2012	RE: Update on Suspicious Ordering Monitoring	WAGMDL00528179	WAGMDL00528180		
P-19782	9/30/2011	Accepting and Filling New Prescriptions Policy	WAGMDL00801185	WAGMDL00801186		
P-19785	11/20/2012	Rex Status 12.12	WAGMDL00574824	WAGMDL00574825		
P-19788	5/3/2012	Dispensing Prescription Drugs Policy	WAGMDL00801301	WAGMDL00801301		
P-19792	4/30/2012	Good Faith Dispensing, Preventing the Inappropriate Use of Controlled Substances, Your Responsibilities	WAGMDL00801324	WAGMDL00801345		
P-19793	6/27/2007	Theft or Diversion of Prescription Drugs by Walgreens Family of Companies Employees	WAGMDL00801468	WAGMDL00801468		
P-19796	11/17/1999	Filling the Prescription	WAGMDL00801539	WAGMDL00801540		
P-19797	N/A	MSL-HCP Interaction Data	ENDO-CHI_LIT-01222012	ENDO-CHI_LIT-01222012		
P-19798	N/A	MSL-HCP Interaction Data	ENDO-CHI_LIT-01222013	ENDO-CHI_LIT-01222013		
P-19799	12/8/2015	PSO Committee Meeting; PSO presentation Feb	WAGMDL00608995	WAGMDL00609009		
P-19800	1/1/2007	Flashcard - TIMERx (OP-0121)	ENDO_FLAG-00694505	ENDO_FLAG-00694506		
P-19802	10/12/2017	Pharmacy Inventory Audit: prior audit documentation; Walgreen - AmerisourceBergen First Amendment to the Pharmaceutical Purchase and Distribution Agreement; Walgreen - AmerisourceBergen Second Amendment to the Pharmaceutical Purchase and Distribution Agreement; Walgreen - AmerisourceBergen Third Amendment to the Pharmaceutical Purchase and Distribution Agreement; Walgreen - AmerisourceBergen Settlement Agreement & Fourth Amendment to the Pharmaceutical Purchase and Distribution Agreement	WAGMDL00609699	WAGMDL00609859		
P-19804	4/1/2007	Opana ER Dosing Pocket Guide (OP-0140)	ENDO_FLAG-00837413	ENDO_FLAG-00837420		
P-19805	8/1/2006	Opana when writing for detail (OP-0058)	ENDO_FLAG-00907012	ENDO_FLAG-00907013		
P-19806	9/1/2006	Opana Dosing Insert (OP-0015A)	ENDO_FLAG-00908675	ENDO_FLAG-00908680		
P-19807	7/1/2006	Opana 4-page journal ad (OP-0016)	ENDO_FLAG-00908871	ENDO_FLAG-00908873		
P-19810	11/29/2016	NACDS PAC & Walgreen CoPAC	WAGMDL00612639	WAGMDL00612654		
P-19814	6/23/2008	The DEA Measurement	WAGMDL00624527	WAGMDL00624532		
P-19817	6/4/2012	CSR Talking Points 06-04-12	WAGMDL00625218	WAGMDL00625265		
P-19821	12/1/2010	Pharmacy Manager Bonus Program	WAGFLDEA00000001	WAGFLDEA00000005		
P-19822	1/1/2006	Patient Profile Oxycodone Conversion (Steve (OP-0165)	ENDO_FLAG-00912098	ENDO_FLAG-00912099		
P-19823	8/28/2009	Suspicious Ordering Pilot	WAGMDL00658227	WAGMDL00658227		
P-19825	10/1/2007	OPANA Detail Aid Navigator (OP-0198)	ENDO_FLAG-00913716	ENDO_FLAG-00913723		
P-19826	10/28/2014	FY14 Staff Pharmacist Bonus Calculations- District 3	WAGMDL00706318	WAGMDL00706319		
P-19827	11/9/2012	November 8th DEA meeting at NABP	WAGMDL00658246	WAGMDL00658248		
P-19830	6/17/2013	Jupiter C2 update	WAGMDL00660146	WAGMDL00660146		
P-19831	11/8/2011	DEA Statistics Aug.2011	WAGMDL00660329	WAGMDL00660330		
P-19832	N/A	FY17 Business Planning, Scorecards/Target Setting/Performance/Bonus, Pharmacy & Retail Operations	WAGMDL00706414	WAGMDL00706459		
P-19833	6/24/2010	Re: Fw: DEA Pilot Updates	WAGMDL00660344	WAGMDL00660353		
P-19835	7/1/2016	Walgreens Boots Alliance, Inc. Management Incentive Plan	WAGMDL00707619	WAGMDL00707623		
P-19840	10/16/2012	Divisional MIP Clarification	WAGMDL00757461	WAGMDL00757461		
P-19842	1/1/2013	FY2013 Management Incentive Plan- Pharmacy Purchasing, Eligibility, Measures, Funding and Computation	WAGMDL00757486	WAGMDL00757488		
P-19852	1/1/2007	OPANA ER Journal Ad Leave Behind (OP-0210)	ENDO_FLAG-00913801	ENDO_FLAG-00913802		
P-19853	5/1/2008	Premium Materials Depicted (OP-0244)	ENDO_FLAG-00916996	ENDO_FLAG-00917000		
P-19856	1/1/2013	Fiscal Year 2013 Management Incentive Plan - Community Operations, Eligibility, Measures, Funding and Compensation	WAGMDL00774326	WAGMDL00774328		
P-19857	5/1/2009	Senior Certified Technician Bonus Plan Details	WAGFLDEA00000006	WAGFLDEA00000006		
P-19858	N/A	Secure Rx Program (OP-0222-A)	ENDO_FLAG-00917523	ENDO_FLAG-00917524		
P-19860	2/1/2008	Patient Prescribing Information (OP-0254E R)	ENDO_FLAG-00917660	ENDO_FLAG-00917663		

P-19861	8/27/2014	FY15 Business Planning & Performance Management	WAGMDL00706320	WAGMDL00706332		
P-19863	2/15/2017	FY16 Business Planning, Scorecards/Target Setting/Performance & Bonus, Pharmacy & Retail Operations	WAGMDL00706364	WAGMDL00706403		
P-19865	N/A	OPANA Brand Dosing Slide Rule (OP-0353)	ENDO_FLAG-00921385	ENDO_FLAG-00921386		
P-19866	2/1/2008	Opiana Sell Sheet (OP-0277)	ENDO_FLAG-00924315	ENDO_FLAG-00924318		
P-19871	10/11/2012	Duane Reade	WAGMDL00757462	WAGMDL00757463		
P-19873	1/1/2013	Fiscal Year 2013 Management Incentive Plan - Pharmacy, Health and Wellness, Eligibility, Measures, Funding and Compensation	WAGMDL00757489	WAGMDL00757491		
P-19880	2/22/2013	Re: Cardinal and DEA/Kaufman Call to Kermit	WAGMDL00705303	WAGMDL00705304		
P-19881	10/1/2012	Re: OXYCODONE no longer being ordered via PDQ	WAGMDL00705321	WAGMDL00705322		
P-19883	5/30/2013	New Rx Integrity Update May 2013	WAGMDL00707955	WAGMDL00707973		
P-19885	1/1/2006	Flashcard (OP-0120)	ENDO_SF-00483465	ENDO_SF-00483466		
P-19888	1/7/2013	Fiscal Year 2013 Management Incentive Plan - Specialty Solutions Group, Eligibility, Measures, Funding and Compensation	WAGMDL00774329	WAGMDL00774331		
P-19891	4/3/2012	DEA Compliance Task Force Meeting	WAGMDL00709482	WAGMDL00709484		
P-19892	1/24/2014	Walgreen Co. - Incentive Compensation Plan for Store Manager Tier 1	WAGMDL00706310	WAGMDL00706317		
P-19894	9/20/2017	Additional Business Planning FAQs	WAGMDL00706469	WAGMDL00706472		
P-19895	N/A	Sir Speedy Report	ENDO_SF-00500952	ENDO_SF-00500952		
P-19896	9/1/2003	Walgreen Management Incentive Plan	WAGMDL00747976	WAGMDL00747982		
P-19898	1/21/2016	Purdue ProductUpdate_MSA_FE	WAGMDL00749580	WAGMDL00749588		
P-19902	10/19/2012	Walgreens Management Incentive Plan (MIP) - Divisional Bonus Design and Calculations	WAGMDL00757464	WAGMDL00757471		
P-19903	1/1/2013	Fiscal Year 2013 Management Incentive Plan, Eligibility, Measures and Computation	WAGMDL00757482	WAGMDL00757483		
P-19904	12/22/2008	Exit Meeting Outline - DEA Review - Perrysburg DC - Date of Review: 11/17/2008 - 11/21/2008	WAGMDLPER00000020	WAGMDLPER00000027		
P-19905	1/1/2013	Fiscal Year 2013 Management Incentive Plan - Retail Pharmacy, Eligibility, Measures, Funding and Computation	WAGMDL00757492	WAGMDL00757494		
P-19908	9/20/2017	Pharmacists Merit Plan & 2017 Merit Conversation	WAGMDL00757627	WAGMDL00757627		
P-19910	10/8/2012	Focus on Profit Program	WAGMDL00767009	WAGMDL00767009		
P-19911	N/A	Sample Suspicious Orders	WAGMDL00767044	WAGMDL00767067		
P-19912	8/22/2011	Walgreen's Management Meeting in Weston	WAGMDL00768931	WAGMDL00768934		
P-19913	N/A	Distribution of Suspicious Order Reports	WAGMDL00768935	WAGMDL00768936		
P-19914	12/18/2012	DBPR v. WAG Final Order	WAGMDL00768937	WAGMDL00768942		
P-19915	2/22/2012	Notes from call with Susan Langston acting Division Program Manager	WAGMDL00770956	WAGMDL00770957		
P-19916	12/12/2018	Bamberg Personnel File - HIGHLY CONFIDENTIAL	WAGMDL00771049	WAGMDL00771140		
P-19917	1/6/2019	Bancroft Personnel File - HIGHLY CONFIDENTIAL	WAGMDL00771141	WAGMDL00771206		
P-19918	1/29/2019	Bish Personnel File - HIGHLY CONFIDENTIAL	WAGMDL00771207	WAGMDL00771272		
P-19919	12/13/2018	Bratton Personnel File - HIGHLY CONFIDENTIAL	WAGMDL00771273	WAGMDL00771356		
P-19920	1/21/2019	Diebert Personnel File - HIGHLY CONFIDENTIAL	WAGMDL00771357	WAGMDL00771401		
P-19921	1/21/2019	Dymon Personnel File - HIGHLY CONFIDENTIAL	WAGMDL00771402	WAGMDL00771468		
P-19922	1/9/2019	Lanzetti Personnel File - HIGHLY CONFIDENTIAL	WAGMDL00771469	WAGMDL00771530		
P-19923	12/13/2018	Martin Personnel File - HIGHLY CONFIDENTIAL	WAGMDL00771531	WAGMDL00771584		
P-19924	1/11/2019	Merritello Personnel File - HIGHLY CONFIDENTIAL	WAGMDL00771585	WAGMDL00771606		
P-19925	9/20/2013	Annual Performance Review (FY11) - Core (Senior Management)	WAGMDL00771607	WAGMDL00771643		
P-19926	12/17/2018	Peterson Personnel File - HIGHLY CONFIDENTIAL	WAGMDL00771644	WAGMDL00771646		
P-19927	1/18/2019	Polster Personnel File - HIGHLY CONFIDENTIAL	WAGMDL00771647	WAGMDL00771753		
P-19928	1/11/2019	Zaccaro Personnel File - HIGHLY CONFIDENTIAL	WAGMDL00771754	WAGMDL00771790		
P-19930	1/6/2013	December Controls Data	WAGMDL00774295	WAGMDL00774295		
P-19931	1/1/2008	Dosing Guide (OP-0255)	ENDO-OPIOID_MDL-07596391	ENDO-OPIOID_MDL-07596396		
P-19932	1/1/2006	OPANA ER Fact Sheet (OP-0160)	ENDO-OPIOID_MDL-07746569	ENDO-OPIOID_MDL-07746570		
P-19933	6/13/2012	Control Substance Suspicious Ordering Team	WAGMDL00774723	WAGMDL00774724		
P-19935	1/2/2013	FW: Top 500	WAGMDL00774760	WAGMDL00774760		
P-19936	4/1/2009	Caregiver Brochure - 10 booklets in 1 pack (OP-0385)	COLOR_ENDO-OPIOID_MDL-07767393	COLOR_ENDO-OPIOID_MDL-07767399		
P-19938	2/1/2007	Patient Product Information Brochure (OP-0123)	ENDO-OPIOID_MDL-07776946	ENDO-OPIOID_MDL-07776953		
P-19940	12/14/2012	Change Request Form-DEA 5a-Zero out order qty	WAGMDL00774793	WAGMDL00774795		



P-19941	12/14/2012	Change Request Form-DEA 5a-Limit Vendor Order at time of Generation	WAGMDL00774796	WAGMDL00774798		
P-19943	4/10/2012	Controlled Substance Order Monitoring and Prevention System	WAGMDL00777098	WAGMDL00777157		
P-19944	4/3/2012	Warrant for Inspection - Jupiter Distribution Center	WAGMDL00777158	WAGMDL00777160		
P-19951	9/13/2016	Walgreen Co. - Incentive Compensation Plan for Field Leaders, Pharmacy & Retail Operations Division - Fiscal Year 2016	WAGMDL00706355	WAGMDL00706362		
P-19952	3/18/2018	FY17 Business Planning, Scorecards/Target Setting/Performance/Bonus, Pharmacy & Retail Operations	WAGMDL00706404	WAGMDL00706413		
P-19953	7/14/2017	FY18 Business Planning, Scorecards/Target Setting/Performance/Bonus, Pharmacy & Retail Operations	WAGMDL00706473	WAGMDL00706520		
P-19954	2/1/2006	Rebate Coupon (OP-0084AR)	ENDO-OPIOID MDL-07821418	ENDO-OPIOID MDL-07821419		
P-19961	10/23/2012	FY2012 Corporate Management Incentive Plan Divisional MIPs, FAQ	WAGMDL00757472	WAGMDL00757477		
P-19963	1/7/2013	Fiscal Year 2013 Management Incentive Plan, Eligibility, Measures and Computation	WAGMDL00757484	WAGMDL00757485		
P-19964	10/11/2012	Retail Pharmacy Communication	WAGMDL00757495	WAGMDL00757496		
P-19972	3/9/2017	Fiscal 2017 Pay Ranges by Area, Store Management	WAGMDL00773914	WAGMDL00773914		
P-19974	3/9/2017	FY17 CSP Structure w Geo Diff	WAGMDL00773923	WAGMDL00773923		
P-19977	5/10/2017	Quintiles IMS and WAG Contract	WAGMDL00710215	WAGMDL00710215		
P-19978	7/25/2017	Notice Regarding Transaction with Walgreens Boots Alliance and Walgreen Co. involving 2,186 Rite Aid Stores, 3 Distribution Centers and Related Assets	WAGMDL00710216	WAGMDL00710218		
P-19979	12/13/2018	Data acquisition agreement for Chain Retail Pharmacy Data and Sales Data pt 2	WAGMDL00710230	WAGMDL00710240		
P-19980	12/28/2010	Data acquisition agreement for Chain Retail Pharmacy Data and Sales Data	WAGMDL00710241	WAGMDL00710249		
P-19981	12/29/2010	DATA ACQUISITION AGREEMENT FOR CHAIN RETAIL PHARMACY DATA AND SALES DATA between IMS Health Incorporated and Walgreens	WAGMDL00710250	WAGMDL00710269		
P-19982	10/1/2013	First Amendment	WAGMDL00710219	WAGMDL00710229		
P-19994	6/1/2009	OPANA Patient Assistance Program -Rolodex Card (OP-0400)	ENO000026879	ENO000026891		
P-19995	N/A	Library Materials	ENDO_SF-00589515	ENDO_SF-00589515		
P-19996	N/A	Library Materials	ENDO_SF-00589516	ENDO_SF-00589516		
P-20012	6/1/2015	GAO-15-471 - Report RE "Prescription Drugs More DEA Information about Registrants' Controlled Substances Role Could Improve Their Understanding and Help Ensure Access	N/A	N/A		
P-20013	6/20/2019	DOJ letter to Special Master Cohen RE "Response to Motion to Compel Filed by Rite Aid of Maryland, d/b/a Mid -Atlantic Customer Support Center"	N/A	N/A		
P-20031	N/A	Library Materials	ENDO_SF-00589529	ENDO_SF-00589529		
P-20032	N/A	Library Materials	ENDO_SF-00589530	ENDO_SF-00589530		
P-20035	N/A	Library Materials	ENDO_SF-00589531	ENDO_SF-00589531		
P-20038	N/A	Library Materials	ENDO_SF-00589538	ENDO_SF-00589538		
P-20040	N/A	Library Materials	ENDO_SF-00589539	ENDO_SF-00589539		
P-20045	N/A	Cadent OPANA ER 2011-2013-Agg Spend Speaker Only	ENDO-OPIOID MDL-07397045	ENDO-OPIOID MDL-07397045		
P-20050	N/A	2021.09.02 SpeakerNet (Blanks and Invalid Values)(AllPgrmDetails)	ENDO-OPIOID_MDL-07540773	ENDO-OPIOID_MDL-07540773		
P-20051	N/A	SpeakerNetReadOnly_ProgramDetails_extracted_20210928	ENDO-OPIOID_MDL-08167703	ENDO-OPIOID_MDL-08167703		
P-20052	N/A	IMSEngage_Pharmacy_Calls_extracted_20210929	ENDO-OPIOID_MDL-08167704	ENDO-OPIOID_MDL-08167704		
P-20074	N/A	OPANA ER Call Data - CA Only	ENDO-CA-00000001	ENDO-CA-00000001		
P-20085	N/A	Materials Dropped Data File - CA Only	ENDO-CA-00164788	ENDO-CA-00164788		
P-20101	N/A	SpeakerNet_EAT_Rpt_Agg_Spend_Report_extracted_20210916	ENDO-OPIOID_MDL-08000597	ENDO-OPIOID_MDL-08000597		
P-20103	2006	Master Grid	KP360_OHIOMDL_000002773	KP360_OHIOMDL_000002777		
P-20106	11/13/2006	San Francisco - CA B151-003	KP360_OHIOMDL_000003337	KP360_OHIOMDL_000003338		
P-20109	10/3/2007	B173 9 San Francisco Invite	KP360_OHIOMDL_000028501	KP360_OHIOMDL_000028502		
P-20113	1/12/2009	DOJ Release: Rite Aid Corporation and Subsidiaries Agree to Pay \$5 Million in Civil Penalties	N/A	N/A		
P-20114	11/3/2007	FINAL Fax Invite 10-1-07	KP360_OHIOMDL_000028505	KP360_OHIOMDL_000028506		
P-20115	2007	B173 Event Grid	KP360_OHIOMDL_000028535	KP360_OHIOMDL_000028535		
P-20117	2007	B174 Part Guide Formatted 9-25-07	KP360_OHIOMDL_000032767	KP360_OHIOMDL_000032823		

P-20121	11/13/2007	B191-18 Fax Invite_San Francisco	KP360_OHIOMDL_000038986	KP360_OHIOMDL_000038987		
P-20130	3/29/2006	B360 Invite 005	KP360_OHIOMDL_000056336	KP360_OHIOMDL_000056339		
P-20131	9/14/2012	DEA Serves A Suspension Order On Walgreens Distribution Center In Jupiter, Florida	N/A	N/A		
P-20149	2008	B442 Event Grid	KP360_OHIOMDL_000082053	KP360_OHIOMDL_000082055		
P-20178	10/16/2008	FaxInvite3 San Francisco	KP360_OHIOMDL_000092649	KP360_OHIOMDL_000092650		
P-20208	12/27/2007	DEA Dear Registrant Letter regarding obligations under the CSA.	US-DEA-00001767	US-DEA-00001772		
P-20213	3/5/2019	E. Bratton Errata	N/A	N/A		
P-20214	10/31/2008	B457 Event Grid	KP360_OHIOMDL_000092815	KP360_OHIOMDL_000092816		
P-20216	2008	B457 Guarantee & Count Grid.	KP360_OHIOMDL_000092939	KP360_OHIOMDL_000092940		
P-20217	4/10/2008	NIPC April 10 2008 Chronic Opioid Therapy Recording	KP360_OHIOMDL_000083738	KP360_OHIOMDL_000083738		
P-20218	5/13/2009	B737-2 Fax Invite - San Francisco	KP360_OHIOMDL_000115612	KP360_OHIOMDL_000115613		
P-20219	5/29/2008	B442-20 Chicago On-Site Recording-Partial	KP360_OHIOMDL_000083954	KP360_OHIOMDL_000083954		
P-20220	8/30/2013	RE: Order(s) on Hold - ABC SD#652245	Acquired Actavis_00877528	Acquired Actavis_00877553		
P-20221	10/9/2014	Email Cardinal Final Report; CARDINAL	ALLERGAN_MDL_03535165	ALLERGAN_MDL_03535167		
P-20222	2/3/2016	DEA Affairs Collaborative Audit Report for Actavis, Gurnee, Illinois, January 26-28, 2016	ALLERGAN_MDL_03535031	ALLERGAN_MDL_03535037		
P-20223	3/28/2016	Agenda; 2016 NJ AUDIT PLANx	ALLERGAN_SF_00168869	ALLERGAN_SF_00168871		
P-20224	4/25/2016	Corporate Controlled Substance Compliance	ALLERGAN_MDL_03535056	ALLERGAN_MDL_03535063		
P-20225	7/2/2015	Buzzco System with documents dated 7/2/2015	ALLERGAN_MDL_03740584	ALLERGAN_MDL_03740591		
P-20226	2/24/2016	2015 Annual Performance Review of William Simmons	ALLERGAN_MDL_03535112	ALLERGAN_MDL_03535116		
P-20227	3/21/2016	E-mail 3/21/2016; SOMS Presentation 3 21	ALLERGAN_MDL_03985536	ALLERGAN_MDL_03985562		
P-20228	3/21/2016	Controlled Substances - Pivot Tables and Raw Data 03.18.2016	ALLERGAN_MDL_03985562	ALLERGAN_MDL_03985562		
P-20229	3/21/2016	SOMS Order Volume Tracking	ALLERGAN_MDL_03985561	ALLERGAN_MDL_03985561		
P-20230	4/14/2016	FW: Chargeback	ALLERGAN_SF_00168882	ALLERGAN_SF_00168884		
P-20231	4/14/2016	00228203110 Feb 2016 slip sheet	ALLERGAN_SF_00168885	ALLERGAN_SF_00168885		
P-20232	2/6/2013	DEA Serves Another Walgreens Pharmacy An Order To Show Cause	N/A	N/A		
P-20233	3/31/2016	ABC 03/29/16 DEA FORM 106; DEA Form 106 for ABC	ALLERGAN_SF_00168876	ALLERGAN_SF_00168878		
P-20234	4/14/2016	RE: Order on Hold - HEB Pharmacy SD# 916555	ALLERGAN_MDL_03985512	ALLERGAN_MDL_03985512		
P-20235	3/23/2016	DI Call re: Suspicious Orders	ALLERGAN_MDL_03985505	ALLERGAN_MDL_03985505		
P-20236	3/16/2016	Email Roundtable	ALLERGAN_MDL_03985513	ALLERGAN_MDL_03985513		
P-20237	5/31/2013	SOMS Calls 05 May 2013	ALLERGAN_MDL_04176543	ALLERGAN_MDL_04176654		
P-20238	3/1/2021	Subpoena	N/A	N/A		
P-20239	12/14/2007	E-mail dated 12/14/2007 with attachment	ALLERGAN_MDL_00134142	ALLERGAN_MDL_00134144		
P-20240	10/3/2012	E-mail chain dated 10/03/2012 with attachments	ALLERGAN_MDL_01684814	ALLERGAN_MDL_01684818		
P-20241	10/3/2012	CEO SOM LIST060712	ALLERGAN_MDL_01684816	ALLERGAN_MDL_01684816		
P-20242	12/13/2011	E-mail chain dated 12/13/11 with attachment	ALLERGAN_MDL_02187950	ALLERGAN_MDL_02187953		
P-20243	1/8/2008	E-mail chain dated 1/8/08	Acquired Actavis_00094374	Acquired Actavis_00094375		
P-20244	1/9/2008	E-mail chain dated 1/9/08	Acquired Actavis_00094371	Acquired Actavis_00094373		
P-20245	6/16/2009	E-mail chain dated 6/16/2009	Acquired Actavis_01403511	Acquired Actavis_01403513		
P-20246	9/11/2009	E-mail chain dated 9/11/09	Acquired Actavis_00223893	Acquired Actavis_00223897		
P-20247	10/26/2009	E-mail chain dated 10/26/09	Acquired Actavis_00223976	Acquired Actavis_00223979		
P-20248	11/10/2009	E-mail chain dated 11/10/09 with attachment	ACTAVIS0638636	ACTAVIS0638640		
P-20249	11/23/2009	E-mail chain dated 11/23/09 with attachment	Acquired Actavis_00224084	Acquired Actavis_00224086		
P-20250	11/25/2009	E-mail dated 11/25/09	Acquired Actavis_00094199	Acquired Actavis_00094199		
P-20251	12/1/2009	E-mail chain dated 12/01/09 with attachment	ALLERGAN_MDL_01406602	ALLERGAN_MDL_01406618		
P-20252	12/3/2009	E-mail dated 12/3/09	Acquired Actavis_00097339	Acquired Actavis_00097339		
P-20253	2/10/2010	E-mail dated 2/10/10	Acquired Actavis_00094385	Acquired Actavis_00094385		
P-20254	3/25/2010	E-mail dated 3/25/10	ALLERGAN_MDL_02960957	ALLERGAN_MDL_02960957		
P-20255	9/20/2010	E-mail chain dated 09/20/10 with attachment	Acquired Actavis_02234660	Acquired Actavis_02234662		
P-20256	10/9/2010	E-mail chain dated 10/9/10	Acquired Actavis_00215788	Acquired Actavis_00215789		
P-20257	3/25/2011	E-mail dated 3/25/11 with attachment	ALLERGAN_MDL_04388147	ALLERGAN_MDL_04388149		
P-20258	5/6/2011	E-mail dated 5/6/11	ALLERGAN_MDL_00145802	ALLERGAN_MDL_00145805		
P-20259	6/28/2011	E-mail chain dated 6/28/2011	ALLERGAN_MDL_00133308	ALLERGAN_MDL_00133309		
P-20260	6/28/2011	E-mail chain dated 6/28/11	ACTAVIS0361554	ACTAVIS0361558		
P-20261	6/30/2011	E-mail chain dated 6/30/11	ACTAVIS0361255	ACTAVIS0361256		
P-20262	8/25/2011	E-mail chain dated 8/25/11 with attachments	ACTAVIS0351275	ACTAVIS0351334		
P-20263	11/15/2011	E-mail chain dated 11/15/11 with attachments	Acquired Actavis_00664496	Acquired Actavis_00664500		

P-20264	12/1/2011	E-mail dated 12/1/11	Acquired_Actavis_00481451	Acquired_Actavis_00481465		
P-20265	1/5/2012	Meeting Reminder for 1/5/12	ALLERGAN_MDL_00235376	ALLERGAN_MDL_00235376		
P-20266	1/10/2012	E-mail chain dated 1/10/12	Acquired_Actavis_00231796	Acquired_Actavis_00231800		
P-20267	2/6/2012	E-mail dated 2/6/12	Acquired_Actavis_01609002	Acquired_Actavis_01609002		
P-20268	2/7/2012	E-mail chain dated 2/7/12 with attachment	ACTAVIS1129569	ACTAVIS1129570		
P-20269	3/28/2012	E-mail chain dated 3/28/12	Acquired_Actavis_00258814	Acquired_Actavis_00258815		
P-20270	12/6/2012	E-mail dated 12/6/12 with attachments	ACTAVIS1134924	ACTAVIS1134928		
P-20271	8/13/2012	E-mail chain dated 8/13/12 with attachments	Acquired_Actavis_01224960	Acquired_Actavis_01224964		
P-20272	10/26/2009	Actavis U.S. Business Overview, October 26, 2009	ALLERGAN_MDL_02103833	ALLERGAN_MDL_02103882		
P-20273	3/16/2010	Law360 Article titled: "Alpharma To Pay \$42.5M Over Morphine Marketing," by Erin Marie Daly, 3/16/10	N/A	N/A		
P-20274	6/30/2011	E-mail chain dated 6/30/11	Acquired_Actavis_00232008	Acquired_Actavis_00232008		
P-20275	8/8/2011	E-mail chain dated 8/8/11	ALLERGAN_MDL_04388444	ALLERGAN_MDL_04388445		
P-20276	1/9/2012	E-mail dated 1/9/12	Acquired_Actavis_00664230	Acquired_Actavis_00664232		
P-20277	2/7/2012	E-mail chain dated 2/7/2012 with attachment	ALLERGAN_MDL_00133407	ALLERGAN_MDL_00133408		
P-20278	3/11/2008	E-mail chain DATED 3/11/08 with attachments	ALLERGAN_MDL_01036958	ALLERGAN_MDL_01036971		
P-20279	4/2/2008	E-mail dated 4/2/08 with attachment	Acquired_Actavis_00002446	Acquired_Actavis_00002447		
P-20280	6/11/2009	Actavis U.S. Business Overview June 11, 2009	ALLERGAN_MDL_01017768	ALLERGAN_MDL_01017796		
P-20281	8/4/2009	E-mail chain dated 8/4/09 with attachment	ACTAVIS1132691	ACTAVIS1132698		
P-20282	12/4/2009	E-mail chain dated 12/4/09	ACTAVIS0638078	ACTAVIS0638079		
P-20283	2/10/2011	E-mail chain dated 2/10/11 with attachment	Acquired_actavis_00225064	Acquired_actavis_00225073		
P-20284	11/15/2011	E-mail chain dated 11/15/11 with attachment	ALLERGAN_MDL_01212165	ALLERGAN_MDL_01212169		
P-20285	11/15/2011	E-mail chain dated 11/15/11	ACTAVIS0337034	ACTAVIS0337037		
P-20286	2/14/2012	E-mail chain dated 2/14/12 with attachment	ALLERGAN_MDL_00134313	ALLERGAN_MDL_00134348		
P-20287	9/23/2011	Certificate of Amendment of Articles of Incorporation	N/A	N/A		
P-20288	7/31/2020	Allergan Finance, LLC, Allergan USA, Inc., and Allergan Sales, LLC's Objections and Responses to Plaintiffs' First Discovery Requests to Defendant Group 3	N/A	N/A		
P-20289	7/15/2011	Latest version of workshop; Targeting and Planning Workshop v15	ALLERGAN-NY-00037113	ALLERGAN-NY-00037140		
P-20290	N/A	Florida/West Virginia 30(b)(6) Quick Reference Sheet	N/A	N/A		
P-20291	11/2/2018	MDL 30(b)(6) Amended Deposition Aid	N/A	N/A		
P-20292	6/13/2019	California PMK Amended Deposition Aid	N/A	N/A		
P-20293	11/2/2018	MDL 30(b)(6) Amended Deposition Aid Topic 12	N/A	N/A		
P-20294	N/A	Timeline of Key Dates	N/A	N/A		
P-20295	N/A	Julie Snyder Continued PMK Deposition - Responses to Questions Provided by Plaintiff's Counsel	N/A	N/A		
P-20296	10/29/2021	Defendant Allergan Finance, LLC's First Amended Responses and Objections to Plaintiff's Rule 1.310(b)(6) Deposition Notice	N/A	N/A		
P-20297	11/19/2021	Allergan Defendants' Objections and Responses to Plaintiff's Notice of Deposition Pursuant to Rule 30(b)(7)	N/A	N/A		
P-20298	9/17/2021	Report of Carl C. Peck, M.D.	N/A	N/A		
P-20299	9/17/2021	Expert Report of Margaret K. Kyle, Ph.D.	N/A	N/A		
P-20300	9/30/2010	Kadian Konnection Newsletter	ALLERGAN_MDL_01115140	ALLERGAN_MDL_01115145		
P-20301	6/24/2010	Kadian Learning System	ALLERGAN_MDL_01108658	ALLERGAN_MDL_01109006		
P-20302	1/7/2011	Kadian Regional Business Update from National Sales Meeting	ALLERGAN_MDL_01745249	ALLERGAN_MDL_01745267		
P-20303	10/21/2010	Fwd: Fulfillment Web-Site	ALLERGAN_MDL_01197607	ALLERGAN_MDL_01197608		
P-20304	6/5/2011	Digital Direct Invoice for May 2011 Storage and Fulfillment	ALLERGAN_MDL_01104918	ALLERGAN_MDL_01104932		
P-20305	11/9/2011	Digital Direct Invoice for September and October 2011 Storage and Fulfillment	ALLERGAN_MDL_01267852	ALLERGAN_MDL_01267881		
P-20306	12/12/2011	Digital Direct Invoice for November 2011 Storage and Fulfillment	ALLERGAN_MDL_01740688	ALLERGAN_MDL_01740706		
P-20307	2/12/2013	DEA Serves An Order To Show Cause On Walgreen's Pharmacy In Fort Pierce	N/A	N/A		
P-20308	2/10/2011	Field Contact Report; Field Contact Form-Debbie Webb 02-01-2011	ALLERGAN_MDL_01200116	ALLERGAN_MDL_01200118		
P-20309	1/12/2012	Field Contact Form	ACTAVIS0475087	ACTAVIS0475090		
P-20310	8/26/2011	Oxymorphone Sellsheet Electronic	ALLERGAN_MDL_00480174	ALLERGAN_MDL_00480210		
P-20311	2/26/2010	Letter to FDA RE: NDA # 20-616 KADIAN Capsules Co-pay Assistance Program	ALLERGAN_MDL_01777324	ALLERGAN_MDL_01777334		

P-20312	2/23/2011	Letter to FDA RE: NDA # 20-616 KADIAN Capsules Co-pay Assistance Program	ALLERGAN_MDL_02105778	ALLERGAN_MDL_02105794		
P-20313	7/25/2011	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use - Kadian Co-Pay Assistance Program	ALLERGAN_MDL_02105545	ALLERGAN_MDL_02105562		
P-20314	4/6/2011	Moving Forward	Acquired_Actavis_01342085	Acquired_Actavis_01342085		
P-20315	1/9/2013	FormTrak On Demand Complete Process Flow	ALLERGAN_MDL_00990339	ALLERGAN_MDL_00990360		
P-20316	2/28/2011	Top Prescribers Gain/Loss	ALLERGAN_MDL_01193020	ALLERGAN_MDL_01193020		
P-20317	1/5/2004	CSC Audit Plan	ALLERGAN_MDL_03951953	ALLERGAN_MDL_03951956		
P-20318	2/2/2004	RE Suspicious Order Reports	ALLERGAN_MDL_02166472	ALLERGAN_MDL_02166473		
P-20319	8/26/2005	RE Licensing Dept. SOMS & FILE CABINETS	ALLERGAN_MDL_03951505	ALLERGAN_MDL_03951507		
P-20320	3/4/2004	RE Presc. Drug Hearing Webcast info	ALLERGAN_MDL_01034430	ALLERGAN_MDL_01034431		
P-20321	2/28/2005	RE Copiague Audit Report	ALLERGAN_MDL_03951925	ALLERGAN_MDL_03951944		
P-20322	3/7/2005	RE SOMS	ALLERGAN_MDL_03951637	ALLERGAN_MDL_03951638		
P-20323	7/19/2005	Email, Effective Immediately	Acquired_Actavis_02614942	Acquired_Actavis_02614942		
P-20324	10/13/2005	FW Oxycodone Quota	ALLERGAN_MDL_03952303	ALLERGAN_MDL_03952305		
P-20325	11/4/2005	FW SOMS Test in Flash	ALLERGAN_MDL_01843703	ALLERGAN_MDL_01843706		
P-20326	3/2/2006	RE FW DEA's response	ALLERGAN_MDL_03951323	ALLERGAN_MDL_03951324		
P-20327	9/1/2006	Email, Increased Fentanyl Abuse	ALLERGAN_NY_00001658	ALLERGAN_NY_00001658		
P-20328	11/27/2006	RE Revised presentation	ALLERGAN_MDL_03951248	ALLERGAN_MDL_03951254		
P-20329	12/11/2006	FW Southwood	ALLERGAN_MDL_03951772	ALLERGAN_MDL_03951821		
P-20330	2/19/2007	Email, Correspondence from DEA	ALLERGAN_SF_00096403	ALLERGAN_SF_00096407		
P-20331	4/25/2007	FW ABC Press Release	ALLERGAN_SF_00097076	ALLERGAN_SF_00097079		
P-20332	2/22/2013	DEA Serves An Order To Show Cause On Walgreen's Pharmacy In Fort Myers	N/A	N/A		
P-20333	9/26/2007	FW 2007 Hydrocodone Procurement Quota	ALLERGAN_MDL_03951635	ALLERGAN_MDL_03951636		
P-20334	9/27/2007	FW DEA-Industry Conference Report	Acquired_Actavis_01186764	Acquired_Actavis_01186765		
P-20335	12/13/2007	Email, Cardinal Health disciplined by DEA	ALLERGAN_MDL_03951072	ALLERGAN_MDL_03951073		
P-20336	1/3/2008	FW LETTER FROM DEA	ALLERGAN_MDL_03952888	ALLERGAN_MDL_03952890		
P-20337	6/11/2013	Walgreens Agrees To Pay A Record Settlement Of \$80 Million For Civil Penalties Under The Controlled Substances Act	N/A	N/A		
P-20338	2/5/2008	RE ZVMULDEA	ALLERGAN_MDL_03962690	ALLERGAN_MDL_03962961		
P-20339	2/6/2009	Email, Carmel Diversion Investigation Update	ALLERGAN_MDL_03955346	ALLERGAN_MDL_03955346		
P-20340	10/3/2012	Email, indirect oxy investigation	Acquired_Actavis_00351948	Acquired_Actavis_00351949		
P-20341	8/24/2017	FW ACTION REQUIRED MSA and SOW Circulating for Symproic Paitnet Buying Process (Walgreens)	PPLPC023000952522	PPLPC023000952528		
P-20342	10/12/2017	Shionogi And Purdue Pharma L.P. Announce U.S. Availability Of Symproic (Naldemedine) For The Treatment Of Opioid-Induced Constipation In Adults With Chronic Non-Cancer Pain	N/A	N/A		
P-20343	12/3/2021	Mary Woods 30(b)(6) Deposition - Amended Dep Aid	N/A	N/A		
P-20344	8/24/2000	DEA Excess-Controlled Substance New Product Launch Memo	ALLERGAN_MDL_02166585	ALLERGAN_MDL_02166585		
P-20345	12/27/2007	Rannazzisi DEA Letter	ALLERGAN_MDL_02187202	ALLERGAN_MDL_02187203		
P-20348	9/21/2011	Buzzeeo-Cegedim SOM Assessment of Watson System	Teva_IQVIA-0020875	Teva_IQVIA-0020882		
P-20349	12/1/2021	Plaintiff's Amended Notice of Deposition Pursuant to Rule 30(b)(7) to Allergan Defendants	N/A	N/A		
P-20350	7/30/2020	Allergan Objections and Responses to Plaintiff's' First Discovery Requests to Defendant Group 3	N/A	N/A		
P-20358	9/1/2011	RE Florida shutting down pill mill clinics.	ALLERGAN_MDL_02128769	ALLERGAN_MDL_02128772		
P-20359	6/3/2011	Email, Spam Pill Mills (Florida)	ALLERGAN_MDL_00641473	ALLERGAN_MDL_00641474		
P-20360	5/14/2012	Email, Stocking Initiatives-Pharmacy Report	ALLERGAN_MDL_00390954	ALLERGAN_MDL_00390954		
P-20361	5/13/2009	Kadian Learning System 5.09	ALLERGAN_MDL_00439499	ALLERGAN_MDL_00439855		
P-20362	5/1/2012	Retailers Purchased last 12 Months	ALLERGAN_MDL_00391451	ALLERGAN_MDL_00391451		
P-20363	7/20/2011	DEA Request 72011 Indirect Sales FL	ALLERGAN_MDL_03799490	ALLERGAN_MDL_03799490		
P-20364	5/5/2010	5-5-10 San Francisco	KP360_OHIOMDL_000132694	KP360_OHIOMDL_000132694		
P-20365	12/20/2017	Symproic Buying Process Qualification - Final Report (Walgreens Project)	PPLPC016000322669	PPLPC016000322713		
P-20366	12/13/2021	Mary Woods PMK Deposition - Amended Dep Aid	N/A	N/A		
P-20367	12/13/2021	Mary Woods 30(b)(6) Deposition - Amended Dep Aid	N/A	N/A		
P-20368	2004	B039-034 Rep Invite San Francisco	KP360_OHIOMDL_000177771	KP360_OHIOMDL_000177777		
P-20369	11/18/2004	B039-034 Fax invite AMA San Francisco	KP360_OHIOMDL_000178305	KP360_OHIOMDL_000178305		

P-20516	6/5/2005	B077-020 Fax Invite AMA San Francisco, CA	KP360_OHIOMDL_000239739	KP360_OHIOMDL_000239739		
P-20529	9/14/2005	B095-07 SAN FRANCISCO Dinner Dialogues Rep Invite	KP360_OHIOMDL_000273155	KP360_OHIOMDL_000273156		
P-20549	9/3/2002	010-San Francisco Rep Invite letter	KP360_OHIOMDL_000284014	KP360_OHIOMDL_000284014		
P-20566	4/22/2014	RE: SUBSYS 222 for Linden Care Now In Route (Clearing Unused Walgreens Stock)	Anda_Opioids_MDL_0000426857	Anda_Opioids_MDL_0000426858		
P-20581	2004	SIF2007Backup_2004_extracted_20210719	ENDO-OPIOID_MDL-07391951	ENDO-OPIOID_MDL-07391951		
P-20582	2005	SIF2007Backup_2005_extracted_20210719	ENDO-OPIOID_MDL-07391953	ENDO-OPIOID_MDL-07391953		
P-20583	2006	SIF2007Backup_2006_extracted_20210719	ENDO-OPIOID_MDL-07391955	ENDO-OPIOID_MDL-07391955		
P-20584	2007	SIF2007Backup_2007_extracted_20210719	ENDO-OPIOID_MDL-07391957	ENDO-OPIOID_MDL-07391957		
P-20589	4/18/2013	FW: Opana ER/LAO Consumer Pathways - Final Results (email 3 of 3)	ENDO-OPIOID_MDL-00489614	ENDO-OPIOID_MDL-00489615		
P-20602	3/11/2016	WALGREENS_STORE_5821_02864	WAGMDL01002678	WAGMDL01002685		
P-20603	4/18/2019	Review GFD build for IT; GFD 2.0 Clinical GFD DUR	WAGMDL00911307	WAGMDL00911321		
P-20631	N/A	4729-5-20 Prospective drug utilization review	N/A	N/A		
P-20633	9/5/2021	Email Pharmacist POWER Schedules Attachments RPhTrainingSchedule_v12_09052012; RPhTrainingSchedule_POWER_v2_090512	WAGMDL00912291	WAGMDL00912293		
P-20634	9/7/2012	RE: Controlled substance language	WAGMDL00873548	WAGMDL00873549		
P-20635	11/15/2012	Respondent's Prehearing Statement	WAGMDL_T1_TX00002807	WAGMDL_T1_TX00002856		
P-20636	12/15/2012	FW: Streamlined Steps to GFD - Revised	WAGMDL00874808	WAGMDL00874810		
P-20637	12/31/2012	FW: Market 7 GFD Operational Plan - Action Required Attachments Good Faith Dispensing Market 7 Operational Plan; Key Points to Remember; Good Faith Dispensing Refusal Verbiage; GFD binder cover page	WAGMDL00905531	WAGMDL00905539		
P-20638	1/6/2013	FW: PRIORITY LIST: January 6th - January 12th	WAGMDL00871296	WAGMDL00871299		
P-20639	1/1/2012	DEA market leadership Jan2013 PowerPoint	WAGMDL01013472	WAGMDL01013497		
P-20640	3/15/2013	FW: National TD GFD Attachments National Target Drug - Good Faith Dispensing; National Target Drug Good Faith Dispensing Checklist; National Target Drug Good Faith Dispensing Policy; Prescriber Good Faith Dispensing Letter; Patient Internal Talking Points	WAGMDL00981059	WAGMDL00981098		
P-20641	4/8/2013	RE: Positions Currently Enrolled in Good Faith Dispensing of Controlled Substances - Policy Acknowledgment	WAGMDL00858191	WAGMDL00858193		
P-20642	9/30/2009	DEA Walgreens Order to Show Cause	WAGMDL00768976	WAGMDL00768979		
P-20654	N/A	Part 1301 - Registration of Manufacturers, Distributors, and Dispensers of Controlled Substances, Section 1301.74 Other Security controls for non-practitioners: narcotic treatment programs and compounders for narcotic treatment programs	N/A	N/A		
P-20656	2/22/2008	DEA Compliance Review - Woodland Distribution Center	WAGMDLPER00000350	WAGMDLPER00000352		
P-20657	2/22/2008	Woodland DC DEAR Review	WAGMDLPER00000338	WAGMDLPER00000349		
P-20658	7/28/2008	Mt. Vernon DC DEA Review	WAGMDLPER00000353	WAGMDLPER00000364		
P-20659	3/9/2006	Add to the DEA Manual	WAGMDL01166369	WAGMDL01166380		
P-20661	11/19/2010	Jupiter DC DEA Review Third Quarter Fiscal 2010 Index	WAGMDLPER00000379	WAGMDLPER00000643		
P-20662	12/15/2010	Controlled Substance / Pseudoephedrine	WAGMDL00851422	WAGMDL00851422		
P-20663	2/26/2012	Fw: C2	WAGFLDEA00001518	WAGFLDEA00001523		
P-20664	3/1/2012	Florida Trip - Best Practices and Comments	WAGFLDEA00001538	WAGFLDEA00001541		
P-20665	4/12/2012	Rescheduled: Policy Committee Meeting (Apr 13 10:00 CDT in 200 Wilmot/1A5)	WAGMDL00607195	WAGMDL00607203		
P-20666	N/A	National Hydrocodone Distributor Market Share to Retail and Chain Pharmacies in Dosage Unit 2004-2014	N/A	N/A		
P-20667	N/A	Candidate handbook, Certified in Healthcare Compliance (CHC)	N/A	N/A		
P-20668	N/A	National Oxycodone Distributor Market Share to Retail and Chain Pharmacies in Dosage Unit 2004-2014	N/A	N/A		
P-20669	N/A	Walgreens National Distribution of Oxycodone & Hydrocodone 2006-2012	N/A	N/A		
P-20670	1/16/2013	DLPM Store Walk Review; Compass DLPM Store Walk Inputs	WAGMDL01167480	WAGMDL01167482		
P-20671	1/16/2013	Quarter 3 Compliance Day Checklist; Quarter 3 Compliance Day Checklist; Help Document - Q3 Compliance Day Checklist	WAGNYAG00006667	WAGNYAG00006690		
P-20672	10/2/2014	Draft Message for Greg Wasson	WAGMDL01174482	WAGMDL01174548	WAGMDL01174482 - WAGMDL01174548	

P-20673	2/24/2019	RE: Monitoring Protocol Policy Mapping; Response to EY questions on Monitoring Assessment 2 23 19	WAGMDL01137448	WAGMDL01137496	WAGMDL01137448 - WAGMDL01137496	
P-20674	4/20/2015	More EOC work; Compliance and Privacy Division Legal Division Town Hall Overview of Compliance and Privacy	WAGMDL01175945	WAGMDL01175945		
P-20675	7/28/2008	Mt-Vernon- Internal Audit Report	WAGMDL00757569	WAGMDL00757570		
P-20711	N/A	Sales calls filtered for Martin Teshar	TEVA_MDL_A_00763717	TEVA_MDL_A_00763717		
P-20713	2004	B273 Neuropathic Pain Spring Meetings-Master Grid	KP360_OHIOMDL_000354126	KP360_OHIOMDL_000354126		
P-20714	5/5/2004	B279 Fax Invite 005 San Francisco AMA Combined Final	KP360_OHIOMDL_000360625	KP360_OHIOMDL_000360627		
P-20715	6/17/2004	B284 Invite 020 San Francisco	KP360_OHIOMDL_000363678	KP360_OHIOMDL_000363680		
P-20718	2019	Physicians' Powerful Ally in Patient Care 2019 Annual Report	N/A	N/A		
P-20719	6/19/2019	MedPage Today, Don't Believe AMA's Hype, Membership Still Declining	N/A	N/A		
P-20721	11/19/2019	Inside Purdue Pharma's Media Playbook: How it Planted the Opioid - ProPublica	N/A	N/A		
P-20725	2/14/2017	Opioid-related morbidity and mortality: What every physician should know	N/A	N/A		
P-20727	11/16/2000	High-Tech Stealth Being Used to Sway Doctor Prescriptions - NYT	N/A	N/A		
P-20728	8/13/2018	The Augusta Chronicle - "Dr. Patrice Harris Talks about Opioids" Transcript of <a href="https://www.youtube.com/watch?v=kbToYDmh16M">https://www.youtube.com/watch?v=kbToYDmh16M</a>	N/A	N/A		
P-20729	2/16/2021	Letter RE: AMA's Opposition to Dose & Duration Guidance for Opioid Prescribing	N/A	N/A		
P-20769	2/24/2014	RANNAZISI MEMO ON SCHEDULED INVESTIGATION 10-27-09	US-DEA-00056902	US-DEA-00056915		
P-20772	10/12/2012	DEA-NABP 2012*Invite Letters	US-DEA-00026067	US-DEA-00026098		
P-20778	N/A	Video - What every prescriber should know about opioid morbidity and mortality	N/A	N/A		
P-20781	2004	Opioid Spring Meetings-Master Grid	KP360_OHIOMDL_000365156	KP360_OHIOMDL_000365156		
P-20782	12/15/2017	RE: OIC / DTC on Symproic (Adheris Health programs & Telephonic programs)	WAGFLAG03932788	WAGFLAG03932789		
P-20783	1/1/2000	"I got my life back" - Patients in pain tell their story. Case studies featuring Alan Spanos, M.D., M.A.	PDD1715107560	PDD1715107560		
P-20785	5/18/2009	Report Re: In-depth regulatory investigation of WALGREEN CO., 28727 Oregon Rd., Perrysburg, OH 43551, DEA #RW0294493	US-DEA-00033081	US-DEA-00033107		
P-20786	6/9/2015	Report Re: Case Closing and Regulatory Investigation of WALGREENS CORPORATION - DEA# RW0294493	US-DEA-00033064	US-DEA-00033077		
P-20787	5/25/2012	INFO: Suspicious Drug process	WAGMDL01172574	WAGMDL01172576		
P-20788	N/A	Steven Kneller CV and Performance Reviews	N/A	N/A		
P-20789	2/23/2013	Email National Target Drug Good Faith Dispensing (TD GFD) Documents Attachments	WAGNYAG00006361	WAGNYAG00006417	WAGNYAG00006361 - WAGNYAG00006417	
P-20790	3/10/2015	Email Stakeholders' Challenges and Red Flag Warning Signs Related to Prescribing and Dispensing Controlled Substances & Press Release Attachments	WAGMDL00502238	WAGMDL00502260		
P-20791	7/2/2015	Email Re: Phone call Attachments Therapeutic Top 20 - Dr. 1 from Advanced Pain Center; Therapeutic Top 20 - Dr. 2 from Advanced Pain Center	WAGMDL00095721	WAGMDL00095724		
P-20792	8/17/2011	Pharmacy Jurisprudence For Pharmacists in States with a Pharmacy Law Continuing Education (CE) requirement	WAGMDL00766972	WAGMDL00766988		
P-20793	12/1/2019	Rx Fulfillment, Research Report	TCS00000196	TCS00000281		
P-20794	11/20/2019	Email Inform: Walgreens Electronic Good Faith Dispensing (GFD) Pilot- Pharmacy Attachments Electronic Good Faith Dispensing Pilot Store List; Electronic Good Faith Dispensing (GFD) FAQs; Electronic Good Faith Dispensing Review Worksheet Job Aid	WAGMDL01037325	WAGMDL01037340		
P-20795	11/21/2019	Re: Inform: Walgreens Electronic Good Faith Dispensing (GFD) Pilot- Pharmacy	WAGMDL01037322	WAGMDL01037324		
P-20796	11/9/2011	Fw: Ohio Board of Pharmacy	WAGMDL00923236	WAGMDL00923237		
P-20797	10/1/2019	Email REVIEW: Sept. Portfolio Slides for Team Tasha Attachment Sept 2019 Portfolio Review	WAGMDL01071830	WAGMDL01071844		



P-20798	2012	Annual Performance Review (FY12) for Senior Managers, Review Period 9/1/2001 - 8/31/2012	N/A	N/A		
P-20799	10/11/2012	Fwd: Good Faith Dispensing - High Risk Products Discussion	WAGMDL01109078	WAGMDL01109081		
P-20800	3/17/2013	Email March legal issues	WAGMDL00797345	WAGMDL00797346		
P-20801	4/8/2013	FW: Target Drug Good Faith Dispensing Questions	WAGMDL00100054	WAGMDL00100056		
P-20802	4/5/2000	Trends in Medical Use and Abuse of Opioid Analgesics	N/A	N/A		
P-20803	6/30/2015	RE: T-GFD Sheets	WAGMDL00045962	WAGMDL00045963		
P-20804	7/13/2015	Controlled Substance Order Monitoring System Attachments	WAGMDL00750667	WAGMDL00750696		
P-20805	11/28/2017	WALGREENS_STORE_13058_05342	WAGMDL00963995	WAGMDL00963998		
P-20806	2/26/2021	Julie DeMay CV	WAGMDL01849126	WAGMDL01849242		
P-20808	4/1/2013	RE: Drug Abuse Powerpoint	WAGMDL01113458	WAGMDL01113482		
P-20810	N/A	4729-5-20 Prospective drug utilization review drafts	N/A	N/A		
P-20811	8/11/2011	Ohio Board New/Concerns	WAGMDL00923252	WAGMDL00923253		
P-20813	6/27/2006	RE Rep. Phil Gingrey, MD	PPLP004302953	PPLP004302953		
P-20814	1/16/2013	FW: Action Requested: NACDS DEA WG -- Code of Conduct Survey; Working Group Survey_Proposed Concepts WG Co-Chairs 1-16-13	WAGMDL00496402	WAGMDL00496418		
P-20815	11/7/2013	OARRS legislation introduced; HB 341 (Smith) 130th	WAGMDL00626214	WAGMDL00626283		
P-20816	9/24/2014	RE: Pharmacy Operations and Care Committee Conference Call; A Pharmacy Pilot or Demonstration Research Project for a New Practice Model for Community Pharmacy; Pharmacist Educational Program: Satisfying DEA Standards When Dispensing Controlled Substances By Larry Cote, Quarles & Brady And The National Association of Chain Drug Stores; Pharmacy Technician Educational Program: Satisfying DEA Standards For Controlled Substances; Store Manager Educational Program: DEA Compliance Overview; Re: Follow-Up Pharmacy Operations & Care Committee Call	WAGMDL01041660	WAGMDL01041713		
P-20861	8/23/2017	RE Question for you	PPLPC020001131773	PPLPC020001131774		
P-20876	11/27/2020	McKinsey Proposed Paying Pharmacy Companies Rebates for OxyContin Overdoses - NYT	N/A	N/A		
P-20877	11/18/2020	US Bankruptcy Court Southern District of New York In re: Purdue Pharma, L.P., et al.	N/A	N/A		
P-20878	11/18/2020	US Bankruptcy Court Southern District of New York In re: Purdue Pharma, L.P., et al. - Exhibits A thru J	N/A	N/A		
P-20879	11/18/2020	US Bankruptcy Court Southern District of New York In re: Purdue Pharma, L.P., et al. - Exhibits K thru Q	N/A	N/A		
P-20880	11/18/2020	US Bankruptcy Court Southern District of New York In re: Purdue Pharma, L.P., et al. - Exhibits R thru T	N/A	N/A		
P-20881	10/21/2020	Purdue 2020 Plea Agreement - Exhibit B	N/A	N/A		
P-20882	10/21/2020	Purdue 2020 Proposed Order in Bankruptcy Case	N/A	N/A		
P-20883	5/10/2007	Purdue Medical Officer, Goldenheim Guilty Plea	N/A	N/A		
P-20884	5/10/2007	Purdue President, Friedman Guilty Plea	N/A	N/A		
P-20885	5/31/2013	Walgreens Floricet Costs; MPU FAQ (2)	ALLERGAN_MDL_00993982	ALLERGAN_MDL_00993986		
P-20897	9/14/2006	Suspicious Week Ending 9-10-06 Pharmacy	Anda Opioids_MDL_0000124854	Anda Opioids_MDL_0000124854		
P-20898	N/A	Dihydromorphinone Hydrochloride (Dilaudid, Belhuber-Knoll): A Powerful Analgesic With Some Advantages Over Morphine.	Herzberg-000001	Herzberg-000004		
P-20899	2/1/2011	RE: Suspicious Order for Oxy SOP	ALLERGAN_MDL_02902065	ALLERGAN_MDL_02902066		
P-20927	2/4/2011	RE: Updated: Oxy IR Tabs Suspicious Order SOP Revised 2.1.2011	ALLERGAN_MDL_02939365	ALLERGAN_MDL_02939366		
P-20951	7/31/2006	Suspicious Week Ending 7-30-06	Anda Opioids_MDL_0000124856	Anda Opioids_MDL_0000124856		
P-20953	6/19/2006	Suspicious Week Ending 6-18-06 Pharmacy	Anda Opioids_MDL_0000124857	Anda Opioids_MDL_0000124857		
P-20967	2/5/2007	Suspicious Week Ending 2/4/07 Wholesalers	Anda Opioids_MDL_0000124859	Anda Opioids_MDL_0000124859		
P-20968	3/13/2012	FW: DEA SOR 03.08.12; DEA_SOR030812	ALLERGAN_MDL_01719895	ALLERGAN_MDL_01719897		
P-20970	5/1/2006	Suspicious Week Ending 4-30-06 Wholesalers	Anda Opioids_MDL_0000124860	Anda Opioids_MDL_0000124860		
P-21032	9/11/2012	FW: SOM Process Introduction, Training & Operating in a Parallel Environment	Acquired_Actavis_00099558	Acquired_Actavis_00099559		
P-21036	9/12/2012	RE: Last Question I Promise	Acquired_Actavis_00099564	Acquired_Actavis_00099564		
P-21042	10/1/2012	RE: Top 50 Oxy 15 and 30mg	Acquired_Actavis_00762262	Acquired_Actavis_00762262		

P-21046	10/18/2012	RE: Top 50 Pharmacies for Oxy 15; image001.gif; Top 50 Pharmacies Sales of Oxycodone 30 mg ABC.xls; Top 50 Pharmacies Sales of Oxycodone 15mg ABC.xls	ALLERGAN_MDL_00291683	ALLERGAN_MDL_00291687		
P-21048	10/8/2012	Cardinal Oxy IR Usages Letter - Updated for Bid; Oxycodone IR Tabs Letter to Cardinal Revised 2012 for Bidx	Actavis0378066	Actavis0378068		
P-21049	11/29/2012	ALERT PBA Oxycodone 30 mg - Keep a Close Eye on Ordering Frequency for the Remainder of Nov.; TMP10378	ACTAVIS0607596	ACTAVIS0607599		
P-21050	2/14/2012	RE: Safe and Secure	ALLERGAN_MDL_01725016	ALLERGAN_MDL_01725019		
P-21113	2/15/2007	Settlement Agreement	WMT_MDL_000043479	WMT_MDL_000043483		
P-21115	3/8/2012	RE: SOM PROJECT TEAM WEEKLY STATUS - Following Our Meeting on Tuesday 3.6, Basic_Compliance_Agreement_Form, Non Practitioner Site Review Questionnaire	TEVA_BALT_00711067	TEVA_BALT_00711074		
P-21135	10/25/2012	RE Indirect SOP, Indirect Sales SOM SOP033012	ALLERGAN_MDL_02448136	ALLERGAN_MDL_02448141		
P-21322	9/17/2012	I Came Up With a Group Name - The Fab 4 (Revised SOP), SOM SOP Direct 091712	ALLERGAN_MDL_02901931	ALLERGAN_MDL_02901935		
P-21325	N/A	Rachelle Galant Resume	GALANT MDL 00000001	GALANT MDL 00000002		
P-21327	1/25/2011	FW: Promotion Justification for Rachelle Galant, Promotion Justification for Rachelle Galant 1-2011	Acquired_Actavis_00184291	Acquired_Actavis_00184292		
P-21330	1/22/2007	Suspicious Week Ending 1-21-07 Wholesalers	Anda_Opioids_MDL_0000124862	Anda_Opioids_MDL_0000124862		
P-21333	N/A	Excerpt from Rachelle Galant Personnel File	ALLERGAN_MDL_SUPP_00000518	ALLERGAN_MDL_SUPP_00000632		
P-21335	4/16/2010	FW: Kadian HDMA Forms, HDMA Form 200mg.xlsx, HDMA Blank Form.xlsx, HDMA Form 10mg.xlsx, HDMA Form 20mg.xlsx, HDMA Form 30mg.xlsx, HDMA Form 50mg.xlsx, HDMA Form 60mg.xlsx, HDMA Form 80mg.xlsx, HDMA Form 100mg.xlsx	ALLERGAN_MDL_01798152	ALLERGAN_MDL_01798156		
P-21339	3/2/2012	RE Review; Rachelle Galant Goals 2011 End Year Appraisal w JM Comments	ACTAVIS0316680	ACTAVIS0316688		
P-21340	1/4/2012	RE: 867 Data	ALLERGAN_MDL_01067715	ALLERGAN_MDL_01067718		
P-21350	3/15/2011	RE: Valuetrak 150 SKUS	ALLERGAN_MDL_00291060	ALLERGAN_MDL_00291061		
P-21353	1/3/2012	Valutrak - Safe and Secure Presentation for Suspicious Order Monitoring	ALLERGAN_MDL_03532139	ALLERGAN_MDL_03532140		
P-21355	2/12/2006	Suspicious Week Ending 2-12-06 Wholesalers	Anda_Opioids_MDL_0000124863	Anda_Opioids_MDL_0000124863		
P-21357	2/7/2012	FW: MorphineER CB Trend Details 2.5.2012.xls, MorphineER CB Trend Details 2.5.2012.xls	ACTAVIS1129567	ACTAVIS1129568		
P-21359	9/21/2012	Kadian Target List T3 2012_20120921.xlsx	ALLERGAN_MDL_00407212	ALLERGAN_MDL_00407212		
P-21369	5/5/2011	Report : Ad hoc request: Opana Writers	ALLERGAN_MDL_00444677	ALLERGAN_MDL_00444677		
P-21370	5/5/2011	Opana ER 2010 YTD.xls	ALLERGAN_MDL_00444678	ALLERGAN_MDL_00444678		
P-21380	9/15/2011	Marketing Plan and Media Plan	ALLERGAN_MDL_00479902	ALLERGAN_MDL_00479902		
P-21399	9/15/2011	Actavis_Media_Plan_2011_110909a.xls	ALLERGAN_MDL_00479904	ALLERGAN_MDL_00479904		
P-21402	9/2/2011	FW: Revised marketing plan; MARKETING PLAN FOR ACTAVIS(3)	ALLERGAN_MDL_00493445	ALLERGAN_MDL_00493447		
P-21404	3/4/2009	Kadian Website Traffic Summary / e-Media	ALLERGAN_MDL_01101331	ALLERGAN_MDL_01101331		
P-21406	3/4/2009	KADIAN_Web_Report_090304	ALLERGAN_MDL_01101332	ALLERGAN_MDL_01101335		
P-21408	8/18/2010	RE Secondary website page	ALLERGAN_MDL_01110696	ALLERGAN_MDL_01110698		
P-21412	1/8/2009	RE Kadian - WEB Files	ALLERGAN_MDL_01190117	ALLERGAN_MDL_01190119		
P-21413	1/12/2009	RE recap of call	ALLERGAN_MDL_01190163	ALLERGAN_MDL_01190170		
P-21417	8/17/2010	RE Kadian Website	ALLERGAN_MDL_01235577	ALLERGAN_MDL_01235578		
P-21419	8/27/2006	Suspicious Week Ending 8-27-06 Wholesalers	Anda_Opioids_MDL_0000124865	Anda_Opioids_MDL_0000124865		
P-21420	1/28/2009	Kadian Co Pay Program Physician Announcement	ALLERGAN_MDL_01751145	ALLERGAN_MDL_01751147		
P-21421	9/1/2012	Kadian Sales Team Goals and Priorities	ALLERGAN_MDL_01782367	ALLERGAN_MDL_01782380		
P-21422	9/22/2010	Disc of Kadian Website	ALLERGAN_MDL_02104599	ALLERGAN_MDL_02104601		
P-21424	N/A	Kadian Website	ALLERGAN_MDL_02104602	ALLERGAN_MDL_02104614		
P-21425	N/A	Kadian Website Co-Pay Program	ALLERGAN_MDL_02104645	ALLERGAN_MDL_02104649		
P-21428	12/22/2011	Brochure for Kadian	ALLERGAN_MDL_02947286	ALLERGAN_MDL_02947287		
P-21430	8/26/2011	Oxymorphone Sellsheet Electronic	ACTAVIS0350872	ACTAVIS0350900		
P-21431	7/1/2012	Kadian Marketing Overview, Sales Representative Training	ALLERGAN_MDL_00026506	ALLERGAN_MDL_00026552		
P-21432	3/13/2009	Impact of Withdrawal of Field-Based Promotion for Kadian	ALLERGAN_MDL_00448421	ALLERGAN_MDL_00448440		
P-21441	8/3/2009	When You Can Prescribe Kadian Capsules	ALLERGAN_MDL_02104934	ALLERGAN_MDL_02104939		
P-21442	6/24/2009	Behind the Scenes The Kadian Capsules Story	ALLERGAN_MDL_02104948	ALLERGAN_MDL_02104951		
P-21443	3/7/2012	Kadian Dosing Guide	ALLERGAN_MDL_02105236	ALLERGAN_MDL_02105247		
P-21444	3/2/2012	NDA #20-616, KADIAN Electronic Sell Sheet	ALLERGAN_MDL_02105256	ALLERGAN_MDL_02105262		

P-21450	11/18/2011	NDA #20-616, KADIAN Co Pay Card	ALLERGAN MDL 02105286	ALLERGAN MDL 02105291		
P-21451	6/16/2011	NDA #20-616, KADIAN Formulary Letter	ALLERGAN MDL 02105564	ALLERGAN MDL 02105571		
P-21457	4/20/2011	NDA #20-616, KADIAN Direct Mail Primary Care	ALLERGAN MDL 02105628	ALLERGAN MDL 02105642		
P-21462	3/30/2011	NDA #20-616, KADIAN Direct Mail Target Non Target	ALLERGAN MDL 02105658	ALLERGAN MDL 02105662		
P-21465	2/23/2011	NDA #20-616, KADIAN Co Pay Assistance Program Professional	ALLERGAN MDL 02105779	ALLERGAN MDL 02105794		
P-21520	2/23/2011	NDA #20-616, KADIAN Co Pay Assistance Program Consumer	ALLERGAN MDL 02105796	ALLERGAN MDL 02105811		
P-21526	10/23/2012	4 New Strengths for Kadian	ALLERGAN MDL 02107016	ALLERGAN MDL 02107024		
P-21537	10/11/2012	4 New Strengths for Kadian	ALLERGAN MDL 02107030	ALLERGAN MDL 02107033		
P-21542	10/11/2012	Kadian 4 New Strengths	ALLERGAN MDL 02107034	ALLERGAN MDL 02107038		
P-21753	6/13/2011	FW: Consulting Proposal	HSI-MDL-00064822	HSI-MDL-00064825		
P-21754	5/26/2011	DRAFT letter re: SOM and Resume	HSI-MDL-00650515	HSI-MDL-00650522		
P-21755	N/A	Mike Mapes LinkedIn profile printout	N/A	N/A		
P-21756	8/12/2005	RE: Internet Pharmacy Presentation	US-DEA-00003880	US-DEA-00003881		
P-21758	9/12/2007	Claimant's Request for Production of Documents to Plaintiff - Presentation RE: DEA and the 13th Pharmaceutical Industry Conference held in TX	HDS_MDL_00002032	HDS_MDL_00002045		
P-21759	1/31/2004	Chemical Handler's Manual: A Guide to Chemical Control Regulations	WAGMDL00395965	WAGMDL00396033		
P-21760	7/1/2011	Walgreen Company - Cephalon (Inventory Data License Agmt)	TEVA MDL A_03448408	TEVA MDL A_03448418		
P-21761	8/25/2011	Introduction of Oxymorphone ER	ALLERGAN MDL 00684896	ALLERGAN MDL 00684902		
P-21769	1/31/2007	FW: Fentora SF-36 outstanding invoice Attachments: CEPHA 113871 NV809069; CEPHA 113871NV809108	TEVA MDL_A_06645189	TEVA MDL_A_06645196		
P-21842	N/A	CMA President elect Robert E. Wailes, M.D	N/A	N/A		
P-21843	N/A	Pain Management Oceanside CA	N/A	N/A		
P-21844	N/A	Wailes Open Payments Data - CMS	N/A	N/A		
P-21845	N/A	CV sent to Purdue by Robert E. Wailes	PDD1701192202	PDD1701192203		
P-21846	7/11/2021	Expert Report of Robert E. Wailes, MD (A1618205)- 7.11.21	N/A	N/A		
P-21847	6/29/2021	IMS Billing Statement	N/A	N/A		
P-21848	1985	Wailes v. Wailes, 480 So. 2d 600 - Ala_ Court of Civil Appeals 1985	N/A	N/A		
P-21852	6/4/2008	Attorney general eyes online drug database - Monterey Herald	N/A	N/A		
P-21853	2009	APS and AAPM Chou - Adler is Pacific Pain Management Consultants	N/A	N/A		
P-21854	1/31/2011	February National Leadership Roundtable	PPLPC022000400860	PPLPC022000400860		
P-21857	11/8/2011	RE: AAPM Delegate to AMA Dinner	PPLP004084753	PPLP004084754		
P-21858	12/15/2011	Prescription Drugs_ San Diego's Leading Cause Of Accidental Death_ KPBS Public Media	N/A	N/A		
P-21859	7/1/2013	AMA meeting_ Pharmacists warned on intruding into prescribing decisions - amednews.com	N/A	N/A		
P-21860	11/4/2013	FW: Clinical Trials - Clinical Investigator Form - Robert Wailes	PPLPC022000670734	PPLPC022000670734		
P-21861	12/21/2015	Robert E. Wailes, MD - Tri-City Medical Center	N/A	N/A		
P-21862	1/28/2019	Doctors call California's probe of opioid deaths a 'witch hunt' - Los Angeles Times	N/A	N/A		
P-21863	10/26/2020	San Diego anesthesiologist named CMA president elect	N/A	N/A		
P-21865	2019	Wailes CV from Pacific Pain Med website	N/A	N/A		
P-21866	N/A	Corresponding Responsibility, It's the Law. - California State Board of Pharmacy	N/A	N/A		
P-21867	9/9/2015	"Red Flag" Signs of Prescription Drug Abuse - State Medical Board of Ohio	N/A	N/A		
P-21871	N/A	What is ABMS Board Certification_ - American Board of Medical Specialties	N/A	N/A		
P-21872	2020	ABMS Guide to Medical Specialties, 2020	N/A	N/A		
P-21873	N/A	Corporate Support - American Academy of Pain Medicine	N/A	N/A		
P-21874	N/A	American Board of Pain Medicine	N/A	N/A		
P-21875	N/A	What about the American Board of Pain Management (ABPM) or the American Academy	N/A	N/A		
P-21876	2/12/2002	Oxycontin: Balancing Risks and Benefits - Senate Hearing 107-287	N/A	N/A		
P-21877	2014	CMA Strong, Physicians dedicated to the health of California - 2014 Annual Report	N/A	N/A		

P-21891	2007	DOJ - United Prescription Services, Inc.; Revocation of Registration	N/A	N/A		
P-21892	2008	DOJ - Medicine Shoppe-Jonesborough; Revocation of Registration	N/A	N/A		
P-21893	2/19/1998	Federal Register Vol. 63, No. 33 - Townwood Pharmacy; Revocation of Registration	N/A	N/A		
P-21894	2012	DOJ - Physicians Pharmacy, L.L.C.; Decision and Order	N/A	N/A		
P-21895	1/30/1998	Federal Register Vol. 63, No. 20 - Singer-Andreini Pharmacy; Revocation of Registration	N/A	N/A		
P-21896	6/14/1979	United States v. Hayes; 595 F.2d 258 (5th Cir. 1979)	N/A	N/A		
P-21909	6/22/2012	Renowned Economist Kevin M. Murphy to Become Senior Consultant to the Antitrust & Competition Economics Practice at Charles River Associates (CRA) - Business Wire	N/A	N/A		
P-21910	N/A	Kevin M. Murphy, Senior Consultant to CRA - Our People, Charles River Associates	N/A	N/A		
P-21911	8/1/1988	Becker, G., Murphy, K. - A Theory of Rational Addiction	N/A	N/A		
P-21916	2021	High & Rising Mortality Rates Among Working-Age Adults	N/A	N/A		
P-21917	8/11/2021	Twenty-Second Monthly Fee Statement of AlixPartners, LLP for Purdue Pharma bankruptcy	N/A	N/A		
P-21918	8/21/2021	Twenty-Third Monthly Fee Statement of AlixPartners, LLP for Purdue Pharma bankruptcy	N/A	N/A		
P-21919	10/12/2021	Twenty-Fourth Monthly Fee Statement of AlixPartners, LLP for Purdue Pharma bankruptcy	N/A	N/A		
P-21923	4/15/2014	DEA Museum - Lecture Series - Rx to Heroin transcript from Wayback Machine	N/A	N/A		
P-21924	N/A	Robert Hill - Prescription Drug Abuse	N/A	N/A		
P-21925	2014	Pharmacy Diversion Awareness Conference - April 5 and 6, 2014; St. Louis, Missouri	N/A	N/A		
P-21926	2009	Using Magic in the Teaching of Probability and Statistics	N/A	N/A		
P-21934	10/11/2021	Notice of Presentment of Application of Debtors for the Authority to Supplement Retention and Employment of Cornerstone Research for Antitrust Consulting Services Effective October 1, 2021	N/A	N/A		
P-21954	10/12/2012	High Value Retention Presentation	WAGFLAG00517805	WAGFLAG00517829		
P-21956	8/7/2015	FW: cii orders	WAGMDL00008287	WAGMDL00008288		
P-21957	7/1/2010	Home Study - KADIAN Learning System; LEARNING SYSTEM 07.01.2010	ALLERGAN_MDL_01739728	ALLERGAN_MDL01739920		
P-21958	6/24/2010	KADIAN Learning System	ALLERGAN_MDL_01108659	ALLERGAN_MDL_01109006		
P-21959	8/23/2010	KADIAN® KONNECTION	ALLERGAN_MDL_01110800	ALLERGAN_MDL_01110801		
P-21960	1/22/2007	Suspicious Week Ending 1-21-07	Anda_Opioids_MDL_0000124866	Anda_Opioids_MDL_0000124866		
P-21961	9/19/2011	Actavis Fee and Expense Invoice	ACTAVIS0810810	ACTAVIS0810810		
P-21962	1/15/2006	Suspicious Week Ending 1-15-06 Pharmacy	Anda_Opioids_MDL_0000124892	Anda_Opioids_MDL_0000124892		
P-21963	2/16/2009	Letter to FDA RE: NDA #20-616 Kadian: Co-pay Assistance Program	ALLERGAN_MDL_01777325	ALLERGAN_MDL_01777334		
P-21964	8/3/2009	Letter to FDA RE: NDA #20-616 Kadian: Sales Aid	ALLERGAN_MDL_01290412	ALLERGAN_MDL_01290420		
P-21965	11/6/2009	Letter to FDA RE: NDA #20-616 Kadian: Reprint	ALLERGAN_MDL_01466309	ALLERGAN_MDL_01466315		
P-21966	1/26/2010	RE: Robin Hagy setup for ordering supplies	Acquired_Actavis_01355763	Acquired_Actavis_01355763		
P-21967	2/3/2010	FW: Order Confirmation - Order Number 2468	Acquired_Actavis_00181720	Acquired_Actavis_00181721		
P-21968	8/24/2012	Kadian® Conversion Guide	ALLERGAN_MDL_00022915	ALLERGAN_MDL_00022946		
P-21971	11/18/2010	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use: Kadian Dosing Guide	ALLERGAN_MDL_02104572	ALLERGAN_MDL_02104583		
P-21972	3/31/2011	Digital Direct Invoice: March 2011 Storage and Fulfillment	ALLERGAN_MDL_01737072	ALLERGAN_MDL_01737091		
P-21973	7/29/2011	FW: Oxymorphone Mailing List to Trukmann; Oxymorphone Mailing List to Trukmann.xlsx	Acquired_Actavis_00380153	Acquired_Actavis_00380154		
P-21974	12/1/2010	KADIAN CARD INVENTORY (in regards to your recent request); 12-1-10 REP MAILING.XLS	ALLERGAN_MDL_01744311	ALLERGAN_MDL_01744312		
P-21975	9/15/2011	Copay Utilization Report	ALLERGAN_MDL_00399873	ALLERGAN_MDL_00399873		
P-21976	6/17/2010	Robin Hagy Field Ride; Robin Hagy Field Ride 0613-061410	ALLERGAN_MDL_01108568	ALLERGAN_MDL_01108571		
P-21977	11/1/2010	Field Contact Report 10-27-2010; Field Contact Form Robin Hagy 10-27-2010	ALLERGAN_MDL_01116177	ALLERGAN_MDL_01116178		

P-21978	12/11/2006	Suspicious Week Ending 12-10-06 Pharmacy	Anda_Opioids_MDL_0000124905	Anda_Opioids_MDL_0000124905		
P-21979	11/13/2006	Suspicious Week Ending 11-12-06 Wholesalers	Anda_Opioids_MDL_0000124906	Anda_Opioids_MDL_0000124906		
P-21980	1/8/2007	Suspicious Week Ending 01-07-07 Wholesalers	Anda_Opioids_MDL_0000124912	Anda_Opioids_MDL_0000124912		
P-21981	10/26/2011	Email, Updated West Region Roster	Acquired_Actavis_00182521	Acquired_Actavis_00182521		
P-21982	11/3/2011	Kadian Konnection November 2011 Newsletter	ACTAVIS0960348	ACTAVIS0960350		
P-21983	7/1/2010	Kadian Learning System	ALLERGAN_MDL_01739729	ALLERGAN_MDL_01739920		
P-21984	4/17/2012	Actavis-inVentive Health Sales Memo	KNOBLAUCH_0001	KNOBLAUCH_0001		
P-21985	7/18/2012	Email, Four Things	ACTAVIS0409702	ACTAVIS0409704		
P-21986	8/3/2012	Email, Confidential	ALLERGAN_MDL_00409199	ALLERGAN_MDL_00409200		
P-21987	1/9/2013	RE: KADIAN Team Aug-Dec 2012 Bonus Schedule; Kadian Team Bonus Payout Aug-Dec 2012	Acquired_Actavis_00364763	Acquired_Actavis_00364763		
P-21989	1/9/2013	Kadian Team Payout Roster Aug-Dec 2012 Bonus Schedule	Acquired_Actavis_00364764	Acquired_Actavis_00364764		
P-21990	11/18/2011	West Region Kadian Conference Call Meeting Invite	Acquired_Actavis_00182552	Acquired_Actavis_00182552		
P-21991	12/26/2006	Suspicious Week Ending 12-24-06 Wholesalers	Anda_Opioids_MDL_0000124913	Anda_Opioids_MDL_0000124913		
P-21992	12/7/2011	Field Contact Report-Knoblauch 12-7-2011	ALLERGAN_MDL_00396748	ALLERGAN_MDL_00396750		
P-21993	10/14/2010	FDA NDA Letter	ALLERGAN_MDL_02104585	ALLERGAN_MDL_02104597		
P-21994	3/29/2011	TeleSales Script Letter and Conversion Guide	ALLERGAN_MDL_02105693	ALLERGAN_MDL_02105724		
P-21995	9/13/2011	Shelf Talker	ALLERGAN_MDL_02105530	ALLERGAN_MDL_02105538		
P-21996	10/31/2011	Digital Direct October 2011 Invoice	ALLERGAN_MDL_01267855	ALLERGAN_MDL_01267856		
P-21997	2011	Medicare Part D Formulary Status Update	ALLERGAN_MDL_02522878	ALLERGAN_MDL_02522879		
P-21998	9/15/2011	Email, Released - KADI1124 & KADI1128	ALLERGAN_MDL_01440037	ALLERGAN_MDL_01440044		
P-21999	12/28/2011	HCP Kadian Co-Pay Marketing Pack	ALLERGAN_MDL_02947284	ALLERGAN_MDL_02947291		
P-22000	7/22/2011	RE A347 Oxymorphone Training materials	Acquired_Actavis_02230857	Acquired_Actavis_02230864		
P-22001	12/12/2011	Kadian Pharmacy Flyer	ALLERGAN_MDL_02105271	ALLERGAN_MDL_02105277		
P-22002	8/26/2011	Actavis oxymorphone campaign	ALLERGAN_MDL_00480175	ALLERGAN_MDL_00480203		
P-22003	1/31/2012	Digital Direct January 2012 Invoice	ALLERGAN_NY_00039039	ALLERGAN_NY_00039057		
P-22004	3/31/2012	March 2012 Storage & Fulfillment Invoice	ALLERGAN_MDL_01111684	ALLERGAN_MDL_01111699		
P-22005	8/30/2012	RE Kadian Co-pay cards	ACTAVIS0394773	ACTAVIS0394774		
P-22006	3/7/2012	RE Co-Pay Cards - Knoblauch	ALLERGAN_MDL_00988764	ALLERGAN_MDL_00988764		
P-22007	6/24/2021	Subpoena	N/A	N/A		
P-22008	N/A	Lisa Pehlke Resume	N/A	N/A		
P-22009	6/5/2009	Email, Oxycodone Sell Sheet	ALLERGAN_MDL_04394337	ALLERGAN_MDL_04394338		
P-22011	6/5/2009	Email, Fentanyl Improvements and sell sheet	ALLERGAN_MDL_04394341	ALLERGAN_MDL_04394345		
P-22012	8/26/2011	Email, Oxymorphone ER - need your help	ALLERGAN_MDL_04398547	ALLERGAN_MDL_04398576		
P-22013	12/1/2009	Email, Monthly Report	ALLERGAN_MDL_04387466	ALLERGAN_MDL_04387468		
P-22014	12/18/2009	FW: Kadian - Cardinal	ALLERGAN_MDL_01859743	ALLERGAN_MDL_01859745		
P-22015	2/26/2010	RE: NuCare Oxycodone Promotion	ALLERGAN_MDL_04395925	ALLERGAN_MDL_04395928		
P-22016	4/15/2010	RE: Kadian Offers	Acquired_Actavis_00399614	Acquired_Actavis_00399617		
P-22017	9/2/2010	RE: NACDS Input	ALLERGAN_MDL_04396677	ALLERGAN_MDL_04396680		
P-22018	10/15/2010	FW: Oxy tabs analysis at the wholesalers	Acquired_Actavis_00397465	Acquired_Actavis_00397467		
P-22019	2/5/2012	Sales Targets 2011	ALLERGAN_MDL_04445759	ALLERGAN_MDL_04445759		
P-22020	6/10/2011	RE: Keysource	Acquired_Actavis_00229510	Acquired_Actavis_00229512		
P-22021	9/26/2011	Email, ValueTrak Scheduled Report - Cardinal weekly inventory	ALLERGAN_MDL_04432741	ALLERGAN_MDL_04432751		
P-22022	10/10/2011	RE: Actavis Oxymorphone ER	ALLERGAN_MDL_04399067	ALLERGAN_MDL_04399072		
P-22023	2/17/2012	Actavis Sales Meeting	ALLERGAN_MDL_04407750	ALLERGAN_MDL_04407785		
P-22024	10/27/2011	RE: accounts that have open orders on Oxy that are not being allocated	Acquired_Actavis_00392713	Acquired_Actavis_00392717		
P-22025	2/21/2012	RE: Follow Up to Discussion	ACTAVIS0320032	ACTAVIS0320038		
P-22026	3/9/2012	FW: Oxycodone allocation agreement	ALLERGAN_MDL_04388984	ALLERGAN_MDL_04388987		
P-22027	2/22/2012	Email, McKesson - please call me...important	ALLERGAN_MDL_04401868	ALLERGAN_MDL_04401869		
P-22028	3/12/2007	Suspicious Week Ending 3-11-07 Pharmacy	Anda_Opioids_MDL_0000124914	Anda_Opioids_MDL_0000124914		
P-22029	12/18/2006	Suspicious Week Ending 12-17-06	Anda_Opioids_MDL_0000124923	Anda_Opioids_MDL_0000124923		
P-22030	7/5/2012	RE: C2 Ordering Contingency Plan	Acquired_Actavis_00353246	Acquired_Actavis_00353247		
P-22031	9/7/2012	FW: Orders on Hold - need a response	Acquired_Actavis_00395687	Acquired_Actavis_00395688		
P-22032	9/26/2012	RE: SOM update	Acquired_Actavis_01509421	Acquired_Actavis_01509421		
P-22033	1/17/2012	RE: NuCare - need a response please	ALLERGAN_MDL_04435652	ALLERGAN_MDL_04435655		
P-22034	3/31/2009	March CY 2009 Sales Report	ALLERGAN_MDL_01040463	ALLERGAN_MDL_01040465		
P-22035	2/16/2010	FW: Sales Report - Jan CY 2010	ALLERGAN_MDL_01698507	ALLERGAN_MDL_01698508		
P-22036	9/7/2012	FW: Orders on Hold - need a response	Acquired_Actavis_00762179	Acquired_Actavis_00762180		
P-22037	12/17/2009	RE: Oxycodone - Actavis	ALLERGAN_MDL_04395624	ALLERGAN_MDL_04395626		

P-22038	12/31/2008	Lisa Pehlke Performance Evaluation for 2008	Acquired_Actavis_00190748	Acquired_Actavis_00190751		
P-22039	12/31/2009	Lisa Pehlke Performance Evaluation for 2009	Acquired_Actavis_00969638	Acquired_Actavis_00969643		
P-22041	12/31/2010	Lisa Pehlke Performance Evaluation for 2010	Acquired_Actavis_01696270	Acquired_Actavis_01696278		
P-22042	12/31/2011	Lisa Pehlke Performance Evaluation for 2011	ALLERGAN_MDL_04407303	ALLERGAN_MDL_04407303		
P-22043	12/31/2012	Lisa Pehlke Performance Evaluation for 2012	Acquired_Actavis_00392084	Acquired_Actavis_00392093		
P-22044	N/A	6-Page Shelley Fitch Resume	N/A	N/A		
P-22045	1/8/2007	Suspicious Week Ending 01-07-07 Pharmacy	Anda Opioids MDL 0000124934	Anda Opioids MDL 0000124934		
P-22046	2/3/2012	RE: Training Agenda for New ABM Shelley Fitch; Kadian Training Agenda Feb. 6-7, 2012 (Fitch)	ALLERGAN_MDL_00000039	ALLERGAN_MDL_00000041		
P-22047	5/20/2009	FW: Kadian PI's; ABM Address File Kadian 74034.xls	Acquired_Actavis_00363568	Acquired_Actavis_00363569		
P-22048	7/6/2009	RE: 74094 Tracking.xls	ALLERGAN_NY_00036067	ALLERGAN_NY_00036068		
P-22049	10/20/2009	RE: 13964 Vis Aid and Insert; Actavis Drop Shipment.csv	ALLERGAN_MDL_01741534	ALLERGAN_MDL_01741541		
P-22050	10/23/2009	RE: 13964 Vis Aid and Insert	ALLERGAN_MDL_01196193	ALLERGAN_MDL_01196202		
P-22051	11/10/2009	RE: Kadian Package Insert; Tracking.xls	ALLERGAN_MDL_01113815	ALLERGAN_MDL_01113820		
P-22052	4/2/2012	FW: March 2012 Storage & Fulfillment; 20120402143740623	ALLERGAN_MDL_01741025	ALLERGAN_MDL_01741041		
P-22053	11/27/2012	RE: KAD-083 Kadian Detail Aid; image003.jpg; image004.gif; image.jpg; Nov 26th Tracking	ACTAVIS0678825	ACTAVIS0678843		
P-22054	6/9/2009	RE: Sales Aid Update; 22 KADI8D0231_Adv_Leave_Behind_DISKED	ALLERGAN_MDL_01103768	ALLERGAN_MDL_01103770		
P-22055	6/19/2009	FW: 74094; 74094A_lr	ALLERGAN_MDL_01103850	ALLERGAN_MDL_01103852		
P-22056	10/20/2009	RE: NDA # 20-616 KADIAN (morphine sulfate extended release) Capsules, 10, 20, 30, 50, 60, 80, 100 and 200 mg; KADIAN Conversion Guide	ALLERGAN_MDL_01466348	ALLERGAN_MDL_01466378		
P-22057	3/7/2012	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use; Kadian Conversion Guide	ALLERGAN_MDL_02105199	ALLERGAN_MDL_02105233		
P-22058	10/29/2009	RE: NDA # 20-616 KADIAN (morphine sulfate extended release) Capsules, 10, 20, 30, 50, 60, 80, 100 and 200 mg; KADIAN Sales Aid	ALLERGAN_MDL_02104857	ALLERGAN_MDL_02104877		
P-22059	2/1/2010	KADIAN Dosing Guide	ALLERGAN_MDL_01411000	ALLERGAN_MDL_01411010		
P-22060	2/16/2009	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use; Kadian Promotional Materials	ALLERGAN_MDL_01466324	ALLERGAN_MDL_01466333		
P-22061	11/4/2009	FW: Discussion at Lunch	ALLERGAN_MDL_01196332	N/A		
P-22062	12/7/2009	RE: October Sales Update	ALLERGAN_MDL_01196486	ALLERGAN_MDL_01196487		
P-22063	7/21/2009	RE: Co-Pay Card Limits	Acquired_Actavis_01350163	Acquired_Actavis_01350163		
P-22064	7/3/2012	RE: Co-Pay Cards West Region	ACTAVIS0867734	ACTAVIS0867739		
P-22065	12/11/2009	RE: Co-Pay Card Service Flash; CH Service Flash v2 121009	ALLERGAN_MDL_01114084	ALLERGAN_MDL_01114086		
P-22066	2/14/2012	RE: Co-Pay Cards - Shelly Fitch	ALLERGAN_MDL_01609574	ALLERGAN_MDL_01609576		
P-22067	7/22/2009	FW: Targets; San Francisco Target List.xlsx; San Diego-LA.xlsx; Las Vegas Target List.xlsx	ALLERGAN_MDL_01736598	ALLERGAN_MDL_01736602		
P-22068	8/9/2012	RE: Universe File 2 of 2; Kadian Drop/Add Listing	ACTAVIS0703331	ALLERGAN_MDL_01890663		
P-22069	3/5/2010	RE: NDA 20-616 Kadian (morphine sulfate extended release) Capsules, CII MACMIS #18148	ALLERGAN_CA_00169045	ALLERGAN_CA_00169051		
P-22070	10/31/2012	Kadian Dosing Guide	ALLERGAN_MDL_01126762	ALLERGAN_MDL_01126779		
P-22071	1/10/2011	NDA #20-616, KADIAN Shelf Talker, KAD11014	ALLERGAN_MDL_02104539	ALLERGAN_MDL_02104545		
P-22072	9/2/2010	RE NDA #20-616 Kadian Dear Consumer Letter	ALLERGAN_MDL_02104760	ALLERGAN_MDL_02104773		
P-22073	9/2/2010	RE NDA #20-616 Kadian Dear Health Care Professional Letter	ALLERGAN_MDL_02104775	ALLERGAN_MDL_02104791		
P-22074	N/A	Table 12 Cumulative and Annual Prescriptions, 1997-2017	CA_PNP_000008672	CA_PNP_000008672		
P-22075	N/A	IQVIA CA Cumulative and annual Prescriptions 1997-2017	CA_PNP_000008675	CA_PNP_000008675		
P-22076	N/A	Table 13 Labeler Market Share of Opioid Prescriptions	CA_PNP_000008670	CA_PNP_000008670		
P-22077	N/A	Table 4 Labeler Market Share of Opioid Prescriptions	CA_PNP_000008669	CA_PNP_000008669		
P-22078	N/A	Table 9 Opioid Prescribing by County	CA_PNP_000008668	CA_PNP_000008668		
P-22079	1/27/2021	California Opioid Overdose Surveillance Dashboard	CA_PNP_000007040	CA_PNP_000007042		
P-22080	6/13/2019	CA PMK Deposition, Topics and Responses, Julie Snyder	N/A	N/A		
P-22081	11/2/2018	MDL 30(b)(6) Deposition - November 2, 2018 Deposition, Topics and Responses	N/A	N/A		
P-22082	11/8/1932	Letter Re: Purchases of Dilaudid from Merck	Herzberg-000005	Herzberg-000005		
P-22083	10/29/1932	Newsletter Re New Drug is Five Times as Powerful as Morphine	Herzberg-000006	Herzberg-000006		
P-22084	7/20/1933	Dilaudid, A Morphine Derivative, An Advance in Opiate Medication; Letter from H.J. Anslinger	Herzberg-000007	Herzberg-000011		



P-22085	N/A	Advertisement, Dilaudid, Five Times Stronger Than Morphine	Herzberg-000012	Herzberg-000012		
P-22086	10/11/1933	Letter from H.J. Anslinger to Bilhuber-Knoll Corporation	Herzberg-000013	Herzberg-000015		
P-22087	8/17/1933	Treasury Dept. Letter Re Dilaudid Pamphlet	Herzberg-000016	Herzberg-000016		
P-22088	10/3/1933	Treasury Dept. Letter Re Dilaudid Pamphlet	Herzberg-000017	Herzberg-000017		
P-22089	10/14/1933	Letter from Bilhuber-Knoll Corp. re Dilaudid Pamphlet	Herzberg-000018	Herzberg-000018		
P-22090	3/25/1944	March 25, 1944 Letter from Robert Hoffman, MD Re Demerol	Herzberg-000019	Herzberg-000021		
P-22091	8/7/1944	Letter from Robert Hoffman, MD to U.S. Treasury Re Demerol	Herzberg-000022	Herzberg-000024		
P-22092	12/12/1944	Treasury Dept. Letter Re Habit Forming Properties of Demerol	Herzberg-000025	Herzberg-000026		
P-22094	12/1/1943	Demerol, a New Departure in Anesthesia, An Evaluation of Present Day Therapeutic Claims	Herzberg-000030	Herzberg-000033		
P-22095	3/1/1943	A Report of Experiences With Demerol, A New Departure in Analgesia	Herzberg-000034	Herzberg-000037		
P-22097	N/A	Patient Rescues Doctor	Herzberg-000038	Herzberg-000039		
P-22098	1/16/1944	Stop Look Listen, When the Prescription Says "Dope"	Herzberg-000040	Herzberg-000040		
P-22099	9/3/1943	Morphine Substitute Now Generally Favorable	Herzberg-000041	Herzberg-000041		
P-22100	9/13/1943	Drug Without Addicts	Herzberg-000042	Herzberg-000042		
P-22101	4/13/1942	Time Magazine, Painkiller	Herzberg-000043	Herzberg-000043		
P-22102	4/1/1942	Minneapolis Star Journal, Non Habit Forming Morphine Substitute	Herzberg-000044	Herzberg-000044		
P-22103	N/A	Non-Habit-Forming Morphine Substitute Proved in Tests	Herzberg-000045	Herzberg-000045		
P-22104	12/3/1943	Letter Re Amendment to Uniform Narcotic Act	Herzberg-000046	Herzberg-000046		
P-22105	12/3/1943	Tentative Itinerary	Herzberg-000047	Herzberg-000047		
P-22106	12/3/1943	Memorandum For The Commissioner	Herzberg-000048	Herzberg-000049		
P-22107	6/29/1944	Brokmeyer Bulletin, June 29, 1944	Herzberg-000050	Herzberg-000050		
P-22108	1/24/1944	Dates of Current Legislative Sessions	Herzberg-000051	Herzberg-000055		
P-22109	N/A	State Demerol Control Measures	Herzberg-000056	Herzberg-000056		
P-22110	4/16/1945	Letter from Commissioner of Narcotics H.J. Anslinger	Herzberg-000057	Herzberg-000057		
P-22111	4/16/1945	Advertisement for Demerol	Herzberg-000058	Herzberg-000058		
P-22112	10/2/1945	Letter from Commissioner of Narcotics H.J. Anslinger	Herzberg-000059	Herzberg-000059		
P-22113	5/15/1944	Nazis' Ersatz Morphine Sold American Addicts	Herzberg-000060	Herzberg-000060		
P-22114	N/A	Talwin Advertisement	Herzberg-000061	Herzberg-000061		
P-22115	7/30/1982	Controlled Substance Profile, Pentarocine Hydrochloride and Naloxone Hydrochloride Combination	Herzberg-000062	Herzberg-000073		
P-22116	1/2/1964	Letter from Nathan Eddy, MD to Dr. Joseph Bird	Herzberg-000074	Herzberg-000074		
P-22117	10/4/1965	Letter from John Enright to Nathan Eddy, M.D.	Herzberg-000075	Herzberg-000075		
P-22118	11/1/1949	Excerpt from Bulletin for Drug Addiction and Narcotics	Herzberg-000076	Herzberg-000076		
P-22119	10/4/1965	Letter from Acting Narcotics Commissioner to Dr. Nathan Eddy	Herzberg-000077	Herzberg-000077		
P-22120	5/11/1949	Excerpt from Bulletin for Drug Addiction and Narcotics	Herzberg-000078	Herzberg-000081		
P-22121	12/12/1995	Letter from Robert Bedford, MD, to James Conover, PhD; NDA 20-553	Herzberg-000083	Herzberg-000378		
P-22124	3/19/1979	FDA Bureau of Drugs Anesthetic and Life Support Drug Advisory Committee Meeting Minutes	Herzberg-000379	Herzberg-000395		
P-22125	11/28/1956	Various Documents and correspondences between Endo and Commissioner of Narcotics	Herzberg-000396	Herzberg-000628		
P-22126	3/19/1959	Letters to and from Commissioner of Narcotics and Documents Re Percoden	Herzberg-000629	Herzberg-000857		
P-22127	6/5/1962	Various Documents Re Codeine and Percoden, 1957 - 1962	Herzberg-000858	Herzberg-001016		
P-22128	5/14/1963	Letter from Commissioner of Narcotics Re Percoden; Police Reports	Herzberg-001017	Herzberg-001024		
P-22129	5/1/1963	CA Board Reprimands 4 Druggists, Refers One for Administrative Hearing	Herzberg-001025	Herzberg-001026		
P-22130	12/6/1948	Over-the-Counter Sales Dexedrine Sulfate, Doc. 20-685 E, Doc. 20-687 E, page 1	Herzberg-001027	Herzberg-001027		
P-22131	12/6/1948	Over-the-Counter Sales Dexedrine Sulfate, Doc. 20-685 E, Doc. 20-687 E, page 2	Herzberg-001028	Herzberg-001028		
P-22132	12/6/1948	Over-the-Counter Sales Dexedrine Sulfate, Doc. 20-685 E, Doc. 20-687 E, page 3	Herzberg-001029	Herzberg-001029		
P-22133	12/6/1948	Over-the-Counter Sales Dexedrine Sulfate, Doc. 20-685 E, Doc. 20-687 E, page 4	Herzberg-001030	Herzberg-001030		
P-22134	12/6/1948	Over-the-Counter Sales Dexedrine Sulfate, 20-686 K, page 1	Herzberg-001031	Herzberg-001031		

P-22135	12/6/1948	Over-the-Counter Sales Dexedrine Sulfate, 20-686 K, page 2	Herzberg-001032	Herzberg-001032		
P-22136	12/14/1948	US Government Letter Re Alleged Injury Case Dexedrine Sulfate	Herzberg-001033	Herzberg-001033		
P-22137	7/6/2012	Endo's KOL payments submitted to Senate Finance Committee	ENDO-OR-CID-00831907	ENDO-OR-CID-00831909		
P-22138	1/3/2001	JCAHO Standards on Pain Management	JAN-MS-00286988	JAN-MS-00286989		
P-22139	6/17/2010	A Vital Balancing Act: Recognizing Prescription Drug Abuse While Ensuring Patient Access PowerPoint	JAN-MS-00330384	JAN-MS-00330384		
P-22140	5/1/1998	Model guidelines for the use of controlled substances for the treatment of pain	P-CA-000984_0002	P-CA-000984_0005		
P-22141	1997	State Intractable Pain Policy: A Current Status	P-CA-001603_0001	P-CA-001603_0008		
P-22142	N/A	Current Issues in the Management of Cancer Pain: Memorial Sloan-Kettering Cancer Center	DEF-CA-EL_00051233	DEF-CA-EL_00051243		
P-22143	6/15/2012	Submission to Senate Finance Committee by Endo Pharmaceuticals Inc.	ENDO-OR-CID-00718228	ENDO-OR-CID-00718236		
P-22144	6/1/2002	The Management of Persistent Pain in Older Persons	ENDO-CA-EL_00020400	ENDO-CA-EL_00020419		
P-22145	10/1/1994	Medical Board of California Action Report: New, Easy Guidelines on Prescribing	DEF-CA-EL_00015702	DEF-CA-EL_00015725		
P-22146	7/1/2013	Risks, Management, and Monitoring of Combination Opioid, Benzodiazepines, and Alcohol Use (Gudin et al.)	N/A	N/A		
P-22147	1988	Ethical criteria for medicinal drug promotion	N/A	N/A		
P-22148	2012	International Federation of Pharmaceutical Manufacturers & Associations IFPMA Code of Practice 2012	N/A	N/A		
P-22149	5/1/2009	Guidance for Industry Presenting Risk Information in Prescription Drug and Medical Device Promotion	N/A	N/A		
P-22150	7/1/2008	Pharmaceutical Marketing in Perspective PhRMA	N/A	N/A		
P-22151	11/4/2011	CDC Vital Signs Overdoses of Prescription Opioid Pain Relievers United States, 1999-2008	N/A	N/A		
P-22152	10/20/1999	Field Force Performance & Development Review	PDD1715089379	PDD1715089389		
P-22153	10/11/2000	RE: Patient Action Pamphlet	PPLPC013000057412	PPLPC013000057421		
P-22154	4/25/2002	Third party statements	PPLPC039000033377	PPLPC039000033401		
P-22155	11/19/2004	Patient and Physician Attitudes and Behaviors Associated With DTC Promotion of Prescription Drugs	N/A	N/A		
P-22156	2/12/2018	Fueling an Epidemic (Report Two), Exposing the Financial Ties Between Opioid Manufacturers and Third-Party Advocacy Groups	N/A	N/A		
P-22157	7/1/2008	FDA's Oversight of the Promotion of Drugs for Off-label Uses (GAO Report)	N/A	N/A		
P-22158	1/4/2022	Guidance for Industry "Help-Seeking" and Other Disease Awareness Communications by or on Behalf of Drug and Device Firms	N/A	N/A		
P-22159	N/A	Fueling an Epidemic Supplement to February 2018 Report	N/A	N/A		
P-22160	1/19/2020	Drug Advertising: A Glossary of Terms	N/A	N/A		
P-22161	3/23/2001	Purdue key selling points memo	PDD1502332817	PDD1502332847		
P-22162	N/A	The Impact of Chronic Pain--an Interdisciplinary Perspective	PDD1501608597	PDD1501608616		
P-22163	5/4/2001	Anti-Diversion Brochures	PDD1502328363	PDD1502328363		
P-22164	11/6/2002	Pain Management for Pharmacists	PPLPC022000022548	PPLPC022000022552		
P-22165	9/27/1995	OXYCONTIN LAUNCH PLAN	PURCHI-003286149	PURCHI-003286349		
P-22166	1/1/2002	2002 BUDGET PLAN	SHC-000001228	SHC-000001285		
P-22167	3/30/2012	Draft - OxyContin Market Events 3-28-12	PPLPC012000371062	PPLPC012000371063		
P-22168	2/15/2012	2012 10-Year Plan Complete Package	PPLP004149692	PPLP004149891		
P-22169	6/25/2015	RE: idea	PPLPC019001155586	PPLPC019001155590		
P-22171	10/9/1996	Standard Operating Procedures	PKY180268536	PKY180268564		
P-22172	6/20/2011	ACAM II prsntd 6-20-11	PPLP003420448	PPLP003420519		
P-22173	6/2/1997	Re: OxyContin Team Meeting - Minutes	PKY180774040	PKY180774041		
P-22174	5/28/1997	Re[2]: oxypblms	PDD1508224775	PDD1508224778		
P-22175	5/29/1997	Re[3]: oxypblms	PDD1701460004	PDD1701460005		
P-22176	9/21/2000	Workshop notes	PPLPC012000018381	PPLPC012000018383		
P-22177	9/1/2016	MR-02015 - POA eCampus Questions	PPLP003288099	PPLP003288115		
P-22178	10/30/1998	Partners Against Pain	PKY180425172	PKY180425624		
P-22179	11/8/1999	Revised press materials	PPLPC009000006346	PPLPC009000006358		
P-22180	2/25/2016	2016 G&O Full Functional team objectives v3	PPLPC034001134946	PPLPC034001134946		

P-22181	9/13/2013	2013 09 12 Final Report Phase I Diagnostic	PPLP004001344	PPLP004001475		
P-22182	3/28/2014	RE Updated version of your EOT presentation (including new slide)	PPLPC019000906695	PPLPC019000906696		
P-22183	8/3/2004	FW Copy of presentation	PPLPC029000132249	PPLPC029000132250		
P-22184	1/16/2007	FW Patient level data - please see attachment for agenda	PPLPC029000182399	PPLPC029000182401		
P-22185	6/1/2021	Impact of drug utilization management policy on prescription opioid use in Georgia Medicaid (Wang, Perri, et al)	N/A	N/A		
P-22186	5/1/2010	Assessment of Changes in Utilization of Health-Care Services After Implementation of a Prior Authorization Policy for Atypical Antipsychotic Agents (Seymour, Perri)	N/A	N/A		
P-22187	3/1/2005	Adverse Outcomes Associated with Inappropriate Drug Use in Nursing Homes (Perri et al)	N/A	N/A		
P-22188	2014	Pharmaceutical Marketing (Rollins and Perri)	N/A	N/A		
P-22189	1996	Assessment of Medicaid prior-approval policies on prescription expenditures: market share analysis of Medicaid and cash prescriptions (Kotzan, Perri)	N/A	N/A		
P-22190	9/1/2018	Opioid Analgesics in Georgia Medicaid: Trends in Potential Inappropriate Prescribing Practices by Demographic Characteristics, 2009-2014 (Perri et al)	N/A	N/A		
P-22191	3/1/1987	An Exploratory Analysis of Consumer Recognition of Direct-to-Consumer Advertising of Prescription Medications (Perri and Nelson)	N/A	N/A		
P-22192	6/1/1988	Consumer Reaction to a Direct-to-Consumer Prescription Drug Advertising Campaign. (Perri and Dickson)	N/A	N/A		
P-22193	10/1/1999	The Past, Present and Future of Direct-to-Consumer Advertising in the Pharmaceutical Industry (Perri)	N/A	N/A		
P-22194	2/23/2011	Nonbranded or Branded Direct-to-consumer Prescription Drug Advertising – Which is More Effective? (Perri et al)	N/A	N/A		
P-22195	2013	An Experimental Examination of Consumer Attitudes, Behavioral Intentions and Information Search Behavior After Viewing A Predictive Genetic Test Direct-to-Consumer Advertisement. (Rollins, Perri)	N/A	N/A		
P-22196	6/25/2019	Transaction Agreement between Abbvie Inc., Venice Subsidiary, and Allergan	N/A	N/A		
P-22197	9/9/2011	New TMS Script/Letters for KADIAN;TMS Generic Letter #1x; TMS Generic Letter #2x; TMS Generic Telescript cleanx; TMS Generic Telescript	Acquired_Actavis_00173401	Acquired_Actavis_00173420		
P-22198	10/6/2009	RE: Service Flash Subscription Expires October 31, 2009;ATT162433.txt; Oxycodone Service Flash	Acquired_Actavis_00612504	Acquired_Actavis_00612508		
P-22199	12/12/2012	October 2012 Reports : 1 of 6; A101_Denver, CO_201210.xlsx; A102_Phoenix West, AZ_201210.xlsx; A103_Las Vegas, NV_201210.xlsx; A104_Los Angeles, CA_201210.xlsx; A105_San Francisco, CA_201210.xlsx; A106_Phoenix East, AZ_201210.xlsx; A107_Portland, OR_201210.xlsx; A108_Sacramento, CA_201210.xlsx; A109_Salt Lake City, UT_201210.xlsx; A110_Orange County, CA_201210.xlsx; A111_Seattle, WA_201210.xlsx	ACTAVIS0675592	ACTAVIS0675603		
P-22200	5/6/2013	ER/LA Opioid Analgesics REMS Website tracked changes	ALLERGAN_MDL_02233231	ALLERGAN_MDL_02233275		
P-22201	6/25/2015	Andrew Khouri, CEO Brent Saunders says Allergan remains committed to Irvine despite sale, Los Angeles Times	N/A	N/A		
P-22202	11/30/2018	Press Release, McKesson Corporation, McKesson Announces New Global Headquarters in Las Colinas, Texas	N/A	N/A		
P-22203	7/23/2019	Whitney Curtis, One Opioid drugmaker's solution to billions of potential liabilities: spin them out into new company, CNBC	N/A	N/A		
P-22204	2/13/2018	Minute Order, California, v. Purdue Pharma	N/A	N/A		
P-22205	11/9/2018	Minutes and Order, In re: Nat'l Prescription Opiate Litig., No. 1:17-md-2804-DAP (N.D. Ohio Nov. 9, 2018), ECF No. 1108	N/A	N/A		

P-22206	2/15/2019	Order, In re: Nat'l Prescription Opiate Litig., No. 1:17-md-2804-DAP (N.D. Ohio Feb. 15, 2019), ECF No. 1377	N/A	N/A		
P-22207	2/9/2017	Allergan Opioid PMR Support Invoice, RPC-13001A	ALLERGAN MDL 04382952	ALLERGAN MDL 04382953		
P-22208	9/27/2016	Press Release, Allergan plc, Orange County Business Council Study Showcases Economic Impact of Allergan on California Economy	N/A	N/A		
P-22209	12/14/2016	McKesson Corporation Confirmation	ALLERGAN_CA_00042256	ALLERGAN_CA_00042257		
P-22210	1/7/2019	Ship Report 01-01-19 TO 01-06-19.XLSX with attachment	ALLERGAN_CA_00422560	ALLERGAN_CA_00422561		
P-22211	8/28/2006	Re: License Fees for 2007 Budget; Registration fees by site	ALLERGAN MDL 04014602	ALLERGAN MDL 04014609		
P-22212	9/15/2008	Global Standard Operating Procedure, CSCD	ALLERGAN_MDL_04016159 ALLERGAN_MDL_04016371	ALLERGAN_MDL_04016374 ALLERGAN_MDL_04016390	ALLERGAN_MDL_04016371 - ALLERGAN_MDL_04016374	
P-22213	7/1/2001	California Board of Pharmacy The Script July 2001	N/A	N/A		
P-22214	4/11/2011	Gomes T., et al. Opioid dose and drug-related mortality in patients with nonmalignant pain	N/A	N/A		
P-22215	11/20/2006	Suspicious Week Ending 11-19-06	Anda Opioids MDL 0000124949	Anda Opioids MDL 0000124949		
P-22216	8/9/2013	In the Matter of the Accusation Against Pacifica Pharmacy; Thang Tran. Board of Pharmacy Case No. 3802; OAH No. 2011010644; Precedential Decision No. 2013-01	N/A	N/A		
P-22217	2/25/2015	State Board of Pharmacy Department of Consumer Affairs SB 493 Implementation Committee Meeting Minutes	N/A	N/A		
P-22218	1/1/2018	Guess K.S., et al. How Do You Respond to Corresponding Responsibility?	N/A	N/A		
P-22219	3/13/0218	FR 83, No. 49: Pharmacy Doctors Enterprises d/b/a Zion Clinic Pharmacy; Decision and Order	N/A	N/A		
P-22220	5/1/2019	Danielson J., Besinque K., et al. Essential Elements for Core Required Advanced Pharmacy Practice Experiences	N/A	N/A		
P-22221	9/20/2019	Pharm. Doctors Enters. v. DEA, 789 Fed. Appx. 724, United States Court of Appeals for the Eleventh Circuit	N/A	N/A		
P-22222	3/1/2020	California Board of Pharmacy The Script March 2020	N/A	N/A		
P-22223	10/20/2020	In the Matter of the Third Amended Accusation Against IV Solutions, Inc. Alireza Varastehpour, President and Renee Sadow. Board of Pharmacy Case No. 3606, OAH No. 2011050988	N/A	N/A		
P-22224	11/1/2021	American Pharmacists Association Oath of a Pharmacist	N/A	N/A		
P-22225	N/A	"Corresponding Responsibility: It's the Law," California State Board of Pharmacy pamphlet	N/A	N/A		
P-22226	N/A	CA Board of Pharmacy Disciplinary Actions	N/A	N/A		
P-22227	N/A	CA Pharmacists Association Corresponding Responsibility Checklist	N/A	N/A		
P-22228	N/A	CDC Calculating Total Daily Dose of Opioids For Safer Dosage	N/A	N/A		
P-22229	6/6/2001	Soft tissue infections among injection drug users	N/A	N/A		
P-22230	2/1/2013	Intertwined epidemics national demographic trends	N/A	N/A		
P-22231	8/1/2017	US regional and demographic differences in prescription opioid and heroin-related overdose hospitalizations	N/A	N/A		
P-22232	2/1/2018	Opioid crisis no easy fix to its social and economic determinants	N/A	N/A		
P-22233	1/1/2020	CDC Drug overdose deaths in the United States, 1999-2018	N/A	N/A		
P-22234	2/1/2021	The rise of illicit fentanyls	N/A	N/A		
P-22235	2021	SF Expert Report track 4 input calculations 092621	N/A	N/A		
P-22236	2021	MME calc SF 122321.xlsx	N/A	N/A		
P-22237	2021	West KL, Lindquist K, Rodda LN. Fentanyl epidemic hits the U.S. West Coast: Opioid Related deaths in San Francisco from 2009-2019. Int J Drug Policy. 2021;95:103402. doi:10.1016/i.drugpo.2021.103402	N/A	N/A		
P-22238	6/1/2003	Davidson PJ, McLean RL, Kral AH, Gleghorn AA, Edlin BR, Moss AR. Fatal heroin-related overdose in San Francisco, 1997-2000: a case for targeted intervention. J Urban Heal. 2003;80(2):261-273. doi:10.1093/urban/ite029	N/A	N/A		

P-22239	2017	Kral AH, Lambdin BH, Browne EN, et al. Transition from injecting opioids to smoking fentanyl in San Francisco, California. Drug Alcohol Depend. 2021;227:109003 <a href="https://doi.org/10.1016/j.drugalcdep.2021.109003">doi:https://doi.org/10.1016/j.drugalcdep.2021.109003</a>	N/A	N/A		
P-22240	2020	United States Census Bureau. QuickFacts: San Francisco County, California. Published online 2020. <a href="https://www.census.gov/quickfacts/fact/table/sanfranciscocountycalifornia,US/PST045219">https://www.census.gov/quickfacts/fact/table/sanfranciscocountycalifornia,US/PST045219</a>	N/A	N/A		
P-22241	1995	Lasfargues JE, Custis D, Morrone F, Cars well J, Nguyen T. A model for estimating spinal cord injury prevalence in the United States. Spinal Cord. 1995;33(2):62-68. doi:10.1038/sc.1995.16	N/A	N/A		
P-22242	3/5/2019	Wallin MT, Culpepper WJ, Campbell JD, et al. The prevalence of MS in the United States: A population-based estimate using health claims data. Neurology. 2019;92(10):e1029-e1040. <a href="https://doi.org/10.1212/WNL.00000000000007035">doi:10.1212/WNL.00000000000007035</a>	N/A	N/A		
P-22243	11/1/2020	Zelaya C, Dahlhamer J, Lucas J, Conner E. Chronic pain and high-impact chronic pain among U.S. adults, 2019. NCHS Data Br No 390. Published online 2020.	N/A	N/A		
P-22244	2021	National Institutes of Health. State cancer profiles: San Francisco - Oakland Historical Trends. Natl Cancer Inst. Published online 2021. <a href="https://statecancerprofiles.cancer.gov/historicaltrend/indph?0&amp;0199&amp;999&amp;7599&amp;001&amp;001&amp;00&amp;0&amp;0&amp;0&amp;1&amp;0&amp;1&amp;1#results">https://statecancerprofiles.cancer.gov/historicaltrend/indph?0&amp;0199&amp;999&amp;7599&amp;001&amp;001&amp;00&amp;0&amp;0&amp;0&amp;1&amp;0&amp;1&amp;1#results</a>	N/A	N/A		
P-22245	10/5/2020	Centers for Disease Control and Prevention. Shingles (Herpes Zoster): Clinical Overview. Natl Cent Immun Respir Dis Div Viral Dis. Published online 2020. <a href="https://www.cdc.gov/shingles/hcp/clinical-overview.html">https://www.cdc.gov/shingles/hcp/clinical-overview.html</a>	N/A	N/A		
P-22246	1/19/2021	NHS. Overview: Post-herpetic neuralgia. Published online 2021. <a href="https://www.nhs.uk/conditions/post-herpetic-neuralgia/">https://www.nhs.uk/conditions/post-herpetic-neuralgia/</a>	N/A	N/A		
P-22247	8/4/2019	Centers for Disease Control and Prevention. Shingles (Herpes Zoster): Shingles Burden and Trends. Natl Cent Immun Respir Dis Div Viral Dis. Published online 2019. <a href="https://www.cdc.gov/shingles/surveillance.html">https://www.cdc.gov/shingles/surveillance.html</a>	N/A	N/A		
P-22248	1/1/1989	Chief Medical Examiner - Coroner San Francisco, CA Annual Report July 1, 1987 - June 30, 1988	N/A	N/A		
P-22249	3/1/1990	Chief Medical Examiner - Coroner San Francisco, CA Annual Report July 1, 1988 - June 30, 1989	N/A	N/A		
P-22250	1/1/1991	Chief Medical Examiner - Coroner CCSF Annual Report July 1, 1989- June 30, 1990	N/A	N/A		
P-22251	1/1/1992	Medical Examiner's Office CCSF Annual Report July 1, 1990 - June 30, 1991	N/A	N/A		
P-22252	1/1/1993	Medical Examiner's Office CCSF Annual Report July 1, 1991 - June 30, 1992	N/A	N/A		
P-22253	2/1/1994	Medical Examiner's Office CCSF Annual Report July 1, 1992 - June 30, 1993	N/A	N/A		
P-22254	6/1/1995	Medical Examiner's Office CCSF Annual Report July 1, 1993 - June 30, 1994	N/A	N/A		
P-22255	6/1/1996	Medical Examiner's Office CCSF Annual Report July 1, 1994 - June 30, 1995	N/A	N/A		
P-22256	12/1/1997	Medical Examiner's Office CCSF Annual Report July 1, 1995 - June 30, 1996	N/A	N/A		
P-22257	3/1/1998	Medical Examiner's Office CCSF Annual Report July 1, 1996 - June 30, 1997	N/A	N/A		
P-22258	1/1/1999	Medical Examiner's Office CCSF Annual Report July 1, 1997 - June 30, 1998	N/A	N/A		
P-22259	4/3/2000	Medical Examiner's Office CCSF Annual Report July 1, 1998 - June 30, 1999	N/A	N/A		
P-22260	12/1/2000	Medical Examiner's Office CCSF Annual Report July 1, 1999 - June 30, 2000	N/A	N/A		

P-22261	6/1/2002	Medical Examiner's Office CCSF Annual Report July 1, 2000 - June 30, 2001	N/A	N/A		
P-22262	3/1/2003	Medical Examiner's Office CCSF Annual Report July 1, 2001 - June 30, 2002	N/A	N/A		
P-22263	4/1/2004	Medical Examiner's Office CCSF Annual Report July 1, 2002 - June 30, 2003	N/A	N/A		
P-22264	11/1/2005	Office of the Chief Medical Examiner CCSF Annual Report July 1, 2003 - June 30, 2004	N/A	N/A		
P-22265	6/1/2007	Office of the Chief Medical Examiner CCSF Annual Report July 1, 2004 - June 30, 2005	N/A	N/A		
P-22266	11/1/2008	Office of the Chief Medical Examiner CCSF Annual Report July 1, 2005 - June 30, 2006	N/A	N/A		
P-22267	2/1/2010	Office of the Chief Medical Examiner CCSF Annual Report Fiscal Year 2006-2007	N/A	N/A		
P-22268	11/1/2010	Office of the Chief Medical Examiner CCSF Annual Report Fiscal Year 2007-2008	N/A	N/A		
P-22269	2/1/2011	Office of the Chief Medical Examiner CCSF Annual Report Fiscal Year 2008-2009	N/A	N/A		
P-22270	6/1/2011	Office of the Chief Medical Examiner CCSF Annual Report Fiscal Year 2009-2010	N/A	N/A		
P-22271	12/1/2013	Office of the Chief Medical Examiner CCSF Fiscal year 2012-2013 Annual Report	N/A	N/A		
P-22272	12/1/2014	Office of the Chief Medical Examiner CCSF Fiscal year 2013-2014 Annual Report	N/A	N/A		
P-22273	12/1/2015	Office of the Chief Medical Examiner CCSF Fiscal year 2014-2015 Annual Report	N/A	N/A		
P-22274	12/1/2016	Office of the Chief Medical Examiner CCSF Fiscal year 2015-2016 Annual Report	N/A	N/A		
P-22275	12/1/2017	Office of the Chief Medical Examiner CCSF Fiscal year 2016-2017 Annual Report	N/A	N/A		
P-22276	5/1/2019	Office of the Chief Medical Examiner CCSF Fiscal year 2017-2018 Annual Report	N/A	N/A		
P-22277	12/1/2019	Fiscal Year 2018-2019 Annual Report of the Office of the Chief Medical Examiner	N/A	N/A		
P-22278	11/1/2021	Office of the Chief Medical Examiner FY19-20 Annual Report	N/A	N/A		
P-22279	1/19/2022	Preliminary Accidental Drug Overdose Data Reports for January 2021 through December 2021	N/A	N/A		
P-22281	10/27/2010	East Main Street Pharmacy Decision	N/A	N/A		
P-22282	8/15/2013	Medical Board of California Department of Consumer Affairs, 12-2008-190960, Decision re Ray Poon-Phang, issued August 15, 2013	N/A	N/A		
P-22283	1/28/2014	Collin Leong 2013 California Medical Board Stipulation for Surrender of Certificate, Exhibit A "Accusation"	N/A	N/A		
P-22284	2015	Bruera, et al. Cancer Pain Management: Safe and Effective Use of Opioids. American Society of Clinical Oncology Educational Book 2015 :35, e593-e599	N/A	N/A		
P-22285	4/10/2015	Lee. Feds say wife of S.F. doctor accused in drug ring laundered money. SF Gate. April 11, 2015.	N/A	N/A		
P-22286	11/10/2016	81, FR 79188: Jones Total Health Care Pharmacy, L.L.C., and SND Health Care, L.L.C.; Decision and Order	N/A	N/A		
P-22287	11/13/2016	DEA Decisions: Evidence of "Red Flags of Drug Diversion," DEA Chronicles, Coe Law PLLC	N/A	N/A		
P-22288	5/31/2017	Bay Area Doctor Sentenced for Running Pill Mill, Involuntary Manslaughter, County of Santa Clara, Office of the District Attorney, Press Release	N/A	N/A		
P-22293	7/19/2018	Halstead. State revokes license of Novato doctor, former nursing home medical director. Marin Independent Journal.	N/A	N/A		
P-22297	2/3/2021	Guido James Gores Jr Stipulated Surrender of License and Order	N/A	N/A		



P-22309	11/16/2021	Pergolizzi, et al . Opioid Therapy in Cancer Patients and Survivors at Risk of Addiction, Misuse or Complex Dependency. Front. Pain Res., 16 November 2021, Vol. 2.	N/A	N/A		
P-22420	2/18/2022	CA Medical Board Licensing Details for G 23663 Donald Richard Dossett	N/A	N/A		
P-22421	2/18/2022	CA Medical Board Licensing Details for G 10958 Andrew Giovannini	N/A	N/A		
P-22422	2/18/2022	CA Medical Board Licensing Details for G 20523 Ray Poon-Phang Seet	N/A	N/A		
P-22423	2/18/2022	CA Medical Board Licensing Details G 45225 John Winthrop Pierce	N/A	N/A		
P-22424	2/18/2022	CA Medical Board Licensing Details for G 61254 Guido James Gores Jr	N/A	N/A		
P-22425	2/1/2007	Johnston, J., Wasunna, A. A., & Hastings Center (2007). Patents, biomedical research, and treatments: examining concerns, canvassing solutions. The Hastings Center report, 37(1), S1–S36. <a href="https://doi.org/10.1353/hcr.2007.0006">https://doi.org/10.1353/hcr.2007.0006</a>	N/A	N/A		
P-22426	11/01/2016	Shmagel, A., Foley, R., & Ibrahim, H. (2016). Epidemiology of Chronic Low Back Pain in US Adults: Data From the 2009-2010 National Health and Nutrition Examination Survey. Arthritis care & research, 68(11), 1688–1694. <a href="https://doi.org/10.1002/acr.22890">https://doi.org/10.1002/acr.22890</a>	N/A	N/A		
P-22427	5/16/2017	Lee, J. S., Hu, H. M., Brummett, C. M., Syrjamaki, J. D., Dupree, J. M., Englesbe, M. J., & Waljee, J. F. (2017). Postoperative Opioid Prescribing and the Pain Scores on Hospital Consumer Assessment of Healthcare Providers and Systems Survey. JAMA, 317(19), 2013–2015. <a href="https://doi.org/10.1001/jama.2017.2827">https://doi.org/10.1001/jama.2017.2827</a>	N/A	N/A		
P-22428	8/30/2017	CDC - Prescribing Data	N/A	N/A		
P-22429	9/27/2017	Fickweiler, F., Fickweiler, W., & Urbach, E. (2017). Interactions between physicians and the pharmaceutical industry generally and sales representatives specifically and their association with physicians' attitudes and prescribing habits: a systematic review. BMJ open, 7(9), e016408. <a href="https://doi.org/10.1136/bmjopen-2017-016408">https://doi.org/10.1136/bmjopen-2017-016408</a>	N/A	N/A		
P-22430	2018	Volkow, N., Benveniste, H., & McLellan, A. T. (2018). Use and Misuse of Opioids in Chronic Pain. Annual review of medicine, 69, 451–465. <a href="https://doi.org/10.1146/annurev-med-011817-044739">https://doi.org/10.1146/annurev-med-011817-044739</a>	N/A	N/A		
P-22431	1/19/2018	Levy, N., Sturgess, J., & Mills, P. (2018). "Pain as the fifth vital sign" and dependence on the "numerical pain scale" is being abandoned in the US: Why?. British journal of anaesthesia, 120(3), 435–438. <a href="https://doi.org/10.1016/j.bja.2017.11.098">https://doi.org/10.1016/j.bja.2017.11.098</a>	N/A	N/A		
P-22432	2019	Higgins, C., Smith, B. H., & Matthews, K. (2019). Evidence of opioid-induced hyperalgesia in clinical populations after chronic opioid exposure: a systematic review and meta-analysis. British journal of anaesthesia, 122(6), e114–e126. <a href="https://doi.org/10.1016/j.bja.2018.09.019">https://doi.org/10.1016/j.bja.2018.09.019</a>	N/A	N/A		
P-22433	11/25/2018	Bernard, S. A., Chelminski, P. R., Ives, T. J., & Ranapurwala, S. I. (2018). Management of Pain in the United States-A Brief History and Implications for the Opioid Epidemic. Health services insights, 11, 1178632918819440. <a href="https://doi.org/10.1177/1178632918819440">https://doi.org/10.1177/1178632918819440</a>	N/A	N/A		
P-22434	12/18/2018	Busse, J. W., Wang, L., Kamaleldin, M., Craigie, S., Riva, J. J., Montoya, L., Mulla, S. M., Lopes, L. C., Vogel, N., Chen, E., Kirmayr, K., De Oliveira, K., Olivieri, L., Kaushal, A., Chaparro, L. E., Oyberman, I., Agarwal, A., Couban, R., Tsoi, L., Lam, T., ... Guyatt, G. H. (2018). Opioids for Chronic Noncancer Pain: A Systematic Review and Meta-analysis. JAMA, 320(23), 2448–2460. <a href="https://doi.org/10.1001/jama.2018.18472">https://doi.org/10.1001/jama.2018.18472</a>	N/A	N/A		

P-22435	7/19/2019	Abbasi K. First do no harm: the impossible oath BMJ 2019; 366 :l4734 doi:10.1136/bmj.l4734	N/A	N/A		
P-22436	12/16/2020	CDC - Data & Statistics on Sickle Cell Disease	N/A	N/A		
P-22437	12/16/2020	CDC -Complications and Treatments of Sickle Cell Disease	N/A	N/A		
P-22438	2/23/2021	Michaleas, S. N., Laios, K., Tsoucalas, G., & Androustos, G. (2021). Theophrastus Bombastus Von Hohenheim (Paracelsus) (1493-1541): The eminent physician and pioneer of toxicology. Toxicology reports, 8, 411–414. <a href="https://doi.org/10.1016/j.toxrep.2021.02.012">https://doi.org/10.1016/j.toxrep.2021.02.012</a>	N/A	N/A		
P-22439	11/3/2021	CDC - Arthritis	N/A	N/A		
P-22440	10/1/2016	San Francisco Sentinel Community Site (SCS) Drug Use Patterns and Trends, 2016	N/A	N/A		
P-22441	11/1/2017	San Francisco Sentinel Community Site (SCS) Drug Use Patterns and Trends, 2017	N/A	N/A		
P-22442	11/1/2018	San Francisco Sentinel Community Site (SCS) Drug Use Patterns and Trends, 2018	N/A	N/A		
P-22443	11/1/2019	San Francisco Sentinel Community Site (SCS) Drug Use Patterns and Trends, 2019	N/A	N/A		
P-22444	8/1/2020	San Francisco Sentinel Community Site (SCS) Drug Use Patterns and Trends, 2020	N/A	N/A		
P-22445	12/1/2019	Substance Use Trends in San Francisco Through 2018	N/A	N/A		
P-22446	8/31/2020	Coffin PO, Rowe C, Gerbino N. Substance Use Trends in San Francisco through 2019. Center on Substance Use and Health. Department of Public Health, City and County of San Francisco.	N/A	N/A		
P-22447	12/20/2021	Substance Use Trends in San Francisco through 2020	N/A	N/A		
P-22448	1/6/2003	Coffin, P. O., Galea, S., Ahern, J., Leon, A. C., Vlahov, D., & Tardiff, K. (2003). Opiates, cocaine and alcohol combinations in accidental drug overdose deaths in New York City, 1990-98. Addiction (Abingdon, England), 98(6), 739–747. <a href="https://doi.org/10.1046/j.1360-0443.2003.00376.x">https://doi.org/10.1046/j.1360-0443.2003.00376.x</a>	N/A	N/A		
P-22449	2/4/2014	Coffin, P., & Banta-Green, C. (2014). The dueling obligations of opioid stewardship. Annals of internal medicine, 160(3), 207. <a href="https://doi.org/10.7326/M13-2781">https://doi.org/10.7326/M13-2781</a>	N/A	N/A		
P-22450	8/16/2016	Coffin, P. O., Behar, E., Rowe, C., Santos, G. M., Coffa, D., Bald, M., & Vittinghoff, E. (2016). Nonrandomized Intervention Study of Naloxone Coprescription for Primary Care Patients Receiving Long-Term Opioid Therapy for Pain. Annals of internal medicine, 165(4), 245–252. <a href="https://doi.org/10.7326/M15-2771">https://doi.org/10.7326/M15-2771</a>	N/A	N/A		
P-22451	10/13/2016	Rowe, C., Vittinghoff, E., Santos, G. M., Behar, E., Turner, C., & Coffin, P. O. (2017). Performance Measures of Diagnostic Codes for Detecting Opioid Overdose in the Emergency Department. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 24(4), 475–483. <a href="https://doi.org/10.1111/acem.13121">https://doi.org/10.1111/acem.13121</a>	N/A	N/A		
P-22452	8/1/2017	Fairbairn, N., Coffin, P. O., & Walley, A. Y. (2017). Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: Challenges and innovations responding to a dynamic epidemic. The International journal on drug policy, 46, 172–179. <a href="https://doi.org/10.1016/j.drugpo.2017.06.005">https://doi.org/10.1016/j.drugpo.2017.06.005</a>	N/A	N/A		
P-22453	4/1/2018	Hurstak, E., Rowe, C., Turner, C., Behar, E., Cabugao, R., Lemos, N. P., Burke, C., & Coffin, P. (2018). Using medical examiner case narratives to improve opioid overdose surveillance. The International journal on drug policy, 54, 35–42. <a href="https://doi.org/10.1016/j.drugpo.2017.12.017">https://doi.org/10.1016/j.drugpo.2017.12.017</a>	N/A	N/A		
P-22454	4/1/2018	Turner, C., Chandrakumar, D., Rowe, C., Santos, G. M., Riley, E. D., & Coffin, P. O. (2018). Cross-sectional cause of death comparisons for stimulant and opioid mortality in San Francisco, 2005-2015. Drug and alcohol dependence, 185, 305–312. <a href="https://doi.org/10.1016/j.drugalcdep.2017.12.030">https://doi.org/10.1016/j.drugalcdep.2017.12.030</a>	N/A	N/A		

P-22455	5/3/2018	Rowe, C., Wheeler, E., Stephen Jones, T., Yeh, C., & Coffin, P. O. (2019). Community-Based Response to Fentanyl Overdose Outbreak, San Francisco, 2015. Journal of urban health : bulletin of the New York Academy of Medicine, 96(1), 6–11. <a href="https://doi.org/10.1007/s11524-018-0250-x">https://doi.org/10.1007/s11524-018-0250-x</a>	N/A	N/A		
P-22456	8/1/2018	Rowe, C., Wheeler, E., Vittinghoff, E., Santos, G. M., Behar, E., & Coffin, P. O. (2018). Quantity fluctuations of illicitly used opioids and overdose risk. The International journal on drug policy, 58, 64–70. <a href="https://doi.org/10.1016/j.drugpo.2018.05.004">https://doi.org/10.1016/j.drugpo.2018.05.004</a>	N/A	N/A		
P-22457	4/25/2020	Behar, E., Bagnulo, R., Knight, K., Santos, G. M., & Coffin, P. O. (2020). "Chasing the pain relief, not the high": Experiences managing pain after opioid reductions among patients with HIV and a history of substance use. PloS one, 15(3), e0230408. <a href="https://doi.org/10.1371/journal.pone.0230408">https://doi.org/10.1371/journal.pone.0230408</a>	N/A	N/A		
P-22458	5/4/2020	Coffin, P. O., Rowe, C., Oman, N., Sinchek, K., Santos, G. M., Faul, M., Bagnulo, R., Mohamed, D., & Vittinghoff, E. (2020). Illicit opioid use following changes in opioids prescribed for chronic non-cancer pain. PloS one, 15(5), e0232538. <a href="https://doi.org/10.1371/journal.pone.0232538">https://doi.org/10.1371/journal.pone.0232538</a>	N/A	N/A		
P-22459	8/1/2015	NDEWS Coordinating Center. Sentinel Community Site Profile 2015: San Francisco. August 2015	N/A	N/A		
P-22460	2020	White Market Drugs: Big Pharma and the Hidden History of Addiction in America (University of Chicago Press, 2020)	TEVA_CAOC_14209083	TEVA_CAOC_14209417		
P-22461	2/5/2007	Suspicious Week Ending 2-04-07 Pharmacy	Anda_Opioids_MDL_0000124954	Anda_Opioids_MDL_0000124954		
P-22462	11/4/1998	Actiq Label	TEVA_MDL_A_13750961	TEVA_MDL_A_13750989		
P-22463	1/1/2004	Actiq Label	TEVA_MDL_A_13745721	TEVA_MDL_A_13745751		
P-22464	1/1/2005	Actiq Label	TEVA_MDL_A_13744637	TEVA_MDL_A_13744667		
P-22465	1/1/2006	Actiq Label	TEVA_MDL_A_13749671	TEVA_MDL_A_13749763		
P-22466	1/1/2007	Actiq Label	TEVA_MDL_A_13745533	TEVA_MDL_A_13745545		
P-22467	12/5/2007	Fentora Label	TEVA_MDL_A_13748837	TEVA_MDL_A_13748878		
P-22468	1/15/2009	Independent Educational Program Grant Agreement (payee: MediCom Worldwide)	TEVA_MDL_A_00850578	TEVA_MDL_A_00850961		
P-22469	4/1/2009	Fentora Label	TEVA_MDL_A_13755545	TEVA_MDL_A_13755573		
P-22470	9/1/2009	Actiq Label	TEVA_MDL_A_13745238	TEVA_MDL_A_13745252		
P-22471	1/1/2011	Actiq Label	TEVA_MDL_A_13748903	TEVA_MDL_A_13748921		
P-22472	1/5/2011	Fentora Label	TEVA_MDL_A_13748710	TEVA_MDL_A_13748723		
P-22473	7/1/2011	Fentora Label	TEVA_MDL_A_13743152	TEVA_MDL_A_13743161		
P-22474	12/20/2011	Actiq Label	TEVA_MDL_A_13744071	TEVA_MDL_A_13744089		
P-22475	12/21/2011	Fentora Label	TEVA_MDL_A_13747680	TEVA_MDL_A_13747695		
P-22476	5/19/2014	Email re FW: Fentora RX Savings Weekly Update	TEVA_MDL_A_01092610	TEVA_MDL_A_01092611		
P-22477	12/1/2016	Actiq Label	TEVA_MDL_A_13748191	TEVA_MDL_A_13748216		
P-22478	2004	Emerging Solutions in Pain...Today's source for tomorrow's pain-management	TEVA_MDL_A_01165591	TEVA_MDL_A_01165596		
P-22479	1/2/2006	Suspicious Week Ending 1-01-06 Pharmacy	Anda_Opioids_MDL_0000124959	Anda_Opioids_MDL_0000124959		
P-22480	N/A	Marchione Resume	TEVA_MDL_A_08607743	TEVA_MDL_A_08608124		
P-22482	12/3/2006	Suspicious Week Ending 12-03-06 Wholesalers	Anda_Opioids_MDL_0000124960	Anda_Opioids_MDL_0000124960		
P-22483	12/4/2006	Suspicious Week Ending 12-03-06 Pharmacy	Anda_Opioids_MDL_0000124974	Anda_Opioids_MDL_0000124974		
P-22484	9/13/2006	ACPA Grant; Grant Agreement	TEVA_MDL_A_01089325	TEVA_MDL_A_01090280		
P-22485	1/29/2007	Suspicious Week Ending 1-28-07 Wholesaler	Anda_Opioids_MDL_0000124980	Anda_Opioids_MDL_0000124980		
P-22486	2012	Fentora Targeting Spreadsheet	TEVA_MDL_A_06627557	TEVA_MDL_A_06627558		
P-22487	2006	4th Quarter 2006 Incentive Compensation Plan	TEVA_CHI_00039254	TEVA_CHI_00039259		
P-22488	N/A	Teva Ltd. Historical Timeline	N/A	N/A		
P-22489	1/26/2006	Press Release: Teva Completes Acquisition of Ivax	N/A	N/A		
P-22490	7/18/2008	Press Release: Teva to Acquire Barr	N/A	N/A		
P-22491	1/31/2018	Settlement Agreement and Mutual Release	N/A	N/A		
P-22492	2/13/2019	Press Release: Teva Reports Fourth Quarter and Full Year 2018 Financial Results	N/A	N/A		
P-22493	N/A	Teva Website: Corporate Officers	N/A	N/A		
P-22494	N/A	Teva Website: Kare Schultz	N/A	N/A		
P-22495	N/A	Teva Website: David M. Stark	N/A	N/A		

P-22496	N/A	Teva Website: Iris Beck-Codner	N/A	N/A		
P-22497	N/A	Teva Website: Michael McClellan	N/A	N/A		
P-22498	N/A	Teva Website: Brendan O'Grady	N/A	N/A		
P-22499	N/A	Teva Website: Dr. Hafun Fridriksdottir	N/A	N/A		
P-22500	N/A	Teva Website: Dr. Carlo de Notaristefani	N/A	N/A		
P-22501	N/A	Teva Website: Nir Baron	N/A	N/A		
P-22502	N/A	Teva Website: Lori Queisser	N/A	N/A		
P-22503	N/A	Teva Website: Sven Dethlefs	N/A	N/A		
P-22504	N/A	Teva Website: Asaph Naaman	N/A	N/A		
P-22505	N/A	Teva Website: Debra Barrett	N/A	N/A		
P-22506	2018	2012 Form 20-F, Segment Reporting Memorandum Q1	N/A	N/A		
P-22507	N/A	Teva Website: Corporate Governance	N/A	N/A		
P-22508	N/A	Teva Website: Committees of the Board	N/A	N/A		
P-22509	N/A	Teva Pharmacuetucial and Teva Parenteral Medicines Inc. Corporate Histories	N/A	N/A		
P-22510	N/A	Summary of Certain Teva Subsidiaries	N/A	N/A		
P-22511	12/1/2015	Guidelines for Composition and Governance of Subsidiary Boards	N/A	N/A		
P-22512	N/A	Ledger Spreadsheet	N/A	N/A		
P-22513	12/31/2018	Teva Ltd. Notes to Consolidated Financial Statements	N/A	N/A		
P-22514	3/6/2007	Press Release: Teva to Sell Oxycodone Through the End of 2007	N/A	N/A		
P-22515	2014	Innovating Better Health, Teva 2014 Global Citizenship Report	N/A	N/A		
P-22516	6/7/2016	Joint Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee	N/A	N/A		
P-22517	N/A	Dan Bar-Zohar LinkedIn	N/A	N/A		
P-22518	1998	1998 21 CFR 314.520	N/A	N/A		
P-22519	2003	Quality Assurance Memo to QA File from David Brennan	N/A	N/A		
P-22520	11/6/2006	Suspicious Week Ending 11-05-06 Pharmacy	Anda_Opioids_MDL_0000124985	Anda_Opioids_MDL_0000124985		
P-22521	9/29/2008	Government's Memo for Entry of Plea and Sentencing	N/A	N/A		
P-22522	10/6/2016	Chicago-Cook Task Force on Heroin Final Report	N/A	N/A		
P-22523	10/4/1998	Actiq Approved Label	N/A	N/A		
P-22524	N/A	Breakthrough Pain Management: The Interface of Pain and Addiction Related Issues Interview with Dr. Steve Passik, Perry Fine, Charles Argoff, Gerald Aronoff	N/A	N/A		
P-22525	7/29/2014	Vantrela Core Team Meeting Kickoff PPT	TEVA_MDL_A_08725394	TEVA_MDL_A_08725395		
P-22526	10/14/2014	Email attaching Vantrela ER Summit PPT	TEVA_MDL_A_03671899	TEVA_MDL_A_03671900		
P-22527	6/26/2015	Email attaching IR Hydrocodone Kick Off Meeting PPT	TEVA_MDL_A_06904379	TEVA_MDL_A_06904380		
P-22528	9/24/2014	Email Attaching 2015 AOP PPT	TEVA_MDL_A_12035954	TEVA_MDL_A_12035955		
P-22529	9/2/2016	Email revising slides to Pain Care	TEVA_MDL_A_08777669	TEVA_MDL_A_08777670		
P-22530	8/26/2014	Email re Teva Financial Support with attachments	TEVA_MDL_A_01529642	TEVA_MDL_A_01529646		
P-22531	2/1/2015	Evolving Roles, Same Goals PPT	TEVA_MDL_A_01136619	TEVA_MDL_A_01136650		
P-22532	2/20/2015	Email re PARC Meeting	TEVA_MDL_A_06906333	TEVA_MDL_A_06906334		
P-22533	2015	Wayback Machine 2015 version of Pain Matters website	N/A	N/A		
P-22534	9/18/2015	Email re CDC Guidelines	TEVA_CHI_00499925	TEVA_CHI_00499925		
P-22535	2021	CDC Website	N/A	N/A		
P-22536	2021	CDC Website	N/A	N/A		
P-22537	2021	CDC Website	N/A	N/A		
P-22538	2021	CDC Website	N/A	N/A		
P-22539	6/9/2015	Email re PainMatters.com Analytics Report 2 with attachment	TEVA_MDL_A_08760981	TEVA_MDL_A_08761002		
P-22540	12/8/2003	Email re October Numbers	TEVA_CAOC_13823465	TEVA_CAOC_13823465		
P-22541	3/27/2003	Email re recap of Medicom info	TEVA_CAOC_13821704	TEVA_CAOC_138821705		
P-22542	3/17/2005	Memo re Emerging Solutions in Pain (ESP) Program	TEVA_MDL_A_01165705	TEVA_MDL_A_01165705		
P-22543	1/29/2007	Suspicious Week Ending 1-28-07 Pharmacy	Anda_Opioids_MDL_0000124988	Anda_Opioids_MDL_0000124988		
P-22544	2/28/2005	Email re MDM 1st Quarter Bonus Plan with attachments	TEVA_MDL_A_08859759	TEVA_MDL_A_08859762		
P-22545	6/8/2005	Email re POA presentation with attachment	TEVA_SF_00001234	TEVA_SF_00001234		
P-22546	3/15/2005	Email re MEP's	TEVA_MDL_A_09741988	TEVA_MDL_A_09741989		
P-22547	3/29/2006	Email re La Jolla National Speaker Training - June 11, 2005 with attachments	TEVA_MDL_A_06468531	TEVA_MDL_A_06468574		

P-22548	3/29/2006	Email re Slide Decks - La Jolla National Speaker Training - June 11, 2005 with attachments	TEVA_MDL_A_06468635	TEVA_MDL_A_06468691		
P-22549	3/15/2005	Email re Actiq slides with attachment	TEVA_MDL_A_08873588	TEVA_MDL_A_08873589		
P-22550	8/19/2005	Email re Provigil & Actiq Slide Kits with attachment	TEVA_SF_00002126	TEVA_SF_00002127		
P-22551	1/20/2006	Email re Actiq slide kit with attachment	TEVA_SF_00002699	TEVA_SF_00002700		
P-22552	3/13/2006	Email re Speaker Interest	TEVA_SF_00002991	TEVA_SF_00002992		
P-22553	2/16/2006	Email re Completed Program - You are required to add Attendees	TEVA_SF_00002806	TEVA_SF_00002809		
P-22554	2021	Patrick J. Hogan, D.O. bio	N/A	N/A		
P-22555	2021	Sharon K. Jung, ARNP bio	N/A	N/A		
P-22556	11/22/2006	Email re End-of-day WSJ Pick-up	TEVA_SF_00004728	TEVA_SF_00004729		
P-22557	3/13/2007	Email re Northwest	TEVA_SF_00005382	TEVA_SF_00005382		
P-22558	3/14/2007	Email re New Teleconference Program Request	TEVA_SF_00005388	TEVA_SF_00005388		
P-22559	6/10/2004	Email re Actiq Sales Spreadsheet	TEVA_MDL_A_04481117	TEVA_MDL_A_04481117		
P-22560	1/7/2004	Email re Important Pricing Info with attachment	TEVA_CAOC_13823701	TEVA_CAOC_13823704		
P-22561	4/26/2004	Email re Medi-Cal E Mail and Percent of Business Spreadsheet	TEVA_MDL_A_00929089	TEVA_MDL_A_00929090		
P-22562	6/24/2004	Email re memo with attachment	TEVA_MDL_A_11186455	TEVA_MDL_A_11186463		
P-22563	1/31/2005	Email re Actiq Sales Update - Medi-Cal	TEVA_MDL_A_00931398	TEVA_MDL_A_00931398		
P-22564	2/27/2006	Email re Sales Specialists Covance cheat sheet with attachment	TEVA_CAOC_13829878	TEVA_CAOC_13829880		
P-22565	1/7/2005	Email re 2005 MEP Guidelines with attachment	TEVA_MDL_A_11187260	TEVA_MDL_A_11187262		
P-22566	3/14/2005	Email re MEP's	TEVA_MDL_A_02772573	TEVA_MDL_A_02772574		
P-22567	12/17/2003	Email re ACTIQ Consultant Meeting - Invitation List Process and Due Dates with attachment	TEVA_MDL_A_09740361	TEVA_MDL_A_09740366		
P-22568	1/30/2004	Email re Actiq Consultants Meeting - Boca Raton, FL with attachments	TEVA_FL_00059857	TEVA_FL_00059868		
P-22569	3/22/2007	MIRF Request and Response	TEVA_AAMD_00274956	TEVA_AAMD_00274971		
P-22570	9/1/2004	Email re Top 2 Obstacles (Action Required)	TEVA_SCAG_00100214	TEVA_SCAG_00100214		
P-22571	9/1/2004	Email re Top 2 Obstacles (Action Required)	TEVA_SCAG_00100224	TEVA_SCAG_00100224		
P-22572	5/25/2005	Email re Actiq Diversion in Detroit with attachment	TEVA_SCAG_00101435	TEVA_SCAG_00101436		
P-22573	5/25/2005	Attachment to Email re Actiq Diversion in Detroit	TEVA_SCAG_00101436	TEVA_SCAG_00101436		
P-22574	3/17/2006	Email re Pain Bowl War Games - THANK YOU	TEVA_AAMD_00790383	TEVA_AAMD_00790384		
P-22575	10/24/2007	Email re ITC with attachments	TEVA_AAMD_00626540	TEVA_AAMD_00626566		
P-22576	8/2/2007	Fentora Initial Training Class Leader Guide	TEVA_AAMD_00162711	TEVA_AAMD_00162778		
P-22577	7/11/2007	Email re Fentora Model Sales Call with attachment	TEVA_MDL_A_00932499	TEVA_MDL_A_00932501		
P-22578	6/26/2007	Email re Final, final Fentora Model Sales Call Presentation with attachment	TEVA_CHI_00109350	TEVA_CHI_00109366		
P-22579	N/A	BTP Pain Assessment excerpt	TEVA_MDL_A_07419582	TEVA_MDL_A_07419582		
P-22580	9/1/2007	Transmittal of Advertisements and Promotional Labeling	TEVA_BALT_00088141	TEVA_BALT_00088246		
P-22581	8/1/2007	Transmittal of Advertisements and Promotional Labeling	TEVA_BALT_00088024	TEVA_BALT_00088113		
P-22582	8/1/2007	Transmittal of Advertisements and Promotional Labeling	TEVA_BALT_00087974	TEVA_BALT_00088007		
P-22583	6/21/2005	Email attaching 6440 Office Visit with attachment	TEVA_SCAG_00038797	TEVA_SCAG_00038798		
P-22584	1/15/2007	Suspicious Week Ending 1-14-07	Anda_Opioids_MDL_0000124992	Anda_Opioids_MDL_0000124992		
P-22585	8/8/2005	Email re Target Sheet June with attachment	TEVA_SCAG_00101799	TEVA_SCAG_00101800		
P-22586	10/14/2005	Email re self appraisal 2005 with attachment	TEVA_SCAG_00039460	TEVA_SCAG_00039463		
P-22587	11/10/2004	Email re Q3 2004 Bonus Payout Information with attachments	TEVA_MDL_A_11442990	TEVA_MDL_A_11442993		
P-22588	12/14/2005	Email re Emailing: quote.htm	TEVA_SCAG_00102219	TEVA_SCAG_00102222		
P-22589	8/6/2006	Email re Q3 2006 PCS Bonus Plan with attachments	TEVA_CAOC_14193276	TEVA_CAOC_14193282		
P-22590	5/22/2008	Email re Q1 2008 Bonus for PCs and Area Manager with attachment	TEVA_CAOC_14195530	TEVA_CAOC_14195531		
P-22591	9/8/2006	Email re Second Quarter Wrap Up	TEVA_SCAG_00102394	TEVA_SCAG_00102395		
P-22592	1/4/2007	Email re 2007 National Sales Meeting	TEVA_CHI_00105521	TEVA_CHI_00105522		
P-22607	2/8/2007	Email re POA Slides with attachment	TEVA_CHI_00106369	TEVA_CHI_00106387		
P-22609	9/1/2010	Email re PCS NSM Agenda with attachment	TEVA_AAMD_00616393	TEVA_AAMD_00616394		
P-22610	11/13/2007	Email re Thank you	TEVA_FL_00087062	TEVA_FL_00087062		
P-22611	11/2/2006	Email re ASRA Profiler with attachment	TEVA_CAOC_14192258	TEVA_CAOC_14192262		
P-22612	10/5/2007	Email re ASA Schedule of Events and Profiler with attachment	TEVA_MDL_A_02773426	TEVA_MDL_A_02773431		
P-22670	3/18/2008	Email re Inventiv overlapping in pain office	TEVA_MDL_A_00970680	TEVA_MDL_A_00970682		
P-22688	N/A	Hassler Handout re call activity, disciplinary actions, and payment data	N/A	N/A		
P-22791	1/9/2012	Fentora Marketing and Sales PPT	TEVA_CAOC_00707632	TEVA_CAOC_00707632		

P-22813	2012	Fentora Targeting Report	TEVA_MDL_A_06627558	TEVA_MDL_A_06627558		
P-22946	3/19/2009	WALGREENS_STORE_5549_00271	WAGMDL01139001	WAGMDL01139009		
P-22947	4/15/2020	Early Inform: Inform: Good Faith Dispensing Policy Update	WAGMDL01168896	WAGMDL01168906		
P-22974	N/A	Promotional item listing excerpt	TEVA_MDL_A_01140792	TEVA_MDL_A_01140792		
P-22977	N/A	Promotional item listing excerpt	TEVA_MDL_A_02215330	TEVA_MDL_A_02215330		
P-22978	N/A	Speaker program listing excerpt	TEVA_CAOC_06648256	TEVA_CAOC_06648256		
P-22979	N/A	Speaker program listing excerpt	TEVA_CAOC_06648257	TEVA_CAOC_06648257		
P-22980	N/A	Speaker program listing excerpt	TEVA_CAOC_09429750	TEVA_CAOC_09429750		
P-22981	N/A	Speaker program listing excerpt	TEVA_CAOC_00696029	TEVA_CAOC_00696029		
P-22982	N/A	Speaker program listing excerpt	TEVA_MDL_A_00008174	TEVA_MDL_A_00008174		
P-22983	N/A	Persistent and Breakthrough Pain Materials	TEVA_CAOC_01372716	TEVA_CAOC_01372788		
P-22984	N/A	Appendix 4 - Topic 10 Hassler Handout	N/A	N/A		
P-22985	4/24/2008	Promotional Response of Fentora Findings	TEVA_MDL_A_01543547	TEVA_MDL_A_01543547		
P-22986	2011	Special Report - An Integrated Risk Evaluation and Mitigation Strategy	TEVA_MDL_A_00890767	TEVA_MDL_A_00890778		
P-22987	N/A	Handout provided by Vitale	N/A	N/A		
P-22988	N/A	Handout provided by Vitale	N/A	N/A		
P-22989	8/4/2006	Cephalon Letter to FDA re Meeting Package for Type A Meeting	TEVA_BALT_00333590	TEVA_BALT_00333599		
P-22990	4/13/2009	Transmittal of Advertisements and Promotional Labeling	TEVA_MDL_A_00027729	TEVA_MDL_A_00027836		
P-22991	12/22/2009	Transmittal of Advertisements and Promotional Labeling	TEVA_MDL_A_00695698	TEVA_MDL_A_00695742		
P-22992	12/8/2013	Transmittal of Advertisements and Promotional Labeling	TEVA_MDL_A_04342838	TEVA_MDL_A_04342849		
P-22993	3/23/2004	Center for Drug Evaluation and Research Approval Package for 76-168	N/A	N/A		
P-22994	12/6/2005	FDA Letter to Teva re ANDA 76-610	N/A	N/A		
P-22997	2/6/2004	FDA Letter to Amide re ANDA 76-636	N/A	N/A		
P-22998	2014	Letter from FDA to Teva USA re ANDA Approval	N/A	N/A		
P-22999	1/25/2017	Industry Meeting to Discuss Opioid Analgesics REMS	N/A	N/A		
P-23000	1/1/2017	Nathalie Leitch's Resume	LEITCH_MDL_00000001	LEITCH_MDL_00000003		
P-23001	1/27/2020	Email Re: Urgent	ALLERGAN_MDL_01196747	ALLERGAN_MDL_01196751		
P-23002	5/11/2009	Email re Commercial Development 2009 Priorities 2009-05-05	ALLERGAN_MDL_01103133	ALLERGAN_MDL_01103136		
P-23003	N/A	Handout provided by Vitale	N/A	N/A		
P-23004	6/29/2009	Email re Business Rules for Inventiv	ALLERGAN_MDL_01192616	ALLERGAN_MDL_01192617		
P-23005	3/30/2009	Email re DDMAC Untitled Letter for Fentora and Treanda with attachment	TEVA_MDL_A_06877152	TEVA_MDL_A_06877159		
P-23006	12/19/2006	Email re Radio Media Tour	TEVA_MDL_A_01327725	TEVA_MDL_A_01327727		
P-23007	6/21/2012	Email re Meeting Summary - Dallas Advisory Board	ALLERGAN_MDL_00028106	ALLERGAN_MDL_00028121		
P-23008	2006	Media Alert re Fentora Offer Option for Chronic Low Back Pain	TEVA_MDL_A_03532825	TEVA_MDL_A_03532828		
P-23009	2007	Fentanyl buccal tablet for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study	TEVA_AAMD_00368538	TEVA_AAMD_00368548		
P-23010	6/9/2007	Regulatory Telephone Contact Report	TEVA_MDL_A_06383979	TEVA_MDL_A_06383981		
P-23014	9/1/2011	Email re Oxymorphone ER pharmacy placement details via charge back and Oxymorphone Chargeback details 8-31-2011 attachment	Acquired_Actavis_00945856	Acquired_Actavis_00945858		
P-23015	2/7/2012	Email re MorphineER CB trend details	ACTAVIS1129567	ACTAVIS1129568		
P-23016	2/27/2012	Email re Renewal and Actavis Amendment #3 - Renewal 022612 attachment	ALLERGAN_MDL_03226918	ALLERGAN_MDL_03226922		
P-23017	3/9/2012	Email re Actavis 852 / 867 data and EAS attachment	Acquired_Actavis_00951998	Acquired_Actavis_00952005		
P-23022	12/15/2009	Myers, David Employee File [REDACTED]	ALLERGAN_MDL_SUPP00000810	ALLERGAN_MDL_SUPP00001121		
P-23024	10/11/2012	Email re Monthly Sales Awards	Acquired_Actavis_00661679	Acquired_Actavis_00661681		
P-23025	6/16/2009	Email re Kadian - New Option for Marketing	ALLERGAN_MDL_01192443	ALLERGAN_MDL_01192444		
P-23026	3/17/2010	Email re CDER New March 16, 2010	ALLERGAN_MDL_02463212	ALLERGAN_MDL_02463215		
P-23027	12/14/2009	Email re Actavis Brand Project update	ALLERGAN_MDL_01234649	ALLERGAN_MDL_01234661		
P-23029	8/2/2011	Email re Marketing SIOP August 3 2011	ALLERGAN_MDL_00504796	ALLERGAN_MDL_00504815		
P-23030	1/18/2012	Email re Oxymorphone mailings	ACTAVIS0618579	ACTAVIS0618584		
P-23031	6/13/2012	Email re Diana Award	ALLERGAN_MDL_00507938	ALLERGAN_MDL_00507944		
P-23032	2/25/2013	Email re Buprenorphine Naloxone Pre-launch Documents	Acquired_Actavis_02048142	Acquired_Actavis_02048193		
P-23033	10/7/2009	Email re Marketing Training for CS Reps DRAFT	Acquired_Actavis_01367233	Acquired_Actavis_01367236		
P-23038	N/A	IQVIA (f/k/a IMS) Data Set	ALLERGAN_MDL_02485011	ALLERGAN_MDL_02485011		



P-23039	6/8/2009	Fw: CSOP 011-004; CSOP_011-004, Suspicious Orders of Controlled Drugs	ALLERGAN_MDL_02467143	ALLERGAN_MDL_02467143		
P-23040	12/14/2010	2011 Goals DEA	ALLERGAN_MDL_02467983	ALLERGAN_MDL_02467998		
P-23041	2/24/2011	2011 Exempt PMPTNap	ALLERGAN_MDL_03535275	ALLERGAN_MDL_03535283		
P-23042	8/2/2011	Customer Services Agreement Statement of Work No. 1 between Watson Pharma and Buzzeo for Suspicious Order Monitoring (SOM) — Onsite System Review	ALLERGAN_MDL_03535028	ALLERGAN_MDL_03535030		
P-23043	9/8/2011	SOMS Meeting Minutes - System Evaluation Cegedim Dendrite, Sept. 8, 2011	ALLERGAN_MDL_02176488	ALLERGAN_MDL_02176492		
P-23044	4/26/2012	RE: Hydrocodone Supply Issues - Market Demand; Hydrocodone APAP Weekly TRx's 2012-04-19; AR-M550N_20120412_082528	ACQUIRED_ACTAVIS_01179002	ACQUIRED_ACTAVIS_01179005		
P-23045	10/2/2012	BuzzeoPDMA SOM Seminar Agenda 2012	ALLERGAN_MDL_02467214	ALLERGAN_MDL_02467216		
P-23046	3/3/2015	William Simmons 2014 Year-End Review 03_03_2015	ALLERGAN_MDL_03535137	ALLERGAN_MDL_03535143		
P-23047	9/6/2007	Email re FDA TC with attachment	TEVA_MDL_A_03400136	TEVA_MDL_A_03400138		
P-23048	2/19/2015	SOM Project Just 2.19.15	ALLERGAN_MDL_03535253	ALLERGAN_MDL_03535257		
P-23049	1/11/2016	RE: Bell Medical	ALLERGAN_MDL_03431731	ALLERGAN_MDL_03431740		
P-23050	12/31/2012	Nancy Baran File2	ALLERGAN_MDL_SUPP_00001391	ALLERGAN_MDL_SUPP_00001435		
P-23051	1/26/2010	FW: 2010 Goals	ALLERGAN_MDL_03317313	ALLERGAN_MDL_03317326		
P-23053	2/1/2008	Alpharma-Actavis Development and Manufacturing Services Agreement, executed; Alpharma-Actavis 1st Amendment to Development and Manufacturing Services agreement, executed; Term Sheet for Embeda	ALLERGAN_MDL_01474505	ALLERGAN_MDL_01474557		
P-23054	2/20/2013	FW: Kadian targeting analysis; Updated list of Kadian Q4 12 targets	ACTAVIS1025294	ACTAVIS1025297		
P-23055	10/12/2011	RE: Monday October 10 Sales Call	ACTAVIS0811957	ACTAVIS0811960		
P-23056	7/9/2012	PO for LAO REMS; RPC Finance Information	ACTAVIS0718476	ACTAVIS0718533		
P-23057	7/11/2018	FW: Kadian information; Kadian FDA Warning Letter; NDA 20-616, Kadian - initial packet for FDA	ALLERGAN_MDL_00780096	ALLERGAN_MDL_00780473		
P-23062	2008	Your Druggist Pharmacy, 73 Fed. Reg. 75,774, 75,775 n.1 (DEA Dec. 2008) -	N/A	N/A		
P-23063	2018	Actions of the 2018 American Pharmacists Association House of Delegates (March 2018),	N/A	N/A		
P-23065	09/00/2012	Institute for Safe Medication Practices, Prescription Drug Time Guarantees and Their Impact on Patient Safety in Community Pharmacies. ISMP Medication Safety Alert!	N/A	N/A		
P-23066	10/00/2008	Institute for Safe Medication Practices, Speed trap. ISMP Medication Safety Alert! Community/Ambulatory Care Edition	N/A	N/A		
P-23067	03/00/2011	Institute for Safe Medication Practices, Return of the speed trap. ISMP Medication Safety Alert! Community/Ambulatory Care Edition	N/A	N/A		
P-23068	N/A	Stakeholders' Challenges and Red Flag Warning Signs Related to Prescribing and Dispensing Controlled Substances	NABP_00022121	NABP_00022137		
P-23069	2021	National Coordinating Council for Medication Error Reporting and Prevention. Statement Advocating for the Elimination of Prescription Time Guarantees in Community Pharmacy	N/A	N/A		
P-23070	2017	Pharmacists Provide Care, Fighting to let pharmacists keep patients safe, APhA	N/A	N/A		
P-23071	2019	Rite Aid Board Report on Opioid Oversight, at 6	N/A	N/A		
P-23076	3/23/2016	FW: 5349	WAGCAS00113475	WAGCAS00113478		
P-23077	7/12/2016	2 of 2 Ohio Store Leadership Launch Event 2-day v2	WAGFLAG00080494	WAGFLAG00080626		
P-23078	8/1/2008	Workflow	WAGMDL00779646	WAGMDL00779658		
P-23087	N/A	Composite of Walgreens Scanned Prescriptions	WAGMDL01190496 - WAGMDL01191333; WAGMDL01191370 - WAGMDL01191400; WAGMDL01191569 - WAGMDL01192642; WAGMDL01197313 - WAGMDL01198246;	Composite		
P-23099	N/A	Composite of Walgreens Electronic Notes	N/A	N/A		
P-23175	4/6/2020	ARCOS Retail Drug Summary Reports, Drug Enforcement Administration, 2019	N/A	N/A		
P-23176	8/1/2009	Masters SOMS Algorithm.	CAH_MDL2804_01423521	CAH_MDL2804_01423598		
P-23207	12/16/2004	Board of Directors Meeting Packet	TEVA_AAMD_00180647	TEVA_AAMD_00180858		

P-23210	11/1/2018	"National Drug Code Dictionary," Drug Enforcement Administration, November 2018	N/A	N/A		
P-23211	1/6/2020	"National Drug Code Dictionary," Drug Enforcement Administration, January 2020	N/A	N/A		
P-23212	N/A	US Processed ARCOS	N/A	N/A		
P-23213	N/A	OH Processed ARCOS	N/A	N/A		
P-23263	10/21/2013	Statement of Work between Purdue Pharma and Adheris, Inc.	PPLP003358929	PPLP003358936		
P-23265	9/18/2013	Exec DC Visit Briefing Book Sep18 13 Final	TEVA MDL A_04208587	TEVA MDL A_04208635		
P-23271	1/18/2017	Daily Health Dashboard V5_Retail_18Jan2017	WAGMDL00078101	WAGMDL00078104		
P-23362	12/19/2006	Board of Directors Meeting Packet	TEVA_AAMD_00182697	TEVA_AAMD_00182818		
P-23459	2/12/2002	Testimony Submitted on behalf of CVS Pharmacy to US Senate	NA	NA		
P-23476	3/17/2021	Declaration of Christopher Ivanoski	NA	NA		
P-23545	12/11/2008	Board of Directors Meeting Packet	TEVA MDL A_00670924	TEVA MDL A_00671122		
P-23560	12/31/2000	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2000	PLTF_2804_000117735	PLTF_2804_000118147		
P-23561	12/31/2001	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2001	PLTF_2804_000118148	PLTF_2804_000119235		
P-23563	12/31/2002	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2002	PLTF_2804_000119236	PLTF_2804_000119958		
P-23564	12/31/2003	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2003	PLTF_2804_000119959	PLTF_2804_000120657		
P-23565	12/31/2004	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2004	PLTF_2804_000120658	PLTF_2804_000121625		
P-23566	12/31/2005	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2005	PLTF_2804_000121626	PLTF_2804_000122352		
P-23567	12/31/2006	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2006	PLTF_2804_000122353	PLTF_2804_000122958		
P-23568	12/31/2006	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2006	PLTF_2804_000122959	PLTF_2804_000122999		
P-23569	12/31/2006	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2006	PLTF_2804_000123000	PLTF_2804_000123043		
P-23570	12/31/2006	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2006	PLTF_2804_000123044	PLTF_2804_000123080		
P-23571	12/31/2006	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2006	PLTF_2804_000123081	PLTF_2804_000123210		
P-23572	12/31/2006	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2006	PLTF_2804_000123211	PLTF_2804_000123215		
P-23573	12/31/2007	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2007	PLTF_2804_000123216	PLTF_2804_000123818		
P-23574	12/31/2007	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2007	PLTF_2804_000123819	PLTF_2804_000123861		
P-23575	12/31/2007	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2007	PLTF_2804_000123862	PLTF_2804_000123908		
P-23576	12/31/2007	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2007	PLTF_2804_000123909	PLTF_2804_000123940		
P-23577	12/31/2007	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2007	PLTF_2804_000123941	PLTF_2804_000124071		
P-23578	12/31/2007	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2007	PLTF_2804_000124072	PLTF_2804_000124077		
P-23579	12/31/2008	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2008	PLTF_2804_000124078	PLTF_2804_000124705		
P-23580	12/31/2008	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2008	PLTF_2804_000124706	PLTF_2804_000124747		
P-23581	12/31/2008	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2008	PLTF_2804_000124748	PLTF_2804_000124791		
P-23582	12/31/2008	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2008	PLTF_2804_000124792	PLTF_2804_000124836		
P-23583	12/31/2008	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2008	PLTF_2804_000124837	PLTF_2804_000124969		

P-23584	12/31/2008	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2008	PLTF_2804_000124970	PLTF_2804_000124975		
P-23585	12/31/2009	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2009	PLTF_2804_000124976	PLTF_2804_000125616		
P-23586	12/31/2009	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2009	PLTF_2804_000125617	PLTF_2804_000125660		
P-23587	12/31/2009	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2009	PLTF_2804_000125661	PLTF_2804_000125706		
P-23588	12/31/2009	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2009	PLTF_2804_000125707	PLTF_2804_000125759		
P-23589	12/31/2009	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2009	PLTF_2804_000125760	PLTF_2804_000125919		
P-23590	12/31/2009	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2009	PLTF_2804_000125920	PLTF_2804_000125924		
P-23591	12/31/2010	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2010	PLTF_2804_000125925	PLTF_2804_000126613		
P-23592	12/31/2010	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2010	PLTF_2804_000126614	PLTF_2804_000126668		
P-23593	12/31/2010	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2010	PLTF_2804_000126669	PLTF_2804_000126705		
P-23594	12/31/2010	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2010	PLTF_2804_000126706	PLTF_2804_000126739		
P-23595	12/31/2010	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2010	PLTF_2804_000126740	PLTF_2804_000126874		
P-23596	12/31/2010	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2010	PLTF_2804_000126875	PLTF_2804_000126880		
P-23597	12/31/2011	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2011	PLTF_2804_000126881	PLTF_2804_000127358		
P-23598	12/31/2011	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2011	PLTF_2804_000127359	PLTF_2804_000127393		
P-23599	12/31/2011	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2011	PLTF_2804_000127394	PLTF_2804_000127429		
P-23600	12/31/2011	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2011	PLTF_2804_000127430	PLTF_2804_000127464		
P-23601	12/31/2011	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2011	PLTF_2804_000127465	PLTF_2804_000127585		
P-23602	12/31/2011	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2011	PLTF_2804_000127586	PLTF_2804_000127591		
P-23603	12/31/2012	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2012	PLTF_2804_000127592	PLTF_2804_000128135		
P-23604	12/31/2012	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2012	PLTF_2804_000128136	PLTF_2804_000128174		
P-23605	12/31/2012	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2012	PLTF_2804_000128175	PLTF_2804_000128209		
P-23606	12/31/2012	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2012	PLTF_2804_000128210	PLTF_2804_000128242		
P-23607	12/31/2012	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2012	PLTF_2804_000128243	PLTF_2804_000128345		
P-23608	12/31/2012	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2012	PLTF_2804_000128346	PLTF_2804_000128349		
P-23609	12/31/2013	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2013	PLTF_2804_000128350	PLTF_2804_000128980		
P-23610	12/31/2013	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2013	PLTF_2804_000128981	PLTF_2804_000129022		
P-23611	12/31/2013	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2013	PLTF_2804_000129023	PLTF_2804_000129060		
P-23612	12/31/2013	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2013	PLTF_2804_000129061	PLTF_2804_000129102		
P-23613	12/31/2013	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2013	PLTF_2804_000129103	PLTF_2804_000129261		

P-23614	12/31/2013	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2013	PLTF_2804_000129262	PLTF_2804_000129266		
P-23615	12/31/2014	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2014	PLTF_2804_000129267	PLTF_2804_000129745		
P-23616	12/31/2014	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2014	PLTF_2804_000129746	PLTF_2804_000129795		
P-23617	12/31/2014	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2014	PLTF_2804_000129796	PLTF_2804_000129835		
P-23618	12/31/2014	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2014	PLTF_2804_000129836	PLTF_2804_000129873		
P-23619	12/31/2014	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2014	PLTF_2804_000129874	PLTF_2804_000130022		
P-23620	12/31/2014	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2014	PLTF_2804_000130023	PLTF_2804_000130028		
P-23621	12/31/2015	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2015	PLTF_2804_000130029	PLTF_2804_000130669		
P-23622	12/31/2015	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2015	PLTF_2804_000130670	PLTF_2804_000130703		
P-23623	12/31/2015	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2015	PLTF_2804_000130704	PLTF_2804_000130758		
P-23624	12/31/2015	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2015	PLTF_2804_000130759	PLTF_2804_000130811		
P-23625	12/31/2015	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2015	PLTF_2804_000130812	PLTF_2804_000130938		
P-23626	12/31/2015	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2015	PLTF_2804_000130939	PLTF_2804_000130944		
P-23627	12/31/2016	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2016	PLTF_2804_000130945	PLTF_2804_000131667		
P-23628	12/31/2017	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2017	PLTF_2804_000131668	PLTF_2804_000132720		
P-23640	N/A	Automation of Reports and Consolidated Orders System ("ARCOS") electronic data, received from the Drug Enforcement Administration	N/A	N/A		
P-23642	N/A	MDL Discovery Ruling No. 12 Regarding Suspicious Order Interrogatory [Doc. 1174]	N/A	N/A		
P-23643	N/A	Controlled Substances by DEA Drug Code Number	PLTF_2804_000117138	PLTF_2804_000117153		
P-23645	N/A	NDC Dictionary Instructions Drug Enforcement Administration, October 2010.	PLTF_2804_000117715	PLTF_2804_000117720		
P-23647	2018	Opioid Oral Morphine Milligram Equivalent (MME) Conversion Factors	PLTF_2804_000117137	PLTF_2804_000117137		
P-23648	5/16/2007	McKesson Operations Manual Lifestyle Drug Monitoring Program	MCKMDL00355251	MCKMDL00355256		
P-23649	12/31/1997	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 1997	N/A	N/A		
P-23650	12/31/1998	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 1998	N/A	N/A		
P-23651	12/31/1999	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 1999	N/A	N/A		
P-23652	12/31/2018	"ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2018	N/A	N/A		
P-23654	1997	ARCOS Registrant Handbook 1997 Version	PLTF_2804_000116946	PLTF_2804_000117136		
P-23665	2/28/2013	RE: CII Processing Update; List of RED Stores and Items 22813	WAGFLAG00358527	WAGFLAG00358529		
P-23667	5/24/2013	FW: current red store list; Walgreens Store Update_May 20 2013 (2)	WAGMDL00413951	WAGMDL00413954		
P-23668	3/6/2013	Fwd: Cardinal Health Follow-up Questions	WAGMDL01107414	WAGMDL01107417		
P-23669	4/10/2013	RE: Controlled Substance Order Quantity Override Form	WAGMDL01107446	WAGMDL01107446		
P-23670	9/19/2013	RE: C-II increase	WAGMDL01107467	WAGMDL01107468		
P-23671	3/4/2013	IMPORTANT INSTRUCTIONS AROUND: Cardinal Health Follow-up Questions; Walgreens Perrysburg Store List	WAGMDL01107511	WAGMDL01107514		

P-23672	4/10/2013	District 305 Business Overview; 305 March District Business Overview Template Corrected	WAGMDL01111936	WAGMDL01111939		
P-23673	3/30/2013	FW: Red Stores/Perrysburg; Red CAH Stores	WAGMDL01113595	WAGMDL01113598		
P-23674	3/4/2013	Fwd: ACTION REQUIRED: Cardinal Site and Surveillance Store Visits ***Do Not Forward***; Cardinal Store list	WAGMDL01113780	WAGMDL01113783		
P-23675	1/2/0213	FW: Top 500; Oxycodone Store Potential Risk Overview	WAGMDL01173810	WAGMDL01173811		
P-23676	N/A	Compilation of selected Dr. Frank Veres TDGFD checklists	WAGMDL01094715	Compilation		
P-23677	3/27/2020	WALGREENS_STORE_10569_01405	WAGMDL01095814	WAGMDL01095814		
P-23678	5/7/2018	WALGREENS_STORE_10569_01429	WAGMDL01095838	WAGMDL01095840		
P-23679	7/13/2016	Re: Walgreens Profile for Mind-Mapping Project; Strategic Account Plan Walgreens 2016 July PDv2bp	PPLPC018001345031	PPLPC018001345032		
P-23680	7/7/2015	Copy of BCI 2015-06 Pharmaceutical Integrity (2)	WAGMDL00487508	WAGMDL00487508		
P-23681	10/19/2005	Email re OVF Pivotal Trial Update with attachment	TEVA_MDL_A_07110351	TEVA_MDL_A_07110353		
P-23682	10/11/2006	Email re Fentora Chronic Low Back Pain Media Coverage	TEVA_CHI_00751362	TEVA_CHI_00751371		
P-23683	7/18/2007	Email re Final Sales Compliance Meeting Questions	TEVA_MDL_A_07353840	TEVA_MDL_A_07353841		
P-23684	10/11/2007	Email re Message with attachment	TEVA_CHI_00762476	TEVA_CHI_00762479		
P-23685	12/14/2006	Email re Fentora Launch Assessment with attachment	TEVA_CHI_00756291	TEVA_CHI_00756292		
P-23686	1/29/2007	Email re Fentora Bonus Plan	TEVA_CHI_00761449	TEVA_CHI_00761449		
P-23687	7/29/2009	Board of Directors Meeting - Audit Committee packet	TEVA_MDL_A_00672990	TEVA_MDL_A_00673319		
P-23688	1/18/2007	FAST Team Meeting Presentation	TEV_FE00008931	TEV_FE00009028		
P-23689	N/A	Stacey Beckhardt Employee File	TEVA_MDL_A_13620152	TEVA_MDL_A_13620319		
P-23690	N/A	Robert P. Roche, Jr. Annual Total Direct Compensation chart and excerpts	N/A	N/A		
P-23691	1/27/2010	Memo re Quarter 4 2009 Global Compliance Report	TEVA_MDL_A_00821008	TEVA_MDL_A_00821047		
P-23692	1/31/2007	Email re 3041 AAN	TEVA_CHI_00759545	TEVA_CHI_00759546		
P-23693	10/1/1996	Article re The Clinical Impact of Adverse Event Reporting	N/A	N/A		
P-23694	N/A	Photos of Teva opioid products	N/A	N/A		
P-23695	N/A	Photo of Actiq and Fentora	N/A	N/A		
P-23696	N/A	Photo of Generic Opioid Products	N/A	N/A		
P-23697	N/A	Photos of Teva Company Opioid Products	N/A	N/A		
P-23699	2013	Joseph Rannazzisi Drug Trends, Albuquerque, New Mexico, March 2013	N/A	N/A		
P-23701	8/3/2009	Letter RE: NDA # 20-616 KADIAN (morphine sulfate extended-release) Capsules, 10 mg, 20 mg, 30 mg, 50 mg, 60 mg, 80 mg, 100 mg and 200 mg and attachments	ALLERGAN_MDL_02104931	ALLERGAN_MDL_02104944		
P-23703	6/1/2016	Executive Briefing Book	TEVA_SF_00104138	TEVA_SF_00104197		
P-23720	11/4/2011	CDC, Morbidity and Mortality Weekly Report	N/A	N/A		
P-23737	3/10/2020	2020-3-10 [DN 5450] Ex. 2 Order Denying McCann & Rafalski Daubert	N/A	N/A		
P-23738	5/17/2006	Letter from DEA to Mr. Todd Polarolo regarding regulatory investigation	WAGMDL00753476	WAGMDL00753641		
P-23741	11/1/2011	CDC Vital Signs, Prescription Painkiller Overdoses in the US	N/A	N/A		
P-23749	12/23/2013	2014 Vantrela ER Launch Plan	TEVA_BALT_00706609	TEVA_BALT_00706638		
P-23750	11/15/2007	LA Opioid Adopters Study Final Report	ENDO-OPIOID_MDL-00688638	ENDO-OPIOID_MDL-00688640		
P-23755b	12/19/2019	Lembke CV	N/A	N/A		
P-23760a	12/19/2019	The Growth and Institutionalization of Narcotics Conservatism: The Historical Background of the Opioid Addiction and Overdose Crisis, Expert Report of David T. Courtwright, Ph.D. - CV only	N/A	N/A		
P-23765	10/2/2013	DEA Diversion Investigators Manual with 2013 DEA cover letter	CAH_MDL2804_01563592	CAH_MDL2804_01563980		
P-23767	2/2/2009	Interview with Endo CEO Carol Ammon	N/A	N/A		
P-23767a_PDF Transcript	2/2/2009	Interview with Endo CEO Carol Ammon Transcript	N/A	N/A		
P-23771	2006	2006 Endo sales training document entitled "Module 3: Oxymorphone Risk Management Program" taught sales reps concept of pseudoaddiction	ENDO-CHI_LIT-00053284	ENDO-CHI_LIT-00053335		
P-23775	2005	2005 Actiq Marketing Plan	TEVA_CHI_00043010	TEVA_CHI_00043093		
P-23777	2/18/2010	2010 Warning letter from DDMAC	ACTAVIS0238310	ACTAVIS0238322		
P-23778	7/27/2011	Email re FINAL VP Presentation	TEVA_SF_00098379	TEVA_SF_00098379		

P-23785	5/27/2010	Regents Notices Dec 1999 - Feb 2008; PPSG spreadsheet of financial contributions	WIS_PPSG_007783	WIS_PPSG_007783		
P-23786	12/14/2001	Optimizing Chronic Pain Management with Duragesic PPT	JAN-MS-00653403	JAN-MS-00653403		
P-23788	2/1/2007	Opana ER Call Plan Document: Message and Support Materials	ENDO-CHI_LIT-00210473	ENDO-CHI_LIT-00210476		
P-23789	7/28/2011	Discussion with the Office of the Vice President of the United States Presentation	N/A	N/A		
P-23790	3/31/2009	Kadian Learning Systems	ALLERGAN_MDL_01052119	ALLERGAN_MDL_01052465		
P-23803	7/11/2011	Email re Vice President Biden Request	TEVA_RI_00842222	TEVA_RI_00842223		
P-23804	6/30/2017	Masters Pharmaceutical Inc v Drug Enforcement Administration	N/A	N/A		
P-23806	7/13/2011	Email re Biden/Rx Drug Abuse Prevention Meeting	TEVA_RI_00870097	TEVA_RI_00870098		
P-23808	9/23/2013	FDA Presentation	TEVA_MDL_A_01087947	TEVA_MDL_A_01087971		
P-23814	10/1/2014	ADF Managed Markets - Government Affairs Summit PPT	TEVA_MDL_A_08846538	TEVA_MDL_A_08846538		
P-23818	2/19/2016	Email re Vantrela ER NDA-Update	TEVA_SF_00102566	TEVA_SF_00102568		
P-23840	2/24/2016	Teva Letter to FDA Commissioner	TEVA_SF_00103061	TEVA_SF_00103062		
P-23843	7/10/2017	Administrative Memorandum of Agreement between DEA and Mallinckrodt	N/A	N/A		
P-23847	4/7/2016	FDA Meeting Packet	TEVA_MDL_A_04207854	TEVA_MDL_A_04207867		
P-23848	1/3/2008	Email re Oxy	TEVA_RI_00807526	TEVA_RI_00807526		
P-23855	6/10/2013	Email, RE: Walgreens 12679	WAGMDL00032660	WAGMDL00032662		
P-23856	4/4/2012	Processing Suspicious Orders and Loss of Controlled Drugs	WAGFLDEA00000028	WAGFLDEA00000028		
P-23857	10/27/2011	Email, DEA Business Reason	WAGMDL00119542	WAGMDL00119548		
P-23858	3/11/2013	Email, Oxy timeline	WAGMDL00246016	WAGMDL00246016		
P-23859	1/31/2004	Chemical Handler's Manual: A Guide to Chemical Control Regulations	WAGMDL00395965	WAGMDL00396033		
P-23860	5/9/2012	Email, FW: Drug Quantities	WAGMDL00751871	WAGMDL00751872		
P-23861	8/9/2017	Email with attachment, RE: RAD/ABC meeting next week to review Action Item tracker	WAGMDL00370894	WAGMDL00371010		
P-23862	9/14/2015	Email, RE: Rx Integrity Process Summaries	WAGMDL00037073	WAGMDL00037075		
P-23863	12/31/2012	Email, SIMS Enhancement for Controlled Substance Orders	WAGMDL00700240	WAGMDL00700241		
P-23864	12/16/2015	Email with attachment, ActavisCSCCompliance & DEA 101NB PowerPoint	ALLERGAN_MDL_03985413	ALLERGAN_MDL_03985473		
P-23882	N/A	Debra Barrett LinkedIn	N/A	N/A		
P-23910	8/17/2012	Email with attachment, DEA Response Letter HSV Tablets	ENDO-OPIOID_MDL-02827462	ENDO-OPIOID_MDL-02827465		
P-23911	9/17/2015	LOA for DEA Audit 7-29-15 to 7-31-15 Received 9-17-15 and family members	ENDO-OPIOID_MDL-02879034	ENDO-OPIOID_MDL-02879051		
P-23913	5/28/2014	Email with attachment, SOM Intro 2014 PowerPoint	Teva_MSAG_03473654	Teva_MSAG_03473656		
P-23914	12/11/2001	2018-01-16 RDC PowerPoint	Teva_MSAG_00633614	Teva_MSAG_00633614		
P-23917	9/28/2010	Endo Announces Agreement to Acquire Qualitest	N/A	N/A		
P-23918	12/1/2010	Endo Successfully Completes Acquisition of Qualitest	N/A	N/A		
P-23919	9/30/2014	DEA Letter to Generics Bidco	PAR_OPIOID_MDL_0002102254	PAR_OPIOID_MDL_0002102264		
P-23975	10/23/2012	Marketing Agreement -Statement of Work	CAH_MDL2804_02958653 CAH_MDL2804_02958781	CAH_MDL2804_02958797 CAH_MDL2804_02958783	CAH_MDL2804_02958781 - CAH_MDL2804_02958783	
P-23996	7/16/1997	Bill to Ease Access to Drugs for Pain Gains. Los Angeles Times. Ingram, Carl. (1997, July 2016).	N/A	N/A		
P-23997	10/10/1997	California Senate Bill 402 Chaptered	N/A	N/A		
P-23998	7/12/1999	California Senate Health and Human Services Committee Analysis AB 791	N/A	N/A		
P-23999	9/15/1999	California Assembly Bill 791 Healing arts pain management	N/A	N/A		
P-24003	4/5/2000	RE: AB 2018 Update	PPLPC010000006787	PPLPC010000006789		
P-24011	4/15/2000	FW: AB 2018	PPLPC010000006874	PPLPC010000006877		
P-24014	2/1/2010	WAG Powerplay book	WAGMDL01064387	WAGMDL01064482		
P-24015	12/6/2011	State Board of Pharmacy Meeting 12-5-2011	WAGMDL00874160	WAGMDL00874160		
P-24016	12/11/2006	Suspicious Week Ending 12-10-06 Wholesalers	Anda_Opioids_MDL_0000124996	Anda_Opioids_MDL_0000124996		
P-24017	7/11/2012	RE: Well Experience Stores/Ohio	WAGMDL00921909	WAGMDL00921911		
P-24018	7/12/2012	Ohio Board of Pharmacy Meeting 7-10-2012	WAGMDL01113970	WAGMDL01113971		
P-24019	10/3/2012	FW: AP Catalog	WAGMDL01113327	WAGMDL01113393		
P-24020	5/9/2000	RE: Medi-Cal Pull-through	JAN-CA-00073892	JAN-CA-00073892		
P-24021	12/15/2012	FW: Suspicious Order Monitoring **Please do not forward**	WAGMDL01113725	WAGMDL01113732		
P-24022	1/14/2013	FW: Retail pharmacy question	WAGMDL00923158	WAGMDL00923159		
P-24023	2/5/2013	FW: Updated DM Walk: Fill-in Fields	WAGMDL01113079	WAGMDL01113088		



P-24024	12/26/2006	Suspicious Week Ending 12-24-06 Pharmacy	Anda_Opioids_MDL_0000124999	Anda_Opioids_MDL_0000124999		
P-24025	1/9/2006	Suspicious Week Ending 1-08-06 Wholesalers	Anda_Opioids_MDL_0000125009	Anda_Opioids_MDL_0000125009		
P-24026	3/19/2013	Re: March Legal Issues	WAGMDL00797342	WAGMDL00797344		
P-24027	3/30/2013	fw: National TD GFD Powerpoint Updated	WAGMDL01112462	WAGMDL01112464		
P-24028	4/10/2013	OARRS registration	WAGMDL00841293	WAGMDL00841293		
P-24029	4/22/2013	Fw: Pam Fohlman needs an OARRS	WAGMDL01113904	WAGMDL01113904		
P-24030	5/23/2013	RE: OARRS/Ohio PMP	WAGMDL00785116	WAGMDL00785117		
P-24031	5/23/2013	RE: OARRS/Ohio PMP	WAGMDL00785118	WAGMDL00785119		
P-24032	6/13/2014	FY14 Q3 Control Adjusted Report - District	WAGMDL01110077	WAGMDL01110109		
P-24033	8/31/2015	Important Good Faith Dispensing Webcast - You are Invited	WAGMDL01113677	WAGMDL01113714		
P-24034	12/18/2015	FY16 Q1 Control Adjusted Report - District	WAGMDL01111822	WAGMDL01111840		
P-24035	1/15/2016	Fwd: INFORM: January Ohio Board of Pharmacy meeting	WAGMDL01113972	WAGMDL01113979		
P-24036	7/7/2016	Undeliverable: Week 5- Focus on the Pharmacy	WAGNYNS00021130	WAGNYNS00021197		
P-24037	2/3/2020	Preread RxR Fulfillment: Rx Intake Session #1	WAGMDL01067940	WAGMDL01067967		
P-24038	4/2/2013	Store Operations Weekly Communications to the Field - 4/1/13	WAGMDL01132234	WAGMDL01132246		
P-24039	5/7/2018	Re: FW: Rx Integrity Reports for the month of May are now available	WAGMDL01116431	WAGMDL01116432		
P-24040	10/7/2019	Re: GFD	WAGMDL01115756	WAGMDL01115757		
P-24042	10/10/2016	FW: September Compliance Walk Results	WAGMDL00112872	WAGMDL00112874		
P-24049	8/17/2000	California Senate Health and Human Services Committee Analysis AB 2018	N/A	N/A		
P-24050	10/2/2000	California Assembly Bill 2018 Controlled substances: Schedule II: triplicate prescription	N/A	N/A		
P-24051	9/27/2002	2002-09-27-Brief History of Treatment of Pain.ppt	PPLPC030000230802	PPLPC030000230802		
P-24052	5/28/2003	SCCPI Analysis & Letter	PPLPC022000030602	PPLPC022000030610		
P-24053	7/14/2003	Review letter to Senator John Burton and Representative Rogers	PPLPC021000035651	PPLPC021000035654		
P-24054	9/17/2003	California Senate Bill 151 Controlled substances: Schedule II	N/A	N/A		
P-24055	9/19/2003	FW: California Triplicate Prescriptions and PMP	PPLPC012000064580	PPLPC012000064582		
P-24056	9/22/2003	RE: California Triplicate Prescriptions and PMP	PPLPC012000064637	PPLPC012000064638		
P-24057	9/22/2003	RE: California Triplicate Prescriptions and PMP	PPLPC030000328514	PPLPC030000328514		
P-24058	9/30/2003	Nursing prn policy	PPLPC022000037364	PPLPC022000037365		
P-24059	11/5/2003	FW: LAS VEGAS SOUTHWEST REGIONAL ACTIQ CONSULTANT MEETING - FINAL AGENDA, ATTENDANCE LIST AND EVALUATION REPORT	TEVA_CAOC_13823270	TEVA_CAOC_13823278		
P-24060	2/25/2004	Re: ASPMN Government Relations Committee	PPLPC021000049821	PPLPC021000049856		
P-24061	6/21/2004	Q2 Bonus Plan and Sales Contests	TEVA_CHI_00052070	TEVA_CHI_00052079		
P-24062	12/3/2004	CA BOP 01_jan_script	CAH_TXMDL_0185578	CAH_TXMDL_0185605		
P-24063	1/4/2005	FW: Cephalon Speaker Survey Responses Final 12-20	TEVA_FL_00076573	TEVA_FL_00076575		
P-24064	12/17/2005	Targets	TEVA_SF_00002513	TEVA_SF_00002514		
P-24065	1/20/2006	Actiq slide kit	TEVA_SF_00002701	TEVA_SF_00002702		
P-24066	1/21/2006	National Sales meeting follow up	TEVA_SF_00002718	TEVA_SF_00002723		
P-24067	8/26/2006	RE: California PMP response	PPLPC020000081752	PPLPC020000081755		
P-24068	5/1/2007	Overcoming Opiophobia and Doing Opioids Right	N/A	N/A		
P-24069	4/7/2008	Chronic Opioid Therapy Dinner 4/10 invitations	ENDO_SF-00008802	ENDO_SF-00008806		
P-24070	4/21/2011	California Assembly Committee on Health Bill Analysis AB 507	N/A	N/A		
P-24071	10/2/2011	California Assembly Bill 507 Controlled substances pain management	N/A	N/A		
P-24072	10/12/2011	RE: Good News! California Pain Management Legislation Passes	ENDO_SF-00354516	ENDO_SF-00354517		
P-24073	2/24/2012	RE: Can you please get a pdf of this article	PPLPC018000645146	PPLPC018000645156		
P-24074	4/25/2008	NIPC Registration Counts	ENDO_FLAG-00421543	ENDO_FLAG-00421545		
P-24075	5/31/2012	CONFIDENTIAL: Copy of NIPC invitation for "Responsible Opioid Prescribing in an Era of REMS"	ENDO_FLAG-01047140	ENDO_FLAG-01047142		
P-24076	2/16/2011	Fentora 2011 Digital Media Recommendations	TEVA_CAOC_00057972	TEVA_CAOC_00057972		
P-24077	6/18/2015	Fentora Agile Marketing Scorecard	TEVA_CAOC_06436982	TEVA_CAOC_06436982		
P-24078	6/30/2015	Fentora Marketing Execution Scorecard - National Summary	TEVA_CAOC_06437008	TEVA_CAOC_06437008		
P-24079	12/2/2015	Fentora Agile Marketing Scorecard	TEVA_CAOC_06437065	TEVA_CAOC_06437065		
P-24080	12/2/2016	Fentora Agile Marketing Scorecard	TEVA_CAOC_07394548	TEVA_CAOC_07394548		
P-24081	6/11/2015	4.24.2015 Radio Program Sponsorship Agmt (2015)	TEVA_MDL_A_06789499	TEVA_MDL_A_06789502		

P-24082	2/1/2016	Pain Matters 2015 end of year report and OGSM; Pain Matters Full Campaign Report 4 15 - 12 31 Final; Pain Matters OGSM 2015 with Pacing up to 12.31	TEVA_MDL_A_08657146	TEVA_MDL_A_08657174		
P-24083	2/15/2017	Pain Matters 2016 Analytics; Pain Matters 2016 End of Year Recap_2-15-17[1]	TEVA_MDL_A_08762980	TEVA_MDL_A_08763011		
P-24084	2/18/2018	Fentora/Actiq REMS Supplement for Pain Audience Published; SR1140 CEPHALON REMS FINALrev	TEVA_MDL_A_07068878	TEVA_MDL_A_07068894		
P-24085	7/1/2012	(ASIPP) guidelines for responsible opioid prescribing	N/A	N/A		
P-24086	6/5/2013	Dowell D, Kunins HV, Farley, TA. Opioid analgesia – Risky drugs, not risky patients. JAMA. 2013;309(21):2219- 2220.	N/A	N/A		
P-24087	7/1/2014	The Role of Opioid Prescription in Incident Opioid Abuse	N/A	N/A		
P-24088	2015	Visconti AJ, et al. Opioid Overdose Deaths in the City and County of San Francisco: Prevalence, Distribution and Disparities. Journal of Urban Health. 2015;92(4):758-772	N/A	N/A		
P-24089	8/1/2015	National Drug Early Warning System (NDEWS) Sentinel Community Site Profile 2015: San Francisco	N/A	N/A		
P-24090	2/1/2016	Novak SP, et al. Initiation of Heroin and Prescription Opioid Pain Relievers by Birth Cohort. American Journal of Public Health. 2016;106(2):298–300	N/A	N/A		
P-24091	4/19/2017	Bluthenthal RN, et al. Drug use generations and patterns of injection drug use: Birth cohort differences among people who inject drugs in Los Angeles and San Francisco, California. Drug and Alcohol Dependence. 2017;175:210–218	N/A	N/A		
P-24092	4/3/2018	Former West Covina mayor, doctor under investigation for over-prescribing opioids closes local practice. San Gabriel Valley Tribune. Yee, Christopher (2018, April 3)	N/A	N/A		
P-24093	10/1/2018	Reduced Opioid Marketing Could Limit Prescribing Information for Physicians	N/A	N/A		
P-24094	5/2/2019	Founder and Four Executives of Insys Therapeutics Convicted of Racketeering Conspiracy	N/A	N/A		
P-24095	2021	High and Rising Mortality Rates Among Working-Age Adults	N/A	N/A		
P-24096	8/2/2017	Fwd: Thank You and Follow-up	PPLPC018001450246	PPLPC018001450247		
P-24097	2/1/2022	CDC Clinical Practice Guideline for Prescribing Opioids-United States	N/A	N/A		
P-24098	2/2/2022	Responding to the opioid crisis in North America	N/A	N/A		
P-24099	5/30/2012	FW: CONFIDENTIAL - NIPC Materials: Responsible Opioid Prescribing in the Era of REMS - File 1of 2	EPI002487098	EPI002487196		
P-24100	N/A	Financial Disclosures for Forest Tennant, MD, Practical Pain Management	N/A	N/A		
P-24101	N/A	Loper Consulting LLC Registration and Quarterly Activity for Teva Pharmaceuticals	N/A	N/A		
P-24102	N/A	Nahigian Strategies LLC Registration and Quarterly Activity for Teva Pharmaceuticals	N/A	N/A		
P-24103	N/A	Rubicon Advisors LLC Registration and Quarterly Activity for Teva Pharmaceuticals	N/A	N/A		
P-24104	N/A	Teva Pharmaceuticals USA Registration and Quarterly Activity Reports	N/A	N/A		
P-24105	7/1/2013	Alliance to Prevent the Abuse of Medicines Letter to Debra Barrett	TEVA_MDL_A_04209621	TEVA_MDL_A_04209622		
P-24106	11/30/2017	Email re Question - please use this response	TEVA_MDL_A_08736255	TEVA_MDL_A_08732664		
P-24107	5/31/2016	CEO Leadership Forum PPT	TEVA_MDL_A_03155608	TEVA_MDL_A_03155608		
P-24108	N/A	Notice of Intent to Serve Amended Subpoena	N/A	N/A		
P-24109	1/6/2013	Email re NYTimes: Drug Makers Losing a Bid to Foil Generic Painkillers	TEVA_CAOC_14036565	TEVA_CAOC_14036567		
P-24110	11/30/2017	Email re Vantrela with attachment	TEVA_MDL_A_08734287	TEVA_MDL_A_08734288		
P-24111	9/17/2015	Email re Teleconf re Teva response to CDC guidelines on chronic pain with attachment	TEVA_AAMD_00750402	TEVA_AAMD_00750408		
P-24112	10/21/2015	Email re Vantrela ER Market Access sub-team meeting with attachment	TEVA_MDL_A_02954965	TEVA_MDL_A_02954981		
P-24113	2/21/2016	Email re BioCentury Extra for Friday	TEVA_SF_00102633	TEVA_SF_00102639		

P-24114	2/25/2016	Email re FYI Only: FDA call request letter with attachment	TEVA_MDL_A_06866365	TEVA_MDL_A_06866377		
P-24115	1/17/2017	Email re Initiate Artwork for Vantrela ER - Message for PARC Team with attachment	TEVA_MDL_A_03721246	TEVA_MDL_A_03721349		
P-24116	3/15/2016	Email re CDC releases final guidelines with attachment	TEVA_MDL_A_08770620	TEVA_MDL_A_08770673		
P-24117	N/A	Debra Barrett Resume	N/A	N/A		
P-24118	N/A	Debra Barrett personnel file	TEVA_SF_00106228	TEVA_SF_00106648		
P-24119	10/3/2012	Letter from Teva to DEA re DEA Inspection	TEVA_MDL_A_06925773	TEVA_MDL_A_06925775		
P-24120	1/11/2013	Email re DEA Letter with attachment	TEVA_MDL_A_03159540	TEVA_MDL_A_03159544		
P-24121	5/22/2013	Email re Can u help with attachment	TEVA_MDL_A_02336882	TEVA_MDL_A_02336883		
P-24122	2/2/2017	Email re Presentation Attached /RE: Regulatory Affairs All Hands Meeting	TEVA_MDL_A_04346122	TEVA_MDL_A_04346125		
P-24123	2/2/2017	Global Regulatory Affairs & Generics Regulatory Affairs PPT	TEVA_MDL_A_04346126	TEVA_MDL_A_04346126		
P-24124	5/30/2012	Email re Some Fentora...	TEVA_MDL_A_00992150	TEVA_MDL_A_00992152		
P-24125	2/9/2010	Email re Suspicious orders system summary	TEVA_CHI_00226506	TEVA_CHI_00226507		
P-24126	8/17/2011	Email re SORDs flow chart with attachments	TEVA_RI_00842909	TEVA_RI_00842912		
P-24127	2014	VAWD Prescription Drug Suspicious Order Monitoring Presentation	TEVA_MDL_A_13759591	TEVA_MDL_A_13759602		
P-24128	7/11/2012	Email re draft guidelines with attachments	TEVA_RI_00850443	TEVA_RI_00850506		
P-24129	12/22/2011	Email re DEA Holds Daily Report with attachment	TEVA_RI_00846185	TEVA_RI_00846186		
P-24130	9/28/2011	Email re DEA Excessive Usage Holds for Medco	TEVA_RI_00843795	TEVA_RI_00843796		
P-24131	6/13/2012	Email re IKON DocSend files for you with attachment	TEVA_MDL_A_02330820	TEVA_MDL_A_02330828		
P-24132	3/26/2007	Email re Oxy quota increase with attachment	TEVA_CAOC_13833486	TEVA_CAOC_13833489		
P-24133	10/11/2007	Email re Oxycodone Update for Q4	TEVA_MDL_A_12131478	TEVA_MDL_A_12131480		
P-24134	9/8/2011	Email re PDF version for viewing on smart technology with attachment	TEVA_RI_00843273	TEVA_RI_00843297		
P-24135	6/21/2006	Email re Precall Preparation Information - Doug Shilling with attachment	TEVA_RI_00684611	TEVA_RI_00684612		
P-24136	11/14/2007	Email re Reimbursement Guide in PDF with attachment	TEVA_RI_00686998	TEVA_RI_00687042		
P-24137	10/30/2006	Email re Cigna Healthcare	TEVA_RI_00685246	TEVA_RI_00685247		
P-24138	11/16/2006	Email re Fentora MC MSL Deck with attachment	TEVA_RI_00685392	TEVA_RI_00685393		
P-24139	11/4/2008	Email re 6th Annual Controlled Substance Conference with attachment	TEVA_RI_00742956	TEVA_RI_00742988		
P-24140	11/20/2008	Email re SOM Client Communication with attachment	TEVA_RI_00743237	TEVA_RI_00743239		
P-24141	10/8/2008	Fentora REMS Program Overview Strategy Discussion Presentation	TEVA_MDL_A_00718738	TEVA_MDL_A_00718738		
P-24142	2009	Fentora 2009 Brand Plan PPT	TEVA_MDL_A_07866711	TEVA_MDL_A_07866711		
P-24143	11/12/2002	Memo re Sales Force Third Quarter 2002 Bonus Approval	TEVA_MDL_A_06070286	TEVA_MDL_A_06070294		
P-24144	4/1/2008	Transmittal of Advertisements and Promotional Labeling	TEVA_MDL_A_00026773	TEVA_MDL_A_00026793		
P-24145	N/A	NAM October Monthly Report	TEVA_MDL_A_04533755	TEVA_MDL_A_04533756		
P-24146	4/24/2003	Note to File: Joe Duarte	TEVA_MDL_A_04516173	TEVA_MDL_A_04516173		
P-24147	2004	Cephalon Minute Book	TEVA_MDL_A_06649419	TEVA_MDL_A_06650043		
P-24148	7/1/2004	Cephalon Board Reports	TEVA_MDL_A_06377159	TEVA_MDL_A_06377181		
P-24149	7/23/2007	Email re BOD Update July 2007 with attachment	TEVA_RI_00862986	TEVA_RI_00862987		
P-24152	5/20/2004	Email re Guideline Presentation with attachment	TEVA_RI_00860064	TEVA_RI_00860065		
P-24153	6/19/2007	Email re Fentora Model Sales Call with attachment	TEVA_RI_00862685	TEVA_RI_00862690		
P-24154	1/2/2006	Suspicious Week Ending 1-01-06 Wholesalers	Anda_Opioids_MDL_0000125021	Anda_Opioids_MDL_0000125021		
P-24155	1/21/2007	Email RE:	TEVA_CHI_00755059	TEVA_CHI_00755060		
P-24156	7/25/2007	Email re Revised/Final Slides Attached	TEVA_RI_00863030	TEVA_RI_00863030		
P-24157	7/26/2007	Cephalon Compliance Program Board of Directors Update PPT	TEVA_RI_00863031	TEVA_RI_00863031		
P-24158	1/16/2006	Suspicious Week Ending 1-15-06 Wholesalers	Anda_Opioids_MDL_0000125023	Anda_Opioids_MDL_0000125023		
P-24159	1/18/2006	The Diversion of Controlled Pharmaceuticals National Sales Meeting PPT	TEVA_MDL_A_03555646	TEVA_MDL_A_03555646		
P-24160	7/19/2007	Sales Bulletin	TEVA_CAOC_08052837	TEVA_CAOC_08052396		
P-24161	1/9/2009	Email re PResentation for makeup Compliance Presentation with attachment	TEVA_MDL_A_11884167	TEVA_MDL_A_11884169		
P-24162	N/A	A message from Mark Sabag	TEVA_MDL_A_13475876	TEVA_MDL_A_13475913		
P-24163	N/A	Teva Ltd. Org Chart	N/A	N/A		
P-24164	N/A	Teva Ltd. Job Listing	N/A	N/A		
P-24165	N/A	Teva Ltd. Irvine Job Listing	N/A	N/A		
P-24166	N/A	Teva Ltd. Irvine Job Listing	N/A	N/A		

P-24167	N/A	Teva Ltd. CA Job Listings	N/A	N/A		
P-24168	N/A	Teva Visual Identity Guidelines	N/A	N/A		
P-24169	8/4/2004	Email re Actiq Revenue Q1/Q2	TEVA MDL A 02772525	TEVA MDL A 02772525		
P-24170	11/8/2002	Email re MEP and CME Website Clarification	TEVA MDL A 05376214	TEVA MDL A 05376124		
P-24171	9/1/2003	Joe Duarte National Account Manager Monthly Highlights	TEVA MDL A 04535643	TEVA MDL A 04535645		
P-24172	5/5/2005	Manage Care Mtg - Area 676 Presentation	TEVA MDL A 05025485	TEVA MDL A 05025515		
P-24173	1/8/2003	Email re PCS 4th Quarter Bonus Plan with attachment	TEVA MDL A 05566392	TEVA MDL A 05566409		
P-24174	2004	Michael Dittbenner Key Objectives/Accomplishments	TEVA MDL A 08873098	TEVA MDL A 08873100		
P-24175	2002	Cephalon Western US Pain Posse Memo	TEVA MDL A 05883251	TEVA MDL A 05883258		
P-24176	2011	Grillone Performance Summary	TEVA MDL A 02393586	TEVA MDL A 02393589		
P-24178	9/29/2006	Email re pharmacy stocking issue	TEVA MDL A 01492233	TEVA MDL A 01492234		
P-24179	9/29/2008	Email re Govt's Memo for Entry of Plea and Sentencing with attachment	TEVA MDL A 07201600	TEVA MDL A 07201616		
P-24180	4/2/2014	Mark Light Medical Board Decision and Surrender of Licenser	N/A	N/A		
P-24181	3/26/2004	List of Off-Label Prescribers	TEVA MDL A 05376601	TEVA MDL A 05376603		
P-24182	12/1/2011	Email re Mark Light	TEVA MDL A 00983963	TEVA MDL A 00983964		
P-24183	3/23/2000	Chris Chen Medical Board Decision and Complaint	N/A	N/A		
P-24184	6/24/2018	DOJ Press Release re San Leandro Physician	N/A	N/A		
P-24185	3/13/2017	David Lague Complaint and Affidavit	N/A	N/A		
P-24186	10/16/2019	Mannie Joel Decision and Complaint	N/A	N/A		
P-24187	10/20/2006	Mannie Joel Speaker Agreement	TEVA MDL A 13602032	TEVA MDL A 13602038		
P-24188	4/20/2018	Franklin Perry Medical Board Decision and Complaint	N/A	N/A		
P-24189	4/2/2007	Franklin Perry Speaker Agreement	TEVA MDL A 13602461	TEVA MDL A 13602463		
P-24190	9/14/2012	Edward Manougian Decision and Complaint	N/A	N/A		
P-24191	5/9/2019	William C. Hopkins Accusation	N/A	N/A		
P-24192	6/8/2016	Munish Lal Decision and Complaint	N/A	N/A		
P-24193	3/19/2007	MIRF Request	TEVA MDL A 00619437	TEVA MDL A 00619438		
P-24194	3/19/2007	MIRF Request	TEVA MDL A 00619453	TEVA MDL A 00619454		
P-24195	2/1/2007	MIRF Request	TEVA MDL A 00611791	TEVA MDL A 00611792		
P-24196	2/1/2005	The ABC's of Pain Management	TEVA MDL A 05376447	TEVA MDL A 05376450		
P-24197	4/29/2005	Email re 2nd Quarter 2005 TSS Bonus Plan with attachments	TEVA MDL A 09742093	TEVA MDL A 09742103		
P-24198	8/2/2005	Email re June Early View	TEVA MDL A 11742574	TEVA MDL A 11742574		
P-24199	8/2/2005	Actiq Early View Spreadsheet	TEVA MDL A 11742575	TEVA MDL A 11742576		
P-24200	7/13/2005	Email re Actiq analysis	TEVA MDL A 11742267	TEVA MDL A 11742269		
P-24201	8/2/2008	Email re Fentora Q4 90 Day Plan with attachment	TEVA MDL A 01485325	TEVA MDL A 01485326		
P-24202	9/8/2008	PCS AM Leadership Meeting & 90 Day Action Plan Meeting PPT	N/A	N/A		
P-24203	1/8/2005	Email re 2005 MEP	TEVA MDL A 09741823	TEVA MDL A 09741824		
P-24204	1/24/2008	Email re Fentora CSP Slides with attachment	TEVA MDL A 01092270	TEVA MDL A 01092347		
P-24205	4/15/2008	Email re February Voucher Report	TEVA MDL A 02161084	TEVA MDL A 02161084		
P-24206	4/15/2008	February Voucher Report	TEVA MDL A 02161085	TEVA MDL A 02161085		
P-24207	4/28/2004	Email re May 2, 2004 Change in Actiq Coverage Medi-Cal	TEVA MDL A 00929124	TEVA MDL A 00929125		
P-24208	7/7/2005	Email re New Reimbursement Hotline Information with Attachment	TEVA MDL A 09742514	TEVA MDL A 09742516		
P-24209	4/6/2005	Email re Emerging Solutions in Pain	TEVA MDL A 02871812	TEVA MDL A 02871813		
P-24210	5/17/2004	Email re Wall Street Journal Article	TEVA MDL A 00928935	TEVA MDL A 00928937		
P-24211	5/1/2012	Email re Fentora Contract - Follow-up	TEVA MDL A 00975729	TEVA MDL A 00975734		
P-24212	8/27/2014	Email re First Time Rx Savings Card users	TEVA MDL A 01329679	TEVA MDL A 01329679		
P-24213	9/5/2012	PAINWeek 2012 Conference Handbook	TEVA MDL A 01445424	TEVA MDL A 01445431		
P-24214	3/11/2013	Email re FENTORA	TEVA MDL A 00977054	TEVA MDL A 00977056		
P-24216	N/A	The ABC's of Pain Management	TEVA MDL A 02590245	TEVA MDL A 02590246		
P-24217	2/27/2012	Email re 2012 Bonus Roll-Out Presentation with attachment	TEVA MDL A 02351662	TEVA MDL A 02351679		
P-24218	8/23/2012	Email re Fentora co-pay cards	TEVA MDL A 01322900	TEVA MDL A 01322900		
P-24219	2/23/2012	Schedule of Events/Backgrounder for AAPM	TEVA MDL A 08711429	TEVA MDL A 08711434		
P-24220	1/28/2013	MIRF Request	TEVA MDL A 02928425	TEVA MDL A 02928425		
P-24221	10/26/2012	MIRF Request	TEVA MDL A 02928676	TEVA MDL A 02928677		
P-24222	7/31/2013	Email re First Time Rx Savings Card users	TEVA MDL A 00693542	TEVA MDL A 00693543		
P-24223	10/26/2012	Email re Field Visit	TEVA MDL A 01118239	TEVA MDL A 01118239		
P-24224	4/4/2012	Email re Important PA Move Examples	TEVA MDL A 00975680	TEVA MDL A 00975681		
P-24226	6/9/2008	MIRF Request	TEVA MDL A 00625324	TEVA MDL A 00625325		
P-24227	1/18/2012	Lloyd Costello Decision and Complaint	N/A	N/A		

P-24228	10/1/2007	MIRF Request	TEVA MDL A_00622057	TEVA MDL A_00622058		
P-24229	10/1/2007	MIRF Response Letter	TEVA MDL A_00622059	TEVA MDL A_00622070		
P-24230	6/20/2019	Jesus Herrera Lao Accusation	N/A	N/A		
P-24231	N/A	Messina CV	N/A	N/A		
P-24232	6/11/2007	Fentora Risk Management Advisory Board Packet	TEVA MDL A_00507972	TEVA MDL A_00508047		
P-24233	9/17/2004	Email re Deliverables and Slides	TEVA MDL A_08245973	TEVA MDL A_08245973		
P-24234	9/17/2004	Clinical Strategy for OVF PPT	TEVA MDL A_08245974	TEVA MDL A_08245974		
P-24235	9/10/2004	Email Re Jim Birchenough Downgrades Cephalon	TEVA MDL A_08245868	TEVA MDL A_08245869		
P-24236	11/2/2007	Fentanyl Buccal Tablet Review and Assessment of Risks for Abuse and Diversion	TEVA MDL A_00038754	TEVA MDL A_00038843		
P-24237	4/1/2008	FDA Review of NDA 21-947/S005 Fentora	TEVA MDL A_09548924	TEVA MDL A_09548930		
P-24238	2008	Fentora RiskMAP Quarterly Report	TEVA MDL A_00439061	TEVA MDL A_00439166		
P-24239	5/6/2008	Review of Fentora and Actiq Adverse Events form AERS Database PPT	N/A	N/A		
P-24240	9/20/2007	Email re pls review by Sept 27 with attachment	TEVA MDL A_02172398	TEVA MDL A_02172436		
P-24241	5/8/2008	Email re 99-15 draft manuscript with attachment	TEVA MDL A_07097230	TEVA MDL A_07097252		
P-24242	9/20/2007	A Multicenter, Open-Label, Long-Term Study of ORAVESCENT Fentanyl Citrate for the Treatment of Breakthrough Pain in Opioid-Tolerant Cancer Patients	TEVA MDL A_01942375	TEVA MDL A_01949290		
P-24243	6/1/2005	2005-2006 FEBT Marketing Plan	TEVA MDL A_02033594	TEVA MDL A_02033813		
P-24244	6/22/2007	Model Sales Call Behavior	TEVA MDL A_00359434	TEVA MDL A_00359435		
P-24245	6/11/2003	Email re Shipment Quarter 3 2003 Actiq	TEVA CHI_00064850	TEVA CHI_00064853		
P-24246	4/1/2001	Transmittal of Advertisements and Promotional Labeling	TEVA MDL A_11110536	TEVA MDL A_11110545		
P-24247	3/1/2002	Transmittal of Advertisements and Promotional Labeling	TEVA MDL A_11115531	TEVA MDL A_11115541		
P-24248	10/1/2002	Transmittal of Advertisements and Promotional Labeling	TEVA MDL A_11117310	TEVA MDL A_11117315		
P-24249	9/18/2006	Suspicious Week Ending 9-17-06 Pharmacy	Anda Opioids MDL_0000125026	Anda Opioids MDL_0000125026		
P-24250	2/1/2002	Transmittal of Advertisements and Promotional Labeling	TEVA MDL A_11115344	TEVA MDL A_11115348		
P-24251	7/12/2002	Marketing Advisory Team Conference Call Summary	TEVA MDL A_05342939	TEVA MDL A_05342940		
P-24252	6/16/2004	Letter from Cephalon to DDMAC re Educational Materials	TEVA MDL A_01584607	TEVA MDL A_01584611		
P-24253	7/22/2003	MEP Summary	TEVA CHI_00064865	TEVA CHI_00064865		
P-24254	8/20/2003	MEP Summary	TEVA CHI_00064881	TEVA CHI_00064881		
P-24255	8/21/2003	MEP Summary	TEVA CHI_00064882	TEVA CHI_00064882		
P-24256	10/14/2009	Email re Onsolis Feedback	TEVA CHI_00059648	TEVA CHI_00059649		
P-24257	6/8/2010	Email re Best Practices from POA	TEVA CHI_00053101	TEVA CHI_00053101		
P-24258	4/2/2008	Email re Checking In	TEVA CHI_00050112	TEVA CHI_00050112		
P-24259	2/22/2012	Fentora Workplan Input Meeting PPT	TEVA CAOC_00707917	TEVA CAOC_00707917		
P-24260	8/20/2014	Marketing Mix and Brand Planning for Teva North American Specialty Brands	TEVA_CAOC_06647377	TEVA_CAOC_06647377		
P-24261	1/26/2009	Medical Information Request Monitoring Procedure	TEVA AAMD_00681827	TEVA AAMD_00681828		
P-24262	11/5/2008	Email re SRL Development and maintenance	TEVA MDL A_10054235	TEVA MDL A_10054235		
P-24263	10/10/2008	Development of Medical Information Database	TEVA MDL A_10054236	TEVA MDL A_10054236		
P-24264	12/1/2011	Letter re LMN and Medical Information	TEVA MDL A_11271779	TEVA MDL A_11271805		
P-24265	N/A	Vitale Handout	N/A	N/A		
P-24266	11/29/2011	Actiq Formulary Dossier	TEVA MDL A_00323062	TEVA MDL A_00323172		
P-24267	7/1/2008	Fentora Reimbursement Program Report	TEVA MDL A_00871274	TEVA MDL A_00871274		
P-24268	1/29/2014	Email re SOPs with attachments	TEVA MDL A_02332290	TEVA MDL A_02332295		
P-24269	8/26/2011	Email re Oxymorphone Promotion and chargeback results with attachment	TEVA_AAMD_00710359	TEVA_AAMD_00710364		
P-24270	N/A	Vitale Handout	N/A	N/A		
P-24271	N/A	Teva Ltd. Form 10-K	N/A	N/A		
P-24272	N/A	Teva Ltd. Schedule 14A	N/A	N/A		
P-24273	N/A	Vitale Handout	N/A	N/A		
P-24274	12/15/2017	Generic Wholesale Service Agreement	TEVA MDL A_03464455	TEVA MDL A_03464484		
P-24275	4/1/2008	Core Distribution Agreement	TEVA MDL A_03444304	TEVA MDL A_03444326		
P-24276	4/21/2020	Responses and Objections to Plaintiff's First Set of Interrogatories	N/A	N/A		
P-24277	7/12/2011	Email re McKesson marketing programs	Acquired Actavis_00603142	Acquired Actavis_00603143		
P-24278	5/20/2016	An Innovative Payer Driven Go-to-Market Strategy	TEVA CAOC_14128191	TEVA CAOC_14128193		
P-24279	4/11/2017	FDA Letter to Cephalon re Supplemental Approval	TEVA CHI_00588753	TEVA CHI_00588918		
P-24280	N/A	Materials Mailed/ Provided Data Files	ENDO_DATA-OPIOID MDL-00000100	ENDO_DATA-OPIOID MDL-00000100		

P-24281	12/20/2007	Email re MSNBC.com Article	TEVA_CHI_00112919	TEVA_CHI_00112920		
P-24282	2006	Prevalence and Characteristics of Breakthrough Pain in Opioid-Treated Patients with Chronic Noncancer pain	TEVA_MDL_A_13744430	TEVA_MDL_A_13744438		
P-24283	2/1/2011	Long-term dosing, safety, and tolerability of fentanyl buccal tablet in the management of noncancer-related breakthrough pain in opioid-tolerant patients	TEVA_MDL_A_02011932	TEVA_MDL_A_02011941		
P-24284	N/A	Appropriate Prescribing of Fentora: A Focus on REMS	TEVA_MDL_A_01154987	TEVA_MDL_A_01155042		
P-24285	1/24/2003	Actiq South East Regional Consultants Meeting Materials	TEVA_CHI_00139319	TEVA_CHI_00139319		
P-24286	1/14/2004	Email re Request for Top Speakers by Brand with attachment	TEVA_MDL_A_05388809	TEVA_MDL_A_05388809		
P-24287	8/22/2003	Actiq Consultants Meeting Event Evaluation	TEVA_MDL_A_05889754	TEVA_MDL_A_05889759		
P-24288	6/1/2007	Email re June 19th	TEVA_OH_00725275	TEVA_OH_00725275		
P-24289	9/1/2016	Fentora Reimbursement promotional material	TEVA_MDL_A_01135270	TEVA_MDL_A_01135271		
P-24291	2010	Treatment of Breakthrough Pain with Fentanyl Buccal Tablet in Opioid-Tolerant Patients with Chronic Pain: Appropriate Patient Selection and Management	TEVA_MDL_A_01953036	TEVA_MDL_A_01953048		
P-24292	2005	Dannemiller Report: Cephalon supported activities on Pain.com as of 6/24/05	TEVA_MDL_A_00836896	TEVA_MDL_A_00836899		
P-24293	11/1/1975	Simon complaint	N/A	N/A		
P-24294	N/A	Simon Open Payments page	N/A	N/A		
P-24295	4/18/2017	US v. Simon materials	N/A	N/A		
P-24296	3/10/2008	Email re Nurses Advisory Board	TEVA_MDL_A_07487782	TEVA_MDL_A_07487782		
P-24297	2008	FDA Abuse materials	TEVA_AAMD_00855439	TEVA_AAMD_00855571		
P-24299	1/10/2007	Email re Radio Media Tour Update	TEVA_MDL_A_00721144	TEVA_MDL_A_00721144		
P-24300	2006	Cephalon Announces FENTORA may offer Therapeutic Option for BTP in Back Pain	TEVA_MDL_A_03532825	TEVA_MDL_A_03532828		
P-24301	N/A	Materials Mailed/ Provided Data Files	ENDO_DATA-OPIOID_MDL-00000101	ENDO_DATA-OPIOID_MDL-00000101		
P-24302	N/A	Call Data Files	ENDO_DATA-OPIOID_SF-00000001	ENDO_DATA-OPIOID_SF-00000001		
P-24303	11/7/2007	Board of Directors Meeting Packet	TEVA_AAMD_00183378	TEVA_AAMD_00183593		
P-24304	4/6/2009	Email re Palio Communications with attachment	TEVA_MDL_A_06883889	TEVA_MDL_A_06883890		
P-24305	5/3/2007	Email re Company valuation Fentora downside	TEVA_CHI_00766016	TEVA_CHI_00766017		
P-24306	7/30/2008	Premium Materials Depicted	ENDO_FLAG-00073650	ENDO_FLAG-00073666		
P-24307	7/27/2006	Email re LAST REMINDER: Aug 11-12 Speaker Training	TEVA_MDL_A_07418592	TEVA_MDL_A_07418592		
P-24308	8/9/2006	Email re Updated Chicago Speaker Training slides with attachment	TEVA_MDL_A_03279433	TEVA_MDL_A_03279434		
P-24309	8/14/2006	Email re Sales Launch meeting slides with attachment	TEVA_MDL_A_03570039	TEVA_MDL_A_03570042		
P-24310	8/16/2010	Email re FENTORA Medical/Scientific Advisory Board with attachment	TEVA_MDL_A_07610501	TEVA_MDL_A_07610523		
P-24311	11/14/2011	Email re MSL Pain Week Meeting Report with attachment	TEVA_MDL_A_01210408	TEVA_MDL_A_01210409		
P-24312	6/11/2013	Email re Med Affairs represented in project teams with attachment	TEVA_MDL_A_01301546	TEVA_MDL_A_01301549		
P-24313	8/24/2010	Email re Neurobiology of Addiction deck with attachment	TEVA_MDL_A_07612113	TEVA_MDL_A_07612114		
P-24314	8/23/2010	Email re Neurobiology of addiction deck with attachments	TEVA_MDL_A_07612110	TEVA_MDL_A_07612112		
P-24315	3/9/2007	Email re slide deck feedback	TEVA_MDL_A_07372343	TEVA_MDL_A_07372344		
P-24316	8/23/2013	Email re Core Team Review with attachment	TEVA_MDL_A_03216928	TEVA_MDL_A_03216946		
P-24317	2015	Order of National Breakthrough Pain Study	TEVA_MDL_A_04312576	TEVA_MDL_A_04312584		
P-24318	3/19/2007	Email re Oprah Actiq Story with attachments	TEVA_CHI_00153557	TEVA_CHI_00153559		
P-24319	4/8/2008	Email re Editorial in the journal Pain with attachment	TEVA_MDL_A_09547983	TEVA_MDL_A_09547986		
P-24320	8/3/2010	Email re Monday's FENTORA Medical/Scientific Cross-functional Team meeting with attachments	TEVA_MDL_A_07610055	TEVA_MDL_A_07610059		
P-24321	10/27/2008	Email re BST Follow Up with attachment	TEVA_MDL_A_01500781	TEVA_MDL_A_01500789		
P-24322	3/20/2007	Email re Are we involved with these guidelines?	TEVA_MDL_A_00634213	TEVA_MDL_A_00634213		
P-24323	1/15/2009	Email re Agenda with attachment	TEVA_RI_00893654	TEVA_RI_00893661		
P-24324	1/30/2009	Email re APS AAPM chronic pain guidelines with attachment	TEVA_MDL_A_03265970	TEVA_MDL_A_03265984		
P-24325	12/1/2008	Email re APS New Pain Guidelines	TEVA_MDL_A_02400692	TEVA_MDL_A_02400693		
P-24326	10/10/2008	Email re Employee self appraisal with attachment	TEVA_MDL_A_07010711	TEVA_MDL_A_07010717		
P-24327	9/8/2021	Notice of Intent to Serve Subpoena	N/A	N/A		
P-24328	N/A	Narayana CV	N/A	N/A		
P-24329	4/26/2007	Premium Materials Depicted	ENDO_FLAG-00353770	ENDO_FLAG-00353799		
P-24330	4/29/2008	Premium Materials Depicted (OP-0264)	ENDO_FLAG-00917017	ENDO_FLAG-00917020		
P-24331	3/8/2013	Email re Q5 aberrant drug-related behaviors	TEVA_MDL_A_07763301	TEVA_MDL_A_07763302		



P-24332	10/17/2008	Email re ICPCD draft poster with attachment	TEVA_MDL_A_02895592	TEVA_MDL_A_02895613		
P-24333	N/A	Field Coaching Reports	ENDO_SF-00324546	ENDO_SF-00324546		
P-24334	7/12/2011	Fentora Medical-Scientific Cross-Functional Team Meeting Minutes	TEVA_MDL_A_01523061	TEVA_MDL_A_01523061		
P-24335	N/A	Pain Management Resource Kit Rebate Program (OP-0254)	ENDO-CHI_LIT-00538450	ENDO-CHI_LIT-00538450		
P-24336	4/13/2010	Call Starter Button	ENDO-OPIOID_MDL-00802416	ENDO-OPIOID_MDL-00802434		
P-24337	12/6/2010	OPANA ER Table Top Panels (1 box = 1 set) (OP-00529)	ENDO-OPIOID_MDL-00817355	ENDO-OPIOID_MDL-00817356		
P-24338	7/23/2012	Email re FENTORA PDRC - Lunch provided	TEVA_MDL_A_08214092	TEVA_MDL_A_08214092		
P-24339	8/1/2012	Breakthrough Pain: An Important Component of Chronic Pain in Patients with Cancer	TEVA_MDL_A_02764110	TEVA_MDL_A_02764172		
P-24340	12/7/2009	Email re characteristics of patients enrolled in our non-cancer clinical studies with attachment	Teva_MSAG_02276767	Teva_MSAG_02278734		
P-24341	2004	Managed Care and Reimbursement Objectives	TEVA_MDL_A_04838763	TEVA_MDL_A_04838677		
P-24342	N/A	Actiq Managed Care Dossier Module 1	TEVA_CHI_00036903	TEVA_CHI_00036930		
P-24343	6/4/2015	Email re Time Magazine Story	TEVA_MDL_A_09219160	TEVA_MDL_A_09218165		
P-24344	N/A	Actiq Lozenges Picture	N/A	N/A		
P-24345	N/A	Fentora Picture	N/A	N/A		
P-24346	N/A	Actiq Picture	N/A	N/A		
P-24347	9/28/2008	DOJ Press Release	N/A	N/A		
P-24348	N/A	Center for Drug Evaluation and Research Application - NDA 2047	N/A	NA		
P-24349	N/A	Dreamland, Sam Quinones excerpts	N/A	N/A		
P-24350	1/29/2010	Email re DVD Script Info with attachments	TEVA_CHI_00009433	TEVA_CHI_00009441		
P-24351	9/12/2008	FDA Letter to Cephalon	TEVA_FE00116840	TEVA_FE00116843		
P-24352	3/1/2006	Teva Ltd. Org Chart	TEVA_MDL_JD_000001	TEVA_MDL_JD_000003		
P-24353	2/1/2009	Teva Ltd. Org Chart	TEVA_MDL_JD_000010	TEVA_MDL_JD_000013		
P-24354	7/1/2011	Teva Ltd. Org Chart	TEVA_MDL_JD_000038	TEVA_MDL_JD_000043		
P-24355	3/1/2010	Teva Ltd. Org Chart	TEVA_MDL_JD_000014	TEVA_MDL_JD_000017		
P-24356	4/17/2019	Teva Ltd. Org Chart	TEVA_MDL_JD_000059	TEVA_MDL_JD_000066		
P-24357	7/27/2013	Email re Life Cycle Management Meeting with Attachment	TEVA_MDL_A_12265534	TEVA_MDL_A_12265535		
P-24358	8/22/2016	Handling Safety Information on Company Products	TEVA_MDL_A_03011230	TEVA_MDL_A_03011237		
P-24359	2015	Foreign Corporation Income Tax Declaration e-file return	TEVA_MDL_JD_000099	TEVA_MDL_JD_000115		
P-24360	1/30/2019	Robert A Barto CV - Barto Ex. 1	N/A	N/A		
P-24361	2018	2018 Independent Directors Report	N/A	N/A		
P-24362	11/30/2012	Endo Health Solutions Sues FDA to Protect Consumers from Non-Tamper Resistant Oxycodone - Lortie 35	N/A	N/A		
P-24363	3/7/2012	2012 Q4 RiskMAP Update Report	ENDO-OR-CID-01044117	ENDO-OR-CID-01044153		
P-24364	1/21/2019	Endo's Open Letter on Opioid Abuse Crisis	N/A	N/A		
P-24365	5/21/2013	Quarterly Data - Abuse Rates Per 100,000 Prescriptions	EPI001932424	EPI001932432		
P-24366	1/21/2019	Provided in Response to Topic 13 of Plaintiffs' Amended Rule 30(b)(6) Notice to Endo Pharmaceuticals Inc. and Endo Health Solutions Inc.	N/A	N/A		
P-24367	1/21/2019	Resume Brian Andrew Lortie	N/A	N/A		
P-24368	3/15/2019	Curriculum Vitae Stephen C. Macrides	N/A	N/A		
P-24369	8/31/2017	Re Privileged & Confidential - Draft Response to Request # 1	ENDO-OPIOID_MDL-06235529	ENDO-OPIOID_MDL-06235537		
P-24370	1/16/2019	Tracy Norton Resume - Par	N/A	N/A		
P-24371	3/13/2017	Summary Minutes of Drug Safety and Risk Management Advisory Committee	N/A	N/A		
P-24372	12/18/2012	Opiana ER Risk Management Team Minutes 2012.12.17	ENDO-OPIOID_MDL-00910315	ENDO-OPIOID_MDL-00910322		
P-24373	9/6/2012	OPANA ER -- Risk Management Team Meeting Minutes	ENDO-OPIOID_MDL-01377402	ENDO-OPIOID_MDL-01377408		
P-24374	10/4/2012	Risk Management Monthly Meeting Minutes	ENDO-OPIOID_MDL-01380250	ENDO-OPIOID_MDL-01380256		
P-24375	11/5/2012	Opiana ER Risk Management Team Minutes 2012 10 24	ENDO-OPIOID_MDL-01381835	ENDO-OPIOID_MDL-01381843		
P-24376	4/13/2011	2011 Q1 PainEDU Final PowerPoint	ENDO_FLAG-00442335	ENDO_FLAG-00442341		
P-24377	1/27/2005	CDE Update 10.06.04 Operations Mtg Part 1.ppt	ENDO_FLAG-01041727	ENDO_FLAG-01041728		
P-24378	8/23/2007	RE: Clarification on new PMRB process	ENDO_FLAG-01167983	ENDO_FLAG-01167984		
P-24379	10/5/2006	Opioid education initiative with Russ Portenoy & Perry Fine	ENDO-OPIOID_MDL-00996690	ENDO-OPIOID_MDL-00996690		
P-24380	5/19/2004	RE: Opioid handbook	ENDO-OPIOID_MDL-02255679	ENDO-OPIOID_MDL-02255681		
P-24381	9/22/2004	Updated Forms	ENDO-OPIOID_MDL-02261053	ENDO-OPIOID_MDL-02261053		
P-24382	6/23/2003	Opioid Handbook Input CAron.doc.rtf	ENDO-OPIOID_MDL-06495834	ENDO-OPIOID_MDL-06495836		
P-24383	10/4/2010	Endo Independent Educational Initiatives.docx	ENDO-OPIOID_MDL-06608367	ENDO-OPIOID_MDL-06608370		

P-24384	12/13/2010	Scientific Affairs - State Pain Initiatives Q3 2010 Report.docx	ENDO-OPIOID_MDL-07517208	ENDO-OPIOID_MDL-07517227		
P-24385	10/31/2012	UPDATED_Street Value of Controlled Prescription Drugs_October_30	EPI001480921	EPI001480922		
P-24386	7/9/2010	FW Opana related topic from the Fource Resource	ENDO-OPIOID_MDL-00725570	ENDO-OPIOID_MDL-00725571		
P-24387	12/17/2010	RE Oxymorphone New Message Testing - ACTION REQUIRED	ENDO-OPIOID_MDL-00737894	ENDO-OPIOID_MDL-00737896		
P-24388	7/9/2010	RE 7-6-10 Dinner Program Recap	ENDO-OPIOID_MDL-00806697	ENDO-OPIOID_MDL-00806697		
P-24389	10/12/2012	RE San Fran VA - Palo Alto VA	ENDO-OPIOID_MDL-00988846	ENDO-OPIOID_MDL-00988847		
P-24390	5/26/2010	FW Grant Request	ENDO-OPIOID_MDL-01127442	ENDO-OPIOID_MDL-01127454		
P-24391	9/27/2016	Fwd ER-LA OPIOID REMS LEAVE BEHIND REPORT - 9.26.16	ENDO-OPIOID_MDL-04667682	ENDO-OPIOID_MDL-04667688		
P-24392	11/17/2009	RDDM Form - 2009 Performance Coaching Development Kelvin Chung Year End.docx	ENDO-OR-CID-01277061	ENDO-OR-CID-01277078		
P-24393	7/10/2009	OpanaER Pullthrough Pilot	ENDO-OR-CID-01277228	ENDO-OR-CID-01277231		
P-24394	1/1/2010	Annual reviews	ENDO-OR-CID-01281583	ENDO-OR-CID-01281728		
P-24395	12/4/2010	RE ACTION by 12-6**RBD Prescriber Removal Submissions	ENDO-OR-CID-01291428	ENDO-OR-CID-01291430		
P-24396	1/14/2011	Kelvin Chung 2010 Sales Performance Coaching and Development Form.docx	ENDO-OR-CID-01292244	ENDO-OR-CID-01292364		
P-24397	2/10/2011	FW Opana.com for Opana ER Rebate cards	ENDO-OR-CID-01292724	ENDO-OR-CID-01292726		
P-24398	6/19/2012	Re Fwd Walgreens	ENDO_AAC_00134021	ENDO_AAC_00134021		
P-24399	11/5/2012	Opana ER dinner programs	ENDO_FLAG-00394111	ENDO_FLAG-00394111		
P-24400	3/23/2011	FW Walgreens that told a customer Opana 10mg does not exist.	ENDO_NMAG-00049775	ENDO_NMAG-00049777		
P-24401	3/6/2013	FW Walgreens Controlled Substance Rx Requirements	ENDO_NMAG-00236839	ENDO_NMAG-00236844		
P-24402	1/24/2013	Re Opana ER Cardinal Wholesaler	ENDO_SF-00398094	ENDO_SF-00398095		
P-24403	10/22/2004	Email re McKesson Excessive - Percocet 5mg x 500	ENDO_SF-00473713	ENDO_SF-00473714		
P-24404	8/16/2012	Channel Strategy Team Account Alignments and Mid year review.	ENDO_TXMDL_00333348	ENDO_TXMDL_00333376		
P-24405	2/10/2013	FW Important Message Regarding Opana ER from Brian Lortie	ENDO-CHI_LIT-00065915	ENDO-CHI_LIT-00065917		
P-24406	10/1/2020	Anda Transactional Data for SF	Anda_Opioid_CA_SF-Tx-Data-SF_0000001	Anda_Opioid_CA_SF-Tx-Data-SF_0000001		
P-24407	7/12/2012	RE 07 Bain Critical Pharmacy Access Sheet III	ENDO-CHI_LIT-01167776	ENDO-CHI_LIT-01167779		
P-24408	11/1/2012	RE Help w- Opana Survey	ENDO-OPIOID_MDL-00761466	ENDO-OPIOID_MDL-00761468		
P-24409	1/21/2013	RE Walgreens-OPANA ER	ENDO-OPIOID_MDL-00766462	ENDO-OPIOID_MDL-00766463		
P-24410	1/31/2008	RE OPANA Integration Team Meeting - Opana Launch	ENDO-OPIOID_MDL-01870384	ENDO-OPIOID_MDL-01870386		
P-24411	8/10/2012	RE WG-Cardinal OER 5mg Issue	ENDO-OPIOID_MDL-02049797	ENDO-OPIOID_MDL-02049801		
P-24412	10/4/2012	RE UPMC-Franck's pharmacy	ENDO-OPIOID_MDL-02192893	ENDO-OPIOID_MDL-02192897		
P-24413	12/5/2012	RE Walgreens	ENDO-OPIOID_MDL-07908768	ENDO-OPIOID_MDL-07908772		
P-24414	N/A	Kelnhofner Resume	N/A	N/A		
P-24415	1/18/2013	FW Opana ER Original Formulation Voluntary Return Program	WAGMDL00066993	WAGMDL00066998		
P-24416	5/15/2006	Candidate Backend Process	ENDO_OPIOID_OHAG-00271502	ENDO_OPIOID_OHAG-00271514		
P-24417	8/29/2006	Opana Training - Print out	ENDO_SF-00007447	ENDO_SF-00007452		
P-24418	9/20/2006	Notes from my conversation with Dr. Brad Carpentier Pain Specialist	ENDO_SF-00015905	ENDO_SF-00015905		
P-24419	10/24/2006	Erin Carlson ECR 10 24 06.DOC	ENDO_SF-00015909	ENDO_SF-00015912		
P-24420	7/18/2006	promise brochure.pdf	ENDO_SF-00154850	ENDO_SF-00154855		
P-24421	8/31/2006	FW Bay Area Pain Medical Associates has sent you an Evite Invitation	ENDO_SF-00294732	ENDO_SF-00294734		
P-24422	7/28/2006	Opana Success Story	ENDO_SF-00479210	ENDO_SF-00479213		
P-24423	10/23/2006	Walgreens Stocking	ENDO_SF-00479492	ENDO_SF-00479493		
P-24424	9/10/2007	FW URGENT Review Required Materials for Web Cast Training Session Sept 11 at 900 AM EST	ENDO_SF-00479975	ENDO_SF-00480011		
P-24425	9/15/2006	FW Endo PROMISE	ENDO_SF-00480706	ENDO_SF-00480707		
P-24426	8/4/2006	RE Walgreens - Opana	ENDO_SF-00481021	ENDO_SF-00481022		
P-24427	8/17/2006	FW Update on competitive chart-sales points	ENDO_SF-00481083	ENDO_SF-00481084		
P-24428	9/25/2006	KK ECR 9 25 06.DOC - Katie King Coaching Report	ENDO_SF-00481311	ENDO_SF-00481313		
P-24429	10/21/2006	RE ACTION REQUIRED IMPORTANT- Walgreens stores that have stocked Opana	ENDO_SF-00481795	ENDO_SF-00481796		
P-24430	11/17/2006	RE Walgreens Reporting Information	ENDO_SF-00482332	ENDO_SF-00482334		
P-24431	11/20/2006	FW Opana Details Made to Decile 0 and 1 MDs	ENDO_SF-00482361	ENDO_SF-00482362		
P-24432	5/1/2007	FW Rep Inventory Report. 4.26	ENDO_SF-00482499	ENDO_SF-00482500		
P-24433	3/3/2007	RE Who is paying for Opana ER...?	ENDO_SF-00483450	ENDO_SF-00483450		
P-24434	3/15/2007	Opana ER Call Continuum Plan	ENDO_SF-00483616	ENDO_SF-00483621		

P-24435	1/2/2007	RE Opana Update from the field	ENDO_SF-00484434	ENDO_SF-00484436		
P-24436	2/19/2007	RE OPANA ER Feb. 23-24 Speaker Training Meeting Attendee Status Report	ENDO_SF-00485206	ENDO_SF-00485208		
P-24437	6/27/2007	FW June 25 Marketing Allocation	ENDO_SF-00485502	ENDO_SF-00485522		
P-24438	12/1/2006	Michael Crawford 06 Year End Review Crawford.doc	ENDO_SF-00485876	ENDO_SF-00485884		
P-24439	7/24/2006	FW IMPORTANT - A Few Things	ENDO_SF-00490357	ENDO_SF-00490361		
P-24440	8/4/2006	FW Dr. Linda Cheek	ENDO_SF-00528351	ENDO_SF-00528351		
P-24441	10/20/2006	RE Generic OxyContin news	ENDO_SF-00528812	ENDO_SF-00528813		
P-24442	7/4/2006	2006 Mid-year review King.doc	ENDO_SF-00530632	ENDO_SF-00530643		
P-24443	4/16/2020	ENDO 1st Quarter press release	N/A	N/A		
P-24444	3/1/2016	Email-A Year of Execution	PAR_OPIOID_MDL_0001046922	PAR_OPIOID_MDL_0001046994		
P-24445	4/16/2014	ENDO Form 8-K	N/A	N/A		
P-24446	12/31/2013	Form 10-K	N/A	N/A		
P-24447	7/3/2014	Transcript pf Q2 2014 Conference Call	N/A	N/A		
P-24448	8/1/2018	Independent Directors Report	N/A	N/A		
P-24449	11/9/2018	Minutes and Order	N/A	N/A		
P-24450	12/10/2013	Registration Statement form S-4	N/A	N/A		
P-24451	N/A	Overlap of Directors	N/A	N/A		
P-24452	2/28/2014	ENDO Form 8-K	N/A	N/A		
P-24453	4/30/2020	Endo About Us	N/A	N/A		
P-24454	12/31/2017	Form 10-K	N/A	N/A		
P-24455	1/1/2016	Annual Report	N/A	N/A		
P-24456	1/1/2020	Corporate Compliance	N/A	N/A		
P-24457	3/15/2017	Statement on FDA Committee Vote	N/A	N/A		
P-24458	4/29/2020	Email not accepting service Endo Intl	N/A	N/A		
P-24459	4/30/2020	Overview	N/A	N/A		
P-24460	1/1/2015	Annual Report	N/A	N/A		
P-24461	5/1/2020	Our Companies	N/A	N/A		
P-24462	6/8/2017	Restated 2015 Stock Incentive Plan	N/A	N/A		
P-24463	2018	Overlap of Directors	N/A	N/A		
P-24464	12/31/2018	Form 10-K	N/A	N/A		
P-24465	1/22/2019	State of Mass Annual Report	N/A	N/A		
P-24466	3/19/2019	Foreign Corp Annual Report	N/A	N/A		
P-24467	3/19/2019	Par Foreign Corp Annual Report	N/A	N/A		
P-24468	6/10/2019	Affidavit Deanna Voss	N/A	N/A		
P-24469	8/5/2019	Order and Opinion	N/A	N/A		
P-24470	10/8/2010	Report of Suspected Diversion for Dickie Hill, DO	ENDO_AR-00129997	ENDO_AR-00129998		
P-24471	2/15/2009	Report of Suspected Diversion - Seet	ENDO_SF-00000810	ENDO_SF-00000820		
P-24472	2/9/2022	Endo CT4 Marketing 30(b)(6) Materials	N/A	N/A		
P-24473	8/17/2012	SFC-00000090.pdf	SFC-00000090	SFC-00000090		
P-24474	7/7/2010	Opana related topic from the Force Resource	ENDO_ALAG-00009363	ENDO_ALAG-00009364		
P-24475	12/31/2007	A Clinical Guide to Opioid Analgesia 2nd Edition Copyright 2007 published by Vendome Group	ENDO-OPIOID_MDL-06234788	ENDO-OPIOID_MDL-06234865		
P-24476	1/8/2010	Web Archive For Caregivers with Caregiver's Guide Brochure	N/A	N/A		
P-24477	1998	Model Guidelines for the Use of Controlled Substances for the Treatment of Pain	MDL_FSMB_000000126	MDL_FSMB_000000126		
P-24478	2/9/2012	EPSP RESOURCE.PDF	ENDO-OPIOID_MDL-00578026	ENDO-OPIOID_MDL-00578054		
P-24479	8/5/2011	RE: EVR Q3 Updates	END00109005	END00109008		
P-24480	2/1/2011	RE: OPANA.com Site Traffic Report	END00703210	END00703216		
P-24481	6/20/2008	RE OPANA.COM Metrics	EPI000559802	EPI000559803		
P-24482	2/20/2014	Fw: Web Analytics - OPANA.com	ENDO-CHI_LIT-00049691	ENDO-CHI_LIT-00049701		
P-24483	2/5/2021	Anda Transactional Data for CA	Anda_Opioid_CA_SF-Tx-Data-SF_0000002	Anda_Opioid_CA_SF-Tx-Data-SF_0000002		
P-24484	9/3/2008	Controls Increase	Anda_Opioids_MDL_0000275798	Anda_Opioids_MDL_0000275799		
P-24485	9/21/2006	RE: Practical Pain Management V - Marina del Rey, CA	ENDO_SF-00355543	ENDO_SF-00355545		
P-24486	10/16/2007	B192 Event Grid in date order.rtf	ENDO_SF-00164778	ENDO_SF-00164786		
P-24487	3/9/2008	NIPC Opioid Dinner Dialogues	ENDO_SF-00120831	ENDO_SF-00120832		
P-24488	10/10/2008	RE: NIPC Dinner Dialogues - Fall Programs	ENDO_SF-00356072	ENDO_SF-00356079		
P-24489	8/15/2012	OPANA Pub Team Meeting Book (081612).pdf	EPI000239927	EPI000239928		
P-24490	2/3/2012	EHC Communications, Inc-PWO_Dec2007_002.pdf	ENDO_SF-00588412	ENDO_SF-00588422		
P-24491	2010	2010 Stock Purchase Agreement	N/A	N/A		

P-24492	2011	2011 Endo Annual Report	N/A	N/A		
P-24493	2015	2015 Endo Annual Report	N/A	N/A		
P-24494	5/5/2016	Endo International plc Q1 2016 Financial Results and Revised Financial Guidance	N/A	N/A		
P-24495	N/A	Sanjay Patel LinkedIn Profile	N/A	N/A		
P-24496	1962	Bloomquist - The Addiction of Oxycodone (Percodan)	N/A	N/A		
P-24497	11/2/2016	Town Hall Meeting Endo Ventures Ltd. Dublin, Ireland	N/A	N/A		
P-24498	3/18/2009	RE Michael Jadali DO	ENDO_AAC_00111382	ENDO_AAC_00111384		
P-24499	10/28/2010	FW Please remove from the call plan - Dr. Dickie Lynn Hill	ENDO_AR-00032392	ENDO_AR-00032392		
P-24500	9/23/2020	Global Exclude - SanFran (full CA state).xlsx	ENDO_DATA-OPIOID_SF-00000003	ENDO_DATA-OPIOID_SF-00000003		
P-24501	12/12/2016	Global Exclude Report 12122016.xlsx	ENDO-STaubus_LIT-00080122	ENDO-STaubus_LIT-00080124		
P-24502	8/28/2017	Global Exclude Report 08282017.xlsx	ENDO-STaubus_LIT-00282086	ENDO-STaubus_LIT-00282087		
P-24503	N/A	Endo Press Releases Dec. 2011 - May 2015	N/A	N/A		
P-24504	N/A	ECR Field Coaching Reports_SF	ENDO_SF-00324546	ENDO_SF-00324546		
P-24505	N/A	Endo Engage CRM Field Coaching Reports_SF	ENDO_SF-00324547	ENDO_SF-00324547		
P-24506	N/A	Navigator Field Coaching Reports_SF	ENDO_SF-00324548	ENDO_SF-00324548		
P-24507	N/A	Veeva Field Coaching Reports_SF	ENDO_SF-00324549	ENDO_SF-00324549		
P-24508	N/A	ECR 2008.1	ENDO_SF-00324550	ENDO_SF-00324550		
P-24509	7/13/2021	SIF2008-2012 Calls With Msgs 2009 Extracted 20210713	ENDO-OPIOID_MDL-07391917	ENDO-OPIOID_MDL-07391917		
P-24510	7/13/2021	SIF2008-2012 Calls With Msgs 2010 Extracted 20210713	ENDO-OPIOID_MDL-07391919	ENDO-OPIOID_MDL-07391919		
P-24511	7/13/2021	SIF2008-2012 Calls With Msgs 2007_2008 Extracted 20210713	ENDO-OPIOID_MDL-07391921	ENDO-OPIOID_MDL-07391921		
P-24512	7/13/2021	SIF2008-2012 Calls With Msgs 2011 Extracted 20210713	ENDO-OPIOID_MDL-07391923	ENDO-OPIOID_MDL-07391923		
P-24513	7/13/2021	SIF2008-2012 Calls With Msgs 2012 Extracted 20210713	ENDO-OPIOID_MDL-07391925	ENDO-OPIOID_MDL-07391925		
P-24514	7/13/2021	cdw ADS Calls With Msgs 2010 Extracted 20210713	ENDO-OPIOID_MDL-07391928	ENDO-OPIOID_MDL-07391928		
P-24515	7/13/2021	cdw ADS Calls With Msgs 2009 Extracted 20210713	ENDO-OPIOID_MDL-07391931	ENDO-OPIOID_MDL-07391931		
P-24516	7/13/2021	cdw ADS Calls With Msgs 2007_2008 Extracted 20210713	ENDO-OPIOID_MDL-07391932	ENDO-OPIOID_MDL-07391932		
P-24517	7/13/2021	cdw ADS Calls With Msgs 2011 Extracted 20210713	ENDO-OPIOID_MDL-07391933	ENDO-OPIOID_MDL-07391933		
P-24518	7/13/2021	cdw ADS Calls With Msgs 2012 Extracted 20210713	ENDO-OPIOID_MDL-07391935	ENDO-OPIOID_MDL-07391935		
P-24519	7/13/2021	cdw ADS Calls With Msgs 2013 Extracted 20210713	ENDO-OPIOID_MDL-07391937	ENDO-OPIOID_MDL-07391937		
P-24520	7/13/2021	cdw ADS Calls With Msgs 2014 Extracted 20210713	ENDO-OPIOID_MDL-07391939	ENDO-OPIOID_MDL-07391939		
P-24521	7/13/2021	cdw ADS Calls With Msgs NoCallDate Extracted 20210713	ENDO-OPIOID_MDL-07391943	ENDO-OPIOID_MDL-07391943		
P-24522	7/1/2007	Lunch & Learn Program Program Folder (OP-01388)	ENDO-OPIOID_MDL-00941865	ENDO-OPIOID_MDL-00941866		
P-24523	7/20/2021	SFA_Materials_Dropped_2013-01-01_to_2015-02-17 Extracted 20210720	ENDO-OPIOID_MDL-07391961	ENDO-OPIOID_MDL-07391961		
P-24524	9/1/2021	SIF2008-2012 Contact Notes extracted 20210901	ENDO-OPIOID_MDL-07540768	ENDO-OPIOID_MDL-07540768		
P-24525	9/1/2021	SIF2008-2012 Organization Notes extracted 20210901	ENDO-OPIOID_MDL-07540771	ENDO-OPIOID_MDL-07540771		
P-24526	9/1/2021	SIF2008-2012 Pharmacy Calls with Notes extracted 20210901	ENDO-OPIOID_MDL-07540772	ENDO-OPIOID_MDL-07540772		
P-24527	9/5/2021	SIF2007Backup Pharmacy Call with Notes 20210905	ENDO-OPIOID_MDL-07542284	ENDO-OPIOID_MDL-07542284		
P-24528	9/8/2021	SIF2007Backup Client Notes 20210908.xlsx	ENDO-OPIOID_MDL-07542287	ENDO-OPIOID_MDL-07542287		
P-24529	9/5/2021	SIF2007Backup Contact Notes 20210905.xlsx	ENDO-OPIOID_MDL-07542288	ENDO-OPIOID_MDL-07542288		
P-24530	9/5/2021	SIF2007Backup locmstr Notes 20210905.xlsx	ENDO-OPIOID_MDL-07542290	ENDO-OPIOID_MDL-07542290		
P-24531	9/11/2021	Navigator_Other_Calls_With_Msgs_2016_extracted_20210911.xlsx	ENDO-OPIOID_MDL-08000581	ENDO-OPIOID_MDL-08000581		
P-24532	9/11/2021	Navigator_HCP_Calls_With_Msgs_2016_extracted_20210911.xlsx	ENDO-OPIOID_MDL-08000584	ENDO-OPIOID_MDL-08000584		
P-24533	9/11/2021	Navigator_HCP_Calls_With_Msgs_2015_extracted_20210911.xlsx	ENDO-OPIOID_MDL-08000585	ENDO-OPIOID_MDL-08000585		
P-24534	9/11/2021	Navigator_Pharmacy_Calls_With_Msgs_2016_extracted_20210911.xlsx	ENDO-OPIOID_MDL-08000588	ENDO-OPIOID_MDL-08000588		
P-24535	9/23/2021	Speakernet_2_cpattendees20210923.xlsx	ENDO-OPIOID_MDL-08000598	ENDO-OPIOID_MDL-08000598		
P-24536	9/23/2021	Speakernet_2_otherattendees20210923.xlsx	ENDO-OPIOID_MDL-08000599	ENDO-OPIOID_MDL-08000599		
P-24537	9/23/2021	Speakernet_2_attendees20210923.xlsx	ENDO-OPIOID_MDL-08000600	ENDO-OPIOID_MDL-08000600		
P-24538	9/23/2021	Speakernet_2_ProgramDetails20210923.xlsx	ENDO-OPIOID_MDL-08000605	ENDO-OPIOID_MDL-08000605		
P-24539	9/23/2021	Speakernet_2_speakersbyprogram20210923.xlsx	ENDO-OPIOID_MDL-08000607	ENDO-OPIOID_MDL-08000607		
P-24540	9/28/2021	SpeakernetReadOnly_speakersbyprogram_extracted_20210928.xlsx	ENDO-OPIOID_MDL-08167707	ENDO-OPIOID_MDL-08167707		
P-24541	1/24/2022	SIF2007Archive_HCP_Calls_2007_Extracted_20220124.xlsx	ENDO-OPIOID_MDL-08526231	ENDO-OPIOID_MDL-08526231		

P-24542	1/24/2022	SIF2007Archive_Pharmacy_Calls_2007_extracted_20220124.xlsx	ENDO-OPIOID_MDL-08526234	ENDO-OPIOID_MDL-08526234		
P-24543	1/8/2009	Physicians Total Care	Anda_Opioids_MDL_0000275957	Anda_Opioids_MDL_0000275957		
P-24544	11/11/2011	OPANA Pub Team Meeting Book (111111).pdf	ENDO_FLAG-00535179	ENDO_FLAG-00535279		
P-24545	11/6/2001	Oxymorphone Marketing Plan 2002	ENDO-OPIOID_MDL-02748283	ENDO-OPIOID_MDL-02748283		
P-24546	12/14/2016	Re Denominator Issue - CDC Data	ENDO-OPIOID_MDL-01199391	ENDO-OPIOID_MDL-01199393		
P-24547	2012	Strategies to Reduce the Tampering and Subsequent Abuse of Long-acting Opioids: Potential Risks and Benefits	N/A	N/A		
P-24548	8/28/2014	August 2014 Risk Management Committee Meeting	ENDO-OPIOID_MDL-01180595	ENDO-OPIOID_MDL-01180598		
P-24549	1/15/2009	FW: PCF REMS Task Force - The PCF is asking for us to sign this....	EPI001676707	EPI001676717		
P-24550	12/11/2008	PCF REMS Task Force - I need your input ASAP	EPI001794412	EPI001794418		
P-24551	2/5/2008	OPANA Brand Positioning Updated 02-05-08	EPI000559487	EPI000559488		
P-24552	4/5/2006	RE: Structured Call Notes	ENDO-OPIOID_MDL-02971023	ENDO-OPIOID_MDL-02971023		
P-24553	3/21/2013	PCF REMS Task Force - I need your input ASAP	EPI002473052	EPI002473075		
P-24554	5/7/2015	FW: EXTERNAL: (BN) Abuse of Pain Pills Fuels VirusGÇOs Spread, Confounding Regul	ENDO-OPIOID_MDL-06196949	ENDO-OPIOID_MDL-06196952		
P-24555	3/24/2015	Endo Healthcare Compliance Guide	END00747514	END00747651		
P-24556	12/29/2008	PhRMA_code_FINAL.2008	ENDO-NY-00254170	ENDO-NY-00254208		
P-24557	5/27/2008	Opana_Nav_17x11_spreads_HighRes	ENDO-CHI_LIT-00027177	ENDO-CHI_LIT-00027188		
P-24558	11/22/2010	Business Plan Presentation LR v6 With Notes	EPI000855703	EPI000855712		
P-24559	7/9/2008	Executive Summary Report Chronic Opioid DD - final	ENDO_FLAG-00455140	ENDO_FLAG-00455150		
P-24561	12/22/2008	FINAL - 2009 OPANA Brand Plan-12-16-08	ENDO-CHI_LIT-00023217	ENDO-CHI_LIT-00023217		
P-24562	1/27/2012	Opana ER Risk Management Team Minutes 2012 01 17 NHS	ENDO-OPIOID_MDL-00824628	ENDO-OPIOID_MDL-00824633		
P-24563	2/1/2008	2008.02.01 Email re Performance evaluations (see Katouli eval at 112)	ENDO-CA-00110102	ENDO-CA-00110112		
P-24564	7/6/2009	Acct 305285	Anda_Opioids_MDL_0000287920	Anda_Opioids_MDL_0000287920		
P-24565	2006	Opana ER Master Visual Aid OP-00115 (Sept. 2006)	END00038091	END00038126		
P-24566	12/30/2008	Opana Pub Team Meeting_12-05-08	ENDO_AR_CRITT_00043697	ENDO_AR_CRITT_00043790		
P-24567	1/21/2009	Opana 01-12-09 Publication Team Minutes	END00655093	END00655101		
P-24568	3/24/2009	Opana Pub Team Meeting Book 03-02-09	END00731623	END00731705		
P-24569	5/4/2009	Opana 040609 Minutes	END00369211	END00369297		
P-24570	12/14/2009	Opana Pub Team Meeting Book (120709)	END00695567	END00695659		
P-24571	1/6/2010	Opana Team Minutes (120709)	END00713666	END00713669		
P-24572	6/2/2010	SA-Article_Kitlinski_draft-060110	END00095235	END00095236		
P-24573	7/9/2010	FW: Opana related topic from the Force Resource	ENDO_AR_CRITT_00011673	ENDO_AR_CRITT_00011676		
P-24574	12/7/2010	OPANA Pub Team Meeting Book (120810)	END00151918	END00152007		
P-24575	12/8/2010	Oxymorphone Monthly Publication Team Meeting Minutes 12-8-10	END00035417	END00035422		
P-24576	1/14/2011	Oxymorphone Monthly Publication Team Meeting Minutes 02-08-11	END00017179	END00017183		
P-24577	2/8/2011	Oxymorphone Monthly Publication Team Meeting Minutes 02-08-11	END00007244	END00007248		
P-24578	12/2/2011	Opana Team Minutes (011411)	END00621894 END00622131	END00622140 END00622134	END00622131 - END00622134	
P-24579	1/6/2012	OPANA Pub Team Meeting Book (010912)	END00621217	END00621336		
P-24580	7/31/2012	Opana ER with INTAC HCP Mailer	END00167512	END00167515		
P-24581	10/22/2012	OPANA Pub Meeting Book (101812)	END00643893	END00643988		
P-24583	11/14/2012	Opana Pub Team Meeting Book (1115120)	END00645734	END00645840		
P-24584	4/19/2013	J13002 Opana ER 2013 Quantitative Pulsing Research Wave 2 Report (041913)	END00464661 END00464663	END00464823 END00464744	END00464663 - END004744	
P-24585	4/24/2013	Oxymorphone Publication Team Meeting Agenda 4-24-13	END00038969	END00038971		
P-24586	3/12/2014	Opana ER Master Visual Aid OP-00907b(1) (Feb. 2013)	END00060539	END00060556		
P-24587	1/7/2002	Email re opioid slide kit draft for discussion	ENDO-OPIOID_MDL-02472793	ENDO-OPIOID_MD5-02472793		
P-24588	4/23/2004	Email FW Pub Team meeting Minutes	ENDO_FLAG-00285785	ENDO_FLAG-00285802		
P-24589	12/29/2004	Email FW DepoDur and Opana Minutes	ENDO_SF-00474818	ENDO_SF-00474849		
P-24590	12/12/2007	Premium Materials Depicted	ENDO-OPIOID_MDL-01504909	ENDO-OPIOID_MDL-01504937		
P-24592	4/24/2006	Email FW Opana Publication Team Minutes	ENDO_SF-00153180	ENDO_SF-00153186		
P-24593	7/11/2006	Email FW Opana June pub team meeting minutes	ENDO_FLAG-00302558	ENDO_FLAG-00302568		
P-24594	8/14/2006	Email FW Opana and Frova Pub Team Books	ENDO_FLAG-00823082	ENDO_FLAG-00823141		

P-24595	10/2/2006	Email FW Opanana September Pub Team Meeting Minutes	ENDO-CHI_LIT-00552234	ENDO-CHI_LIT-00552254		
P-24596	1/12/2007	Opana Brand Monthly Publication Team Meeting Minutes	ENDO-OPIOID_MDL-00366281	ENDO-OPIOID_MDL-00366288		
P-24597	3/22/2007	Opana 2007 Publication Plan Gap Analysis Summary & Strategic Recommendations	ENDO-CHI_LIT-00544148	ENDO-CHI_LIT-00544157		
P-24598	3/28/2007	Email re Opana Pub Team Info	ENDO-OPIOID_MDL-00541677	ENDO-OPIOID_MDL-00541716		
P-24599	9/26/2007	Email re Opana Pub Team Booklet 9-07	ENDO-OPIOID_MDL-00542038	ENDO-OPIOID_MDL-00542111		
P-24600	10/23/2007	Email re Oct Opana Pub Team Mtg with attachment	ENDO-OPIOID_MDL-00542188	ENDO-OPIOID_MDL-00542252		
P-24601	2/4/2008	Email FW Opana Publication Team Meeting Book - Feb. 4, 2008	ENDO_FLAG-00286936	ENDO_FLAG-00287011		
P-24602	5/14/2010	Oxymorphone Situation Analysis Pre-Read	EPI002386765	EPI002386789		
P-24603	11/14/2008	Email FW FOR Distribution-Opana Publication Team Meeting Minutes	ENDO_FLAG-00891523	ENDO_FLAG-00891531		
P-24604	2/20/2009	Email FW February Opana minutes	ENDO_FLAG-00867406	ENDO_FLAG-00867489		
P-24605	4/14/2009	Opana Brand Publication Team Meeting Minutes	ENDO-CHI_LIT-00024921	ENDO-CHI_LIT-00024924		
P-24606	7/16/2009	ECR Chris Pastor	ENDO-CA-00006464	ENDO-CA-00006464		
P-24607	11/18/2010	Email re Media Plan	ENDO-CHI_LIT-00056847	ENDO-CHI_LIT-00056849		
P-24608	1/31/2011	Opana ATU Wave 3 Final Report 01_31_11 Feb 7 with Links	ENDO-CHI_LIT-00556061	ENDO-CHI_LIT-00556061		
P-24609	5/9/2011	Email re Opana Publication Meeting with attachment	ENDO-CHI_LIT-00001502	ENDO-CHI_LIT-00001605		
P-24610	7/7/2011	Email re CBP Update	ENDO_GAAG_0082361	ENDO_GAAG_0082363		
P-24611	9/9/2011	Meeting Invite re Opana Publication Meeting	ENDO_FLAG-00538779	ENDO_FLAG-00538898		
P-24612	4/18/2012	Email re Opana ER Publication Meeting -- April Booklet with attachment	ENDO-CHI_LIT-00002063	ENDO-CHI_LIT-00002186		
P-24613	6/13/2012	Email attaching Creative Project Brief-Opioid Patient Brochure	ENDO-CHI_LIT-00208240	ENDO-CHI_LIT-00208250		
P-24614	11/8/2012	Email FW: Weekly Analytics Mtg-Extended Team PMO Review with attachments	ENDO-OPIOID_MDL-00846321	ENDO-OPIOID_MDL-00846324		
P-24615	3/20/2013	Journal ROI for Opana ER	ENDO-OPIOID_MDL-06669901	ENDO-OPIOID_MDL-06669902		
P-24616	4/6/2013	Email RE ROI on Opana ER Copay Cards	ENDO-OPIOID_MDL-07782704	ENDO-OPIOID_MDL-07782705		
P-24617	7/11/2013	Email re PMO Overview slides	ENDO-OPIOID_MDL-06521142	ENDO-OPIOID_MDL-06521195		
P-24618	10/24/2013	Email re Adheris Opana ER Latest Results	ENDO-OPIOID_MDL-02824887	ENDO-OPIOID_MDL-02824888		
P-24619	1/18/2016	Email re OP-2510(1) Appropriate Use Brochure Reprint	ENDO-OPIOID_MDL-02708694	ENDO-OPIOID_MDL-02708710		
P-24620	12/17/2007	Premium Materials Depicted	ENDO-OPIOID_MDL-02084919	ENDO-OPIOID_MDL-02084947		
P-24621	3/15/2004	Opioid Abuse Addiction and Diversion	STANOS_0000419	STANOS_0000491		
P-24622	8/21/2007	Dannemiller-Rational Opioid Prescribing Presentation - 2nd half	STANOS_0001214	STANOS_0001246		
P-24623	1/2/2017	Chronic Pain Mgmt and Opioid Use_10-11-12 Webpage_41103.pdf	PPLP003471411	PPLP003471454		
P-24624	8/1/2011	minutes from latest OXM pub team meeting	ENDO-OPIOID_MDL-00614586	ENDO-OPIOID_MDL-00614709		
P-24625	5/1/2008	Opioid Analgesia 2008 SK Final 4-24-08.ppt	ENDO_FLAG-00306923	ENDO_FLAG-00306923		
P-24626	11/15/2010	Bryant ranch	Anda_Opioids_MDL_0000286324	Anda_Opioids_MDL_0000286325		
P-24627	3/1/2011	potential exporters	Anda_Opioids_MDL_0000710987	Anda_Opioids_MDL_0000710988		
P-24628	3/4/2011	potential exporters	Anda_Opioids_MDL_0000710997	Anda_Opioids_MDL_0000710999		
P-24629	1/30/2007	JFP 2007 Manuscript.pdf	ENDO-OPIOID_MDL-06233835	ENDO-OPIOID_MDL-06233866		
P-24630	1/30/2012	BRP Prtho-Indy	Anda_Opioids_MDL_0001088761	Anda_Opioids_MDL_0001088780		
P-24631	1/30/2012	BRP Center for Interventional Spine	Anda_Opioids_MDL_0001088735	Anda_Opioids_MDL_0001088760		
P-24632	5/9/2012	Bryant Ranch Prepack	Anda_Opioids_MDL_0000070081	Anda_Opioids_MDL_0000070081		
P-24633	6/1/2012	Bryant Ranch	Anda_Opioids_MDL_0000086820	Anda_Opioids_MDL_0000086821		
P-24634	1/15/2013	Bryant Ranch 305285 Lyrica	Anda_Opioids_MDL_0000570186	Anda_Opioids_MDL_0000570186		
P-24635	1/16/2013	Bryant Ranch SOP	Anda_Opioids_MDL_0001088781	Anda_Opioids_MDL_0001088801		
P-24636	1/16/2013	Bryant Ranch Prepack	Anda_Opioids_MDL_0000570156	Anda_Opioids_MDL_0000570156		
P-24637	1/16/2013	Bryant Ranch Prepack	Anda_Opioids_MDL_0000570157	Anda_Opioids_MDL_0000570157		
P-24638	8/27/2013	Volume By PillsWorks	Anda_Opioids_MDL_0000340128	Anda_Opioids_MDL_0000340130		
P-24639	10/11/2013	Bryant Ranch Codeine Limit Acct 305285	Anda_Opioids_MDL_0000351078	Anda_Opioids_MDL_0000351078		
P-24640	10/14/2013	Bryant Ranch Codeine Limit Acct 305285	Anda_Opioids_MDL_0000353948	Anda_Opioids_MDL_0000353949		
P-24641	10/14/2013	Bryant Ranch Codeine Limit Acct 305285	Anda_Opioids_MDL_0000562010	Anda_Opioids_MDL_0000562012		
P-24642	10/14/2013	Bryant Ranch Codeine Limit Acct 305285	Anda_Opioids_MDL_0000363821	Anda_Opioids_MDL_0000363823		
P-24643	10/15/2013	Bryant Ranch Codeine Limit Acct 305285	Anda_Opioids_MDL_0000353945	Anda_Opioids_MDL_0000353947		
P-24644	10/16/2013	Controls Sold ItemDetail	Anda_Opioids_MDL_0000339691	Anda_Opioids_MDL_0000339691		
P-24645	10/16/2013	Controls Sold ItemDetail	Anda_Opioids_MDL_0000339692	Anda_Opioids_MDL_0000339693		
P-24646	8/27/2013	Volume By PillsWorks	Anda_Opioids_MDL_0000354012	Anda_Opioids_MDL_0000354013		
P-24647	1/13/2014	Bryant Ranch 305285 Codeine	Anda_Opioids_MDL_0000353923	Anda_Opioids_MDL_0000353925		
P-24648	2/13/2014	Bryant Ranch Prepack	Anda_Opioids_MDL_0000338842	Anda_Opioids_MDL_0000338843		
P-24649	11/3/2014	BRP 305285	Anda_Opioids_MDL_0000360255	Anda_Opioids_MDL_0000360258		



P-24650	11/4/2014	BRP 305285	Anda_Opioids_MDL_0000360204	Anda_Opioids_MDL_0000360208		
P-24651	12/9/2014	BRP 305285	Anda_Opioids_MDL_0000336898	Anda_Opioids_MDL_0000336905		
P-24652	10/14/2016	MEETING RECAP Oct 14 Vendor Credit Processing and Impact on Business	Anda_Opioids_MDL_0000118997	Anda_Opioids_MDL_0000119004		
P-24653	12/1/2016	Control Limit Increase	Anda_Opioids_MDL_0000304541	Anda_Opioids_MDL_0000304542		
P-24654	12/2/2016	Control Limit Increase	Anda_Opioids_MDL_0000327810	Anda_Opioids_MDL_0000327811		
P-24655	1/12/20108	305285	Anda_Opioids_MDL_0000387380	Anda_Opioids_MDL_0000387380		
P-24656	1/29/2018	305285	Anda_Opioids_MDL_0001152480	Anda_Opioids_MDL_0001152490		
P-24657	1/29/2018	305285	Anda_Opioids_MDL_0001174978	Anda_Opioids_MDL_0001174988		
P-24658	3/7/2018	305285	Anda_Opioids_MDL_0001151168	Anda_Opioids_MDL_0001151169		
P-24659	3/7/2018	305285	Anda_Opioids_MDL_0001088803	Anda_Opioids_MDL_0001088804		
P-24660	3/15/2018	305285	Anda_Opioids_MDL_0001151012	Anda_Opioids_MDL_0001151014		
P-24661	3/23/2018	36C77018Q0378-BRP	Anda_Opioids_MDL_0000385692	Anda_Opioids_MDL_0000385695		
P-24662	4/26/2018	BRP Pharma	Anda_Opioids_MDL_0001163570	Anda_Opioids_MDL_0001163572		
P-24663	5/10/2018	Idea	Anda_Opioids_MDL_0000401254	Anda_Opioids_MDL_0000401254		
P-24664	5/11/2018	305285 Bryant Ranch Prepack	Anda_Opioids_MDL_0000323636	Anda_Opioids_MDL_0000323636		
P-24665	5/11/2018	305285 Bryant Ranch Prepack	Anda_Opioids_MDL_0000323631	Anda_Opioids_MDL_0000323631		
P-24666	5/25/2018	305285 Meeting	Anda_Opioids_MDL_0001160868	Anda_Opioids_MDL_0001160872		
P-24667	1/16/2013	ANDA application	Anda_Opioids_MDL_0001088707	Anda_Opioids_MDL_0001088708		
P-24668	5/21/2013	Possible Fraudulent License	Anda_Opioids_MDL_0000127341	Anda_Opioids_MDL_0000127347		
P-24669	5/27/2016	305285 Bryant Ranch Prepack	Anda_Opioids_MDL_0000303573	Anda_Opioids_MDL_0000303576		
P-24670	5/27/2016	Fax received	Anda_Opioids_MDL_0000729698	Anda_Opioids_MDL_0000729700		
P-24671	5/25/2018	Bryant Ranch Prepack Total	Anda_Opioids_MDL_0000008096	Anda_Opioids_MDL_0000008097		
P-24672	1/16/2013	CUSTOMER QUESTIONNAIRE	Anda_Opioids_MDL_0001088713	Anda_Opioids_MDL_0001088717		
P-24673	9/20/2007	Premium Materials Depicted	ENDO-OPIOID_MDL-06662223	ENDO-OPIOID_MDL-06662224		
P-24674	12/20/2016	Vendor	Anda_Opioids_MDL_0000525754	Anda_Opioids_MDL_0000525758		
P-24675	3/7/2018	Controlled Substance Suspicious Order Sample Protocol 2	Anda_Opioids_MDL_0001088805	Anda_Opioids_MDL_0001088808		
P-24676	12/5/2016	12-05-16 All Inactive and Active Accounts	Anda_Opioids_MDL_0000148658	Anda_Opioids_MDL_0000148659		
P-24677	12/14/2017	Quality Agreement	Anda_Opioids_MDL_0000034526	Anda_Opioids_MDL_0000034534		
P-24678	12/14/2017	Quality Agreement	Anda_Opioids_MDL_0000007822	Anda_Opioids_MDL_0000007823		
P-24679	12/15/2017	Quality Agreement	Anda_Opioids_MDL_0000144597	Anda_Opioids_MDL_0000144598		
P-24680	4/23/2018	TEVA PRODUCTS UNITS NET BY CUSTOMER	Anda_Opioids_MDL_0000786243	Anda_Opioids_MDL_0000786244		
P-24681	11/21/2012	NEW VENDOR NOTIFICATION - HARVARD-RUGBY RETURN POLICY	Anda_Opioids_MDL_0000017030	Anda_Opioids_MDL_0000017037		
P-24682	4/7/2011	Generic Adderall XR 30mg Allocation	Anda_Opioids_MDL_0000108676	Anda_Opioids_MDL_0000108681		
P-24683	6/18/2010	Important Information from the Harvard Drug Group	Anda_Opioids_MDL_0000078666	Anda_Opioids_MDL_0000078668		
P-24684	3/29/2011	Harvard controls	Anda_Opioids_MDL_0000078537	Anda_Opioids_MDL_0000078537		
P-24685	2/3/2015	Account 499752-Mt. Vernon	Anda_Opioids_MDL_0000097882	Anda_Opioids_MDL_0000097896		
P-24686	11/9/2016	Harvard Contract Change Notification	Anda_Opioids_MDL_0001115545	Anda_Opioids_MDL_0001115547		
P-24687	1/3/2008	vendors w controls 010308	Anda_Opioids_MDL_0000272702	Anda_Opioids_MDL_0000272703		
P-24688	4/17/2008	DEACOMP	Anda_Opioids_MDL_0000257906	Anda_Opioids_MDL_0000257907		
P-24689	10/21/2008	Fentanyl Patch	Anda_Opioids_MDL_0000612257	Anda_Opioids_MDL_0000612259		
P-24690	11/20/2008	Hydrocodone APAP 10mg 325mg 500 tablets	Anda_Opioids_MDL_0000277511	Anda_Opioids_MDL_0000277511		
P-24691	11/25/2008	Read This	Anda_Opioids_MDL_0000272489	Anda_Opioids_MDL_0000272490		
P-24692	2/25/2009	Eligibility Matrix Update	Anda_Opioids_MDL_0000611969	Anda_Opioids_MDL_0000612040		
P-24693	6/15/2010	Scanned image from MX-5500N	Anda_Opioids_MDL_0000104236	Anda_Opioids_MDL_0000104238		
P-24694	3/10/2011	Target Pilot Program	Anda_Opioids_MDL_0000474956	Anda_Opioids_MDL_0000474979		
P-24695	3/28/2011	Controls	Anda_Opioids_MDL_0000282061	Anda_Opioids_MDL_0000282062		
P-24696	3/29/2011	Harvard controls	Anda_Opioids_MDL_0000711266	Anda_Opioids_MDL_0000711266		
P-24697	3/29/2011	Harvard controls	Anda_Opioids_MDL_0000078538	Anda_Opioids_MDL_0000078538		
P-24698	4/7/2011	Chains	Anda_Opioids_MDL_0000105969	Anda_Opioids_MDL_0000107647		
P-24700	10/25/2011	Pharmacy Information	Anda_Opioids_MDL_0001099640	Anda_Opioids_MDL_0001099641		
P-24701	4/20/2011	Pharmaceutical Agreements	N/A	N/A		
P-24702	4/18/2014	Purdue follow-up	Anda_Opioids_MDL_0000604364	Anda_Opioids_MDL_0000604365		
P-24703	12/10/2014	2015 THDG Strategic Portfolio RFP Review Packet	Anda_Opioids_MDL_0001125474	Anda_Opioids_MDL_0001125483		
P-24704	11/18/2016	Major Rugby Transition	Anda_Opioids_MDL_0001115313	Anda_Opioids_MDL_0001115339		
P-24705	8/16/2007	Controls Usage for Nucare	Anda_Opioids_MDL_0000275250	Anda_Opioids_MDL_0000275253		
P-24706	8/16/2007	Approval	Anda_Opioids_MDL_0000275211	Anda_Opioids_MDL_0000275211		
P-24707	9/6/2007	New control file	Anda_Opioids_MDL_0001155038	Anda_Opioids_MDL_0001155039		
P-24708	1/16/2008	Control Limits for Account 129640	Anda_Opioids_MDL_0000274090	Anda_Opioids_MDL_0000274091		

P-24709	3/17/2008	URGENT REQUEST	Anda_Opioids_MDL_0000276981	Anda_Opioids_MDL_0000276984		
P-24710	3/18/2008	URGENT REQUEST	Anda_Opioids_MDL_0000273980	Anda_Opioids_MDL_0000273984		
P-24711	10/21/2009	DEA Copy in PDF	Anda_Opioids_MDL_0000077732	Anda_Opioids_MDL_0000077847		
P-24712	1/7/2010	January Marketing Driver	Anda_Opioids_CA_SF_0019833	Anda_Opioids_CA_SF_0019837		
P-24713	2/3/2011	nu-care account # 129640	Anda_Opioids_MDL_0000283307	Anda_Opioids_MDL_0000283307		
P-24714	10/18/2012	Lake Erie/NuCare	Anda_Opioids_MDL_0000711014	Anda_Opioids_MDL_0000711016		
P-24715	1/27/2006	southwood 051798 hydrocodone recap purchases 11/05 thru jan 26 06	Anda_Opioids_MDL_0000272628	Anda_Opioids_MDL_0000272628		
P-24716	8/24/2006	pedigree southwood	Anda_Opioids_MDL_0000271432	Anda_Opioids_MDL_0000271433		
P-24717	12/6/2006	Southwood_notice to distributors	Anda_Opioids_MDL_0000272292	Anda_Opioids_MDL_0000272293		
P-24718	8/3/2007	Letter and Questionnaire	Anda_Opioids_MDL_0000275549	Anda_Opioids_MDL_0000275553		
P-24719	2/2/2006	Stat pharmaceuticals account 51844	Anda_Opioids_MDL_0000272625	Anda_Opioids_MDL_0000272625		
P-24720	9/22/2008	Stat Pharmaceuticals	Anda_Opioids_MDL_0000273257	Anda_Opioids_MDL_0000273260		
P-24721	9/22/2008	control limit increase request	Anda_Opioids_MDL_0000275870	Anda_Opioids_MDL_0000275871		
P-24722	6/17/2010	Customer list to cut off from buying controls	Anda_Opioids_MDL_0000078695	Anda_Opioids_MDL_0000078696		
P-24723	7/30/2007	Pharmedix approval	Anda_Opioids_MDL_0000275628	Anda_Opioids_MDL_0000275628		
P-24724	8/3/2010	Pharmedix SOP for controls	Anda_Opioids_MDL_0000728341	Anda_Opioids_MDL_0000728365		
P-24726	10/22/2012	Pharmedix Questionnaire	Anda_Opioids_MDL_0000134559	Anda_Opioids_MDL_0000134560		
P-24727	7/6/2010	Pharmedix Control Limit Review	Anda_Opioids_CA_SF_0040209	Anda_Opioids_CA_SF_0040226		
P-24728	9/20/2007	QVL Limits	ALLERGAN_MDL_03951330	ALLERGAN_MDL_03951339		
P-24729	1/30/2008	Anda SOMs and DEA	ALLERGAN_MDL_03963054	ALLERGAN_MDL_03963055		
P-24730	7/22/2007	Anda communication w. DEA	ALLERGAN_SF_00098084	ALLERGAN_SF_00098084		
P-24731	7/30/2007	Controls Limits	ALLERGAN_SF_00098246	ALLERGAN_SF_00098248		
P-24732	6/20/2016	SOP Email	Anda_Opioids_MDL_0000132145 Anda_Opioids_MDL_0000132164	Anda_Opioids_MDL_0000132171 Anda_Opioids_MDL_0000132166	Anda_Opioids_MDL_0000132164 - Anda_Opioids_MDL_0000132166	
P-24733	1/31/2008	Scanned image from MX-4501N	Anda_Opioids_MDL_0000276154	Anda_Opioids_MDL_0000276157		
P-24734	11/30/2011	Please Review	Anda_Opioids_MDL_0000133117	Anda_Opioids_MDL_0000133119		
P-24735	9/22/2016	Current Suspicious Order SOPs	Anda_Opioids_MDL_0000294649	Anda_Opioids_MDL_0000294703		
P-24736	1/4/2008	Methadone Tablets	Anda_Opioids_MDL_0000276164	Anda_Opioids_MDL_0000276165		
P-24737	4/14/2009	Assured Pharmacies	Anda_Opioids_MDL_0000078139	Anda_Opioids_MDL_0000078139		
P-24738	5/7/2012	Chain Pharmacy Letter	Anda_Opioids_MDL_0000082681	Anda_Opioids_MDL_0000082682		
P-24739	4/3/2007	Suspicious Week Ending 4-01-07 Pharmacy	Anda_Opioids_MDL_0000124928	Anda_Opioids_MDL_0000124928		
P-24740	1/8/2007	Excessive Order Report December 2006	Anda_Opioids_MDL_0000124943	Anda_Opioids_MDL_0000124943		
P-24741	7/2/2007	Suspicious Week Ending 7-1-07 Wholesalers	Anda_Opioids_MDL_0000124945	Anda_Opioids_MDL_0000124945		
P-24742	2/20/2006	Suspicious Week Ending 2-19-06 Pharmacy	Anda_Opioids_MDL_0000124963	Anda_Opioids_MDL_0000124963		
P-24743	11/11/2013	Customers Cut Off	Anda_Opioids_CA_SF_0041977	Anda_Opioids_CA_SF_0041978		
P-24744	12/20/2013	Customers Cut Off	Anda_Opioids_MDL_0000078299	Anda_Opioids_MDL_0000078300		
P-24745	9/23/2014	Updated List of Customers Not Eligible to Purchase Controls	Anda_Opioids_AL_DCH_0020495	Anda_Opioids_AL_DCH_0020496		
P-24746	10/7/2014	Updated List of Customers Not Eligible to Purchase Controls	Anda_Opioids_AL_DCH_0005930	Anda_Opioids_AL_DCH_0005931		
P-24747	2/12/2018	Anda Updated List of Reportable Customers as of February 6 2018	Anda_Opioids_MDL_0000479654	Anda_Opioids_MDL_0000479655		
P-24748	3/2/2018	Anda Updated List of Reportable Customers as of March 2 2018	Anda_Opioids_MDL_0000306559	Anda_Opioids_MDL_0000306560		
P-24749	3/20/2018	Anda Updated List of Reportable Customers as of March 20 2018	Anda_Opioids_MDL_0000010148	Anda_Opioids_MDL_0000010149		
P-24750	4/6/2018	Anda Updated List of Reportable Customers as of April 6 2018	Anda_Opioids_MDL_0000011020	Anda_Opioids_MDL_0000011021		
P-24751	5/2/2018	Anda Updated List of Reportable Customers as of May 02 2018	Anda_Opioids_MDL_0000326304	Anda_Opioids_MDL_0000326305		
P-24752	5/18/2018	Anda Updated List of Reportable Customers as of May 18 2018	Anda_Opioids_MDL_0000325956	Anda_Opioids_MDL_0000325957		
P-24753	6/8/2018	Anda Updated List of Reportable Customers as of June 08 2018	Anda_Opioids_CA_SF_0035249	Anda_Opioids_CA_SF_0035250		
P-24754	6/18/2018	Anda Updated List of Reportable Customers as of June 18 2018	Anda_Opioids_CA_SF_0036510	Anda_Opioids_CA_SF_0036511		
P-24755	6/26/2018	Anda Updated List of Reportable Customers as of June 26 2018	Anda_Opioids_CA_SF_0035056	Anda_Opioids_CA_SF_0035057		
P-24758	7/13/2018	Anda Updated List of Reportable Customers as of July 13 2018	Anda_Opioids_CA_SF_0034954	Anda_Opioids_CA_SF_0034955		
P-24759	7/19/2018	Anda Updated List of Reportable Customers as of July 19 2018	Anda_Opioids_CA_SF_0034353	Anda_Opioids_CA_SF_0034354		
P-24760	8/6/2018	Anda Updated List of Reportable Customers as of August 6 2018	Anda_Opioids_CA_SF_0035549	Anda_Opioids_CA_SF_0035550		
P-24763	8/21/2018	Anda Updated List of Reportable Customers as of August 21 2018	Anda_Opioids_CA_SF_0036436	Anda_Opioids_CA_SF_0036437		
P-24776	8/30/2018	Anda Updated List of Reportable Customers as of August 30 2018	Anda_Opioids_CA_SF_0032637	Anda_Opioids_CA_SF_0032638		
P-24781	9/14/2018	Anda Updated List of Reportable Customers as of September 14 2018	Anda_Opioids_CA_SF_0033847	Anda_Opioids_CA_SF_0033848		

P-24785	2006	Pain Medicine Independent Medical Education 2006 Year-End Report; Documents referenced by Teva Defendants in response to Interrogatory No. 51 of their July 23, 2020 Supplemental Responses to People's Second Set of Interrogatories, served in The People v. State of California v. Purdue Pharma L.P. et al, Orange County California Superior Court Case No. 30-2014-00725287-CU-BT-CXC - Documents related to Teva Defendants' Continuing Medical Education grant requests	TEVA_MDL_A_00564864	TEVA_MDL_A_00564916		
P-24791	9/27/2018	Anda Updated List of Reportable Customers as of September 27 2018	Anda_Opioids_CA_SF_0035736	Anda_Opioids_CA_SF_0035737		
P-24793	2017	Documents referenced by Teva Defendants in response to Interrogatory No. 39 of their July 23, 2020 Supplemental Responses to People's Second Set of Interrogatories, served in The People v. State of California v. Purdue Pharma L.P. et al, Orange County California Superior Court Case No. 30-2014-00725287-CU-BT-CXC - Fentora voucher and co-pay redemption data from 2009 to 2017	TEVA_MDL_A_00763716	TEVA_MDL_A_00763716		
P-24796	10/2/2018	Anda Updated List of Reportable Customers as of October 2 2018	Anda_Opioids_CA_SF_0051661	Anda_Opioids_CA_SF_0051662		
P-24797	10/8/2018	Anda Updated List of Reportable Customers as of October 8 2018	Anda_Opioids_CA_SF_0033318	Anda_Opioids_CA_SF_0033319		
P-24801	7/31/2018	Documents referenced by Teva Defendants in response to Interrogatory No. 35 of their July 23, 2020 Supplemental Responses to People's Second Set of Interrogatories, served in The People v. State of California v. Purdue Pharma L.P. et al, Orange County California Superior Court Case No. 30-2014-00725287-CU-BT-CXC - Documents containing information on call activity for FENTORA performed by third party. Publicis	TEVA_MDL_A_01130614	TEVA_MDL_A_01130614		
P-24805	10/11/2018	Anda Updated List of Reportable Customers as of October 11 2018	Anda_Opioids_CA_SF_0036645	Anda_Opioids_CA_SF_0036646		
P-24811	5/9/2011	MCT Agenda	TEVA_MDL_A_01866662	TEVA_MDL_A_01866675		
P-24814	1/23/2012	Pharmacy Times Fentora/Actiq REMS Supplement published	TEVA_MDL_A_02057215	TEVA_MDL_A_02057223		
P-24817	2008	APF Target chronic pain notebook	TEVA_MDL_A_02291004	TEVA_MDL_A_02291041		
P-24820	2018	Documents referenced by Teva Defendants in response to Interrogatory No. 50 of their July 23, 2020 Supplemental Responses to People's Second Set of Interrogatories, served in The People v. State of California v. Purdue Pharma L.P. et al, Orange County California Superior Court Case No. 30-2014-00725287-CU-BT-CXC -An extract from Teva's system for payments to certain third party vendors for 2003-2018, which may include payments related to speaker programs	TEVA_MDL_A_02401119	TEVA_MDL_A_02401119		
P-24822	2018	Documents referenced by Teva Defendants in response to Interrogatory No. 51 of their July 23, 2020 Supplemental Responses to People's Second Set of Interrogatories, served in The People v. State of California v. Purdue Pharma L.P. et al, Orange County California Superior Court Case No. 30-2014-00725287-CU-BT-CXC - Extract from Teva's Oracle system for payments to certain third party vendors for 2006-2018	TEVA_MDL_A_02401119	TEVA_MDL_A_02401119		
P-24828	11/9/2018	Anda Updated List of Reportable Customers as of November 09 2018	Anda_Opioids_CA_SF_0052088	Anda_Opioids_CA_SF_0052089		
P-24834	12/5/2006	Excessive Order Report November 2006	Anda_Opioids_MDL_0000271720	Anda_Opioids_MDL_0000271721		
P-24837	8/17/2002	Launch of pain.com	TEVA_MDL_A_04411207	TEVA_MDL_A_04411207		

P-24839	9/26/2005	Documents referenced by Teva Defendants in response to Interrogatory No. 56 of their July 23, 2020 Supplemental Responses to People's Second Set of Interrogatories, served in The People v. State of California v. Purdue Pharma L.P. et al, Orange County California Superior Court Case No. 30-2014-00725287-CU-BT-CXC - Teva Defendants' August 2005 Activity Report for the Actiq Reimbursement Hotline and Patient Assistance Program.	TEVA_MDL_A_04413569	TEVA_MDL_A_04413581		
P-24840	9/23/2014	Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_MDL_0000601074	Anda_Opioids_MDL_0000601075		
P-24847	N/A	Documents referenced by Teva Defendants in response to Interrogatory No. 51 of their July 23, 2020 Supplemental Responses to People's Second Set of Interrogatories, served in The People v. State of California v. Purdue Pharma L.P. et al, Orange County California Superior Court Case No. 30-2014-00725287-CU-BT-CXC - Information regarding Teva Defendants' CMEs.	TEVA_MDL_A_05816085	TEVA_MDL_A_05816117		
P-24849	10/7/2014	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_AL_DCH_0005932	Anda_Opioids_AL_DCH_0005933		
P-24850	10/23/2014	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_CA_SF_0000417	Anda_Opioids_CA_SF_0000418		
P-24861	11/3/2014	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_CA_SF_0000419	Anda_Opioids_CA_SF_0000420		
P-24871	3/26/2019	Documents referenced by Teva Defendants in response to Interrogatory No. 61 of their July 23, 2020 Supplemental Responses to People's Second Set of Interrogatories, served in The People v. State of California v. Purdue Pharma L.P. et al, Orange County California Superior Court Case No. 30-2014-00725287-CU-BT-CXC - Data associated with the total number of website views of Teva Defendants' <u>TevaGenerics.com website from 2007 to 2019</u>	TEVA_MDL_A_13742899	TEVA_MDL_A_13742899		
P-24875a	N/A	Documents referenced by Teva Defendants in response to Interrogatory No. 29 of their July 23, 2020 Supplemental Responses to People's Second Set of Interrogatories, served in The People v. State of California v. Purdue Pharma L.P. et al, Orange County California Superior Court Case No. 30-2014-00725287-CU-BT-CXC - Teva Defendants opioid sales and receivable data (1) - removed all <u>pages not part of ROG 29</u>	Compilation Exhibit: Non-Sequential Bates - see Attachment to P-24875	Compilation Exhibit: Non-Sequential Bates - see Attachment to P-24875		
P-24884	11/10/2014	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_CA_SF_0000421	Anda_Opioids_CA_SF_0000422		
P-24911	9/17/2008	FDA Letter to Cephalon	TEV_FE00116840	TEV_FE00116843		
P-24917	12/5/2014	Updated List Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_CA_SF_0000423	Anda_Opioids_CA_SF_0000424		
P-24931	12/22/2014	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_CA_SF_0038197	Anda_Opioids_CA_SF_0038198		
P-24935	2004	2004 Actiq Marketing Plan	TEVA_CHI_00042951	TEVA_CHI_00043009		
P-24944	1/5/2015	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_CA_SF_0000425	Anda_Opioids_CA_SF_0000426		
P-24955	2002	2002 ACTIQ Marketing Plan	TEVA_MDL_A_00454816	TEVA_MDL_A_00454871		
P-24956	8/17/2006	A Change is Coming ... Effervescent Speed launch meeting powerpoint; Fent LncH Mkt Pres 8-17_ADMRev	TEVA_CHI_00041330 TEVA_CHI_00041330	TEVA_CHI_00041348 TEVA_CHI_00041331	TEVA_CHI_00041330- TEVA_CHI_00041331	
P-24960	10/17/2017	pain all requests	TEVA_MDL_A_00565051	TEVA_MDL_A_00565051		
P-24972	2006	2006-2015 Fentora National Sales Call Activity Database	TEVA_MDL_A_00763717	TEVA_MDL_A_00763717		
P-24979	11/25/2008	Meeting Reminder by A. Jordheim	TEVA_MDL_A_00890304	TEVA_MDL_A_00890382		
P-24980	1/31/2018	Settlement Agreement and Mutual Release/Indemnity Agreement between Teva and Allergan	N/A	N/A		
P-24983	1/14/2015	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_CA_SF_0000438	Anda_Opioids_CA_SF_0000439		
P-24990	2/3/2015	Updated List of of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_CA_SF_0000440	Anda_Opioids_CA_SF_0000441		
P-24993	7/26/2015	Allergan and Teva Master Purchase Agreement	ALLERGAN_MDL_SUPP00000174	ALLERGAN_MDL_SUPP00000308		

P-25010	5/22/2014	Best of Teva: Attacking Prescription Drug Abuse in the U.S.	TEVA_MDL_A_01088080	TEVA_MDL_A_01088081		
P-25013	6/29/2006	FDA letter to Cephalon, Inc. approving application and draft labeling for Fentora subject to approved RMP	TEVA_MDL_A_00263638	TEVA_MDL_A_00263678		
P-25030	10/3/2012	Transmission of Fentora promotional materials	TEVA_MDL_A_00032112	TEVA_MDL_A_00032218		
P-25034	3/18/2014	Vantrela ER Strategic Brand Plan	TEVA_MDL_A_01204073	TEVA_MDL_A_01204092		
P-25038	12/18/2014	Distribution and supply agreement between Purdue and Teva	TEVA_MDL_A_03434545	TEVA_MDL_A_03434611		
P-25040	5/17/2007	Cephalon, Inc. Board of Directors Meeting packet	TEVA_MDL_A_06654815	TEVA_MDL_A_06655042		
P-25043	2/11/2015	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_CA_SF_0000442	Anda_Opioids_CA_SF_0000443		
P-25045	10/31/2005	Email re meeting with managed care organization about Actiq coverage	TEVA_MDL_A_04466850	TEVA_MDL_A_04466850		
P-25047	7/3/2007	Southwood Drug Enforcement Agency Decision at 72 FR 36487	N/A	N/A		
P-25071	2/19/2015	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_CA_SF_0019446	Anda_Opioids_CA_SF_0019447		
P-25075	3/5/2015	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_CA_SF_0000446	Anda_Opioids_CA_SF_0000447		
P-25087	3/19/2015	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_CA_SF_0000448	Anda_Opioids_CA_SF_0000449		
P-25089	8/17/2004	Cephalon, Inc. Meeting Minutes from July 14, 2004 FDA meeting and attached powerpoint presented	TEVA_MDL_A_01575991	TEVA_MDL_A_01576038		
P-25111	4/8/2015	Updated List of Customer Not Eligible to Purchase Controls from Anda	Anda_Opioids_CA_SF_0000450	Anda_Opioids_CA_SF_0000451		
P-25112	3/9/2009	Letter to Dr. Frauwrith from Teva Professional Services and Medical Information Department regarding his request for information regarding Fentora	TEVA_MDL_A_00619439	TEVA_MDL_A_00619452		
P-25114	1/13/2012	Email Prescriber Targeting Reports in New Alignment; Attachment Prescriber Targeting Reports in New Alignment	TEVA_MDL_A_01097267	TEVA_MDL_A_01097268		
P-25118	3/26/1999	Actiq Approval Letter and Risk Management Program attached.	N/A	N/A		
P-25121	1/19/2018	Renewal of Determination that a Public Health Emergency Exists	N/A	N/A		
P-25133	N/A	Exit Wounds Publication	N/A	N/A		
P-25150	2007	Spreadsheet	TEVA_MDL_A_03413816	TEVA_MDL_A_03413816		
P-25154	N/A	Prescribing Opioids: Reduce the Risk (one-pager)	N/A	N/A		
P-25155	2016	Opioid Infographic (one-pager)	N/A	N/A		
P-25156	12/18/2006	Email re Radio Media Tour	TEVA_MDL_A_07417449	TEVA_MDL_A_07417450		
P-25158	10/31/2014	WBAD Actavis US Generics PPT	Acquired Actavis_02293296	Acquired Actavis_02293297		
P-25164	9/19/2006	Letter to Rappaport Re Fentora NDA	TEVA_CHI_00028341	TEVA_CHI_00028691		
P-25164a	9/19/2006	Letter to Rappaport Re Fentora NDA	TEVA_CHI_00028343	TEVA_CHI_00028408		
P-25166	2/1/2007	Quarterly Compliance Update--1Q2007	TEVA_MDL_A_06654414	TEVA_MDL_A_06654417		
P-25167	10/10/2007	Email Re Verbatim Audit Letter to Field Management	TEVA_MDL_A_09057266	TEVA_MDL_A_09057272		
P-25170	2/11/2016	Integrating Actavis Brand Controlled Products into the new Allergan	MULTI1603405	MULTI1603521		
P-25171	12/31/2014	William Simmons Year End Review	MULTI3746416	MULTI3746422		
P-25172	11/13/2013	Actavis Controlled Substance Compliance	MULTI3118887	MULTI3118890		
P-25173	9/15/2014	KPH Healthcare PO 000832 Follow Up	Acquired Actavis_01675901	Acquired Actavis_01675909		
P-25174	10/26/2017	Determination that a Public Health Emergency Exists	N/A	N/A		
P-25175	8/14/2014	Actavis CII List with Kinney Usage	ALLERGAN_MDL_04497406	ALLERGAN_MDL_04497413		
P-25176	2/17/2015	Order(s) on Hold - ABC	TEVA_MDL_A_01040752	TEVA_MDL_A_01040766		
P-25177	7/9/2015	New DC Rochester Drug - Orders and Account	Teva_MSAG_00633979	Teva_MSAG_00633985		
P-25178	9/9/2015	Critical - LOOK please Optisource - Lake Erie Medical Kadian Order	MULTI3593474	MULTI3593479		
P-25179	6/26/2014	SOMS investigation form for Belco Drug Corp	MULTI1931188	MULTI1931188		
P-25180	11/17/2015	Customer Analysis and SOMS Overview	MULTI2963574	MULTI2963591		
P-25181	6/30/2014	SOMS investigation form for RDC	MULTI1931219	MULTI1931219		
P-25182	9/22/2014	SOMS investigation form for KPH Healthcare Services	TEVA_MDL_A_01040623	TEVA_MDL_A_01040629		
P-25183	10/27/2014	SOMS investigation form for McKesson	MULTI1932520	MULTI1932520		
P-25184	10/27/2014	SOMS investigation form for McKesson	MULTI1932524	MULTI1932524		
P-25185	10/28/2014	SOMS investigation form for RDC	TEVA_MDL_A_01058344	TEVA_MDL_A_01058353		
P-25186	10/28/2014	Rochester po# 2126886 order on hold	Teva_MSAG_00633967	Teva_MSAG_00633976		
P-25187	10/5/2015	Order of interest: Major/Legacy SD 870165	Acquired Actavis_00247076	Acquired Actavis_00247085		

P-25188	7/8/2015	SOMS investigation form for RDC	MULTI2283627	MULTI2283628		
P-25189	7/9/2015	SOMS investigation form for RDC	MULTI2285867	MULTI2285874		
P-25207	10/21/2014	Joint Business Planning H&W PPT	Anda_Opioids_MDL_0001126039	Anda_Opioids_MDL_0001126080		
P-25212	5/9/2016	Email re LA Times Investigation: OxyContin's 12 Hour Problem	TEVA_MDL_A_01506130	TEVA_MDL_A_01506131		
P-25213	N/A	DHHS letter to Regulatory Affairs	TEVA_MDL_A_07679522	TEVA_MDL_A_07679663		
P-25214	12/11/0212	RE: DEA	Anda_Opioids_MDL_0000085675	Anda_Opioids_MDL_0000085676		
P-25215	5/21/2003	POA Presentations - Fall 2002 National New	TEVA_MDL_A_09061551	TEVA_MDL_A_09061554		
P-25216	10/22/2003	Actiq Presentation - The Management of Actiq PPT	TEVA_MDL_A_09062110	TEVA_MDL_A_09062112		
P-25217	7/19/2018	Renewal of Determination that a Public Health Emergency Exists	N/A	N/A		
P-25219	4/20/2018	Renewal of Determination that a Public Health Emergency Exists	N/A	N/A		
P-25225	8/24/2015	Email re CI NEWS - Opioid Use Disorder - The Continued Rise of Opioid Abuse and Misuse	TEVA_MDL_A_13615290	TEVA_MDL_A_13615296		
P-25227	2007	Responsible Opioid Prescribing - A Physician's Guide	TEVA_MDL_A_13615313	TEVA_MDL_A_13615322		
P-25228	6/13/2006	The American Pain Foundation & The Pain Care Forum in cooperation with Representative Mike Rogers (R-MI) - THE EPIDEMIC OF PAIN IN AMERICA	TEVA_MDL_A_13615323	TEVA_MDL_A_13615329		
P-25229	7/1/2006	Making Pain Talk PAINLESS - A guide to help you talk with your doctor about pain management	TEVA_MDL_A_13615330	TEVA_MDL_A_13615333		
P-25230	12/2/2004	Directors Meeting ACTIQ	TEVA_MDL_A_13615334	TEVA_MDL_A_13615422		
P-25231	2005	ACTIQ (oral transmucosal fentanyl citrate) [C-II] Learning System - Competitive Positioning in the Marketplace - For Training Purposes Only	TEVA_MDL_A_13615423	TEVA_MDL_A_13615495		
P-25232	2008	FENTORA Brand Plan 2008 - Contributed content: Marketing, Sales, HCS, AMFE, Sales Operations, Sales Training, Market Research, Public Relations, Regulatory, Clinical, Medical, SciCom, VVWPP & Legal	TEVA_MDL_A_13615496	TEVA_MDL_A_13615506		
P-25238	7/9/2007	Educational Grant Draft Request	TEVA_MDL_A_13738182	TEVA_MDL_A_13738232		
P-25239	2005	American Pain Foundation - Consensus Statement in support of H.R. 1020, the National Pain Care Policy Act of 2005	TEVA_MDL_A_13738233	TEVA_MDL_A_13738236		
P-25243	2015	2015 - Incremental Performance Detail	TEVA_MDL_A_08657217	TEVA_MDL_A_08657224		
P-25244	8/3/2004	Letter from the American Academy of Pain Medicine to Mrs. Meyers re Approved Proposal for a commercially supported symposium at the AAPM's 21st Annual Meeting	TEVA_MDL_A_13738866	TEVA_MDL_A_13738867		
P-25245	2/26/2005	MediCom Worldwide, Inc. Letter Of Agreement Regarding Terms, Conditions and Purposes of an Educational Grant	TEVA_MDL_A_13738868	TEVA_MDL_A_13738869		
P-25248	2003	2003 Actiq Marketing Plan	TEVA_MDL_A_13738941	TEVA_MDL_A_13739010		
P-25249	11/16/2000	Actiq "Master Plan"	TEVA_MDL_A_13739011	TEVA_MDL_A_13739071		
P-25252	2/1/2005	Letter of Agreement Regarding Terms, Conditions and Purposes of an Educational Grant Between Medscape and Cephalon	TEVA_MDL_A_13739091	TEVA_MDL_A_13739094		
P-25253	11/14/2007	Cephalon Approval Grant - Support of Pain.com and the Breakthrough Pain Category from October 2006 - September 2007. Grant number 401.	TEVA_MDL_A_13739095	TEVA_MDL_A_13739127		
P-25254	3/1/2007	Fentora Speaker Utilization	TEVA_MDL_A_13739128	TEVA_MDL_A_13739133		
P-25256	10/12/2006	Pain Franchise Public Relations 2006 Budget Supplement	TEVA_MDL_A_13739139	TEVA_MDL_A_13739141		
P-25257	2003	2003 Program Honorarium by Speaker	TEVA_MDL_A_13739143	TEVA_MDL_A_13739186		
P-25263	9/23/2005	Call Center Operations	Acquired_Actavis_01495929	Acquired_Actavis_01495930		
P-25267	10/1/2011	Sales Representative Training	ACTAVIS0264950	ACTAVIS0265018		
P-25270	7/25/2011	Compliance Update	ACTAVIS0357903	ACTAVIS0357931		
P-25271	6/30/2011	Kadian Sales Training	ACTAVIS0361321	ACTAVIS0361344		
P-25272	2011	Sales Representative Training	ACTAVIS0413235	ACTAVIS0413321		
P-25274	6/21/2011	Email re Marketing Plans	ACTAVIS0971969	ACTAVIS0971972		
P-25276	8/13/2013	Kadian Call List	ALLERGAN_MDL_00003122	ALLERGAN_MDL_00003124		
P-25277	9/17/2012	Sales Representative Training	ALLERGAN_MDL_00026504	ALLERGAN_MDL_00026552		
P-25289	7/16/2010	Communication with FDA	ALLERGAN_MDL_01237737	ALLERGAN_MDL_01237762		
P-25293	10/29/2010	FINAL reports; Actavis Field Status Report FINAL 10-29-10.xls; Team Reps Field Status Report FINAL 10-29-10.xls	ALLERGAN_MDL_01399180	ALLERGAN_MDL_01399182		
P-25295	1/6/2009	Kadian Call List	ALLERGAN_MDL_01540065	ALLERGAN_MDL_01540065		
P-25297	6/14/2002	Memorandum re SOMS program	ALLERGAN_MDL_01844724	ALLERGAN_MDL_01844725		



P-25300	1/11/2016	Memorandum re SOMS program	ALLERGAN_MDL_02146075	ALLERGAN_MDL_02146081		
P-25301	1/11/2016	Memorandum re SOMS program	ALLERGAN_MDL_02146312	ALLERGAN_MDL_02146315		
P-25304	10/18/2013	Memorandum re SOMS program	ALLERGAN_MDL_02176554	ALLERGAN_MDL_02176557		
P-25305	1/8/2013	Cover email re SOMS Presentation, SOM Process	ALLERGAN_MDL_02187160	ALLERGAN_MDL_02187170		
P-25306	5/14/2009	SOM Process	ALLERGAN_MDL_02467151	ALLERGAN_MDL_02467154		
P-25309	4/25/2006	Advocacy Development Brainstorming Meeting	ALLERGAN_MDL_02513100	ALLERGAN_MDL_02513130		
P-25327	9/19/2015	Suspicious Orders of Controlled Drug Standard Operating Procedure	ALLERGAN_MDL_03951884	ALLERGAN_MDL_03951888		
P-25328	4/22/2015	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_MDL_0000095923	Anda_Opioids_MDL_0000095924		
P-25329	7/23/2007	Emails re SOMS Program	ALLERGAN_MDL_03952864	ALLERGAN_MDL_03952866		
P-25330	1/19/2005	Call Center Operations	ALLERGAN_MDL_03953019	ALLERGAN_MDL_03953065		
P-25332	2/1/2013	Memorandum re SOMS Program	ALLERGAN_MDL_04175804	ALLERGAN_MDL_04175845		
P-25333	3/1/2013	Memorandum re SOMS Program	ALLERGAN_MDL_04175964	ALLERGAN_MDL_04175985		
P-25335	6/1/2013	Memorandum re SOMS Program	ALLERGAN_MDL_04176625	ALLERGAN_MDL_04176635		
P-25347	2/1/2007	Actiq Managed Care Dossier	TEVA_CHI_00036931	TEVA_CHI_00036955		
P-25350	5/21/2015	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_CA_SF_0000452	Anda_Opioids_CA_SF_0000453		
P-25355	7/2/2007	Fentora Marketing Materials	TEVA_MDL_A_00026098	TEVA_MDL_A_00026106		
P-25376	3/26/2009	2009 Fentora Brand Plan	TEVA_MDL_A_00371710	TEVA_MDL_A_00371754		
P-25379	5/23/2012	Fentora Message Recall Tracking Study	TEVA_MDL_A_00501903	TEVA_MDL_A_00501948		
P-25384	2/1/2007	Response to Product Inquiry	TEVA_MDL_A_00611793	TEVA_MDL_A_00611806		
P-25385	3/19/2007	Response to Product Inquiry	TEVA_MDL_A_00619455	TEVA_MDL_A_00619468		
P-25386	6/9/2008	Response to Product Inquiry	TEVA_MDL_A_00625326	TEVA_MDL_A_00625339		
P-25393	3/24/2011	Market 3 Meeting / Market 28 Pharmacy Meeting / Sarasota Walgreen's Diversion Presentation	WAGFLDEA00000925	WAGFLDEA00000987		
P-25397	3/1/2012	DEA Compliance Committee Formation (Invitation)	WAGFLDEA00001536	WAGFLDEA00001536		
P-25398	5/31/2011	Florida June Focus on Compliance- Filling Pain Management Prescriptions (FLORIDA MARKETS ONLY)	WAGFLDEA00001704	WAGFLDEA00001709		
P-25402	6/28/2012	Fentora Marketing Plan	TEVA_MDL_A_00755335	TEVA_MDL_A_00755365		
P-25408	7/20/2009	Email re Model Sales Call Behavior	TEVA_MDL_A_00917975	TEVA_MDL_A_00917977		
P-25411	5/27/2015	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_CA_SF_0000403	Anda_Opioids_CA_SF_0000404		
P-25413	10/3/2013	Rx Integrity Update Market Leadership Meeting	WAGMDL00018597	WAGMDL00018610		
P-25414	6/27/2018	Pain Matters Script	TEVA_MDL_A_01136529	TEVA_MDL_A_01136562		
P-25415	9/19/2017	Fentora Scenario Resource Cards	TEVA_MDL_A_01150310	TEVA_MDL_A_01150316		
P-25434	6/3/2015	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_CA_SF_0000401	Anda_Opioids_CA_SF_0000402		
P-25437	6/12/2015	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_CA_SF_0000399	Anda_Opioids_CA_SF_0000400		
P-25438	6/22/2015	Information Request	Anda_Opioids_CA_SF_0000396	Anda_Opioids_CA_SF_0000398		
P-25439	6/22/2015	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_CA_SF_0000394	Anda_Opioids_CA_SF_0000395		
P-25441	6/23/2015	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_CA_SF_0000458	Anda_Opioids_CA_SF_0000459		
P-25463	10/22/2012	Fentora Brand Meeting Powerpoint	TEVA_MDL_A_00881566	TEVA_MDL_A_00881573		
P-25464	8/12/2013	Fentora Marketing Presentation	TEVA_MDL_A_00881679	TEVA_MDL_A_00881680		
P-25468	1/23/2017	Shipment Tracker	TEVA_MDL_A_01317332	TEVA_MDL_A_01317337		
P-25473	6/29/2015	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_CA_SF_0000460	Anda_Opioids_CA_SF_0000461		
P-25475	7/10/2015	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_CA_SF_0000462	Anda_Opioids_CA_SF_0000463		
P-25476	4/26/2012	Anti-Diversion Walgreens 2012 PPT	WAGFLAG00063627	WAGFLAG00063645		
P-25477	7/20/2015	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_CA_SF_0000465	Anda_Opioids_CA_SF_0000465		
P-25478	7/27/2015	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_CA_SF_0000466	Anda_Opioids_CA_SF_0000467		
P-25479	6/13/2013	FW: Site-visit locations	WAGMDL00021431	WAGMDL00021433		
P-25480	7/30/2015	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_CA_SF_0000486	Anda_Opioids_CA_SF_0000487		

P-25481	6/5/2015	RE: IA - Audit response for B	WAGMDL00062359	WAGMDL00062361		
P-25482	12/20/2012	Target Drug Good Faith Dispensing Policy V2	WAGMDL00066585	WAGMDL00066591		
P-25483	8/5/2015	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_CA_SF_0000488	Anda_Opioids_CA_SF_0000489		
P-25484	8/14/2015	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_CA_SF_0000490	Anda_Opioids_CA_SF_0000491		
P-25485	1/8/2016	Updated List of Customers Not Eligible to Purchase Controls	Anda_Opioids_MDL_0000093041	Anda_Opioids_MDL_0000093042		
P-25486	2/17/2016	Updated List of Customers Not Eligible to Purchase Controls	Anda_Opioids_MDL_0000143242	Anda_Opioids_MDL_0000143243		
P-25487	2/26/2016	Updated List of Customers Not Eligible to Purchase Controls	Anda_Opioids_MDL_0000473073	Anda_Opioids_MDL_0000473074		
P-25488	7/30/2015	Updated List of Customers Not Eligible to Purchase Controls	Anda_Opioids_MDL_0000591615	Anda_Opioids_MDL_0000591616		
P-25489	9/28/2016	RE: SOM documents	WAGMDL00403753	WAGMDL00403756		
P-25490	9/22/2016	RE: number of SOM blocks for the year	WAGMDL00423925	WAGMDL00423928		
P-25491	3/8/2016	Updated List of Customers Not Eligible to Purchase Controls	Anda_Opioids_MDL_0000544532	Anda_Opioids_MDL_0000544532		
P-25492	3/22/2015	Controlled Substance Order Monitoring Process Review Report Final031815	WAGMDL00674320	WAGMDL00674348		
P-25493	2/5/2013	Patty Suspicious Order_pd	WAGMDL00675580	WAGMDL00675580		
P-25494	10/18/1999	Suspicious Controlled Drug report	WAGMDL00751562	WAGMDL00751563		
P-25496	4/6/2015	RE: Dr. Whitecloud	WAGMDL00774369	WAGMDL00774371		
P-25497	2/23/2018	RE: Question	WAGMDL00774438	WAGMDL00774439		
P-25498	10/31/2013	RE: WAG #6574 - GFD concern	WAGMDL00774502	WAGMDL00774509		
P-25499	3/17/2016	Updated List of Customers Not Eligible to Purchase Controls	Anda_Opioids_MDL_0000473079	Anda_Opioids_MDL_0000473080		
P-25500	11/27/2017	RE: Inquiry to Block 2 Physicians	WAGMDL00774755	WAGMDL00774756		
P-25501	5/14/2009	TOP100_By_Rxs_04.2009	WAGMDL00774761	WAGMDL00774768		
P-25502	11/26/2012	Executive Summary - DEA Action Plan	WAGMDL00774769	WAGMDL00774772		
P-25503	12/21/2012	FW: top pbr report	WAGMDL00781632	WAGMDL00781633		
P-25504	4/23/2012	Invitation (delegated): Jupiter Business Continuity Plan: Cardinal Meeting (Apr 26 12:30 PM CDT in Store OPs 1- 200 Building)	WAGMDL00844988	WAGMDL00844998		
P-25505	2/22/2013	RE: Cardinal and DEA/Kaufman Call to Kermit	WAGMDL00851368	WAGMDL00851372		
P-25506	1/28/2013	Good Faith Dispensing Policy - Drug Diversion Self-Education Module	WAGMDL00851511	WAGMDL00851542		
P-25507	3/14/2017	Re: PDQ orders data for C2's	WAGNYNS00009557	WAGNYNS00009561		
P-25509	1/29/2013	DEA Weekly Report	WAGNYNS00032974	WAGNYNS00032975		
P-25510	11/20/2013	RE: Limit Analysis for 427079	WAGNYNS00033400	WAGNYNS00033403		
P-25511	10/8/2013	Data	WAGNYNS00037337	WAGNYNS00037338		
P-25512	2/28/2013	RE: CII Processing Update	WAGNYNS00042370	WAGNYNS00042372		
P-25513	3/2/2020	records request suffolk nassau	WAGNYNS00049768	WAGNYNS00049768		
P-25514	3/13/2020	NY-flagged-orders	WAGNYNS00052075	WAGNYNS00052075		
P-25515	3/10/2020	Research Report V6 Presentation	WAGNYNS00055995	WAGNYNS00056051		
P-25516	6/11/2020	SORs (Nassau and Suffolk)	WAGNYNS00056073	WAGNYNS00056073		
P-25517	5/3/2012	WALGREENS Rx Quick Order Add Items by Item Description AS/400 Steps	WAGFLDEA00000293	WAGFLDEA00000293		
P-25518	10/22/2011	CS Update - FI Prescription Drug Monitoring Program E-FORCSE	WAGFLDEA00000403	WAGFLDEA00000405		
P-25519	2/17/2012	DEA conference	WAGFLDEA00000520	WAGFLDEA00000521		
P-25520	1/14/2011	Ft Pierce	WAGFLDEA00000867	WAGFLDEA00000871		
P-25521	1/28/2011	Rx Numbers - Oviedo FL (Svihra)	WAGFLDEA00000885	WAGFLDEA00000886		
P-25522	2/9/2011	Oviedo FL (Stahmann)	WAGFLDEA00000887	WAGFLDEA00000889		
P-25523	2/11/2011	Oviedo, FL	WAGFLDEA00000890	WAGFLDEA00000890		
P-25524	2/11/2011	Re: Fw: 682971 - OXYCODONE HCL 30MG TAB	WAGFLDEA00000891	WAGFLDEA00000901		
P-25525	4/7/2015	Customer to be Reported	Anda_Opioids_MDL_0000354978	Anda_Opioids_MDL_0000354978		
P-25526	4/14/2011	Re: Store #06997	WAGFLDEA00001032	WAGFLDEA00001033		
P-25527	8/20/2011	FL FOC - Recap of Meeting with DEA (Forbes)	WAGFLDEA00001162	WAGFLDEA00001167		
P-25528	1/12/2012	Re: Fw: Oxycodone fills	WAGFLDEA00001728	WAGFLDEA00001729		
P-25529	9/21/2010	CII-CV Controlled Substances Mini Audit for Jupiter June 10- Aug 10	WAGFLDEA00001747	WAGFLDEA00001766		
P-25530	11/19/2010	Internal Audit Report - DEA Compliance — Jupiter Distribution Center	WAGFLDEA00001767	WAGFLDEA00001775		
P-25531	1/1/2012	Handling Suspicious Orders and Loss of Controlled Drugs	WAGFLDEA00001856	WAGFLDEA00001857		
P-25532	1/22/2011	WAGFLDEA00001314_unitized	WAGFLDEA00001314_unitized	WAGFLDEA00001315_unitized		

P-25533	9/2/2013	WAG/ABDC - First Amendment to the Pharmaceutical Purchase And Distribution Agreement	WAGMDL00000390	WAGMDL00000393		
P-25534	9/1/2013	WAG / ABDC - Second Amendment to the Pharmaceutical Purchase And Distribution Agreement	WAGMDL00000394	WAGMDL00000397		
P-25535	10/1/2014	Settlement Agreement & Fourth Amendment to the Pharmaceutical Purchase And Distribution Agreement	WAGMDL00000402	WAGMDL00000416		
P-25536	8/9/2017	RE: SOM	WAGMDL00006645 WAGMDL00006645	WAGMDL00006669 WAGMDL00006646	WAGMDL00006645 - WAGMDL00006646	
P-25537	4/18/2018	Accounts to be Reported	Anda_Opioids_MDL_0000324754	Anda_Opioids_MDL_0000324754		
P-25538	11/13/2014	RE: Rex Deck - almost complete	WAGMDL00015270	WAGMDL00015286		
P-25539	8/21/2015	Updated List of Customer Not Eligible to Purchase Controls from Anda	Anda_Opioids_MDL_0000465222	Anda_Opioids_MDL_0000465223		
P-25540	7/3/2013	Powerpoint for this morning's meeting	WAGMDL00021351	WAGMDL00021361		
P-25541	8/25/2015	Updated List of Customer Not Eligible to Purchase Controls from Anda	Anda_Opioids_MDL_0000465220	Anda_Opioids_MDL_0000465221		
P-25542	4/4/2013	Re: Thought from the Project forest meetings	WAGMDL00021479	WAGMDL00021479		
P-25543	4/17/2013	RE: ABC Threshold Analysis	WAGMDL00021613	WAGMDL00021616		
P-25544	9/2/2015	Updated List of Customer Not Eligible to Purchase Controls from Anda	Anda_Opioids_CA_SF_0000501	Anda_Opioids_CA_SF_0000502		
P-25545	5/2/2013	CDC Data Project	WAGMDL00030705	WAGMDL00030705		
P-25546	4/23/2018	Silence the Stigma: Opioid Use Disorder and Addressing Stigma Walgreen Co./Purdue University College of Pharmacy	WAGMDL00035669	WAGMDL00035683		
P-25547	6/7/2017	RE: Drug Takeback Program	WAGMDL00038786	WAGMDL00038791		
P-25548	12/15/2015	FW: RxIC Approvals Requested	WAGMDL00042452	WAGMDL00042464		
P-25549	9/16/2015	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_MDL_0000143252	Anda_Opioids_MDL_0000143253		
P-25550	10/2/2015	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_MDL_0000143250	Anda_Opioids_MDL_0000143251		
P-25551	8/12/2016	RE: Media Inquiry, Bakersfield Californian by Noon PT tomorrow	WAGMDL00044770	WAGMDL00044773		
P-25552	2/22/2013	RE: Cardinal Health/Walgreens QRA Discussion	WAGMDL00049750	WAGMDL00049751		
P-25553	2/10/2017	RE: Approved Controlled Substance Order for store 16559	WAGMDL00056871	WAGMDL00056877		
P-25554	7/2/2015	RE: C-2 order	WAGMDL00059074	WAGMDL00059081		
P-25555	3/1/2013	FW: Market leadership presentation	WAGMDL00060739	WAGMDL00060767		
P-25556	3/9/2018	FW: EDI OMIT Codes	WAGMDL00060931	WAGMDL00060933		
P-25557	1/30/2016	Re: Policy Question	WAGMDL00062061	WAGMDL00062061		
P-25558	11/13/2017	RE: Requesting your support for AMCP Day of Education - CE documentation	WAGMDL00064176	WAGMDL00064186		
P-25559	6/30/2017	Multi Wholesaler Options	WAGMDL00076693	WAGMDL00076695		
P-25560	11/25/2015	FW: CSOS Received Quantity Touch Base	WAGMDL00079943	WAGMDL00079946		
P-25561	2/27/2014	RE: DEA Publishes Proposal to Reschedule Hydrocodone	WAGMDL00085856	WAGMDL00085858		
P-25562	3/25/2013	FW: Controlled Substance Order Quantity Override Form	WAGMDL00092708	WAGMDL00092709		
P-25563	8/14/2013	RE: Controlled Substance Order Quantity Override Form	WAGMDL00095568	WAGMDL00095569		
P-25564	8/13/2012	RE: Controlled Substance Order Quantity Override Form	WAGMDL00101703	WAGMDL00101706		
P-25565	2/8/2013	RE: 11137 generic lortab	WAGMDL00101769	WAGMDL00101770		
P-25566	11/12/2012	RE: GFD Audit for store 2865 in Modesto, CA	WAGMDL00102390	WAGMDL00102392		
P-25567	2/14/2013	Reports for DEA	WAGMDL00102645	WAGMDL00102648		
P-25568	4/11/2013	FW: Controlled Substance Order Quantity Override Form	WAGMDL00106910	WAGMDL00106912		
P-25569	12/26/2012	RE: Controlled Substance Order Quantity Override Form	WAGMDL00107173	WAGMDL00107177		
P-25570	12/31/2012	FW: RxIntegrity Investigation for store 05814	WAGMDL00107267	WAGMDL00107271		
P-25571	10/31/2012	FW: Controlled Substance Order Quantity Override Form	WAGMDL00107384	WAGMDL00107386		
P-25572	8/23/2012	FW: Controlled Substance Order Quantity Override Form	WAGMDL00107468	WAGMDL00107469		
P-25573	8/15/2012	FW: Controlled Substance Order Quantity Override Form	WAGMDL00107473	WAGMDL00107474		
P-25574	10/12/2012	FW: Walgreens 04243	WAGMDL00107497	WAGMDL00107500		
P-25575	1/31/2013	FW: Norco 7.5- 7158	WAGMDL00107557	WAGMDL00107564		
P-25576	1/31/2013	District 200 Hydrocodone 7.5-325 purchases	WAGMDL00107565	WAGMDL00107565		
P-25577	11/13/2012	RE: can I see an example of what you faxed to DEA	WAGMDL00107582	WAGMDL00107584		
P-25578	3/1/2017	RE: Opioid Medical Policy	WAGMDL00108483	WAGMDL00108485		
P-25579	9/21/2017	RE: Controlled Substance Order Quantity Override Requests	WAGMDL00110737	WAGMDL00110738		
P-25580	10/5/2012	RE: oxycodone	WAGMDL00127695	WAGMDL00127695		
P-25581	8/10/2017	RE: C2 NDC - missing SOM limit	WAGMDL00128748	WAGMDL00128750		

P-25582	8/10/2017	Not_in_SOM	WAGMDL00128751	WAGMDL00128751		
P-25583	12/13/2016	Meeting Minutes - DMIT 1232 - 340B Consider DEA Limits - 12/13/2016	WAGMDL00129005	WAGMDL00129007		
P-25584	7/8/2016	RE: INCO00016708337: Raised for 340B ordering	WAGMDL00129607	WAGMDL00129610		
P-25585	3/13/2013	FW: Perrysburg C-II In-Stock Status	WAGMDL00131602	WAGMDL00131602		
P-25586	8/9/2012	FW: Controlled Substance Order Quantity Override Form	WAGMDL00132758	WAGMDL00132759		
P-25587	8/16/2017	CD orders- 2	WAGMDL00183798	WAGMDL00208716		
P-25589	10/12/2016	Purdue Compass communication - review requested	WAGMDL00234555	WAGMDL00234559		
P-25590	10/14/2015	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_MDL_0000335062	Anda_Opioids_MDL_0000335063		
P-25592	3/6/2013	Red Flag to consider in the reponses	WAGMDL00237599	WAGMDL00237605		
P-25593	9/22/2014	RE: HCP Formulary Items	WAGMDL00244813	WAGMDL00244815		
P-25594	4/8/2013	New Hire Docs	WAGMDL00245867	WAGMDL00245920		
P-25595	10/19/2015	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_AL_DCH_0006500	Anda_Opioids_AL_DCH_0006503		
P-25596	10/22/2015	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_AL_DCH_0006509	Anda_Opioids_AL_DCH_0006510		
P-25597	11/2/2015	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_MDL_0000143248	Anda_Opioids_MDL_0000143249		
P-25598	11/27/2015	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_MDL_0000546265	Anda_Opioids_MDL_0000546266		
P-25599	11/30/2015	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_MDL_0000093575	Anda_Opioids_MDL_0000093576		
P-25600	10/1/2012	FW: OXYCODONE no longer being ordered via PDQ	WAGMDL00252575	WAGMDL00252576		
P-25601	8/19/2013	FW: ABC Call Recap Attachment ABC Store Visit Recap 7-16-13	WAGFLAG00001076	WAGFLAG00001078		
P-25602	7/25/2018	Merch SC Logistics Org Chart 7.24.18.vsd	WAGMDL00254645	WAGMDL00254648		
P-25603	12/23/2013	RE: A Painful Dilemma	WAGMDL00267660	WAGMDL00267667		
P-25604	9/25/2012	PDQ letter	WAGMDL00278104	WAGMDL00278104		
P-25605	10/5/2012	FW: WAGs Line Limit C2 orders	WAGMDL00278108	WAGMDL00278111		
P-25606	1/15/2013	RE: Tableau overview; Prescriber Dashboard User Guide	WAGFLAG00002633	WAGFLAG00002641		
P-25607	5/6/2013	FW: ARCOS error Reports that need Correction	WAGMDL00282342	WAGMDL00282345		
P-25608	11/28/2012	FW: DEA SERVES ORDER TO SHOW CAUSE TO THREE WALGREENS PHARMACIES	WAGMDL00282353	WAGMDL00282354		
P-25609	10/22/2012	RE: Prescriber Leonard Haimes	WAGFLAG00007433	WAGFLAG00007435		
P-25610	8/1/1997	ARCOS Registrant Handbook - V 1.0 (1997) DEA ARCOS Registrant Handbook	WAGMDL00282650	WAGMDL00282841		
P-25611	1/13/2017	RE: CSOS Lock & Load	WAGMDL00282973	WAGMDL00282981		
P-25612	4/1/2013	RE: 340B	WAGMDL00284079	WAGMDL00284080		
P-25613	4/17/2013	CII Program Letter	WAGMDL00286210	WAGMDL00286212		
P-25614	4/1/2008	Purchase Agmt for Wag Facilities 4-1-08 ABDC	WAGMDL00286213	WAGMDL00286243		
P-25615	4/3/2013	Pharmaceutical Integrity Biosx	WAGMDL00289186	WAGMDL00289188		
P-25616	2/17/2015	FW: Rx Integrity Internal Audit	WAGMDL00299885	WAGMDL00299888		
P-25617	4/8/2013	FW: Blocking interstore transfers	WAGMDL00302946	WAGMDL00302947		
P-25618	3/20/2013	FW: Cardinal Red Store Status	WAGMDL00303186	WAGMDL00303187		
P-25619	2/15/2013	FW: draft communication	WAGMDL00303243	WAGMDL00303245		
P-25620	1/22/2016	RE: Integrity Info Request Attachment Non-dispensing Pharmacist report for Jackie Donovan	WAGFLAG00024322	WAGFLAG00024324		
P-25621	5/22/2014	RE: GFD Comments	WAGFLAG00028501	WAGFLAG00028502		
P-25622	6/25/2012	Audit / Board of Pharmacy Inspection Report	WAGFLAG00069878	WAGFLAG00069880		
P-25623	7/17/2017	RE: National TD GFD policy powerpoint; Stover- DM deck	WAGMDL00002899	WAGMDL00002909		
P-25624	9/12/2013	RE: Cocktail example; Dur	WAGMDL00021191	WAGMDL00021193		
P-25625	7/26/2017	FW: REMINDER: (ACTION REQUIRED) PF Presentation Materials Attachment PF August 2017 PSTB Rx Integrity PPT	WAGMDL00033704	WAGMDL00033713		
P-25626	2/7/2018	RE: Advice on Dr issue	WAGMDL00042038	WAGMDL00042039		
P-25627	9/14/2016	RE: scanning ID question	WAGMDL00057261	WAGMDL00057263		
P-25628	6/6/2012	FW: Controlled Substance Order Quantity Override Process	WAGMDL00308178	WAGMDL00308181		
P-25629	10/10/2013	Email Market 20 Attachment Market 20 (1) PPT	WAGMDL00060489	WAGMDL00060506		
P-25630	12/14/2012	Draft 1 SOM war room process 12 14 12	WAGMDL00308192	WAGMDL00308212		

P-25631	10/22/2012	Email GFD PPT; Attachments Controlled Substance Action Plan (Market / District Leaders Version); Controlled Substance Action Plan (Stores Version)	WAGMDL00066600	WAGMDL00066630		
P-25632	10/19/2012	WAG SOM	WAGMDL00308265	WAGMDL00308266		
P-25633	4/20/2018	RE: Concern at 2670 RE: PA-C Leinweber	WAGMDL00090034	WAGMDL00090036		
P-25634	1/14/2013	FW: Review application screens and proposed changes to make navigation easier	WAGMDL00308327	WAGMDL00308349		
P-25635	8/28/2017	RE: Joseph Sierra	WAGMDL00090935	WAGMDL00090936		
P-25636	1/3/2018	RE: Dr. Gary Heath	WAGMDL00091443	WAGMDL00091444		
P-25637	10/28/2017	Re: Local MD under ACTIVE investigation - Please advise	WAGMDL00091641	WAGMDL00091642		
P-25638	6/4/2018	RE: Dr. Behzad Aalaei	WAGMDL00091654	WAGMDL00091655		
P-25639	12/28/2012	SIMS compass communication	WAGMDL00308497	WAGMDL00308498		
P-25640	2/16/2015	RE: Rx Integrity Internal Audit	WAGMDL00312091	WAGMDL00312093		
P-25641	12/3/2012	Review application screens and proposed changes to make navigation easier	WAGMDL00314367	WAGMDL00314389		
P-25642	5/8/2015	FW: CVS and Dr Alexander in Seymour	WAGMDL00094723	WAGMDL00094726		
P-25643	6/3/2015	FW: DR WITH OXY	WAGMDL00094759	WAGMDL00094760		
P-25644	1/22/2015	Re: CVS refusing scripts from Comprehensive Pain and Headache Treatment Center	WAGMDL00094838	WAGMDL00094839		
P-25645	7/25/2013	Re: DEA	WAGMDL00095830	WAGMDL00095831		
P-25646	4/9/2018	RE: Kiosk Questions	WAGMDL00315889	WAGMDL00315904		
P-25647	3/21/2013	RE: Dr. Kotsonis	WAGMDL00100077	WAGMDL00100079		
P-25648	3/15/2017	RE: INFO: Dr. William Logan GFD Concerns	WAGMDL00103452	WAGMDL00103456		
P-25649	6/28/2012	FW: czar doc from S. Thoss	WAGMDL00317097	WAGMDL00317098		
P-25650	5/17/2016	RE: GFD Policy	WAGMDL00104540	WAGMDL00104541		
P-25651	1/8/2013	Prescriber Sanctioning Documents; Official Prescriber Sanction Letter; Sanctioned Prescriber Compass Communication; Prescriber Sanctioning FAQ	WAGMDL00297386	WAGMDL00297390		
P-25652	3/12/2013	Email previous ppt Attachments TD GFDP_webinar v6 PPT; Questions TD GFD from pilot	WAGMDL00303474	WAGMDL00303514		
P-25653	8/5/2014	RE: GFD report criteria; Market 7 Overview	WAGMDL00310337	WAGMDL00310371		
P-25654	10/12/2012	2012 Powerpoint: System Considerations - Computer Models, Algorithms, Statistics and More	WAGMDL00319188	WAGMDL00319202		
P-25655	5/24/2012	Email Sorry this is so late....Attachments District Checklist for CII plus 2 Removal vF; Store Action Plan CII Plus Two vF	WAGMDL00317139	WAGMDL00317155		
P-25656	1/30/2014	RE: Early Refill DUR for C2-C5 - Follow-up questions	WAGMDL00329835	WAGMDL00329836		
P-25657	4/26/2013	RE: Communication Regarding C2 Transition	WAGMDL00324902	WAGMDL00324905		
P-25658	5/7/2008	Re: Fw: Pharmacy Shrink Task Force	WAGMDL00324911	WAGMDL00324914		
P-25659	8/28/2015	"Compliance with Compassion" - FL DM Good Faith Dispensing Training V4	WAGMDL00389199	WAGMDL00389211		
P-25660	3/27/2009	Re: Revised Suspicious Order Document	WAGMDL00325368	WAGMDL00325378		
P-25661	3/2/2016	RE: Prescriber issue, C Morgan, McMinnville	WAGMDL00404572	WAGMDL00404575		
P-25662	4/29/2015	cocktails; Federal Register - Vol. 77 No. 198, Part II - Holiday CVS, L.L.C., d/b/a CVS/Pharmacy Nos. 219 and 5195; Decision and Order and Denial of Request for Redactions; Notices	WAGMDL00405921	WAGMDL00405954		
P-25663	5/29/2013	FW: Revised Draft Presentation	WAGMDL00330437	WAGMDL00330443		
P-25664	3/10/2014	FW: GFD; Prescriber Profile Dr Frank Ling	WAGMDL00412285	WAGMDL00412289		
P-25665	5/16/2014	Re: Potential Mail order rule for controlled drugs in Ohio	WAGMDL00333310	WAGMDL00333313		
P-25666	3/9/2018	Email RxIC Prescriber & DEA Projects Attachments RxIC RelayHealth COB Blocking 3-1-18 PPT; RxIC Master Prescriber System Updates 3-1-18 PPT; RxIC LexisNexis Master File Migration 3-1-18 PPT; RxIC LexisNexis - Master Prescriber 1-2-18 PPT; RxIC LexisNexis Prescriber Pilot 11-6-17 PPT; RxIC Cover Sheet - Prescriber DEA Block Message PPT	WAGMDL00422308	WAGMDL00422321		
P-25667	8/10/2012	RE: NACDS Pharmacy Operations Committee -- Action Requested: DEA Interim Solution	WAGMDL00334305	WAGMDL00334308		
P-25668	2/18/2013	Email New Enhancement Attachment Mail Controlled Substance Early Refills	WAGMDL00437787	WAGMDL00437793		
P-25669	2/27/2013	Perrysburg CIII-CV - follow up	WAGMDL00335835	WAGMDL00335837		
P-25670	12/2/2013	RE: Controlled Substance Special Order	WAGMDL00336103	WAGMDL00336106		

P-25671	2/20/2013	Re: Perrysburg CIII-CV - follow up	WAGMDL00357519	WAGMDL00357520		
P-25672	3/19/2015	TG Responsibilities; Rx Integrity Tools Reports	WAGMDL00442473	WAGMDL00442477		
P-25673	2/21/2013	Re: Perrysburg CIII-CV - follow up	WAGMDL00357543	WAGMDL00357548		
P-25674	2/26/2013	RE: Perrysburg CIII-CV - follow up	WAGMDL00358459	WAGMDL00358462		
P-25675	3/22/2013	Re: Perrysburg CIII-CV - follow up	WAGMDL00358555	WAGMDL00358557		
P-25676	4/4/2013	Re: C2 Customer List WAG Perrysburg Start 4.9.13 WAG225+3	WAGMDL00358567	WAGMDL00358570		
P-25677	8/10/2017	RE: question about reporting offices	WAGMDL00489440	WAGMDL00489441		
P-25678	4/9/2013	RE: Walgreens Woodland Data - Red Stores	WAGMDL00358578	WAGMDL00358580		
P-25679	2/13/2012	Quarterly DEA "Meeting Minutes" - February 10, 2012	WAGMDL00358746	WAGMDL00358750		
P-25680	1/3/2018	RE: Dr. Gary Heath	WAGMDL00490069	WAGMDL00490070		
P-25681	10/19/2017	RE: Rx from Dr David M Kowal	WAGMDL00490225	WAGMDL00490226		
P-25682	4/5/2016	RE: Doctor that May Need Investigation	WAGMDL00490674	WAGMDL00490675		
P-25683	12/22/2011	340B Discussion	WAGMDL00363134	WAGMDL00363144		
P-25684	4/17/2018	FW: Prescriber Verification; RE: Controls BY MD	WAGMDL00495182	WAGMDL00495186		
P-25685	4/25/2014	RE: MDP/MVP videoconference Attachment Good Faith Dispensing Western Op V2 PPT	WAGMDL00576462	WAGMDL00576465		
P-25686	11/6/2012	DEA Validation Procedures for Good Faith Dispensing of Controlled Substances	WAGMDL00582966	WAGMDL00582966		
P-25687	11/12/2013	FW: CII orders	WAGMDL00363660	WAGMDL00363663		
P-25689	6/27/2013	Compliance Issues	WAGMDL00363749	WAGMDL00363750		
P-25690	9/18/2014	Analytics Metadata Survey and Interviews POC Report - Dave Jennings PPT	WAGMDL00672069	WAGMDL00672081		
P-25691	3/19/2013	RE: January 2013 ARCOS Report Transmission Issue	WAGMDL00363767	WAGMDL00363770		
P-25692	8/14/2013	RE: Arcos 7 Type for this month	WAGMDL00364632	WAGMDL00364633		
P-25693	7/17/2017	RE: BCBSA   Walgreens Catch Up re: Follow Ups and Next Steps	WAGMDL00374710	WAGMDL00374719		
P-25694	8/19/2014	Market 5 GFD and Controlled Substance Trends PPT	WAGMDL00672331	WAGMDL00672358		
P-25695	11/2/2016	FW: Drug Take Back Program	WAGMDL00375070	WAGMDL00375071		
P-25696	10/15/2012	IMS Pilot demonstration - updated with presentation materials provided by IMS Calendar or Calendar; CS Ratings - WAG WB; IMS CS Ratings Offering WAG PILOT	WAGMDL00677965	WAGMDL00678016		
P-25697	6/19/2018	RE: Policy Papers and Direction	WAGMDL00376065	WAGMDL00376072		
P-25699	1/8/2013	GFDP - Top 500 Potential Stores	WAGMDL00700278	WAGMDL00700278		
P-25700	10/11/2013	Market Leadership Meeting Oct 13 v11Edit	WAGMDL00708570	WAGMDL00708593		
P-25701	3/30/2016	RE: Safe disposal Joint Op-ed 3 15 16 930p et	WAGMDL00377962	WAGMDL00377967		
P-25702	4/30/2013	Market 22 Leadership Meeting	WAGMDL00708605	WAGMDL00708624		
P-25703	6/13/2016	NACDS Take Back Policy Strategy--Thoughts?	WAGMDL00378634	WAGMDL00378639		
P-25704	11/29/2012	November legal issues	WAGMDL00741585	WAGMDL00741586		
P-25705	2/2/2018	RE: A request	WAGMDL00774440	WAGMDL00774443		
P-25706	10/22/2015	FW: DSN A.M. - Obama announces massive push to curb opioid abuse, heroin use	WAGMDL00383497	WAGMDL00383700		
P-25707	12/18/2012	Rx Advisor Approval Meeting; RCA Approval Minutes; Front Door-Cap Block request form v8 fv-DEA Sanctioned Presc; DEA Sanctioned Presc - screen; Blocks Per Store Per Day	WAGMDL00782363	WAGMDL00782367		
P-25708	3/10/2010	Email DUR documentation for early refill of controlled substances Attachment Controlled Substance Early Refill PPT	WAGMDL00784104	WAGMDL00784116		
P-25709	5/21/2018	FW: great to meet you- Disposal RX getting with Walgreens	WAGMDL00384341	WAGMDL00384357		
P-25710	2/25/2015	RE: GFD question	WAGMDL00799324	WAGMDL00799324		
P-25711	1/12/2015	FW: Doctor issue	WAGMDL00801881	WAGMDL00801882		
P-25712	4/30/2019	RE: Discovery Session - GFD 2.0 Compliance Project; Calculating Total Daily Dose of Opioids For Safer Dosage; Target Drug Good Faith Dispensing Checklist; Controlled Substance Prescriptions & Good Faith Dispensing Policy; Target Drug Good Faith Dispensing Policy; DEA CS Training Tool	WAGMDL00859484	WAGMDL00859521		
P-25713	9/20/2017	RE: WSB Following up CRM:0167829	WAGMDL00385105	WAGMDL00385110		
P-25714	8/14/2017	Re: For 5 pm call	WAGMDL00385259	WAGMDL00385260		
P-25715	10/31/2017	FW: [EXTERNAL] Re: Joint Industry Letter - Edited Version	WAGMDL00385788	WAGMDL00385789		
P-25716	10/30/2017	LETTER ON PHARMACY INDUSTRY JOINT EFFORT TO ADDRESS AND HELP PREVENT OPIOID MISUSE AND ABUSE	WAGMDL00385790	WAGMDL00385791		
P-25717	10/23/2017	Draft SP statement for WH event	WAGMDL00385895	WAGMDL00385896		
P-25718	10/23/2017	WAG statement WH opioid event 10-23-17 3 pm draftx	WAGMDL00385897	WAGMDL00385897		



P-25719	11/14/2012	Resp't 226: DEA website printout, Knowing Your Customer/Suspicious Orders Reporting	WAGMDL00387625	WAGMDL00387628		
P-25720	7/18/2012	Resp't 237-E - Loss Prevention Org Chart	WAGMDL00387633	WAGMDL00387634		
P-25721	12/20/2012	Email Target Drug GFD V2 (qty increased) documents Attachments Target Drug Good Faith Dispensing Policy; Target Drug Good Faith Dispensing Policy	WAGMDL00862209	WAGMDL00862214		
P-25722	2/3/2014	RE: R69 "What's New" Webinar; What's New in Intercom Plus Release 69	WAGMDL00862251	WAGMDL00862289		
P-25723	8/6/2007	2007-8 DC13 Page 000261	WAGMDL00390362	WAGMDL00390363		
P-25724	11/1/2012	Controlled Substances Ordering - Evolution of Controlled Substance Ordering Process AND SOM Policy and Procedures	WAGMDL00395923	WAGMDL00395936		
P-25725	2/20/2012	Resp 259-B - Controlled Substance Reporting	WAGMDL00395937	WAGMDL00395964		
P-25726	6/29/2016	Pharmacy Losses Dashboard: HRxD	WAGMDL00878535	WAGMDL00878535		
P-25727	4/6/2012	Resp't 259-C Functional Requirements & (Macro) Design DEA Suspicious Ordering - Phase III (Controlled Substance Threshold) Project Number W0018238 Resp't Exhibit 259-C - DEA Suspicious Ordering - Phase III v.1.1	WAGMDL00400342	WAGMDL00400356		
P-25728	2/28/2013	FW: CII Processing Update	WAGMDL00407724	WAGMDL00407726		
P-25729	5/24/2013	Re: current red store list	WAGMDL00413949	WAGMDL00413950		
P-25730	3/1/2016	RE: Prescriber issue, C Morgan, McMinnville	WAGMDL00414646	WAGMDL00414648		
P-25731	11/15/2012	Anderson DEA Fax template Jupiter DEA Fax Template Perrysburg DEA Fax Template Waxahachie DEA Fax Template Woodland DEA Fax Template Mt Vernon DEA Fax Template	WAGMDL00415363	WAGMDL00415368		
P-25733	3/18/2013	FW: District Leader Meeting - March 18th, 2013	WAGMDL00890004	WAGMDL00890006		
P-25734	10/7/2012	DEA Update; DEA Board Briefing Document	WAGMDL00897151	WAGMDL00897153		
P-25736	11/14/2013	RE: Kerr Drug Phase 2 and 3 Training; USA Pharmacy Training Program Guide03252013 MERGED	WAGMDL00913492	WAGMDL00913538		
P-25737	5/30/2012	FW: Meeting Notes to Outline new Procedures for DCs	WAGMDL00429424	WAGMDL00429426		
P-25738	11/27/2012	RE: 11/21 OSC Release: Audit Spurs Improvements At Health Department's Bureau of Narcotic Enforcement	WAGMDL00440895	WAGMDL00440897		
P-25739	7/2/2012	FW: PMP pilots in IN & OH	WAGMDL00441530	WAGMDL00441537		
P-25740	2/5/2013	Quarterly DEA Agenda for Feb 6th 10 a.m. and Meeting Minutes from November 15th; Quarterly November 15th 2012 Meeting Minutes Quarterly February 6th 2013 Meeting Agenda	WAGMDL00451632	WAGMDL00451636		
P-25741	4/28/2019	RE: GFD 2.0 Compliance project; GFD 2.0 - Clinical GFD DUR	WAGMDL00918327	WAGMDL00918344		
P-25742	5/2/2014	FW: Webinar; What's New in Intercom Plus Release 70	WAGMDL00922086	WAGMDL00922124		
P-25743	10/14/2012	Re: verifying pbr in GFD	WAGMDL00931151	WAGMDL00931151		
P-25744	3/2/2012	FW: IC+ R65 Executive Summary; Intercom Plus Release 65 Executive Summary; JUNK	WAGMDL00973902	WAGMDL00973904		
P-25745	2/12/2013	FW: CSOS Phase II ?	WAGMDL00478001	WAGMDL00478002		
P-25746	2/12/2013	RE: CSOS Phase II ?	WAGMDL00478056	WAGMDL00478057		
P-25747	7/26/2012	FW: DEA Meeting Minutes July 25, 2012	WAGMDL00482264	WAGMDL00482266		
P-25748	1/31/2012	INFO: Western Division Update 2.25.12	WAGMDL00974031 WAGMDL00974032 WAGMDL00974050	WAGMDL00974215 WAGMDL00974035 WAGMDL00974088	WAGMDL00974032 - WAGMDL00974035; WAGMDL00974050 - WAGMDL00974088	
P-25749	6/11/2013	FW: WALGREENS AGREES TO PAY A RECORD SETTLEMENT OF \$80 MILLION FOR CIVIL PENALTIES UNDER THE CONTROLLED SUBSTANCES ACT	WAGMDL00485056	WAGMDL00485058		
P-25751	6/7/2016	RE: Your part of the Request List Prime	WAGMDL00987026	WAGMDL00987192	WAGMDL00987026 - WAGMDL00987192	
P-25752	11/20/2015	Retail Hub Portfolio Update: Week Ending 11-20; Retail Hub Weekly Portfolio Update	WAGMDL01043245	WAGMDL01043355		
P-25753	10/30/2019	Business Outcomes and Capabilities for GFD 2.0 Phase 2; GFD 2.0 Process Flow- IT Discovery	WAGMDL01064499	WAGMDL01064516		
P-25754	9/13/2016	FW: Update: Good Faith and Target Good Faith Dispensing Policies Reminder	WAGMDL01108982	WAGMDL01108983		

P-25755	9/25/2012	RE: Please create these 2 lists; Ad-hoc reports - 09242012	WAGMDL01133018	WAGMDL01133020		
P-25756	7/30/2018	RE: Suspicious Prescribing Habits	WAGNYNS00020842	WAGNYNS00020844		
P-25757	3/22/2012	Fw: Pharmacy Diversion Awareness Conference held by the DEA	WAGFLDEA00000609	WAGFLDEA00000610		
P-25758	3/22/2016	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_MDL_0000473077	Anda_Opioids_MDL_0000473078		
P-25759	3/23/2016	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_MDL_0000091887	Anda_Opioids_MDL_0000091888		
P-25760	5/14/2008	2008 DEA Quarterly Meetings	WAGMDL00491150	WAGMDL00491152		
P-25761	8/2/2012	Requirements	WAGMDL00491251	WAGMDL00491258		
P-25762	2/1/2009	Intercepted /Suspicious Store Orders Project #: P99999 Version 1.0	WAGMDL00491863	WAGMDL00491877		
P-25763	3/13/2009	Controlled Substance Threshold Project #: P09002	WAGMDL00491896	WAGMDL00491912		
P-25764	4/20/2009	MICRO-ORPB305	WAGMDL00491918	WAGMDL00491923		
P-25765	6/1/2009	P09002 - Macro Design	WAGMDL00491961	WAGMDL00491989		
P-25766	3/25/2016	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_MDL_0000091885	Anda_Opioids_MDL_0000091886		
P-25767	5/5/2016	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_MDL_0000473069	Anda_Opioids_MDL_0000473070		
P-25768	10/6/2015	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_CA_SF_0000492	Anda_Opioids_CA_SF_0000495		
P-25769	5/30/2006	Suspicious Orders Week Ending 5-21-06	Anda_Opioids_MDL_0000271813	Anda_Opioids_MDL_0000271815		
P-25770	8/3/2012	Customers Cut Off	Anda_Opioids_CA_SF_0041880	Anda_Opioids_CA_SF_0041882		
P-25771	8/10/2012	Customers Cut Off	Anda_Opioids_CA_SF_0042894	Anda_Opioids_CA_SF_0042896		
P-25772	8/31/2012	Customers Cut Off	Anda_Opioids_CA_SF_0040202	Anda_Opioids_CA_SF_0040204		
P-25773	9/14/2012	Customers Cut Off	Anda_Opioids_CA_SF_0072913	Anda_Opioids_CA_SF_0072914		
P-25774	9/26/2012	Customers Cut Off	Anda_Opioids_CA_SF_0072703	Anda_Opioids_CA_SF_0072704		
P-25775	6/24/2008	DEA Intercept Suspicious Order	WAGMDL00492032	WAGMDL00492037		
P-25776	9/25/2009	P09002 Threshold Controlled Substance MACRO Design II DEA Suspicious Ordering	WAGMDL00492038	WAGMDL00492066		
P-25777	10/23/2012	Customers Cut Off	Anda_Opioids_CA_SF_0041990	Anda_Opioids_CA_SF_0041992		
P-25778	4/14/2016	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_MDL_0000532845	Anda_Opioids_MDL_0000532845		
P-25779	5/18/2016	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_MDL_0000543145	Anda_Opioids_MDL_0000543146		
P-25780	5/19/2016	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_MDL_0000543143	Anda_Opioids_MDL_0000543144		
P-25781	6/10/2016	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_MDL_0000036692	Anda_Opioids_MDL_0000036693		
P-25782	6/16/2016	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_MDL_0000036681	Anda_Opioids_MDL_0000036682		
P-25783	7/19/2016	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_MDL_0000036015	Anda_Opioids_MDL_0000036016		
P-25784	9/23/2016	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_MDL_0000621302	Anda_Opioids_MDL_0000621302		
P-25785	1/16/2018	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_MDL_0000012941	Anda_Opioids_MDL_0000012941		
P-25786	10/1/2009	DEA Suspicious Order Item Part II - Phase II	WAGMDL00492070	WAGMDL00492072		
P-25787	2/1/2009	Controlled Substance Threshold Project #: P09002 Version 1.0	WAGMDL00492132	WAGMDL00492152		
P-25788	10/31/2012	Customer Cut Off	Anda_Opioids_CA_SF_0066967	Anda_Opioids_CA_SF_0066968		
P-25789	8/30/2011	DEA Statistics Aug.2011x	WAGMDL00492169	WAGMDL00492169		
P-25790	1/26/2012	DEA Metrics Validation - Systems Order Cut/Reduced	WAGMDL00492178	WAGMDL00492183		
P-25791	11/8/2012	Customer Cut Off	Anda_Opioids_CA_SF_0041023	Anda_Opioids_CA_SF_0041025		
P-25792	2/22/2012	ORPB306 updated V1 3	WAGMDL00492209	WAGMDL00492211		
P-25793	11/23/2011	DEA Phase III - Questions & Comments2	WAGMDL00492375	WAGMDL00492376		
P-25794	9/23/2011	DEA Phase III - Questions & Comments	WAGMDL00492378	WAGMDL00492380		
P-25795	6/5/2006	Project Request Form - Stores	WAGMDL00493647	WAGMDL00493648		
P-25796	8/10/2015	20150810 Hensley Email re DEA Chemical Application More Info	WAGMDL00493727	WAGMDL00493729		
P-25797	8/2/2012	CLAAD Policy Brief, July 31, 2012	WAGMDL00515588	WAGMDL00515589		
P-25798	9/25/2012	RE: APHA information request for FDA hydrocodone meeting	WAGMDL00517021	WAGMDL00517023		

P-25799	9/10/2012	RE: APhA information request for FDA hydrocodone meeting	WAGMDL00517040	WAGMDL00517044		
P-25800	2/18/2013	Perrysburg Plan - week of 2/18.	WAGMDL00524429	WAGMDL00524430		
P-25801	2/28/2013	RE: CII Processing Update	WAGMDL00524815	WAGMDL00524817		
P-25802	4/3/2013	FW: CII transition plan document	WAGMDL00525116	WAGMDL00525119		
P-25803	6/13/2013	FW: Ordering Issues - Controlled Substances	WAGMDL00240837	WAGMDL00240842		
P-25804	3/26/2013	FW: Perrysburg Accelerated C2 Plan	WAGMDL00528072	WAGMDL00528073		
P-25805	3/8/2013	RE: Dear Colleague on Safe Prescribing Act of 2013	WAGMDL00533039	WAGMDL00533041		
P-25806	2/28/2013	CII jobber list & Red flag Store list for Perrysburg	WAGMDL00541412	WAGMDL00541412		
P-25807	2/19/2013	MOA	WAGMDL00574919	WAGMDL00574926		
P-25808	N/A	RX Sales by store	WAGMDL00851845	WAGMDL00851845		
P-25809	3/19/2013	RE: Questions from 3/18 District Leader meeting	WAGMDL00574927	WAGMDL00574930		
P-25810	6/12/2013	FW: Final MOA/Compliance Addendum	WAGMDL00575931	WAGMDL00575934		
P-25811	N/A	Transactional Data	WAGMDL00851846	WAGMDL00851846		
P-25812	1/25/2013	Status	WAGMDL00577118	WAGMDL00577119		
P-25813	N/A	Ohio Ceiling Override Data	WAGMDL00852037	WAGMDL00852037		
P-25814	4/10/2012	RE: Update - Response From HealthCare LP	WAGMDL00580316	WAGMDL00580318		
P-25815	4/6/2012	FW: Update	WAGMDL00580319	WAGMDL00580320		
P-25816	5/30/2013	FW: Stores (#3629, #4727, #6997, #3836, #4391 and #3099)	WAGMDL00583296	WAGMDL00583301		
P-25817	3/18/2013	RE: Any time today to talk and get an update?	WAGMDL00585578	WAGMDL00585583		
P-25818	N/A	Flagged Orders	WAGMDL00852038	WAGMDL00852038		
P-25819	5/28/2013	FW: Compliance timeline	WAGMDL00585822	WAGMDL00585825		
P-25820	10/5/2011	FW: Documents Held from Receiving through Shipping at DCs for CII and for CIII-CV	WAGMDL00586171	WAGMDL00586176		
P-25821	2/13/2013	Perrysburg DEA Fax Template Susp Drug	WAGMDL00752231	WAGMDL00752231		
P-25822	1/6/2020	Control Data OH	WAGMDL00779463	WAGMDL00779463		
P-25823	2/6/2013	Fw: DEA at Perrysburg Now	WAGMDL00818453	WAGMDL00818455		
P-25824	6/13/2012	PPT for tomorrow's 11:00 meeting	WAGMDL00589674	WAGMDL00589679		
P-25825	6/11/2020	SORs (Summit and Cuyahoga)	WAGMDL00847636	WAGMDL00847636		
P-25826	1/17/2018	FW: RX Kiosk Takeback program RFQ results	WAGMDL00591948	WAGMDL00591951		
P-25827	2/12/2013	RE: Drug Reports	WAGMDL00847774	WAGMDL00847778		
P-25828	9/6/2017	FW: Walgreens Partnership Agreement	WAGMDL00595580	WAGMDL00595586		
P-25829	5/19/2016	RE: Drug Take Back Event recap	WAGMDL00600854	WAGMDL00600860		
P-25830	4/27/2016	FW: Funding for Naloxone Training	WAGMDL00603118	WAGMDL00603128		
P-25831	1/19/2012	RE: DEA reduced item ordered from Cardinal.	WAGNMAG00025728	WAGNMAG00025729		
P-25832	2/22/2013	GFD Pilot - Drug Sales Trends	WAGFLAG00093644	WAGFLAG00093650		
P-25833	11/29/2012	RE: Tolerance; Tolerance Limit	WAGMDL00609440	WAGMDL00609443		
P-25834	10/1/2018	ARCOS Overall	WAGMDL00293631	WAGMDL00293631		
P-25835	12/29/2017	RAD Rx Inventory Management PPT	WAGMDL00609618	WAGMDL00609628		
P-25836	10/24/2018	ARCOS Total Data	WAGMDL00490979	WAGMDL00490979		
P-25837	5/8/2014	Internal Audit of AmerisourceBergen Ordering, Receiving, and Invoice Processes	WAGMDL00610722	WAGMDL00610732		
P-25839	3/1/2017	opioid study	WAGMDL00611377	WAGMDL00611384		
P-25840	2/5/2019	Spreadsheet re ARCOS Data	WAGMDL00773926	WAGMDL00773926		
P-25841	6/19/2017	FW: Walgreens-BCBSA Strategic Partnership Agreement - UPDATE	WAGMDL00612155	WAGMDL00612157		
P-25842	1/29/2016	RE: DEA meeting	WAGMDL00613455	WAGMDL00613467		
P-25843	12/3/2012	Customer Cut Off	Anda_Opioids_CA_SF_0066787	Anda_Opioids_CA_SF_0066788		
P-25844	12/18/2012	Customer Cut Off	Anda_Opioids_CA_SF_0071756	Anda_Opioids_CA_SF_0071757		
P-25845	1/14/2013	Customer Cut Off	Anda_Opioids_CA_SF_0041958	Anda_Opioids_CA_SF_0041960		
P-25846	5/6/2016	Mandatory Take Back amendment	WAGMDL00615477	WAGMDL00615477		
P-25847	5/3/2016	Fwd: Urgent Drug Take-Back Issues	WAGMDL00615504	WAGMDL00615509		
P-25848	1/24/2013	Customer Cut Off	Anda_Opioids_CA_SF_0040516	Anda_Opioids_CA_SF_0040518		
P-25849	2/6/2013	Customer Cut Off	Anda_Opioids_CA_SF_0042949	Anda_Opioids_CA_SF_0042951		
P-25850	5/24/2018	RE: Holaday Testimony	WAGMDL00616784	WAGMDL00616787		
P-25851	5/24/2012	FW: [RxNews] Senators approve Manchin amendment to reclassify hydrocodone drugs	WAGMDL00617478	WAGMDL00617481		
P-25852	11/25/2013	Micro - DEA 6 - Load 2 - ORPB393 - DEA_V1.0	WAGMDL00624441	WAGMDL00624451		
P-25853	3/26/2014	Micro - DEA 6 - Order on the fly_VOPB332_V1	WAGMDL00624487	WAGMDL00624497		
P-25854	1/4/2017	FW: Document Request	WAGMDL00625153	WAGMDL00625160		
P-25855	2/22/2013	Customer Cut Off	Anda_Opioids_CA_SF_0041035	Anda_Opioids_CA_SF_0041037		

P-25856	5/3/2013	Customer Cut off	Anda_Opioids_CA_SF_0067140	Anda_Opioids_CA_SF_0067141		
P-25857	5/15/2013	Customer Cut off	Anda_Opioids_CA_SF_0061233	Anda_Opioids_CA_SF_0061235		
P-25858	10/28/2011	SOR	WAGMDL00850183	WAGMDL00850184		
P-25859	7/21/2011	SOR	WAGMDL00850190	WAGMDL00850191		
P-25860	6/23/2011	SOR	WAGMDL00850192	WAGMDL00850193		
P-25861	7/6/2011	SOR	WAGMDL00850195	WAGMDL00850196		
P-25862	6/8/2011	SOR	WAGMDL00851269	WAGMDL00851270		
P-25863	6/10/2020	Flagged Order Production	WAGMDL00847635	WAGMDL00847635		
P-25864	2/22/2020	Research Report	WAGNYNS00055938	WAGNYNS00055994		
P-25865	5/29/2013	Customer Cut off	Anda_Opioids_CA_SF_0041816	Anda_Opioids_CA_SF_0041818		
P-25866	6/11/2013	Customer Cut off	Anda_Opioids_CA_SF_0065689	Anda_Opioids_CA_SF_0065690		
P-25867	9/21/2016	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_MDL_0000540850	Anda_Opioids_MDL_0000540851		
P-25868	10/5/2016	Updated List of Customers Not Eligible to Purchase Controls	Anda_Opioids_MDL_0000540503	Anda_Opioids_MDL_0000540504		
P-25869	11/15/2016	Anda Updated List of Customers Not Eligible to Purchase Controls	Anda_Opioids_MDL_0000540128	Anda_Opioids_MDL_0000540129		
P-25870	11/16/2016	Anda Updated List of Customers Not Eligible to Purchase Controls	Anda_Opioids_MDL_0000540113	Anda_Opioids_MDL_0000540114		
P-25871	11/28/2016	Anda Updated List of Customers Not Eligible to Purchase Controls	Anda_Opioids_MDL_0000540024	Anda_Opioids_MDL_0000540025		
P-25872	1/11/2017	Revised Updated List of Customer Not Eligible to Purchase Controls from Anda	Anda_Opioids_MDL_0000539655	Anda_Opioids_MDL_0000539656		
P-25873	3/2/2012	FW: Recap of Drug Diversion Hearing	WAGMDL00642592	WAGMDL00642594		
P-25874	3/2/2018	FW: Language on Pharmacist Interventions to Prevent Prescription Drug Abuse	WAGMDL00644179	WAGMDL00644182		
P-25875	1/18/2017	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_MDL_0000149256	Anda_Opioids_MDL_0000149257		
P-25876	1/5/2010	Resp't 259-E Cover Letters	WAGMDL00655723	WAGMDL00655738		
P-25877	2/1/2009	Intercepted/Suspicious Store Orders	WAGMDL00658202	WAGMDL00658216		
P-25878	9/18/2008	Cardinal SOM	WAGMDL00658228	WAGMDL00658229		
P-25879	7/28/2008	Barb Martin handwritten notes	WAGMDL00658242	WAGMDL00658242		
P-25880	9/18/2008	Handwritten Notes from Barb Martin	WAGMDL00658243	WAGMDL00658243		
P-25881	11/30/2018	Martin handwritten notes	WAGMDL00658254	WAGMDL00658255		
P-25882	9/17/2012	FW: CONTROL DRUG ADJUSTMENTS	WAGMDL00659076	WAGMDL00659078		
P-25884	7/17/2012	Walgreen Co. Controlled Substance Anti-Diversion and Compliance Program	WAGMDL00659802	WAGMDL00659856		
P-25885	1/23/2017	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_MDL_0000350876	Anda_Opioids_MDL_0000350877		
P-25886	11/3/2012	FW: SOM	WAGMDL00660341	WAGMDL00660343		
P-25887	5/12/2017	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_MDL_0000390838	Anda_Opioids_MDL_0000390839		
P-25888	7/12/2012	iSTOP workgroup	WAGMDL00662135	WAGMDL00662135		
P-25889	3/26/2013	Forest meeting notes and action items	WAGMDL00663366	WAGMDL00663376		
P-25890	5/22/2017	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_MDL_0000021099	Anda_Opioids_MDL_0000021100		
P-25891	5/26/2017	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_MDL_0000018775	Anda_Opioids_MDL_0000018776		
P-25892	9/14/2012	FW: DEA at Jupiter DC 9/14/2012	WAGMDL00667935	WAGMDL00667935		
P-25893	6/6/2012	FW: Meeting Notes for Suspicious Ordering Phase 5- 6/05/2012	WAGMDL00670686	WAGMDL00670694		
P-25894	6/14/2017	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_MDL_0000020981	Anda_Opioids_MDL_0000020982		
P-25895	6/16/2017	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_MDL_0000020902	Anda_Opioids_MDL_0000020903		
P-25896	3/25/2011	Analysis Data for Wayne.xls	WAGMDL00673894	WAGMDL00673894		
P-25897	2/15/2013	2013.02.15 - Letter to DEA re. Perrysburg DC (2435285 1 DC)	WAGMDL00674277	WAGMDL00674279		
P-25898	4/9/2013	FW: PDF Image Attached	WAGMDL00674545	WAGMDL00674549		
P-25899	6/23/2017	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_MDL_0000018603	Anda_Opioids_MDL_0000018604		
P-25900	8/25/2009	ORDER ITEM DETAIL SUSPICIOUS ORDER	WAGMDL00674550	WAGMDL00674550		
P-25901	8/25/2009	ORDER ITEM DETAIL SUSPICIOUS ORDER	WAGMDL00674553	WAGMDL00674553		

P-25902	8/18/2010	ORDER ITEM DETAIL SUSPICIOUS ORDER	WAGMDL00674562	WAGMDL00674575		
P-25903	2/17/2010	THRESHOLD VIOLATIONS-WEEKLY	WAGMDL00674576	WAGMDL00674594		
P-25904	9/23/2009	Threshold Violations - Monthly	WAGMDL00674619	WAGMDL00674619		
P-25905	9/23/2009	Threshold Violations - Monthly	WAGMDL00674620	WAGMDL00674620		
P-25906	8/25/2009	Threshold Violations - Monthly	WAGMDL00674623	WAGMDL00674623		
P-25907	2/14/2013	Chris D Status 2-14-13x	WAGMDL00675586	WAGMDL00675586		
P-25908	8/30/2012	RE: IMS Controlled Substance Reporting	WAGMDL00678523	WAGMDL00678540		
P-25909	6/30/2017	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_MDL_0000018549	Anda_Opioids_MDL_0000018550		
P-25910	3/30/2013	Walgreen Letter - Final Draft	WAGMDL00682159	WAGMDL00682166		
P-25911	8/28/2018	Urgent: GFD	WAGMDL00688181	WAGMDL00688181		
P-25912	8/13/2015	RE: ceiling limit tool	WAGMDL00688364	WAGMDL00688365		
P-25913	6/8/2015	FW: URGENT Re: *** Controlled Substance Ordering Immediate Action Required ***	WAGMDL00688373	WAGMDL00688374		
P-25914	6/1/2015	RE: Override Quantity Request Submitted for Approval	WAGMDL00688378	WAGMDL00688378		
P-25915	9/23/2013	Controlled Substances Ordering System (CSOS)	WAGMDL00692141	WAGMDL00692145		
P-25916	7/7/2017	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_MDL_0000020837	Anda_Opioids_MDL_0000020838		
P-25917	7/14/2017	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_MDL_0000018516	Anda_Opioids_MDL_0000018517		
P-25918	1/31/2014	Controlled Substances Ordering System (CSOS) Activation	WAGMDL00697865	WAGMDL00697870		
P-25920	2/8/2013	FW: Important DEA Reminder	WAGMDL00698433	WAGMDL00698434		
P-25921	1/7/2013	FW: Top 500	WAGMDL00698453	WAGMDL00698455		
P-25922	10/7/2013	FW: CANCELLED: Controlled Substances Ordering System (CSOS)	WAGMDL00699676	WAGMDL00699677		
P-25923	7/10/2013	RE: PPT	WAGMDL00700032	WAGMDL00700060		
P-25924	9/3/2009	Email	WAGMDL00425919	WAGMDL00425922		
P-25925	12/4/2018	Goal Performance	WAGMDL00709450	WAGMDL00709469		
P-25927	2/8/2013	Important DEA Reminder	WAGMDL00700236	WAGMDL00700237		
P-25928	8/10/2012	Re: lpxrx	WAGMDL00700311	WAGMDL00700312		
P-25929	8/9/2012	Re: lpxrx	WAGMDL00700314	WAGMDL00700315		
P-25930	6/21/2012	Re: lpxrx report	WAGMDL00700940	WAGMDL00700942		
P-25931	10/10/2011	CII access and key control	WAGMDL00700974	WAGMDL00700975		
P-25932	4/22/2010	lpxrx	WAGMDL00700993	WAGMDL00700993		
P-25933	7/11/2007	Re: NSF CHECKS	WAGMDL00701013	WAGMDL00701016		
P-25934	4/9/2010	Fw: Item from Kermit Crawford	WAGMDL00704351	WAGMDL00704378		
P-25937	5/9/2018	Email	WAGMDL00383697	WAGMDL00383700		
P-25938	10/25/2013	csos_webinar_v10_093013 CD edit	WAGMDL00707883	WAGMDL00707914		
P-25939	1/29/2013	Chris D Status 1-28-13x	WAGMDL00708763	WAGMDL00708763		
P-25940	12/19/2013	Chris D Status 12-19-13x	WAGMDL00708764	WAGMDL00708764		
P-25941	4/17/2014	Chris D Status 4-17-14x	WAGMDL00708766	WAGMDL00708766		
P-25942	5/26/2012	Fwd: INFO: Suspicious Drug process	WAGMDL00709301	WAGMDL00709303		
P-25943	11/30/2018	0389_001	WAGMDL00709393	WAGMDL00709393		
P-25944	11/30/2018	0366_001	WAGMDL00709431	WAGMDL00709431		
P-25945	11/13/2014	Walgreens Internal Audit Documentation - Part II of III	WAGMDL00734289	WAGMDL00734552		
P-25953	N/A	Eric Stahmann LinkedIn Profile	N/A	N/A		
P-25956	11/13/2014	Walgreens Internal Audit Documentation - Part II	WAGMDL00734929	WAGMDL00735627	WAGMDL00734929 -	
			WAGMDL00734929	WAGMDL00734930	WAGMDL00734930	
P-25957	10/2/2018	ohio_current_ceiling_limits	WAGMDL00400359	WAGMDL00400359		
P-25959	N/A	CV / Resume / Biography	Martin Personnel File - HIGHLY CONFIDENTIAL	Martin Personnel File - HIGHLY CONFIDENTIAL		
P-25967	7/20/2017	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_MDL_0000018505	Anda_Opioids_MDL_0000018506		
P-25972	4/5/2012	Jupiter/Perrysburg C2 Orders	WAGMDL00751658	WAGMDL00751659		
P-25973	4/10/2012	RE: Suspicious Drug Order Report and onLine DEA Manual	WAGMDL00751806	WAGMDL00751807		
P-25974	5/29/2012	RE: Suspicious Drug process	WAGMDL00751808	WAGMDL00751810		
P-25975	5/30/2012	RE: Suspicious Drug process	WAGMDL00752192	WAGMDL00752194		
P-25976	12/22/2008	Perrysburg - Internal Audit Report - 12/22/2008	WAGMDL00757148	WAGMDL00757163		
P-25977	7/1/2011	Document Request List - Perrysburg DC DEA Review - July 2011	WAGMDL00757170	WAGMDL00757171		
P-25978	8/13/2012	Controlled Substance Order Quantity Override Form	WAGMDL00757172	WAGMDL00757187		

P-25979	11/1/2012	Document Request List Perrysburg DC DEA Review - November 2012	WAGMDL00757188	WAGMDL00757192		
P-25981	4/4/2012	Handling Suspicious Drug Orders	WAGFLDEA00000027	WAGFLDEA00000027		
P-25983	8/12/1999	Letter Agreement re that Joanie Smoot presentation "Current Trends and the Pharmacist's Role in the Treatment of Chronic Non-Malignant Pain".	PKY180524065	PKY180524065		
P-25984	12/21/1998	Use of Opioids - A Pharmacist Responsibilities. "Legal Implications and the Use of Opioids".	PKY180836236	PKY180836236		
P-25985	1/5/1999	Letter of Agreement between Walgreen Co and Purdue Pharma LP	PKY180836239	PKY180836239		
P-25987	8/11/2008	RE: Oxycontin Product Replacement Program	PPLPC004000170570	PPLPC004000170572		
P-25988	11/6/2017	Walgreens University Information	PPLPC014000362724	PPLPC014000362773		
P-25989	7/28/2017	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_MDL_0000020678	Anda_Opioids_MDL_0000020679		
P-25990	6/12/2015	FW: APPROVED FOR USE: Walgreens email for Pharmacists 2015	PPLPC031001349510	PPLPC031001349545		
P-25991	8/25/2017	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_MDL_0000020636	Anda_Opioids_MDL_0000020637		
P-25992	9/1/2017	Updated List of Customers Not Eligible to Purchase Controls from Anda	Anda_Opioids_MDL_0000018382	Anda_Opioids_MDL_0000018383		
P-25993	11/7/2017	Updated List of Customers Not Eligible to Purchase Controls	Anda_Opioids_MDL_0000312494	Anda_Opioids_MDL_0000312495		
P-25994	11/16/2017	ANDA Updated List of Customers Not Eligible to Purchase Controls	Anda_Opioids_MDL_0000320412	Anda_Opioids_MDL_0000320413		
P-26010	11/20/2017	ANDA Updated List of Customers Not Eligible to Purchase Controls	Anda_Opioids_MDL_0000320408	Anda_Opioids_MDL_0000320409		
P-26011	12/14/2017	ANDA Updated List Customers Not Eligible for Purchase Controls	Anda_Opioids_MDL_0000382366	Anda_Opioids_MDL_0000382367		
P-26012	1/5/2018	Anda Updated List of Customers to Be reported	Anda_Opioids_MDL_0000479958	Anda_Opioids_MDL_0000479959		
P-26018	1/10/2018	Anda Updated List of Customers Not Eligible to Purchase Controls	Anda_Opioids_MDL_0000479885	Anda_Opioids_MDL_0000479886		
P-26019	1/22/2018	Anda Updated List of Customers Not Eligible to Purchase Controls	Anda_Opioids_MDL_0000993508	Anda_Opioids_MDL_0000993509		
P-26020	2/6/2018	Anda Updated List of Reportable Customers as of February 6, 2018	Anda_Opioids_MDL_0000308132	Anda_Opioids_MDL_0000308133		
P-26022	2/14/2018	Anda Updated List of Reportable Customers as of February 14 2018	Anda_Opioids_MDL_0000307497	Anda_Opioids_MDL_0000307498		
P-26030	8/20/2014	Customers Cut Off	Anda_Opioids_CA_SF_0061156	Anda_Opioids_CA_SF_0061157		
P-26037	4/26/2013	RE: OMP Family Limits and Walgreens Ceilings	ABDCMDL04057668	ABDCMDL04057670		
P-26047	7/28/2014	Customers Cut Off	Anda_Opioids_CA_SF_0040753	Anda_Opioids_CA_SF_0040754		
P-26048	7/3/2014	Customers Cut Off	Anda_Opioids_CA_SF_0061154	Anda_Opioids_CA_SF_0061155		
P-26062	2/7/1997	Email Re: Walgreens	PDD8801156563	PDD8801156565		
P-26063	8/8/2000	Email btwn Purdue execs	PDD8801159660	PDD8801159663		
P-26066	6/26/2000	Email re Walgreens	PKY182851611	PKY182851613		
P-26074	9/1/2002	Teva Sales & Mktg Gateway PPT	TEVA_MDL_A_13254730	TEVA_MDL_A_13254730		
P-26084	6/12/2014	Customers Cut Off	Anda_Opioids_CA_SF_0061198	Anda_Opioids_CA_SF_0061199		
P-26099	5/16/2014	Customers Cut Off	Anda_Opioids_CA_SF_0040637	Anda_Opioids_CA_SF_0040638		
P-26104	4/23/2014	Customers Cut Off	Anda_Opioids_CA_SF_0044009	Anda_Opioids_CA_SF_0044010		
P-26135	4/3/2014	Customers Cut Off	Anda_Opioids_CA_SF_0040180	Anda_Opioids_CA_SF_0040182		
P-26146	3/7/2014	Customers Cut Off	Anda_Opioids_CA_SF_0041933	Anda_Opioids_CA_SF_0041934		
P-26147	2/27/2014	Customers Cut Off	Anda_Opioids_CA_SF_0041687	Anda_Opioids_CA_SF_0041688		
P-26173	2/12/2013	Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers – United States, 2002-2004 and 2008-2010. Drug Alcohol Depend 2013;132(1-2):95-100	N/A	N/A		
P-26174	2/20/2014	Customers Cut Off	Anda_Opioids_CA_SF_0043403	Anda_Opioids_CA_SF_0043405		
P-26184	6/8/2017	FDA requests removal of Opana ER for risks related to abuse- FDA news release	N/A	N/A		
P-26226	2/11/2014	Customers Cut Off	Anda_Opioids_CA_SF_0040305	Anda_Opioids_CA_SF_0040307		
P-26227	1/28/2014	Customers Cut Off	Anda_Opioids_CA_SF_0040394	Anda_Opioids_CA_SF_0040395		
P-26236	10/9/2013	Customers Cut Off	Anda_Opioids_CA_SF_0061165	Anda_Opioids_CA_SF_0061166		



P-26295	9/18/2013	Customers Cut Off	Anda_Opioids_CA_SF_0040400	Anda_Opioids_CA_SF_0040401		
P-26296	8/23/2017	FW Question for you	PPLPC018001455993	PPLPC018001455994		
P-26297	11/22/2013	Customers Cut Off	Anda_Opioids_CA_SF_0044246	Anda_Opioids_CA_SF_0044247		
P-26298	12/6/2013	Customers Cut Off	Anda_Opioids_CA_SF_0040887	Anda_Opioids_CA_SF_0040889		
P-26299	6/3/2018	Re Pain management task force in OASH, HHS	KOLODNY SUB_000072514	KOLODNY SUB_000072516		
P-26332	6/24/2013	Customers Cut Off	Anda_Opioids_CA_SF_0072227	Anda_Opioids_CA_SF_0072228		
P-26333	7/29/2013	Customers Cut Off	Anda_Opioids_CA_SF_0041906	Anda_Opioids_CA_SF_0041908		
P-26334	9/4/2013	Customers Cut Off	Anda_Opioids_CA_SF_0041949	Anda_Opioids_CA_SF_0041951		
P-26335	5/30/2013	WAGs Red Flag Analysis	Anda_Opioids_MDL_0000598153	Anda_Opioids_MDL_0000598153		
P-26336	6/17/2010	Controlled Substance Sales to Physicians, Wholesalers, Distributors and Repackagers	Anda_Opioids_MDL_0000104230	Anda_Opioids_MDL_0000104230		
P-26337	7/30/2003	Major Trade Customer Contact Report; Personal Meeting- Walgreens call Report 730	ENDO-OPIOID_MDL-04912099	ENDO-OPIOID_MDL-04912129	ENDO-OPIOID_MDL-04912099 - ENDO-OPIOID_MDL-04912129	
P-26338	6/11/2007	Walgreens Magnacet \$40 stocking rebate request letter	MNK-MDL_001732103	MNK-MDL_001732115	MNK-MDL_001732103 - MNK-MDL_001732115	
P-26339	12/10/2012	2012 June Inv # 546338 Walgreens \$143,113	ENDO-CHI_LIT-01065236 ENDO-CHI_LIT-01065596	ENDO-CHI_LIT-01065768 ENDO-CHI_LIT-01065599	ENDO-CHI_LIT-01065596 - ENDO-CHI_LIT-01065599	
P-26340	3/23/2013	National Target Drug Good Faith Dispensing (TD GFD) Documents	WAGCASF00094660	WAGCASF00094715		
P-26341	9/6/2011	Proposal for RPh and MD Education Programs for Actavis	WAGFLAG03916475	WAGFLAG03916477		
P-26342	1/17/2003	SB#9: OxyContin Replacement Policy	6017818032	6017818034		
P-26343	N/A	Counseling Patients & Their Families on the Role of Opioid Analgesics in Pain Management: A Pharmacist's Guide	7001107315	7001107327		
P-26344	5/11/2001	RE: CVS Pharmacy	7003203712	7003203712		
P-26345	6/22/2001	RE: Eckerd Call June 19, 2001	7003203839	7003203841		
P-26346	10/19/2001	RE: Field Contact 10/8-10/9/01	7003217715	7003217721		
P-26347	2/14/2013	RE: Walgreens RFP	ABDCMDL10924886	ABDCMDL10924946		
P-26348	4/10/2012	ISF Portal -- Customer Intelligence	CAH_FEDWV_00387843	CAH_FEDWV_00387979		
P-26349	3/29/2007	FW: Updated PI Instructions	CAH_MDL_PRIORPROD_DEA07_00978240	CAH_MDL_PRIORPROD_DEA07_00978255		
P-26350	8/21/2014	Hydrocodone Reschedule from III to CII	CAH_MDL2804_00011925	CAH_MDL2804_00012010		
P-26351	5/4/2015	PVA 45692 - Walgreen Co. 20130901	CAH_MDL2804_03212881	CAH_MDL2804_03212896		
P-26352	8/22/2014	Policy Council Action Items and Information	CVS-MDLT1-000106705	CVS-MDLT1-000106733		
P-26353	4/5/2001	CE Programming in WAGS	E15_00011149	E15_00011149		
P-26354	5/8/2001	RE: Knoxville,TN.-July 31st,2001-Walgreens	E15_00038792	E15_00038792		
P-26355	1/9/2007	RE: Opana Stocking Update	ENDO_FLAG-00685838	ENDO_FLAG-00685839		
P-26356	9/21/2005	RE: Patient Information on Pain Management at Pharmacy Level	ENDO-OPIOID_MDL-00445048	ENDO-OPIOID_MDL-00445049		
P-26357	11/16/2006	FW: Opana at Walgreens	ENDO-OPIOID_MDL-00678935	ENDO-OPIOID_MDL-00678937		
P-26358	11/10/2006	Project Pizza	ENDO-OPIOID_MDL-00857613	ENDO-OPIOID_MDL-00857615		
P-26359	10/20/2006	IMPORTANT- Walgreens stores that have stocked Opana	ENDO-OPIOID_MDL-01053452	ENDO-OPIOID_MDL-01053453		
P-26360	1/4/2006	DM #241442 for \$321,394.96 & DM #241888 for \$748,000	ENDO-OPIOID_MDL-04139591	ENDO-OPIOID_MDL-04139597		
P-26361	9/18/2006	FW: Opana	ENDO-OPIOID_MDL-04921277	ENDO-OPIOID_MDL-04921278		
P-26362	9/26/2006	Re: Opana/Oxy at Walgreens	ENDO-OPIOID_MDL-04921570	ENDO-OPIOID_MDL-04921573		
P-26363	N/A	SIFPROD002_Part2of4	ENDO-OPIOID_MDL-07391909	ENDO-OPIOID_MDL-07391909		
P-26364	N/A	SIFPROD003	ENDO-OPIOID_MDL-07391912	ENDO-OPIOID_MDL-07391912		
P-26365	8/6/2009	RE: the almost done draft	ENDO-OPIOID_MDL-07485510	ENDO-OPIOID_MDL-07485512		
P-26366	8/26/2009	FW: Cephalon Abuse, Addiction & Diversion Program Invite - Meghan Grillone & Rani Pabla	TEVA_CAOC_13918081	TEVA_CAOC_13918082		
P-26367	3/7/2008	Opana Tracking Report for New Strength Stocking Programs	EPI000299049	EPI000299050		
P-26368	1/11/2008	FW: Opana Stocking Program	EPI000559394	EPI000559403		
P-26369	11/16/2015	FW: 415-	GAYLE-00000001	GAYLE-00000001		
P-26370	7/6/2015	Incident on 7/6/15	GAYLE-00000002	GAYLE-00000003		
P-26371	3/15/2004	Analgesic Surveillance Report	JAN-MS-00837963	JAN-MS-00837975		
P-26372	4/3/2014	RE: XARTEMIS XR CoPay Recap_March 26	MNK-MDL_000912095	MNK-MDL_000912096		
P-26373	4/30/2014	FW: Co-Pay Discount Program Training	MNK-MDL_000914946	MNK-MDL_000914948		
P-26374	2/3/2014	FW: Success story	MNK-MDL_000974277	MNK-MDL_000974278		
P-26376	2017	Drug Therapy Monitoring System (DTMS)/ Prior Adverse Reaction (PAR) Process Manual	MSPN0002797	MSPN0002837		
P-26377	6/24/2021	Medi-Span's response to questions	N/A	N/A		
P-26378	7/5/2013	License Agreement Amendment	MSPN0001928	MSPN0001939		
P-26379	11/3/2014	License Agreement Amendment	MSPN0001940	MSPN0001949		

P-26380	11/12/2004	Second Amendment to the Licensing and Nondisclosure Agreement between MEDI-SPAN, a division of Wolters Kluwer Health, Inc. (MEDI-SPAN) and Walgreen Company	MSPN0001809	MSPN0001810		
P-26381	1/8/2009	Third Amendment to the Licensing and Nondisclosure Agreement between Medi-Span, a part: of Wolters KluWer Health, Inc. ("Medi-Span") and Walgreen Co	MSPN0001811	MSPN0001829		
P-26382	6/14/2010	Fourth Amendment to the Licensing and Nondisclosure Agreement between Medi-Span, a part of Wolters Kluwer Health, Inc. ("Medi-Span") and Walgreen Co.	MSPN0001830	MSPN0001836		
P-26383	N/A	Monographs	MSPN0002879	MSPN0002879		
P-26384	1/9/2017	Twelfth Amendment to the Licensing and Nondisclosure Agreement between Wolters Kluwer Clinical Drug Information, Inc., a subsidiary of Wolters Kluwer Health, Inc., assignee of Clinical Drug Information, LLC, a subsidiary of Wolters Kluwer Health, Inc. and Walgreen Company	MSPN0001790	MSPN0001801		
P-26385	N/A	Monograph 1015 Excel Spreadsheet	N/A	N/A		
P-26386	8/1/2019	Drug Therapy Monitoring System Reference Manual	MSPN0000872	MSPN0000981		
P-26387	11/1/2017	Cross-Chek Version 2 Documentation Manual	MSPN0000151	MSPN0000248		
P-26388	2019	Medi-Span Clinical Drug Interactions API Quick Start Guide	MSPN0002683	MSPN0002687		
P-26389	2015	Drug Interactions API Documentation Manual	MSPN0002688	MSPN0002769		
P-26390	12/1/2020	Medi-Span Clinical API Documentation Manual	MSPN0002219	MSPN0002406		
P-26391	10/1/2015	Controlled Substances File Documentation Manual	MSPN0002026	MSPN0002107		
P-26392	2020	Medi-Span Databases Overview	MSPN0002018	MSPN0002025		
P-26393	N/A	Medi-Span Interaction Data Reports, Descriptions and Comments	MSPN0002883	MSPN0002887		
P-26394	7/21/2008	LICENSE AGREEMENT between MEDI-SPAN, a part of Wolters Kluwer Health, Inc. and LICENSEE Giant Eagle	MSPN0001604	MSPN0001609		
P-26398	N/A	U.S. Census Data	N/A	N/A		
P-26527	7/16/2013	REVIEW: Walgreens Revised VIP 5.20.13.docx Email from Ashley Kempfer to Ginger Collier	MNK-T1_0000607652	MNK-T1_0000607655		
P-26590	2/5/2016	WAG-RAD emails discussing email from OH BOP RE CSI BIA 4729-5, 9 & 37 BIA - Dangerous Drugs - REVISED 2.5.2016	WAGMDL00269157	WAGMDL00269159		
P-26753	2014	The Script - California State Board of Pharmacy Spring 2014	N/A	N/A		
P-26767	N/A	RTF, BRTF, and blocked prescriber lists and webforms	Compilation Exhibit - See Attachment to P-26767	Compilation Exhibit - See Attachment to P-26767		
P-26798	7/12/2019	20190712 Lazzerini daily-jeff.com-UPDATE Judge calls Frank Lazzerini Dr Frankenstein	WAGMDL_T1_TX00011942	WAGMDL_T1_TX00011945		
P-26834	10/6/2009	Fw: Pharmacy Market Share in Florida; FL Share Insights	WAGFLAG00016437	WAGFLAG00016444		
P-26835	11/5/2012	IMS CS Ratings Pilot Update	WAGMDL01132740	WAGMDL01132741		
P-26836	6/19/2013	CS Ratings and IMS	WAGMDL01132049	WAGMDL01132051		
P-26899	10/1/2009	RE: FW: Methadone 10mg Short-Dated Material	MNK-T1_0004879985	MNK-T1_0004879990		
P-26900	3/24/2014	RE: Relay Health link	MNK-T1_0005932878	MNK-T1_0005932880		
P-26901	10/14/2008	Mallinckrodt_BR Review_Magnacet v7 PPT	MNK-T1_0006717596	MNK-T1_0006717602		
P-26902	11/18/2013	DEA Red Flags - Patient And Physician Conduct (2	NABP_00019878	NABP_00019880		
P-26903	N/A	Counseling Patients & Their Families on the Role of Opioid Analgesics in Pain Management: A Pharmacist's Guide	PDD1501613462	PDD1501613473		
P-26904	6/1/2001	Dear Walgreens Pharmacists	PDD1501724898	PDD1501724898		
P-26905	12/2/2009	Cephalon Dinner Program 12.16 at 7pm Chantilly Restaurant Redwood City	TEVA_CAOC_13930226	TEVA_CAOC_13930227		
P-26906	4/27/2001	RE: Walgreens Meeting April 25, 2001	PDD1701046871	PDD1701046874		
P-26907	2/21/1998	Letter of Agreement	PDD1701618944	PDD1701618944		
P-26908	8/23/1999	RE: Walgreens Palm City	PDD1715220945	PDD1715220945		
P-26909	6/24/2002	Re: Competitor's Promotional Advertising	PDD8013015138	PDD8013015149		
P-26910	4/1/2013	A Pharmacist's Guide	PDD8013706138	PDD8013706144		
P-26911	1/16/1997	Walgreens-OxyContin 80mg/Rebate	PDD8801118201	PDD8801118201		
P-26912	8/13/2000	Walgreens OxyContin Retail Coverage	PDD8801139044	PDD8801139045		
P-26927	5/13/2015	PAIN-40222 APS Pain Matters Screening Discussion Guide	TEVA_MD_L_A_01136947	TEVA_MD_L_A_01136951		

P-26930	2/27/2015	FW: Ad Board Summaries; TEVA_Pain Specialist Advisory Board_Executive Summary_02.13.15; CDM Combined Executive Summary 01.06.15; Chronic Pain Advocacy Summit Internal Recap Report FINAL; Summary_Report_Appropriate_and_Safe_Use_of_Prescription_Pain_Medications	TEVA_MDL_A_08769254	TEVA_MDL_A_08769311		
P-26936	1/10/2014	Fentora Speaker	TEVA_MDL_A_02295458	TEVA_MDL_A_02295458		
P-26937	9/15/2006	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use - Actiq	TEVA_MDL_A_00695612	TEVA_MDL_A_00695615		
P-26949	10/28/2015	Pain Matters Documentary - <a href="https://www.youtube.com/watch?v=N4Hwx99y02k">https://www.youtube.com/watch?v=N4Hwx99y02k</a>	N/A	N/A		
P-26950	6/17/2010	Customer list to cut off from buying controls; Untitled attachment 00643; Customers to cut off Controls 061710 (IT Upload File)	Anda_Opioids_AL_DCH_0010913	Anda_Opioids_AL_DCH_0010915		
P-26955	3/11/2015	Speaker agreement for Promotional Programs - Rosenblatt, Melanie	TEVA_MDL_A_03314692	TEVA_MDL_A_03314703		
P-26957	7/16/2020	US Patent Application Rosenblatt et al; Patent US20200227174A1	N/A	N/A		
P-26959	5/27/2014	Speaker agreement for Promotional Programs - Rosenblatt, Melanie	TEVA_MDL_A_13597079	TEVA_MDL_A_13597099		
P-26960	12/18/2014	Speaker agreement for Promotional Programs - Rosenblatt, Melanie	TEVA_MDL_A_13597651	TEVA_MDL_A_13597663		
P-26963	6/30/2015	FW: Revised CDM Showfile with attachments	TEVA_MDL_A_08731727	TEVA_MDL_A_08731736		
P-26964	6/2/2021	Declaration of Michael Ciaramitaro re TEVA video collection	N/A	N/A		
P-26964 A	6/2/2021	Pain Matters list from ILS	N/A	N/A		
P-26975	5/23/2016	Newsmax Health "Opioid Epidemic Is Real" by Melanie Rosenblatt	N/A	N/A		
P-26979	5/5/2016	EXTERNAL: TIRF REMS Status Call Documents - 5/5/16 with attachments	ENDO_SF-00533999	ENDO_SF-00534029		
P-26980	5/22/2019	Corrupting Influence, Purdue & the WHO	N/A	N/A		
P-27000	11/11/2009	Note to LK's Personal File	ENDO_SF-00588257	ENDO_SF-00588259		
P-27001	7/11/2016	FW: Check Requests 07/11/2016; Rush check requests	Allergan_SF_00083255	Allergan_SF_00083262		
P-27010	1/15/2009	FW: Kadian customer letter; PR Kadian v7	Acquired_Actavis_00463682	Acquired_Actavis_00463686		
P-27012	N/A	Product Schedule	ALLERGAN_MDL_03367178	ALLERGAN_MDL_03367178		
P-27014	1/23/2012	FW: Pharmacy Times Fentora/Actiq REMS Supplement published; Fentora REMS Pharmacy Times Monograph FINAL	TEVA_MDL_A_12109966	TEVA_MDL_A_12109975		
P-27015	4/1/2020	Drug Fact Sheet - Fentanyl	N/A	N/A		
P-27016	1/1/2018	Segment Reporting Memorandum Q1 2018	TEVA_MDL_JD_000839	TEVA_MDL_JD_000861		
P-27017	3/20/2001	LIPMAN CE (MC 113)	PDD8801280222	PDD8801280222		
P-27018	1/1/2001	National Accounts Business Conditions Report	PKY180264116	PKY180264118		
P-27019	4/19/1996	Letter re Walgreens-Purdue Warehouse Rebate	PKY180416649	PKY180416649		
P-27020	12/31/2000	Use of Opioids in Chronic Noncancer Pain	PKY181071048	PKY181071063		
P-27027	N/A	Rosenblatt Santa Clara Rebuttal CV	N/A	N/A		
P-27036	2015	Today's Heroin Epidemic More People at Risk, Multiple Drugs Abused	N/A	N/A		
P-27038	3/4/2000	Summary/Conclusions	PKY181218532	PKY181218545		
P-27042	10/21/2020	Justice Department Announces Global Resolution of Criminal and Civil Investigations with Opioid Manufacturer Purdue Pharma and Civil Settlement with Members of the Sackler Family	N/A	N/A		
P-27043	1/11/2019	CDC's Response to the Opioid Overdose Epidemic - A Public Health Crisis	N/A	N/A		
P-27048	2008	American Academy of Psychiatry and the Law, 39th Annual Meeting October 23-26, 2008, Seattle, Washington	N/A	N/A		
P-27050	12/7/2012	Walgreens-Meritello-001	WAGMDL00114602	WAGMDL00114625		
P-27051	N/A	Walgreens-Meritello-002	N/A	N/A		
P-27052	11/9/2012	Walgreens-Meritello-011	WAGMDL00658246	WAGMDL00658248		
P-27053	12/2/2013	Walgreens-Meritello-013	WAGMDL00336103	WAGMDL00336106		
P-27070	4/16/1996	U.S. Department of Justice, DEA, Diversion Investigators Manual, letter to Robert Giacalone	CAH_MDL2804_02203353	CAH_MDL2804_02203357		

P-27075	6/3/2014	In Re Lamictal Direct Purchaser Antitrust Litigation	N/A	N/A		
P-27077	8/2/2016	Termination Agreement among Purdue and Allergan Finance, LLC	Anda_Opioids_MDL_0001117634	Anda_Opioids_MDL_0001117643		
P-27078	7/25/2018	IQVIA - Allergan letter	N/A	N/A		
P-27080	11/18/2016	FW: Oxycontin Opp	Anda_Opioids_MDL_0000294581	Anda_Opioids_MDL_0000294581		
P-27081	1/19/2017	RE: C2 McKesson	Anda_Opioids_MDL_0000019361	Anda_Opioids_MDL_0000019364		
P-27082	9/22/2017	Article	Anda_Opioids_MDL_0000018341	Anda_Opioids_MDL_0000018341		
P-27083	8/4/2017	FW: Acct 380297 Willakenzie Inventory CK for Packet	Anda_Opioids_MDL_0000018427	Anda_Opioids_MDL_0000018428		
P-27084	11/22/2017	Canceled: DEA Response Letter; DEA WH 41 Record Keeping Violations	Anda_Opioids_MDL_0000013173	Anda_Opioids_MDL_0000013174		
P-27085	N/A	Performance and Development Process (P.D.P.)	Anda_Opioids_MDL_0000152155	Anda_Opioids_MDL_0000152155		
P-27086	7/12/2017	FW: Senate letter to DEA on production quotas for schedule II opioids	Anda_Opioids_MDL_0000316783	Anda_Opioids_MDL_0000316783		
P-27087	11/24/2014	Anda Overview for Putnam 9-17-14	Anda_Opioids_AL_DCH_0049300 Anda_Opioids_AL_DCH_0049301	Anda_Opioids_AL_DCH_0049318 Anda_Opioids_AL_DCH_0049301	Anda_Opioids_AL_DCH_0049301 - Anda_Opioids_AL_DCH_0049301	
P-27088	1/7/2010	Re: Fw: January Marketing Driver	Anda_Opioids_AL_MOB_0026258	Anda_Opioids_AL_MOB_0026262		
P-27089	N/A	The One to Stay With OxyContin materials	PKY181266833	PKY181266846		
P-27090	1/18/2017	RE: C2 McKesson	Anda_Opioids_MDL_0000031939	Anda_Opioids_MDL_0000031942		
P-27091	10/6/2010	FW: SURPRISE LAUNCH: Generic Tussionex CIII (Hydrocodone Polistirex/Chlorpheniramine Polistirex) ER Suspension	Anda_Opioids_MDL_0000077465	Anda_Opioids_MDL_0000077466		
P-27092	11/6/2009	Talking Points for Anda/VIP Pharmacy - Programs & Products to Generate Revenue	Anda_Opioids_MDL_0000110849	Anda_Opioids_MDL_0000110859		
P-27093	10/6/2009	Talking Points for Anda/VIP Pharmacy - Programs & Products to Generate Revenue	Anda_Opioids_MDL_0000110906	Anda_Opioids_MDL_0000110918		
P-27094	8/5/2009	Re: Fw: July Marketing Driver	Anda_Opioids_MDL_0000619354	Anda_Opioids_MDL_0000619358		
P-27095	2/18/2010	Leadership Minutes DRAFT; A-LEADERSHIP MEETING MINUTES - FEBRUARY 16, 201	Anda_Opioids_MDL_0000710419	Anda_Opioids_MDL_0000710423		
P-27096	N/A	Sabrina Solis LinkedIn Profile	N/A	N/A		
P-27098	N/A	Solis - Teva and Purdue	N/A	N/A		
P-27100	2019	Pre-Charge Consent Order signed by Jay Spellman	N/A	N/A		
P-27101	3/6/2019	Anda Inc. Third Supplemental Response to Plaintiff's First Set of Interrogatories	N/A	N/A		
P-27102	7/31/2017	Report: Compliance - Cust Allowed Controls	Anda_Opioids_NY_0020570	Anda_Opioids_NY_0020571		
P-27103	3/27/2018	Active accounts allowed to buy controls	Anda_Opioids_NY_0018081	Anda_Opioids_NY_0018081		
P-27104	6/6/2017	New Controlled Substance Customer Questionnaire	Anda_Opioids_MDL_0000672216	Anda_Opioids_MDL_0000672219		
P-27105	12/3/2009	Important Opportunity: Prebook - Generic Name (Pramipexole Dihydrochloride) Brand Name Mirapex	Anda_Opioids_MDL_0000110637	Anda_Opioids_MDL_0000110642		
P-27106	9/17/2021	Teva Supplemental Responses and Objections Plaintiffs' First Set of Interrogatories (4, 8, 11, 15)	N/A	N/A		
P-27107	9/24/2021	Letter from Morgan Lewis regarding Teva Pharmaceuticals USA, Inc., Cephalon, Inc., Actavis Pharma, Inc. Actavis LLC and Watson Laboratories, Inc. additional NDC codes	N/A	N/A		
P-27108	10/22/2021	In re opioid litigation - Letter to State from Rebecca Hillyer	N/A	N/A		
P-27110	N/A	Actavis/Watson Total Shipped to Retail and Chain Pharmacies by Dosage Unit	N/A	N/A		
P-27111	N/A	Teva/Cephalon Total Shipped to Retail and Chain Pharmacies by Dosage Unit	N/A	N/A		
P-27112	N/A	Teva NDC codes	N/A	N/A		
P-27113	7/21/2006	Sales Launch Planning Meeting Agenda - 7/21/06	TEVA_MDL_A_01105498	TEVA_MDL_A_01105499		
P-27114	7/21/2006	Key Points for Roy & Lynne; royandlynne	TEVA_MDL_A_02494131	TEVA_MDL_A_02494133		
P-27115	7/31/2006	Re: A Few Good Men; A Few Good Salesman_v1_072106	TEVA_MDL_A_02881821	TEVA_MDL_A_02881826		
P-27116	8/17/2006	FW: Fentora Launch Meeting; Fentora Launch Agenda 8-08	TEVA_MDL_A_09067661	TEVA_MDL_A_09067662		
P-27117	5/1/2001	National Accounts Business Conditions Report	PKY181284751	PKY181284753		
P-27118	2/12/2002	RE: Grant Request	PKY181866860	PKY181866860		
P-27119	8/23/1999	RE: Walgreens Palm City	PKY181866992	PKY181866992		
P-27120	6/20/2005	Disclosure of Arthur G. Lipman	PKY183265978	PKY183266040		
P-27121	9/10/2014	pharmacistguide_173628	PPLP003276068	PPLP003276074		
P-27122	4/15/2016	MR-01188 - April 18th Connect4Success 04.12.16 (10am)	PPLP003498766	PPLP003498777		
P-27123	7/23/2016	Weekly Highlights for P/E 7/22/16	PPLP004211696	PPLP004211709		
P-27124	6/17/2016	Weekly Highlights for PE 6/17/16	PPLP004212024	PPLP004212045		

P-27125	7/29/2016	Weekly Highlights P/E 7/29/16	PPLP004212157	PPLP004212169		
P-27126	8/5/2016	PD Team update	PPLP004215398	PPLP004215406		
P-27127	12/11/2015	FINAL 2112015 Medical Affairs Roles and Responsibilities	PPLPC001000221920	PPLPC001000221921		
P-27128	5/25/2006	Purdue News Summary - AM Report	PPLPC004000072128	PPLPC004000072142		
P-27129	6/15/2006	RE: Walgreen's Post Audit Buysins DM243029~\$40,634.78	PPLPC004000072870	PPLPC004000072873		
P-27130	8/22/2006	RE: Walgreens	PPLPC004000076969	PPLPC004000076970		
P-27131	11/13/2006	FW: Coupons and Savings Cards Redemption Report sorted by Chain Pharmacy	PPLPC004000089723	PPLPC004000089725		
P-27132	1/15/2007	RE: Oxycontin --Walgreen top to top meeting--Agenda	PPLPC004000097020	PPLPC004000097024		
P-27133	4/15/2008	RE: Oxycontin Product Replacement Program	PPLPC004000158026	PPLPC004000158027		
P-27134	8/8/2008	FW: Walgreens in PR - OxyContin \$60 Patient Savings Card	PPLPC004000170400	PPLPC004000170409		
P-27135	9/26/2008	RE: Meeting/October 14th	PPLPC004000176088	PPLPC004000176090		
P-27136	2/3/2009	This is the one for file	PPLPC004000189988	PPLPC004000189989		
P-27137	5/8/2009	FW: July-Sept 08 Service Level	PPLPC004000201481	PPLPC004000201483		
P-27138	1/26/2010	FW: RxPatrol Alert / Pharmacy Robbery- Sarasota, Florida-Suspect shot and killed by Law enforcement	PPLPC004000224201	PPLPC004000224203		
P-27139	6/28/2010	RE: Data Agreement	PPLPC004000240350	PPLPC004000240352		
P-27140	11/23/2010	112310 TS FU	PPLPC004000258239	PPLPC004000258240		
P-27141	1/10/2011	Re: Butrans - Walgreens	PPLPC004000264228	PPLPC004000264228		
P-27142	3/25/2011	RE: savings cards	PPLPC004000275508	PPLPC004000275509		
P-27143	4/8/2011	RE: Butrans edit on Medispan	PPLPC004000277033	PPLPC004000277035		
P-27144	8/22/2011	claims PDF thru 8-20-11	PPLPC004000291439	PPLPC004000291444		
P-27145	10/26/2011	RE: Walgreens - Butrans Savings Card Request	PPLPC004000299663	PPLPC004000299664		
P-27146	11/1/2011	RE: Patient Saving Cards-- Butrans Walgreens	PPLPC004000300253	PPLPC004000300256		
P-27147	1/18/2012	RE: Walgreen e-vouchers and pharmacy supervisory meetings.	PPLPC004000308323	PPLPC004000308324		
P-27148	3/18/2012	Walgreens District Manager Sales Calls	PPLPC004000316824	PPLPC004000316825		
P-27149	3/23/2012	Recent Meeting	PPLPC004000317515	PPLPC004000317516		
P-27150	5/21/2012	Updated MAY 18 _Walgreens Pharmacy Supervisor Calls Control Form	PPLPC004000323637	PPLPC004000323638		
P-27151	10/23/2012	Re: walgreen e-vouchers	PPLPC004000338431	PPLPC004000338432		
P-27152	11/19/2012	FW: performance Appraisal	PPLPC004000340400	PPLPC004000340407		
P-27153	4/24/2013	RE: Additional Calls Regarding Walgreens Activities and Duane Reade - FYI	PPLPC004000354859	PPLPC004000354861		
P-27154	6/25/2013	FW: Walgreens Policy on Filling Prescriptions for Controlled Substances	PPLPC004000361251	PPLPC004000361255		
P-27155	8/30/2013	Minutes from 8/29/13 ACT meeting	PPLPC004000370145	PPLPC004000370146		
P-27156	9/10/2013	Re: Walgreens	PPLPC004000371296	PPLPC004000371298		
P-27157	10/15/2013	RE: eVoucher Status	PPLPC004000377572	PPLPC004000377574		
P-27158	12/18/2013	RE: 2013 Performance Appraisal, 2014 Individual Objectives, and 2014 IDP Process and Timeline Information	PPLPC004000385390	PPLPC004000385396		
P-27159	11/12/1997	Daily sales	PPLPC008000002006	PPLPC008000002006		
P-27160	4/19/2000	FW: OxyContin 160mg Stocking *****ACTION REQUIRED*****	PPLPC008000008095	PPLPC008000008097		
P-27161	1/31/2001	RE: Walgreen's Annual Wisconsin Meeting	PPLPC008000014078	PPLPC008000014079		
P-27162	2/2/2001	RE: Walgreen's Annual Wisconsin Meeting (addendum)	PPLPC008000014107	PPLPC008000014109		
P-27163	2/2/2001	RE: Walgreen's Annual Wisconsin Meeting (addendum)	PPLPC008000014124	PPLPC008000014127		
P-27164	2/26/2001	RE: Publix Pharmacy Program- 2/20/01 Success	PPLPC008000014757	PPLPC008000014758		
P-27165	3/20/2001	National Accounts Account Contact Report	PPLPC008000015247	PPLPC008000015250		
P-27166	3/23/2001	RE: Analysis of zip codes	PPLPC008000015396	PPLPC008000015398		
P-27167	4/17/2001	RE: [pain] Oxycontin and Duragesic advertisement	PPLPC008000015865	PPLPC008000015865		
P-27168	4/19/2001	FW: Walgreens District Mgrs. Meeting --4/17/01	PPLPC008000015960	PPLPC008000015961		
P-27169	4/19/2001	RE: Lipman CE for Walgreens	PPLPC008000015992	PPLPC008000015992		
P-27170	5/3/2001	RE: Walgreens Anti-Diversion - Literature order due for May 9, 2001	PPLPC008000016471	PPLPC008000016473		
P-27171	5/8/2001	RE: Walgreens CME	PPLPC008000016594	PPLPC008000016597		
P-27172	6/20/2001	FW: Eckerd Pharmacy Program Re-cap	PPLPC008000017922	PPLPC008000017924		
P-27173	6/27/2001	FW: Port St. Lucie Walgreens DM Request	PPLPC008000018142	PPLPC008000018144		
P-27174	9/10/2001	RE: Walgreens Speaker program	PPLPC008000020183	PPLPC008000020185		
P-27175	9/17/2001	RE: Walgreen Florida Speaker Program	PPLPC008000020434	PPLPC008000020436		
P-27176	10/3/2001	RE: Room Confirmations for CE	PPLPC008000020805	PPLPC008000020811		
P-27177	10/19/2001	FW: Walgreen	PPLPC008000021157	PPLPC008000021163		

P-27178	11/5/2001	RE: Walgreens Program Feedback from October 28	PPLPC008000021438	PPLPC008000021440		
P-27179	11/12/2001	RE: Walgreens Pharmacy Meeting	PPLPC008000021540	PPLPC008000021543		
P-27180	11/20/2001	Sales Bulletin #259	PPLPC008000021636	PPLPC008000021637		
P-27181	1/24/2002	FW: Litlist	PPLPC008000022546	PPLPC008000022550		
P-27182	2/1/2002	RE: Walgreens Update	PPLPC008000022681	PPLPC008000022683		
P-27183	3/13/2002	RE: Walgreen program- Human Factors in Pharmacy Errors	PPLPC008000023258	PPLPC008000023259		
P-27184	4/5/2002	RE: RE: Walgreen's OxyContin rx instruction sheet	PPLPC008000023735	PPLPC008000023736		
P-27185	5/7/2002	RE: Announcement Message from Michael Friedman	PPLPC008000024306	PPLPC008000024308		
P-27186	7/24/2002	FW: Talking Points	PPLPC008000026018	PPLPC008000026020		
P-27187	3/30/2003	CE programs and grants at Walgreens	PPLPC008000029907	PPLPC008000029910		
P-27188	8/5/2004	Conference Call Memo	PPLPC008000037026	PPLPC008000037029		
P-27189	10/6/2004	RE: Presentation	PPLPC008000038148	PPLPC008000038150		
P-27190	4/7/2005	RE: HDMA MARKETING CONFERENCE FOLLOW UP	PPLPC008000041397	PPLPC008000041399		
P-27191	4/18/2001	RE: [pain] Oxycontin and Duragesic advertisement	PPLPC009000037900	PPLPC009000037901		
P-27192	4/27/2001	RE: [pain] Oxycontin and Duragesic advertisement	PPLPC009000038812	PPLPC009000038814		
P-27193	6/20/2002	FW: PROMOTIONAL MATERIALS - OPO365 - Revised NAM Pharmacists Guide	PPLPC009000068205	PPLPC009000068207		
P-27194	8/18/2016	FW: Exhibit Opportunities in S CA	PPLPC010000087598	PPLPC010000087599		
P-27195	10/19/2016	Re: BEP kits	PPLPC010000088839	PPLPC010000088840		
P-27196	2/27/2017	Re: 96817 DAM Grid Hysingla ER	PPLPC010000090336	PPLPC010000090336		
P-27197	11/5/2001	Revised Budget Presentation	PPLPC012000040663	PPLPC012000040664		
P-27198	12/16/2005	Coupon redemption	PPLPC014000040243	PPLPC014000040244		
P-27199	6/18/2015	Fwd: Walgreens	PPLPC015000217960	PPLPC015000217962		
P-27200	11/20/2015	Link4Success Field Sales E-Newsletter - Week of November 16th, 2015	PPLPC015000231335	PPLPC015000231342		
P-27201	4/11/2016	Road to Success: Mandatory LTC Training WebEx for the Pittsburgh, Philly, Newark, SNJ and Cleveland Butrans Leads	PPLPC015000242748	PPLPC015000242750		
P-27202	10/24/2016	FW: Promotional Material Volume	PPLPC016000291966	PPLPC016000291968		
P-27203	10/31/2016	FW: American Society of Consultant Pharmacists, (ASCP) National Conference in Dallas TX, Hilton Anatole, Nov 4th -6th 2016 Please review, possible action needed	PPLPC016000293113	PPLPC016000293116		
P-27204	1/20/2017	Weekly Highlights P/E 1/20/2017	PPLPC018001400813	PPLPC018001400834		
P-27205	2/17/2017	Weekly Highlights P/E 2/17/2017	PPLPC018001406348	PPLPC018001406368		
P-27206	3/3/2017	Weekly Highlights P/E 3/3/2017	PPLPC018001410026	PPLPC018001410048		
P-27207	3/15/2016	RE: Consumer unable to fill script - CA	PPLPC019001251868	PPLPC019001251869		
P-27208	2/10/2017	FW: Weekly Highlights P/E 2/3/2017 and 2/10/2017	PPLPC019001350388	PPLPC019001350433		
P-27209	11/16/2000	FW: Continuing Education	PPLPC020000008349	PPLPC020000008363		
P-27210	6/6/2013	FW: CEAC Minutes June 4th	PPLPC020000688698	PPLPC020000688722		
P-27211	8/16/2002	FW: FW: Port St. Lucie Robberies	PPLPC021000022020	PPLPC021000022023		
P-27212	1/11/2017	Requested Information for 2016/2017	PPLPC021000876939	PPLPC021000876945		
P-27213	7/1/2002	Should I Dispense Programs	PPLPC022000019177	PPLPC022000019179		
P-27214	12/15/2015	FW: Recently Trained Speakers in West Region	PPLPC022000917118	PPLPC022000917122		
P-27215	1/16/2017	ARK Insights for Use	PPLPC022000982658	PPLPC022000982663		
P-27216	4/20/2017	FW: Walgreens capability presentation	PPLPC022000992950	PPLPC022000992993		
P-27217	5/13/2016	LELE Program Description	PPLPC023000886684	PPLPC023000886687		
P-27218	10/5/2016	RE: Managed Medicaid	PPLPC023000910266	PPLPC023000910268		
P-27219	1/12/2018	APPROVED - OxyContin- "MR-00796 - OxyContin Savings Card - Downloadable version - Eligibility language update" is APPROVED FOR USE.	PPLPC023000969885	PPLPC023000969888		
P-27220	5/1/1997	OxyContin Super Stores!!!	PPLPC024000002380	PPLPC024000002381		
P-27221	6/21/2001	RE: Port St. Lucie Walgreens DM Request	PPLPC024000044089	PPLPC024000044090		
P-27222	3/28/2002	FW: RE: Walgreen's oxycontin rx instruction sheet.	PPLPC024000067598	PPLPC024000067599		
P-27223	2/15/2006	RE: Walgreens and Coupon Redemption	PPLPC024000152810	PPLPC024000152810		
P-27224	2/4/2016	Re: Evoucher in California	PPLPC024000967797	PPLPC024000967802		
P-27225	3/17/2016	CDC Guidelines Background and FAQ Responses - Bulletin#33	PPLPC024000970716	PPLPC024000970729		
P-27226	6/14/2016	Actions to Address our External Environment	PPLPC024000980392	PPLPC024000980397		
P-27227	8/29/2017	FW: Answer included:: Question if Phoenix is getting updated with the current changes - Fwd: Meal Tracking	PPLPC024001013980	PPLPC024001013985		
P-27228	4/16/2001	RE: [pain] Oxycontin and Duragesic advertisement	PPLPC025000021494	PPLPC025000021496		
P-27229	1/15/2015	FW: action required: Walgreen Supervisor Meetings	PPLPC025000188741	PPLPC025000188743		



P-27230	6/12/2015	FW: Walgreens- Pharmacist Issue Response sent to all regional Managers	PPLPC025000204908	PPLPC025000204910		
P-27231	7/26/2016	RAE MBO 2016 1st Semester Final	PPLPC025000231951	PPLPC025000232000		
P-27232	12/2/2016	Salesforce District Business Reviews & Plans for 2017 - Group 4	PPLPC025000238325	PPLPC025000238331		
P-27233	9/29/2000	EOM Reports	PPLPC029000026208	PPLPC029000026224		
P-27234	6/12/2015	FW: Walgreens- Pharmacist Issue Response	PPLPC030000937197	PPLPC030000937197		
P-27235	10/11/2007	Fw: Proposal for Pain Management Webinars	PPLPC031000393649	PPLPC031000393661		
P-27236	1/29/2015	FW: Hysingla ER follow up--- Walgreens website	PPLPC031001290102	PPLPC031001290105		
P-27237	3/18/2016	Approved for Use - Butrans downloadable savings cards (desktop & mobile)	PPLPC031001423849	PPLPC031001423858		
P-27238	8/25/2014	Re: Walgreen robberies replacement product	PPLPC034000962391	PPLPC034000962392		
P-27239	12/8/2014	RE: Oxycontin Reporting	PPLPC034001004458	PPLPC034001004462		
P-27240	9/9/2016	RE: Weekly Highlights P/E 9/9/2016	PPLPC036000257026	PPLPC036000257042		
P-27241	10/16/2001	FW: Live & Teleconference Format	PPLPC046000001754	PPLPC046000001763		
P-27242	7/25/2003	Walgreens1	PPLPC051000013543	PPLPC051000013548		
P-27243	5/23/2013	Fwd: OxyContin availability in Las Vegas - FYI	PPLPC053000080786	PPLPC053000080789		
P-27244	1/27/2017	Weekly Highlights P/E 1/27/2017	PPLPC053000120592	PPLPC053000120617		
P-27245	5/17/2012	FW: OutReach Data	PPLPC057000011119	PPLPC057000011123		
P-27246	4/23/2004	OxyContin Rebate Program	PURCHI-003288172	PURCHI-003288172		
P-27247	5/19/2004	Oxycontin Rebate	PURCHI-003288173	PURCHI-003288174		
P-27248	10/10/2012	RE: Time Sensitive - Drafts Comments to FDA on Hydrocodone Rescheduling	Rite_Aid_OMDL_0019442	Rite_Aid_OMDL_0019443		
P-27249	3/10/2013	RE: Issue Brief or letter on rescheduling	Rite_Aid_OMDL_0027468	Rite_Aid_OMDL_0027470		
P-27250	5/18/2005	05 18 2005 AUSA Contact Letter	US-DEA-00032411	US-DEA-00032412		
P-27251	3/15/2005	03 15 2005 Closing Discussion with Mgmt	US-DEA-00032414	US-DEA-00032423		
P-27252	5/1/2005	05 01 2005 Spreadsheet Preparation	US-DEA-00032424	US-DEA-00032426		
P-27253	11/2/2006	11 02 2006 Signed MOU and Case Closure	US-DEA-00032427	US-DEA-00032427		
P-27254	6/12/2009	Walgreens Scheduled Investigation 06 12 2009	US-DEA-00032611	US-DEA-00032632		
P-27255	6/17/2015	RE: Notes from call/Walgreens DPA CPhA	WAGCASF00002605	WAGCASF00002610		
P-27256	5/28/2019	FW: Prescribers with Controlled Substances Restrictions	WAGCASF00010545	WAGCASF00010586		
P-27257	2/10/2016	Region 11 Pharmacist GFD Opportunities	WAGCASF00016889	WAGCASF00016899		
P-27258	3/26/2019	FW: Concerns about overprescribing CII	WAGCASF00019407	WAGCASF00019407		
P-27259	12/24/2012	Daily C-2 Report	WAGCASF00042976	WAGCASF00042977		
P-27260	10/7/2013	106 Report 04950	WAGCASF00044716	WAGCASF00044719		
P-27261	6/21/2013	RE: Question	WAGCASF00044734	WAGCASF00044736		
P-27262	9/19/2015	Fwd: Good Faith Dispensing	WAGCASF00060684	WAGCASF00060712		
P-27263	6/2/2015	Fwd: Easy 123DM	WAGCASF00060931	WAGCASF00061015		
P-27264	4/4/2018	RE: R. Yagar	WAGCASF00099600	WAGCASF00099611		
P-27265	10/5/2020	RE: Fwd: Ref #12906940	WAGCASF00103765	WAGCASF00103770		
P-27266	5/14/2013	RE: Cardinal 340B CII's	WAGCASF00119453	WAGCASF00119455		
P-27267	7/31/2017	Re: ACTION: HRxD Report of Drugs Needing Research	WAGCASF00121999	WAGCASF00122001		
P-27268	3/11/2020	Fwd: URGENT - assist with Disclosure Log for CIA	WAGCASF00122935	WAGCASF00122938		
P-27269	9/5/2018	RE: Review:Respond: YAGAR Concern Reporting Party [?] (1)	WAGCASF00123881	WAGCASF00123884		
P-27270	8/29/2018	RE: Review:Respond: YAGAR Concern Reporting Party [?] (1)	WAGCASF00123893	WAGCASF00123895		
P-27271	5/26/2017	Weekly Communications 5-26	WAGCASF00124269	WAGCASF00124271		
P-27272	10/30/2017	Support Requested: Annual GFD Training and TDGFD Checklist Update	WAGCASF00124307	WAGCASF00124307		
P-27273	1/4/2017	RE: CII Discrepancy	WAGCASF00125101	WAGCASF00125101		
P-27274	4/7/2021	18	WAGCASF00127776	WAGCASF00127783		
P-27275	5/12/2013	Re: Oxycodone 30 mg	WAGCASF00128664	WAGCASF00128665		
P-27276	2/11/2013	RE: Conference Call Monday 02/11/2012	WAGCASF00129576	WAGCASF00129581		
P-27277	3/8/2018	APM Investigation Needed - RPSH Robert Yagar (Long Beach, CA)	WAGCASF00142021	WAGCASF00142032		
P-27278	9/24/2018	Fwd: Hello Waymin	WAGCASF00158959	WAGCASF00158963		
P-27279	8/14/2018	CA Counseling CAP RPh Decline Summary_07.2018 vF	WAGCASF00158984	WAGCASF00158986		
P-27280	12/21/2017	Fwd: California State Board of Pharmacy Subscriber Alert	WAGCASF00159408	WAGCASF00159409		
P-27281	10/15/2019	FW: Prescribers with Controlled Substances Restrictions	WAGCASF00160045	WAGCASF00160093		
P-27282	6/25/2018	Action: CII Reconciliation clarification	WAGCASF00167446	WAGCASF00167446		
P-27283	6/28/2016	FY16 Q3 Control Adjusted Report - District	WAGCASF00308868	WAGCASF00308892		
P-27284	9/11/2018	R. Yagar	WAGCASF00309583	WAGCASF00309583		

P-27285	1/27/2014	National Target Drug Good Faith Dispensing Checklist	WAGCASF00313394	WAGCASF00313398		
P-27286	10/13/2010	self appraisal 2010	TEVA_CAOC_13973739	TEVA_CAOC_13973743		
P-27287	4/4/2018	Robert Statement	WAGCASF00314285	WAGCASF00314291		
P-27288	11/1/2021	IC10001237824 - incident level	WAGCASF00599480	WAGCASF00599481		
P-27289	11/1/2021	IC10001237907 - investigation related to IC10001237824	WAGCASF00599482	WAGCASF00599484		
P-27290	11/1/2021	IC10005690721	WAGCASF00599490	WAGCASF00599494		
P-27291	11/1/2021	IC10006786668	WAGCASF00599495	WAGCASF00599499		
P-27292	11/1/2021	IC10007187502	WAGCASF00599500	WAGCASF00599504		
P-27293	11/1/2021	IC10007443194	WAGCASF00599505	WAGCASF00599508		
P-27294	11/1/2021	IC10007999450 - case related to IC10007999047	WAGCASF00599512	WAGCASF00599514		
P-27295	11/1/2021	IC10010513959 - incident level	WAGCASF00599517	WAGCASF00599519		
P-27296	11/1/2021	Record related to IC10002424074	WAGCASF00599528	WAGCASF00599530		
P-27297	11/1/2021	Record related to IC10002558608	WAGCASF00599531	WAGCASF00599533		
P-27298	11/1/2021	Record related to IC100027244937	WAGCASF00599534	WAGCASF00599537		
P-27299	11/3/2021	CM-HTL-IN-116857890 - related to IC10002576683	WAGCASF00600080	WAGCASF00600082		
P-27300	11/3/2021	CM-HTL-IN-118340970 - record related to IC10002478716	WAGCASF00600089	WAGCASF00600091		
P-27301	11/3/2021	IC10007475204	WAGCASF00600150	WAGCASF00600153		
P-27302	9/10/2015	2015 COBC response	WAGCASF00607090	WAGCASF00607090		
P-27303	11/10/2021	IC10000316819 - incident level	WAGCASF00611507	WAGCASF00611509		
P-27304	11/16/2021	CM-HTL-IN-117216061 - related to IC10002380664	WAGCASF00611514	WAGCASF00611516		
P-27305	11/16/2021	IC10005617104 - incident level	WAGCASF00611558	WAGCASF00611560		
P-27306	11/16/2021	IC10006265556 - incident level	WAGCASF00611566	WAGCASF00611567		
P-27307	9/6/2016	APIS	WAGCASF00611984	WAGCASF00611986		
P-27308	12/6/2021	1158492_KAMALI_GOLNAZ_Discipline for Misconduct_20150717_23	WAGCASF00612096	WAGCASF00612104		
P-27309	10/21/2014	1158492_KAMALI_GOLNAZ_Discipline for Misconduct_20160620_25	WAGCASF00612114	WAGCASF00612117		
P-27310	12/6/2021	1158492_KAMALI_GOLNAZ_Discipline for Misconduct_20160620_26	WAGCASF00612118	WAGCASF00612120		
P-27311	9/17/2015	Cori Evans Emails re Kamali	WAGCASF00612175	WAGCASF00612235		
P-27312	10/6/2016	Golnaz Kamali Personnel File	WAGCASF00612437	WAGCASF00612514		
P-27313	12/9/2021	CM-HTL-IN-113454064 - related to IC10002390614	WAGCASF00612946	WAGCASF00612948		
P-27314	12/9/2021	CM-HTL-IN-113571398 - related to IC10002392446	WAGCASF00612949	WAGCASF00612952		
P-27315	12/9/2021	CM1195547 - related to IC10001463370	WAGCASF00612957	WAGCASF00612961		
P-27316	12/9/2021	CM1199032 - related to IC10001495802	WAGCASF00612962	WAGCASF00612965		
P-27317	12/9/2021	CM952285 - related to IC10001822526	WAGCASF00612970	WAGCASF00612973		
P-27318	12/20/2021	IC10004973110 - incident level	WAGCASF00612985	WAGCASF00612987		
P-27319	12/20/2021	IC10004973565 - investigation related to IC10004973110	WAGCASF00612988	WAGCASF00612991		
P-27320	12/20/2021	IC10006196942 - incident level	WAGCASF00613020	WAGCASF00613022		
P-27321	12/20/2021	IC10008699893	WAGCASF00613027	WAGCASF00613030		
P-27322	12/20/2021	IC10008905787	WAGCASF00613036	WAGCASF00613040		
P-27323	12/20/2021	IC10009798801	WAGCASF00613045	WAGCASF00613048		
P-27324	12/20/2021	IC10010216397	WAGCASF00613053	WAGCASF00613056		
P-27325	12/20/2021	IC10010313210	WAGCASF00613057	WAGCASF00613060		
P-27326	12/20/2021	IC10010552619	WAGCASF00613069	WAGCASF00613072		
P-27327	1/12/2022	IC10000867902	WAGCASF00613199	WAGCASF00613202		
P-27328	1/12/2022	IC10005445944	WAGCASF00613206	WAGCASF00613210		
P-27329	8/16/2018	RE: Hello and update!	WAGCASF00613211	WAGCASF00613213		
P-27330	10/11/2017	Fully Executed_Purdue_PNE	WAGCASF00613242	WAGCASF00613244		
P-27331	6/26/2006	good_faith_dispensing	WAGFLAG00019484	WAGFLAG00019485		
P-27332	3/26/2014	FW: DEA#	WAGFLAG00099937	WAGFLAG00099939		
P-27333	2/17/2013	Market 5 Visit - 2/12 thru 2/14	WAGFLAG00634374	WAGFLAG00634377		
P-27334	2/7/2012	Re: Suspicious Activity Report	WAGFLAG01230566	WAGFLAG01230567		
P-27335	5/14/2012	Vicodin - June & Sept Communications Walgreens HQC - 050812	WAGFLAG03915801	WAGFLAG03915802		
P-27336	10/12/2012	Mallinckrodt-Covidient MPU Exhibit 2_Exalgo_Final Sig_101212	WAGFLAG03916473	WAGFLAG03916473		
P-27337	12/12/2013	RTS-1116_Abbvie_Vicodin_RPh_EDU	WAGFLAG03916482	WAGFLAG03916482		
P-27338	1/25/2012	WAG-1216_Janssen_Pharmaceuticals_Nucynta_MPU_Alert_Program	WAGFLAG03916483	WAGFLAG03916483		
P-27339	10/23/2012	Exalgo 32 mg MPU Walgreen	WAGFLAG03916486	WAGFLAG03916512		

P-27340	5/22/2015	pharmacy and retail operations news you can use	WAGFLAG03916607	WAGFLAG03916612		
P-27341	10/13/2011	NUCYNTA ER Manufacturer Product Update	WAGFLAG03916622	WAGFLAG03916629		
P-27342	3/6/2012	NUCYNTA ER MPU Submission 11 11 11	WAGFLAG03916630	WAGFLAG03916636		
P-27343	2/12/2015	RE: Walgreens Pharmacy will not fill any Hysingal	WAGFLAG03925450	WAGFLAG03925451		
P-27344	3/17/2015	FW: Walgreens New Castle - RPH unfamiliar with Hysingla ER	WAGFLAG03931562	WAGFLAG03931588		
P-27345	3/2/2015	RE: Hysingla ER Trade Communication Program - Walgreens	WAGFLAG03931983	WAGFLAG03932010		
P-27346	3/3/2015	FW: Walgreens	WAGFLAG03932011	WAGFLAG03932013		
P-27347	4/6/2016	Re: Walgreens educational opportunities. Purdue.	WAGFLAG03932245	WAGFLAG03932247		
P-27348	8/26/2016	RE: Walgreens University October 18th / MSA attached	WAGFLAG03935409	WAGFLAG03935410		
P-27349	10/18/2011	Market Action Plan/Guidelines for CII Dispensing	WAGFLDEA00000447	WAGFLDEA00000448		
P-27350	10/18/2011	Market Action Plan/Guidelines for CII Dispensing	WAGFLDEA00000741	WAGFLDEA00000762		
P-27351	3/9/2011	Action Plan to Reduce CII Dispensing	WAGFLDEA00000912	WAGFLDEA00000912		
P-27352	6/12/2018	Store #7832 Update	WAGMDL00041551	WAGMDL00041552		
P-27353	10/12/2016	FW: Purdue Compass communication - review requested	WAGMDL00234674	WAGMDL00234678		
P-27354	6/9/2015	CE Webinar - Opioids Use or Abuse	WAGMDL00266725	WAGMDL00266726		
P-27355	4/30/2008	Retention Schedule	WAGMDL00286244	WAGMDL00286424		
P-27356	4/13/2015	Walgreens Enterprise Record Retention Schedule	WAGMDL00286425	WAGMDL00286425		
P-27357	10/19/2014	FW: CE Live:Update on Pharmacological Management of Pain	WAGMDL00406275	WAGMDL00406277		
P-27358	5/16/2012	Confirmed: C2-5 Hospice Ordering	WAGMDL00425779	WAGMDL00425781		
P-27359	4/1/2013	RE: C2 transfer	WAGMDL00525172	WAGMDL00525186		
P-27360	5/17/2013	RE: Woodland inventory bleed out	WAGMDL00525280	WAGMDL00525285		
P-27361	5/25/2016	RE: Drug Diversion Training Review Meeting Documents	WAGMDL00707283	WAGMDL00707306		
P-27362	7/17/2012	0347_001	WAGMDL00709367	WAGMDL00709392		
P-27363	1/30/2015	GFD Checklist	WAGMDL00736119	WAGMDL00736142		
P-27364	3/4/2014	FW: March 11 ABC Update : Agenda and slide template	WAGMDL00746498	WAGMDL00746545		
P-27365	8/18/2014	Schedule drugs WAG and COT 0714	WAGMDL00749589	WAGMDL00749589		
P-27366	1/14/2016	Schedule drugs 1215	WAGMDL00749646	WAGMDL00749646		
P-27367	9/18/2013	RE: Prescriber Indexing Criteria	WAGMDL00749744	WAGMDL00749748		
P-27368	12/27/2007	Rannazzisi Letter to Walgreens Perrysburg DC	WAGMDL00753975	WAGMDL00753995		
P-27369	1/14/2013	List of prescribers with at least 13 overall Oxy 15/30 scripts, avg 1/wk, including Gores	WAGMDL00779371	WAGMDL00779371		
P-27370	6/4/2007	CD5002R1.TXT	WAGMDL00852170	WAGMDL00852170		
P-27371	11/1/2010	CDCORP	WAGMDL00852176	WAGMDL00852176		
P-27372	7/5/2011	CDCORP	WAGMDL00852183	WAGMDL00852183		
P-27373	2/6/2012	CDCORP	WAGMDL00852185	WAGMDL00852185		
P-27374	12/3/2007	CDCORP	WAGMDL00852189	WAGMDL00852189		
P-27375	6/2/2008	SUSPICIOUS DRUG CONTROL ORDERS	WAGMDL00852194	WAGMDL00852194		
P-27376	12/1/2008	CDCORP	WAGMDL00852195	WAGMDL00852195		
P-27377	8/3/2009	SUSPICIOUS DRUG CONTROL ORDERS	WAGMDL00852204	WAGMDL00852204		
P-27378	11/18/2021	2015_Code_of_Business_Conduct_Questionnaire_(T1)_11-18-2021.xlsx	WAGMDL01198492	WAGMDL01198492		
P-27379	11/18/2021	2015_Code_of_Business_Conduct_Questionnaire_(T2)_11-18-2021.xlsx	WAGMDL01198493	WAGMDL01198493		
P-27380	11/18/2021	2015_Code_of_Business_Conduct_Questionnaire_(T3)_Code_of_Business_Conduct_Questionnaire_Cuestionario_de_Código_de_Conducta (T3) 11-18-2021.xlsx	WAGMDL01198494	WAGMDL01198494		
P-27381	11/18/2021	2016_Code_of_Conduct_&_Business_Ethics_Questionnaire_11-18-2021.xlsx	WAGMDL01198495	WAGMDL01198495		
P-27382	11/18/2021	2017_Code_of_Conduct_&_Business_Ethics_Questionnaire_11-18-2021.xlsx	WAGMDL01198496	WAGMDL01198496		
P-27383	11/18/2021	Code_of_Business_Conduct_Questionnaire_Cuestionario_de_Código de Conducta (T1) 11-18-2021.xlsx	WAGMDL01198497	WAGMDL01198497		
P-27384	9/16/2011	Woodland DC DEA Review 4th Quarter Fiscal 2011 Index	WAGMDLPER00000644	WAGMDLPER00000912		
P-27385	4/18/2018	FW: Medical Board Notification of Actions Relating to the License or Practice of Physicians and Surgeons	WAGNMAG00073559	WAGNMAG00073561		
P-27386	6/6/2012	C2 order	WAGNVAG00050090	WAGNVAG00050090		
P-27387	1/23/2018	CA BOP Stipulated Settlement and Disciplinary Order re Walgreens 04170 Sacramento	N/A	N/A		
P-27388	5/8/2018	CA BOP Stipulated Settlement and Disciplinary Order re Walgreens 02126 San Carlos	N/A	N/A		

P-27389	1/14/2019	CA BOP Stipulated Settlement and Disciplinary Order re Walgreens 13000 Chico	N/A	N/A		
P-27390	11/6/2013	CA BOP Stipulated Settlement and Disciplinary Order re Walgreens 06683 Visalia	N/A	N/A		
P-27391	1/20/2016	CA BOP Stipulated Settlement and Disciplinary Order re Walgreens 2306 Hayward	N/A	N/A		
P-27392	10/18/2017	CA BOP Stipulated Settlement and Disciplinary Order re Walgreens 06036 Granite Bay	N/A	N/A		
P-27393	3/1/2001	Pain Education for the Pharmacist	E513_00018951	E513_00018951		
P-27394	5/3/2010	SUSPICIOUS DRUG CONTROL ORDERS	WAGMDL00852173	WAGMDL00852173		
P-27395	1/3/2011	Suspicious Drug Control Orders	WAGMDL00852174	WAGMDL00852174		
P-27396	4/5/2010	CDCORP.TXT	WAGMDL00852175	WAGMDL00852175		
P-27397	5/5/2008	CDCORP.TXT	WAGMDL00852193	WAGMDL00852193		
P-27398	10/24/2011	Information Update - Description has changed: Hospice Ordering Procedures (Long Term and Emergency Procedures)	WAGMDL00881285	WAGMDL00881287		
P-27399	10/9/2012	FW: DEA 106 Report 04242	WAGNVAG00048543	WAGNVAG00048545		
P-27400	8/13/2014	Bi-Weekly WAG/ABC Call	ABDCMDL05503627	ABDCMDL05503627		
P-27401	10/2/2006	RE: Walgreens/Opana	ENDO_DEAG_00000275	ENDO_DEAG_00000276		
P-27402	1/16/2013	Action Requested: NACDS DEA WG -- Code of Conduct Survey	NACDS_MDL0000918	NACDS_MDL0000933		
P-27403	9/28/2012	Update and October EC Call	NACDS_MDL0001695	NACDS_MDL0001702		
P-27404	7/24/2013	RE: Thank You	PPLP004471561	PPLP004471562		
P-27405	10/15/2013	FW: Walgreens and Rebate Cards	PPLP004471876	PPLP004471876		
P-27406	10/15/2013	Fwd: as per your request - OxyContin rebate card	PPLPC004000377458	PPLPC004000377461		
P-27407	3/20/2014	General Session Presentations (All).pptx	PPLPC012000469238	PPLPC012000469239		
P-27408	3/9/2015	Re: Hysingla ER 30 mg Walgreens stores in Amityville, N.Y. PRODUCT WAS ORDERED FOR THE PATIENT	PPLPC020000883651	PPLPC020000883655		
P-27409	12/16/2014	Walgreens pre call notes	PPLPC031001274529	PPLPC031001274530		
P-27410	12/22/2014	RE: Hysingla ER Pharmacist Guide	PPLPC034001013154	PPLPC034001013187		
P-27411	7/13/2016	FW: Walgreens Agreement for Hysingla ER MPU Program	PPLPC035000264294	PPLPC035000264299		
P-27412	6/27/2005	Report Re: Scheduled Investigation of Walgreen Co., DEA #RW0152467 - Mt Vernon	US-DEA-00030763	US-DEA-00030786		
P-27413	9/13/1999	Controlled Substance Storage Facility Relocated - Mt Vernon	US-DEA-00030921	US-DEA-00030925		
P-27414	3/12/2015	Report Re: Scheduled Investigation/Case Closing WALGREENS CO, 5100 Lake Terrace NE, Mount Vernon, Illinois, DEA Registration Number RW0152467	US-DEA-00031015	US-DEA-00031029		
P-27415	5/27/1999	Report re: Scheduled Regulatory	US-DEA-00031084	US-DEA-00031099		
P-27416	6/23/2006	[REDACTED] DEA6 found under [REDACTED] (Search2.0)	US-DEA-00031395	US-DEA-00031398		
P-27417	1/7/2013	Report Re: Pre-Onsite Investigation re: WALGREENS CORPORATION, Perrysburg, Ohio, DEA# RW0294493	US-DEA-00031425	US-DEA-00031428		
P-27418	6/9/2015	Report Re: Case Closing and Regulatory Investigation of WALGREENS CORPORATION - DEA# RW0294493	US-DEA-00031492	US-DEA-00031505		
P-27419	12/1/2004	[REDACTED] Scheduled Investigation DEA 6	US-DEA-00032745	US-DEA-00032760		
P-27420	10/14/2009	Jupiter Inspection File	US-DEA-00032761	US-DEA-00032803		
P-27421	8/17/2009	Response to LOA, Case Closing	US-DEA-00033080	US-DEA-00033080		
P-27422	10/6/2010	Modification of Work Plan Requirements 10 05 2010.pdf	US-DEA-00056901	US-DEA-00056901		
P-27423	6/15/2018	RHD Hydrocodone.pptx	WAGCASF00000137	WAGCASF00000137		
P-27424	3/10/2016	RE: Murrieta Man Steals \$10,000 of OxyContin Pills in Walgreens...	WAGCASF00002339	WAGCASF00002341		
P-27425	5/24/2019	Re: Prescribers with Controlled Substances Restrictions	WAGCASF00010409	WAGCASF00010448		
P-27426	8/26/2014	Re: norco becoming a CII	WAGCASF00018434	WAGCASF00018435		
P-27427	2/26/2018	FW: Controlled Faxes	WAGCASF00023951	WAGCASF00023953		
P-27428	3/21/2016	CA BOP CITATION AND FINE	WAGCASF00025539	WAGCASF00025542		
P-27429	5/23/2018	FW: Ca BOP citation Walgreens 7751.pdf	WAGCASF00025877	WAGCASF00025880		
P-27430	6/7/2018	FW: Pharmacy #4559 Update	WAGCASF00036662	WAGCASF00036665		
P-27431	5/22/2018	Fwd: Pharmacy Security & Loss Prevention	WAGCASF00036901	WAGCASF00036902		
P-27432	2/4/2019	INFO: R11 Virtual Meeting RVP Topics	WAGCASF00050251	WAGCASF00050282		
P-27433	3/21/2020	0913_001.pdf	WAGCASF00051359	WAGCASF00051386		
P-27434	6/25/2018	C2 Reconciliation Call	WAGCASF00052834	WAGCASF00052837		
P-27435	6/8/2020	RE: Inform: Fraudulent Controlled Prescriptions	WAGCASF00063350	WAGCASF00063354		
P-27436	12/12/2013	Re: suspicious prescriber	WAGCASF00079666	WAGCASF00079666		

P-27437	5/22/2018	FW: Initial List: Store #04559: 35 Potential Violations: & Follow Up Call Today	WAGCASF00104067	WAGCASF00104070		
P-27438	5/30/2018	FW: Urgent:#4559 Roger Granados Techn Quitting / State of Store	WAGCASF00104071	WAGCASF00104073		
P-27439	10/12/2016	Re: ABC	WAGCASF00304289	WAGCASF00304293		
P-27440	10/13/2016	Re: ABC	WAGCASF00304403	WAGCASF00304408		
P-27441	3/2/2018	FW: DEA Site Visit in California	WAGCASF00315707	WAGCASF00315725		
P-27442	3/11/2021	Inspection Report Walgreens #01327	WAGCASF00333359	WAGCASF00333389		
P-27443	1/5/2018	Inspection Report Walgreens #04318	WAGCASF00333393	WAGCASF00333397		
P-27444	10/23/2020	Inspection Report Walgreens #04558	WAGCASF00333398	WAGCASF00333404		
P-27445	2/18/2015	Inspection Report Walgreens #5599	WAGCASF00333450	WAGCASF00333469		
P-27446	1/27/2017	Checklist for Gores Prescription [Walgreens Store 13666 Gores Rx]	WAGCASF00335442	WAGCASF00335448		
P-27447	8/29/2016	Pharmaceutical Manufacturer Representative Access Policy	WAGCASF00613216	WAGCASF00613218		
P-27448	6/22/2015	Pharmaceutical Manufacturer Representative Access Policy	WAGCASF00613219	WAGCASF00613219		
P-27449	5/9/2013	Pharmaceutical Manufacturer Representative Access Policy 5.9.13.pdf	WAGCASF00613220	WAGCASF00613221		
P-27450	6/1/2015	Pharmaceutical Manufacturer Representative Access Policy 6.2015.pdf	WAGCASF00613222	WAGCASF00613223		
P-27451	8/22/2011	Pharmaceutical Sales Representative Access Policy 8.22.11.pdf	WAGCASF00613224	WAGCASF00613225		
P-27452	7/27/2020	Inform: Clinical Newsletter The Quarterly Dose – July 2020	WAGCASF00613226	WAGCASF00613238		
P-27453	4/25/2016	FW: Connect and Protect Question	WAGCASF00613239	WAGCASF00613241		
P-27454	12/2/2011	Background to share with stores on CII - Stay current on protocols	WAGFLDEA00000426	WAGFLDEA00000427		
P-27455	3/25/2011	NUMEROUS EMAILS AND DOCUMENTS re FL OXY	WAGFLDEA00000661	WAGFLDEA00000693		
P-27456	5/17/2011	Re: Fw: CII Order	WAGFLDEA00001060	WAGFLDEA00001076		
P-27457	3/2/2018	RE: TDGFD discount cards	WAGMDL00002680	WAGMDL00002682		
P-27458	3/25/2016	Coupons for Target Drugs Update	WAGMDL00004167	WAGMDL00004168		
P-27459	3/21/2016	Walgreens and accepting drug discount cards for narcotics	WAGMDL00004169	WAGMDL00004174		
P-27460	3/13/2013	Oxycodone 15mg and 30mg Trend	WAGMDL00021559	WAGMDL00021560		
P-27461	2/9/2018	RE: SB 8 concerns	WAGMDL00037773	WAGMDL00037780		
P-27462	11/7/2017	FW: Purdue Insights Meeting	WAGMDL00043008	WAGMDL00043022		
P-27463	8/8/2013	RE: Need an executive summary	WAGMDL00049384	WAGMDL00049386		
P-27464	4/10/2013	FW: TD GFD questions	WAGMDL00049630	WAGMDL00049631		
P-27465	3/1/2013	Market leadership presentation	WAGMDL00055824	WAGMDL00055851		
P-27466	10/17/2016	FW: Controlled Substance report - September 2016	WAGMDL00065271	WAGMDL00065273		
P-27467	7/18/2017	RE: Team Status Meeting	WAGMDL00068060	WAGMDL00068112		
P-27468	5/1/2013	FW: Cardinal	WAGMDL00099954	WAGMDL00099972		
P-27469	5/8/2013	RE: are Good Rx Discount Drug Coupons causing Drug Diversion?	WAGMDL00100089	WAGMDL00100091		
P-27470	8/24/2017	RE: Stocking Analysis Request - Daiichi's Morphabond	WAGMDL00114901	WAGMDL00114909		
P-27471	4/16/2012	RE: C2 orders	WAGMDL00119534	WAGMDL00119535		
P-27472	10/14/2013	RE: Very Large Controlled Substance Order!	WAGMDL00132791	WAGMDL00132797		
P-27473	12/19/2014	Hysingla ER Pharmacist Guide	WAGMDL00236422	WAGMDL00236483		
P-27474	5/12/2011	Cephalon - Fentora educational dinner program	TEVA CAOC 13994498	TEVA CAOC 13994498		
P-27475	6/4/2015	Indivior deck final.pptx	WAGMDL00267076	WAGMDL00267099		
P-27476	12/31/2014	FW: Hysingla Launch & Stocking FAQ	WAGMDL00299875	WAGMDL00299883		
P-27477	6/8/2012	FW: Controlled Substance Order Quantity Override Process	WAGMDL00325135	WAGMDL00325138		
P-27478	11/23/2012	Suspicious Drug Orders	WAGMDL00325282	WAGMDL00325285		
P-27479	5/25/2012	REMINDER: Stop NY Hydrocodone Rescheduling Alliance Call	WAGMDL00372992	WAGMDL00372993		
P-27480	2/17/2011	Re: Fw: Order Quantity being reduced due to Tolerance Limit	WAGMDL00379140	WAGMDL00379144		
P-27481	4/25/2017	Purdue slides	WAGMDL00485034	WAGMDL00485040		
P-27482	1/8/2014	RxIntegrity (2).docx	WAGMDL00487850	WAGMDL00487851		
P-27483	7/28/2009	Kneller (Perrysburg DC) Response Letter to DEA	WAGMDL00493688	WAGMDL00493691		
P-27484	10/16/2012	FW: PSC drug removal	WAGMDL00502505	WAGMDL00502508		
P-27485	10/8/2014	Discuss the Walgreen Enterprise Retention Schedule	WAGMDL00578061	WAGMDL00578071		
P-27486	4/18/2014	NACDS Policy Council Action Items and Information	WAGMDL00590683	WAGMDL00590702		
P-27487	7/18/2013	Wins List	WAGMDL00591576	WAGMDL00591601		
P-27488	6/15/2017	Following Up - Rx Abuse Initiative	WAGMDL00599271	WAGMDL00599285		
P-27489	12/17/2015	RE: MOA audit document	WAGMDL00674282	WAGMDL00674319		

P-27490	1/24/2018	FW: ABC Materials	WAGMDL00682669	WAGMDL00682793		
P-27491	1/28/2013	Good Faith Dispensing Policy - Drug Diversion Self-Education Module	WAGMDL00700244	WAGMDL00700274		
P-27492	2/27/2013	Purchase Price of Certain CII Controlled Substances Sold to Certain Walgreens Locations Affected by the Immediate Suspension Order Served on the Jupiter, Florida Facility	WAGMDL00705907	WAGMDL00705909		
P-27493	4/21/2014	Schedule drugs wo ESI-WAG and COT_0314.xls	WAGMDL00749592	WAGMDL00749592		
P-27494	1/16/2014	1477609899 Wladislaw Fedoriw - Walgreens Prescriber Index.pdf	WAGMDL00750721	WAGMDL00750721		
P-27495	10/23/2012	pharmacist trainee_guide 10.23.12.pdf	WAGMDL00784713	WAGMDL00784735		
P-27496	2/15/2018	FL Opioid Bill	WAGMDL00788708	WAGMDL00788712		
P-27497	4/15/2013	RE: Top 500 Potential Risk Stores - Oxycodone - 3 months ending February 2013 *UPDATED TOP 100*	WAGMDL00817354	WAGMDL00817359		
P-27498	N/A	Process: New Inbound Trading Partner - Mt. Vernon	WAGMDL00845937	WAGMDL00846346		
P-27499	1/11/2016	Oxycontin Updates - Purdue's Policy and Action Requested - Police Reports Needed For Previous Claims	WAGMDL00870092	WAGMDL00870094		
P-27500	2/5/2014	FW: PSC Controlled Substances Pricing Recommendation	WAGMDL00871214	WAGMDL00871217		
P-27501	11/27/2012	RE: Fwd: Payroll Concerns	WAGMDL00875598	WAGMDL00875603		
P-27502	7/15/2013	PowerPoint Presentations from Market Leader Meeting (Wed. AM - set 2)	WAGMDL00905011	WAGMDL00905081		
P-27503	9/21/2016	FW: number of SOM blocks for the year	WAGMDL01041353	WAGMDL01041354		
P-27504	3/22/2013	National Target Drug Good Faith Dispensing (TD GFD) Documents	WAGMDL01178940	WAGMDL01178987		
P-27505	1/29/2014	Monthly Change Summary	WAGMDL01180428	WAGMDL01180428		
P-27506	11/12/2012	FW: November 8th DEA meeting at NABP	WAGMDL01184256	WAGMDL01184259		
P-27507	11/30/2012	Significant Cases - with attachment	WAGMDL01189267	WAGMDL01189269		
P-27508	7/20/2018	RE: OxyContin Manufacturer Reimbursement	WAGNMAG00049560	WAGNMAG00049572		
P-27509	8/6/2013	RE: Pharmacy Integrity Monthly meeting	WAGNVAG00006383	WAGNVAG00006384		
P-27510	6/9/2014	Re: Xartemis XR	WAGNVAG00040929	WAGNVAG00040931		
P-27511	11/19/2012	GFDP Update	WAGNVAG00047811	WAGNVAG00047811		
P-27512	1/12/2021	Walgreens Pharmacy Software Inspection Transcript	N/A	N/A		
P-27513	1/12/2021	Walgreens Pharmacy Software Inspection Video	N/A	N/A		
P-27514	5/22/2012	Giovannini License Surrender Decision and Order	N/A	N/A		
P-27515	9/11/2018	Petrosky, E., Harpaz, R., Fowler, K. A., Bohm, M. K., Helmick, C. G., Yuan, K., & Betz, C. J. (2018). Chronic Pain Among Suicide Decedents, 2003 to 2014: Findings From the National Violent Death Reporting System. Annals of internal medicine, 169(7), 448-455. <a href="https://doi.org/10.7326/M18-0830">https://doi.org/10.7326/M18-0830</a>	N/A	N/A		
P-27516	1/1/2016	Scherrer, J. F., Salas, J., Copeland, L. A., Stock, E. M., Ahmedani, B. K., Sullivan, M. D., Burroughs, T., Schneider, F. D., Bucholz, K. K., & Lustman, P. J. (2016). Prescription Opioid Duration, Dose, and Increased Risk of Depression in 3 Large Patient Populations. Annals of family medicine, 14(1), 54-62. <a href="https://doi.org/10.1370/afm.1885">https://doi.org/10.1370/afm.1885</a>	N/A	N/A		
P-27517	6/4/2018	U.S. Pain reps take part in first meeting of major pain task force	N/A	N/A		
P-27518	9/25/2018	Pain Management Best Practices Inter-Agency Task Force September 25, 2018 Meeting Summary - Day 1	N/A	N/A		
P-27519	5/31/2017	Santa Clara DA Press Release: Mrdjen Sentenced for Running Pill Mill, Involuntary Manslaughter	N/A	N/A		
P-27520	1/13/2010	Giovannini prescription labels & handwritten prescriptions	WAGCASF00312899	WAGCASF00312900		
P-27521	2/23/2010	Giovannini prescription labels & handwritten prescriptions	WAGCASF00333510	WAGCASF00333511		
P-27522	11/11/2010	Giovannini prescription labels & handwritten prescriptions	WAGCASF00312982	WAGCASF00312983		
P-27523	1/19/2010	Giovannini prescription labels & handwritten prescriptions	WAGCASF00312901	WAGCASF00312902		
P-27524	3/18/2010	Giovannini prescription labels & handwritten prescriptions	WAGCASF00312909	WAGCASF00312910		
P-27525	3/22/2010	Giovannini prescription labels & handwritten prescriptions	WAGCASF00312913	WAGCASF00312914		
P-27526	4/21/2010	Giovannini prescription labels & handwritten prescriptions	WAGCASF00312919	WAGCASF00312920		
P-27527	4/20/2010	Giovannini prescription labels & handwritten prescriptions	WAGCASF00312923	WAGCASF00312924		
P-27528	6/17/2010	Giovannini prescription labels & handwritten prescriptions	WAGCASF00312931	WAGCASF00312932		
P-27529	7/20/2010	Giovannini prescription labels & handwritten prescriptions	WAGCASF00312935	WAGCASF00312936		
P-27530	8/2/2010	Giovannini prescription labels & handwritten prescriptions	WAGCASF00312939	WAGCASF00312940		



P-27531	10/5/2020	Email re filling for Gores	WAGCASF00103780	WAGCASF00103785		
P-27532	N/A	Refusal to Fill & Comments re Gores	WAGCASF00127813	WAGCASF00127816		
P-27533	1/25/2013	Refusal to fill Leong	WAGCASF00128218	WAGCASF00128226		
P-27534	5/14/2013	Email re Leong high prescribing	WAGCASF00022408	WAGCASF00022409		
P-27535	11/14/2018	GFD Checklist for prescription from Pierce	WAGCASF00127828	WAGCASF00127830		
P-27536	9/3/2019	Prescribers w/ controlled substance restrictions including Pierce	WAGCASF00046727	WAGCASF00046762		
P-27537	12/18/2018	Senator Wyden to the U.S. Pain Foundation	N/A	N/A		
P-27538	6/6/2013	Hattori GFD checklist & prescriptions w CURES reports	WAGCASF00334428	WAGCASF00334432		
P-27539	7/25/2013	Hattori GFD checklist & prescriptions w CURES reports	WAGCASF00313108	WAGCASF00313113		
P-27540	9/29/2014	Hattori prescription images, noting failed GFD, includes CURES report	WAGCASF00127477	WAGCASF00127480		
P-27541	5/7/2019	GFD report with issues re Hattori	WAGCASF00124644	WAGCASF00124645		
P-27542	5/15/2012	CBS article Mrdjen arraignment for operating pill mill	N/A	N/A		
P-27543	11/15/2012	Email & spreadsheet re historical Rx data incl Mrdjen	WAGCASF00006507	WAGCASF00006508		
P-27544	11/27/2012	CA Med Board Mrdjen Decision	N/A	N/A		
P-27545	N/A	Los Angeles County District Attorney News Release re: Tseng	N/A	N/A		
P-27546	8/31/2013	High Ranked Prescribers	WAGDR22MDL00004192	WAGDR22MDL00004269		
P-27547	8/30/2013	Selected Prescribers for Review by CMO	WAGMDL00749775	WAGMDL00749852		
P-27548	9/27/2013	Prescriber Ranking Strategies	WAGMDL00774204	WAGMDL00774216		
P-27549	9/25/2013	Prescriber Ranking Strategies	WAGMDL00868001	WAGMDL00868002		
P-27550	12/4/2012	RE: analytic help - with attachments	WAGPADC00026541	WAGPADC00026545		
P-27551	1/30/2014	summary document - final	WAGMDL00237220	WAGMDL00237221		
P-27552	9/18/2014	Analytics Metadata Survey and Interviews POC Report	WAGMDL00015292	WAGMDL00015307		
P-27553	12/1/2008	CA Summary of Wag SOR Report	WAGMDL00852195	WAGMDL00852195		
P-27554	12/1/2008	Full Version of Wag SOR Report summarized in Ferry 47	WAGMDL00852195	WAGMDL00852195		
P-27555	5/3/2010	Full Version of Wag SOR Report summarized in Ferry 48	WAGMDL00852173	WAGMDL00852173		
P-27556	1/3/2011	Full Version of Wag SOR Report summarized in Ferry 49	WAGMDL00852174	WAGMDL00852174		
P-27557	4/5/2010	Full Version of Wag SOR Report summarized in Ferry 50	WAGMDL00852175	WAGMDL00852175		
P-27558	5/5/2008	Full Version of Wag SOR Report summarized in Ferry 51	WAGMDL00852193	WAGMDL00852193		
P-27559	4/9/1998	Andrew Giovannini v. Antonio Ramirez, SF County Superior Court Case No. CGC98155212. Personal Injury/Prop Damage/Auto-Related	N/A	N/A		
P-27560	3/22/1995	The Travelers Insurance Company v. Mission Orthopaedic Medical Group, SF County Superior Court Case No. CGC95116484. Contract/Warranty	N/A	N/A		
P-27561	7/22/2014	Glory Sturiale v. Dr. Guido Gores, Jr. SF County Superior Court Case No. CSM 14847417 (07/22/2014) Small Claims	N/A	N/A		
P-27562	4/4/2003	Jack Cooper v. Guido Gores, SF Superior Court Case No. CGC03419023 (04/04/2003) Personal/Non-Injury	N/A	N/A		
P-27563	11/13/1998	GOES: Blansky v. Haddad, SF Superior Court Case No. CGC98999230. Medical Negligence	N/A	N/A		
P-27564	7/17/2000	GOES: Martinez v. Skidmore CGC 00313659, (07/017/2000) Medical Malpractice	N/A	N/A		
P-27565	3/19/2013	Estate of Emmanuel C. Montoya, et al v. Sai-Sun S. Ho MD, of CPMC St. Luke's Hospital, et al. SF County Superior Court Case No. CGC-13-529703	N/A	N/A		
P-27566	2/24/2015	USA v. Leong, et al (Indictment)	N/A	N/A		
P-27567	1/2/2015	U.S. v. 929 Clay Street, #7, US District Court for the Northern District of California, Case No.15-CV-00010-JD (Leong Forfeiture Action).	N/A	N/A		
P-27568	9/23/2013	U.S. v. Collin Leong- US District Court for the Northern District of California, Case No. 15-cr-00127-WHO	N/A	N/A		
P-27569	10/27/2008	Nikita Hoang; Crystal Huang, a minor et al v. Collin Leong M.D.; Does San Francisco County Superior Court. CGC-08-481310.Complaint for medical malpractice and wrongful death.	N/A	N/A		
P-27570	12/27/2013	Mark Hoffenberg v. Collin Leong MD; CVS Caremark Corporation; CVS Pharmacy Inc.; Does SF County Superior Court Case No. CGC-13-536473. Violation of the Drug Dealer Liability Act, medical malpractice and wrongful death.	N/A	N/A		

P-27571	4/20/1993	PIERCE: Brosnan v. Miller CGC-93-951155 – Medical Malpractice	N/A	N/A		
P-27572	10/30/1997	PIERCE: Fields v. Moreno CGC-97-990704 – Medical Malpractice	N/A	N/A		
P-27573	9/27/2001	Whaley v. Pierce CGC-01-324954 – Medical Malpractice	N/A	N/A		
P-27574	12/5/1980	John Elloway MD v. Ray Seet MD, Marin County Case No.CIV101081 (Unspecified Civil Filing)	N/A	N/A		
P-27575	1/31/2013	WAGs Red Flag Analysis by Store	Anda_Opioids_MDL_0000725050	Anda_Opioids_MDL_0000725058		
P-27577	3/10/2008	Raymond Seet MD v. Pleasant Care Corporation, Marin County Case No.CIV081155 (Contract/Money Damages)	N/A	N/A		
P-27578	3/20/2008	Mary Peyton, et al. v. Ray Poon-Phang Seet, M.D. et al. Action for elder abuse, medical malpractice and wrongful death.	N/A	N/A		
P-27580	11/7/2014	Bishop v. White, Shasta Count Superior Court Case No. SCRDCVPO14-0181097-002 Personal Injury.	N/A	N/A		
P-27581	10/25/2019	White v. Medical Board of California, Shasta County Superior Court Case No. SCRDCVCV19-0193760-001. Civil Complaint	N/A	N/A		
P-27582	10/28/2020	White v. White, Shasta County Superior Court Case No. SCRDCVFL20-0196085-002 . Family Law	N/A	N/A		
P-27583	10/21/2020	White DBA North Valley Medical Corporation, et al. v. State of California Dept. of Health, Shasta County Court Case No. SCRDCVCV10-0170604-001. Civil Complaint	N/A	N/A		
P-27584	4/21/2014	WHITE: U.S. Justice Department - Drug Enforcement Administration. Case No.: N/A. DEA Registration was revoked. Based on action taken by the CA Medical Board.	N/A	N/A		
P-27585	3/19/2013	Elizabeth Depiccio v. James Gregory White MD aka J. Gregory White MD aka Gregory White MD; North Valley Medical Corporation; Does Shasta County Superior Court Case No. 181098 (03/19/2013). Medical malpractice.	N/A	N/A		
P-27586	10/15/2014	Amanda Mattsson v. James Gregory White MD aka J. Gregory White MD, et al. Shasta County Superior Court Case No. 180929. Medical malpractice.	N/A	N/A		
P-27587	6/30/2014	Robert Winstead v. James Gregory White M.D. et al. Shasta County Superior Court Case No. 180209. Wrongful death and medical malpractice.	N/A	N/A		
P-27588	6/30/2014	Robin Nelson v. James Gregory White M.D. aka J. Gregory White M.D. aka Gregory White M.D.; North Valley Medical Corporation; Does Shasta County Superior Court Case No. 180211. Medical malpractice and negligence.	N/A	N/A		
P-27589	6/30/2014	Kristopher Webb v. James Gregory White MD aka J. Gregory White MD aka Gregory White MD; North Valley Medical Corporation; Does Shasta County Superior Court Case No. 180210. Medical malpractice.	N/A	N/A		
P-27590	6/30/2014	WHITE: Jessica Duguay-Williams; Chara H. Duguay; Jasmine M. Duguay; Amber Duguay; Julianne Duguay, by and through her guardian ad litem Chara H. Duguay v. James Gregory White MD aka J. Gregory White MD aka Gregory White MD; North Valley Medical Corporation; Does Shasta County Superior Court Case No. 180208. Wrongful death and negligence.	N/A	N/A		
P-27591	10/19/2010	HATTORI Denise Ohlssen v. Hieu Ball M.D.; Boston Scientific; California Comprehensive Spine Institute Inc.; Masami Hattori M.D.; Kenneth Light M.D.; Petra Mofazelli; San Ramon Surgery Center; Saint Francis Memorial Hospital,SF County Superior Court Case No. CGC-10-504720. Medical malpractice complaint.	N/A	N/A		
P-27592	2/2/2016	HATTORI: US Bank Trust v. State of California Franchise Tax Board; Masami Hattori; Gramercy Park Owners Assoc.; Mildred E. Decastro; First Financial Bank, Orange County Superior Court Case No. Superior Court 00833338CJC. Property.	N/A	N/A		

P-27593	7/23/2015	The State of California v. Mrdjen, Jasna, Santa Clara County Superior Court Case No. C1232016. Criminal case	N/A	N/A		
P-27594	6/29/2012	J. Mrdjen v. State of California, Santa Clara County Superior Court Case No. 2012-1-CV-227509. Asset forfeiture Unlimited (Active)	N/A	N/A		
P-27595	6/29/2012	J. Mrdjen v. State of California, Santa Clara County Superior Court Case No. 2012-1-CV-227508. Asset forfeiture Unlimited (Inactive/Closed)	N/A	N/A		
P-27596	5/10/2012	The State of California v. Mrdjen, Santa Clara County Superior Court Case No. C1232016. (Inactive)	N/A	N/A		
P-27597	6/26/2016	People v. Hsiu Ying "Lisa" Tseng, Los Angeles County Superior Court Case No. BA394495.	N/A	N/A		
P-27598	12/14/2018	People v. Hsiu Ying Lisa Tseng, Court of Appeal 2nd District, 30 Cal.App.5th 117.	N/A	N/A		
P-27599	7/17/2013	Verna Huggard et al. v. James Hung Nguyen; Hsiu-Ying Lisa Tseng, et al. Orange County Superior Court 00663007CJC. Medical Malpractice	N/A	N/A		
P-27600	8/9/2012	Nolan Kenney, a minor, et al v. Lisa Tseng DO, aka Hsiu-Ying Lisa Tseng DO, et al. Orange County Superior Court 00589919CJC. Medical malpractice.	N/A	N/A		
P-27601	6/4/2012	Brandon Bender, et al. v. Lisa Tseng DO, aka Hsiu-Ying Lisa Tseng DO, et al. Orange County Superior Court Case No. 00573797CJC. Medical negligence.	N/A	N/A		
P-27602	10/12/2011	Jolie Podraza; Frank Podraza v. Lisa Tseng DO, aka Hsiu-Ying Lisa Tseng DO, et al. Orange County Superior Court Case No. 00514484CJC. Medical negligence.	N/A	N/A		
P-27603	7/8/2011	Michael Winter; Julie Winter v. Lisa Tseng DO, aka Hsiu-Ying Tseng, DO: White Front Pharmacy; Advance Care AAA Medical Group; Gene Chang Tu DO; Orange County Superior Court Case No. 00489638CJC. Medical malpractice.	N/A	N/A		
P-27604	7/1/2011	Clinton Carson v. Advance Care AAA Medical Group; Hsiu-Ying Lisa Tseng D.O.; Tseng's Medical Center Inc. Los Angeles County Superior Court Branches Pomona Case No. KC061580. Medical Malpractice	N/A	N/A		
P-27605	2/2/2011	John Mata; Melissa Mata v. Advance Care AAA Medical Group; Lisa Hsiu-Ying Tseng D.O.; Tseng's Medical Center Inc.; Gene Tu M.D. Los Angeles County Superior Court Branches Pomona Case No. KC060485. Other PI/PD/WD (General Jurisdiction)	N/A	N/A		
P-27606	12/1/2010	Joseph Rovero, Jr.; April Rovero v. Hsiu-Ying Lisa Tseng, D.O.; Pacific Pharmacy Orange County Superior Court Case No. 00429167CJC (12/01/2010) Medical malpractice. Complaint for wrongful death.	N/A	N/A		
P-27607	9/15/2010	Bruce Stavron; Kelle Stavron v. Lisa Hsiu-Ying Tseng; Tseng's Medical Center Inc., et al.; Los Angeles County Superior Court Branches Pomona Case No. KC059602. Other PI/PD/WD (General Jurisdiction)	N/A	N/A		
P-27608	2/29/2012	Decision and Order re Tseng	N/A	N/A		
P-27609	8/5/2013	Seet License Surrender Decision and Order	N/A	N/A		
P-27610	4/16/2013	Leong Exhibit A to California Medical Board Stipulation for Surrender of Certificate	N/A	N/A		
P-27611	6/4/2001	Illinois Dept of Regulations indefinitely suspended White's medical license	N/A	N/A		
P-27612	9/25/2005	CA Med Board White Decision probation	N/A	N/A		
P-27613	8/31/2015	CA Med Board White Decision surrender	N/A	N/A		
P-27614	9/17/2002	Redding Record Searchlight News article "Redding Doctor Faces Wrongful Death Suit, Pain Treatment with Methadone Blamed for Death" re White	N/A	N/A		
P-27615	2/3/2003	Redding Record Searchlight "A Year After Drug Agent's Raid, Redding Doctor Hasn't Faced Charges" re White	N/A	N/A		
P-27616	1/5/2014	FR 79 No. 84, DEA Decision and Order re White	N/A	N/A		

P-27617	4/23/2019	CA Med Board Dossett decision	N/A	N/A		
P-27618	1/31/2013	Email re Questions for Walgreen Store	WAGFLAG00057156	WAGFLAG00057169		
P-27619	11/15/2012	Email re Review of Florida Walgreen Locations	WAGMDL00882033	WAGMDL00882037		
P-27620	11/15/2012	Email re Review of Florida Walgreen Locations	WAGFLAG00011357	WAGFLAG00011361		
P-27621	11/20/2012	Email re GFD Audit of Store 2865 in Modesto, CA	WAGMDL00132764	WAGMDL00132771		
P-27622	11/20/2012	Email re Survey	WAGFLAG00447713	WAGFLAG00447716		
P-27623	11/28/2012	Email re 3-Month Dispensing Data	WAGALDCH00008739	WAGALDCH00008754		
P-27624	5/8/2020	Lucid Lane has developed a service to get patients off of pain meds and avoid dependence	N/A	N/A		
P-27625	1/11/2022	Burt Rosen - VP Government Affairs - Purdue Pharma   LinkedIn	N/A	N/A		
P-27626	2/23/2013	Orlando meeting decks; DEA Update - Midwest Operations Meeting; Orlando Pharmacy Centralization Midwest Ops Offsite 2013-02-18 vfinal	WAGMDL01849450	WAGMDL01849562		
P-27627	7/30/2013	GFD Checklist and AAPM	WAGMDL01849430	WAGMDL01849432		
P-27628	1/21/2014	IMS CS National Top Prescribers - Prescriber Total Rating Incl. Hattori	WAGMDL00681769	WAGMDL00681769		
P-27629	3/8/2012	List of TDGFD with Hattori listed as prescriber for multiple early fillers	WAGCASF00106243	WAGCASF00106243		
P-27630	10/31/2012	OIG Excluded-Sanction Providers Incl Tseng	WAGFLAG02290224	WAGFLAG02290226		
P-27631	12/12/2012	Emails re Completed Surveys	WAGFLAG00096821	WAGFLAG00097406		
P-27632	12/18/2012	Email re Update	WAGFLAG00057411	WAGFLAG00057411		
P-27633	12/27/2012	Email re Red Line and Initial Compliance Review	WAGFLAG00096794	WAGFLAG00096820		
P-27634	1/2/2013	Email re Questions 7936	WAGFLAG00011298	WAGFLAG00011306		
P-27635	1/7/2013	Email re CII Data for Anda	WAGFLAG00057378	WAGFLAG00057381		
P-27636	1/18/2013	Email re Store Information	WAGFLAG00057233	WAGFLAG00057235		
P-27637	1/31/2013	Email re Anda Questionnaire	WAGFLAG00057216	WAGFLAG00057217		
P-27638	4/8/2014	OMP Process Discussion	ABDCMDL05502879	ABDCMDL05502881		
P-27639	N/A	APPRISS 000125 - HIGHLY CONFIDENTIAL	APPRISS 000125	APPRISS 000125		
P-27640	9/20/2006	Walgreens Offer Letter	ENDO-OPIOID_MDL_04921426	ENDO-OPIOID_MDL_04921428		
P-27641	1/24/2012	Purdue News Summary - PM Report	PPLPC004000309306	PPLPC004000309366		
P-27642	N/A	California call notes	TEVA_CAOC_01903919	TEVA_CAOC_01903919		
P-27643	6/13/2017	Report of Investigation	US-DEA-00031513	US-DEA-00031522		
P-27644	6/1/2011	Focus on Compliance for Florida	WAGFLAG00000939	WAGFLAG00000963		
P-27645	1/27/2016	Re: Override Quantity Request Rejected	WAGFLAG00002985	WAGFLAG00002985		
P-27646	3/18/2013	FW: Controlled Substance Order Quantity Override Form	WAGFLAG00004015	WAGFLAG00004017		
P-27647	11/20/2012	RE: Stores to Receive Questionnaire	WAGFLAG00004123	WAGFLAG00004128		
P-27648	11/26/2012	RE: Stores to Receive Questionnaire	WAGFLAG00004221	WAGFLAG00004227		
P-27649	6/15/2011	Re: FL Control Level Data	WAGFLAG00005224	WAGFLAG00005226		
P-27650	11/14/2012	Review of Florida Walgreen Locations	WAGFLAG00011373	WAGFLAG00011374		
P-27671	1/27/2017	RE: Drug takeback & conference call	WAGFLAG00011910	WAGFLAG00011912		
P-27684	6/25/2018	Re: Florida PDMP	WAGFLAG00011959	WAGFLAG00011960		
P-27685	8/24/2016	Take Back event in Hialeah	WAGFLAG00012020	WAGFLAG00012021		
P-27686	1/6/2016	Old Oxycontin Reports	WAGFLAG00015146	WAGFLAG00015147		
P-27690	4/7/2011	Service Provider Master Agreement between Watson Pharma Inc. and BuzzeroPDMA LLC	Anda_Opioids_MDL_0000281069	Anda_Opioids_MDL_0000281075		
P-27712	1/5/2013	GFD impact on sales	WAGFLAG00016469	WAGFLAG00016473		
P-27713	10/31/2013	673087.txt	WAGFLAG00019034	WAGFLAG00019035		
P-27714	11/13/2013	New York Hydrocodone Study	WAGFLAG00023201	WAGFLAG00023203		
P-27715	5/23/2018	Fwd: Dr. Frey arrested for fraud	WAGFLAG00023674	WAGFLAG00023675		
P-27716	7/19/2017	RE: Override Quantity Request Rejected	WAGFLAG00023944	WAGFLAG00023945		
P-27719	6/9/2014	FW: Xartemis XR	WAGFLAG00027188	WAGFLAG00027191		
P-27727	12/27/2012	FW: Walgreens/Cardinal Health QRA Update	WAGFLAG00029387	WAGFLAG00029391		
P-27728	9/19/2014	RE: New Item Analysis - Butrans 7.5mcg	WAGFLAG00036694	WAGFLAG00036700		
P-27733	1/20/2016	FW: Belbuca - Stocking Analysis Request	WAGFLAG00036838	WAGFLAG00036842		
P-27734	6/29/2017	FW: PDQ orders data for C2's	WAGFLAG00037225	WAGFLAG00037232		
P-27735	3/29/2016	RE: discuss the inventory side of WPC machine for CS	WAGFLAG00038355	WAGFLAG00038358		
P-27736	9/14/2012	FW: DEA at Jupiter DC 9/14/2012	WAGFLAG00039112	WAGFLAG00039112		
P-27738	7/20/2012	FW: Florida C2-C3 5,000 Units	WAGFLAG00039306	WAGFLAG00039307		
P-27740	2/22/2012	Suspicious Ordering: Florida	WAGFLAG00039312	WAGFLAG00039312		
P-27741	1/11/2016	Re: Pharmacy lock box- FL	WAGFLAG00040925	WAGFLAG00040926		

P-27747	3/25/2013	Re: Florida HB 831	WAGFLAG00043303	WAGFLAG00043303		
P-27752	12/6/2012	RE: Massachusetts reporting	WAGFLAG00043480	WAGFLAG00043482		
P-27753	2/22/2018	FW: FL Opioid Legislation	WAGFLAG00044836	WAGFLAG00044837		
P-27754	12/22/2017	Re: FL Senate Bill	WAGFLAG00045007	WAGFLAG00045010		
P-27769	11/3/2017	RE: Xtampza ER added to Florida Blue commercial plans	WAGFLAG00056186	WAGFLAG00056196		
P-27770	11/8/2017	RE: Xtampza ER added to Florida Blue commercial plans	WAGFLAG00056303	WAGFLAG00056314		
P-27786	7/17/2012	RE: Florida Department of Business & Professional Regulation	WAGFLAG00057538	WAGFLAG00057540		
P-27803	9/22/2011	Cover email from Robert Williamson (Cegedim) to Tom Napoli and Scott Soltis re Cegedim audit report re Watson's Suspicious Order Monitoring (SOM) system	Teva_IQVIA_0020874	Teva_IQVIA_0020874		
P-27804	9/21/2011	Cegedim audit report re Watson's Suspicious Order Monitoring (SOM) system	Teva_IQVIA_0020875	Teva_IQVIA_0020882		
P-27806	7/16/2014	RE: Florida Prescription Drug Monitoring Program	WAGFLAG00058431	WAGFLAG00058432		
P-27809	6/27/2014	Government Affairs Week in Review - Week Ending 6/27/2014	WAGFLAG00058439	WAGFLAG00058444		
P-27810	9/27/2011	Oxymorphone Promotion at McKesson	ACTAVIS0622089	ACTAVIS0622090		
P-27811	1/14/2011	2010 Budget Planning Model - FINAL	ALLERGAN_MDL_01493707	ALLERGAN_MDL_01493708		
P-27812	1/15/2013	RE: Kadian Training Manual References - Detective work required!	ALLERGAN_MDL_01610520	ALLERGAN_MDL_01611060		
P-27814	2/12/2014	RE: Florida Tech Bill	WAGFLAG00058591	WAGFLAG00058595		
P-27818	2/2/2012	Email re Kadian Warning Letter	ACTAVIS0799201	ACTAVIS0799214		
P-27819	8/2/2013	FL Atty General Meeting	WAGFLAG00059091	WAGFLAG00059091		
P-27820	2011	Fw: Sales rep training material draft; Attachment; 2011 - Sales Training Class	ACTAVIS0506794	ACTAVIS0506814		
P-27821	5/23/2013	RE: DEA & Pharmacies	WAGFLAG00059106	WAGFLAG00059107		
P-27822	2/16/2018	RE: Asks for the Opioid bill	WAGFLAG00059495	WAGFLAG00059497		
P-27823	2/5/2013	Dept. Meeting Presentations	WAGFLAG00059601	WAGFLAG00059651		
P-27824	10/22/2015	Fwd: SENATE COMMITTEE TO TACKLE PATIENTS' PAIN MED PROBLEMS	WAGFLAG00060885	WAGFLAG00060888		
P-27825	3/13/2015	RE: Response Requested - FL communications activities on access and abuse	WAGFLAG00061101	WAGFLAG00061103		
P-27826	7/7/2015	DEA Subpoena No. IA-15-741648; DEA Subpoena No. IA-15-741648 07	TEVA_MDL_A_02063557	TEVA_MDL_A_02063701	TEVA_MDL_A_02063557 - TEVA_MDL_A_02063701	
P-27827	12/29/2015	Fwd: First letter re: restrictive networks	WAGFLAG00061388	WAGFLAG00061396		
P-27828	1/6/2016	Oxycontin Updates - Purdue's Policy and Action Requested - Police Reports Needed For Previous Claims	WAGFLAG00084527	WAGFLAG00084530		
P-27829	7/6/2016	FW: information on recent overdosing	WAGFLAG00088431	WAGFLAG00088432		
P-27830	12/30/2010	Re: FYI: Relative to "Corruption" Email on Which You Were Copied	WAGFLAG00093302	WAGFLAG00093304		
P-27831	5/12/2020	Ceiling Override Report - FL	WAGFLAG00099472	WAGFLAG00099472		
P-27832	9/25/2020	Flagged Order Production - Florida	WAGFLAG00099473	WAGFLAG00099473		
P-27833	9/29/2014	RE: HCP	WAGFLAG00099646	WAGFLAG00099648		
P-27834	10/17/2012	RE: GFDP 3574 10-17-2012	WAGFLAG00100168	WAGFLAG00100169		
P-27835	5/13/2013	Re: CII order	WAGFLAG00102653	WAGFLAG00102657		
P-27836	6/28/2016	Fwd: More CVS press in FL on Naloxone	WAGFLAG00103485	WAGFLAG00103486		
P-27837	11/1/2017	RE: Safe Medication Disposal Kiosk locations for phase 2.1	WAGFLAG00103582	WAGFLAG00103584		
P-27838	8/6/2010	Re: Fw: POWER concerns - June 2010 - FYI	WAGFLAG00104679	WAGFLAG00104681		
P-27839	11/16/2017	Re: GFD	WAGFLAG00108808	WAGFLAG00108811		
P-27840	10/20/2015	Fwd: SENATE COMMITTEE TO TACKLE PATIENTS' PAIN MED PROBLEMS	WAGFLAG00109901	WAGFLAG00109903		
P-27841	12/10/2012	RE: Question from FL	WAGFLAG00111186	WAGFLAG00111187		
P-27842	12/17/2012	Inventory checks in PCC	WAGFLAG00111575	WAGFLAG00111577		
P-27843	5/19/2016	RE: Override Quantity Request Rejected	WAGFLAG00113812	WAGFLAG00113813		
P-27844	5/30/2012	Word Copy of latest contingency plan	WAGFLAG00115968	WAGFLAG00116065		
P-27845	5/17/2012	Final Contingency Task Force Plan	WAGFLAG00116066	WAGFLAG00116163		
P-27846	9/18/2012	FW: Final media statement	WAGFLAG00122828	WAGFLAG00122830		
P-27847	6/12/2012	CAH/FL store review status	WAGFLAG00122931	WAGFLAG00122932		
P-27848	4/9/2012	FL DEA Dispensing report - 4727	WAGFLAG00123011	WAGFLAG00123012		
P-27849	2/19/2012	Fw: Orlando Loss of Controlled Substances	WAGFLAG00123645	WAGFLAG00123647		
P-27850	11/25/2012	Fw: Target Drug - Good Faith Dispensing Policy (TD-GFD) webinar - conference call materials	WAGFLAG00127192	WAGFLAG00127242		

P-27851	11/20/2018	Re: opioid crisis	WAGFLAG00130117	WAGFLAG00130117		
P-27852	11/1/2017	RE: October 30, 2017 Stat News	WAGFLAG00136919	WAGFLAG00136923		
P-27853	8/24/2017	FW: INFORM: Opioid and South Florida	WAGFLAG00137349	WAGFLAG00137350		
P-27854	4/17/2012	c2	WAGFLAG00138151	WAGFLAG00138180		
P-27855	4/17/2012	c2	WAGFLAG00138181	WAGFLAG00138190		
P-27856	4/16/2012	Re: Oxy PSC price change	WAGFLAG00138191	WAGFLAG00138192		
P-27857	2/26/2016	Staff RPh Presentation	WAGFLAG00140129	WAGFLAG00140154		
P-27858	8/15/2015	RE: GFD training for district managers	WAGFLAG00140879	WAGFLAG00140881		
P-27859	7/2/2015	Re: Pharmacy Access Issue	WAGFLAG00141025	WAGFLAG00141027		
P-27860	10/6/2015	RE: PHARMACY PANEL ADDRESS PAIN PATIENT PROBLEMS	WAGFLAG00142340	WAGFLAG00142343		
P-27861	9/18/2012	RE: CII Ordering Update - Select stores	WAGFLAG00146252	WAGFLAG00146253		
P-27862	8/14/2015	FW: Store #3963, 3/18/2009 documents included: 106 and police report)	WAGFLAG00153294	WAGFLAG00153298		
P-27863	10/6/2015	Re: 3428 robbery	WAGFLAG00153299	WAGFLAG00153299		
P-27864	3/18/2021	Re: ARNP sending fraudulent rx's	WAGFLAG00153517	WAGFLAG00153518		
P-27865	11/13/2017	RE: Upcoming legislative bills on Controlled Substances	WAGFLAG00154532	WAGFLAG00154534		
P-27866	8/20/2014	RE: SOP for C2 Inspection INC000012088466	WAGFLAG00155048	WAGFLAG00155051		
P-27867	7/9/2014	Re: *** Controlled Substance Ordering Immediate Action Required ***	WAGFLAG00155120	WAGFLAG00155121		
P-27868	5/20/2014	Fw: Override Quantity Request Rejected	WAGFLAG00155332	WAGFLAG00155332		
P-27869	1/5/2015	Override Quantity Request Rejected	WAGFLAG00155631	WAGFLAG00155631		
P-27870	10/16/2015	Email from J. Tomkiewicz to C. McGinn; 2015-10-16 Christine Baeder Phone Call	TEVA_MDL_A_02063723	TEVA_MDL_A_02063728		
P-27871	8/10/2017	Email from J. Tomkiewicz to C. McGinn; 2014-12-01 Richie Suspicious Order Report; 2015-06-25 Richie Suspicious Order Report; 2017-04-19 EMED Suspicious Order Report; 2017-06-08 EMED Suspicious Order Report; 2017-04-19 DV Medical Suspicious Order Report	TEVA_MDL_A_02342524	TEVA_MDL_A_02342529		
P-27875	11/18/2014	Re: C2 Policy Clarification	WAGFLAG00155992	WAGFLAG00155992		
P-27876	11/25/2014	RE: Reminder	WAGFLAG00155996	WAGFLAG00155997		
P-27877	6/4/2018	RE: Florida PDMP	WAGFLAG00156958	WAGFLAG00156961		
P-27879	2/7/2015	FW: GFD	WAGFLAG00159176	WAGFLAG00159189		
P-27898	2/8/2015	RE: Coupon for Oxycontin	WAGFLAG00162301	WAGFLAG00162303		
P-27902	1/30/2012	Email, SOM follow up; Due Diligence McKesson	ALLERGAN_MDL_03401836	ALLERGAN_MDL_03401841		
P-27910	N/A	Few Good Men	TEVA_MDL_A_00715631	TEVA_MDL_A_00715631		
P-27929	N/A	Centers for Disease Control and Prevention	N/A	N/A		
P-27945	N/A	Database/Data Set: Walgreens Flagged Ohio Orders Data	WAGMDL00400360	WAGMDL00400360		
P-27946	N/A	Database/Data Set: Walgreens Ohio CSO Override History Data	WAGMDL00400358	WAGMDL00400358		
P-27947	N/A	Database/Data Set: Walgreens Ohio Current Ceiling Limits Data	WAGMDL00400359	WAGMDL00400359		
P-27951	N/A	Database/Data Set: Medispan Data Price Rx Pro	N/A	N/A		
P-27952	N/A	Database/Data Set: First Databank	N/A	N/A		
P-27953	N/A	Database/Data Set: Anonymized High MME Patients Claims Data. Exhibit A to Plaintiff's responses to Manufacturer Interrogatories 6, 7 and 10 & Pharmacy Interrogatories 2 and 3	N/A	N/A		
P-27954	2/4/2014	FW: Override Quantity Request Rejected	WAGFLAG00166588	WAGFLAG00166588		
P-27957	N/A	High def video - Pain Lingers (Fentora)	TEVA_NY_01011124	TEVA_NY_01011124		
P-27959	11/1/2007	A Supplement to: Resident & Staff Physician Pain: Improving patient Outcomes and Optimizing Risk in Opioid Therapy of Chronic Pain. (November / December 2007); Medical Center Briefings: Managing Pain: Improving Patient Outcomes and Minimizing Risk in Opioid Therapy of Chronic Pain, a CME program supported by an educational grant from Cephalon	TEVA_MDL_A_00835445	TEVA_MDL_A_00835622		
P-27960	6/9/2015	Str 6751	WAGFLAG00172534	WAGFLAG00172534		
P-27962	12/28/2011	FDA letter approving Teva's Actiq REMS, with attached REMS	TEVA_MDL_A_07679381	TEVA_MDL_A_07679878		
P-27971	N/A	Pain Products Learning System document re Opiophobia	TEVA_MDL_A_00404998	TEVA_MDL_A_00405071		
P-27974	N/A	McGinn white paper email	TEVA_MDL_A_01453866	TEVA_MDL_A_01453897		
P-27975	N/A	DDMAC Meeting Minutes and Concerns re Off-Label Promotion	TEVA_MDL_A_01584973	TEVA_MDL_A_01584987		
P-27976	10/8/2018	Annual Review Pre-Read	WAGFLAG00172609	WAGFLAG00172622		
P-27977	12/4/2019	Partnering	WAGFLAG00172850	WAGFLAG00172850		



P-27978	N/A	Email and PPT titled "Evolving Roles, Same Goals The Changing Landscape of Pain Management"; Email re ERSG Video Script with Script Attached Unbranded PAINWeek Presentation_To Faculty	TEVA_MDL_A_08652121	TEVA_MDL_A_08652172		
P-27980	N/A	Teva Market Share Report Distribution List Sept 2008	TEVA_MDL_A_12150090	TEVA_MDL_A_12150362		
P-27983	N/A	High def video - Glengarry Glen Ross video	TEVA_NY_01011127	TEVA_NY_01011127		
P-27984	5/31/2018	FW: Request- DMs, C2 Time Delay Go-Live	WAGFLAG00173730	WAGFLAG00173758		
P-27987	N/A	Pain Matters Documents Combined [composite exhibit]	TEVA_MDL_A_08657349	composite		
P-27988	5/22/2018	RE: Mandatory Drugs for Time Delay door in new safe	WAGFLAG00178340	WAGFLAG00178342		
P-27990	5/17/2018	RE: CII safe information request	WAGFLAG00178394	WAGFLAG00178415		
P-27992	12/12/2017	Re: Pharmacy Bills	WAGFLAG00180126	WAGFLAG00180128		
P-27993	1/12/2017	Re: ARNP's/PA's prescribing controls	WAGFLAG00180610	WAGFLAG00180611		
P-27995	4/14/2014	FW: ABC Controlled Substances Thresholds	WAGFLAG00182104	WAGFLAG00182105		
P-27996	8/28/2008	Cephalon Guilty Plea Agreement	N/A	N/A		
P-27999	N/A	Teva Completes Acquisition of Actavis Generics Press Release	N/A	N/A		
P-28000	N/A	Appendix 2 - Topic 3 - Boards of Directors	N/A	N/A		
P-28002	N/A	Appendix 5-Topic 11	N/A	N/A		
P-28004	N/A	Austin Powers sales video - high def	TEVA_NY_01011128	TEVA_NY_01011128		
P-28021	2010	Branded Strategic Sourcing, EDI 852/867 requirements	CAH_MDL2804_02103498	CAH_MDL2804_02103527		
P-28023	2/9/2014	Re: Controls	WAGFLAG00182357	WAGFLAG00182357		
P-28024	7/6/2011	Controlled Substance Update: Florida Prescription Drug Monitoring Program	WAGFLAG00204896	WAGFLAG00204896		
P-28026	12/2/2011	Background to share with stores on CII	WAGFLAG00205509	WAGFLAG00205510		
P-28030	12/13/2012	Summary: Capital Wholesale	ALLERGAN_MDL_02187194	ALLERGAN_MDL_02187195		
P-28031	5/21/2015	Kick Off.one	ALLERGAN_MDL_03755062	ALLERGAN_MDL_03755078		
P-28033	5/16/2013	FW: ANDA Update	WAGFLAG00206272	WAGFLAG00206274		
P-28034	2/9/2018	Fwd: Update: Safe Medication Disposal Expansion 2018 - Program Rollout	WAGFLAG00216964	WAGFLAG00216978		
P-28036	7/10/2012	sheet from Jupiter	WAGFLAG00222027	WAGFLAG00222031		
P-28037	12/8/2015	FW: Controlled Substance Standards Committee	WAGFLAG00225084	WAGFLAG00225414		
P-28039	11/16/2015	RE: Community Inspection Form	WAGFLAG00225444	WAGFLAG00225446		
P-28053	5/5/2015	RE: FYI - FL BOP : Controlled Substance Committee Meeting	WAGFLAG00228110	WAGFLAG00228112		
P-28068	3/14/2016	Fwd: GFD processes	WAGFLAG00239479	WAGFLAG00239479		
P-28069	4/9/2013	Re: Monday's Lunch Notes	WAGFLAG00255026	WAGFLAG00255029		
P-28070	2/15/2012	Fw: Pharmacy Complaints	WAGFLAG00255668	WAGFLAG00255669		
P-28072	7/23/2010	Handling Pain Management RXs	WAGFLAG00255766	WAGFLAG00255766		
P-28074	9/22/2012	Fw: Meeting with FMA and Retail Federation	WAGFLAG00260091	WAGFLAG00260095		
P-28084	11/13/2015	GFD Meeting Notes	WAGFLAG00260286	WAGFLAG00260287		
P-28086	7/16/2014	Controlled Substance Dispensing Trends	WAGFLAG00261907	WAGFLAG00261913		
P-28087	5/6/2013	Fwd: Pain Management- Clinical Information	WAGFLAG00277036	WAGFLAG00277073		
P-28093	1/27/2013	FW: Controls Removed From Formulary	WAGFLAG00277213	WAGFLAG00277215		
P-28098	7/8/2008	Re: Fw: Walgreen stores Puerto Rico	WAGFLAG00302134	WAGFLAG00302143		
P-28099	6/19/2013	top 200 sold and dispensed quantities	WAGFLAG00515869	WAGFLAG00515871		
P-28107	4/16/2014	RE: LEAP Content Review - Planning and Engagement and FE Rx Alliance - Response requested by 4/18	WAGFLAG00576506	WAGFLAG00576669		
P-28110	5/4/2010	Fw: updated document - Response to Kermit - FL plan to win deux	WAGFLAG00629227	WAGFLAG00629242		
P-28113	4/19/2010	Fw: Pharmacy Operations Sales and Profit Plan	WAGFLAG00630852	WAGFLAG00630887		
P-28117	4/19/2010	Fw: updated document - Response to Kermit - FL plan to win deux	WAGFLAG00630888	WAGFLAG00630901		
P-28124	1970	HR 91-1444 - Comprehensive Drug Abuse Prevention & Control Act House Report	N/A	N/A		
P-28126	4/23/2010	March 2010 IMS Market Share Report	WAGFLAG00631013	WAGFLAG00631017		
P-28134	5/18/2011	Re: Fw: Wagner blog feedback - POWER - FYI	WAGFLAG00633097	WAGFLAG00633100		
P-28140	1/28/2016	Re: FPA ACTION ALERT - Bill Addressing Network Closure Pending	WAGFLAG00735009	WAGFLAG00735013		
P-28142	1/13/2013	FW: ITOE Meeting Recap and Action Items	WAGFLAG00768506	WAGFLAG00768510		
P-28153	12/3/2012	Re: GFD	WAGFLAG00769393	WAGFLAG00769395		
P-28161	12/3/2014	FW: Holiday Trade Meetings Field Feedback Week 1 ***DUE by Noon 12/4/14***	WAGFLAG00924190	WAGFLAG00924194		

P-28163	1/13/2012	CDC Morbidity and Mortality Weekly Report, CDC Grand Rounds: Prescription Drug Overdoses - a US Epidemic	N/A	N/A		
P-28180	7/28/2004	Letter to Cristina V. Beato, Acting Assistant Secretary for Health from the Department of Justice & DEA	N/A	N/A		
P-28182	2/13/2020	RE: BioPharma One Plan Steering Committee	WAGFLAG00932351	WAGFLAG00932398		
P-28195	4/24/2012	Re: ACTION REQUIRED: Complete E-Mail Pre-Migration Activities	WAGFLAG01159539	WAGFLAG01159540		
P-28201	1/3/2017	RE: Informational	WAGFLAG01268362	WAGFLAG01268363		
P-28202	N/A	Annual Performance Review for Managers	N/A	N/A		
P-28207	N/A	Hearing before Subcommittee on oversight and investigations	N/A	N/A		
P-28209	11/27/2015	FY16 Inventory Savings Goal	WAGFLAG01268632	WAGFLAG01268634		
P-28210	6/20/2017	Excerpt of Transcript of Proceedings Before the Honorable Judge Faber	N/A	N/A		
P-28211	4/16/2019	NWDA Controlled Substances Manual	HDA MDL 000219360	HDA MDL 000219632		
P-28214	6/6/2012	"American Pain: The Largest US Pill Mills Rise and Fall" Bloomberg	N/A	N/A		
P-28215	N/A	"The opioid epidemic_ How Congress and drug company lobbyists worked to neutralize the DEA" - Washington Post article	N/A	N/A		
P-28216	5/29/2001	I suggest that we consider sending the following via email fax and regular mail Tuesday:	PPLPC045000005405	PPLPC045000005425		
P-28217	6/8/2001	Re: Contemplated action to reduce the production quota for oxycodone	PKY181383991	PKY181383994		
P-28219	2018	2018 DEA Controlled Substance Quotas 21 CFR 1303, Fed. Reg p 17329 from DOJ, DEA Diversion Control Division	N/A	N/A		
P-28221	6/1/2018	"Debunking the Myths of Controlled Substance Quotas, June 1, 2018 interview with J Rannazzisi Pharmacy Times	N/A	N/A		
P-28257	4/22/2019	Opioids and ORC - How they are linked	WAGFLAG01271955	WAGFLAG01271967		
P-28260	4/4/2017	Fwd: FYI	WAGFLAG01284019	WAGFLAG01284019		
P-28267	2/4/2014	Market Meeting Notes	WAGFLAG01309341	WAGFLAG01309348		
P-28288	2006	Walgreens - 10ks 2006- present	N/A	N/A		
P-28294	2017	HBO Documentary "Warning this Drug will kill you" 2017	N/A	N/A		
P-28295	1/1/2004	Chemical Handler's 754 Manual A Guide to Chemical Control Regulations	CAH_MDL_PRIORPROD_DEA07_01198690	CAH_MDL_PRIORPROD_DEA07_01198758		
P-28296	3/10/2014	Override Quantity Request Rejected	WAGFLAG01392190	WAGFLAG01392190		
P-28297	5/5/2011	Prescription Drug Abuse Healthcare & Pharmacy Workgroup Resolution Advocating Support for the PDMP	WAGFLAG01535886	WAGFLAG01535888		
P-28298	7/7/2014	FW: Basic Control Initiative (BCI) Results / Rx Health & Wellness	WAGFLAG01542605	WAGFLAG01542606		
P-28300	N/A	Mary Woods 30(b)(6) Deposition - Dep Aid	N/A	N/A		
P-28301	1/6/2016	Email re SOMS - Policy & Process Flow	MULTI2961603	MULTI2961617		
P-28304	2/5/2012	Email re January 2012 Invoice	ALLERGAN_NY_00039037	ALLERGAN_NY_00039057		
P-28319	9/27/2010	DOJ Investigation of Vintage Pharmaceuticals, LLC	PAR OPIOID MDL 0002102288	PAR OPIOID MDL 0002102310		
P-28328	4/8/2008	The 7 Essentials: The Endo Pharmaceuticals Story (Video included) <a href="https://www.youtube.com/watch?v=6fqFOy-bZ1k&amp;t=233s">https://www.youtube.com/watch?v=6fqFOy-bZ1k&amp;t=233s</a>	N/A	N/A		
P-28338	9/14/2012	RE: Jupiter Whse	WAGFLAG01543961	WAGFLAG01543961		
P-28346	N/A	Youtube video with Portenoy explaining how he would use Porter and Jick and other studies to destigmatize opioids	N/A	N/A		
P-28365	10/24/1970	Comprehensive Drug Abuse Prevention and Control Act of 1970, Public Law 91-513, October 27, 1970,	N/A	N/A		
P-28372	9/15/2009	McKinsey Project Sales Slides	WAGFLAG01544406	WAGFLAG01544457		
P-28390	1/4/2012	Fw: Yesterday's PSC Stats	WAGFLAG01784948	WAGFLAG01784953		
P-28391	2/7/2011	FYI: PSC Community vs Community Challenge	WAGFLAG01784957	WAGFLAG01784959		
P-28392	5/25/2012	Follow-up to Conference Call: Call Center Outreach	WAGFLAG01844479	WAGFLAG01844481		
P-28393	5/23/2014	FW: GFD Comments	WAGFLAG01844663	WAGFLAG01844664		
P-28394	11/9/2016	Excellent service please///FL Blue Reg 12 counties Walgreens exclusive	WAGFLAG01845297	WAGFLAG01845298		
P-28395	4/18/2015	FW: Monthly Operating Performance Meeting	WAGFLAG02102127	WAGFLAG02102377		
P-28396	7/29/2016	WAG.POL.RIG-003.pdf	WAGFLAG02276782	WAGFLAG02276787		

P-28397	12/3/2020	WBA.DPR-1.pdf	WAGFLAG02276845	WAGFLAG02276857		
P-28398	2/6/2013	Government Affairs Week In Review - Weeks Ending 1/25 & 2/1/13	WAGFLAG02299560	WAGFLAG02299572		
P-28399	10/24/2013	From the Government Affairs Week In Review - Weeks Ending 10/11 & 10/18/13	WAGFLAG02318314	WAGFLAG02318316		
P-28400	8/1/2013	RE: State Political Activity Updates	WAGFLAG03014766	WAGFLAG03014768		
P-28401	1/22/2018	State & Local Team Meeting Agenda	WAGFLAG03054941	WAGFLAG03054974		
P-28402	5/25/2018	RE: Rx Technician BOP Letters 05-2018	WAGFLAG03081972	WAGFLAG03081974		
P-28403	6/17/2013	FW: Contract Received	WAGFLAG03104116	WAGFLAG03104119		
P-28404	10/26/2021	FL Supplemental Custodian Production Full Time Period (2021.10.26).xlsx	WAGFLAG03133638	WAGFLAG03133638		
P-28405	11/12/2012	Political Budget FY2013	WAGFLAG03135900	WAGFLAG03135952		
P-28406	5/25/2012	Video/Audio Conference Call	WAGFLAG03151210	WAGFLAG03151226		
P-28407	10/25/2013	RE: F.D.A. Seeks Tighter Control on Prescriptions for Class of Painkillers	WAGFLAG03671451	WAGFLAG03671453		
P-28408	4/23/2009	Re: Fw: Rx Strategy and Deliverables - NEED ACTION	WAGFLAG03797628	WAGFLAG03797656		
P-28409	6/18/2011	Re Str 6674 oxycodone robbery 6/18/11, 8:30pm, no injuries	WAGFLDEA00000376	WAGFLDEA00000380		
P-28410	8/19/2015	FW: RHD Meeting - Govt. Relations Presentation	WAGMDAA00013008	WAGMDAA00013030		
P-28411	9/15/2015	BCI audit and November presentations	WAGMDL00014994	WAGMDL00015015		
P-28412	11/1/2017	RE: Xtampza ER and Florida Blue	WAGMDL00090707	WAGMDL00090709		
P-28413	9/27/2012	PDQ Email	WAGMDL00113825	WAGMDL00113826		
P-28414	5/14/2013	RE: C-2 ORDERS QUESTION	WAGMDL00240982	WAGMDL00240984		
P-28415	12/19/2014	Hysingla follow up	WAGMDL00253361	WAGMDL00253457		
P-28416	1/26/2017	RE: Drug takeback & conference call	WAGMDL00374175	WAGMDL00374177		
P-28417	5/28/2015	Florida Conference Call - Monday, June 1st at 11:00am EST	WAGMDL00508819	WAGMDL00508825		
P-28418	6/26/2013	Fwd: CII Communications	WAGMDL00528063	WAGMDL00528064		
P-28419	1/19/2018	E-Rx Presentation	WAGMDL00594359	WAGMDL00594391		
P-28420	3/13/2015	FW Response Requested - FL communications activities on access and abuse	WAGMDL00602538	WAGMDL00602563		
P-28421	5/19/2016	RE: Drug Take Back Event recap	WAGMDL00604282	WAGMDL00604288		
P-28422	7/8/2014	Fwd: BOD LRP Slide Talking Points	WAGMDL00705128	WAGMDL00705143		
P-28423	4/6/2013	FW: Board ABC Update discussion	WAGMDL00871290	WAGMDL00871294		
P-28424	4/15/2012	Pharmacy Health and Wellness Updates - 4/16	WAGMDL00898166	WAGMDL00898225		
P-28425	11/5/2012	RE: G-II budget	WAGMDL00931239	WAGMDL00931241		
P-28426	3/21/2013	Status 3-21-13	WAGMDL00981050	WAGMDL00981053		
P-28427	10/11/2012	Re: Good Faith Dispensing - High Risk Products Discussion	WAGMDL01132862	WAGMDL01132863		
P-28428	5/5/2016	RE: PAC Presentation + Question	WAGMDL01186052	WAGMDL01186072		
P-28429	11/3/2017	Re: from MIRS	WAGMIAG00006205	WAGMIAG00006206		
P-28430	7/31/2019	In the Matter of the Accusation Against John Winthrop Pierce MD	N/A	N/A		
P-28431	12/17/2013	S.F. doctor charged in homeless drug ring (SF Gate)	N/A	N/A		
P-28432	1/28/2014	In the Matter of the Accusation Against Collin Leong MD	N/A	N/A		
P-28433	9/10/2021	Hourigan LinkedIn profile	N/A	N/A		
P-28434	11/21/2016	Golnaz Kamali vs. Walgreen Co.	N/A	N/A		
P-28435	7/3/2017	Full and Complete Confidential Settlement Agreement and Release of Claims (Kamali)	N/A	N/A		
P-28436	9/17/2021	Lowe LinkedIn profile	N/A	N/A		
P-28437	11/3/2021	Wong LinkedIn profile	N/A	N/A		
P-28438	N/A	Ferry LinkedIn profile	N/A	N/A		
P-28439	11/4/2019	Walgreens Co. Records & Information Retention Schedule	N/A	N/A		
P-28440	2/1/2020	Walgreens Pharmacy Record Keeping Policy	N/A	N/A		
P-28441	1/17/2019	Walgreens Written 30(b)(6) Responses (CT1)	N/A	N/A		
P-28442	7/20/2020	Walgreens Responses and Objections to Plaintiff's First Set of Request for Production (CT4)	N/A	N/A		
P-28443	12/28/2020	Walgreens Responses and Objections to Plaintiff's First Set of Interrogatories (CT4)	N/A	N/A		
P-28444	12/28/2020	Walgreens Responses and Objections to Plaintiff's Second Set of Request for Production (CT4)	N/A	N/A		
P-28445	2/15/2021	Walgreens Written Responses to Certain 30(b)(6) Topics (CT3)	N/A	N/A		
P-28446	2/26/2021	Walgreens Written Responses to Certain 30(b)(6) Topics (CT3)	N/A	N/A		

P-28447	3/8/2021	Walgreens Objections and Responses to Plaintiff's First Set of Interrogatories NS Defendants (CT4)	N/A	N/A		
P-28448	3/31/2021	Walgreens Supp Responses and Objections to Plaintiff's First Set of Interrogatories (CT4)	N/A	N/A		
P-28449	5/7/2021	Walgreens 2nd Supp Responses and Objections to Plaintiff's First Set of Interrogatories (CT4)	N/A	N/A		
P-28450	5/7/2021	Walgreens Supp Objections and Responses to Plaintiff's First Set of Interrogatories NS Defendants (CT4)	N/A	N/A		
P-28451	6/28/2021	Walgreens Responses and Objections to Plaintiff's Third Set of Request for Production (CT4)	N/A	N/A		
P-28452	10/18/2021	Walgreens Responses and Objections to Plaintiff's Fourth Set of Request for Production (CT4)	N/A	N/A		
P-28453	11/11/2021	Walgreens Answers and Objections to Plaintiff's Second Set of Interrogatories NS Defendants (CT4)	N/A	N/A		
P-28454	11/12/2021	Defendant Walgreens Written Responses to Certain of Plaintiff's' Rule 30(b)(6) Topics (CT4)	N/A	N/A		
P-28455	11/12/2021	Walgreens Answers and Objections to Plaintiff's Second Set of Interrogatories (CT4)	N/A	N/A		
P-28456	11/12/2021	Walgreens Responses and Objections to Plaintiff's Fifth Set of Request for Production (CT4)	N/A	N/A		
P-28457	11/12/2021	Walgreens Responses and Objections to Plaintiff's' First Set of Request for Admissions (CT4)	N/A	N/A		
P-28458	12/9/2021	Walgreens 30(b)(6) Topics 2 and 3	N/A	N/A		
P-28459	12/17/2021	Walgreens 3rd Supp Responses and Objections to Plaintiff's First Set of Interrogatories (CT4)	N/A	N/A		
P-28460	12/23/2021	Walgreens 1st Supp Responses and Objections to Plaintiff's Fifth Set of Request for Production (CT4)	N/A	N/A		
P-28461	12/23/2021	Walgreens 1st Supp Responses and Objections to Plaintiff's First Set of Requests for Admission (CT4)	N/A	N/A		
P-28462	12/23/2021	Walgreens 1st Supp Responses and Objections to Plaintiff's Second Set of Interrogatories (CT4)	N/A	N/A		
P-28463	12/23/2021	Rebuttal and Supplemental Expert Report, Anna Lembke M.D.	N/A	N/A		
P-28464	12/31/2020	ARCOS Retail Drug Summary Reports, Drug Enforcement Administration, 2020	N/A	N/A		
P-28465	10/5/2021	McCann CT4 Appendix 1 Craig McCann Resume	N/A	N/A		
P-28466	10/5/2021	McCann CT4 Appendix 2 Corrections to the ARCOS Data	N/A	N/A		
P-28467	10/5/2021	McCann CT4 Appendix 3 Frequency and Definition of Transaction Codes	N/A	N/A		
P-28468	10/5/2021	McCann CT4 Appendix 4 Corrections to DEA's NDC Dictionary	N/A	N/A		
P-28469	10/5/2021	McCann CT4 Appendix 5 MME Conversion Factors (from CDC)	N/A	N/A		
P-28470	10/5/2021	McCann CT4 Appendix 6 MME on Base Weight and on Label	N/A	N/A		
P-28471	10/5/2021	McCann CT4 Appendix 7 Processing the Dispensing Data	N/A	N/A		
P-28472	10/5/2021	McCann CT4 Appendix 8a. ARCOS Summary	N/A	N/A		
P-28473	10/5/2021	McCann CT4 Appendix 8b. ARCOS Top-Down Reports	N/A	N/A		
P-28474	10/5/2021	McCann CT4 Appendix 8c. State Oxycodone and Hydrocodone MME Per Capita, 1997-2020	N/A	N/A		
P-28475	10/5/2021	McCann CT4 Appendix 8d. All Seller 12 Opioid Drugs Distribution, by Zip Code and by Drug	N/A	N/A		
P-28476	10/5/2021	McCann CT4 Appendix 9a. Distributor Reports	N/A	N/A		
P-28477	10/5/2021	McCann CT4 Appendix 9b. Average and Total Shipments to Walgreens	N/A	N/A		
P-28478	10/5/2021	McCann CT4 Appendix 9c. Average and Total Shipments from Walgreens	N/A	N/A		
P-28479	10/5/2021	McCann CT4 Appendix 9d. All Defendants, Combined and Individually, 12 Opioid Drug Distribution by Defendant	N/A	N/A		
P-28480	10/5/2021	McCann CT4 Appendix 9e. All Defendants, Combined and Individually, 12 Opioid Drug Distribution by Drug Code	N/A	N/A		
P-28481	10/5/2021	McCann CT4 Appendix 9f. Individual Defendant Oxycodone Distribution in San Francisco County, CA	N/A	N/A		

P-28482	10/5/2021	McCann CT4 Appendix 9g. Individual Defendant Hydrocodone Distribution in San Francisco County, CA	N/A	N/A		
P-28483	10/5/2021	McCann CT4 Appendix 9h. San Francisco County, CA Flagged Distributor Defendant Transaction Reports	N/A	N/A		
P-28484	10/5/2021	McCann CT4 Appendix 10a. Pharmacy Reports	N/A	N/A		
P-28485	10/5/2021	McCann CT4 Appendix 10b. Oxycodone and Hydrocodone Distribution to Individual Pharmacies by All Distributors	N/A	N/A		
P-28486	10/5/2021	McCann CT4 Appendix 10c. Oxycodone and Hydrocodone Distribution to Individual Pharmacies by Defendant	N/A	N/A		
P-28487	10/5/2021	McCann CT4 Appendix 10d. Pharmacy Reports on Combined Walgreens Stores	N/A	N/A		
P-28488	10/5/2021	McCann CT4 Appendix 10e. Flagged Chain Pharmacy Defendant Transaction Reports	N/A	N/A		
P-28489	10/5/2021	McCann CT4 Appendix 10f. Summary of Dispensing Red Flag Analysis All Walgreens Stores	N/A	N/A		
P-28490	10/5/2021	McCann CT4 Appendix 10g. Summary of Dispensing Red Flag Analysis Selected 12 Walgreens Stores	N/A	N/A		
P-28491	10/5/2021	McCann CT4 Appendix 10h. Dispensing Data Quality Summary	N/A	N/A		
P-28492	10/5/2021	McCann CT4 Appendix 10i. Walgreens Market Share	N/A	N/A		
P-28493	10/5/2021	McCann CT4 Appendix 10j. High Dosage Patient Summary	N/A	N/A		
P-28494	10/5/2021	McCann CT4 Appendix 10k. Single Ingredient Drug Summary	N/A	N/A		
P-28495	10/5/2021	McCann CT4 Appendix 11a. Manufacturer Attribution of Flagged Distributor Transactions	N/A	N/A		
P-28496	10/5/2021	McCann CT4 Appendix 11b. Flagged Manufacturer Defendant Transaction Reports	N/A	N/A		
P-28497	10/5/2021	McCann CT4 Appendix 11c. Actavis Watson Flagging Algorithm	N/A	N/A		
P-28498	10/5/2021	McCann CT4 Appendix 11d. Production Bates Summary	N/A	N/A		
P-28499	10/5/2021	McCann CT4 Appendix 11e. Manufacturer Monthly Bar Chart	N/A	N/A		
P-28500	10/5/2021	Craig J. McCann, Ph.D, CFA Report Coding and Files for 10.5.2021 Report. CODE TO PRODUCE	N/A	N/A		
P-28501	10/26/2021	McCann CT4 Supplemental Report	N/A	N/A		
P-28502	10/26/2021	McCann CT4 Supplemental Report - Appendix 1 - Column Headers of Walgreens' Electronic Notes	N/A	N/A		
P-28503	10/26/2021	McCann CT4 Supplemental Report - Appendix 2 - Confidence Intervals for Sample Observations	N/A	N/A		
P-28504	10/26/2021	McCann CT4 Supplemental Report - Appendix 3 - CA CURES	N/A	N/A		
P-28505	10/26/2021	Craig J. McCann, Ph.D, CFA Report Coding and Files for 10.26.2021 Supplemental Report	N/A	N/A		
P-28506	12/23/2021	Craig J. McCann, Ph.D, CFA Report Coding and Files for 12.23.2021 Rebuttal Report	N/A	N/A		
P-28507	2/17/2022	McCann CT4 Second Supplemental Report	N/A	N/A		
P-28508	2/17/2022	McCann CT4 Second Supplemental Report - Appendix 1 - Column Headers of Walgreens' Electronic Notes	N/A	N/A		
P-28509	N/A	San Francisco Processed ARCOS	N/A	N/A		
P-28510	N/A	CA Processed ARCOS	N/A	N/A		
P-28511	5/31/2019	Allergan Finance, LLC's First Amended Objections and Responses to Plaintiff's Fourth Set of Interrogatories, All Cases,	N/A	N/A		
P-28512	N/A	Walgreens Electronic Notes Composite	WAGSFDATA00004 - WAGSFDATA00020	Composite		
P-28513	11/4/2020	Walgreens Transactional Data	WAGCASF00000002; WAGCASF00000006	Composite		
P-28514	N/A	AmerisourceBergen's Transactional Data	ABDC-SF-FED000000001 - ABDC-SF-FED000000011, ABDC-SF-FED00001215, ABDC-SF-FED00001225 - ABDC-SF-FED00001226, ABDC-SF-FED00001247 - ABDC-SF-FED00001288	Composite		
P-28515	N/A	Cardinal Health's Transactional Data	CAH_FEDSF_0000011_HIGHLY CONFIDENTIAL	CAH_FEDSF_0000011_HIGHLY CONFIDENTIAL		
P-28516	N/A	McKesson's Transactional Data	MCK-SF-00000003_HIGHLY CONFIDENTIAL	MCK-SF-00000003_HIGHLY CONFIDENTIAL		
P-28517	N/A	Walgreens dispensing data and due diligence materials	N/A	N/A		
P-28518	N/A	Walgreens Dispensing Data	WAGSFDATA00001	WAGSFDATA00003		
P-28519	N/A	US Census Data	N/A	N/A		

P-28520	N/A	Processed Walgreens Dispensing Data	N/A	N/A		
P-28521	N/A	Processed Distribution Data	N/A	N/A		
P-28522	5/14/2021	CURES Data - Produced 5/14/2021	N/A	N/A		
P-28523	10/5/2021	CURES Data - Produced 10/5/2021	N/A	N/A		
P-28524	1/12/2022	CURES Data - Produced 1/12/2022	N/A	N/A		
P-28525	10/31/2012	Watson completed the acquisition of Actavis on October 31, 2012 (see <a href="https://www.sec.gov/Archives/edgar/data/0001578845/000119312514066242/d648811d10k.htm">https://www.sec.gov/Archives/edgar/data/0001578845/000119312514066242/d648811d10k.htm</a> )	N/A	N/A		
P-28526	5/1/1998	Agresti, A., & Coull, B. A. (1998). Approximate Is Better than "Exact" for Interval Estimation of Binomial Proportions. The American Statistician, 52(2), 119. <a href="https://doi.org/10.2307/2685469">https://doi.org/10.2307/2685469</a>	N/A	N/A		
P-28527	N/A	WAG Hard Copy Scripts - Composite of Walgreens Store 01126	WAGCASf00309584 - WAGCASf00309678; WAGCASf00309682 - WAGCASf00310020; WAGCASf00310974 - WAGCASf00311219; WAGCASf00333506 - WAGCASf00333515	Composite		
P-28528	N/A	WAG Hard Copy Scripts - Composite of Walgreens Store 01327	WAGCASf00310039 - WAGCASf00310073; WAGCASf00310078 - WAGCASf00310098; WAGCASf00310101 - WAGCASf00310144; WAGCASf00311289 - WAGCASf00311533; WAGCASf00312435 - WAGCASf00312565; WAGCASf00312569 - WAGCASf00312780; WAGCASf00333563 - WAGCASf00333661; WAGCASf00333931 - WAGCASf00333948	Composite		
P-28529	N/A	WAG Hard Copy Scripts - Composite of Walgreens Store 02088	WAGCASf00311670 - WAGCASf00311729; WAGCASf00312781 - WAGCASf00312895; WAGCASf00333662 - WAGCASf00333815; WAGCASf00334418 - WAGCASf00334553; WAGCASf00335281 - WAGCASf00335325	Composite		
P-28530	N/A	WAG Hard Copy Scripts - Composite of Walgreens Store 04318	WAGCASf00312896 - WAGCASf00312952; WAGCASf00333816 - WAGCASf00333830; WAGCASf00334301	Composite		
P-28531	N/A	WAG Hard Copy Scripts - Composite of Walgreens Store 04558	WAGCASf00310021 - WAGCASf00310038; WAGCASf00311220 - WAGCASf00311236; WAGCASf00333516 - WAGCASf00333521; WAGCASf00334554 - WAGCASf00334562	Composite		
P-28532	N/A	WAG Hard Copy Scripts - Composite of Walgreens Store 04609	WAGCASf00310263 - WAGCASf00310413; WAGCASf00311730 - WAGCASf00311788; WAGCASf00312953 - WAGCASf00313291	Composite		
P-28533	N/A	WAG Hard Copy Scripts - Composite of Walgreens Store 05487	WAGCASf00310414 - WAGCASf00310480; WAGCASf00311789 - WAGCASf00312379; WAGCASf00313292 - WAGCASf00313300; WAGCASf00334302 - WAGCASf00334417	Composite		
P-28534	N/A	WAG Hard Copy Scripts - Composite of Walgreens Store 05599	WAGCASf00311237 - WAGCASf00311288; WAGCASf00333831 - WAGCASf00333930; WAGCASf00334563 - WAGCASf00334597	Composite		
P-28535	N/A	WAG Hard Copy Scripts - Composite of Walgreens Store 07044	WAGCASf00312380 - WAGCASf00312434; WAGCASf00333491 - WAGCASf00333505; WAGCASf00334598 - WAGCASf00334621	Composite		
P-28536	N/A	WAG Hard Copy Scripts - Composite of Walgreens Store 11385	WAGCASf00313301 - WAGCASf00314273; WAGCASf00333522 - WAGCASf00333562; WAGCASf00334622 - WAGCASf00334983	Composite		
P-28537	N/A	WAG Hard Copy Scripts - Composite of Walgreens Store 13666	WAGCASf00311534 - WAGCASf00311580; WAGCASf00334984 - WAGCASf00335115; WAGCASf00335326 - WAGCASf00335565	Composite		
P-28538	N/A	WAG Hard Copy Scripts - Composite of Walgreens Store 13668	WAGCASf00310145 - WAGCASf00310262; WAGCASf00311581 - WAGCASf00311669; WAGCASf00333949 - WAGCASf00334300; WAGCASf00335116 - WAGCASf00335280	Composite		



P-28539	N/A	SF Sample Prescription Summary - Walgreens	N/A	N/A		
P-28540	N/A	Walgreens Suspicious Control Drug Order Report Composite	WAGMDL00852082; WAGMDL00852084; WAGMDL00852102; WAGMDL00852105; WAGMDL00852107; WAGMDL00852109- WAGMDL00852112; WAGMDL00852114- WAGMDL00852115; WAGMDL00852117; WAGMDL00852119; WAGMDL00852121- WAGMDL00852122; WAGMDL00852124- WAGMDL00852125; WAGMDL00852127; WAGMDL00852129; WAGMDL00852131; WAGMDL00852133; WAGMDL00852135; WAGMDL00852137; WAGMDL00852139; WAGMDL00852141; WAGMDL00852143; WAGMDL00852145-WAGMDL00852146; WAGMDL00852148-WAGMDL00852162; WAGMDL00852164-WAGMDL00852170; WAGMDL00852173-WAGMDL00852207; WAGMDL00852345; WAGMDL00852347; WAGMDL00852349; WAGMDL00852351; WAGMDL00852393; WAGMDL00852395; WAGMDL00852397; WAGMDL00852399; WAGMDL00852401; WAGMDL00852403; WAGMDL00852405; WAGMDL00852407; WAGMDL00852409; WAGMDL00852411; WAGMDL00999814;; WAGMDL01089094 -	Composite		
P-28542	N/A	WAG TD GFD and Refusal To Fill Composite	N/A	N/A		
P-28543	N/A	Trends in Medical Use of Opioids in the US 2006-2016	N/A	N/A		
P-28544	1/15/2019	Opioid distribution trends (2006-2017) in the US Territories	N/A	N/A		
P-28545	12/19/2019	Ceiling Override Production - San Francisco	WAGCASF000000001	WAGCASF000000001		
P-28546	9/28/2020	Override Quantity Request Rejected	WAGCASF00014890	WAGCASF00014890		
P-28547	4/6/2020	Override Quantity Request Rejected	WAGCASF00065445	WAGCASF00065445		
P-28548	9/29/2020	Override Quantity Request Rejected	WAGCASF00066316	WAGCASF00066316		
P-28549	4/5/2013	Re: *** Controlled Substance Ordering Immediate Action Required ***	WAGCASF00017860	WAGCASF00017860		
P-28550	12/22/2008	DEA Compliance - Perrysburg Distribution Center	WAGMDL00757193	WAGMDL00757211		
P-28551	10/7/2011	Watson Susp Order Invest Report	ALLERGAN_MDL_02467197	ALLERGAN_MDL_02467197		
P-28552	12/19/2011	Capital Drug.one	ALLERGAN_MDL_03765702 ALLERGAN_MDL_03765702	ALLERGAN_MDL_03765743 ALLERGAN_MDL_03765763	ALLERGAN_MDL_03765702 - ALLERGAN_MDL_03765743	
P-28553	7/26/2010	Watson Susp Order Invest. Summary	ALLERGAN_MDL_02176522	ALLERGAN_MDL_02176522		
P-28554	1/13/2022	Amended Notice of Videotaped Rule 30(b)(6) Deposition of Walgreens (CT4)	N/A	N/A		
P-28555	1/22/2013	RE: Watson Follow-up to Data Requested	Acquired_Actavis_01675041	Acquired_Actavis_01675042		
P-28556	2/25/2013	FW: Response to Compliance Questions; Signed Letter to Tom Napoli; Control Product sales - Watson - Actavis products 2012; Nulife Pharmaceuticals	ALLERGAN_MDL_03407210	ALLERGAN_MDL_03407232		
P-28557	12/26/2013	PCG Due Diligence Questionnaire - RDC copy3	Teva_MDL_A_02248096	Teva_MDL_A_02248100		
P-28558	12/31/2014	EXTERNAL: RE: Generics BidCo	PAR_OPIOID_MDL_0002108005	PAR_OPIOID_MDL_0002108012		
P-28559	4/6/2013	Flagged Order Production - All States	WAGMDL01109283	WAGMDL01109283		
P-28560	2/1/2021	Store Data - Expanded SF CA	WAGCASF00000633	WAGCASF00000633		
P-28561	7/10/2012	RE: PDQ Order Analysis	WAGFLAG00031502	WAGFLAG00031504		
P-28562	12/8/2013	FW:	WAGFLAG00920190	WAGFLAG00920221		
P-28563	3/16/2011	Email re: CA State Board of Pharmacy	Anda_Opioids_MDL_0000130916	Anda_Opioids_MDL_0000130920		
P-28564	4/4/2018	James_Statement	WAGCASF00314278	WAGCASF00314280		
P-28565	3/16/2011	Email re: 2nd Street Pharmacy et al	Anda_Opioids_MDL_0000133943	Anda_Opioids_MDL_0000133951		
P-28566	4/4/2018	Melanie_Statement	WAGCASF00314281	WAGCASF00314282		
P-28567	4/4/2018	Mohammed_Statement	WAGCASF00314283	WAGCASF00314284		
P-28568	10/29/2009	Moms Pharmacy Retail Pharmacy Permit	Anda_Opioids_MDL_0001026014	Anda_Opioids_MDL_0001026024		
P-28569	2/2/2011	Email re: Moms New Account	Anda_Opioids_CA_SF_0015217	Anda_Opioids_CA_SF_0015219		

P-28570	2/2/2011	Email re: Moms New Account	Anda_Opioids_CA_SF_0017606	Anda_Opioids_CA_SF_0017608		
P-28571	4/4/2018	Scott_Hanson_Statement	WAGCASF00314292	WAGCASF00314292		
P-28572	11/2/2021	IC10007999450 - case related to IC10007999047 - Written Statement (William Buckley)	WAGCASF00599854	WAGCASF00599854		
P-28573	12/6/2019	Report reveals loose conflict-of-interest policies, deference to donors benefitted Purdue Pharma	N/A	N/A		
P-28574	12/31/2018	83 FR 67729	N/A	N/A		
P-28575	8/1/2013	email re: 830157 - Charlie's Controls	Anda_Opioids_MDL_0000515090	Anda_Opioids_MDL_0000515091		
P-28576	8/23/2013	email re: 830157 - Charlie's Controls	Anda_Opioids_MDL_0000514564	Anda_Opioids_MDL_0000541566		
P-28577	N/A	Ownership Appendix from 11/16/2018 Depo. of John Hassler, Ex. 4	N/A	N/A		
P-28578	N/A	Teva Transactional Data	TEVA_NY_01019779	TEVA_NY_01019863		
P-28579	N/A	Teva_NY - Summary Direct and Indirect Sales Data - CONFIDENTIAL.xlsx	N/A	N/A		
P-28580	1/11/2022	Kathleen Konka - Director, Health Policy - Purdue Pharma L.P.   LinkedIn	N/A	N/A		
P-28581	10/1/2015	Pseudoaddiction: Fact or Fiction? An Investigation of the Medical Literature	N/A	N/A		
P-28582	N/A	Walgreens Pharmacy Notes	WAGCASF012	WAGCASF017		
P-28583	N/A	Compilation of Manufacturer (Allergan Specific) Produced Files for NDC  Allergan Amended Objections and Responses to Plaintiff's Interrogatories (03/20/2019, all cases; 05/31/2019 Response, Cuyahoga & Summit; 07/30/2019, Cuyahoga & Summit) and supporting files (ALLERGAN_MDL_01852265 - ALLERGAN_MDL_01852266)	Compilation	Compilation		
P-28584	7/3/2007	Southwood Pharmaceuticals Revocation of Registration	n/a	n/a		
P-28585	11/5/2011	Discussion Points	ALLERGAN_MDL_02187200	ALLERGAN_MDL_02187203		
P-28586	N/A	Compilation of Manufacturer (Endo Specific) Produced Files for NDC.  Endo Health Solutions Inc. and Endo Pharmaceuticals Inc.'s Objections and Responses to Plaintiff's Third Set of Interrogatories (01/07/2019, Cleveland, Cuyahoga & Summit) and supporting files (ENDO_DATA-OPIOID_MDL-00000017 - ENDO_DATA-OPIOID_MDL-00000041)	Compilation	Compilation		
P-28587	N/A	Compilation of Manufacturer (Par Specific) Produced Files for NDC  Par Pharmaceutical, Inc. and Par Pharmaceutical Companies, Inc.'s Second Supplemental Objections and Responses to Plaintiff's Interrogatory Nos. 5, 22, 23, 24, 27, and 33 (06/27/2019, Cleveland, Cuyahoga & Summit) and supporting files (PAR_OPIOID_MDL_0001596806 - PAR_OPIOID_MDL_0001596819; PAR_OPIOID_MDL_0001596821 - PAR_OPIOID_MDL_0001596826; PAR_OPIOID_MDL_0002016639 - PAR_OPIOID_MDL_0002016785)	Compilation	Compilation		
P-28588	3/5/2021	Report P-Births: Historical and Projected Fertility Rates and Births, Calendar Year 1990-2040, California and Counties	N/A	N/A		
P-28589	4/1/2021	2018-2028 Occupational Employment Projections, San Francisco and San Mateo Counties	N/A	N/A		
P-28590	5/1/2019	2016-2026 Occupational Employment Projections, San Francisco and San Mateo Counties	N/A	N/A		
P-28591	N/A	Urban Institute CA county NAS incidence and treatment distances	N/A	N/A		

P-28592	N/A	2015-2019 National TEDS-D length of stay distribution code Stata output	N/A	N/A		
P-28593	N/A	2015-2019 National and California TEDS-A MAT Utilization Stata Output	N/A	N/A		
P-28594	8/20/2010	2011 Tactical Plan 08-20-10.pptx; Microsoft Office Excel Worksheet1.xlsx.	ENDO-CHI_LIT-00546731	ENDO-CHI_LIT-00546732		
P-28595	11/9/2011	FW: Generic equivalent to Opana ER® now available from Actavis; image001.gif; Oxymorphone Summary for Walgreens 7-22-2011.pdf	ACTAVIS0338562	ACTAVIS0338573		
P-28596	2/11/2010	Pain Assessment Tool	ALLERGAN_MDL_03321681	ALLERGAN_MDL_03321687		
P-28597	1/11/2011	2011 NPL Summary (confidential) 1-11-10.xlsx	ALLERGAN_MDL_03732971	ALLERGAN_MDL_03732971		
P-28598	10/19/2009	2009 NPL Summary (confidential) 10-19-09.xls	ALLERGAN_MDL_03735764	ALLERGAN_MDL_03735764		
P-28599	6/29/2010	Fentanyl Buccal.one (On 11-23-2010).one; 1-2-1-cover-letter.pdf; watson-riskmap-summary.pdf; 1-16-risk-management-plan.pdf; 65be52db-bbb2-4d53-9444-9997c61a5f461-2-1-cover-letter.pdf; Watson RiskMAP Summary.pdf	ALLERGAN_MDL_03827108	ALLERGAN_MDL_03827560		
P-28600	12/8/2011	2018.06.01 - ALLERGAN-MDL001; image001.gif; image002.jpg; KADI1194-Pharmacy Flyer.pdf	ALLERGAN_MDL_00723485	ALLERGAN_MDL_0072349312/8/2011		
P-28601	11/23/2011	FW: KAD-071 Generic Physician Flyer; image001.gif; KAD-071 Kadian Generic Physician Flyer 11-23-11.pdf	ACTAVIS0334875	ACTAVIS0334879		
P-28602	11/23/2011	FW: KAD-071 Generic Physician Flyer; KAD-071 Kadian Generic Physician Flyer 11-23-11.pdf	ALLERGAN_MDL_01213002	ALLERGAN_MDL_01213005		
P-28603	12/8/2011	Fw: RE: KADI1194: Pharmacy Flyer; image001.gif; image002.jpg; KADI1194-Pharmacy Flyer.pdf	ACTAVIS0806956	ACTAVIS0806964		
P-28604	10/17/2012	FW: Generic Kadian Flyer; image001.gif; KAD-071 Kadian Generic Physician Flyer FINAL 11-30-11[1].pdf	ALLERGAN_MDL_00164106	ALLERGAN_MDL_00164109		
P-28605	6/8/2009	Fw: Forecast; 3 yr fcst May 09 live pipeline.xls; 2009 Forecast Planning Model (CE) v1.xls	ALLERGAN_MDL_01027493	ALLERGAN_MDL_01027495		
P-28606	9/9/2011	Actavis Client Status 110909.xlsx; Actavis Media Plan 2011_110902.xls	ACTAVIS0349218	ACTAVIS0349219		
P-28607	3/8/2012	Ad Expense Reporting 2011 - M Clarke.xls	Acquired_Actavis_02118235	Acquired_Actavis_02118235		
P-28608	7/12/2011	Oxymorphone ER Promotion Plan; Oxymorphone HCl Tablets Promotional Plan.pdf	Acquired_Actavis_00098054	Acquired_Actavis_00098055		
P-28609	7/7/2011	RE: PDQ Quote For Your Review; image001.gif; image002.gif; Opana ER Docs Mailing List to PDQ.xls; Oxymorphone PDQ Mailing Insertion Order.pdf	ALLERGAN_MDL_00492055	ALLERGAN_MDL_00492065		
P-28610	3/29/2012	12Diana Actavis Oxymorphone Narrative.pdf	Acquired_Actavis_01061973	Acquired_Actavis_01061974		
P-28611	N/A	CC_511_3YP Version 3.xls; CC_512_3YP Version 3.xls; CC_513_3YP Version 3.xls; CC_551-02_3YP Version 2.xls	ACTAVIS0600872	ACTAVIS0600875		
P-28612	9/18/2012	Technekes; Kadian TeleSales Technekes 20120918.xlsx	ALLERGAN_MDL_00443993	ALLERGAN_MDL_00443994		
P-28613	7/13/2011	TMS update for T2; Proposed_Actavis46_TMSDetail_20110713.xls	ALLERGAN_MDL_00402769	ALLERGAN_MDL_00402770		
P-28614	3/29/2011	Salmoren sent Altier and Garcia KADI1115(1-2) approval; Approved-KADI1115(1-2).pdf; image001.gif	ACTAVIS0374771	ACTAVIS0374775		
P-28615	2/17/2011	Smart Scan Suspicious: Marketing Opportunities Outline + Pricing; Actavis_Marketing Opportunities 2.11.pdf; PHN DMA Overview Q1 2011.pdf; PHN Network Facts.pdf; PHN Planning Calendar 2011.pdf; PHN_ROI.pdf	ALLERGAN_MDL_04397228	ALLERGAN_MDL_04397237		
P-28616	3/23/2011	FW: Cardinal Health eConnection Proof	ALLERGAN_MDL_01193255	ALLERGAN_MDL_01193257		
P-28617	10/22/2012	Actavis Promotional Program; Cardinal email.pdf; image001.gif; img238.pdf	ACTAVIS0220732	ACTAVIS0220735		
P-28618	10/24/2012	RE: Actavis eConnection proof for the Campaign Kadian; EAS	ALLERGAN_MDL_01000328	ALLERGAN_MDL_01000336		
P-28619	10/24/2012	RE: Actavis eConnection proof for the Campaign Kadian; EAS	ALLERGAN_MDL_01001415	ALLERGAN_MDL_01001424		
P-28620	6/3/2009	Cardinal Marketing Form, Service Flash	CAH_MDL2804_02959980	CAH_MDL2804_02959980		
P-28621	11/2/2009	Cardinal Marketing Form, Service Flash	CAH_MDL2804_02959971	CAH_MDL2804_02959971		
P-28622	9/17/2009	Cardinal Marketing Form, First Fax	CAH_MDL2804_02959979	CAH_MDL2804_02959979		
P-28623	12/10/2009	RE: Service Flash Update	ALLERGAN_MDL_01196493	ALLERGAN_MDL_01196495		
P-28624	4/18/2011	Zuchelli & Johnson Batch Posting Report	AM00152	AM00162		
P-28625	3/31/2011	Re: e-Med/Alert	Acquired_Actavis_00364165	Acquired_Actavis_00364166		

P-28626	3/31/2011	Fw: e-Med/Alert; KAD-038 Kadian Med Alert Neuro Email 03-31-11.pdf	ACTAVIS0374389	ACTAVIS0374390		
P-28627	11/16/2012	RE: Kadian Campaign Open Rates; image001.gif; Kadian Stocking Offer metrics report.pdf	ACTAVIS0215418	ACTAVIS0215423		
P-28628	12/17/2012	Scanned from a Xerox multifunction device; Invoice: Zuchelli & Johnson	ALLERGAN_MDL_00383460	ALLERGAN_MDL_00383466		
P-28629	9/18/2012	Fw: e-Pharm/alert - Metrics for Wave 1; 16808_Actavis.pdf	ALLERGAN_MDL_03677297	ALLERGAN_MDL_03677299		
P-28630	5/13/2010	FW: Kadian re-launch budget; Kadian Relaunch selected.doc; Kadian Direct Mail.doc	ALLERGAN_MDL_00221769	ALLERGAN_MDL_00221775		
P-28631	8/24/2012	RE: MediMedia Contract addendum; image001.gif; MediMedia Agreement (Execution Copy).pdf; MediMedia Amendment 3.pdf; MediMedia First Amendment.pdf; SDOC0005136_Kadian Coupon Reprint_10K_081712.docx	ALLERGAN_MDL_01401181	ALLERGAN_MDL_01401221		
P-28632	7/16/2010	Actavis letter to DDMAC re NDA 20-616 Kadian MACMIS #18148	ALLERGAN_MDL_02106570 ALLERGAN_MDL_02106591	ALLERGAN_MDL_02106610 ALLERGAN_MDL_02106834	ALLERGAN_MDL_02106591 - ALLERGAN_MDL_02106610	
P-28633	3/21/2012	Feb 2012 Pharmacy Ranking.xlsx	ALLERGAN_MDL_00060032	ALLERGAN_MDL_00060032		
P-28634	8/22/2012	FW: Actavis RepOnCall Program Proposal; Actavis_Kadian_Kick-Off_Questions_20120822.docx; image001.gif; image002.gif; image003.png; image004.png; image005.png	Acquired_Actavis_00584255	Acquired_Actavis_00584277		
P-28635	4/16/2013	Kadian Follow; Actavis_RoC_20130411 AD.pptx;image001.gif;image002.png;image003.png;image004.png;image007.png	ACTAVIS0188583	ACTAVIS0188599		
P-28636	8/27/2009	Media Schedule; 2009 Media plan.xls	Acquired_Actavis_00612288	Acquired_Actavis_00612289		
P-28637	8/20/2010	RE: PDQ Mailing :-); pdq2010.pdf	Acquired_Actavis_00628015	Acquired_Actavis_00628018		
P-28638	1/7/2015	FW: PDQ Physician Follow Up; ActavisPain121214.csv	Acquired_Actavis_01374032	Acquired_Actavis_01374037		
P-28639	2/1/2010	Scheduled Report-www.actavis.us-Actavis.us - Quarterly report; EAS	Acquired_Actavis_00628930	Acquired_Actavis_00628936		
P-28640	5/1/2010	Spam: Spam: Scheduled Report-www.actavis.us-Actavis.us - Quarterly report	ALLERGAN_MDL_01235077	ALLERGAN_MDL_01235087		
P-28641	7/1/2010	Scheduled Report-www.actavis.us-Actavis.us - Quarterly report	ALLERGAN_MDL_01235154	ALLERGAN_MDL_01235163		
P-28642	N/A	Compilation of Manufacturer (Teva/Actavis/Cephalon Specific) Produced Files for NDC  Teva Defendants' Supplemental Responses and Objections to Plaintiff's First Set of Interrogatories (09/17/2021, City & County of San Francisco), 09/24/2021 Letter from Harvey Bartle, and supporting files (TEVA_MDL_A_02401117; TEVA_MDL_A_02416192; TEVA_MDL_A_02416205; TEVA_MDL_A_02416208; TEVA_MDL_A_02419959 - TEVA_MDL_A_02419960; TEVA_MDL_A_02419962 - TEVA_MDL_A_02419969; TEVA_MDL_A_02627770)	Compilation	Compilation		
P-28643	10/5/2011	FW: Fentanyl Ad; Fentanyl-ad-CDR-2011-02-11.pdf; image001.gif	ALLERGAN_MDL_00479723	ALLERGAN_MDL_00479734		
P-28644	7/14/2009	Actavis Contractual Agreements with various parties	ALLERGAN_MDL_01474262	ALLERGAN_MDL_01474451		
P-28645	4/8/2009	Adjudicated Discount Coupon Program Agreement	ALLERGAN_MDL_01891508	ALLERGAN_MDL_01891531		
P-28646	2/3/2010	RE: Order Confirmation - Order Number 2468	ALLERGAN_MDL_01196792	ALLERGAN_MDL_01196793		
P-28647	10/5/2006	Fw: Watson Info-Lert 2006-0058 - Product Launch Fentanyl Citrate OTFC; Watson Infolert 2006-0058 - Product Launch Fentanyl Citrate OTFC.pdf	ALLERGAN_MDL_01144536	ALLERGAN_MDL_01144539		
P-28648	6/19/2006	061906 Sem II IC Planning v2.0.ppt	ENDO-OPIOID_MDL-00940006	ENDO-OPIOID_MDL-00940024		
P-28649	7/30/2012	Polaris/Grants & Aggregate Spend with Attachments:Educational Grants Decision Report 2011.xlsx; Endo RMS Home Page - Welcome.pdf; Profile Registration - Terms and Conditions.pdf; Profile Registration.pdf; Request - View 1.pdf; Request - General Info - View 2.pdf; Request Instructions - View 2.pdf; SAMPLE Completed Request.pdf; SAMPLE Check Request.pdf	END00448665	END00448694		
P-28650	4/2/2020	Physician list	ENDO-CA-DATA-00000001	ENDO-CA-DATA-00000001		

P-28651	9/17/2020	Opana IR	ENDO-CA-DATA-00000006	ENDO-CA-DATA-00000006		
P-28652	4/27/2020	Meal Compensation Data 2007 - 2012	ENDO-CA-00164784	ENDO-CA-00164784		
P-28653	4/2/2020	Meal Compensation Data 2012-2015	ENDO-CA-00164785	ENDO-CA-00164785		
P-28654	4/2/2020	Meal Compensation Data 2016-2017	ENDO-CA-00164786	ENDO-CA-00164786		
P-28655	N/A	Opana ER Call Data 2015	ENDO-OPIOID MDL-07391941	ENDO-OPIOID MDL-07391941		
P-28656	N/A	Call Data 12-31-1987	ENDO-OPIOID MDL-07391945	ENDO-OPIOID MDL-07391945		
P-28657	2/17/2011	NIPC Status Update with attachments:NIPC status update_021711.doc; Pre-reg Grid for APF-NIPC Dinner Dialogues 021711.xls	END00446251	END00446260		
P-28658	11/24/2009	OPANA Practitioners YTD: e-mail 3 of 3 with attachments: Opana_LetterDetailsReport_01012009to11202009-3.xlsx	ENDO-OPIOID_MDL-00923056	ENDO-OPIOID_MDL-00923058		
P-28659	11/24/2009	OPANA Practitioners YTD: e-mail 1 of 3 with attachments:Opana_LetterDetailsReport_01012009to11202009-1.xlsx	ENDO-OPIOID_MDL-00923050	ENDO-OPIOID_MDL-00923052		
P-28660	11/24/2009	OPANA Practitioners YTD: e-mail 2 of 3 with attachments:Opana_LetterDetailsReport_01012009to11202009-2.xlsx	ENDO-OPIOID_MDL-00923053	ENDO-OPIOID_MDL-00923055		
P-28661	8/26/2011	RE: OPANA ER - 2011 Media Plan Review & Q3-Q4 Recommendations with attachments: OPANA ER - Q3-Q4 Media Buy-up Opportunities.xlsx; OPANA ER - 2011 Media Plan Review & Q3-Q4 Recommendations_8-11-11.pdf; Opana ER - 2011 Media Plan Summary + Buy-up Opportunities; OPANA ER 2011 Media Plan Overview_1-20-11.pdf; OPANA ER - Q3-Q4 Media Buy-up Opportunities.xlsx	END00551118	END00551163		
P-28662	6/14/2012	2012 SOW for Media Campaign	EPI000005372	EPI000005385		
P-28663	8/3/2011	FW: Your NetInsight Executive Dashboard	ENDO-OPIOID MDL-00395886	ENDO-OPIOID MDL-00395887		
P-28664	12/5/2012	Confirmed Opana ER programs with attachments:Confirmed Opana ER Programs_12_05_12.xlsx	ENDO-CHI_LIT-00280922	ENDO-CHI_LIT-00280923		
P-28665	1/3/2013	2012 Opana ER Program Report with attachments:Confirmed Opana ER Programs_01_03_13.xlsx	ENDO-OPIOID_MDL-00483946	ENDO-OPIOID_MDL-00483947		
P-28666	1/3/2011	Speaker programs with attachments:2010 OPANA 12-30-10.xlsx	ENDO-CHI_LIT-00395461	ENDO-CHI_LIT-00395462		
P-28667	12/28/2009	2009 Speaker Programs to be Completed - 12/26/09 Update with attachments:2009 OPANA 12-26-09.xlsx	ENDO-OPIOID_MDL-00673955	ENDO-OPIOID_MDL-00673957		
P-28668	11/15/2008	FW: reports; Lidoderm.xls; Opana.xls	ENDO-OPIOID_MDL-00786302	ENDO-OPIOID_MDL-00786304		
P-28669	6/27/2007	OPANA ER Speaker Program Weekly Status Report - 3 attachments; Dinner Meeting Master List 2007 (6-26-07).xls; May 2007 Attendee Evaluations Executive Summary Final.doc; May Executive Summary - Sales Representative Evaluations doc.doc	ENDO-OPIOID_MDL-00866675	ENDO-OPIOID_MDL-00866681		
P-28670	9/8/2008	2008 Plan; 2008 OPANA Brand Tactical Plan-08-23-07.ppt	EPI000560275	EPI000560276		
P-28671	6/7/2013	FW: How are you doing vs. your peers in resource utilization?	MNK-T1_0001553091	MNK-T1_0001553095		
P-28672	3/23/2009	TE Stuff (cover email); all cams.xls; TE interactions .xls	ENDO-OPIOID_MDL-07397140	ENDO-OPIOID_MDL-07397142		
P-28673	5/21/2012	RTTW Follow Up; EXALGO Fast Start Challenge Reward Trip Follow.docx	MNK-T1_0000747113	MNK-T1_0000747115		
P-28674	2/1/2013	National Successes and what YOU can do to drive - Q2 ***Action Required***	MNK-T1_0000950037 MNK-T1_0000950064	MNK-T1_0000950067 MNK-T1_0000950065	MNK-T1_0000950064 - MNK-T1_0000950065	
P-28675	6/21/2012	EXALGO Free Trial Regional Training Call; image001.jpg; image002.png; image003.jpg; Free trial traningFINAL.pptx; Free Trial Target list final.xlsx	MNK-T1_0001143820	MNK-T1_0001143825		
P-28676	6/19/2012	RE: Speaker Program Budgets for FY13	MNK-T1_0001475963	MNK-T1_0001475964		
P-28677	4/7/2010	March 2010 comparison 040810.ppt	TEVA_MDL_A_00555493	TEVA_MDL_A_00555493		
P-28678	11/14/2005	FINAL 2006 ACTIQ Marketing Plan 11_8_05.ppt; [Unnamed Document]; [Unnamed Presentation]; [Unnamed Presentation]	TEVA_MDL_A_01163388	TEVA_MDL_A_01163391		
P-28679	12/5/2007	FENTORA Assessment Strategy tactics 2007	TEV_FE00033412	TEV_FE00033458		
P-28680	3/11/2011	Teledetail Analysis 03022011 v2.xls	TEVA_MDL_A_00681247	TEVA_MDL_A_00681247		

P-28681	8/1/2015	Nahin R. L. (2015). Estimates of pain prevalence and severity in adults: United States, 2012. The journal of pain, 16(8), 769–780. <a href="https://doi.org/10.1016/j.jpain.2015.05.002">https://doi.org/10.1016/j.jpain.2015.05.002</a>	N/A	N/A		
P-28682	11/22/2005	Velasar Zero-Based Option Revisions; Velasar 2006 Media Recommendation - Revised 11.10.05.ppt; [Unnamed Presentation]; velasar 2006 journal schedule- client copy 11.22.05.pdf	TEVA_MDL_A_02875706	TEVA_MDL_A_02875719		
P-28683	N/A	Fentora Print proposal Jan. 2011	TEVA_CAOC_00057971	TEVA_CAOC_00057971		
P-28684	N/A	Ready for REMS Campaign Performance report, March 1, 2011-September 5, 2011	TEVA_CAOC_08791796	TEVA_CAOC_08791796		
P-28685	10/14/2014	FW: Aches and gains; 6.27.13%20Sponsorship%20Agreement[1].pdf	TEVA_MDL_A_08726891	TEVA_MDL_A_08726894		
P-28686	N/A	ACTIQ National Consultant Meetings Attendance and Speaker list, 2003	TEVA_CAOC_02134227	TEVA_CAOC_02134227		
P-28687	7/17/2002	ACTIQ 2003 Planning Meeting	TEVA_MDL_A_03248892	TEVA_MDL_A_03248892		
P-28688	N/A	Teva Speaker Honoraria data 2002-2008	TEVA_CAOC_01160585	TEVA_CAOC_01160585		
P-28689	1/11/2005	2004 SELVA CONSENSUS FINAL ATTENDANCE REPORT.xls	TEVA_MDL_A_06877976	TEVA_MDL_A_06877976		
P-28690	4/8/2005	Cephalon CME activities; Status 4 8.xls	TEVA_MDL_A_04110452	TEVA_MDL_A_04110454		
P-28691	5/24/2006	FEET Launch Playbook	TEVA_CAOC_01806007	TEVA_CAOC_01806007		
P-28692	11/20/2006	Fentora Programs Weekly Report 11.20.06.xls	TEVA_MDL_A_00338667	TEVA_MDL_A_00338667		
P-28693	2/7/2007	Brookes_FENTORA NSM_020707.ppt	TEVA_MDL_A_00365421	TEVA_MDL_A_00365421		
P-28694	1/15/2009	Letter of Agreement; Independent Educational Program Grant Agreement and copies of grant request materials for grant #2569; Independent Educational Program Grant Agreement; Report post programs for grant #2569 "Persistent and Breakthrough Pain: Multidimensional Assessment and Multimodal Opioid-Based Treatment Strategies"	TEVA_MDL_A_00849961	TEVA_MDL_A_00850152		
P-28695	11/18/2010	Medical Education 2011 Planning - Pain	TEVA_MDL_A_01397430	TEVA_MDL_A_01397431		
P-28696	N/A	Analysis of State Laws & Requirements for Prescribing/Dispensing/Record-Keeping for CII Narcotics - Recommendations for Pre-launch Strategies for Combunox	ALLERGAN_MDL_03295322	ALLERGAN_MDL_03295474		
P-28697	11/2/1994	Fax Memorandum, City of Hope	ALLERGAN_MDL_03332674	ALLERGAN_MDL_03332729		
P-28698	10/1/1998	Fostering Change in the Pain Policy Environment	PKY180117238	PKY180117247		
P-28699	8/23/2005	FW: Medical Board of California - Pain Management Laws Task Force Meeting - August 22, 2005.msg	PPLPC025000084075	PPLPC025000084101		
P-28700	4/4/2003	RE: CV; CV	TEVA_MDL_A_02683926	TEVA_MDL_A_02683927		
P-28701	3/21/2008	REGULATORY DECK Refs for AAD slide deck for PDRC, APS rights responsibilities annotated.pdf; DEA Controlled Substances Actannotated.pdf; FSMBannotated.pdf; GOURLAY2005Bannotated.pdf; JOHNSON1996annotated.pdf; MANCHIKANTI2006annotated.pdf; MANCHIKANTI2007Cannotated.pdf; NSDUH2006annotated.pdf; PAIN POLICY STUDY GROUP GUIDE 2004nonannotated.pdf; PISANO1996annotated.pdf	TEVA_MDL_A_07178500	TEVA_MDL_A_07179296		
P-28702	6/8/2005	TODAY: Serono; Abbott; King; OxyContin; Novartis; Daxas; Cell Genesys	TEVA_MDL_A_13252317	TEVA_MDL_A_13252318		
P-28703	4/21/2011	RE: Confusion About the Joint Commission Standards	WIS_PPSG_005818	WIS_PPSG_005818		
P-28704	7/30/2014	Achieving Balance in State Pain Policy - A Progress Report Card (CY 2013)	WIS_PPSG_007344	WIS_PPSG_007344		
P-28705	12/31/1997	State Intractable Pain Policy: Current Status	WIS_PPSG_012866	WIS_PPSG_012866		
P-28706	10/25/2004	DDD Mailorder v Xponent Mailorder	TEVA_MDL_A_10120809	TEVA_MDL_A_10120816		
P-28707	N/A	IQVIA Data- '03: GPS_084_73_non-USC022_mkt_def_JUL2018.xlsx	ALLERGAN_MDL_03320303	ALLERGAN_MDL_03320303		
P-28708	6/13/2018	IQVIA Data- '11: CDS.ZWK.TOUTPT.CTLTOT.F2.M04.CSV (describing total controlled substance amounts)	ALLERGAN_MDL_03320311	ALLERGAN_MDL_03320311		
P-28709	3/31/2011	FW: e-Med/Alert; KAD-038 Kadian Med Alert Neuro Email 03-31-11.pdf	ALLERGAN_MDL_00406525	ALLERGAN_MDL_00406526		
P-28710	2/28/2014	FULLY-EXECUTED: MediMedia Amendment #8 Kadian Discount Coupon Program Agreement; MediMedia Amend. #8 Kadian Discount Coupon Prgrm. Agre..pdf	ALLERGAN_MDL_01862603	ALLERGAN_MDL_01862605		



P-28711	8/26/2012	FW: RESUBMIT PROOF: PI FPO 40-9166 (VC111169) Kadian (morphine sulfate); Actavis Coupon Program_Amendment 5 to extend to 12-31-12 and Name Change.pdf	ALLERGAN_MDL_01861840	ALLERGAN_MDL_01861857		
P-28712	8/15/2010	Re: Distribution of Corrective Information	Acquired Actavis_00263464	Acquired Actavis_00263465		
P-28713	10/25/2010	FW: Cardinal Marketing Update - Kadian Service Flash; DSP Manf Program Overview_2010.pdf; Kadian Service Flash.pdf	ALLERGAN_MDL_01115956	ALLERGAN_MDL_01115961		
P-28714	1/7/2014	Kadian RepOnCall Program - HCP Target List; Actavis Kadian RepOnCall Program - HCP Target Database.xlsx; ATT00001	ALLERGAN_MDL_01614092	ALLERGAN_MDL_01614094		
P-28715	2/13/2013	FULLY-EXECUTED: Tecknekes RepOnCall Program, Work Order #1; Tecknekes RepOnCall Prgm-Work Order#1.pdf	ALLERGAN_MDL_00076478	ALLERGAN_MDL_00076485		
P-28716	5/7/2013	FW: Technes SOW Kadian RepOnCall; Technes SOW Kadian RepOnCall001.pdf	ALLERGAN_MDL_00002070	ALLERGAN_MDL_00002075		
P-28717	9/27/2012	Kadian Whitespace Outreach is Officially Underway!; AC3151_ActavisLetter.pdf; AC3151_ActavisLetter_Clinical.pdf; AC3151_ActavisLetter_Copay.pdf; AC3151_ActavisLetter_Copay_Info.pdf; AC3151_BubbleEnv_LabelOrange.pdf; AC3151_Env_No10_Window_stickerbar.pdf; AC3151_Env_No10_Window_stickercircle.pdf; AC3151_Env_No9_Window_StickerBar.pdf; AC3151_Env_No9_Window_StickerCircle.pdf; image001.gif; image002.png; image003.png; image004.png	ACTAVIS0228157	ACTAVIS0228176		
P-28718	10/25/2011	Re: BPC Follow Up - Telemarketing Program; image001.gif	ALLERGAN_MDL_00141659	ALLERGAN_MDL_00141662		
P-28719	8/12/2011	Fw: RE: KADIAN eBlast: Mock-ups and timeline for review - Status call at 10:30am this morning; image001.png; Kadian_W1.pdf; Kadian_W2.pdf; Kadian_W3.pdf; Kadian_W5.pdf; Kadian_W6.pdf	ACTAVIS0353806	ACTAVIS0353815		
P-28720	6/6/2011	Fw: MSA/SOW for eBlast; Kadian Agreement Full.docx	ACTAVIS0363313	ACTAVIS0363323		
P-28721	12/4/2011	Fw: RE: Kadian - Wave 4 Statistics and Call at 10:30am	ACTAVIS0480457	ACTAVIS0480462		
P-28722	3/18/2013	FW: MediMedia Amendment #7 to Adjudicated Discount Coupon Agreement; MediMedia Amendment 7 to Atjctd.Discount Program.pdf	ALLERGAN_MDL_00001625	ALLERGAN_MDL_00001628		
P-28723	1/14/2005	2001-2004 Symposia and Meetings	TEVA_CAOC_01196126	TEVA_CAOC_01196126		
P-28724	6/23/2010	Emerging Solutions in Pain (May Metrics) 6-23-10; MWW_May_2010_Metrics_Report_6-1-10.xls	TEVA_MDL_A_02487628	TEVA_MDL_A_02487629		
P-28725	7/6/2005	CME Calendar June 2005	TEVA_MDL_A_01856751	TEVA_MDL_A_01856751		
P-28726	1/15/2008	Emailing: CLOSED FALL 2007 Regional Program Report (1-14-08); CLOSED FALL 2007 Regional Program Report (1-14-08).xls	ENDO-CHI_LIT-00154562	ENDO-CHI_LIT-00154563		
P-28727	4/20/2009	FW: report; OPANA 4-20-09.xls	ENDO-CHI_LIT-00184663	ENDO-CHI_LIT-00184665		
P-28728	5/13/2013	Confirmed Opana ER program report; OPANA ER Confirmed Programs 051313.xlsx	ENDO-CHI_LIT-00473077	ENDO-CHI_LIT-00473078		
P-28729	2/7/2011	PERs 2009.xls; PERs 2009.xls	ENDO-OPIOID_MDL-01607904	ENDO-OPIOID_MDL-01607905		
P-28730	12/13/2012	RE: SOW attached; SOW with BioPharm Communications (Opana ER Email Campaign) (execution copy) 12-13-12.pdf	ENDO-OPIOID_MDL-01960575	ENDO-OPIOID_MDL-01960580		
P-28731	6/7/2013	FW: How are you doing vs. your peers in resource utilization?	MNK-T1_0001553091	MNK-T1_0001553094		
P-28732	5/30/2013	FW: Operation Change Agent - Resources	MNK-T1_0000949449	MNK-T1_0000949450		
P-28733	12/9/2011	FW: FY12 Q2 Speaker Programs	MNK-T1_0001476129	MNK-T1_0001476130		
P-28734	4/26/2002	FW: Copies of QBR Slides; EN3202 Q102 Update.ppt; Jerry's 1Q2002 Quarterly Review April 25 2002.ppt; Joe ambrefe Slides.ppt; Lidodermbusinessreview4_24_02.ppt; Percocet_1Q02.ppt; Q102 Business Review - EGP.ppt; YEAR 2002 PERFORMANCE TO-DATE.xls	ENDO-OPIOID_MDL-04906522	ENDO-OPIOID_MDL-04908590		
P-28735	9/23/2011	Current Opana ER Inventory PDF Attached; Opana ER Inventory Update as of 09-19-11.pdf	END00190190	END00190192		
P-28736	2/4/2011	RE: Updated Rep Materials	ENDO-CHI_LIT-00128404	ENDO-CHI_LIT-00128405		
P-28737	5/9/2008	Please review: PMRB Re-Review report: OPANA Brand; Re-Review Planning 5-5-08.xls	ENDO_FLAG-00053538	ENDO_FLAG-00053540		
P-28738	3/28/2011	Opana ER Inventory Management Report for: 03-28-2011; Inventory Management Report 03112011.xlsx	ENDO-OPIOID_MDL-00456375	ENDO-OPIOID_MDL-00456376		

P-28739	10/7/2006	FW: Opana 2007 draft operational plan from Mktg; 2007 Draft Operational Plan 8-22-06.ppt	ENDO-OPIOID_MDL-01606463	ENDO-OPIOID_MDL-01606465		
P-28740	8/5/2009	FW: Opana Non-Personal Outreach Program - Representative Requested Information; RepRequestSheet.xls	ENDO_ALAG-00544932	ENDO_ALAG-00544935		
P-28741	5/6/2019	Carter J, Zevin B, Lum PJ. Low Barrier Buprenorphine Treatment for Persons Experiencing Homelessness and Injecting Heroin in San Francisco.	N/A	N/A		
P-28742	10/1/2020	San Francisco Department of Public Health. Mental Health Report Updated Report	N/A	N/A		
P-28743	9/29/2020	San Francisco Department of Public Health. HIV Epidemiology Annual Report 2019	N/A	N/A		
P-28744	6/1/2020	End Hep C San Francisco. Strategic Plan 2020-2022.	N/A	N/A		
P-28745	9/26/2019	End Hep C San Francisco. 2018 Annual Evaluation.	N/A	N/A		
P-28746	4/18/2019	San Francisco Health Improvement Partnership. San Francisco Community Health Needs Assessment.	N/A	N/A		
P-28747	10/1/2019	San Francisco Department of Public Health. Methamphetamine Task Force, 2019 Final Report.	N/A	N/A		
P-28748	4/18/2019	San Francisco Health Improvement Partnership. San Francisco Community Health Needs Assessment. Published 2019	N/A	N/A		
P-28749	12/1/2010	Enteen L, Bauer J, McLean R, Wheeler E, Hurliaux E, Kral AH, Bamberger JD. Overdose Prevention and Naloxone Prescription for Opioid Users in San Francisco.	N/A	N/A		
P-28750	6/1/2003	Seal KH, Downing M, Kral AH, Singleton-Banks S, Hammond JP, Lorrwick J, Ciccarone D, Edlin BR. Attitudes About Prescribing Take-Home Naloxone to Injection Drug Users for the Management of Heroin Overdose: A Survey of Street-Recruited Injectors in the San Francisco Bay Area.	N/A	N/A		
P-28751	7/21/2021	Center for Innovation in Academic Detailing on Opioids at the San Francisco Department of Public Health. Opioids and Chronic Pain: A Guide for Primary Care Providers (California Edition). San Francisco, CA.	N/A	N/A		
P-28752	9/1/2017	San Francisco Department of Public Health. San Francisco Safe Injections Services Task Force, 2017 Final Report.	N/A	N/A		
P-28753	2/1/2017	Behar E, Rowe C, Santos GM, Santos N, Coffin PO. Academic Detailing Pilot for Naloxone Prescribing Among Primary Care Providers in San Francisco	N/A	N/A		
P-28754	4/1/2021	San Francisco Department of Public Health. Drug Sobering Center Issue Brief.	N/A	N/A		
P-28755	12/31/2020	San Francisco Department of Public Health. HIV Semi-Annual Surveillance Report.	N/A	N/A		
P-28756	2/1/2021	San Francisco Department of Public Health. Street Crisis Response Team (SCRT).	N/A	N/A		
P-28757	5/1/2009	The Superior Court of California, County of San Francisco. San Francisco Collaborative Courts Research Review	N/A	N/A		
P-28758	10/1/2019	Wenger LD, Showalter D, Lambdin B, Leiva D, Wheeler E, Davidson PJ, Coffin PO, Binswanger IA, Kral AH. Overdose Education and Naloxone Distribution in the San Francisco County Jail.	N/A	N/A		
P-28759	N/A	City and County of San Francisco. Reentry Council. Housing Programs.	N/A	N/A		
P-28760	2019	San Francisco Homeless Count & Survey. 2019 Comprehensive Report	N/A	N/A		
P-28761	6/1/2019	San Francisco Department of Public Health. Low Barrier Buprenorphine Pilot Program.	N/A	N/A		
P-28762	9/1/2018	Urban Institute. Neonatal Abstinence Syndrome and Maternal Access to Treatment for Opioid Use Disorder in California Counties.	N/A	N/A		
P-28763	4/14/2016	Auerswald CL, Lin JS, Parriott A. Six-Year Mortality in a Street-Recruited Cohort of Homeless Youth in San Francisco, California.	N/A	N/A		

P-28764	12/1/2004	Removal of Vioxx Shifts Drug Landscape	N/A	N/A		
P-28765	11/1/2014	National Drug Threat Assessment Summary 2014	N/A	N/A		
P-28766	10/1/2015	National Drug Threat Assessment Summary 2015	N/A	N/A		
P-28767	11/1/2016	National Drug Threat Assessment Summary 2016	N/A	N/A		
P-28768	12/21/2017	Increase in hepatitis C infections linked to worsening opioid epidemic	N/A	N/A		
P-28769	10/1/2017	National Drug Threat Assessment 2017	N/A	N/A		
P-28770	N/A	Opioid Use Disorder and Homelessness in the VHA	N/A	N/A		
P-28771	8/1/2021	Origins of the Opioid Crisis and its Enduring Impacts	N/A	N/A		
P-28772	N/A	Supply Side Drug Policy in the Presence of Substitutes	N/A	N/A		
P-28773	N/A	Ch. 23 Empirical Strategies in Labor Economics	N/A	N/A		
P-28774	N/A	San Francisco Annual Report 7-1-96 - 6-30-97	N/A	N/A		
P-28775	N/A	The State of Applied Econometrics	N/A	N/A		
P-28776	8/8/2016	China Shock Learning from Labor Market Adjustment to Large Changes in Trade	N/A	N/A		
P-28777	10/1/2013	China Syndrome Local Labor Market Effects of Import Competition in US	N/A	N/A		
P-28778	7/1/2020	The Drug Crisis and the Living Arrangements of Children	N/A	N/A		
P-28779	6/8/2021	The Opioid Epidemic Causes and Consequences	N/A	N/A		
P-28780	N/A	Mortality and Morbidity in the 21st Century	N/A	N/A		
P-28781	12/8/2015	Rising Morbidity and Mortality in Midlife.	N/A	N/A		
P-28782	10/6/2015	CDC - Increases in Fentanyl Drug Confiscations	N/A	N/A		
P-28783	1/3/2021	CDC - Vital Statistics Rapid Release, Provisional Drug Overdose Data.	N/A	N/A		
P-28784	7/25/2008	CDC Non Pharmaceutical Fentanyl-Related Deaths April 2005-March 2007	N/A	N/A		
P-28785	7/1/1960	Tests of equality between sets of coefficients in two linear regressions	N/A	N/A		
P-28786	5/1/2015	Abuse Deterrent Formulations	N/A	N/A		
P-28787	4/1/2013	S.F. painkiller overdoses eclipse heroin	N/A	N/A		
P-28788	10/31/2015	Addicts Learn to Save Others From Death - Los Angeles Times	N/A	N/A		
P-28789	8/1/2020	The Opioid Epidemic Was Not Caused by Economic Distress	N/A	N/A		
P-28790	5/1/2021	When Innovation Goes Wrong	N/A	N/A		
P-28791	N/A	Determinants of Mortality	N/A	N/A		
P-28792	5/1/2016	Economic Approaches to Estimating Benefits of Regulations	N/A	N/A		
P-28793	N/A	Why Have Americans Become More Obese	N/A	N/A		
P-28794	1/1/2001	Explaining the Rise in Youth Suicide	N/A	N/A		
P-28795	8/31/2006	Value of Medical Innovation in the US	N/A	N/A		
P-28796	4/1/2019	Can Economic Policies Reduce Deaths of Despair	N/A	N/A		
P-28797	12/15/2021	Drug Abuse Warning Network 2011	N/A	N/A		
P-28798	4/25/2016	Identifying cases of heroin toxicity where 6-acetylmorphine is not detected	N/A	N/A		
P-28799	3/1/2019	How the Reformulation of Oxycontin Ignited the Heroin Epidemic	N/A	N/A		
P-28800	3/1/1970	Tests of equality between sets of coefficients in two linear regressions	N/A	N/A		
P-28801	7/1/2012	The Economic Benefits of Pharmaceutical Innovations	N/A	N/A		
P-28802	12/2/2002	LA Times - Addicts Treat Others Overdoses	N/A	N/A		
P-28803	11/1/2021	Fentanyl has changed the whole landscape - SF Chron Web	N/A	N/A		
P-28804	10/31/2018	House Ways and Means Committee Green Book Chapter 11 - Figure 11-3 and Table 11-3	N/A	N/A		
P-28805	5/11/2017	Inside the opioid epidemic - A selective scourge	N/A	N/A		
P-28806	3/1/1989	Sharing Damages Among Multiple Tortfeasors	N/A	N/A		
P-28807	6/30/2020	Economic analysis of joint and several liability	N/A	N/A		
P-28808	7/1/2002	The neurobiology of opioid dependence	N/A	N/A		
P-28809	6/1/1980	Joint and Multiple Tortfeasors	N/A	N/A		
P-28810	6/28/2021	Maclean, et al. Economic Studies on the Opioid Crisis Costs, Causes, and Policy	N/A	N/A		

P-28811	7/1/2014	Mateu-Gelabert, et al. Injection and sexual HIV/HCV risk behaviors associated with nonmedical use of prescription opioids among young adults in New York City	N/A	N/A		
P-28812	5/14/2018	Associations of Nonmedical Pain Reliever Use and Initiation of Heroin Use in the United States	N/A	N/A		
P-28813	2016	Opioid Drug Side Effects	N/A	N/A		
P-28814	11/1/2017	San Francisco SCS Drug Use Patterns and Trends, 2017	N/A	N/A		
P-28815	10/1/2005	Measuring Diagnoses, ICD Code Accuracy	N/A	N/A		
P-28816	4/5/2016	Opioid Abuse and Homelessness - National Alliance to End Homelessness	N/A	N/A		
P-28817	8/26/2011	Pope, Crime and property values Evidence from the 1990s crime drop	N/A	N/A		
P-28818	6/1/2021	Powell, The Labor Supply Consequences of the Opioid Crisis	N/A	N/A		
P-28819	1/15/2019	Tests of the Hypothesis that a Linear Regression System Obeys Two Separate Regimes	N/A	N/A		
P-28820	11/17/2021	NYT, Overdose Deaths Reached Record High as the Pandemic Spread	N/A	N/A		
P-28821	N/A	Rubinfeld - Reference Guide on Multiple Regression	N/A	N/A		
P-28822	12/1/2017	Ruhm, Geographic Variation in Opioid and Heroin Involved Drug Poisoning Mortality Rates	N/A	N/A		
P-28823	12/20/2017	Ruhm, Corrected US opioid-involved drug poisoning deaths and mortality rates, 1999–2015	N/A	N/A		
P-28824	1/14/2019	Drivers of the Fatal Drug Epidemic	N/A	N/A		
P-28825	1/23/2020	It's a wake-up call' — fentanyl crisis grips San Francisco as body count skyrockets	N/A	N/A		
P-28826	12/18/2021	Skylab - CA Overdose Dashboard, Updated 11-30-2021	N/A	N/A		
P-28827	10/1/2014	Stewart & Cutler, The Contribution of Behavior Change	N/A	N/A		
P-28828	4/6/2021	Support to Address the Infectious Disease Consequences of the Opioid Crisis	N/A	N/A		
P-28829	6/14/2021	Enough fentanyl to kill San Francisco, the new wave of the opioid crisis sweeping California	N/A	N/A		
P-28830	1/15/2001	Changing Method Of Treatment for Drug Addiction, S.F. models 'harm reduction' theory	N/A	N/A		
P-28831	N/A	DEA, Drugs of Abuse 2017 Edition	N/A	N/A		
P-28832	3/16/2012	Wagstaff & Culyer, Four Decades of Health Economics through a bibliometric lens.	N/A	N/A		
P-28833	2/27/2020	What is Black Tar Heroin, Dangers, Effects & Appearance	N/A	N/A		
P-28834	7/6/2018	Winkelman, et al. Health, Polysubstance Use, and Criminal Justice Involvement Among Adults With Varying Levels of Opioid Use	N/A	N/A		
P-28835	2010	Wooldridge, Econometric analysis of cross section and panel data, p. 80-81	N/A	N/A		
P-28836	2/25/2013	RE: Kadian Targeting Analysis; image001.gif; image002.jpeg	ACTAVIS0195728	ACTAVIS0195737		
P-28837	6/5/2012	Decile x Specialty	ACTAVIS0284119	ACTAVIS0284119		
P-28838	1/27/2010	Re: urgent; NSM Presentation Jan 2010.ppt	ALLERGAN_MDL_01692522	ALLERGAN_MDL_01692552		
P-28839	1/2/2012	questions on Dexmed; Precedex_PI_Revised 09_2010.pdf	Acquired_Actavis_00181327	Acquired_Actavis_00181351		
P-28840	5/20/2009	InVentiv Sales Training Actavis Overview & Kadian Introduction	ACTAVIS0581557	ACTAVIS0581572		
P-28841	4/20/2012	RE: introduction of Actavis to APS	ALLERGAN_MDL_01010175	ALLERGAN_MDL_01010180		
P-28842	7/27/2018	FW: (NORAC): [FDA Acknowledgement] FDA Safety Labeling Change Notification for Opioid Products (KADIAN, NORCO, Fiorinal w/Codeine); 20180711 KAD FDA Letter_Acknowledgment Prior Approval Supplement S-062.pdf;	ALLERGAN_CA_00021903	ALLERGAN_CA_00021910		
P-28843	8/3/2010	Kadian Corrective Message Training; KADIAN Corrective Message Training FINAL.ppt	ALLERGAN_MDL_01051294	ALLERGAN_MDL_01051333		
P-28844	7/23/2010	KADIAN warning letter material; 10-03-26 FDA Response.pdf; 04-03-10 Response to FDA.pdf; 10-02-18 FDA Warning Letter.pdf; 10-03-05 Amendment to Response.pdf	ALLERGAN_MDL_01237689	ALLERGAN_MDL_01237736		
P-28845	12/28/2010	Kadian Topline Report; 10-38 Topline Report Final.docx	ALLERGAN_MDL_01744601	ALLERGAN_MDL_01744605		
P-28846	10/19/2011	Actavis Pipeline Committee Meeting	Acquired_Actavis_00895387 Acquired_Actavis_00895387	Acquired_Actavis_00895387 Acquired_Actavis_00895422	Acquired_Actavis_00895387 - Acquired_Actavis_00895387	

P-28847	2/16/2012	Team overview; image001.gif; Leadership Summit Presentation final MP 2-2012.pptx	ACTAVIS0321894	ACTAVIS0321930		
P-28848	8/28/2012	Slides for PCM; 20120829_PCM slides.pptx; image001.gif	ACTAVIS0395283	ACTAVIS0395347		
P-28849	6/19/2012	FW: PCM glaurur; 20120620_PCM slides.pptx; image001.gif	ACTAVIS0422011	ACTAVIS0422066		
P-28850	11/23/2011	PCM at 14.00 to 18.00 CET; 20111123_PCM Agenda.doc; 20111123_PCM slides.pptx; Telco Numbers any MT.pdf	ALLERGAN_MDL_00185487	ALLERGAN_MDL_00185643		
P-28851	6/12/2013	Edited Transcript ACT - Actavis Inc at Goldman Sachs Healthcare Conference.	ALLERGAN_MDL_01747524 ALLERGAN_MDL_01748522	ALLERGAN_MDL_01748533 ALLERGAN_MDL_01748881	ALLERGAN_MDL_01748522 - ALLERGAN_MDL_01748533	
P-28852	4/12/2007	2007/2008 AG Targets; 2007 & 2008 AG Targets.xls	ALLERGAN_MDL_03722180	ALLERGAN_MDL_03722857		
P-28853	11/12/2012	Quality Agreements (Par and Sandoz); image001.gif; Sandoz QAg 25 Oct 2012.pdf; Summary of Required Actions for Par and Sandoz Quality Agreements.pdf; Watson Actavis Quality Agreement 05 NOV 2012 with PAR.pdf	ACTAVIS0608038	ACTAVIS0608152		
P-28854	7/11/2011	RE: REMS & REMS SD Ready for IWG Review and IWG F2F Meeting Agenda for July 13-14 is attached;	ACTAVIS1130366	ACTAVIS1130368		
P-28855	3/30/2013	Kadian Sales Training Presentation	ACTAVIS0000564	ACTAVIS0000603		
P-28856	2/20/2013	Sales Training Slides for Kadian; 09197 KADIAN Marketing Sales Training Presentation Feb 2013 Template.ppt	ALLERGAN_MDL_00001524	ALLERGAN_MDL_00001570		
P-28857	4/20/2011	RE: KADIAN and the FDA audit at Elizabeth Attachments: Actavis HCC Training-LMS_070810(Official).ppt;ACTAVISAdmin PresentationforBackfillTraining2010.ppt;CWEmbed1.xls;HR Overview.July 2010..ppt;image001.gif;Interplx presentation.ppt;KADIAN Marketing Programs 9.8.2010.ppt;KADIAN Objection Handling 7.7.2010.ppt;KADIAN PI Workshop 9.13.2010.ppt;KADIAN Support Programs 7.7.2010.ppt	ALLERGAN_MDL_00405352	ALLERGAN_MDL_00405583		
P-28858	2/21/2012	MoxDuo FAQs; Key Document: ACTAVIS0795954 - Kadian and Abuse Potential FAQ's	ACTAVIS0795883	ACTAVIS0796019		
P-28859	5/7/2009	Emailing: Kadian_Slides_for_Speaker_Training_with_MLRCmts_2_22, Managing Chronic Pain and the Importance of Customizing Opioid Treatment [Kadian_Slides_for_Speaker_Training_with_MLRCmts_2_22.ppt	ALLERGAN_MDL_00449945	ALLERGAN_MDL_00449997		
P-28860	1/20/2005	Kadian 2005 Publication Plan	ACTAVIS0006930	ACTAVIS0006978		
P-28861	7/8/2011	Actavis/Supervalu - Oxymorphone, image001.gif;Oxymorphone ER PI-final.pdf;Oxymorphone ER 15mg 100s HDMA 0228-3262-11.pdf;Oxymorphone ER 7.5mg 100s HDMA 0228-3261-11.pdf;SuperValu (AC0273) Oxymorphone 7.8.11.pdf	ALLERGAN_MDL_00145637	ALLERGAN_MDL_00145643		
P-28862	8/1/2012	ANDA 40-800 periodic report, pi-final OXY APAP Rev3-12.pdf	Acquired_Actavis_00400290	Acquired_Actavis_00400292		
P-28863	7/12/2012	Fentanyl sxs v2.doc; Fentanyl Transdermal System - Rev 07-2012 FINAL.doc	Acquired_Actavis_01406608	Acquired_Actavis_01406710		
P-28864	12/31/2001	Norco Training Binder	ALLERGAN_MDL_03255938	ALLERGAN_MDL_03256055		
P-28865	2/16/2009	Kadian Copay Brochure	ALLERGAN_MDL_01787026	ALLERGAN_MDL_01787026		

P-28866	11/15/2012	KADIAN Conversion Guide KADI1215 - Highlighted References Attachments: image001.gif;REFERENCE _10 McCaffery Pain KADIAN Conversion Guide KADI1215.pdf;REFERENCE _11 Vicodin USPI Accessed Oct 24_ 2012 KADIAN Conversion Guide KADI1215.pdf;REFERENCE _12 Extra Strength Tylenol USPI Accessed Nov 13_ 2012 KADIAN Conversion Guide KADI1215.pdf;REFERENCE _13 DILAUDID USPI Accessed Nov 13_ 2012 KADIAN Conversion Guide KADI1215.pdf;REFERENCE _2 KADIAN USPI (July 2012) Conversion Guide KADI1215.pdf;REFERENCE _20 OxyContin USPI Accessed Nov 13_ 2012 KADIAN Conversion Guide KADI1215.pdf;REFERENCE _22 OPANA ER USPI Accessed Nov 14_ 2012 KADIAN Conversion Guide KADI1215.pdf;REFERENCE _23 Nucynta (Tarpentadol) USPI AUG 2012 KADIAN Conversion Guide KADI1215.pdf;REFERENCE _24 Tapentadol IR KADIAN Conversion Guide KADI1215.pdf;REFERENCE _25 KADIAN DATA ON FILE KADIAN Conversion Guide KADI1215.pdf;REFERENCE _26 Gourlay_ Pharmacokinetics___ Pain_ KADIAN Conversion Guide KADI1215.pdf;REFERENCE _3 Chou_Opioid Treatment Guidelines Conversion Guide KADI1215.pdf;REFERENCE _4 Smith_ Opioid Metabolism Conversion Guide KADI1215.pdf;REFERENCE _5 Gordon_ Opioid Equianalgesic Calculations KADIAN Conversion Guide KADI1215.pdf;REFERENCE _7 Baumann_ Pain Management KADIAN Conversion Guide KADI1215.pdf;REFERENCE _9 DURAGESIC USPI_ Accessed November 14_ 2012 KADIAN Conversion Guide KADI1215.pdf	ACTAVIS0680609 ACTAVIS0680886	ACTAVIS0680905 ACTAVIS0680905	ACTAVIS0680886 - ACTAVIS0680905	
P-28867	11/6/2009	Journal of Pain OFFICIAL JOURNAL OF THE AMERICAN PAIN SOCIETY Effect of Concomitant Ingestion of Alcohol on the In Vivo Pharmacokinetics of KADIAN (Morphine Sulfate Extended-Release) Capsules	ALLERGAN_MDL_01466308	ALLERGAN_MDL_01466386		
P-28868	4/30/2011	IWG: CME/CE Proposals from two vendors, CE City CME proposal for IWG REMS.docx;PDR Network CME proposal for IWG REMS.docx	ALLERGAN_MDL_00950092	ALLERGAN_MDL_00950116		
P-28869	N/A	Launch Strategy and Tactics	ALLERGAN_MDL_03352611	ALLERGAN_MDL_03352620		
P-28870	11/10/2011	KADI1133 and KADI1156, KADI1133.pdf, KADI1156.pdf	ALLERGAN_MDL_01283523	ALLERGAN_MDL_01283533		
P-28871	2/22/2016	RE WAGs MORPHINE SULF ER - KADIAN	ALLERGAN_MDL_01338506	ALLERGAN_MDL_01338507		
P-28872	N/A	Norco Sales Training Manual	ALLERGAN_MDL_03352621	ALLERGAN_MDL_03352627		
P-28873	10/14/2011	FW: Training Presentation, 2011 October Pilot Rep Training FINAL.pptx, image001.gif	ALLERGAN_MDL_00419787	ALLERGAN_MDL_00419810		
P-28874	1/18/2002	Norco/Maxidone Stocking Program	ALLERGAN_MDL_03733544	ALLERGAN_MDL_03733545		
P-28875	6/8/2012	Med Info; image001.gif; MOXDUO Drug Interactions sample.docx; MOXDUO Storage and stability.docx; Standard Response documents for MOXDUO.docx; Style Guide Draft.docx	ALLERGAN_MDL_00459123	ALLERGAN_MDL_00459173		
P-28876	2012.02.28	RE: Reports (Debbie Webb)	ALLERGAN_NY_00039119	ALLERGAN_NY_00039124		
P-28877	4/3/2002	Award Bios, Award Bios.doc	ALLERGAN_MDL_01679056	ALLERGAN_MDL_01679069		
P-28878	3/8/2013	FW: Agenda for Cancelled Nov-12 Meeting Attachments: image001.gif;JA NSM Presentation - KADI1224_Four strengths_Presentation Draft_09 11 2012.pptx;KAD-084 Kadian Intro Stocking Offer PrintFlyer 09-13-12 (2).pdf;KAD-089 Kadian Now Available Flyer 09-21-12.pdf;Kadian Launch Scenarios.pptx;Kadian New Strengths recommendations.docx;New Strength Physician Flyer.pdf;New Strengths Pharmacy Flyer.pdf;New Strengths(2).docx;NSM Objection Handling Tool_LAM edits 09 10 12.docx;NSM Presentation - Marketing Presentation.pptx	ALLERGAN_MDL_00072867 ALLERGAN_MDL_00072907	ALLERGAN_MDL_00072938 ALLERGAN_MDL_00072938	ALLERGAN_MDL_00072907 - ALLERGAN_MDL_00072938	
P-28879	6/28/2011	FW: Oxymorphone ER 7.5 mg & 15 mg; image001.gif; Opana ER Annual Usage 062811.xlsx	ALLERGAN_MDL_00132474	ALLERGAN_MDL_00132478		
P-28880	8/17/2010	Oxymorphone HCl ER CMC Deficiency Response	ACTAVIS1143873	ACTAVIS1143879		
P-28881	8/27/2009	Kadian Weekly Reports; ValueTrak Weekly Report Ending 8-23-09.xls; Contract Status Report of Open Items.xls	ALLERGAN_MDL_01898076	ALLERGAN_MDL_01898078		



P-28882	1/4/2010	Email re Tegra Analysis; Preliminary results	ALLERGAN_MDL_01742612	ALLERGAN_MDL_01742614		
P-28883	11/4/2004	Actavis 2003-2004 Budget Review Presentation	ALLERGAN_MDL_01838560 ALLERGAN_MDL_01838560	ALLERGAN_MDL_01838593 ALLERGAN_MDL_01838606	ALLERGAN_MDL_01838560 - ALLERGAN_MDL_01838593	
P-28884	9/8/2003	Watson Call Center Productivity Reports	ALLERGAN_MDL_01843905 ALLERGAN_MDL_01843905	ALLERGAN_MDL_01843906 ALLERGAN_MDL_01843936	ALLERGAN_MDL_01843905 - ALLERGAN_MDL_01843925	
P-28885	10/29/2002	2002/2003 Call Center Operations Budget Plan Review	ALLERGAN_MDL_01845631 ALLERGAN_MDL_01845631	ALLERGAN_MDL_01845657 ALLERGAN_MDL_01845648	ALLERGAN_MDL_01845631 - ALLERGAN_MDL_01845648	
P-28886	10/23/2001	Norco Promotion Script	ALLERGAN_MDL_03733190	ALLERGAN_MDL_03733191		
P-28887	4/30/2018	FW: APS Investigative Standards Manual	WAGMDL01135268	WAGMDL01135406		
P-28888	2/17/2022	Inherited Patients Taking Opioids for Chronic Pain - Considerations for Primary Care (Coffin and Barreveld)	N/A	N/A		
P-28889	5/12/2021	Drug Overdose Deaths Before and After Shelter-in-Place Orders During the COVID-19 Pandemic in San Francisco. (Appa et al)	N/A	N/A		
P-28890	10/1/2019	Prolonged ethanol administration prevents the development of tolerance to morphine-induced respiratory depression (Hill et al)	N/A	N/A		
P-28891	6/20/2013	Reports	WAGMDL00414050	WAGMDL00414051		
P-28892	9/18/2017	DEA Audit-Promethazine Data Request	WAGFLAG00029039	WAGFLAG00029040		
P-28893	1/3/2014	Records Requests	WAGMDAA00014201	WAGMDAA00014201		
P-28894	2/13/2012	Store 2609, Prescriber Toni Daniels	WAGCASF00004325	WAGCASF00004325		
P-28895	3/28/2016	FW: 1403 Pharmacy (technician) budget review/reassessment PDF list	WAGCASF00023244	WAGCASF00023246		
P-28896	6/14/2013	Patient Report for Toni Daniels	WAGCASF00033313	WAGCASF00033313		
P-28897	4/16/2015	RE Prescriber checks - Fruitvale	WAGCASF00088280	WAGCASF00088286		
P-28898	2/10/2012	Daniels Subpoena	WAGCASF00092671	WAGCASF00092674		
P-28899	3/8/2021	SF Stores eTDGFD Work Sheet and Detail (2021.03.08)	WAGCASF00106243	WAGCASF00106243		
P-28900	12/2/2014	RE: Dr William Bresnick DEA TITLE 21 CFR part 1306 1306.25	WAGCASF00119804	WAGCASF00119806		
P-28901	3/2/2018	Fwd: Store 4609 CA BOP hard copy request	WAGCASF00166656 WAGCASF00166737	WAGCASF00166757 WAGCASF00166758	WAGCASF00166737 - WAGCASF00166757	
P-28902	3/1/2018	Re: CA BOP hard copy request	WAGCASF00167946	WAGCASF00167965		
P-28903	7/12/2019	H. Geoffrey Watson script	WAGCASF00184499	WAGCASF00184503		
P-28904	5/24/2018	940; CURES report	WAGCASF00207805	WAGCASF00207809		
P-28905	1/27/2017	690; CURES report	WAGCASF00219080	WAGCASF00219084		
P-28906	5/5/2021	1499; CURES report	WAGCASF00251681	WAGCASF00251688		
P-28907	9/12/2012	BASCOY	WAGFLAG01933792	WAGFLAG01933792		
P-28908	9/5/2018	Pierce MBC and Death Certificate Deaths	N/A	N/A		
P-28909	11/30/2018	Pierce -Stumbled on Investiation	N/A	N/A		
P-28910	11/7/2013	Seet -Painkiller shift aims at rising overdoses	N/A	N/A		
P-28911	12/18/2018	Tseng PR AGOffice Appeal Upheld	N/A	N/A		
P-28912	N/A	IQVIA Data- '04: MHJ_Layout_Xponent.xlsx (Exponent Layout Codes for Internal Reports)	ALLERGAN_MDL_03320304	ALLERGAN_MDL_03320304		
P-28913	N/A	IQVIA Data- '05: GPS_084_71_USC022_mkt_def_APR2018.xlsx (describing 4656 lines of data with controlled substance names_	ALLERGAN_MDL_03320305	ALLERGAN_MDL_03320305		
P-28914	6/13/2018	IQVIA Data- '06: XPO_CONTROL_TOTALS_1997-2007\ CDS.ZWKT.OUTPT.CTLTOT.F4.M04.CSV (describing total controlled substance amounts)	ALLERGAN_MDL_03320306	ALLERGAN_MDL_03320306		
P-28915	6/13/2018	IQVIA Data- '07: CDS.ZWKT.OUTPT.CTLTOT.F3.M04.CSV (describing total controlled substance amounts)	ALLERGAN_MDL_03320307	ALLERGAN_MDL_03320307		
P-28916	6/13/2018	IQVIA Data- '08: CDS.ZWKT.OUTPT.CTLTOT.F6.M04.CSV (describing total controlled substance amounts)	ALLERGAN_MDL_03320308	ALLERGAN_MDL_03320308		
P-28917	6/13/2018	IQVIA Data- '09: CDS.ZWKT.OUTPT.CTLTOT.F5.M04.CSV (describing total controlled substance amounts)	ALLERGAN_MDL_03320309	ALLERGAN_MDL_03320309		
P-28918	6/13/2018	IQVIA Data- '10: CDS.ZWKT.OUTPT.CTLTOT.F1.M04.CSV (describing total controlled substance amounts)	ALLERGAN_MDL_03320310	ALLERGAN_MDL_03320310		
P-28919	8/15/2011	Email re Updated TMS List	ALLERGAN_MDL_01746793	ALLERGAN_MDL_01746794		
P-28920	2016	Comprehensive Pain Medicine	N/A	N/A		
P-28921	1/10/2022	U.S. Pain Foundation Resources Infographics and handouts	N/A	N/A		

P-28922	1/24/2020	Spithoff, S., Leece, P., Sullivan, F., Persaud, N., Belesiotis, P., & Steiner, L. (2020). Drivers of the opioid crisis: An appraisal of financial conflicts of interest in clinical practice guideline panels at the peak of opioid prescribing. PLoS one, 15(1), e0227045. <a href="https://doi.org/10.1371/journal.pone.0227045">https://doi.org/10.1371/journal.pone.0227045</a>	N/A	N/A		
P-28923	4/1/2019	RE: Comments on the "Draft Report on Pain Management Best Practices: Updates, Gaps, Inconsistencies, and Recommendations" Docket Number: HHS-OS-2018-0027	N/A	N/A		
P-28924	10/13/2021	Vanila M. Singh, MD on Twitter <a href="https://twitter.com/VanilaSingh/status/1448186962544783360">https://twitter.com/VanilaSingh/status/1448186962544783360</a>	N/A	N/A		
P-28925	11/12/2018	This is Opioids Hidden Dangers, New Hope Podcast	N/A	N/A		
P-28926	5/9/2019	U.S. Department of Health and Human Services (2019, May). Pain Management Best Practices Inter-Agency Task Force Report: Updates, Gaps, Inconsistencies, and Recommendations. Retrieved from U. S. Department of Health and Human Services website: <a href="https://www.hhs.gov/ash/advisory-committees/pain/reports/index.html">https://www.hhs.gov/ash/advisory-committees/pain/reports/index.html</a>	N/A	N/A		
P-28927	5/14/2020	Manchikanti, L., Singh, V., Kaye, A. D., & Hirsch, J. A. (2020). Lessons for Better Pain Management in the Future: Learning from the Past. Pain and therapy, 9(2), 373–391. <a href="https://doi.org/10.1007/s40122-020-00170-8">https://doi.org/10.1007/s40122-020-00170-8</a>	N/A	N/A		
P-28928	12/9/2019	SEC FORM 4 - Dr. Vanila M. Singh	N/A	N/A		
P-28929	9/5/2011	Consultant Services Agreement	PPLP003478494	PPLP003478500		
P-28930	7/25/2014	FW Adherence Program Overviews	PPLPC017000552798	PPLPC017000552800		
P-28931	1/25/2001	MO DUR Meeting handout	PPLPC036000002756	PPLPC036000003003		
P-28932	6/3/2010	A Representative's Guide to Xponent	ALLERGAN_MDL_01183849	ALLERGAN_MDL_01183877		
P-28933	3/27/2007	IMS Health, Information Services Agreement, J&J-MasterAgreement07-09	JAN-MS-03108975	JAN-MS-03109026		
P-28934	5/21/2018	IQVIA Statement of Work, 1259413	ALLERGAN_MDL_02949563	ALLERGAN_MDL_02949564		
P-28935	10/19/2021	IQVIA Declaration Re: Documents Provided by IQVIA To Defendants CVS, Walgreens, and Walmart, and to Plaintiffs Pursuant to Discovery Ruling No. 15	N/A	N/A		
P-28936	2/6/2007	Patent No. 7,174,304 BI	N/A	N/A		
P-28937	N/A	Monthly Data MHJ IMS Xponent	N/A	N/A		
P-28938	10/5/2018	Letter from Kirkland & Ellis, LLP on behalf of Allergan Finance, LLP re: In re National Prescription Opiate Litigation, MDL No. 2804	N/A	N/A		
P-28939	N/A	Spreadsheet of data extract: Dr. Giovannini	N/A	N/A		
P-28940	2012	Washington Legal Foundation, Winter 2012, Conversations With...	N/A	N/A		
P-28941	8/1/2011	HSRN Data Brief: Xponent	DEF_00082126	DEF_00082127		
P-28942	3/15/2022	Effects of State Opioid Prescribing Laws on Use of Opioid and Other Pain Treatments Among Commercially Insured U.S. Adults	N/A	N/A		
P-28943	1/3/2021	Griffith, K. N., Feyman, Y., Auty, S. G., Crable, E. L., & Levengood, T. W. (2021). Implications of county-level variation in U.S. opioid distribution. Drug and alcohol dependence, 219, 108501. <a href="https://doi.org/10.1016/j.drugalcdep.2020.108501">https://doi.org/10.1016/j.drugalcdep.2020.108501</a>	N/A	N/A		
P-28944	1/1/2013	2013 U.S. DOJ DEA Chemical Handler's Manual	N/A	N/A		
P-28945	1/1/2022	2022 U.S. DOJ DEA Chemical Handler's Manual	N/A	N/A		
P-28946	12/31/2018	Allergan plc Form 10-K fiscal year end December 31, 2018	N/A	N/A		
P-28947	5/11/2019	Allergan PLC's Responses and Objections to Plaintiffs' First Set of Interrogatories to Allergan PLC	N/A	N/A		
P-28948	3/11/2019	Mar. 11, 2019 letter from D. Welch	N/A	N/A		
P-28949	10/22/2018	Allergan Finance, LLC's Second Amended Responses and Objections to Plaintiffs' Amended Notice of Deposition Pursuan to Rule 30(b)(6) and Document Request Pursuant to Rule 30(b)(2) and Rule 34	N/A	N/A		
P-28950	10/19/2018	Oct. 19, 2018 letter from D. Welch	N/A	N/A		
P-28951	3/18/2022	Sir Speedy Orders 2006-2016	ENDO_SF-00589717	ENDO_SF-00589717		
P-28952	5/14/2016	Tormo texts with Brown re: Indiana Situation	TORMO-TEXTS-0000045	TORMO-TEXTS-0000045		

P-28953	9/5/2012	FW: Pain Week Schedule	ENDO_FLAG-00563556	ENDO_FLAG-00563560		
P-28954	9/8/2012	SIS-15 Jesus, Bacon, and Hyperalgesia (Passik)	ENDO-OPIOID_MDL-00528908	ENDO-OPIOID_MDL-00528924		
P-28955	N/A	Patient Pain Diary OP-0254D	ENDO_SF-00589546	ENDO_SF-00589562		
P-28956	N/A	Patient Brochure OP-0254C	ENDO_SF-00589563	ENDO_SF-00589571		
P-28957	N/A	Book-Responsible Opioid Prescribing - A Physician's Guide-OP-428	ENDO_SF-00589572	ENDO_SF-00589716		
P-28958	2/2/2007	Austin Powers video; APowersindianmatt2_02001	TEVA_MDL_A_00717106	TEVA_MDL_A_00717106		
P-28959	8/18/2006	A Few Good Men video; FewGoodMen06	TEVA_MDL_A_00720808	TEVA_MDL_A_00720808		
P-28960	1/7/2019	Action Item: Inbound / Outbound Data Feed Updates	WAGFLAG03160626	WAGFLAG03160631		
P-28961	4/13/2016	NACDS Policy Council	WAGMDL00638845	WAGMDL00638847		
P-28962	8/29/2017	RE: 2 things	WAGMDL00649325	WAGMDL00649327		
P-28963	N/A	CDC WONDER Multiple Cause of Death; Website	N/A	N/A		
P-28964	N/A	U.S. Census Bureau's county population estimates 1990s; Website	N/A	N/A		
P-28965	N/A	U.S. Census Bureau's county population estimates 2000-2010s; Website	N/A	N/A		
P-28966	N/A	U.S. Census Bureau's county population estimates 2010s; Website	N/A	N/A		
P-28967	N/A	The U.S. Census Bureau's cartographic boundary files (shapefiles); Website	N/A	N/A		
P-28968	2/17/2022	McCann CT4 Second Supplemental Report - Code to Produce	N/A	N/A		
P-28969	8/6/2007	Catalina; Catalina - ROI	TEVA_MDL_A_01404009	TEVA_MDL_A_01404010		
P-28970	1/5/2010	FW Room to Grow Tracker for Maria's Contest - Action Required	ENDO-CHI_LIT-01224683	ENDO-CHI_LIT-01224689		
P-28971	3/22/2010	RE SUCCESS STORY - HELPED PHYSICIAN TO FIND PHARMACY THAT STOCKED OPANA ER (24-HOUR KROGER)	ENDO-CHI_LIT-01018100	ENDO-CHI_LIT-01018101		
P-28972	3/2/2018	Fox News Interview of Dr. Stanos	N/A	N/A		
P-28973	12/30/2004	NIPC Grantor Status Report December 2004	ENDO_ANK_CHI_0466776	ENDO_ANK_CHI_0466788		
P-28974	3/24/2004	NIPC Grantor Status Report March 2004	ENDO_ANK_CHI_0466958	ENDO_ANK_CHI_0466958		
P-28975	6/2/2004	CD&E 2004 Opioid Education Initiatives	ENDO_ANK_CHI_0467009	ENDO_ANK_CHI_0467018		
P-28976	10/8/2004	NIPC Grantor Status Report October 2004	ENDO_ANK_CHI_0469590	ENDO_ANK_CHI_0469600		
P-28977	6/10/2004	NIPC Grantor Status Report June 2004	ENDO_ANK_CHI_0469812	ENDO_ANK_CHI_0469819		
P-28978	12/10/2010	Scientific Affairs Monthly Highlight Report: November 2010	ENDO_ANK_CHI_0880587	ENDO_ANK_CHI_0880589		
P-28979	7/19/2002	RE Kitlinski List - Possible Invitees for Friendo Dinner	ENDO_ANK_CHI_0166113	ENDO_ANK_CHI_0166119		
P-28980	8/8/2001	RE Agenda for FDA Meeting - APF Alert	ENDO_FLAG-00376582	ENDO_FLAG-00376585		
P-28981	8/20/2003	Opiana 2004 Business Plan	ENDO-NY-00381925	ENDO-NY-00381931		
P-28982	9/14/2004	AAHPM exhibits and APS/AAPM/AAHPM totebags	ENDO-OPIOID_MDL-01761384	ENDO-OPIOID_MDL-01761389		
P-28983	2/5/2008	NIPC Brochure	ENDO-OPIOID_MDL-06598339	ENDO-OPIOID_MDL-06598341		
P-28984	10/11/2004	RE Urgent Message Re Lido CD&E Budget Revisions	ENDO_ANK_000001347	ENDO_ANK_000001350		
P-28985	2/19/2004	Surveillance PowerPoint	ENDO_FLAG-00285780	ENDO_FLAG-00285784		
P-28986	12/17/2012	RE Get-together Mon, Tues or Wed this week	ENDO_FLAG-00406770	ENDO_FLAG-00406778		
P-28987	3/17/2000	1Q 1999 Goals & Objectives Update-CD&E.doc	ENDO_FLAG-00426429	ENDO_FLAG-00426437		
P-28988	4/25/2001	VT Objectives 2001 - Q1 Update.doc	ENDO_FLAG-00426476	ENDO_FLAG-00426483		
P-28989	10/30/2010	Addiction 101	ENDO-OPIOID_MDL-00653449	ENDO-OPIOID_MDL-00653449		
P-28990	9/2/2003	FW Opioid Patient Brochure - version for Portenoy review	ENDO-OPIOID_MDL-01762094	ENDO-OPIOID_MDL-01762101		
P-28991	3/9/2002	Advisory Meeting slides	ENDO-OPIOID_MDL-02343790	ENDO-OPIOID_MDL-02343793		
P-28992	5/30/2013	FDA OPANA ER Reply talking points-reactive only-Non-Promotional Endo Staff	EPI001272505	EPI001272507		
P-28993	1/17/2004	02 NIPC 2003 Results - Steve Rifkind NEW.ppt	KP360_OHIOMDL_000347652	KP360_OHIOMDL_000347707		
P-28994	5/24/2019	Text re APS May be Ending	TORMO-00001201	TORMO-00001201		
P-28995	6/30/2017	Text exchange between Vin Tormo & Steve Passik re Trump nomination	TORMO-TEXTS-00000017	TORMO-TEXTS-00000018		
P-28996	11/7/2006	RE CL Attendance - Opiana "Unleashing Our Power" Cluster Meetings	ENDO_ANK_CHI_0471077	ENDO_ANK_CHI_0471079		
P-28997	8/17/2019	Pierce Controlled Substance Restrictions E-mail	WAGCASF00163530	WAGCASF00163573		
P-28998	6/20/2008	Update on New Opiana Targets E-mail re Leong	ENDO_SF-00010764	ENDO_SF-00010765		
P-28999	10/2/2013	State revokes license of Novato former doctor Seet	N/A	N/A		
P-29000	12/29/2014	SFPD Incident Report 12/29/14	SF-Opioids02104287	SF-Opioids02104289		
P-29001	2/1/2022	Commission on Combating Synthetic Opioid Trafficking Report	N/A	N/A		
P-29002	11/19/2012	SFPD Incident Report 11/19/12	SF-Opioids02104213	SF-Opioids02104217		
P-29003	6/29/2016	SFPD Incident Report 6/29/16	SF-Opioids02104408	SF-Opioids02104410		

P-29004	6/29/2016	Attachment 1 to 6/29/16 Police Report	SF-Opioids02104411	SF-Opioids02104413		
P-29005	6/29/2016	Attachment 2 to 6/29/16 Police Report	SF-Opioids02104414	SF-Opioids02104415		
P-29006	1/1/2020	LEAD Evaluation	SF-Opioids01948664	SF-Opioids01948816		
P-29007	12/21/2020	Understanding Serious Violence in San Francisco Powerpoint From Partnership For Safer Communities	SF-Opioids02638128	SF-Opioids02638128		
P-29008	7/10/2019	Geier CV	SF-Opioids00296534	SF-Opioids00296538		
P-29009	10/17/2019	Challenges facing SFFD EMS, a data driven evaluation; Challenges Facing the San Francisco Fire Department EMS Division.docx	SF-Opioids00091230	SF-Opioids00091236		
P-29010	9/25/2019	Re: Recruit # 17, Emily Tam	SF-Opioids01949882	SF-Opioids01949883		
P-29011	9/23/2019	FW Project FRIEND - EMS Pilot Program; EMS System Memo 9.12.19 Project FRIEND.pdf; Appendix 1- SF EMS Naloxone Leave Behind-Pilot Workflow.pdf	SF-Opioids00091507	SF-Opioids00091510		
P-29012	6/22/2020	EMS-6 update 6/22/20	SF-Opioids01070670	SF-Opioids01070670		
P-29013	6/22/2020	Overdose Data - Update; Drug Related V2.xlsx	SF-Opioids00091519	SF-Opioids00091520		
P-29014	9/20/2019	FW: (U) NC HIDTA Public Health Advisory: San Francisco Department of Public Health: Health Update, Fentanyl Overdose; FENTANYL OD.pdf	SF-Opioids00091592	SF-Opioids00091595		
P-29015	6/19/2020	Fwd: Community Paramedic OD Field Save on site of an HSOC operation	SF-Opioids01070691	SF-Opioids01070692		
P-29016	8/2/2019	RE: clinical impression data - # of incidents; 2018-07 thru 2019-07 Clinical Impression Breakdown.xls	SF-Opioids00092015	SF-Opioids00092016		
P-29017	7/10/2019	FW: FW: Narcan info	SF-Opioids00092126	SF-Opioids00092127		
P-29018	6/5/2019	Re: San Francisco Drug Users Armed With Naloxone Double As Medics	SF-Opioids00093419	SF-Opioids00093419		
P-29019	7/1/2020	Email, 2018-07 to present Narcan Use.xlsx; 2018-07 to present Narcan Use.xlsx	SF-Opioids01070912	SF-Opioids01070913		
P-29020	7/6/2020	EMS Monthly Report for Fire Commission; EMS6 Operations Report - June 2020.docx; Identifiable Home Address Report - June 2020.pdf; June Report (given July 2020).docx; Monthly Response to Medical Calls - June 2020.pdf; Narcan Use - by Battalion- June 2020.xlsx; Narcan use - Multiple doses - June 2020.xlsx; XXM Pages - June 2020.pdf	SF-Opioids00450388	SF-Opioids00450408		
P-29021	4/20/2020	FW: Please Read: Street Medicine Unsheltered Outreach; WPIC SMSHUC covid19 response 041620.docx; FINAL Schedule 04.20-26.pdf; FINAL Individual Schedule 04.20-26.pdf; Unsheltered Data Tracking.pdf; Unsheltered Docu Follow-up Request.pdf	SF-Opioids03394563	SF-Opioids03394571		
P-29022	7/6/2020	Budget Analyst Report 2014; 49337-EMS Audit_Final Report_061014.pdf	SF-Opioids00115443	SF-Opioids00115502		
P-29023	11/13/2020	2020.11.13 Press Release from SFPD	N/A	N/A		
P-29024	2/18/2020	2020.02.18 Tweet from SFPD Tenderloin Station	N/A	N/A		
P-29025	2/16/2020	2021.02.16 Tweet from SFPD Tenderloin Station	N/A	N/A		
P-29026	8/30/2020	2018.08.30 Tweet from SFPD Northern Station	N/A	N/A		
P-29027	6/11/2021	2021.06.11 Tweet from SFPD Chief Scott	N/A	N/A		
P-29028	12/1/2014	Office of the Chief Medical Examiner CCSF Fiscal Year 2011-2012 Annual Report	SF-Opioids03972296	SF-Opioids03972404		
P-29029	7/1/2013	Office of the Chief Medical Examiner CCSF Fiscal Year 2010-2011 Annual Report	SF-Opioids03511237	SF-Opioids03511367		
P-29030	1/7/2015	Geier Findings From CURES Review	SF-Opioids00931820	SF-Opioids00931820		
P-29031	2018	Geier OUD presentation	SF-Opioids00105884	SF-Opioids00105884		
P-29032	10/16/2019	Concerning Behavior in the Use of Controlled Substances in the Treatment of Chronic Non-Malignant Pain	SF-Opioids02102583	SF-Opioids02102586		
P-29033	4/16/2011	Mechanisms of Annual Review Opioids	SF-Opioids03108647	SF-Opioids03108649		
P-29034	4/27/2021	Use of Controlled Substances for Chronic Pain Management in Primary Care	SF-Opioids02102580	SF-Opioids02102582		
P-29035	3/28/2013	Fw: RSVP for Pain Day 2.0 May 2nd, 2013	SF-Opioids00170958	SF-Opioids00170959		
P-29036	8/7/2017	Pain Management Conference; Pain Day Flyer 2017.pdf	SF-Opioids00431033	SF-Opioids00431034		
P-29037	2/2/2021	January QPM Slides and CME Surveys; Jan 26_21 QPM SlideDeck.pptx; Outlook-1501610198.png	SF-Opioids03862939	SF-Opioids03862941		

P-29038	4/9/2013	NonDelivery Report: Router: Unable to dispatch message. Size exceeds 20000 KBytes; Manual MASTER draft DPH version 12.28.12.doc	SF-Opioids00816634	SF-Opioids00816849		
P-29039	8/13/2013	New Pain Management Tools: Patient Notice, Utox Interpretation, Opioid Tapering & Switching; TWUHC Patient Notice of New Policy 08012013.pdf et al.	SF-Opioids02153349	SF-Opioids02153373		
P-29040	9/5/2014	TWUCC Policy; Tom Waddell Urgent Care Policy Pain Management Policy final 121013.doc	SF-Opioids00422082	SF-Opioids00422089		
P-29041	6/8/2015	Draft Transitions pain medicine policy for review	SF-Opioids00606994	SF-Opioids00607020		
P-29042	10/2/2015	TWUH Policy: Prescribing controlled substances for chronic pain	SF-Opioids02102603	SF-Opioids02102608		
P-29043	8/24/2011	DPH 2009-2010 Annual Report	SF-Opioids00047872	SF-Opioids00047994		
P-29044	6/16/2016	Recreation and Park Commission Meeting Minutes 6-16-16	SF-Opioids00026244	SF-Opioids00026255		
P-29045	3/1/2016	Health Commission Meeting Minutes 3-1-16	SF-Opioids00031573	SF-Opioids00031581		
P-29046	2/27/2018	Joint Conference Committee for SFGH Meeting Minutes 2-27-18	SF-Opioids00015495	SF-Opioids00015510		
P-29047	5/17/2016	Health Commission Meeting Minutes 5-17-16	SF-Opioids00031461	SF-Opioids00031475		
P-29048	3/6/2018	Health Commission Meeting Minutes 3-6-18	SF-Opioids00031833	SF-Opioids00031841		
P-29049	5/1/2018	Health Commission Meeting Minutes 5-1-18	SF-Opioids00031866	SF-Opioids00031874		
P-29050	1/27/2017	SFDPH Annual Report 2015-2016	SF-Opioids00048196	SF-Opioids00048229		
P-29051	2/3/2005	Minutes, Joint Conference Committee for San Francisco General Hospital Meeting, December 14, 2004	SF-Opioids00013834	SF-Opioids00013844		
P-29052	12/6/2013	Agenda, Joint Conference Committee for San Francisco General Hospital Meeting, December 10, 2013	SF-Opioids00014729	SF-Opioids00014732		
P-29053	2/20/2014	Minutes, Joint Conference Committee for San Francisco General Hospital Meeting, December 10, 2013	SF-Opioids00014742	SF-Opioids00014750		
P-29054	10/28/2014	Joint Conference Committee for SFGH Meeting Minutes 10-28-14	SF-Opioids00014851	SF-Opioids00014861		
P-29055	10/22/2019	Joint Conference Committee SFGH Meeting Agenda 10-22-19	SF-Opioids00015683	SF-Opioids00015686		
P-29056	11/18/2014	Health Commission Meeting Agenda 11-18-14	SF-Opioids00016545	SF-Opioids00016548		
P-29057	11/17/2015	Health Commission Meeting Agenda 11-17-15	SF-Opioids00016615	SF-Opioids00016618		
P-29058	11/15/2016	Health Commission Meeting Agenda 11-15-16	SF-Opioids00028597	SF-Opioids00028600		
P-29059	11/21/2017	Health Commission Meeting Agenda 11-21-17	SF-Opioids00028678	SF-Opioids00028681		
P-29060	11/19/2019	Health Commission Meeting Agenda 11-19-19	SF-Opioids00028918	SF-Opioids00028921		
P-29061	1/20/2011	Health Commission Meeting Minutes 12-07-10	SF-Opioids00030118	SF-Opioids00030132		
P-29062	11/15/2011	Health Commission Minutes 11-15-11	SF-Opioids00030395	SF-Opioids00030401		
P-29063	11/20/2012	Health Commission Meeting Minutes 11-20-12	SF-Opioids00030792	SF-Opioids00030800		
P-29064	12/17/2013	Health Commission Meeting Minutes 12-17-13	SF-Opioids00030868	SF-Opioids00030883		
P-29065	4/30/2003	SF General Annual Report 2001-2002	SF-Opioids00048778	SF-Opioids00048826		
P-29066	2008	annual deidentified 2008	SFCURES-00000001	SFCURES-00000001		
P-29067	2009	annual deidentified 2009	SFCURES-00000002	SFCURES-00000002		
P-29068	2010	annual deidentified 2010	SFCURES-00000003	SFCURES-00000003		
P-29069	2011	annual deidentified 2011	SFCURES-00000004	SFCURES-00000004		
P-29070	2012	annual deidentified 2012	SFCURES-00000005	SFCURES-00000005		
P-29071	2013	annual deidentified 2013	SFCURES-00000006	SFCURES-00000006		
P-29072	2014	annual deidentified 2014	SFCURES-00000007	SFCURES-00000007		
P-29073	2015	annual deidentified 2015	SFCURES-00000008	SFCURES-00000008		
P-29074	2016	annual deidentified 2016	SFCURES-00000009	SFCURES-00000009		
P-29075	2017	annual deidentified 2017	SFCURES-00000010	SFCURES-00000010		
P-29076	2018	annual deidentified 2018	SFCURES-00000011	SFCURES-00000011		
P-29077	2019	annual deidentified 2019	SFCURES-00000012	SFCURES-00000012		
P-29078	3/19/2021	Incident Tracker Reports #12896-12945	SF-Opioids02652847	SF-Opioids02652939		
P-29079	9/26/2014	Library Incident Tracker Reports Re: Category 13, Drugs, 2013-2014	SF-Opioids02652940	SF-Opioids02652996		
P-29080	N/A	Drug Incidents, 2013-2020	SF-Opioids02652997	SF-Opioids02652997		
P-29081	3/24/2021	Under the Influence Incident Tracker, 2013-2020	SF-Opioids02652998	SF-Opioids02652998		
P-29082	11/18/2020	Incident Tracker Reports, Possession of illegal drugs	SF-Opioids02652999	SF-Opioids02653098		
P-29083	N/A	Possession of illegal drugs Incident Tracker, 2013-2020	SF-Opioids02653099	SF-Opioids02653099		
P-29084	4/21/2021	Incident Tracker Report re Category 13, smoking	SF-Opioids02687483	SF-Opioids02687580		
P-29085	4/21/2021	Incident Tracker Reports re Category 13, smoking	SF-Opioids02687581	SF-Opioids02687581		
P-29086	4/21/2021	Incident Tracker Report re Category 13, smoking	SF-Opioids02687582	SF-Opioids02687644		

P-29087	4/21/2021	Incident Tracker Report re Category 4, under the influence of alcohol	SF-Opioids02687645	SF-Opioids02687694		
P-29088	4/21/2021	Incident Tracker Report re Category 4, possession/use of illegal drugs, 2013-2020	SF-Opioids02687695	SF-Opioids02688958		
P-29089	4/21/2021	Incident Tracker Reports re Category 004, under the influence of alcohol	SF-Opioids02688959	SF-Opioids02688959		
P-29090	4/21/2021	Incident Tracker Reports re Category 4, possession/use of illegal drugs	SF-Opioids02688960	SF-Opioids02688960		
P-29091	N/A	Incident Tracker Report re Category 13, smoking	SF-Opioids03436632	SF-Opioids03436729		
P-29092	N/A	Incident Tracker Report re Category 13, smoking	SF-Opioids03436730	SF-Opioids03436792		
P-29093	4/15/2021	Incident Tracker Reports re Category 13, smoking	SF-Opioids03436793	SF-Opioids03436793		
P-29094	N/A	Incident Tracker Report re Category 4, possession/use of illegal drugs, 2013-2020	SF-Opioids03436794	SF-Opioids03438057		
P-29095	5/7/2021	Incident Tracker Reports re Category 10, under the influence of drugs/alcohol	SF-Opioids03438058	SF-Opioids03438058		
P-29096	4/15/2021	Incident Tracker Reports re Category 4, possession/use of illegal drugs	SF-Opioids03438059	SF-Opioids03438059		
P-29097	N/A	Incident Tracker Report re Category 10, under the influence of drugs/alcohol, 2019-2021	SF-Opioids03438060	SF-Opioids03438158		
P-29098	N/A	Incident Tracker Report re Category 10, under the influence of drugs/alcohol, 2019	SF-Opioids03438159	SF-Opioids03438257		
P-29099	N/A	Incident Tracker Report re Category 10, under the influence of drugs/alcohol, 2019	SF-Opioids03438258	SF-Opioids03438357		
P-29100	N/A	Incident Tracker Report re Category 10, under the influence of drugs/alcohol, 2018-2019	SF-Opioids03438358	SF-Opioids03438459		
P-29101	N/A	Incident Tracker Report re Category 10, under the influence of drugs/alcohol, 2018	SF-Opioids03438460	SF-Opioids03438558		
P-29102	N/A	Incident Tracker Report re Category 10, under the influence of drugs/alcohol, 2018	SF-Opioids03438559	SF-Opioids03438657		
P-29103	N/A	Incident Tracker Report re Category 10, under the influence of drugs/alcohol, 2018	SF-Opioids03438658	SF-Opioids03438754		
P-29104	N/A	Incident Tracker Report re Category 10, under the influence of drugs/alcohol, 2017-2018	SF-Opioids03438755	SF-Opioids03438851		
P-29105	N/A	Incident Tracker Report re Category 10, under the influence of drugs/alcohol, 2017	SF-Opioids03438852	SF-Opioids03438935		
P-29106	N/A	Incident Tracker Report re Category 10, under the influence of drugs/alcohol, 2016-2017	SF-Opioids03438936	SF-Opioids03439016		
P-29107	N/A	Incident Tracker Report re Category 10, under the influence of drugs/alcohol, 2016	SF-Opioids03439017	SF-Opioids03439093		
P-29108	N/A	Incident Tracker Report re Category 10, under the influence of drugs/alcohol, 2015-2016	SF-Opioids03439094	SF-Opioids03439171		
P-29109	N/A	Incident Tracker Report re Category 10, under the influence of drugs/alcohol, 2015	SF-Opioids03439172	SF-Opioids03439247		
P-29110	N/A	Incident Tracker Report re Category 10, under the influence of drugs/alcohol, 2014-2015	SF-Opioids03439248	SF-Opioids03439319		
P-29111	N/A	Incident Tracker Report re Category 10, under the influence of drugs/alcohol, 2014	SF-Opioids03439320	SF-Opioids03439382		
P-29112	N/A	Incident Tracker Report re Category 10, under the influence of drugs/alcohol, 2013-2014	SF-Opioids03439383	SF-Opioids03439449		
P-29113	N/A	Incident Tracker Report re Category 10, under the influence of drugs/alcohol, 2013	SF-Opioids03439450	SF-Opioids03439452		
P-29114	6/30/1995	SF Consolidated Budget and Annual Appropriation Ordinance FY 94-95	SF-Opioids00000001	SF-Opioids00000178		
P-29115	6/30/1996	SF Consolidated Budget and Annual Appropriation Ordinance FY95-96	SF-Opioids00000179	SF-Opioids00000356		
P-29116	6/30/1997	SF Consolidated Budget and Annual Appropriation Ordinance FY 96-97	SF-Opioids00000357	SF-Opioids00000574		
P-29117	6/30/1998	SF Consolidated Budget and Annual Appropriation Ordinance FY 97-98	SF-Opioids00000575	SF-Opioids00000786		



P-29118	6/30/1999	SF Consolidated Budget and Annual Appropriation Ordinance FY 98-99	SF-Opioids00000787	SF-Opioids000001017		
P-29119	6/30/2000	SF Consolidated Budget and Annual Appropriation Ordinance FY 99-00	SF-Opioids000001018	SF-Opioids000001261		
P-29120	6/30/2001	SF Final Consolidated Budget and Annual Appropriation Ordinance FY 00-01	SF-Opioids000001262	SF-Opioids000001485		
P-29121	6/30/2002	SF Final Consolidated Budget and Annual Appropriation Ordinance FY 01-02	SF-Opioids000001486	SF-Opioids000001740		
P-29122	6/30/2004	SF Consolidated Budget and Annual Appropriation Ordinance FY 03-04	SF-Opioids000001981	SF-Opioids000002225		
P-29123	6/30/2005	SF Consolidated Budget and Annual Appropriation Ordinance FY 04-05	SF-Opioids000002226	SF-Opioids000002488		
P-29124	6/30/2006	SF Consolidated Budget and Annual Appropriation Ordinance FY 05-06	SF-Opioids000002489	SF-Opioids000002758		
P-29125	6/30/2007	SF Consolidated Budget and Annual Appropriation Ordinance FY 06-07	SF-Opioids000002759	SF-Opioids000003054		
P-29126	6/30/2008	SF Consolidated Budget and Annual Appropriation Ordinance FY 07-08	SF-Opioids000003055	SF-Opioids000003349		
P-29127	6/30/2009	SF Consolidated Budget and Annual Appropriation Ordinance FY 08-09 and MTA 08-09, 09-10	SF-Opioids000003350	SF-Opioids000003648		
P-29128	5/12/2010	SF Consolidated Budget and Annual Appropriation Ordinance 6-30-10	SF-Opioids000003649	SF-Opioids000003954		
P-29129	1/28/2011	Budget and Ordinance SF 2011 MTA, Port, Airport, PUC 2011 and 2012, File No. 100701, Ordinance 190-10	SF-Opioids000003955	SF-Opioids000004252		
P-29130	8/3/2011	Budget and Ordinance SF 2012, Port, Airport, PUC 2012 and 2013, File No. 110387, Ordinance 147-11	SF-Opioids000004253	SF-Opioids000004555		
P-29131	8/2/2016	SF Budget and Appropriation Ordinance 2017-18, File No. 160628, Ordinance 145-16	SF-Opioids000004556	SF-Opioids000004869		
P-29132	7/27/2017	SF Budget and Appropriation Ordinance 2018-19, File No. 170653, Ordinance 156-17	SF-Opioids000004870	SF-Opioids000005182		
P-29133	8/2/2018	SF Budget and Appropriation Ordinance 2019-20, File No. 180574, Ordinance 181-18	SF-Opioids000005183	SF-Opioids000005485		
P-29134	8/2/2012	SF Annual Appropriation Ordinance 2013-14, File No. 120591, Ordinance 164-12	SF-Opioids000005486	SF-Opioids000005783		
P-29135	7/31/2013	SF Budget and Appropriation Ordinance 2014-15, File No. 130535, Ordinance 159-13	SF-Opioids000005784	SF-Opioids000006074		
P-29136	7/22/2014	SF Budget and Appropriation Ordinance 2015-16, File No. 140619, Ordinance 146.14	SF-Opioids000006075	SF-Opioids000006373		
P-29137	7/29/2015	SF Budget and Appropriation Ordinance 2016-17, File No. 150610, Ordinance 128-15	SF-Opioids000006374	SF-Opioids000006673		
P-29138	1/8/2018	Dept. of Homeless and Supportive Housing Budget Overview FY2018-19 and FY2019-20	SF-Opioids00011684	SF-Opioids00011690		
P-29139	1/6/2020	Dept. of Homeless and Supportive Housing Budget Overview FY2020-21 and FY2021-22	SF-Opioids00011691	SF-Opioids00011698		
P-29140	3/2/2020	Dept. of Homeless and Supportive Housing Budget Process Update FY2021-22 and FY2021-22	SF-Opioids00011699	SF-Opioids00011704		
P-29141	12/16/2019	Budget Outlook and Department Instructions, December 16, 2019	SF-Opioids00011705	SF-Opioids00011730		
P-29142	3/18/2020	SF Budget Appropriations and Hearing Calendar FY 2020-21 and 2021-22	SF-Opioids00011731	SF-Opioids00011732		
P-29143	2/25/2020	Homelessness and Supportive Housing_Proposed Budget_FY21 and FY22	SF-Opioids00011733	SF-Opioids00011748		
P-29144	2/13/2020	FY19-20 Six Month Budget Status Report	SF-Opioids00011749	SF-Opioids00011781		
P-29145	1/3/2020	5 year Financial Plan Update FY 20-21 - FY 23-24	SF-Opioids00011782	SF-Opioids00011823		
P-29146	3/31/2020	SF Budget Outlook Update (March Joint Report)	SF-Opioids00011824	SF-Opioids00011835		
P-29147	10/4/2018	Dept. of Homeless and Supportive Housing Budget Revision Policy	SF-Opioids00011836	SF-Opioids00011838		
P-29148	7/1/2019	Dept. of Homeless and Supportive Housing Budget FY2019-2020 and 20-21	SF-Opioids00011839	SF-Opioids00011843		
P-29149	2/15/2020	HSH Budget Conversation December 2019	SF-Opioids00011844	SF-Opioids00011849		

P-29150	6/1/2016	Policy Analysis on Homelessness and Cost of Quality of Life Laws	SF-Opioids00011850	SF-Opioids00011868		
P-29151	8/18/2020	Budget File Structure for DSHS	SF-Opioids00011869	SF-Opioids00011869		
P-29152	4/15/2014	Dept. of Public Health Budget FY 2014-15; 2015-16	SF-Opioids00033704	SF-Opioids00033712		
P-29153	4/10/2014	Memo Re Dept. of Public Health Proposed Budget FY 2014-15; 2015-16	SF-Opioids00033713	SF-Opioids00033772		
P-29154	2/18/2014	Dept. of Public Health Budget FY 2014-15; 2015-16	SF-Opioids00033773	SF-Opioids00033783		
P-29155	2/14/2014	Health Commission Meeting Re Proposed Budget FY 2014-16	SF-Opioids00033784	SF-Opioids00033806		
P-29156	6/17/2014	Dept. of Public Health Budget FY 2014-15; 2015-16	SF-Opioids00033807	SF-Opioids00033810		
P-29157	5/6/2014	Dept. of Public Health Budget FY 2014-15; 2015-16	SF-Opioids00033811	SF-Opioids00033824		
P-29158	5/1/2014	Health Commission Meeting Re Proposed Budget FY 2014-16	SF-Opioids00033825	SF-Opioids00033837		
P-29159	1/29/2015	Memo Re Dept. of Public Health Proposed Budget FY 2015-16; 2016-17	SF-Opioids00033838	SF-Opioids00033857		
P-29160	2/3/2015	Dept. of Public Health Budget FY 2015-16; 2016-17	SF-Opioids00033858	SF-Opioids00033870		
P-29161	2/25/2015	Memo Re Dept. of Public Health Proposed Budget FY 2015-16; 2016-17	SF-Opioids00033871	SF-Opioids00033903		
P-29162	3/3/2015	Dept. of Public Health Budget FY 2015-16; 2016-17	SF-Opioids00033904	SF-Opioids00033915		
P-29163	5/5/2015	Dept. of Public Health Budget FY 2015-16; 2016-17	SF-Opioids00033916	SF-Opioids00033925		
P-29164	4/29/2015	Memo Re Dept. of Public Health Proposed Budget FY 2015-16; 2016-17 3d Hearing	SF-Opioids00033926	SF-Opioids00033957		
P-29165	2/2/2016	Dept. of Public Health Budget FY 2016-17; 2017-18	SF-Opioids00033958	SF-Opioids00033969		
P-29166	1/27/2016	Memo Re Dept. of Public Health Proposed Budget FY 2016-17; 2017-18	SF-Opioids00033970	SF-Opioids00033987		
P-29167	2/14/2017	FY 2017-18 and 2018-19 Proposed Budget - Second Hearing	SF-Opioids00033988	SF-Opioids00034017		
P-29168	2/21/2017	DPH FY 17-19 Budget Presentation	SF-Opioids00034018	SF-Opioids00034032		
P-29169	2/1/2017	FY 2017-18 and FY 2018-19 Proposed Budget - First Hearing	SF-Opioids00034033	SF-Opioids00034035		
P-29170	2/7/2017	DPH FY 17-19 Budget Presentation	SF-Opioids00034036	SF-Opioids00034053		
P-29171	2/20/2018	DPH FY 18-20 Budget Presentation	SF-Opioids00034054	SF-Opioids00034059		
P-29172	2/14/2018	FY 2018-19 and 2019-20 Proposed Budget - Second Hearing	SF-Opioids00034060	SF-Opioids00034082		
P-29173	2/6/2018	DPH FY 18-20 Budget Presentation	SF-Opioids00034083	SF-Opioids00034095		
P-29174	2/1/2018	FY 2018-19 and 2019-20 Proposed Budget - First Hearing	SF-Opioids00034096	SF-Opioids00034124		
P-29175	2/5/2019	DPH FY 19-21 Budget Presentation	SF-Opioids00034125	SF-Opioids00034140		
P-29176	2/1/2019	FY 2019-2020 and FY 2020-2021 Proposed Budget - First Hearing	SF-Opioids00034141	SF-Opioids00034161		
P-29177	3/13/2019	FY 2019-2020 and FY 2020-2021 Proposed Budget - Second Hearing	SF-Opioids00034162	SF-Opioids00034185		
P-29178	3/19/2019	DPH FY 19-21 Budget Presentation	SF-Opioids00034186	SF-Opioids00034193		
P-29179	2/13/2020	FY 2020-2021 and FY 2021-2022 Proposed Budget - Second Hearing	SF-Opioids00034194	SF-Opioids00034227		
P-29180	2/18/2020	DPH FY 20-22 Budget Presentation	SF-Opioids00034228	SF-Opioids00034235		
P-29181	2/4/2020	DPH FY 20-21 and FY 21-22 Budget Presentation	SF-Opioids00034236	SF-Opioids00034256		
P-29182	1/30/2020	FY 2020-2021 and FY 2021-2022 Proposed Budget - First Hearing	SF-Opioids00034257	SF-Opioids00034260		
P-29183	3/23/2009	Notice of Public Hearing on Proposed Mid-Year Reductions in Health Services, FY 2008-09	SF-Opioids00034261	SF-Opioids00034263		
P-29184	2/14/2009	Message from the Director of Health on FY 2009-10 Budget	SF-Opioids00034264	SF-Opioids00034339		
P-29185	5/31/2011	Notice of Public Hearing, Proposed Reductions in Health Services FY 2011-2012	SF-Opioids00034340	SF-Opioids00034343		
P-29186	5/27/2011	Beilenson Hearing Notice, Proposed Reductions to Health Services for FY 2011-12	SF-Opioids00034344	SF-Opioids00034346		
P-29187	6/1/2010	Notice of Public Hearing, Proposed Reductions in Health Services FY 2010-2011	SF-Opioids00034347	SF-Opioids00034353		
P-29188	10/14/2010	Department of Public Health FY 2010-11 Budget	SF-Opioids00034354	SF-Opioids00034355		
P-29189	4/30/2010	2010-2011 Program Change Request, Health Care Budget Summary Meeting	SF-Opioids00034356	SF-Opioids00034415		
P-29190	4/30/2010	Message from the Director of Health on FY 2010-11 Budget	SF-Opioids00034416	SF-Opioids00034488		
P-29191	6/1/2009	Notice of Public Hearing Proposed Reductions in Health Services FY 2009-2010	SF-Opioids00034489	SF-Opioids00034496		
P-29192	5/19/2009	RE: 2009-10 budget presentation	SF-Opioids00034497	SF-Opioids00034562		

P-29193	6/3/2013	Notice of Public Hearing, Proposed Reductions in Health Services for FY 2013-2014 and 2014-2015	SF-Opioids00034563	SF-Opioids00034573		
P-29194	4/12/2007	Message from the Director of Health on FY 07-08 Base Budget and Contingency Plan	SF-Opioids00034574	SF-Opioids00034579		
P-29195	4/12/2007	Department of Public Health FY 2007-08 Budget	SF-Opioids00034580	SF-Opioids00034619		
P-29196	4/12/2007	Budget Form 11 - 3% Ongoing Reductions and Revenue Proposals, One Time Savings	SF-Opioids00034620	SF-Opioids00034621		
P-29197	4/12/2007	2007-2008 Program Change Request, Regulatory	SF-Opioids00034622	SF-Opioids00034641		
P-29198	4/12/2007	2007-2008 Program Change Request, Inflationary	SF-Opioids00034642	SF-Opioids00034653		
P-29199	4/12/2007	2007-2008 Program Change Request, Revenue Neutral A	SF-Opioids00034654	SF-Opioids00034685		
P-29200	4/12/2007	2007-2008 Program Change Request, Revenue Neutral B	SF-Opioids00034686	SF-Opioids00034725		
P-29201	4/12/2007	2007-2008 Program Change Request, Revenues	SF-Opioids00034726	SF-Opioids00034767		
P-29202	4/12/2007	2007-2008 Program Change Request, Structural A	SF-Opioids00034768	SF-Opioids00034791		
P-29203	4/12/2007	2007-2008 Program Change Request, Structural B	SF-Opioids00034792	SF-Opioids00034815		
P-29204	4/12/2007	2007-2008 Program Change Request, Health Access Plan A	SF-Opioids00034816	SF-Opioids00034839		
P-29205	4/12/2007	2007-2008 Program Change Request, Health Access Plan B	SF-Opioids00034840	SF-Opioids00034865		
P-29206	4/12/2007	2007-2008 Program Change Request, Reductions	SF-Opioids00034866	SF-Opioids00034887		
P-29207	4/12/2007	2007-2008 Program Change Request, Expired Grants A	SF-Opioids00034888	SF-Opioids00034917		
P-29208	4/12/2007	2007-2008 Program Change Request, Expired Grants B	SF-Opioids00034918	SF-Opioids00034955		
P-29209	4/12/2007	2007-2008 Program Change Request, Restoration of Addbacks	SF-Opioids00034956	SF-Opioids00034997		
P-29210	4/12/2007	2007-2008 Program Change Request, New Fund A	SF-Opioids00034998	SF-Opioids00035035		
P-29211	4/12/2007	2007-2008 Program Change Request, New Fund B	SF-Opioids00035036	SF-Opioids00035069		
P-29212	4/12/2007	2007-2008 Program Change Request, New Fund C	SF-Opioids00035070	SF-Opioids00035101		
P-29213	3/15/2007	Message from the Director of Health on FY 07-08 Base Budget	SF-Opioids00035102	SF-Opioids00035111		
P-29214	3/15/2007	Department of Public Health FY 2007-08 Budget	SF-Opioids00035112	SF-Opioids00035145		
P-29215	3/15/2007	2007-2008 Program Change Request, Regulatory Inflationary Revenues	SF-Opioids00035146	SF-Opioids00035187		
P-29216	3/15/2007	2007-2008 Program Change Request, Structural	SF-Opioids00035188	SF-Opioids00035233		
P-29217	3/15/2007	2007-2008 Program Change Request, Reductions Expired Grants	SF-Opioids00035234	SF-Opioids00035277		
P-29218	3/15/2007	2007-2008 Program Change Request, Restoration of Addbacks	SF-Opioids00035278	SF-Opioids00035319		
P-29219	3/15/2007	2007-2008 Program Change Request, Enhancements 1	SF-Opioids00035320	SF-Opioids00035365		
P-29220	3/15/2007	2007-2008 Program Change Request, Enhancements 2	SF-Opioids00035366	SF-Opioids00035423		
P-29221	3/14/2008	Proposed Resolution Approving the Closure of the Bridge to Wellness Program	SF-Opioids00035424	SF-Opioids00035424		
P-29222	3/14/2008	Proposed Resolution Approving Selected Reduction Initiative for DPH for FY 2008-09.	SF-Opioids00035425	SF-Opioids00035425		
P-29223	3/14/2008	2008-2009 Program Change Request, Details	SF-Opioids00035426	SF-Opioids00035457		
P-29224	3/14/2008	Message from the Director of Health on FY 08-09 Base Budget	SF-Opioids00035458	SF-Opioids00035477		
P-29225	4/1/2008	Message from the Director of Health on FY 08-09 Base Budget	SF-Opioids00035478	SF-Opioids00035489		
P-29226	3/28/2008	Department of Public Health FY 2008-09 Base Budget	SF-Opioids00035490	SF-Opioids00035501		
P-29227	3/28/2008	2008-2009 Program Change Request, Revenue Regulatory	SF-Opioids00035502	SF-Opioids00035517		
P-29228	3/28/2008	2008-2009 Program Change Request, Structural Reductions	SF-Opioids00035518	SF-Opioids00035536		
P-29229	4/11/2008	Message from the Director of Health on FY 08-09 Base Budget	SF-Opioids00035537	SF-Opioids00035542		
P-29230	4/11/2008	Department of Public Health FY 2008-09 Base Budget	SF-Opioids00035543	SF-Opioids00035554		
P-29231	4/11/2008	2008-2009 Program Change Request, Details	SF-Opioids00035555	SF-Opioids00035572		
P-29232	11/17/2008	Message from the Director on FY 08-09 Mid-Year Reductions	SF-Opioids00035573	SF-Opioids00035604		
P-29233	11/18/2008	Re: Revenue and Expenditure Report - 1st Quarter FY 2008-09	SF-Opioids00035605	SF-Opioids00035620		
P-29234	12/22/2008	Notice of Public Hearing on Proposed Mid-Year Reductions in Health Services, FY 2008-09	SF-Opioids00035621	SF-Opioids00035636		
P-29235	12/16/2008	Re: Mid-Year Reductions for the Department of Health	SF-Opioids00035637	SF-Opioids00035647		
P-29236	11/19/2008	FY 2008-09 Mid-Year Reductions	SF-Opioids00035648	SF-Opioids00035674		
P-29237	6/3/2008	Department of Public Health, FY 2008-2009 Beilenson Notice	SF-Opioids00035675	SF-Opioids00035677		
P-29238	5/3/2008	NOTICE OF PUBLIC HEARING PROPOSED REDUCTIONS IN HEALTH SERVICES FISCAL YEAR 2008-2009	SF-Opioids00035678	SF-Opioids00035679		
P-29239	5/30/2008	FY 2008-2009 Community Program Contractors	SF-Opioids00035680	SF-Opioids00035694		
P-29240	5/16/2008	Professional Services Reduction by Modality	SF-Opioids00035695	SF-Opioids00035696		
P-29241	5/15/2008	Memorandum 2008-2009 Budget Update	SF-Opioids00035697	SF-Opioids00035698		
P-29242	5/16/2008	Community Programs FY 08-09 Budget Allocations	SF-Opioids00035699	SF-Opioids00035709		

P-29243	5/16/2008	Reduction List, 5/15/2008	SF-Opioids00035710	SF-Opioids00035711		
P-29244	6/4/2007	NOTICE OF PUBLIC HEARING PROPOSED REDUCTIONS IN HEALTH SERVICES FISCAL YEAR 2007-2008	SF-Opioids00035712	SF-Opioids00035717		
P-29245	4/27/2007	Attachment A Department of Public Health FY 2007-2008 Budget	SF-Opioids00035718	SF-Opioids00035723		
P-29246	4/3/2007	Attachment B, HAP Advisory Committee Enrollment Estimates	SF-Opioids00035724	SF-Opioids00035726		
P-29247	4/27/2007	Attachment C - San Francisco Healthy San Francisco - Project Structure	SF-Opioids00035727	SF-Opioids00035746		
P-29248	1/17/2007	2007-2008 Program Change Request, Primary Care, HAP Expansion - Primary Care	SF-Opioids00035747	SF-Opioids00035770		
P-29249	1/9/2007	2007-2008 Program Change Request, San Francisco General Hospital, HAP Inpatient Costs	SF-Opioids00035771	SF-Opioids00035791		
P-29250	5/1/2007	Re: Health Access Program Proposed 2007-08 Budget and Project Update	SF-Opioids00035792	SF-Opioids00035800		
P-29251	2/15/2008	NOTICE OF PUBLIC HEARING PROPOSED REDUCTIONS IN HEALTH SERVICES FY 2007-2008, March 4, 2008	SF-Opioids00035801	SF-Opioids00035804		
P-29252	2/15/2008	NOTICE OF PUBLIC HEARING PROPOSED REDUCTIONS IN HEALTH SERVICES FY 2007-2009, April 15, 2008	SF-Opioids00035805	SF-Opioids00035807		
P-29253	8/22/2002	Community Health Network Budget Fiscal Year 2001-2002	SF-Opioids00035808	SF-Opioids00035817		
P-29254	8/26/2002	DPH FY01-02 Budget Expenditures by Division	SF-Opioids00035818	SF-Opioids00035819		
P-29255	8/26/2002	DPH FY01-02 Budget Expenditures	SF-Opioids00035820	SF-Opioids00035821		
P-29256	8/26/2002	DPH FY01-02 Budget Revenues by Source	SF-Opioids00035822	SF-Opioids00035823		
P-29257	9/5/2002	Public Health Budget Fiscal Year 2002-2003	SF-Opioids00035824	SF-Opioids00035832		
P-29258	10/30/2002	DPH General Fund Contribution FY 02-03 Budget	SF-Opioids00035833	SF-Opioids00035838		
P-29259	3/24/2003	Health Department Budget for FY 03-04	SF-Opioids00035839	SF-Opioids00035888		
P-29260	3/24/2003	Contingency Cuts to the FY 2003-2004 DPH Budget	SF-Opioids00035889	SF-Opioids00035934		
P-29261	6/2/2003	Notice of Public Hearing Proposed Reductions in Health Services Fiscal Year 2003-04	SF-Opioids00035935	SF-Opioids00035939		
P-29262	6/2/2003	Notice of Public Hearing Proposed Reductions in Health Services Fiscal Year 2003-04	SF-Opioids00035940	SF-Opioids00035944		
P-29263	4/7/2003	Memo Re: FY 03-04 Health Department Budget	SF-Opioids00035945	SF-Opioids00035952		
P-29264	2/4/2003	DPH Summary of FY 03-04 Base Budget	SF-Opioids00035953	SF-Opioids00035962		
P-29265	2/4/2003	2003-2004 Program Change Request - SFGH - Adjusted Pharmacy Model	SF-Opioids00035963	SF-Opioids00036098		
P-29266	2/4/2003	DPH Proposed FY 03-04 Budget Presented to the Health Commission	SF-Opioids00036099	SF-Opioids00036147		
P-29267	11/19/2003	Public Health Budget Fiscal Year 2003-2004	SF-Opioids00046649	SF-Opioids00046655		
P-29268	11/25/2003	DPH General Fund Contribution FY 03-04 Budget	SF-Opioids00046656	SF-Opioids00046661		
P-29269	5/7/2004	2004-2005 Program Change Request - SFGH - Increased Healthy Workers Premiums	SF-Opioids00046662	SF-Opioids00046695		
P-29270	5/7/2004	DPH Proposed FY 04-05 Contingency Plan Presented to the Health Commission	SF-Opioids00046696	SF-Opioids00046710		
P-29271	3/23/2004	Memo Re: FY 04-05 Health Department Budget	SF-Opioids00046711	SF-Opioids00046715		
P-29272	5/10/2004	Attachment B Summary of Program Cost - Primary Care Restructure	SF-Opioids00046716	SF-Opioids00046716		
P-29273	8/9/2004	Public Health Budget Fiscal Year 2004-2005	SF-Opioids00046717	SF-Opioids00046724		
P-29274	2/4/2004	2003-2004 Program Change Request - Department Wide - Worker's Compensation	SF-Opioids00046725	SF-Opioids00046784		
P-29275	2/4/2004	Message from the Director of Health on FY 04-05 Budget	SF-Opioids00046785	SF-Opioids00046790		
P-29276	2/4/2004	Health Commission FY 2004-2005 Spreadsheet	SF-Opioids00046791	SF-Opioids00046795		
P-29277	8/12/2004	DPH FY 04-05 Budget Expenditures by Division and Type	SF-Opioids00046796	SF-Opioids00046801		
P-29278	12/17/2004	Beilenson Hearing FY 2004-05 Mid-Year Reduction Plan	SF-Opioids00046802	SF-Opioids00046805		
P-29279	12/13/2004	Notice of Public Hearing Proposed Reductions in Health Services Fiscal Year 2004-05, January 4, 2005	SF-Opioids00046806	SF-Opioids00046806		
P-29280	5/27/2004	Beilenson Hearing FY 2004-05 Budget	SF-Opioids00046807	SF-Opioids00046810		
P-29281	5/27/2004	Notice of Public Hearing Proposed Reductions in Health Services Fiscal Year 2004-05, June 15, 2004	SF-Opioids00046811	SF-Opioids00046811		

P-29282	6/2/2005	Notice of Public Hearing Proposed Reductions in Health Services Fiscal Year 2005-2006, June 21, 2005	SF-Opioids00046812	SF-Opioids00046819		
P-29283	3/16/2004	2004-2005 Program Change Request - SFGH - Eliminate UCSF Social Workers	SF-Opioids00046820	SF-Opioids00046821		
P-29284	3/12/2004	DPH Proposed FY 04-05 Base Budget Presented to the Health Commission	SF-Opioids00046822	SF-Opioids00046867		
P-29285	3/12/2004	2003-2004 Program Change Request - Department Wide - Worker's Compensation	SF-Opioids00046868	SF-Opioids00046986		
P-29286	8/16/2005	Memo Re: Revenue and Expenditure Report - 4th Quarter FY 2004-05	SF-Opioids00046987	SF-Opioids00047000		
P-29287	11/5/2004	DPH Statement of Revenue and Expenses, Month Ending 09-30-2004	SF-Opioids00047001	SF-Opioids00047009		
P-29288	11/5/2004	Memo Re: Revenue and Expenditure Report - 1st Quarter FY 2004-05	SF-Opioids00047010	SF-Opioids00047013		
P-29289	6/15/2005	DPH Statement of Revenue and Expenses, Month Ending 02-28-2005	SF-Opioids00047014	SF-Opioids00047022		
P-29290	6/15/2005	Memo Re: Revenue and Expenditure Report - 3rd Quarter FY 2004-05	SF-Opioids00047023	SF-Opioids00047027		
P-29291	8/24/2005	DPH General Fund Contribution FY 05-06 Budget	SF-Opioids00047028	SF-Opioids00047033		
P-29292	8/1/2005	Public Health Fiscal Year 2005-2006 Sources of Funds	SF-Opioids00047034	SF-Opioids00047041		
P-29293	1/14/2005	2005-2006 Program Change Request - CBHS-Mental Health - Pharmacy Increases	SF-Opioids00047042	SF-Opioids00047117		
P-29294	1/14/2005	2004-2005 Program Change Request - SFGH - 23-Hour Chest Pain Unit	SF-Opioids00047118	SF-Opioids00047185		
P-29295	1/13/2005	Message from the Director of Health on FY 05-06 Budget	SF-Opioids00047186	SF-Opioids00047195		
P-29296	1/14/2005	DPH Base Budget FY 2005-06	SF-Opioids00047196	SF-Opioids00047203		
P-29297	3/28/2005	DPH Proposed FY 05-06 Base Budget Presented to the Health Commission	SF-Opioids00047204	SF-Opioids00047227		
P-29298	3/25/2005	Attachment 1 - Acupuncture for the Treatment of Cocaine Addiction	SF-Opioids00047228	SF-Opioids00047283		
P-29299	3/25/2005	DPH Base Budget FY 2005-06	SF-Opioids00047284	SF-Opioids00047299		
P-29300	3/25/2005	Summary of Proposed Budget for FY 05-06	SF-Opioids00047300	SF-Opioids00047327		
P-29301	3/25/2005	2005-2006 Program Change Request - SFGH - Implementation of the second phase of the nurse ratio law	SF-Opioids00047328	SF-Opioids00047363		
P-29302	3/25/2005	2005-2006 Program Change Request - SFGH - Short Stay Skilled Nursing Unit	SF-Opioids00047364	SF-Opioids00047421		
P-29303	3/25/2005	2005-2006 Program Change Request - CBHS Mental Health - Napa State Hospital Bed Conversion	SF-Opioids00047422	SF-Opioids00047469		
P-29304	3/25/2005	2005-2006 Program Change Request Contingency - CBHS Mental Health - UC Crisis Resolution Team	SF-Opioids00047470	SF-Opioids00047497		
P-29305	11/17/2005	Memo Re: Revenue and Expenditure Report - 1st Quarter FY 2005-06	SF-Opioids00047498	SF-Opioids00047500		
P-29306	11/17/2005	DPH Statement of Revenue and Expenses, Month ending 09-30-2005	SF-Opioids00047501	SF-Opioids00047509		
P-29307	2/7/2006	Memo Re: Revenue and Expenditure Report - 2nd Quarter FY 2005- 06	SF-Opioids00047510	SF-Opioids00047521		
P-29308	5/2/2006	Memo Re: Revenue and Expenditure Report - 3rd Quarter FY 2005-06	SF-Opioids00047522	SF-Opioids00047533		
P-29309	8/15/2006	Memo Re: Revenue and Expenditure Report - 4th Quarter FY 2005-06	SF-Opioids00047534	SF-Opioids00047545		
P-29310	11/28/2006	Memo Re: Revenue and Expenditure Report - 1st Quarter FY 2006-07	SF-Opioids00047546	SF-Opioids00047557		
P-29311	2/16/2006	Message from the Director of Health on FY 06-07 Base Budget	SF-Opioids00047558	SF-Opioids00047573		
P-29312	2/16/2006	2006-2007 Program Change Request - SFGH - Quality Data Reporting	SF-Opioids00047574	SF-Opioids00047603		
P-29313	2/16/2006	2006-2007 Program Change Request - Jail Health - Jail Health Performing Work Order with Sheriff	SF-Opioids00047604	SF-Opioids00047623		
P-29314	1/13/2006	2006-2007 Program Change Request - Public Health - Agricultural Commissioner for Weights, Measures & Agriculture Program	SF-Opioids00047624	SF-Opioids00047651		

P-29315	1/13/2006	2006-2007 Program Change Request - CBHS Mental Health - Mental Health Services Act Community Services and Supports	SF-Opioids00047652	SF-Opioids00047735		
P-29316	1/13/2006	2006-2007 Program Change Request - CBHS Mental Health - Private Provider Network (PPN) Shortfall	SF-Opioids00047736	SF-Opioids00047805		
P-29317	1/13/2006	Message from the Director of Health on FY 06-07 Budget	SF-Opioids00047806	SF-Opioids00047815		
P-29318	1/13/2006	DPH FY 2006-07 Base Budget	SF-Opioids00047816	SF-Opioids00047824		
P-29319	4/14/2006	Message from the Director of Health on FY 06-07 Contingency Budget	SF-Opioids00047825	SF-Opioids00047851		
P-29320	8/15/2006	Public Health DPH Budget Fiscal Year 2006-2007	SF-Opioids00047852	SF-Opioids00047859		
P-29321	9/7/2006	DPH General Fund Contribution FY 06-07 Budget	SF-Opioids00047860	SF-Opioids00047865		
P-29322	1/12/2010	Notice of Public Hearing Proposed Reductions in Health Services Fiscal Year 2009-2010	SF-Opioids00047866	SF-Opioids00047871		
P-29323	11/6/2012	Letter to J. Suko re Reformulated Opana ER	ENDO-OR-CID-00703628 ENDO-OR-CID-00772464	ENDO-OR-CID-00772465 ENDO-OR-CID-00801648	ENDO-OR-CID-00772464 - ENDO-OR-CID-00772465	
P-29324	5/13/2020	Email from L. Rodda, Harm Reduction Services in San Francisco Issue Brief.	SF-Opioids01069877	SF-Opioids01069908		
P-29325	N/A	Substance Abuse Prevention Policy	SF-Opioids02103852	SF-Opioids02103867		
P-29326	N/A	San Francisco Recreation and Park Department's Policy for Property Found on Park Property	SF-Opioids02103868	SF-Opioids02103872		
P-29327	2/6/2020	Policy Memo - Property Found on Park Property - Revised	SF-Opioids02103873	SF-Opioids02103878		
P-29328	1/1/2017	San Francisco Recreation and Park Department's Policy for Property Found on Park Property	SF-Opioids02103879	SF-Opioids02103883		
P-29329	2/1/2004	Shelter Training Manual for San Francisco Single-Adult Shelters	SF-Opioids02103884	SF-Opioids02104063		
P-29330	1/1/2020	Meth Sobering Site (Draft Project Budget from Public Works)	SF-Opioids02384597	SF-Opioids02384597		
P-29331	2/4/2020	Drug Sobering Center Project	SF-Opioids02384239	SF-Opioids02384240		
P-29332	1/21/2020	180 Jones Project Description	SF-Opioids02384241	SF-Opioids02384248		
P-29333	N/A	Neighborhood-Based Drug Sobering Center	SF-Opioids02384251	SF-Opioids02384257		
P-29334	N/A	Neighborhood-Based Drug Sobering Center Proposal	SF-Opioids02384258	SF-Opioids02384261		
P-29335	1/7/2020	Meth Sobering Site Management Hand-off	SF-Opioids02384262	SF-Opioids02384263		
P-29336	6/30/2020	Appendix A an dProgram Protocol	SF-Opioids03524385	SF-Opioids03524391		
P-29337	N/A	Needle Clean up Photo	SF-Opioids02385184	SF-Opioids02385184		
P-29338	N/A	Needles on Sidewalk Photo	SF-Opioids02385185	SF-Opioids02385185		
P-29339	N/A	Needles Closeup Photo	SF-Opioids02385186	SF-Opioids02385186		
P-29340	N/A	Tenderloin Toilet Access Pilot Project	SF-Opioids02385189	SF-Opioids02385193		
P-29341	N/A	Email re: adding 6 new park rangers	SF-Opioids02359854	SF-Opioids02359856		
P-29342	11/2/2017	Harm Reduction & Street Safety Unified Command Presentation	SF-Opioids01412463	SF-Opioids01412466		
P-29343	4/5/2018	2018 Budget and Priority Report	SF-Opioids01410790	SF-Opioids01410810		
P-29344	4/17/2018	June 2017-April 2018 Harm Reduction Stats	SF-Opioids01412127	SF-Opioids01412129		
P-29345	4/23/2018	April 16-20 2018 Harm reduction stats	SF-Opioids01412125	SF-Opioids01412126		
P-29346	5/3/2018	Needles found by swing shift	SF-Opioids01410153	SF-Opioids01410153		
P-29347	9/27/2018	PitStop Stats	SF-Opioids01410220	SF-Opioids01410234		
P-29348	N/A	PitStop Usage Stats aug 13-Sep9, 2019	SF-Opioids01437963	SF-Opioids01437970		
P-29349	10/31/2018	Harm Reduction & PitStop Data	SF-Opioids01410301	SF-Opioids01410304		
P-29350	1/22/2019	D6 Cleaning Programs	SF-Opioids01409500	SF-Opioids01409516		
P-29351	1/25/2019	Needle Syringe Recovery in Public Works	SF-Opioids01408785	SF-Opioids01408792		
P-29352	1/25/2019	Needle Syringe Recovery in Public Works	SF-Opioids01408796	SF-Opioids01408804		
P-29353	3/28/2019	More than 20 Needles on Public Property	SF-Opioids03870867	SF-Opioids03870867		
P-29354	3/28/2019	More than 20 Needles on Public Property	SF-Opioids03870869	SF-Opioids03870871		
P-29355	8/22/2019	Disposal of Sharps at UN Plaza Fountain	SF-Opioids01406642	SF-Opioids01406646		
P-29356	9/3/2019	director signed MOU for syringe boxes	SF-Opioids01404708	SF-Opioids01404714		
P-29357	9/4/2019	Syringe Disposal Kiosk Program MOU	SF-Opioids01950485	SF-Opioids01950488		
P-29358	9/10/2019	24 Hour Syringe Disposal Location	SF-Opioids01950484	SF-Opioids01950484		
P-29359	9/27/2019	Syringe Disposal Kiosk Program Work Order	SF-Opioids01950489	SF-Opioids01950489		
P-29360	9/30/2019	Syringe Kiosk MOU	SF-Opioids02165873	SF-Opioids02165880		
P-29361	11/1/2019	Analysis of 10 Point Plan for Clean and Healthy Downtown	SF-Opioids01437927	SF-Opioids01437962		
P-29362	12/11/2019	Syringe Kiosk Maintenance Costs FY 19-20	SF-Opioids01433390	SF-Opioids01433394		
P-29363	4/22/2013	Details and Agenda :: Chronic Pain Management Workshop:: May 2, 2013 at the Jewish Community Center of San Francisco; Building a Policy for Your Clinic.pdf; Details Agenda May 2.pdf	SF-Opioids02147737	SF-Opioids02147743		



P-29364	4/16/2015	yellow flag committee referrals - now easier to do than ever!; TWUHC Patient Handout opioid policies 05.07.14.pptx	SF-Opioids00224073	SF-Opioids00224075		
P-29365	3/2/2018	Email re: M-Team Meeting on Tuesday, February 27, 2 p.m. in Room 601 - DRAFT Agenda; SF Employee Portal.pdf; Civic Center Common Budget Request.pdf; Cybersecurity awareness and training standard.pdf; MT Assignment Chart.pdf; Procedure for Severe Incidents if Lib Staff Assaulted.pdf; Software.pdf; Civic Center Commons 2018.pdf; Mteam minutes 02.27.18.docx	SF-Opioids00275526	SF-Opioids00275522		
P-29366	9/12/2017	Email re: Agenda-SCTF for 9/14; 2017 09-14 Security and Communications Agenda.docx; OD Procedure SFPL 8.22.17.doc	SF-Opioids00085186	SF-Opioids00085189		
P-29367	8/18/2017	Email re: All Staff Security Update - reply; To All Staff revised Luis Michael Tom.docx	SF-Opioids00085198	SF-Opioids00085203		
P-29368	7/10/2018	Email re: LJ Library of the Year digital scans; lj_8.pdf; lj_22-26.pdf; LJJune152018CV.pdf	SF-Opioids00085227	SF-Opioids00085238		
P-29369	3/16/2018	Email re: overview of safety /other interventions at the Main; incidentssummary031518.pdf; Safety031518.pdf; popupvillage031518.pdf; Protocol for severe incident.FINAL.docx	SF-Opioids01289631	SF-Opioids01289661		
P-29370	6/4/2018	Email re: Exciting news to be released tomorrow; SFPL Library of the Year submission.pdf; SFPL Library of the Year letters of support.pdf	SF-Opioids01289697	SF-Opioids01289739		
P-29371	3/14/2018	Email attaching Library Commission Meeting 3.15.18 notes; Library Commission 3.15.18.docx	SF-Opioids00085336	SF-Opioids00085338		
P-29372	3/19/2019	Email re: BALIS Meeting item: Suspension/Safety and Security; annotatedCodeofConduct.docx; Notice of Suspension of Library Privileges.pdf; Protocol for severe incident.FINAL.docx; December 2018.pdf	SF-Opioids00982505	SF-Opioids00982587		
P-29373	7/11/2018	Email re: meeting minutes 7/9/18; Mteam 070918.docx; mteam 070918 sup.pdf	SF-Opioids00084953	SF-Opioids00084960		
P-29374	10/21/2017	Email re: First aid kits at service desks	SF-Opioids00085154	SF-Opioids00085154		
P-29375	3/1/2018	Email re: NYTimes: Once It Was Overdue Books. Now Librarians Fight Overdoses.	SF-Opioids00085341	SF-Opioids00085341		
P-29376	8/21/2017	Email re: Security Task Force Update	SF-Opioids00085385	SF-Opioids00085386		
P-29377	2/26/2018	Email re: FW: i-Report Alert: Report #8875 'Submitted'	SF-Opioids01289527	SF-Opioids01289529		
P-29378	1/30/2018	Email re: Library Syringe Disposal Kiosk Installation	SF-Opioids02692727	SF-Opioids02692739		
P-29379	2/26/2018	Email re: i-Report Alert: Report #8875 'Submitted'	SF-Opioids03716260	SF-Opioids03716264		
P-29380	10/11/2017	San Francisco Public Library Opioid Overdose Response Procedure	SF-Opioids02406360	SF-Opioids02406361		
P-29381	3/29/2018	Whole Person Care Presentation on 4/3/18 to Health Commission; 2018 04 03 HC WPC load in laptop Presentation.pptx; pdf 2018 04 03 HC WPC Handout Presentation.pdf	SF-Opioids00427352	SF-Opioids00427373		
P-29382	5/12/2020	Homeless Deaths Manuscript Latest Version; HDR Manuscript Draft 3 hkk.docx	SF-Opioids00430944	SF-Opioids00430978		
P-29383	3/16/2018	FW: BHS Pharmacy Request for Pharmacist for Low-Threshold Buprenorphine Services; image001.jpg; BHS Pharmacy Low Threshold Bupe Services 2018_03_12.doc; Low Threshold Buprenorphine Program_Dr. J Martin_2017_08_03.pdf; ASAM CONFERENCE Poster 2018 ib final.pdf	SF-Opioids00427509	SF-Opioids00427515		
P-29384	6/18/2020	Fw: homelessness data; SFDPH homeless deaths 03.30-05.24.20.pdf	SF-Opioids00882716	SF-Opioids00882721		
P-29385	6/17/2019	RE: media roundup this week - help needed	SF-Opioids01081570	SF-Opioids01081571		
P-29386	7/10/2019	Re: Fw: Carfentanyl; transdermal fentanyl exposure links.docx; Fentanyl Safety San Francisco.docx	SF-Opioids00903122	SF-Opioids00903137		
P-29387	1/22/2019	slides - RE: WPC Update "Homeless Mortality in San Francisco: Opportunities for Prevention"; Homeless Deaths in San Francisco - WPC Stakeholders - 18 Jan 2019.pdf	SF-Opioids01086306	SF-Opioids01086332		
P-29388	1/16/2019	Slides for 1/18 HDR presentation to WPC stakeholders; Homeless Deaths in San Francisco - WPC Stakeholders - 18 Jan 2019.pptx	SF-Opioids01086402	SF-Opioids01086403		

P-29389	8/20/2018	HDR Slides; HDR interval Report 082018 draft.pptx	SF-Opioids00746044	SF-Opioids00746046		
P-29390	11/30/2016	Updated pain policy review tomorrow (12/1) 11-11:30; TWUHC Patient Notice of new policy 11172016.pptx; Pseudoaddiction article.pdf; TWUH Pain policy summary.docx; TWUH controlled substance policy.doc; Pseudoaddiction article.pdf; Overdose and prescribed opioids.pdf	SF-Opioids00563859	SF-Opioids00563911		
P-29391	12/23/2008	GMC Contract Working Group Minutes and Next Steps; GMC Pain Policy 12.18.08.doc	SF-Opioids00421431	SF-Opioids00421436		
P-29392	8/26/2015	Final Poster; Pace CHIP Poster 082615 v3.pptx	SF-Opioids02153679	SF-Opioids02153681		
P-29393	2/12/2019	Low Threshold Bupe; low barrier bupe paper final.docx; 8.31.2018 Treating Addiction in Homeless Population_Slides.pptx; low barrier bupe presentation for ISC.pptx; LBMAT FAQ 081918.docx; Press Release for low barrier bupe LBMAT 5.17.18.pdf; public injector pilot description and results presentation 011817.pptx	SF-Opioids00891986	SF-Opioids00892018		
P-29394	2/25/2014	E-mail re Pharmacist Recommending Oxy	SF-Opioids00811719	SF-Opioids00811722		
P-29395	8/5/2019	Coffin Mortality Data Table	SF-Opioids00350056	SF-Opioids00350056		
P-29396	5/25/2016	SFPD Press Release re Overdose Reversals	N/A	N/A		
P-29397	N/A	BHS/ZSFG bup data (3 excel files)	SF-Opioids03863085-SF-Opioids03863087	Composite		
P-29398	N/A	OTOP methadone data (20 excel files)	SF-Opioids03863475-SF-Opioids03863494	Composite		
P-29399	5/30/2019	Q11 IA Summary of Major Changes	SF-Opioids02359277	SF-Opioids02359277		
P-29400	2/21/2019	Recreation and Park Department's Proposed Budget for FY2019-20 and FY2020-21	SF-Opioids02359274	SF-Opioids02359286		
P-29401	7/12/2019	Urban Alchemy.Parks Alliance Grant Agreement.pdf; Urban Alchemy.Parks Alliance Grant Agreement.pdf; Urban Alchemy.Parks Alliance Grant Agreement.pdf	SF-Opioids03465875	SF-Opioids03465910		
P-29402	11/20/2015	Fwd Meeting Notes	SF-Opioids01825216	SF-Opioids01825225		
P-29403	3/14/2017	MTeam 3.13.17 Minutes; Mteam 031317.docx; Mteam 031317.docx	SF-Opioids01832272	SF-Opioids01832276		
P-29404	2/14/2020	Re: pain group toolkit/video; IPMP Toolkit draft 3.pdf	SF-Opioids00561217	SF-Opioids00561447		
P-29405	11/15/2019	Email re: CATS Med Res BHS/COPC CID#1000006000 FY19-20 HVAC; CATS 1000006000 19-20 FN2 10-08-19.pdf; CATS BHS Med Respite Appendix A-1 CID#1000006000 FY19-20 11-15-19.docx; CATS BHS Med Respite Appendix B CID#1000006000 FY19-20 11-13-19 HVAC.xlsx	SF-Opioids00561459	SF-Opioids00561469		
P-29406	11/12/2019	FW: Documenting Pain Agreement and Cures	SF-Opioids00208303	SF-Opioids00208304		
P-29407	6/14/2019	Email re: Overdose Update; DOPE_ODAdvisory_Fentanyl6.14.19.pdf	SF-Opioids00209302	SF-Opioids00209304		
P-29408	8/28/2018	Re: Public Library Responses to Policy Summit Recommendations	SF-Opioids02407536	SF-Opioids02407539		
P-29409	9/12/2017	Opioid Crisis Town Hall: Library Needs and Responses	SF-Opioids02405686	SF-Opioids02405715		
P-29410	12/23/2017	RE Syringe Disposal Boxes	SF-Opioids01825276	SF-Opioids01825281		
P-29411	2/25/2020	Re Draft- Eureka Valley Branch Incident on Saturday, February, 22nd	SF-Opioids03426269	SF-Opioids03426270		
P-29412	3/9/2018	New research out on opioids; Effect of Opioid vs. Nonopioid Medications on Pain-Related Function in Patients with Chronic Back Pain or Hip or Knee Osteoarthritis Pain	SF-Opioids00212635	SF-Opioids00212647		
P-29413	5/20/2015	SF Safety Net Pain Management Workgroup 2nd Strategic Planning Session, SF Safety Net Pain Management Workgroup Strategic Planning Meeting MINUTES, SF Safety Net Pain Pain Management Workgroup Charter, SF Safety Net Pain Management Workgroup Strategic Planning Meeting	SF-Opioids00563688	SF-Opioids00563704		
P-29414	8/25/2014	Discuss SFHP Pain Mgmt Program - timeline and details, Provider Letter Updated, Pain Management Program Executive Overview	SF-Opioids00216351	SF-Opioids00216354		
P-29415	1/24/2017	Re: Naloxone Standing Order	SF-Opioids00563849	SF-Opioids00563851		
P-29416	1/24/2017	Re Naloxone Standing Order, Delivering Innovation in Supportive Housing Standing Order to Administer Naloxone Hydrochloride	SF-Opioids00563852	SF-Opioids00563856		
P-29417	1/3/2017	Re: Updated pain policy documents for January 1	SF-Opioids00218148	SF-Opioids00218150		

P-29418	12/30/2016	Updated pain policy and info for Tuesday, Prescribing Controlled Substances for Chronic Pain, Opioid Refill Appointment Scheduling Policy Summary, Prescribing Controlled Substances for Chronic Pain: Summary of Policy	SF-Opioids00218155	SF-Opioids00218174		
P-29419	6/25/2020	SF Rec & Park Restroom Monitor Program (park stop)	SF-Opioids01910848	SF-Opioids01910850		
P-29420	12/27/2018	e-mail redevelopment of park restroom monitor program	SF-Opioids01235579	SF-Opioids01235582		
P-29421	9/8/2016	Meth Camp west Coon Hollow Oak Woodlands	SF-Opioids01198236	SF-Opioids01198236		
P-29422	8/27/2019	discussing Citywide Syringe Recovery data collection/reporting	SF-Opioids01198238	SF-Opioids01198243		
P-29423	8/29/2018	Possible training	SF-Opioids01198293	SF-Opioids01198293		
P-29424	5/1/2016	Opioid dose and risk of suicide, U.S. Department of Veteran Affairs, Mark A. Ilgen et al	N/A	N/A		
P-29425	1/1/2018	Deaths of despair or drug problems? Christopher Ruhm	N/A	N/A		
P-29426	9/21/2019	Changing dynamics of the drug overdose epidemic in the United States from 1979 through 2016, Hawre Jalal et al	N/A	N/A		
P-29427	7/17/2019	Opioid death rates soared in communities where pain pills flowed, Washington Post, Sari Horwitz, Steven Rich and Scott Higham	N/A	N/A		
P-29428	2019	Risk of adverse events in patients prescribed long-term opioids: A cohort study in the UK Clinical Practice Research Datalink, John Bedson et al	N/A	N/A		
P-29429	1/1/2020	Associations between stopping prescription opioids, length of opioid treatment, and overdose or suicide deaths in US veterans: observational evaluation, Elizabeth M. Oliva et al.	N/A	N/A		
P-29430	N/A	Website datasf.org/opendata/ including underlying datasets	N/A	N/A		
P-29431	12/17/2021	Proclamation by the Mayor Declaring the Existence of a Local Emergency	N/A	N/A		
P-29432	1/24/2012	FW NIPC Dinner Dialogue Meetings	ENDO-OPIOID MDL-00995017	ENDO-OPIOID MDL-00995019		
P-29433	10/19/2006	Email Broadcast Services Request Form	KP360_OHIOMDL_000003060	KP360_OHIOMDL_000003060		
P-29434	2006	Initiating a Trial of Opioid Therapy Slides	KP360_OHIOMDL_000010255	KP360_OHIOMDL_000010256		
P-29435	12/12/2006	NIPC Dinner Dialogue Advances in Opioid Analgesia Maximizing Benefit While Minimizing Risk Executive Summary	KP360_OHIOMDL_000007613	KP360_OHIOMDL_000007616		
P-29436	7/10/2012	Direct Mail # 4 - Janice	ENDO-CHI_LIT-00354601	ENDO-CHI_LIT-00354607		
P-29437	6/30/2006	Letter from Barto to Rappaport at FDA	ENDO-OPIOID MDL-00299009	ENDO-OPIOID MDL-00299010		
P-29438	1/1/2009	Information on Taking a Long-Acting Opioid	ENDO-CHI_LIT-00251356	ENDO-CHI_LIT-00251572	ENDO-CHI_LIT-00251553 - ENDO-CHI_LIT-00251572	
P-29439	10/1/2011	Letter to Opana sales team regarding abuse	ENDO-CHI_LIT-00251553	ENDO-CHI_LIT-00251584		
P-29440	8/17/2012	Opana ER Scientific Slide Kit	ENDO-OR-CID-01299014	ENDO-OR-CID-01299015		
P-29441	9/22/2006	Opana Tactical Plan	ENDO-OPIOID MDL-00585975	ENDO-OPIOID MDL-00586140		
P-29442	N/A	Opana ER for the Management of Chronic Pain	ENDO-CHI_LIT-00545908	ENDO-CHI_LIT-00545908		
P-29443	2005	Endo Pharmaceuticals Holdings Inc. Preliminary Prospectus Supplement	ENDO-CHI_LIT-00024587	ENDO-CHI_LIT-00024587	ENDO-CHI_LIT-00024587-ENDO-CHI_LIT-00024587	
P-29444	5/18/2005	Email re Actiq Targets with attachment	ENDO-CHI_LIT-00024587	ENDO-CHI_LIT-00024597		
P-29445	6/1/2009	Fentanyl Buccal Tablet for the Treatment of Breakthrough Pain in Opioid-Tolerant Patients with Chronic Cancer Pain	N/A	N/A		
P-29446	2004	Actiq 2004 Dinner CME Lectures Sign Up Sheets	TEVA_MD_L_A_01225652	TEVA_MD_L_A_01225653		
P-29447	5/16/2006	Memo re Draft 1 of Oravescence Technology, Module 1 of the Fentanyl Effervescent Buccal Tablet (FEBT) Learning System	TEVA_AAMD_00820974	TEVA_AAMD_00820995		
P-29448	N/A	TRA-FENT06-013 FENTORA Launch Packet	TEVA_CAOC_09105006	TEVA_CAOC_09105006		
P-29449	10/19/2009	Executive Committee Presentation	TEVA_MD_L_A_00003586	TEVA_MD_L_A_00004011		
P-29450	4/15/2008	Email re For Review: FENTORA World Cup Briefing Booklet with attachment	TEVA_MD_L_A_00004012	TEVA_MD_L_A_00004094		
P-29451	N/A	FENTORA Objections and Company-Approved Responses	TEVA_MD_L_A_00008515	TEVA_MD_L_A_00008516		
P-29452	10/1/2006	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use	TEVA_MD_L_A_00008543	TEVA_MD_L_A_00008575		
P-29453	4/1/2011	FENTORA Phase II Marketplace Workshop PCS Training Facilitator's Guide	TEVA_MD_L_A_00021115	TEVA_MD_L_A_00021125		
P-29454	2008	Fentora Brand Plan 2008 PPT	TEVA_MD_L_A_00025378	TEVA_MD_L_A_00025405		
P-29455	9/4/2012	Email re Dr. Gatz	TEVA_MD_L_A_00346497	TEVA_MD_L_A_00346515		
			TEVA_MD_L_A_00369565	TEVA_MD_L_A_00369565		
			TEVA_MD_L_A_00399758	TEVA_MD_L_A_00399760		

P-29456	N/A	Message Recall Tracking Study; Fentora Patient Analysis; A Day In The Life Of A Breakthrough Pain Patient: Final Report; Fentora Breakthrough Pain Conversation Study	TEVA_MDL_A_00499823 TEVA_MDL_A_00499863 TEVA_MDL_A_00500603 TEVA_MDL_A_00500697 TEVA_MDL_A_00500779	TEVA_MDL_A_00500832 TEVA_MDL_A_00499884 TEVA_MDL_A_00500620 TEVA_MDL_A_00500774 TEVA_MDL_A_00500832	TEVA_MDL_A_00500603 - TEVA_MDL_A_00500620, TEVA_MDL_A_00500697 - TEVA_MDL_A_00500774, TEVA_MDL_A_00500779 - TEVA_MDL_A_00500832	
P-29457	N/A	Etiology of Migraine Presentation	TEVA_MDL_A_00505284 TEVA_MDL_A_00505311	TEVA_MDL_A_00505491 TEVA_MDL_A_00505327	TEVA_MDL_A_00505311 - TEVA_MDL_A_00505327	
P-29458	N/A	Doctor-Sales Representative Fentora video	TEVA_MDL_A_00717110	TEVA_MDL_A_00717110		
P-29459	8/1/2006	Breakthrough Pain ATU Final Report PPT	TEVA_MDL_A_00730456	TEVA_MDL_A_00730456		
P-29460	2012	Fentora Brand Review May 2012	TEVA_MDL_A_00763828	TEVA_MDL_A_00763880		
P-29461	N/A	Why Teva Generics Homepage	TEVA_MDL_A_00764247	TEVA_MDL_A_00764253		
P-29462	N/A	FEN-40372 Fentora Website-HCP Metadata	TEVA_MDL_A_00764613	TEVA_MDL_A_00764673		
P-29463	N/A	Teva Generics Webpage	TEVA_MDL_A_00764694	TEVA_MDL_A_00764720		
P-29464	N/A	Teva Global Elements	TEVA_MDL_A_00764831	TEVA_MDL_A_00764939		
P-29465	N/A	Pain Matters Website page	TEVA_MDL_A_00765014	TEVA_MDL_A_00765014		
P-29466	N/A	Introducing PainMatters.com	TEVA_MDL_A_00765104	TEVA_MDL_A_00765104		
P-29467	N/A	American Pain Society Annual Meeting Pain Matters program description	TEVA_MDL_A_00765105	TEVA_MDL_A_00765105		
P-29468	N/A	Pain Matters Visit Booth 101 flyer	TEVA_MDL_A_00765491	TEVA_MDL_A_00765492		
P-29469	8/1/2015	Conversations That Matter: Addressing Challenging Topics in the Exam Room discussion guide	TEVA_MDL_A_01138181	TEVA_MDL_A_01138186		
P-29470	8/1/2012	FEN-2475 Fentora Smart PDF Weinstein Study	TEVA_MDL_A_01140658	TEVA_MDL_A_01140671		
P-29471	2011	Fentora 2011 Brand Plan	TEVA_MDL_A_01184455	TEVA_MDL_A_01184507		
P-29472	2006	2006 Actiq Marketing PPT	TEVA_MDL_A_02047669	TEVA_MDL_A_02047670		
P-29473	9/18/2015	Email re AAPMed Update	TEVA_MDL_A_02768974	TEVA_MDL_A_02768974		
P-29474	8/12/2010	Email re Burden of Illness Poster Draft for Review with attachment	TEVA_MDL_A_07030364	TEVA_MDL_A_07030381		
P-29475	8/17/2010	Email re burden of illness study/advisory board with attachment	TEVA_MDL_A_07030502	TEVA_MDL_A_07030503		
P-29476	4/24/2009	Email re FENTORA Medical/Scientific Advisory Board with attachment	TEVA_MDL_A_07547524	TEVA_MDL_A_07547527		
P-29477	2015	2015 Medical Education Programs - Pain Matters	TEVA_MDL_A_08657806 TEVA_MDL_A_08657807	TEVA_MDL_A_08657807 TEVA_MDL_A_08657879		
P-29478	11/5/2015	Email re Pain Matters Year End Recommendation with attached PPT	TEVA_MDL_A_08727485	TEVA_MDL_A_08727486		
P-29479	9/16/2015	Email re Pain Matters Q2 Analytics with attachment	TEVA_MDL_A_08761816	TEVA_MDL_A_08761854		
P-29480	1/22/2008	Email re most recent FENTORA promotional deck with attached PPT	TEVA_MDL_A_11320671	TEVA_MDL_A_11320672		
P-29481	N/A	Medicom Grants spreadsheet	N/A	N/A		
P-29482	N/A	Fentora Speaker Program Spreadsheet	TEVA_CAOC_00696030	TEVA_CAOC_00696030		
P-29483	3/18/2015	Email re Teva Pain Care Marketing Launches Pain Matters Educational Initiative	TEVA_CHI_00477160	TEVA_CHI_00477161		
P-29484	N/A	Physician Payment Spreadsheet	TEVA_MDL_A_00553218	TEVA_MDL_A_00553218		
P-29485	N/A	APF Treatment Options: A Guide for People Living with Pain	TEVA_MDL_A_01090493	TEVA_MDL_A_01090579		
P-29486	1/13/2015	Email re NMM Pres - Pain Care Marketing Overview with attached PPT	TEVA_MDL_A_08730937	TEVA_MDL_A_08730946		
P-29487	3/4/2015	Email re Pain Matters Status Report (All Agency Partners) with attachments	TEVA_MDL_A_08731040	TEVA_MDL_A_08731044		
P-29488	11/5/2016	Email re Thank you for sharing your story with attachments	TEVA_MDL_A_08762967	TEVA_MDL_A_08762971		
P-29489	12/21/2007	Email re Target Card from the American Pain Foundation with attachments	TEVA_MDL_A_09544530	TEVA_MDL_A_09544535		
P-29490	5/11/2010	Long-Term Safety and Tolerability of Fentanyl Buccal Tablet for the Treatment of Breakthrough Pain in Opioid-Tolerant Patients with Chronic Pain	TEVA_MDL_A_13755704	TEVA_MDL_A_13755717		
P-29491	2015	Pain Matters Website from Wayback Machine	N/A	N/A		
P-29492	2017	Pain Matters Website	TEVA_MDL_A_00766164	TEVA_MDL_A_00766345		
P-29493	2015	Pain Matters Website	TEVA_MDL_A_01137174	TEVA_MDL_A_01137221		
P-29494	2/4/2022	Teva Written Responses to 30.b.6	N/A	N/A		
P-29495	7/30/2020	Teva Response to People's Second Set of Interrogatories	N/A	N/A		
P-29563	10/3/2012	Oxycodone 30mg 100's #287911	Acquired Actavis 00601959	Acquired Actavis 00601960		

P-29564	3/16/2010	Alpharma to Pay \$42.5 Million to Resolve False Claims Act Allegations in Connection with Promotion of Drug Kadian	N/A	N/A		
P-29565	9/11/2012	Email, Actavis_Media_Plan; Actavis_Media_Plan_September 2012.xls	ALLERGAN_MDL_02128327	ALLERGAN_MDL_02128328		
P-29566	5/25/2005	Rep Invite San Francisco	KP360_OHIOMDL_000377990	KP360_OHIOMDL_000377991		
P-29567	4/21/2010	2010 KOL Agreement with Fishman	CHI_001207848	CHI_001207856		
P-29568	5/11/2011	20017-6 San Francisco CA	KP360_OHIOMDL_000162639	KP360_OHIOMDL_000162640		
P-29569	10/12/2004	B298-002 Rep Invites San Francisco	KP360_OHIOMDL_000177737	KP360_OHIOMDL_000177740		
P-29570	2/27/2012	Responsible Opioid Prescribing in the Era of REMS Dinner Program 3/6/2012 (San Francisco, CA)	KP360_OHIOMDL_000336620	KP360_OHIOMDL_000336622		
P-29571	8/24/2011	18009 Event Grid	ENDO_ANK_CHI_0490880	ENDO_ANK_CHI_0490882		
P-29572	11/13/2007	San Francisco (B192) Houskeeping Notes	KP360_OHIOMDL_000029092	KP360_OHIOMDL_000029097		
P-29573	9/25/2007	B192 Event Grid in date order	KP360_OHIOMDL_000033236	KP360_OHIOMDL_000033247		
P-29574	10/19/2006	Fax Invite San Francisco B382-006	KP360_OHIOMDL_000072946	KP360_OHIOMDL_000072948		
P-29575	2008	B442 Grantor Attendee Grid	KP360_OHIOMDL_000082232	KP360_OHIOMDL_000082234		
P-29576	3/23/2022	1006 - Master SORs 2005-2007	N/A	N/A		
P-29577	3/23/2022	1006 - Bryant Ranch Prepack SORs	N/A	N/A		
P-29578	3/23/2022	1006 - Dispensing Solutions SORs	N/A	N/A		
P-29579	3/23/2022	1006 - H J Harkins Company SORs	N/A	N/A		
P-29580	3/23/2022	1006 - Harvard Drug Group SORs	N/A	N/A		
P-29581	3/23/2022	1006 - Southwood SORs	N/A	N/A		
P-29582	3/23/2022	1006 - Specialty Pharmacies Inc SORs	N/A	N/A		
P-29583	7/20/2009	RE May Rank Summary - West Region	ENDO_AAC_00268507	ENDO_AAC_00268512		
P-29584	10/28/2010	FW OxyContin Formulation Leading to Better Deterrence	ENDO_FLAG-00247879	ENDO_FLAG-00247880		
P-29585	11/30/2009	Re Dr. Pergolizzi	ENDO_FLAG-00542413	ENDO_FLAG-00542414		
P-29586	4/20/2010	FW Dr. Stanos Consulting Agreement and APS Training Plan	ENDO_FLAG-00542419	ENDO_FLAG-00542421		
P-29587	5/25/2010	FW Gordon Irving, MD - STOMP Program	ENDO_FLAG-00824884	ENDO_FLAG-00824886		
P-29588	7/13/2010	RE Kaiser Permanente Recommends Brief Screening tool to Mitigate risk of Opioid Abuse	ENDO_FLAG-00839151	ENDO_FLAG-00839154		
P-29589	1/27/2010	OPANA Publication Team Meeting	ENDO_FLAG-00866195	ENDO_FLAG-00866270		
P-29590	2/3/2010	RE ESN FAQs	ENDO_FLAG-00918723	ENDO_FLAG-00918731		
P-29591	2/23/2010	RE manuscript "Prevalence of Exposure to CYP450 Pharmacokinetic Drug-Drug Interactions among Patients with Chronic Low Back Pain"	ENDO_FLAG-01034019	ENDO_FLAG-01034051		
P-29592	12/9/2009	OPANA ER Phase I 12-9-09	ENDO-OPIOID_MDL-00797436	ENDO-OPIOID_MDL-00797442		
P-29593	7/6/2010	RE OPANA Speakers	ENDO-OPIOID_MDL-00806612	ENDO-OPIOID_MDL-00806613		
P-29594	8/5/2009	FW 2010 Brand Planning Process next steps	ENDO-OPIOID_MDL-00918615	ENDO-OPIOID_MDL-00918621		
P-29595	8/27/2010	2011 Tactical Plan 08-27-10	ENDO-OPIOID_MDL-00934674	ENDO-OPIOID_MDL-00934676		
P-29596	9/1/2010	2011 Tactical Plan 08-27-10	ENDO-OPIOID_MDL-00934731	ENDO-OPIOID_MDL-00934733		
P-29597	8/17/2009	ACTION REQUIRED Speaker Program Update - FROVA, LIDODERM, and OPANA ER	ENDO-OPIOID_MDL-01035705	ENDO-OPIOID_MDL-01035708		
P-29598	5/24/2010	RE March Scorecard Achievement	ENDO-OPIOID_MDL-02187883	ENDO-OPIOID_MDL-02187887		
P-29599	10/1/2010	RE ALERT	ENDO-OPIOID_MDL-02734143	ENDO-OPIOID_MDL-02734147		
P-29600	6/28/2004	Org Chart	TEVA_AAMD_00703291	TEVA_AAMD_00703382		
P-29601	7/21/2005	Email re BTP Portenoy with Attachment	TEVA_AAMD_00792832	TEVA_AAMD_00792996		
P-29602	3/12/2003	Actiq Sales Training Presentation	TEVA_MDL_A_05304016	TEVA_MDL_A_05304063		
P-29603	3/6/2003	Email re Actiq Market Research with Attachment	TEVA_CHI_00769438	TEVA_CHI_00769439		
P-29604	6/24/2007	Email re Sales Meeting Speech with attachment	TEVA_CHI_00752657	TEVA_CHI_00752667		
P-29605	7/26/2007	Board of Directors Meeting Packet	TEVA_AAMD_00183206	TEVA_AAMD_00183365		
P-29606	10/18/2007	Email re James Kenville with attachment	TEVA_MDL_A_01095945	TEVA_MDL_A_01095949		
P-29607	10/18/2007	Email re David Peter with attachment	TEVA_CHI_00111593	TEVA_CHI_00111598		
P-29608	10/18/2007	Email re Lucas McAlpin with attachment	TEVA_CHI_00111599	TEVA_CHI_00111604		
P-29609	10/3/2008	Email from Father re Son Overdose	TEVA_CHI_00762444	TEVA_CHI_00762445		
P-29610	10/27/2003	Medwatch Report	TEVA_MDL_A_11122783	TEVA_MDL_A_11122785		
P-29611	3/12/2003	Actiq Sales Training Presentation	TEVA_MDL_A_05304016	TEVA_MDL_A_05304063		
P-29612	12/5/2003	Email re City Selection for 2004 Saturday Actiq CME with attachment	TEVA_MDL_A_07182275	TEVA_MDL_A_07182276		
P-29613	10/27/2007	Emerging Solutions in Pain: The Interface of Pain and Addiction Materials	TEVA_MDL_A_00827353	TEVA_MDL_A_00827409		
P-29614	12/8/2004	Email re Invitation to be an Expert Interview with attachments	TEVA_MDL_A_02589820	TEVA_MDL_A_02589833		

P-29615	11/9/2007	Email re Cephalon Announces Strong Third Quarter Financial Results	TEVA_MDL_A_02027119	TEVA_MDL_A_02027123		
P-29616	2004	Pain.com Dannemiller Supplemental Materials	TEVA_MDL_A_01166729	TEVA_MDL_A_01166741		
P-29617	6/1/2017	Email re Provider to Patient	TEVA_MDL_A_01529772	TEVA_MDL_A_01529775		
P-29618	9/14/2016	Email re NAMA External Insights with attachment	TEVA_MDL_A_02005992	TEVA_MDL_A_02005994		
P-29619	4/28/2016	Dierks and Bearer ADT Portfolio PPT	TEVA_MDL_A_09191674	TEVA_MDL_A_09191674		
P-29620	N/A	Spreadsheet of Front Group Payments	TEVA_MDL_A_00565051	TEVA_MDL_A_00565051		
P-29621	N/A	Spreadsheet of Front Group Payments	TEVA_MDL_A_02401119	TEVA_MDL_A_02401119		
P-29622	N/A	La Jolla Speaker Training Intro PPT	TEVA_MDL_A_06468651	TEVA_MDL_A_06468651		
P-29623	N/A	La Jolla Speaker Training Pharmacoeconomics and Managed Care PPT	TEVA_MDL_A_06468653	TEVA_MDL_A_06468653		
P-29624	N/A	Prescription Drug Abuse PPT	TEVA_MDL_A_06468638	TEVA_MDL_A_06468638		
P-29625	3/15/2005	Email re National Meeting follow up with attachment	TEVA_MDL_A_08873572	TEVA_MDL_A_08873587		
P-29626	N/A	Fortescue Fentora Sales Visit Excerpt	TEVA_MDL_A_00763717	TEVA_MDL_A_00763717		
P-29627	N/A	Fortescue Fentora Speaker Program spreadsheet excerpt	TEVA_MDL_A_00696812	TEVA_MDL_A_00696812		
P-29628	N/A	A Few Good Salesman Video	TEVA_CAOC_13692683	TEVA_CAOC_13692683		
P-29629	N/A	GlenGarry Video	TEVA_CAOC_13692685	TEVA_CAOC_13692685		
P-29630	N/A	Austin Powers Video	TEVA_MDL_A_00717115	TEVA_MDL_A_00717115		
P-29631	8/12/2006	Cephalon Pain Franchise Speaker Training Presentation	TEVA_BALT_00469770	TEVA_BALT_00469770		
P-29632	9/2/2015	Government Affairs Summit PPT	TEVA_MDL_A_03548147	TEVA_MDL_A_03548147		
P-29633	N/A	Brand/Generic YTD TRx, Market Share, and Sales Chart	TEVA_MDL_A_08734288	TEVA_MDL_A_08734288		
P-29634	10/17/2016	Vantrela ER Pre-Launch ATU PPT	TEVA_MDL_A_07174647	TEVA_MDL_A_07174647		
P-29635	N/A	Specialty Code Description	TEVA_MDL_A_00700492	TEVA_MDL_A_00700492		
P-29636	N/A	Imagine the Possibilities PPT	TEVA_MDL_A_00693559	TEVA_MDL_A_00693559		
P-29637	N/A	Fentora Sales Visit Excerpt	TEVA_MDL_A_00763717	TEVA_MDL_A_00763717		
P-29638	5/1/2008	PCS West Business Review PPT	TEVA_MDL_A_00398749	TEVA_MDL_A_00398749		
P-29639	2012	Fentora Targeting Report	TEVA_MDL_A_01097268	TEVA_MDL_A_01097268		
P-29640	N/A	Make It Happen PPT	TEVA_CHI_00006983	TEVA_CHI_00006983		
P-29641	N/A	Screenshots of Garner Targeting Report	N/A	N/A		
P-29642	N/A	Screenshots of Garner Targeting Report	N/A	N/A		
P-29643	N/A	Fentora Speaker Program Excerpts	TEVA_MDL_A_00696812	TEVA_MDL_A_00696812		
P-29644	3/18/2014	DEA Compliance Organization PPT	TEVA_MDL_A_01464603	TEVA_MDL_A_01464603		
P-29645	N/A	Expansion within Chronic Pain Summary Slides	TEVA_TRI_00016568	TEVA_TRI_00016569		
P-29646	6/28/2011	Influence Mapping Results Review	TEVA_MDL_A_00874287	TEVA_MDL_A_00874287		
P-29647	N/A	Fentora Speaker Program Excerpts	TEVA_MDL_A_00696812	TEVA_MDL_A_00696812		
P-29648	N/A	Actiq and Fentora Sales Visit excerpts	TEVA_MDL_A_00455095	TEVA_MDL_A_00455095		
P-29649	N/A	Listing of Actiq Meetings	N/A	N/A		
P-29650	N/A	Make It Happen PPT	TEVA_CHI_00006983	TEVA_CHI_00006983		
P-29651	2006	Fentora Launch Video	TEVA_MDL_A_03571751	TEVA_MDL_A_03571751		
P-29652	8/13/2007	Email re Final Pain Slides approved by LT with attachment	TEVA_MDL_A_07454512	TEVA_MDL_A_07454518		
P-29653	7/15/2013	Email re Pain Care AOP Planning Meeting Presentations with attachment	TEVA_MDL_A_01281312	TEVA_MDL_A_01281317		
P-29654	2/27/2014	Email re AOP Slides + Larry Downey TEC Set with attachment	TEVA_MDL_A_06924704	TEVA_MDL_A_06924785		
P-29655	6/1/2009	Weinstein Reprint	TEVA_MDL_A_02238177	TEVA_MDL_A_02238185		
P-29656	2/16/2011	Email attaching investigator brochure	TEVA_MDL_A_07630263	TEVA_MDL_A_07630437		
P-29657	7/15/2013	Email with EU Request for Written Responses	TEVA_MDL_A_01891177	TEVA_MDL_A_01891340		
P-29658	9/7/2012	Email with EU Questions re safety and efficacy	TEVA_MDL_A_02355564	TEVA_MDL_A_02355648		
P-29659	9/1/2012	Email with FEN-2491 Slim Jim	TEVA_MDL_A_00883342	TEVA_MDL_A_00883370		
P-29660	11/26/2013	Email attaching Correction to FEN-2491	TEVA_MDL_A_03039577	TEVA_MDL_A_03039578		
P-29661	11/26/2013	Narayana Edits to Slim Jim	TEVA_MDL_A_03039579	TEVA_MDL_A_03039579		
P-29662	5/1/2008	Review of Fentora and Actiq AEs	TEVA_MDL_A_09554095	TEVA_MDL_A_09554095		
P-29663	2010	Fine, Messina, Xie Article	TEVA_MDL_A_01448167	TEVA_MDL_A_01448180		
P-29664	12/1/2006	A Randomized, Placebo-controlled study of Fentanyl Buccal Tablet	TEVA_MDL_A_01131136	TEVA_MDL_A_01131142		
P-29665	N/A	Excerpt of Fentora Sales Visits	TEVA_MDL_A_00763717	TEVA_MDL_A_00763717		
P-29666	1/11/2008	Email re Reimbursement Policy with Attachment	TEVA_SF_00017090	TEVA_SF_00017093		
P-29667	11/11/2008	Email re Fentora Learning System with Attachments	TEVA_AAMD_00628752	TEVA_AAMD_00629059		
P-29668	11/12/2008	Email re Managed Care Question with Attachment	TEVA_NV_00129872	TEVA_NV_00129880		
P-29669	12/19/2008	Email re October Prescriber Reports with Attachment	TEVA_NV_00130043	TEVA_NV_00130045		
P-29670	1/6/2009	Email re Fentora 90 Day Plan with attachment	TEVA_CAOC_13712977	TEVA_CAOC_13713004		



P-29671	3/5/2009	Email re Fentora 90 Day Plan with attachment	TEVA_CAOC_13717722	TEVA_CAOC_13717737		
P-29672	3/5/2009	Email re Marketing Presentation at NSM with attachment	TEVA_CAOC_13717617	TEVA_CAOC_13717646		
P-29673	6/1/2009	Fentanyl Buccal Tablet for the Treatment of BTP in Opioid-Tolerant Patients with Chronic Cancer Pain	TEVA_AAMD_00875486	TEVA_AAMD_00875494		
P-29674	6/29/2009	Email re Prescriber Targeting Data	TEVA_SF_00020266	TEVA_SF_00020267		
P-29675	7/13/2009	Email re Model Sale Call Behavior with attachment	TEVA_MDL_A_00923617	TEVA_MDL_A_00923620		
P-29676	9/17/2009	Email re Presentation with attachment	TEVA_SF_00021360	TEVA_SF_00021361		
P-29677	9/18/2009	Email re No Subject with attachment	TEVA_SF_00021492	TEVA_SF_00021493		
			TEVA_SF_00021492	TEVA_SF_00021501		
P-29678	1/17/2011	Email re Lates Fentora Speaker List with attachment	TEVA_CAOC_13755445	TEVA_CAOC_13755446		
P-29679	2/28/2011	Endicott Field Contact Report	TEVA_AAMD_00192053	TEVA_AAMD_00192057		
P-29680	3/4/2011	MIRF Request	TEVA_BALT_000447376	TEVA_BALT_00047376		
P-29681	3/4/2011	MIRF Response	TEVA_AAMD_00284980	TEVA_AAMD_00284986		
P-29682	7/11/2011	Email re Field Ride Plan with attachment	TEVA_SF_00051648	TEVA_SF_00051650		
P-29683	N/A	Excerpts of Fentora Sales Visit	TEVA_MDL_A_00763717	TEVA_MDL_A_00763717		
P-29684	8/22/2011	Email re Field Ride Agenda with attachment	TEVA_SF_00051770	TEVA_SF_00051771		
P-29685	N/A	Excerpts of Fentora Sales Visits	TEVA_MDL_A_00763717	TEVA_MDL_A_00763717		
P-29686	9/16/2011	Email re PCS NWBusiness Review with attachment	TEVA_SF_00051821	TEVA_SF_00051822		
P-29687	2/6/2012	Email re Head's Up...	TEVA_CAOC_13777577	TEVA_CAOC_13777577		
P-29688	2/21/2012	Email re New Hire Training Guide with attachment	TEVA_NM_00154463	TEVA_NM_00154489		
P-29689	2/24/2012	Email re Slides from Bonus Roll-Out Phone Conference with attachment	TEVA_CAOC_13778474	TEVA_CAOC_13778492		
P-29690	4/18/2012	Email re Data Questions	TEVA_CAOC_13779827	TEVA_CAOC_13779828		
P-29691	7/1/2012	Targeting Assessment and Call Activity Policy	TEVA_MDL_A_02395398	TEVA_MDL_A_02395400		
P-29692	8/17/2012	Email re 2S MBO's with attachment	TEVA_AAMD_00816726	TEVA_AAMD_00816806		
P-29693	10/26/2012	Email re New Hire with attachments	TEVA_SF_00035671	TEVA_SF_00035694		
P-29694	1/8/2013	Email re Sales Rep Midpoints	TEVA_MDL_A_02865191	TEVA_MDL_A_02865191		
P-29695	3/25/2013	Email re Fentora Training Overview with attachment	TEVA_MDL_A_02972233	TEVA_MDL_A_02972503		
P-29696	5/14/2013	Email re March IC Stats	TEVA_MDL_A_01319597	TEVA_MDL_A_01319598		
P-29697	8/1/2013	How would you describe your pain?	TEVA_MDL_A_01136152	TEVA_MDL_A_01136153		
P-29698	1/1/2014	FEN-40103	TEVA_MDL_A_01131696	TEVA_MDL_A_01131757		
P-29699	1/1/2014	FEN-40118	Teva_NY_00033333	Teva_NY_00033338		
P-29700	3/25/2014	Email re ACTION Requested with attachment	TEVA_SF_00040039	TEVA_SF_00040040		
P-29701	8/7/2014	Email re DO NOT FORWARD with attachment	TEVA_NV_00153195	TEVA_NV_00153196		
P-29702	8/22/2014	Email re Breaking News: DEA rules to reschedule hydrocodone	TEVA_CAOC_14078698	TEVA_CAOC_14078698		
P-29703	10/2/2014	Email re FENTORA FIRST contest	TEVA_MDL_A_01332644	TEVA_MDL_A_01332645		
P-29704	10/9/2014	Email re Fentora Training Through with attachment	Teva_NY_00032773	Teva_NY_00033065		
P-29705	12/12/2014	Email re October Sales Results	TEVA_MDL_A_01332697	TEVA_MDL_A_01332698		
P-29706	5/19/2015	Email re Teva LMS Overdue Assignments	TEVA_NV_00156075	TEVA_NV_00156076		
P-29707	5/12/2015	Email re DO NOT FORWARD with attachment	TEVA_NV_00156068	TEVA_NV_00156069		
P-29708	8/6/2015	Email re PainWeek Preconference Planning Meeting with attachment	TEVA_MDL_A_01346139	TEVA_MDL_A_01346141		
P-29709	12/1/2015	FEN-40337	TEVA_MDL_A_01134377	TEVA_MDL_A_01134406		
P-29710	12/1/2016	FEN-40453	TEVA_MDL_A_08734766	TEVA_MDL_A_08734840		
P-29711	5/1/2017	FEN-40535	TEVA_MDL_A_01135946	TEVA_MDL_A_01136019		
P-29712	2018	Zinc Catalog of Materials	TEVA_MDL_A_01140791	TEVA_MDL_A_01140791		
P-29713	1/1/2014	FEN-40119	Teva_NY_00033352	Teva_NY_00033357		
P-29714	4/23/2009	Email re Model Sales Call Behavior	TEVA_SF_00019077	TEVA_SF_00019078		
P-29715	1/3/2012	Email re Q3 11 Fentora Consolidated Findings with attachment	TEVA_SF_00050750	TEVA_SF_00050754		
P-29716	2010	Sweet Self-Appraisal	TEVA_TX_00188380	TEVA_TX_00188384		
P-29717	1/11/2011	Email re Final Convention Staffings Results with attachment	TEVA_CAOC_13755366	TEVA_CAOC_13755367		
P-29718	2009	PCS Northwest Map	N/A	N/A		
P-29719	11/15/2011	Email re Pain Care Sales Force Update	TEVA_MDL_A_11574785	TEVA_MDL_A_11574786		
P-29720	N/A	Excerpts of Speaker Program Database	TEVA_MDL_A_00696812	TEVA_MDL_A_00696812		
P-29721	9/7/2017	FW Oxycodone IR - increase in usage	EEOC00096862	EEOC00096871		
P-29722	11/2/2009	FW One of my doctors made the news today	ENDO_AAC_00036172	ENDO_AAC_00036173		
P-29723	2/12/2013	RE Only oxymorphone opioid medicine that is designed to be crush resistant	ENDO_AAC_00102702	ENDO_AAC_00102707		
P-29724	6/3/2014	RE requesting removal from IC plan	ENDO_ALAG-00351060	ENDO_ALAG-00351061		
P-29725	7/22/2013	RE RE Removal of Dr. George Williams	ENDO_ALAG-00404429	ENDO_ALAG-00404430		

P-29726	5/8/2007	FW continued positive opinions - fyi	ENDO_AR_CRITT_00007711	ENDO_AR_CRITT_00007728		
P-29727	10/30/2012	FW Dr Jain license suspended	ENDO_AR-00130092	ENDO_AR-00130094		
P-29728	8/20/2010	Re Gerson M. Sternstein, MD. sensitive issue	ENDO_AR-00131479	ENDO_AR-00131484		
P-29729	10/22/2010	FW Dr. Tiwari- Indianapolis South Specialty	ENDO_AR-00132060	ENDO_AR-00132063		
P-29730	12/11/2007	RE Prescription drugs top cause of overdoses in Florida	ENDO_FLAG-00126477	ENDO_FLAG-00126480		
P-29731	7/15/2009	FW Inappropriate behavior	ENDO_FLAG-00169588	ENDO_FLAG-00169591		
P-29732	11/21/2012	RE Inflexion Opana ER Data Manuscript	ENDO_FLAG-00272672	ENDO_FLAG-00272703		
P-29733	6/18/2003	RE Pain Management and the Appropriate Care of the Terminally Ill	ENDO_FLAG-00374490	ENDO_FLAG-00374518		
P-29734	4/15/2005	RE Spring NIPC Activities	ENDO_FLAG-00377364	ENDO_FLAG-00377368		
P-29735	12/19/2006	RE Opioid Rotation Consensus Meeting	ENDO_FLAG-00404496	ENDO_FLAG-00404500		
P-29736	12/11/2006	RE Private Message for BSB & Carey only	ENDO_FLAG-00404537	ENDO_FLAG-00404540		
P-29737	11/20/2006	RE Opioid book	ENDO_FLAG-00404564	ENDO_FLAG-00404566		
P-29738	5/16/2005	RE Clarification on previous message regarding street address	ENDO_FLAG-00405670	ENDO_FLAG-00405671		
P-29739	3/28/2004	2004 NIPC Programs	ENDO_FLAG-00405672	ENDO_FLAG-00405676		
P-29740	6/10/2004	FW EN 3202-03 Primary Care Executive Summary	ENDO_FLAG-00405710	ENDO_FLAG-00405734		
P-29741	5/19/2004	RE Update on the Physician Tool Kit	ENDO_FLAG-00405827	ENDO_FLAG-00405828		
P-29742	7/1/2009	Percocet - Copy of PAIN CARE FORUM LISTS	ENDO_FLAG-00437054	ENDO_FLAG-00437056		
P-29743	8/14/2002	Fall NIPC Schedule	ENDO_FLAG-00595531	ENDO_FLAG-00595534		
P-29744	9/18/2011	RE TE recommendations follow up	ENDO_FLAG-00600053	ENDO_FLAG-00600056		
P-29745	9/14/2007	FW Hansen contact info	ENDO_FLAG-00699673	ENDO_FLAG-00699676		
P-29746	12/7/2005	Updated Opioid Abuse Deterrent Formulation In-Depth Review	ENDO_FLAG-00755746	ENDO_FLAG-00755747	ENDO_FLAG-00755746 - ENDO_FLAG-00755747	
P-29747	7/5/2001	FW OxyContin Focus Groups Results	ENDO_FLAG-00755746	ENDO_FLAG-00755767		
P-29748	7/10/2001	FW Results from Business Planning Kick-Off Meeting	ENDO_FLAG-00836712	ENDO_FLAG-00836742		
P-29749	11/18/2010	RE opioid REMS	ENDO_FLAG-01041402	ENDO_FLAG-01041409		
P-29750	11/15/2007	FW LA Opioid Adopters Study Final Report	ENDO_FLAG-01052830	ENDO_FLAG-01052831		
P-29751	9/29/2010	RE please remove from the call plan - Dr. Mark Braunstein	ENDO_PA_00223643	ENDO_PA_00223645		
P-29752	5/6/2008	RE Urgent for APS sorry - Scott Fishman	ENDO_SF-00001477	ENDO_SF-00001479		
P-29753	3/27/2012	OPANA in the lay press	ENDO_SF-00116220	ENDO_SF-00116222		
P-29754	7/18/2006	RE AAPM&R out reach meeting	ENDO_SF-00126747	ENDO_SF-00126750		
P-29755	5/8/2007	RE Opana NTB	ENDO_SF-00154864	ENDO_SF-00154866		
P-29756	10/2/2006	Answering more questions from sales	ENDO_SF-00158754	ENDO_SF-00158770		
P-29757	8/4/2006	FW Target Audiences	ENDO_SF-00161500	ENDO_SF-00161501		
P-29758	8/14/2007	RE 2008 partnership opportunities	ENDO_SF-00162357	ENDO_SF-00162358		
P-29759	2/2/2007	FW 2007 CA Budget Update	ENDO_SF-00173096	ENDO_SF-00173100		
P-29760	4/16/2013	FW Attorney General Kamala D. Harris Applauds Senate Committee's Passage of Legislation to Upgrade California's Prescription Drug Monitoring Program	ENDO_SF-00356880	ENDO_SF-00356885		
P-29761	5/3/2012	FW NY Times meeting action items	ENDO_SF-00360786	ENDO_SF-00360788		
P-29762	3/5/2009	RE FDA Industry REMS meeting	ENDO_SF-00416360	ENDO_SF-00416365		
P-29763	7/27/2013	Fwd Oscar Gosien Diversion Form	ENDO_SF-00504807	ENDO_SF-00504809		
P-29764	7/22/2013	RE Opana ER Rebates - New Alignment	ENDO_TXMDL_00173545	ENDO_TXMDL_00173553		
P-29765	5/21/2008	Updated Debrief OPANA PCP ACCELERATOR RESEARCH	ENDO_TXMDL_00173608	ENDO_TXMDL_00173613		
P-29766	12/4/2012	FW Please Remove from the Call Plan - Dr. Pawankumar Jain	ENDO-CA-00045000	ENDO-CA-00045001		
P-29767	3/19/2015	FW Dr. Philip Cantu Suspected Diversion Form	ENDO-CA-00225707	ENDO-CA-00225707		
P-29768	10/4/2009	RE Department of Community Health- For educational purposes only	ENDO-CA-00227453	ENDO-CA-00227454		
P-29769	4/23/2008	FW IR strategy	ENDO-CHI_LIT-00636291	ENDO-CHI_LIT-00636293		
P-29770	1/11/2008	RE HDMA Letter and DEA Restrictions	ENDO-CHI_LIT-00640635	ENDO-CHI_LIT-00640638		
P-29771	6/2/2010	RE please remove from call plan - Dr. Michael Lazzopina	ENDO-CHI_LIT-01032897	ENDO-CHI_LIT-01032898		
P-29772	6/5/2012	Fwd Notes from the Field Advisory Board	ENDO-CHI_LIT-01046744	ENDO-CHI_LIT-01046744		
P-29773	5/22/2007	FW Dr. Zolot	ENDO-CHI_LIT-01181667	ENDO-CHI_LIT-01181669		
P-29774	9/22/2017	RE Mallinckrodt's Prescription for America's Opioid Epidemic	ENDO-CHI_LIT-01211701	ENDO-CHI_LIT-01211702		
P-29775	2/7/2010	FW OPANA ER Speaker Program Update 2-5-2010	ENDO-NY-00480621	ENDO-NY-00480622		
P-29776	10/18/2013	RE Suspected diversion Form submission PA Larry Marchetta	ENDO-NY-00521572	ENDO-NY-00521575		
P-29777	3/7/2011	RE Opioid Issues Preparedness and Response Initiative	ENDO-NY-00641599	ENDO-NY-00641600		
P-29778	2/10/2009	RE TRF Conference Call Wednesday, February 4th @ 300PM	ENDO-OPIOID_MDL-06524103	ENDO-OPIOID_MDL-06524104		
P-29779	10/19/2006	RE Thoughts on CDE-MedAff-PE Support of Sharp Stick	ENDO-OPIOID_MDL-06563163	ENDO-OPIOID_MDL-06563166		
			ENDO-OPIOID_MDL-06834103	ENDO-OPIOID_MDL-06834106		

P-29780	12/4/2018	RE Early Management Alert - Oxycodone 30mg Tab 500 alleged diversion	ENDO-OPIOID_MDL-06933090	ENDO-OPIOID_MDL-06933092		
P-29781	7/7/2016	FW Draft Interim CARA Victory	ENDO-OPIOID_MDL-06976602	ENDO-OPIOID_MDL-06976604		
P-29782	6/13/2017	RE Confidential- Opana meeting with division director tomorrow	ENDO-OPIOID_MDL-06989285	ENDO-OPIOID_MDL-06989286		
P-29783	6/8/2017	Re URGENT - FDA Opana	ENDO-OPIOID_MDL-07012572	ENDO-OPIOID_MDL-07012574		
P-29784	1/9/2008	DEA Notice	ENDO-OPIOID_MDL-07222830	ENDO-OPIOID_MDL-07222833		
P-29785	5/8/2013	RE I'm not sure where to take this question...	ENDO-OPIOID_MDL-07335501	ENDO-OPIOID_MDL-07335503		
P-29786	7/14/2005	RE FDA Asks Purdue Pharma to Withdraw Palladone for Safety Reasons Topic 13 Knowledge	ENDO-OPIOID_MDL-07470967	ENDO-OPIOID_MDL-07470968		
P-29787	4/12/2011	Fwd Kentucky abuse - Opana	ENDO-OPIOID_MDL-07473162	ENDO-OPIOID_MDL-07473166		
P-29788	1/26/2007	Annals article	ENDO-OPIOID_MDL-07493126	ENDO-OPIOID_MDL-07493143		
P-29789	8/10/2007	RE M-S Pain Journal Club	ENDO-OPIOID_MDL-07494331	ENDO-OPIOID_MDL-07494338		
P-29790	6/8/2012	RE max dose Opana	ENDO-OPIOID_MDL-07683410	ENDO-OPIOID_MDL-07683413		
P-29791	10/27/2006	RE IMPORTANT- Walgreens stores that have stocked Opana	ENDO-OPIOID_MDL-07694638	ENDO-OPIOID_MDL-07694639		
P-29792	12/5/2011	RE Nancy-Adrienne-Anthony See note in Email....2012 R&D Departmental Budget Calendarization	ENDO-OPIOID_MDL-07704304	ENDO-OPIOID_MDL-07704304		
P-29793	1/11/2008	RE Launch of 2008 Speakers Programs	ENDO-OPIOID_MDL-07792129	ENDO-OPIOID_MDL-07792134		
P-29794	11/30/2011	RE INTAC Technology	ENDO-OPIOID_MDL-07798263	ENDO-OPIOID_MDL-07798263		
P-29795	10/1/2012	RE NPRC Expedited Review-AAPMed abstracts and OMED posters - US-RD-PAIN-2012-00035	ENDO-OPIOID_MDL-07810545	ENDO-OPIOID_MDL-07810547		
P-29796	2/19/2013	FW DEA Compliance Update - SOMS	ENDO-OPIOID_MDL-07878651	ENDO-OPIOID_MDL-07878662		
P-29797	5/13/2009	FW Fort Lauderdale News Sun - Sentinel	ENDO-OPIOID_MDL-07887483	ENDO-OPIOID_MDL-07887484		
P-29798	3/23/2015	RE Texas Medical Board disciplines 41 physicians at August meeting - Philip Cantu MD	ENDO-OPIOID_MDL-07971096	ENDO-OPIOID_MDL-07971097		
P-29799	3/18/2016	Re Government Affairs Update DEA Imminent Danger	ENDO-OPIOID_MDL-08307306	ENDO-OPIOID_MDL-08307307		
P-29800	2/19/2010	FW daniel scott	ENDO-STAUBUS_LIT-00038845	ENDO-STAUBUS_LIT-00038848		
P-29801	7/2/2013	RE Dr Lawrence Wilkin- license removed	ENDO-STAUBUS_LIT-00860585	ENDO-STAUBUS_LIT-00860586		
P-29802	3/10/2014	RE CII orders handled by Memphis	MAC_TX_MDL_00051868	MAC_TX_MDL_00051869		
P-29803	2011	The Essence of Analgesia and Analgesics	N/A	N/A		
P-29804	8/16/2007	Opana ER & Lidoderm "Best Practices"	ENDO_ALAG-00465412	ENDO_ALAG-00465415		
P-29805	11/11/2013	Pew Charitable Trust, "Persuading the Prescribers: Pharmaceutical Industry Marketing and its Influence on Physicians and Patients. (November 11, 2013). <a href="https://www.pewtrusts.org/en/research-and-analysis/factsheets/2013/11/11/persuading-the-prescribers-pharmaceutical-industry-marketing-and-its-influence-on-physiciansand-patients">https://www.pewtrusts.org/en/research-and-analysis/factsheets/2013/11/11/persuading-the-prescribers-pharmaceutical-industry-marketing-and-its-influence-on-physiciansand-patients</a>	N/A	N/A		
P-29806	9/17/2012	More presentations	ACTAVIS0237770	ACTAVIS0237796		
P-29807	4/3/2013	RE: Question from Maria on KADIAN(R) Co-Pay Card Handling Fees	ACTAVIS0190232	ACTAVIS0190239		
P-29808	5/7/2010	RE: KADIAN co-pay program	ACTAVIS0636185	ACTAVIS0636186		
P-29809	9/1/2017	Hadland, S. E., Krieger, M. S., & Marshall, B. (2017). Industry Payments to Physicians for Opioid Products, 2013-2015. American journal of public health, 107(9), 1493-1495. <a href="https://doi.org/10.2105/AJPH.2017.303982">https://doi.org/10.2105/AJPH.2017.303982</a>	N/A	N/A		
P-29810	1/4/2013	RE: Kadian request	ACTAVIS0673137	ACTAVIS0673142		
P-29811	3/14/2012	FW: January 2012 Monthly Reports 1 of 4	ACTAVIS0791943	ACTAVIS0791957		
P-29812	4/10/2017	Participant Handout_ 2012 PI-CME Syllabus	ENDO-OPIOID_MDL-04066791	ENDO-OPIOID_MDL-04066801		
P-29813	11/25/2009	cv-webster	ENDO-OPIOID_MDL-00307222	ENDO-OPIOID_MDL-00307254		
P-29814	12/17/2019	Anderson, Timothy & Krieger, Maxwell & Marshall, Brandon & Cerda, Magdalena & Hadland, Scott. (2019). Financial Payments to Teaching Hospitals by Companies Marketing Opioids. Journal of General Internal Medicine. 35. 10.1007/s11606-019-05596-1.	N/A	N/A		

P-29815	7/1/2020	Taitsman, J. K., VanLandingham, A., & Grimm, C. A. (2020). Commercial Influences on Electronic Health Records and Adverse Effects on Clinical Decision-making. JAMA internal medicine, 180(7), 925–926. <a href="https://doi.org/10.1001/jamainternmed.2020.1318">https://doi.org/10.1001/jamainternmed.2020.1318</a>	N/A	N/A		
P-29816	10/21/2020	Hoffman, J. Purdue Pharma Pleads Guilty to Criminal Charges for Opioid Sales. Oct 21, 2020. <a href="https://www.nytimes.com/2020/10/21/health/purdue-opioids-criminalcharges.html">nytimes.com/2020/10/21/health/purdue-opioids-criminalcharges.html</a>	N/A	N/A		
P-29817	2005	Vila, H., Jr, Smith, R. A., Augustyniak, M. J., Nagi, P. A., Soto, R. G., Ross, T. W., Cantor, A. B., Strickland, J. M., & Miguel, R. V. (2005). The efficacy and safety of pain management before and after implementation of hospital-wide pain management standards: is patient safety compromised by treatment based solely on numerical pain ratings?. Anesthesia and analgesia, 101(2), 474–480. <a href="https://doi.org/10.1213/01.ANE.0000155970.45321.A8">https://doi.org/10.1213/01.ANE.0000155970.45321.A8</a>	N/A	N/A		
P-29818	2005	Frasco, P. E., Sprung, J., & Trentman, T. L. (2005). The impact of the joint commission for accreditation of healthcare organizations pain initiative on perioperative opiate consumption and recovery room length of stay. Anesthesia and analgesia, 100(1), 162–168. <a href="https://doi.org/10.1213/01.ANE.0000139354.26208.1C">https://doi.org/10.1213/01.ANE.0000139354.26208.1C</a>	N/A	N/A		
P-29819	4/8/2015	HRP - Letter Summary presentation 10-16-14v2	WAGFLAG03932385	WAGFLAG03932389		
P-29820	10/17/2011	OPANA-ER Tactical Plan - Catalina Health	ENDO-CHI_LIT-00389982	ENDO-CHI_LIT-00389982	ENDO-CHI_LIT-00389982 - ENDO-CHI_LIT-00389982	
P-29821	11/4/2011	OPANA-ER Tactical Plan - Catalina Health	ENDO-CHI_LIT-00389982 ENDO_FLAG-00492423 ENDO_FLAG-00492435	ENDO-CHI_LIT-00389994 ENDO_FLAG-00492435 ENDO_FLAG-00492448	ENDO_FLAG-00492435 - ENDO_FLAG-00492435	
P-29822	8/4/2011	Email re: Exalgo retention Compliance Estimate; Catalina_Creative-Style-Guide_0511; Catalina CHR Capabilities Overview Deck; Exalgo_Adherence_Customer_Estimates_072811	MNK-T1_0004657733	MNK-T1_0004657758		
P-29823	2/14/2013	2008-08-Brad Stone - Catalina Health Resources to DTAB re CheckoutRx	PPLPC030000234192	PPLPC030000234192		
P-29824	2/17/2022	IQVIA Records Declaration regarding documents provided by IQVIA Inc. to Teva defendants	N/A	N/A		
P-29825	7/17/2015	EXTERNAL: Abstract submission to AAPMgt	ENDO-OPIOID MDL-03699941	ENDO-OPIOID MDL-03700114		
P-29826	9/28/2009	2005 article on Impact of opioids on Endocrine system	ENDO_SF-00108422	ENDO_SF-00108428		
P-29827	6/19/2006	RE: third party presentations	ENDO_FLAG-00405575	ENDO_FLAG-00405580		
P-29828	3/4/2022	CA DOJ Re-Identified CURES Data	N/A	N/A		
P-29829	3/24/2022	AFFIDAVIT OF NATHANIEL E FRANK-WHITE and Exhibits re Internet Archive	N/A	N/A		
P-29830	N/A	Distribution of Opioids in California, Bay Area, and Zip Code 941	N/A	N/A		
P-29831	N/A	Opioids Distributed by Anda, Inc in Dosage Units	N/A	N/A		
P-29832	N/A	Opioids Distributed by Walgreens in Dosage Units	N/A	N/A		
P-29833	N/A	Anda Distribution of 14 Opioid Drugs	N/A	N/A		
P-29834	N/A	Walgreens Distribution of 14 Opioid Drugs	N/A	N/A		
P-29835	N/A	Opioids Distributed to Retail and Chain Pharmacies in Dosage Units	N/A	N/A		
P-29836	N/A	Distribution of Opioids by Drug	N/A	N/A		
P-29837	N/A	Nine Prescription Opioids Dispensed by Walgreens, by Drug in Dosage Units	N/A	N/A		
P-29838	N/A	Nine Prescription Opioids Shipped into vs. Dispensed from Walgreens Pharmacies	N/A	N/A		

P-29839	N/A	Walgreens Distribution and Dispensing of Opioid Drugs in Dosage Units	N/A	N/A		
P-29840	N/A	Manufacturer Market Share by Drug Code	N/A	N/A		
P-29841	N/A	All Manufacturer Market Share	N/A	N/A		
P-29842	N/A	Manufacturer Defendant Family Market Share	N/A	N/A		
P-29843	N/A	Distributor Market Share of Actavis Manufactured Opioids	N/A	N/A		
P-29844	N/A	Distributor Market Share of Allergan Manufactured Opioids	N/A	N/A		
P-29845	N/A	Distributor Market Share of Cephalon Manufactured Opioids	N/A	N/A		
P-29846	N/A	Distributor Market Share of Endo Manufactured Opioids	N/A	N/A		
P-29847	N/A	Distributor Market Share of Par Manufactured Opioids	N/A	N/A		
P-29848	N/A	Distributor Market Share of Teva Manufactured Opioids	N/A	N/A		
P-29849	N/A	Target Drug Opioid Prescriptions Versus Target Drug Checklists	N/A	N/A		
P-29850	N/A	Walgreens Suspicious Control Drug Orders Reports Summary	N/A	N/A		
P-29851	N/A	Walgreens Electronic Notes Field Summary	N/A	N/A		
P-29852	N/A	Walgreens Pharmacy Notes, Scanned Prescriptions and Other Documents Summary	N/A	N/A		
P-29853	N/A	Summary of Walgreens Dispensing Data Quality	N/A	N/A		
P-29854	N/A	Opioid Summary on Bryant Ranch Prepack	N/A	N/A		
P-29855	N/A	Opioid Summary on Dispensing Solutions	N/A	N/A		
P-29856	N/A	Opioid Summary on Aidarex Pharmaceuticals LLC	N/A	N/A		
P-29857	N/A	Opioid Summary on Harvard Drug Group	N/A	N/A		
P-29858	N/A	Opioid Summary on Southwood Pharmaceuticals Inc	N/A	N/A		
P-29859	N/A	Opioid Summary on HJ Harkins	N/A	N/A		
P-29860	N/A	Anda Shipments into Four Fifty Sutter Pharmacy	N/A	N/A		
P-29861	N/A	Anda Shipments into Visitacion Valley Pharmacy	N/A	N/A		
P-29862	N/A	Anda Shipments into Reliable Drug	N/A	N/A		
P-29863	N/A	Anda Shipments into Lucky Pharmacy #756	N/A	N/A		
P-29864	N/A	ARCOS Summary of Shipments to Bryant Ranch Prepack	N/A	N/A		
P-29865	N/A	ARCOS Summary of Shipments to Dispensing Solutions	N/A	N/A		
P-29866	N/A	ARCOS Summary of Shipments to Aidarex	N/A	N/A		
P-29867	N/A	ARCOS Summary of Shipments to Harvard Drug Group	N/A	N/A		
P-29868	N/A	ARCOS Summary of Shipments to Southwood Pharmaceuticals Inc	N/A	N/A		
P-29869	N/A	ARCOS Summary of Shipments to HJ Harkins	N/A	N/A		
P-29870	N/A	12 Opioid Drug to San Francisco, CA from Manufacturers to Anda Inc in Total Dosage Units by Year	N/A	N/A		
P-29871	N/A	Anda Shipments to San Francisco, CA in Dosage Units by Manufacturer	N/A	N/A		
P-29872	N/A	Re: Updated Walgreens Store List	Anda_Opioids_MDL_0000967819	Anda_Opioids_MDL_0000967820		
P-29873	N/A	Opioids Distributed by All Distributors to Anda's Retail and Chain Customers	N/A	N/A		
P-29874	N/A	CURES Data - Opioids Dispensed	N/A	N/A		
P-29875	N/A	CURES Data Summary on Opioids	N/A	N/A		
P-29876	N/A	CURES Data - Opioid Prescriptions Written by Selected Prescribers	N/A	N/A		
P-29877	N/A	CURES Data - Opioids Dispensed by Selected Pharmacies	N/A	N/A		
P-29878	N/A	Opioids Distributed by All Distributors to Walgreens by Drug	N/A	N/A		
P-29879	9/11/2008	Re For the Meeting this morning	Anda_Opioids_MDL_0000273281	Anda_Opioids_MDL_0000273284		
P-29880	4/12/2013	RE: Rite Aid Presentation	Anda_Opioids_MDL_0000566962	Anda_Opioids_MDL_0000566984		
P-29881	10/10/2007	2007 NIPC Dinner Dialogue	KP360_OHIOMDL_000035946	KP360_OHIOMDL_000036019		
P-29883	9/24/2013	Collin Leong Arrest Warrant	N/A	N/A		
P-29884	N/A	Photo of Andrew Giovannini	N/A	N/A		
P-29885	4/10/2015	Photo of Colin Leung	N/A	N/A		
P-29886	N/A	Photo of Guido James Gores	N/A	N/A		
P-29887	2/5/2016	Photo of Hsiu-Ying Lisa Tseng	N/A	N/A		
P-29888	5/6/2014	Photo of James Gregory White	N/A	N/A		
P-29889	8/12/2016	Photo of Jasna Mrdjen	N/A	N/A		
P-29890	N/A	Photo of John Winthrop Pierce	N/A	N/A		
P-29891	N/A	Photo of Donald Dossett	N/A	N/A		

P-29892	N/A	Photo of Ray Poon-Phang Seet	N/A	N/A		
P-29893	N/A	Photo of Sai-Sun Ho	N/A	N/A		
P-29894	N/A	Photo of Masami Hattori	N/A	N/A		
P-29895	6/26/2013	Addressing Use, Misuse and Abuse of Opioid Pain Medications PPT	ENDO-OPIOID_MDL-02828924	ENDO-OPIOID_MDL-02828924		
P-29896	3/14/2007	Re: Urgent Complaint from AAPM	ENDO ANK CHI_0892127	ENDO ANK CHI_0892130		
P-29897	N/A	Compilation of Teva Suspicious Order Reports through 2018	N/A	N/A		
P-29898						
	N/A	Sir Speedy Orders for Sales Representatives Who Logged Opana ER Calls to Bay Area Prescribers and Shipped to Address in California	N/A	N/A		
P-29899	N/A	All Recorded Materials Provided by Sales Representatives to Bay Area Prescribers	N/A	N/A		
P-29900	N/A	San Francisco NIPC Programs Solely Supported by Endo Pharmaceuticals	N/A	N/A		
P-29901	5/22/2013	New Mexico Controlled Substance Trends	WAGNMAG00040224	WAGNMAG00040242		
P-29902	12/9/2014	RE: inventory of duties	WAGMDL00299802	WAGMDL00299803		
P-29903	6/1/2020	RE: High Control Prescribing	WAGCN00027146	WAGCN00027148		
P-29904	4/30/2020	FW: Dr Kelly	WAGCN00027173	WAGCN00027175		
P-29905	4/2/2013	RE: GFD Clarification	WAGNMAG00082945	WAGNMAG00082946		
P-29906	4/12/2013	FW Cocktail medications	WAGNMAG00073976	WAGNMAG00073977		
P-29907	12/7/2015	RE triple cocktail	WAGMDL00037521	WAGMDL00037554		
P-29908	4/4/2013	RE patient comments	WAGNMAG00073791	WAGNMAG00073791		
P-29909	6/30/2015	FW T-GFD Sheets	WAGNMAG00052775	WAGNMAG00052776		
P-29910	10/7/2015	GFD DM Webinar- Final.	WAGMDL00492888	WAGMDL00492897		
P-29911	N/A	Stahmann LinkedIn resume	N/A	N/A		
P-29912	11/2/2006	<u>Opana 10-26-06 Publication Team-Minutes 10-26-06</u>	ENDO-CHI_LIT-00552315	ENDO-CHI_LIT-00552335		
P-29913	8/1/2012	Promo Mix Optimization Review-ZS Associates	EPI000182736 EPI000182737	EPI000182737 EPI000182775	EPI000182737-EPI000182737	
P-29914	1/11/2008	Opana Publication Meeting 12-12-08	EPI000299152	EPI000299231		
P-29915	12/15/2018	Pharmacy Wrap-Up Meeting-Specialty follow-up	WAGMDL00866954	WAGMDL00866979		
P-29916	10/21/2006	Walgreens stores that have stocked Opana	ENDO-OPIOID_MDL-00856864	ENDO-OPIOID_MDL-00856865		
P-29917	9/20/2006	Opana Oxy Offer Letter	ENDO-OPIOID_MDL-04921426	ENDO-OPIOID_MDL-04921428		
P-29918	10/19/2007	PPT Sales Force Effectiveness	ENDO-OPIOID_MDL-00915021	ENDO-OPIOID_MDL-00915021		
P-29919	9/4/2013	Q4 FCR Carmen Melton August 2013	MNK-T1_0000543165	MNK-T1_0000543169		
P-29919	N/A	Data Sheets	PAR_OPIOID_MDL_0002203447	PAR_OPIOID_MDL_0002203447		
P-29920	N/A	Data Sheets	PAR_OPIOID_MDL_0002203448	PAR_OPIOID_MDL_0002203448		
P-29921	N/A	Data Sheets	PAR_OPIOID_MDL_0002203449	PAR_OPIOID_MDL_0002203449		
P-29922	N/A	Data Sheets	PAR_OPIOID_MDL_0002203450	PAR_OPIOID_MDL_0002203450		
P-29923	N/A	Data Sheets	PAR_OPIOID_MDL_0002203451	PAR_OPIOID_MDL_0002203451		
P-29924	N/A	Data Sheets	PAR_OPIOID_MDL_0002203452	PAR_OPIOID_MDL_0002203452		
P-29925	3/1/2013	Re:Walgreens Woodland Data - Red Stores	CAH_ALASKA_00006706	CAH_ALASKA_00006709		
P-29926	4/3/2013	Re: C2 Customer List_WAG Perrysburg	WAGCN00021820	WAGCN00021823		
P-29927	5/9/2011	Accenture Audit PPT	WAGMDL00883946	WAGMDL00883995		
P-29928	9/10/2014	Pharmacy Technology IC+ Constraints and Risks	WAGFLAG00829289	WAGFLAG00829317		
P-29929	N/A	I Got My Life Back	PDD1572023004	PDD1572023004		
P-29930	7/9/2015	Email and Spreadsheet re Walgreens Large Orders	Anda_Opioids_MDL_0000114611	Anda_Opioids_MDL_0000114613		
P-29931	7/29/2012	Email re KMart	Anda_Opioids_MDL_0000086419	Anda_Opioids_MDL_0000086419		
P-29932	5/7/2013	Email re bucket orders	Anda_Opioids_MDL_0000089506	Anda_Opioids_MDL_0000089506		
P-29933	3/8/2018	Re account 519162	Anda_Opioids_MDL_0000306066	Anda_Opioids_MDL_0000306068		
P-29934	3/10/2014	86945: SaveMart Pharmacy	Anda_Opioids_MDL_0000362927	Anda_Opioids_MDL_0000362927		
P-29935	1/15/2014	Re:143334: Family Physicians	Anda_Opioids_MDL_0000371938	Anda_Opioids_MDL_0000371939		
P-29936	8/4/2014	Re:230692: Putvin Drug Store	Anda_Opioids_MDL_0000464539	Anda_Opioids_MDL_0000464541		
P-29937	4/8/2022	What is the prevalence of and trend in opioid use disorder in the United States from 2010 to 2019? Using multiplier approaches to estimate prevalence for an unknown population size - Drug and Alcohol Dependence Reports	N/A	N/A		
P-29938	2/27/2014	Email, Opana ER - 2013 Media Authorization; Opana ER - 2013 Media Plan & Auth Rev1_2-22-13.xlsx	ENDO-CHI_LIT-00423180	ENDO-CHI_LIT-00423181		
P-31009	N/A	Simmons LinkedIn Profile	N/A	N/A		



P-31012	6/1/2019	Standards for Person-centered Medication Treatment at OASAS Certified Programs	N/A	N/A		
P-31040	9/28/2010	Endo 9-28-2010 Investor Presentation re QT	N/A	N/A		
P-31215	12/1/2009	Opana ER Instant Savings Card and Resource Kit (part 2)	ENDO-CHI LIT-00541211	ENDO-CHI LIT-00541226		
P-31232	9/3/2001	Watson Pharma, Inc. Memo To Customer Support Services From Lynn DaCunha Re: DEA Excess/Max. Qty. - Suspicious Orders of Controlled Drugs	ALLERGAN_MDL_01844864	ALLERGAN_MDL_01844865		
P-31233	9/22/2004	Deposition Exhibit: Allergan-Woods-003	ALLERGAN_MDL_01839001	ALLERGAN_MDL_01839024		
P-31234	9/19/2005	Deposition Exhibit: Allergan-Woods-004	ALLERGAN_MDL_03951885	ALLERGAN_MDL_03951888		
P-31235	4/7/2009	Deposition Exhibit: Allergan-Woods-008	ALLERGAN_MDL_03641386	ALLERGAN_MDL_03641389		
P-31236	3/19/2012	Deposition Exhibit: Allergan-Woods-011	ALLERGAN_MDL_01175574	ALLERGAN_MDL_01175585		
P-31237	8/18/2009	FW: Suspicious Orders	ALLERGAN_MDL_02081243	ALLERGAN_MDL_02081245		
P-31238	10/26/2012	Deposition Exhibit: Allergan-Woods-015	ALLERGAN_MDL_01684748	ALLERGAN_MDL_01684752		
P-31239	10/26/2012	Deposition Exhibit: Allergan-Woods-016	ALLERGAN_MDL_01979834	ALLERGAN_MDL_01979838		
P-31240	6/27/2014	Deposition Exhibit: Allergan-Woods-017	ALLERGAN_MDL_03750135	ALLERGAN_MDL_03750146		
P-31241	N/A	Deposition Exhibit: Allergan-Woods-018	ALLERGAN_MDL_02146301	ALLERGAN_MDL_02146307		
P-31242	1/11/2016	Actavis DEA Affairs, Controlled Substance Suspicious Order Monitoring: 'Order of Interest' Evaluation	ALLERGAN_MDL_02146077	ALLERGAN_MDL_02146080		
P-31243	N/A	Mary Woods 30(b)(6) Documents January 9, 2019	N/A	N/A		
P-31244	N/A	Mary Woods 30(b)(6) Deposition - Dep Aid	N/A	N/A		
P-31245	2/9/2004	Re: Suspicious Order Reports	ALLERGAN_MDL_02166476	ALLERGAN_MDL_02166477		
P-31246	N/A	Email Investigation Summary - DEA Affairs Attachment Investigation Summary Top Rx	ALLERGAN_MDL_02187196	ALLERGAN_MDL_02187199		
P-31247	11/8/2011	2012 Budget Customer Relations Presentation MW 3 - slide 4 modified using marketing template	ALLERGAN_MDL_02187056	ALLERGAN_MDL_02187091		
P-31248	12/13/2012	Summary: Capital Wholesale; Investigation Summary Capital	ALLERGAN_MDL_02187194	ALLERGAN_MDL_02187195		
P-31249	2012	Customer Relations Operations	ALLERGAN_MDL_03802654	ALLERGAN_MDL_03802706		
P-31250	N/A	Deposition Exhibit: Allergan-Woods-036	ALLERGAN_MDL_03776365	ALLERGAN_MDL_03776678		
P-31252	9/9/2015	RE: CRITICAL - LOOK please Optisource - Lake Erie Medical Kadian Order	MULTI3593474	MULTI3593478		
P-31253	6/26/2014	SOMS Investigation Form for BellCo Drug	MULTI1931188	MULTI1931188		
P-31254	11/17/2015	Customer Analysis and SOMS Overview Import/Export	MULTI2963574	MULTI2963591		
P-31261	9/13/2012	Email Marketing Manager Opportunities	Acquired_Actavis_00626098	Acquired_Actavis_00626100		
P-31262	10/11/2012	Deposition Exhibit: Allergan-Myers-004_Acquired_Actavis_00661681	Acquired_Actavis_00661679	Acquired_Actavis_00661681		
P-31263	6/16/2009	Deposition Exhibit: Allergan-Myers-005_2009-06-16 ALLERGAN_MDL_01192443	ALLERGAN_MDL_01192443	ALLERGAN_MDL_01192444		
P-31264	3/17/2010	Deposition Exhibit: Allergan-Myers-006_2010-03-17 ALLERGAN_MDL_02463212	ALLERGAN_MDL_02463212	ALLERGAN_MDL_02463215		
P-31265	2/2/2012	Deposition Exhibit: Allergan-Myers-007_2010-02-18 ACTAVIS0799203	ACTAVIS0799201	ACTAVIS0799214		
P-31266	12/14/2009	Deposition Exhibit: Allergan-Myers-008_2009-12-14 ALLERGAN_MDL_01234649	ALLERGAN_MDL_01234649	ALLERGAN_MDL_01234661		
P-31267	7/14/2010	Deposition Exhibit: Allergan-Myers-009_2010-07-14 Acquired_Actavis_01373039	Acquired_Actavis_01373039	Acquired_Actavis_01373041		
P-31268	7/27/2010	RE: Fentanyl VA Mailer and 7/26/10 Weekly Status	ALLERGAN_MDL_01235205	ALLERGAN_MDL_01235209		
P-31269	9/13/2010	Re: Buprenorphine advertisement	Acquired_Actavis_01373136	Acquired_Actavis_01373160		
P-31270	9/15/2011	2011 Budget Launches	ALLERGAN_MDL_01211800	ALLERGAN_MDL_01211800		
P-31271	6/20/2011	Oxymorphone Launch Preparation	ALLERGAN_MDL_03684488	ALLERGAN_MDL_03684492		
P-31272	7/7/2011	Re: PDQ Quote For Your Review	ACTAVIS1130369	ACTAVIS1130379		
P-31273	7/19/2011	Deposition Exhibit: Allergan-Myers-016_2011-07-19 ALLERGAN_MDL_00505041	ALLERGAN_MDL_00505041	ALLERGAN_MDL_00505044		
P-31274	7/22/2011	Email Oxymorphone training to KADIAN sales Team Attachment Oxymorphone Sales Training v2 A347	ALLERGAN_MDL_00504974	ALLERGAN_MDL_00504994		
P-31275	8/2/2011	Deposition Exhibit: Allergan-Myers-018_2011-08-02 ALLERGAN_MDL_00504796	ALLERGAN_MDL_00504796	ALLERGAN_MDL_00504815		
P-31276	8/18/2011	Deposition Exhibit: Allergan-Myers-019_2011-08-18 ALLERGAN_MDL_00504574	ALLERGAN_MDL_00504574	ALLERGAN_MDL_00504584		

P-31277	8/26/2011	Email Oxymorphone Promotion and chargeback results to date; Attachment Oxymorphone ER charge back detail to 8-19-2011; Promotion of Oxymorphone	ALLERGAN_MDL_00508576	ALLERGAN_MDL_00508580		
P-31278	9/27/2011	Deposition Exhibit: Allergan-Myers-021_2011-09-27 ACTAVIS0622089	ACTAVIS0622089	ACTAVIS0622089		
P-31279	10/5/2011	FW: Fentanyl Ad	ACTAVIS0343310	ACTAVIS0343321		
P-31280	1/18/2012	Deposition Exhibit: Allergan-Myers-023_2012-01-18 ACTAVIS0618579	ACTAVIS0618579	ACTAVIS0618584		
P-31281	3/26/2012	Email Oxymorphone Prescriptions/Sales Trend Attachment Oxymorphone WK Sales TREND 2-2021	ALLERGAN_MDL_00291742	ALLERGAN_MDL_00291744		
P-31282	6/13/2012	Deposition Exhibit: Allergan-Myers-025_2012-06-13 ALLERGAN MDL 00507938	ALLERGAN_MDL_00507938	ALLERGAN_MDL_00507944		
P-31283	2/25/2013	Deposition Exhibit: Allergan-Myers-026_2013-02-25 Acquired Actavis 02048142	Acquired_Actavis_02048142	Acquired_Actavis_02048193		
P-31284	10/7/2009	Actavis Marketing Department Overview PPT	Acquired_Actavis_01367234	Acquired_Actavis_01367234		
P-31285	7/19/2011	Deposition Exhibit: Allergan-Myers-029_2011-07-19 ACTAVIS0819308	ACTAVIS0819308	ACTAVIS0819312		
P-31289	3/3/2015	Simmons Deposition Exhibit 03	MULTI3746416	MULTI3746422		
P-31293	7/22/2001	Email FW: Oxymorphone Product Profile and attachment	ENDO_FLAG-01041410	ENDO_FLAG-01041412		
P-31294	5/26/2009	Email Opana ER Strategic Imperatives	ENDO_ALAG-00413097	ENDO_ALAG-00413097		
P-31300	3/23/2016	Email – RE: Fentanyl Transdermal System 50MCG Patches Overdose	PAR_OPIOID_MDL_0000847528	PAR_OPIOID_MDL_0000847529		
P-31301	4/14/2016	Email – Re: Fentanyl Lozenges	PAR_OPIOID_MDL_0000882521	PAR_OPIOID_MDL_0000882537		
P-31306	2019	2019 - DEA/NYS Inspection Log	PAR_GAAG-00105973	PAR_GAAG-00105988		
P-31307	8/24/2015	Email – FW: Suspicious Order Monitoring SOP; SOP-SO-0002	PAR_OPIOID_MDL_0000334646	PAR_OPIOID_MDL_0000334653		
P-31310	5/14/2012	Email – RE: Fentanyl lozenge on invoice 1630937RI - SHORTAGE ON CONTROLLED SUBSTANCE MEDCO	PAR_OPIOID_MDL_0000358494	PAR_OPIOID_MDL_0000358496		
P-31314	N/A	SIF2007Backup_2003_extracted_20210719 Spreadsheet	ENDO-OPIOID_MDL-07391949	ENDO-OPIOID_MDL-07391949		
P-31315	N/A	SIF2007Backup_2002_extracted_20210719 Spreadsheet	ENDO-OPIOID_MDL-07391947	ENDO-OPIOID_MDL-07391947		
P-31321	12/31/2016	Allergan PLC 10-K for the year ending Dec. 2016	N/A	N/A		
P-31322	12/31/2015	Allergan PLC 10-K for the year ending Dec. 2015	N/A	N/A		
P-31323	12/31/2011	Watson Pharmaceuticals, Inc. 2011 Form 10-K	N/A	N/A		
P-31325	12/31/2012	Actavis, Inc. 2012 Form 10-K	N/A	N/A		
P-31326	9/16/2005	Initial statement of beneficial ownership of securities - Paonessa Albert III	N/A	N/A		
P-31327	9/19/2005	Statement of changes in beneficial ownership of securities - Paonessa Albert III	N/A	N/A		
P-31328	1/1/2006	Statement of changes in beneficial ownership of securities - Paonessa Albert III	N/A	N/A		
P-31329	2/28/2006	Statement of changes in beneficial ownership of securities - Paonessa Albert III	N/A	N/A		
P-31330	4/14/2006	Statement of changes in beneficial ownership of securities - Paonessa Albert III	N/A	N/A		
P-31331	11/3/2006	Initial statement of beneficial ownership of securities - Paonessa Albert III	N/A	N/A		
P-31332	11/3/2006	Statement of changes in beneficial ownership of securities - Paonessa Albert III	N/A	N/A		
P-31333	6/26/2007	Statement of changes in beneficial ownership of securities - Paonessa Albert III	N/A	N/A		
P-31334	3/12/2008	Statement of changes in beneficial ownership of securities - Paonessa Albert III	N/A	N/A		
P-31335	3/5/2009	Statement of changes in beneficial ownership of securities - Paonessa Albert III	N/A	N/A		
P-31336	3/11/2009	Statement of changes in beneficial ownership of securities - Paonessa Albert III	N/A	N/A		
P-31337	2/24/2010	Statement of changes in beneficial ownership of securities - Paonessa Albert III	N/A	N/A		
P-31338	3/14/2010	Statement of changes in beneficial ownership of securities - Paonessa Albert III	N/A	N/A		

P-31339	11/29/2010	Statement of changes in beneficial ownership of securities - Paonessa Albert III	N/A	N/A		
P-31340	3/2/2011	Statement of changes in beneficial ownership of securities - Paonessa Albert III	N/A	N/A		
P-31341	3/5/2011	Statement of changes in beneficial ownership of securities - Paonessa Albert III	N/A	N/A		
P-31342	3/11/2011	Statement of changes in beneficial ownership of securities - Paonessa Albert III	N/A	N/A		
P-31343	3/17/2011	Statement of changes in beneficial ownership of securities - Paonessa Albert III	N/A	N/A		
P-31344	8/29/2011	Statement of changes in beneficial ownership of securities - Paonessa Albert III	N/A	N/A		
P-31345	2/24/2012	Statement of changes in beneficial ownership of securities - Paonessa Albert III	N/A	N/A		
P-31346	3/8/2012	Statement of changes in beneficial ownership of securities - Paonessa Albert III	N/A	N/A		
P-31347	3/14/2012	Statement of changes in beneficial ownership of securities - Paonessa Albert III	N/A	N/A		
P-31348	5/8/2012	Statement of changes in beneficial ownership of securities - Paonessa Albert III	N/A	N/A		
P-31349	3/2/2013	Statement of changes in beneficial ownership of securities - Paonessa Albert III	N/A	N/A		
P-31350	3/5/2013	Statement of changes in beneficial ownership of securities - Paonessa Albert III	N/A	N/A		
P-31351	3/6/2013	Statement of changes in beneficial ownership of securities - Paonessa Albert III	N/A	N/A		
P-31352	8/15/2013	Statement of changes in beneficial ownership of securities - Paonessa Albert III	N/A	N/A		
P-31353	9/30/2013	Statement of changes in beneficial ownership of securities - Paonessa Albert III	N/A	N/A		
P-31354	10/1/2013	Statement of changes in beneficial ownership of securities - Paonessa Albert III	N/A	N/A		
P-31355	10/1/2013	Initial statement of beneficial ownership of securities - Paonessa Albert III	N/A	N/A		
P-31356	11/11/2013	Statement of changes in beneficial ownership of securities - Paonessa Albert III	N/A	N/A		
P-31357	5/9/2014	Statement of changes in beneficial ownership of securities - Paonessa Albert III	N/A	N/A		
P-31358	9/8/2014	Statement of changes in beneficial ownership of securities - Paonessa Albert III	N/A	N/A		
P-31359	7/1/2015	Initial statement of beneficial ownership of securities - Paonessa Albert III	N/A	N/A		
P-31360	2/5/2016	Statement of changes in beneficial ownership of securities - Paonessa Albert III	N/A	N/A		
P-31361	7/22/2016	Statement of changes in beneficial ownership of securities - Paonessa Albert III	N/A	N/A		
P-31362	7/21/2017	Statement of changes in beneficial ownership of securities - Paonessa Albert III	N/A	N/A		
P-31363	7/20/2018	Statement of changes in beneficial ownership of securities - Paonessa Albert III	N/A	N/A		
P-31364	12/13/2018	Statement of changes in beneficial ownership of securities - Paonessa Albert III	N/A	N/A		
P-31365	7/19/2019	Statement of changes in beneficial ownership of securities - Paonessa Albert III	N/A	N/A		
P-31366	9/6/2019	Statement of changes in beneficial ownership of securities - Paonessa Albert III	N/A	N/A		
P-31367	9/9/2019	Statement of changes in beneficial ownership of securities - Paonessa Albert III	N/A	N/A		
P-31368	10/15/2014	Actavis Funding SCS - Prospectus	N/A	N/A		

P-31371	8/26/2016	CDC's Morbidity and Mortality Weekly Report Vol. 65/No. 33 – Fentanyl Law Enforcement Submissions and Increases in Synthetic Opioid-Involved Overdose Deaths — 27 States, 2013–2014	N/A	N/A		
P-31373	9/1/2021	Katherine M. Keyes's CV	N/A	N/A		
P-31424	8/9/2016	Email between Sabrina Solis and Lynn DaCunha	ALLERGAN MDL 04018977	ALLERGAN MDL 04018978		
P-31432	5/10/2017	Amphetamine one	TEVA_MDL_A_01045021 TEVA MDL A_01045021	TEVA_MDL_A_01045036 TEVA MDL A_01045140	TEVA_MDL_A_01045021 - TEVA MDL A_01045036	
P-31437	1/12/2017	Anda, Inc. January 12, 2017 Annual Report	N/A	N/A		
P-31438	1/21/2019	Anda, Inc. January 21, 2019 Annual Report	N/A	N/A		
P-31439	1/31/2017	Anda, Inc. January 21, 2017 Amended Annual Report	N/A	N/A		
P-31440	4/9/2021	Anda, Inc. April 9, 2021 Annual Report	N/A	N/A		
P-31441	4/10/2020	Anda, Inc. April 10, 2020 Annual Report	N/A	N/A		
P-31442	5/1/2018	Anda, Inc. May 1, 2018 Annual Report	N/A	N/A		
P-31443	9/16/2021	Anda, Inc. September 16, 2021 Amended Annual Report	N/A	N/A		
P-31449	5/4/2012	Anda-Cochrane-019: Email and attached Mallinckrodt CDA	Anda_Opioids MDL 0001222751	Anda_Opioids MDL 0001222758		
P-31450	7/31/2007	Anda-Cochrane-032: Email re: DEA Teleconference	Anda_Opioids MDL 0000275627	Anda_Opioids MDL 0000275627		
P-31455	N/A	Kadian & Norco Direct and Indirect Gross Sales Summaries - Teva_NY – Summary Direct and Indirect Sales Data – CONFIDENTIAL	N/A	N/A		
P-31456	N/A	Mckinney's Public Health Law Section 3302, Definitions of terms of general use in this article	N/A	N/A		
P-41748	11/13/2019	U.S. Department of Justice Title 21 Code of Federal Regulations part 1301- registration of manufacturers, distributors, and dispensers of controlled substances	N/A	N/A		
P-41771	10/23/2017	The family that built an empire of pain: The New Yorker article	N/A	N/A		
P-41780	5/5/2017	United States Senate Committee on Finance letter	N/A	N/A		
P-41829	7/16/2019	76 billion opioid pills: Newly released federal data unmasks the epidemic	N/A	N/A		
P-41915	4/2/2020	Alexander GC, Stoller KB, Haffajee RL, Saloner B. An Epidemic in the Midst of a Pandemic: Opioid Use Disorder and COVID-19. Annals of Internal Medicine. 2020;173:57-58.	N/A	N/A		
P-41917	1/18/2018	National Governors Association. Governors' Recommendations for Federal Action to End the Nation's Opioid Crisis.	N/A	N/A		
P-41918	2016	Centers for Disease Control and Prevention. Contextual Evidence Review for the CDC Guideline for Prescribing Opioids for Chronic Pain – United States, 2016.	N/A	N/A		
P-41919	2018	Centers for Disease Control and Prevention. U.S. County Prescribing Rates, 2018	N/A	N/A		
P-41920	2017	Centers for Disease Control and Prevention. Addressing the Prescription Opioid Crisis.	N/A	N/A		
P-41921	9/17/2018	U.S. Department of Human and Health Services. 5-Point Strategy To Combat the Opioid Crisis.	N/A	N/A		
P-41922	11/1/2016	National Institutes on Drug Abuse. Effective Treatments for Opioid Addiction.	N/A	N/A		
P-41923	N/A	McCance-Katz EF. The National Survey on Drug Use and Health. Substance Abuse and Mental Health Services Administration.	N/A	N/A		
P-41929	06/00/2021	Compton, et al. Pathways to Heroin Use: Commentary on McCabe et al. J. Addict Med. Vol. 15, No. 3, May/June 2021	N/A	N/A		
P-41935	2018	Rosenberg et al., Opioid Therapy for Chronic Pain: Overview of the 2017 US Department of Veterans Affairs and US Department of Defense Clinical Practice Guideline, Pain Medicine 2018; 19: 928-941 doi: 10.1093/pm/pnx203	N/A	N/A		
P-42067	6/17/2015	Diversion Investigators Manual 2011 QBDIManual	CAH MDL2804_01483146	CAH MDL2804_01483530		
P-42147	10/12/2012	FR 77, No. 198: Holiday CVS, L.L.C., d/b/a CVS/ Pharmacy Nos. 219 and 5195; Decision and Order	N/A	N/A		
P-42199	8/3/2020	Craig J. McCann, Ph.D, CFA Raw ARCOS data	N/A	N/A		
P-42277	2001	Dark Paradise: A History of Opiate Addiction in America, rev. ed. (Cambridge, Mass.: Harvard University Press, 2001).	N/A	N/A		

P-42287	8/28/2015	Deposition Richard Sackler Transcript	PPLP004030482	PPLP004030872		
P-42289	10/13/1999	Email re using David Haddox as a speaker	PPLPC01000005050	PPLPC01000005051		
P-42295	1986	Portenoy RK, Foley KM. (1986). Chronic use of opioid analgesics in non-malignant pain: report of 38 cases. Pain 25(2), 171-86. doi: 10.1016/0304-3959(86)90091-6	N/A	N/A		
P-42299	8/26/2011	RE: Follow-up discussion re: Actavis oxymorphone campaign	ALLERGAN_MDL_00684866	ALLERGAN_MDL_00684902		
P-42372	2020	Modeling Mitigation Strategies to Reduce Opioid-Related Morbidity and Mortality in the US	N/A	N/A		
P-42373	8/0/2020	Stone EM, et al., Implementation and Enforcement of State Opioid Prescription Laws	N/A	N/A		
P-42374	9/29/2020	Heyward, J., Key Evidence Supporting Prescription Opioids Approved by the U.S. Food and Drug Administration	N/A	N/A		
P-42375	11/2/2020	Ballreich, J., APOLLO: A Model of the Opioid Epidemic in the United States	N/A	N/A		
P-42376	2/1/2021	Canan, C., Estimating the Prevalence of and characteristics associated with Prescription Opioid Diversion among a clinic population living with HIV: Indirect and direct questioning techniques	N/A	N/A		
P-42377	11/23/2020	Park, JN, Fentanyl and fentanyl analogs in the illicit stimulant supply: Results from US drug seizure data	N/A	N/A		
P-42378	1/31/2020	Jones, CM, et al., The Evolving Overdose Epidemic: Synthetic Opioids and Rising Stimulant-Related Harms	N/A	N/A		
P-42379	12/21/2020	Nguyen TD, Gupta S, Ziedan E, et al. Assessment of Filled Buprenorphine Prescriptions for Opioid Use Disorder During the Coronavirus Disease 2019 Pandemic	N/A	N/A		
P-42380	5/1/2021	Anderson, KE, Quality of Buprenorphine Care for Opioid Use Disorder. Medical Care	N/A	N/A		
P-42381	2/23/2021	Daubresse, M., et al., High-dose Opioid Utilization and Mortality Among Individuals Initiating Hemodialysis	N/A	N/A		
P-42382	2021	Anderson, KE., et al., Quality of Preventive and Chronic Care for Individuals with Opioid Use Disorder	N/A	N/A		
P-42509	12/1/2010	JnJ Nucynta Business Review	JAN-MS-01130535	JAN-MS-01130566		
P-42920	1/28/2013	McKesson Pharmacy Intervention Program: Butrans	PPLPC002000140782	PPLPC002000140783		
P-42946	10/22/2016	Investigation_ The DEA slowed enforcement while the opioid epidemic grew out of control - The Washington Post	N/A	N/A		
P-42972	2001	Chemical Handler's Manual (2001)	N/A	N/A		
P-42973	1/1/2004	Chemical Handler's Manual (January 2004)	N/A	N/A		
P-42983	4/1/2009	Settlement and Release Agreement and Administrative Memorandum of Agreement between DEA and Masters Pharmaceutical, Inc.	N/A	N/A		
P-42996	9/19/2020	Ciccarone, Daniel, The Triple Wave Epidemic: Supply and Demand Drivers of the US Opioid Overdose Crisis	N/A	N/A		
P-43003	9/10/2015	Center for Behavioral Health Statistics and Quality. 2014 National Survey on Drug Use and Health: detailed tables. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2015.	N/A	N/A		
P-43005	9/1/2017	Substance Abuse and Mental Health Services Administration, Key Substance Use and Mental Health Indicators in the United States: Results from the 2016 National Survey on Drug Use and Health	N/A	N/A		
P-43013	10/1/2011	Kadian Marketing Overview - Sales Representative Training	ALLERGAN_MDL_00007267	ALLERGAN_MDL_00007312		
P-43026	5/10/2012	Endo website for Opana	END00474710	END00474804		
P-43027	2006	Oxymorphone Learning System, Module 3, Oxymorphone Risk Management Program	ENDO-CHI_LIT-00053281	ENDO-CHI_LIT-00053809		
P-43087	5/8/2012	Charles Ornstein, et al., American Pain Foundation Shuts Down as Senators Launch Investigation of Prescription Narcotics, ProPublica	N/A	N/A		
P-43092	2018	Centers for Disease Control and Prevention, Data Brief 356. Drug Overdose Deaths in the United States, 1999-2018, at Data Table for Figure 3	N/A	N/A		

P-43093	N/A	Centers for Disease Control and Prevention. Prescription Opioids	N/A	N/A		
P-43094	N/A	Centers for Disease Control and Prevention. Prescription Painkiller Overdoses in the US infographic.	N/A	N/A		
P-43104	2020	National Academies of Sciences, Engineering, and Medicine (NASEM 2020). 2020. Framing Opioid Prescribing Guidelines for Acute Pain: Developing the Evidence. Washington, DC: The National Academies Press	N/A	N/A		
P-43124	11/1/2019	Association of Schools & Programs of Public Health (ASPPH) Report, "Bringing Science to Bear on Opioids"	N/A	N/A		
P-43134	2016	Lembke, Anna. Drug Dealer, MD: How Doctors Were Duped, Patients Got Hooked, and Why It's so Hard to Stop. Johns Hopkins University Press, 2016.	N/A	N/A		
P-43137	9/1/2013	United States Department of Health and Human Services. Addressing Prescription Drug Abuse in the United States: Current Activities and Future Opportunities	N/A	N/A		
P-43146	1/4/2001	2001 Email between Purdue execs discussing the impact of JCAHO standards on pain management	PDD8801183361	PDD8801183364		
P-43147	5/7/2000	Pain Management Speaker Training Program for Physicians	PKY180170528	PKY180170653		
P-43148	8/9/2000	HSS Training Presentation	PKY180435433	PKY180435707		
P-43149	6/15/1998	OxyContin Advertising and Black Box Warnings	PKY180625450	PKY180625745		
P-43150	N/A	CME: Legal and Ethical Issues Affecting Pain Management	PKY180769094	PKY180769535		
P-43151	4/5/2000	Accredited Pain Management Program for the Educator	PKY180775599	PKY180775707		
P-43152	N/A	OxyContin Files (HD): HealthSouth Pain Management Plan	PKY181246683	PKY181247419		
P-43153	4/18/1997	Purdue Physicians' Pain Management Speaker Training Program	PKY181654940	PKY181654982		
P-43154	3/20/1998	Physicians' Pain Management Speakers Training Program	PKY181655057	PKY181655139		
P-43155	11/5/1999	Purdue Physician's Pain Management Speakers Training Program	PKY181655140	PKY181655233		
P-43156	3/24/2006	Purdue's First Supplement to Written Statement of Initial Disclosure	PKY182921037	PKY182921073		
P-43157	12/31/1997	I got my life back.	PKY183063227	PKY183063231		
P-43158	12/23/2005	Statement From Stefan P. Kruszewski, M.D.	PKY183320282	PKY183320575		
P-43160	9/5/2011	Master Consultant Services Agreement	PPLP003478540	PPLP003478553		
P-43161	5/18/2006	Re: DSM V	PPLP004058443	PPLP004058444		
P-43163	11/10/1997	Pain Management Video Transcription - Dr. Spanos	PPLPC009000022560	PPLPC009000022582		
P-43164	9/26/2006	PRC final	PPLPC017000046138	PPLPC017000046173		
P-43165	3/25/2008	Email re DSM	PPLPC018000201219	PPLPC018000201222		
P-43166	11/14/2008	Purdue email	PPLPC018000252189	PPLPC018000252191		
P-43167	3/24/2008	Email re DSM	PPLPC031000425439	PPLPC031000425440		
P-43168	9/27/1995	OxyContin Launch Plan	PURCHI-003286781	PURCHI-003286781		
P-43170	2005	2005 ACTIQ Marketing Plan	TEVA_CAOC_00759630	TEVA_CAOC_00759713		
P-43183	2013	Chaparro - Opioids compared to placebo or other treatments for chronic low-back pain	N/A	N/A		
P-43274	10/21/2015	Teva_Cardinal Health Statement of Work_VantrelaER_Fully Executed_102115	CAH_MDL2804_00132725	CAH_MDL2804_00132735		
P-43569	2017	National Academies of Sciences Engineering and Medicine - Pain Management and the Opioid epidemic, 2017	N/A	N/A		
P-43576	2015	Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP, van der Goes DN. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain. 2015;156(4).	N/A	N/A		
P-43594	2020	Pills to Powder: A 17-Year Transition from Prescription Opioids to Heroin Among US Adolescents Followed Into Adulthood - McCabe, et al	N/A	N/A		
P-43621	11/1/2018	"National Drug Code Dictionary," Drug Enforcement Administration, November 2018	PLTF_2804_000117160	PLTF_2804_000117714		
P-43623	1/1/2018	"NDC/NHRIC Labeler Codes," U.S. Food & Drug Administration, January 2018	N/A	N/A		
P-43624	8/1/2017	Opioid Oral Morphine Milligram Equivalent (MME) Conversion Factors," Centers for Disease Control and Prevention	N/A	N/A		



P-43625	11/1/2018	Full Replacement Monthly NPI File," Centers for Medicare and Medicaid Services	N/A	N/A		
P-43771	4/20/2018	Suspicious Order Reports produced by the DEA	DEA_000000001	DEA_000000001		
P-43773	N/A	Controlled Substances by DEA Drug Code Number, Current version available	N/A	N/A		
P-44153	2019	Gregory Midgette, Steven Davenport, Jonathan P. Caulkins, Beau Kilmer. What America's Users Spend on Illegal Drugs, 2006–2016. RAND Corporation, Santa Monica, CA	N/A	N/A		
P-44166	6/18/2012	Email re IMS Attached Contract - Xponent with attachments	ACTAVIS0280758	ACTAVIS0280766		
P-44167	3/1/2017	Kadian Specialty IMS National 2011-2017	ALLERGAN_MDL_00327297	ALLERGAN_MDL_00327297		
P-44169	N/A	IQVIA Data Set (ALLERGAN-MDL021)	ALLERGAN_MDL_03281086	ALLERGAN_MDL_03281086		
P-44467	2016	2016 Death Map	N/A	N/A		
P-44594	N/A	United States Code - Section 823	N/A	N/A		
P-44660	N/A	House Hearing 107 Congress	N/A	N/A		
P-44661	N/A	Federal Register Vol. 83, No. 76 4-19-18	N/A	N/A		
P-44662	1970	HathiTrust Drug Abuse Control Amendments 1970	N/A	N/A		
P-44663	3/13/1971	Proposed Rulemaking, Part 301 Federal Register Vol. 36, No. 50	N/A	N/A		
P-44664	4/24/1971	Rules & Regulations Title 21 Food and Drugs Federal Register Vol. 36 4/24/71	N/A	N/A		
P-44665	N/A	Reservation of Rights 730 Cardinal Health's Third Supplemental Objections	N/A	N/A		
P-44666	9/10/2008	Federal Register Vol. 73 9/10/08 08-33	N/A	N/A		
P-44667	N/A	NWDA Develops DEA Compliance Institute to Reduce Industry Exposure to Fines	N/A	N/A		
P-44668	3/20/2009	DEA Letter 9/24/06 - Southwood Pharm Revocation SOM	MNK-T1_0000421082	MNK-T1_0000421107		